<SEC-DOCUMENT>0001193125-21-286877.txt : 20210929
<SEC-HEADER>0001193125-21-286877.hdr.sgml : 20210929
<ACCEPTANCE-DATETIME>20210929171031
ACCESSION NUMBER:		0001193125-21-286877
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20210929
DATE AS OF CHANGE:		20210929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tango Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259448
		FILM NUMBER:		211292648

	BUSINESS ADDRESS:	
		STREET 1:		100 BINNEY ST
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(857) 320-4900

	MAIL ADDRESS:	
		STREET 1:		100 BINNEY ST
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BCTG Acquisition Corp.
		DATE OF NAME CHANGE:	20200723
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d118907d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-259448 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g01q37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 68,175,412 Shares of Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or
any of their pledgees, donees, assignees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> or collectively, the permitted transferees, of (i)&nbsp;up to 18,610,000 shares of our common stock
that were issued to certain investors, or collectively, the PIPE Investors, in a private placement in connection with the closing of the Business Combination (as defined below) and (ii)&nbsp;up to 49,565,412 shares of our common stock that were
issued to certain former shareholders of Tango Therapeutics Sub, Inc. at the closing of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from
the sale of shares of common stock by the Selling Securityholders pursuant to this prospectus. However, we will pay the expenses, other than underwriting discounts and commissions and certain expenses incurred by the Selling Securityholders in
disposing of the securities, associated with the sale of securities pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the securities described above for
resale pursuant to certain registration rights we have granted. Our registration of the securities covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the securities. The Selling Securityholders and
any of their permitted transferees may offer, sell or distribute all or a portion of the securities covered by this prospectus in a number of different ways and at varying prices. Additional information on the Selling Securityholders, and the times
and manner in which they may offer and sell the securities covered by this prospectus, is provided under &#147;<I>Selling Securityholders</I>&#148; and &#147;<I>Plan of Distribution</I>&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;TNGX&#148;. On September 28, 2021, the closing price of our common stock was
$12.65 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as that term is defined under the federal securities laws and, as such, are subject to
certain reduced public company reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves risks that are described in the &#147;</B><B><I><A HREF="#toc118907_6">Risk
 Factors</A></I></B><B>&#148; section beginning on page 12 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&nbsp;September 29, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_1">INTRODUCTORY NOTE AND FREQUENTLY USED TERMS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_2">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_5">MARKET AND INDUSTRY DATA AND FORECASTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_9">DETERMINATION OF OFFERING PRICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_10">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 <BR>OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_13">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_14">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_15">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_16">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_17">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_18">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_19">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_20">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_21">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_22">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_23">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc118907_24">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_1"></A>INTRODUCTORY NOTE AND FREQUENTLY USED TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2021, or the Closing Date, BCTG Acquisition Corp., a Delaware corporation and our predecessor, or BCTG, consummated a business combination,
or the Business Combination, pursuant to the terms of the Agreement and Plan of Merger, dated as of April&nbsp;13, 2021, or the Merger Agreement, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation, or BCTG Merger Sub, and Tango
Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc.), a Delaware corporation, or Old Tango. Prior to consummation of the Business Combination, Old Tango changed its name from &#147;Tango Therapeutics, Inc.&#148; to &#147;Tango Therapeutics
Sub, Inc.&#148; and in connection with the Business Combination, BCTG changed its name to &#147;Tango Therapeutics, Inc.&#148; (the former name of Old Tango). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on the Closing Date, BCTG Merger Sub merged with and into Old Tango, or the Merger, with Old Tango surviving the Merger as a
wholly-owned subsidiary of BCTG, and BCTG changed its name to &#147;Tango Therapeutics, Inc.&#148;, or New Tango. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, BCTG agreed
to acquire all of the outstanding shares of Tango common stock (including any options or warrants exercisable therefor) for $550,000,000 in aggregate consideration, comprising 55,000,000 shares of BCTG common stock, based on a price of $10.00 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, BCTG entered into subscription agreements, or the Subscription Agreements with the PIPE
Investors pursuant to which, at the closing of the Merger, the PIPE Investors subscribed for and purchased an aggregate of 18,610,000 shares of our common stock, or the Investor Shares, at a price of $10.00 per share for aggregate gross proceeds of
$186,100,000. We refer to the foregoing transaction in this prospectus as the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, references in this
prospectus to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and the &#147;Company&#148; refer to Tango Therapeutics, Inc., and its consolidated subsidiaries (including Old Tango). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in this prospectus, unless otherwise stated or the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Founders Shares&#148; means the outstanding shares of BCTG&#146;s Common Stock held by the Sponsor, its
directors and affiliates of its management team since June 2020 and includes the Private Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Consideration&#148; and &#147;Merger Consideration Shares&#148; means the 55,000,000 shares of
Common Stock issued as part of the consideration for the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Private Placement&#148; means the private placement consummated simultaneously with BCTG&#146;s initial
public offering in which BCTG issued to the Sponsor the Private Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Private Shares&#148; means the shares of Common Stock of BCTG issued in the Private Placement to the
Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Sponsor&#148; means BCTG Holdings, LLC, a Delaware limited liability company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Tango&#148; or &#147;New Tango&#148; means Tango Therapeutics, Inc., a Delaware corporation, (f/k/a BCTG
Acquisition Corp.) following the closing of the Business Combination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_2"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that we filed with the Securities and Exchange
Commission, or the SEC, using a &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Securityholders and their permitted transferees may, from time to time, sell the securities offered by them described in this
prospectus. We will not receive any proceeds from the sale by the Selling Securityholders of the securities offered by them described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Securityholders and their permitted transferees may use the shelf registration statement to sell such securities from time to time through any
means described in the section entitled &#147;<I>Plan of Distribution</I>.&#148; More specific terms of any securities that the Selling Securityholders and their permitted transferees offer and sell may be provided in a prospectus supplement that
describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also provide a
prospectus supplement or post-effective&nbsp;amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement
or post-effective&nbsp;amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#147;<I>Where You Can Find More Information.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholders have authorized anyone to provide any information or to make any representations other than those contained in this
prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and
the Selling Securityholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under
circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any free
writing prospectuses prepared by or on behalf of us or to which we have referred you. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not
permitted. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable
prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors outside the United States: neither we nor the Selling Securityholders have done anything that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe
any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described in this
prospectus under &#147;<I>Where You Can Find More Information</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus contains references to trademarks, trade names and service
marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and
trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entities. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this prospectus and does not contain all of the information that is important to you in making an
investment decision. This summary is qualified in its entirety by the more detailed information included elsewhere in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire
prospectus, including the information under &#147;Risk Factors,&#148; &#147;Cautionary Note Regarding Forward-Looking Statements,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and
&#147;Unaudited Pro Forma Condensed Combined Financial Information,&#148; as well as the financial statements included elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a precision oncology company leveraging
our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art&nbsp;target</FONT></FONT></FONT> discovery platform to identify novel targets and develop new drugs directed at tumor suppressor
gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be directly targeted. Empowered by recent advances in CRISPR
technology, we are now able to employ a unique functional genomics approach and apply the principles of synthetic lethality to target the loss of specific tumor suppressor genes at scale. We believe this will result in establishing a sustainable
pipeline optimized to deliver meaningfully clinical benefit to patients. Our novel small molecules are designed to be selectively active in cancer cells with specific tumor suppressor gene loss, killing those cancer cells while being relatively
inert in normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse the effects of tumor suppressor gene loss that prevent
the immune system from recognizing and killing cancer cells (immune evasion). We believe this approach will provide the ability to deliver the deep, sustained target inhibition necessary for prolonged tumor regression and meaningful clinical benefit
as a result of the unique ability of synthetic lethal targeting to spare normal cells. We believe our approach also opens possibilities of histology-agnostic treatments for patients harboring specific genome alternations, regardless of cancer type,
in cases where a specific tumor suppressor gene loss is common to more than one subgroup of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our first product candidate, TNG908, is a potent,
selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5, or PRMT5, designed to work selectively in cancer cells with an -methylthioadenosine phosphorylase, or MTAP, deletion. MTAP-deletion occurs in
approximately 10% to 15% of all human tumors, including many common cancers with high unmet need such as squamous cell lung, esophageal and bladder cancer, creating a significant therapeutic opportunity for patients. The challenge <FONT
STYLE="white-space:nowrap">of&nbsp;non-synthetic&nbsp;lethal</FONT> PRMT5 inhibitors in treating cancer is that they kill rapidly growing normal cells (bone marrow cells in particular) as effectively as cancer cells and therefore the dose needed to
kill cancer cells often cannot be achieved without endangering patients. To address this problem, we designed TNG908 to be selectively active (synthetic lethal) in cancer cells that have a deletion of MTAP, which is not present in normal cells. MTAP
encodes the enzyme that <FONT STYLE="white-space:nowrap">degrades&nbsp;5&#146;-deoxy-5&#146;-methylthioadenosine,</FONT> or MTA, an intrinsic inhibitor of PRMT5. Deletion of MTAP is not tumor-promoting by itself but occurs as a &#147;passenger&#148;
with deletion of the tumor suppressor gene CDKN2A. As the normal function of MTAP is to degrade MTA, MTAP deletion results in marked accumulation of MTA in cancer cells. This increase in MTA results in partial PRMT5 inhibition, creating a
vulnerability that is not sufficient alone to kill tumor cells but makes them more susceptible to PRMT5 inhibition than normal cells. As PRMT5 is an essential gene, treatment with a PRMT5 inhibitor like TNG908 is sufficient to cause cancer cell
death without killing normal cells. However, treatment with <FONT STYLE="white-space:nowrap">a&nbsp;non-selective</FONT> PRMT5 inhibitor kills cancer cells and normal cells at approximately the same exposure, markedly limiting potential efficacy.
This difference in mechanism of inhibition occurs because TNG908 binds much more efficiently to <FONT STYLE="white-space:nowrap">the&nbsp;PRMT5-MTA&nbsp;complex,</FONT> so the increased MTA levels in MTAP-deleted cancer cells make TNG908 more potent
in MTAP-deleted cancer cells than in normal cells. In our preclinical studies, TNG908 has <FONT STYLE="white-space:nowrap">demonstrated&nbsp;15-fold&nbsp;greater</FONT> potency in MTAP-deleted cancer cells versus normal cells. This unique
selectivity of TNG908 for MTAP-deleted cancer cells allows for the near-complete and sustained inhibition of PRMT5 needed to induce tumor cell death while sparing normal cells, including bone marrow cells which is likely
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsible for the dose-limiting toxicity <FONT STYLE="white-space:nowrap">of&nbsp;non-synthetic&nbsp;lethal</FONT> PRMT5 inhibitors currently in clinical development. In our preclinical
studies, TNG908&nbsp;demonstrated selectivity for MTAP-deleted tumors, anti-tumor effects<I></I><I>&nbsp;in vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>, and pharmacokinetics that, if approved, support its potential to be a highly differentiated
synthetic lethal PRMT5 inhibitor. We plan to file an Investigational New Drug, or IND, application for TNG908 in the fourth quarter of 2021 and initiate a Phase 1/2 clinical trial in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second product candidate has the potential to be a highly differentiated small molecule inhibitor of ubiquitin-specific protease 1, or USP1, a synthetic
lethal target for BRCA1-mutant breast, ovarian and prostate cancer. USP1 has the potential to treat a patient population that is comparable in size to approximately half of the patient population for
<FONT STYLE="white-space:nowrap">poly&nbsp;(ADP-ribose)&nbsp;polymerase,</FONT> or PARP, inhibitors that are effective against cancers with BRCA1 and BRCA2 mutations. BRCA1 mutations are present in approximately 15% of ovarian cancer, 5% of breast
cancer, and 1% of prostate cancer.<I></I><I>&nbsp;In vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>&nbsp;preclinical data demonstrate potent anti-tumor activity with a lead series compound used as a single agent. Preclinical data further demonstrate
that USP1 inhibition is synergistic with PARP inhibition in BRCA1 mutant cancer cell lines and murine xenograft models, providing the basis for the future clinical trials of a USP1 inhibitor both as a single agent and in combination with PARP
inhibitors in BRCA1-mutant breast, ovarian and prostate cancer. We anticipate advancing a clinical candidate and filing an IND for this program in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third program, an undisclosed target (Target 3), exploits our platform developed to find synthetic lethal targets that reverse the immune evasion effects
of tumor suppressor gene loss, in this case serine-threonine kinase&nbsp;11, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">STK11,&nbsp;loss-of-function&nbsp;mutations.</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">STK11&nbsp;loss-of-function&nbsp;mutations</FONT></FONT> are present in approximately 20% <FONT STYLE="white-space:nowrap">of&nbsp;non-small&nbsp;cell</FONT> lung cancers. Using our proprietary target discovery platform,
we identified STK11 as a tumor suppressor gene responsible for mediating cancer cell resistance to immunotherapy when deleted (immune evasion) and then identified a novel drug target (Target 3) that reverses this effect when inhibited in preclinical
studies. We expect the clinical development plan for this inhibitor in STK11-mutant lung cancer to be the first to combine the power of genetically-based patient selection and checkpoint inhibitor therapy. We anticipate advancing a clinical
candidate for this <FONT STYLE="white-space:nowrap">target&nbsp;into&nbsp;IND-enabling&nbsp;studies&nbsp;in</FONT> the second half of 2022 and filing an IND in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October&nbsp;2018, we entered into a collaboration agreement with Gilead Sciences Inc., or Gilead, and this collaboration was expanded in August&nbsp;2020,
or the Gilead Agreement. Our immune evasion platform is the foundation for our collaboration with Gilead. Under the Gilead Agreement, we and Gilead collaborate to identify and develop novel immune evasion targets by leveraging our proprietary
functional genomics-based discovery platform. To date, Gilead has licensed two of our programs and has research-extended two programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our collaboration
with Gilead excludes our lead program, PRMT5, as well as USP1 and our undisclosed target (Target 3) in STK11-mutant cancers. We retain the right to identify and validate targets outside the scope of our collaboration with Gilead, which includes all
cell autonomous targets except those discovered in immune evasion contexts, and to develop and commercialize products directed to such targets on our own or in collaboration with third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, Gilead elected to extend a program for a research extension fee of $12.0&nbsp;million. Consideration pertaining to the research extension
is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of scientific failure, the Company determined that the variable
consideration of $12.0&nbsp;million should not be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore the research extension consideration will be added to the
transaction price under the Gilead Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our current portfolio of product candidates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g06w69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements in this prospectus and only two years
of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our periodic reports and registration statements, including this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes- Oxley
Act of 2002, as amended, or the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements, including in this prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until we are no longer an
emerging growth company. We will remain an emerging growth company until the earliest of: (i)&nbsp;December&nbsp;31, 2025, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion,
(iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange
Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, provided we have been
subject to the Exchange Act for at least 12 calendar months and have filed at least one annual report pursuant to the Exchange Act or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition
period and, as a result, we may adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for <FONT STYLE="white-space:nowrap">non-public</FONT> companies instead of the dates required for other
public companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous material and other risks that you should be aware of before making an investment decision. These risks are described more
fully in the section entitled &#147;<I>Risk Factors</I>.&#148; These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a precision oncology company with a limited operating history. We have no products approved for commercial
sale, have not generated any revenue from product sales and may never become profitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses
for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms
acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never successfully completed any clinical trials and we may be unable to do so for any product candidates
we develop. Certain of our programs are still in preclinical development and may never advance to clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or
biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests
for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> and preliminary data from our future clinical trials
that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results from early preclinical studies of our programs and product candidates are not necessarily predictive of
the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies of our programs and product candidates in our later preclinical studies and
clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our
receipt of necessary regulatory approvals could be delayed or prevented. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future clinical trials or those of our current or future collaborators may reveal significant adverse events
not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Some of our product candidates modulate pathways for which there are currently no approved or effective
therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product
candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or outbreak of an
infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to rely on third parties to conduct our future clinical trials, as well as investigator-sponsored
clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or
commercialize our product candidates and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We contract with third parties for the manufacture of our product candidates for preclinical development and
expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost,
which could delay, prevent or impair our development or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The third parties upon whom we rely for the supply of the active pharmaceutical ingredients and drug product to
be used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address for our
principal executive office is 100 Binney Street, Suite 700, Cambridge, MA 02142, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-320-4900.</FONT></FONT> Our website address is https://tangotx.com.
The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual
reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares of Common Stock that may be offered and sold from time to time by the Selling
Securityholders named herein</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Up to 68,175,412 shares of Common Stock consisting of (i) 18,610,000 shares of Common Stock issued in a private placement consummated concurrently with the Merger and (ii) 49,565,412 shares of Common Stock issued to certain
former shareholders of Tango Therapeutics Sub, Inc. at the closing of the Business Combination.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">87,474,258 shares of Common Stock as of August&nbsp;31, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">All of the shares of Common Stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from these
sales.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Market for our common stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;TNGX.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Risk factors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Any investment in the Common Stock offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under &#147;<I>Risk Factors</I>&#148; in this prospectus.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this prospectus may constitute &#147;forward-looking statements&#148; for purposes of the federal securities laws. Our forward-looking
statements include, but are not limited to, express or implied statements regarding our or our management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148;
&#147;will,&#148; &#147;would&#148; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for
example, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to discover and develop product candidates efficiently; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to manufacture our drug substances and product candidates successfully for
preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability and willingness of our third-party strategic collaborators to continue research and development
activities relating to our development candidates and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our future expenses, capital requirements, and our need for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations
or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other
approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing
cost; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and its industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including mitigation efforts and
economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this prospectus are based on current expectations and beliefs concerning future
developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are
beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks and uncertainties include, but are not limited to, those factors described under the heading &#147;<I>Risk Factors.</I>&#148; Should one or more
of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the
future be amplified by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake
any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_5"></A>MARKET AND INDUSTRY DATA AND FORECASTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We obtained the industry and market data used throughout this prospectus from our own internal estimates and research, as well as from independent market
research, industry and general publications and surveys, governmental agencies, publicly available information and research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released
by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some
cases, we do not expressly refer to the sources from which this data is derived. In addition, while we believe the industry and market data included in this prospectus is reliable and based on reasonable assumptions, such data involve material risks
and other uncertainties and are subject to change based on various factors, including those discussed in the section entitled &#147;<I>Risk Factors</I>.&#148; These and other factors could cause results to differ materially from those expressed in
the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all
other information in this prospectus, including our financial statements and the related notes and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus before deciding
whether to invest in our securities. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business,
reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of our common stock could decline, and you could lose part or all of your investment. Unless otherwise indicated, reference in this
section and elsewhere in this prospectus to our business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, our business, reputation, financial condition, results of
operations, revenue and our future prospects. The material and other risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently
known to us or that we currently deem immaterial may also impair our business operations. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those
anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See the section titled &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a precision oncology company with a limited operating history. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced operations in 2017 and are a precision oncology company with a limited operating history. Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital,
conducting discovery, research and development activities, and providing general and administrative support for these operations. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and
we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and there is no assurance that we will obtain approvals in the future. Our precision oncology programs are still in
preclinical development. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have
an adverse effect on our stockholders&#146; deficit and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses since our inception and anticipate
that we will continue to incur losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses since our inception. For the years ended
December&nbsp;31, 2020 and 2019, and the six months ended June&nbsp;30, 2021, our net losses were $52.0&nbsp;million, $14.1&nbsp;million and $16.6&nbsp;million, respectively. As of June&nbsp;30, 2021, we had an accumulated deficit of
$119.7&nbsp;million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and
development expenses to increase significantly in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant
sales, marketing and manufacturing expenses. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing
pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual
basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate
significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a
variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of future clinical trials for our product candidates or competing product
candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully open clinical trial sites and recruit and retain subjects for clinical trials, and
any delays caused by difficulties in such efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such
approvals we may receive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research and development activities relating to our product
candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates and products, should they receive regulatory approval, which may
vary depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we will or may incur to develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our products should they receive regulatory approval, which may vary significantly;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved,
and existing and potential future therapeutics that compete with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the changing and volatile U.S. and global economic environments, including as a result of the <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;pandemic;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period&nbsp;basis</FONT></FONT> may not be meaningful. This variability and unpredictability could also result in our failing to meet
the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we
provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may
provide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no products approved for commercial sale and have not generated any revenue from product sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from product sales, and we do not
expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant product revenue unless and until we obtain regulatory approval of, and begin to sell, one or more of our product candidates. Our
ability to generate revenue depends on a number of factors, including, but not limited to, our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete our planned preclinical studies for our novel precision oncology development programs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely file and the acceptance of our IND for TNG908 and our other programs in order to commence our future
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully enroll subjects in, and complete, our planned clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory
approval for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish commercial manufacturing capabilities or make arrangements with third-party&nbsp;manufacturers for
clinical supply and commercial manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain acceptance of our products, if and when approved, by patients, the medical community and
third-party&nbsp;payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">position our products to effectively compete with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain healthcare coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforce and defend intellectual property rights and claims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement measures to help minimize the risk of <FONT STYLE="white-space:nowrap">COVID-19&nbsp;to</FONT> our
employees as well as patients and subjects enrolled in our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain a continued acceptable safety profile of our products following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully
commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to
delay, reduce or eliminate some of our product development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development of pharmaceutical products is
capital-intensive. We are currently advancing our precision oncology programs through preclinical development. We plan to file an IND for TNG908 in the fourth quarter of 2021 and begin a Phase 1/2 clinical trial in the first half of 2022. We also
plan to file an IND for our USP1 inhibitor program in 2022 and file an IND for our undisclosed target for STK11-mutant&nbsp;cancers (Target 3) in 2023. Consequently, we expect our expenses to significantly increase in connection with our ongoing
activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek regulatory approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain
regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to
pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we will incur additional costs associated with operating as a public company.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our
research and development programs or future commercialization efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our existing cash, cash equivalents and marketable securities will fund our projected
operating requirements at least into the second half of 2024. However, our future capital requirements will depend on and could increase significantly as a result of many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of product discovery, preclinical and clinical development, and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential additional expenses attributable to adjusting our development plans (including any supply related
matters) to the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, prioritization and number of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under our existing
collaboration agreements or any additional collaboration agreements we may establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under
future collaboration agreements, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related&nbsp;claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license&nbsp;other</FONT> product
candidates and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of securing manufacturing arrangements for clinical and commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the development of any companion diagnostics we may use in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals
to market our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical development testing and clinical
trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates,
if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on
additional financing to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day&nbsp;activities,</FONT></FONT> which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets in general and
more recently due to the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot
guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a
timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product that has received regulatory approval or be unable to
expand our operations or otherwise capitalize on our business opportunities as desired, which could materially affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a
combination of private and public equity offerings, debt financings, collaborations, strategic alliances </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and licensing arrangements. We do not have any committed external source of funds. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of common stock or securities
convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that may materially adversely affect your rights as a common stockholder. Debt
financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, acquiring, selling or licensing
intellectual property rights, and making capital expenditures, declaring dividends or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet certain milestones in connection
with debt financing and the failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which could have a material adverse
effect on our business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also could be required to seek funds through arrangements with additional collaborators or
otherwise at an earlier stage than otherwise would be desirable. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual
property, future revenue streams, research programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market
ourselves, any of which may have a material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development of our
Precision Oncology and Other Programs and Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never successfully completed any clinical trials and we may be unable to do
so for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet demonstrated our ability to successfully complete clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals,
manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Our programs are still in preclinical development and may never
advance to clinical development. We plan to file an IND for TNG908 in the fourth quarter of 2021 and expect to begin a Phase 1/2 clinical trial in the first half of 2022. We also plan to file an IND for our USP1 inhibitor program in 2022 and file an
IND for our undisclosed target for STK11-mutant&nbsp;cancers (Target 3) in 2023. We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. Moreover, we cannot be sure that submission
of an IND will result in the U.S. Food and Drug Administration, or FDA, allowing clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials
is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their
position, including on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or result in the composition of stricter approval conditions than we currently expect.
Successful completion of our clinical trials is a prerequisite to submitting a new drug application, or NDA to the FDA, a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, or other marketing applications to
regulatory authorities in other jurisdictions, for each product candidate and, consequently, the regulatory approval of each product candidate. We currently do not have any product candidates in clinical development. Our lead development candidate,
TNG908, is currently in <FONT STYLE="white-space:nowrap">IND-enabling&nbsp;studies.</FONT> However, we do not know whether this will advance to future clinical trials, and if so, whether it or any of our future clinical trials will begin on time or
be completed on schedule, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional preclinical studies or clinical trials of our product candidates
beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are
safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining regulatory approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not obtain regulatory approval at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to be subject to post-marketing&nbsp;testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience having the product removed from the market after obtaining regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a
rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discovery and development of oncology therapeutics for patients with genetically defined or biomarker-driven&nbsp;cancers is an emerging field, and the
scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. Our unique functional genomics discovery approach is based on the genetic concept of synthetic lethality. The scientific
evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, that the genetic markers targeted by our programs drive the
formation and spread of certain cancers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific
target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is
dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients with specific
targets, we cannot be certain that the resulting patient populations for each alternation will be large enough to allow us to successfully obtain approval for each alternation type and commercialize our product candidates and achieve profitability.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our preclinical studies and future clinical trials may not be successful. Currently, all our programs are in preclinical development. It is impossible to
predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete
preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and outcomes
are uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of
a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily
in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. Our preclinical studies and future and ongoing clinical trials may not be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully validate, develop and obtain regulatory approval for companion
diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or otherwise obtain
access to<I></I><I>&nbsp;in vitro</I>&nbsp;companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics would be used during
our clinical trials as well as in connection with the commercialization of our products that receive regulatory approval. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical
challenges. The FDA and comparable foreign regulatory authorities regulate<I></I><I>&nbsp;in vitro</I>&nbsp;companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to
demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may
require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to
resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and
early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future
collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including
issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics
for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain regulatory approval, and we may not
realize the full commercial potential of any of these therapeutic products that obtain regulatory approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with
whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic
company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product
candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> and preliminary data from our future clinical trials that we announce or publish from time to
time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, <FONT STYLE="white-space:nowrap">top-line&nbsp;or</FONT> preliminary data from our future clinical trials,
which is based on a preliminary analysis of then-available&nbsp;data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, <FONT STYLE="white-space:nowrap">top-line&nbsp;or</FONT> preliminary results
that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or <FONT STYLE="white-space:nowrap">top-line&nbsp;data</FONT> also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary <FONT STYLE="white-space:nowrap">top-line&nbsp;data</FONT> we
previously published. As a result, preliminary, interim and <FONT STYLE="white-space:nowrap">top-line&nbsp;data</FONT> should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and
final data could significantly harm our business prospects and may cause the price of our common stock to fluctuate or decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, regulatory
agencies and others may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular program,
the likelihood of obtaining regulatory approval of the particular product candidate, commercialization of any approved product and the business prospects of our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is derived from information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the preliminary, interim or <FONT STYLE="white-space:nowrap">top-line&nbsp;data</FONT> that we report differ from actual results, or if regulatory
authorities or others disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or
financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in initiating or completing our preclinical studies or
clinical trials, including as a result of delays in obtaining, or failure to obtain, the FDA&#146;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our
product candidates will not require redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical
trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our
preclinical studies or clinical trials or to delay or terminate a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or institutional review boards, or IRBs, or ethics committees may delay or may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial
sites and prospective clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise
produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically
significant results across tumor types or indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for <FONT STYLE="white-space:nowrap">post-treatment&nbsp;follow-up&nbsp;at</FONT> a higher rate than we
anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality
controls, be unable to provide us with sufficient product supply to conduct or complete </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial,
which may require that we add new clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or
terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may be delayed due to complications associated with the evolving <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;pandemic;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as
we anticipate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments with respect to our competitors&#146; products, including any developments, litigation or
public concern about the safety of such products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is suspended or terminated by us, by
the IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or
clinical hold due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial site by the
FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the
clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with our
clinical trial design or our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our current and future clinical trials may serve as scientific advisors or consultants to us from time to time and
receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority
may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question
the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or
comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical
trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
study or clinical trial delays, including those caused by the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> also could shorten any periods during which we may have the exclusive
right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating
results, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt
of necessary regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to initiate clinical trials for our product candidates if we
are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In
particular, because we are focused on patients with specific genetic mutations for the development of our precision oncology programs and because orphan indications have small populations, our ability to enroll eligible patients may be limited or
may result in slower enrollment than we anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience difficulties with identifying specific patient populations for any
biomarker-defined&nbsp;trial cohorts. The patient eligibility criteria defined in our trial protocols, including biomarker-driven&nbsp;identification may limit the patient populations eligible for our clinical trials to a greater extent than
competing clinical trials for the same indication that do not have biomarker-driven&nbsp;patient eligibility criteria. We will also rely on the willingness and ability of clinicians to screen their patients for biomarkers to indicate which patients
may be eligible for enrollment in our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, some of our competitors have ongoing clinical trials for product candidates that
treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors&#146; product candidates. Furthermore, our ability to
enroll patients may be significantly delayed by the evolving <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> and we cannot accurately predict the extent and scope of such delays at this point. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the competitive trial environment, the eligibility criteria of our future clinical trials will further limit the pool of available study
participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove
costly. We also may not be able to identify, recruit or enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of
competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the
timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also engage third
parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, limiting our ability to identify patients with the targeted genetic mutations for our
clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#146;s expedited review and
development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial
completion; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reporting of the preliminary results of any of our clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">factors we may not be able to control, including the impacts of the
<FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> that may limit patients, principal investigators or staff or clinical site availability. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We anticipate that certain of our current product candidates and future product candidates could be used in combination with third-party drugs or
biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our current product candidates and any future product candidates have the potential to be administered in combination with existing standards of
care like checkpoint inhibitor immunotherapies, chemotherapies, targeted therapies or radiotherapy. Our ability to develop and ultimately commercialize our current programs and product candidates and any future programs or product candidates used in
combination with other therapies will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain
that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint inhibitor immunotherapies or other
comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these
occur, our business, financial condition, operating results, stock price and prospects may be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the development of product
candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA or comparable foreign regulatory authorities may require us to use more complex
clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the
combination therapy and not our current product candidates and any future product candidates. Moreover, following product approval, the FDA or comparable foreign regulatory authorities may require that products used in conjunction with each other be
cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical
trials for the combination as well as our commercial prospects should we receive regulatory approval. Such developments may include changes to the other product&#146;s safety or efficacy profile, changes to the availability of the other product,
quality, manufacturing and supply issues with respect to the other product, and changes to the standard of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any future
collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing potential combination or targeted therapies. Additionally, should the supply of products from
any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially
reasonable terms, our business, financial condition, operating results, stock price and prospects may be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results from early
preclinical studies of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier
preclinical studies of our programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any results from our early preclinical studies of our programs or our product candidates may not necessarily be predictive of the results from later
preclinical studies and clinical trials. Similarly, even if we are able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete our planned preclinical studies and clinical trials of our product candidates according to our current development timeline, the results from such preclinical studies and clinical trials
of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in late-stage&nbsp;clinical trials after achieving positive results in early-stage&nbsp;development, and we cannot be certain that we will not face similar setbacks. These setbacks have
been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety, pharmacokinetic or efficacy observations made in preclinical studies and clinical trials, including previously
unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies
and clinical trials nonetheless failed to obtain regulatory approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to file INDs for our precision oncology and other programs
to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to file an IND
for TNG908 in the fourth quarter of 2021, file an IND for our USP1 inhibitor program in 2022 and file an IND for our undisclosed target for STK11-mutant&nbsp;cancers (Target 3) in 2023. However, we may not be able to file such INDs or INDs for
future product candidates for our precision oncology or other programs on the timelines we expect. For example, we may experience manufacturing delays or other delays with <FONT STYLE="white-space:nowrap">IND-enabling&nbsp;studies.</FONT> Moreover,
we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if the FDA agrees with the design and
implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new
IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis,
if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our
preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies
and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time
during the clinical trial process. Because our precision oncology programs and our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. There is
typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite
having progressed through nonclinical studies and initial clinical trials. If the results of our future preclinical studies and clinical trials are inconclusive with respect to the safety, pharmacokinetics or efficacy of our product candidates, if
we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented from, or delayed in, obtaining regulatory approval for such
product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in
protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we have not yet initiated clinical trials for our
precision oncology programs, it is likely, as is the case with many oncology therapies, that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In
such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related&nbsp;side effects could also affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our product candidates could cause
undesirable side effects in clinical trials related to <FONT STYLE="white-space:nowrap">on-target&nbsp;toxicity.</FONT> If <FONT STYLE="white-space:nowrap">on-target&nbsp;toxicity</FONT> is observed, or if our product candidates have characteristics
that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a
risk-benefit&nbsp;perspective. In addition, our product candidates could cause undesirable side effects that we have not yet observed. Many compounds that initially showed promise in early-stage&nbsp;testing for treating cancer have later been found
to cause side effects that prevented further development of the compound. Most product candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials will
ultimately be successful or support further clinical development or regulatory approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may develop future product
candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical
trials. As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our
future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We,
the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health
risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage&nbsp;trials have later been found to cause side effects that prevented their further
development. Even if the side effects do not preclude the product from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any
of these developments could materially harm our business, operating results, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of our product candidates
modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or
discovery of unknown or unanticipated adverse effects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our product candidates modulate pathway for which there are currently no approved
or effective therapies, which may result in uncertainty regarding our current and future development efforts and ability to obtain regulatory approval for such candidates. We select programs for cancer driver targets based on compelling biological
rationale. We explore new programs based on extensive preclinical data analysis which sometimes cannot predict efficacy or safety in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our
product candidates utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. We utilize
structural biology in tight integration with our medicinal chemistry and biology capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and
drug-like&nbsp;properties. A disruption in any of these capabilities may have significant adverse effects in our ability to expand our pipeline of product candidates, and we cannot predict whether we will continue to have access to these
capabilities in the future to support our pipeline development. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development
of product candidates will not arise in the future, which may cause significant delays or we raise problems we may not be able to resolve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer
than for other, more well-known&nbsp;or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#146; lack of experience with them. The novelty of the mechanism of action of any of our product
candidates may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and
commercialization of our product candidates or lead to significant post-approval&nbsp;limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which
may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. If our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more
well-known&nbsp;product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business
prospects, operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical trials for our product candidates outside the
United&nbsp;States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future choose to
conduct additional clinical trials outside the United&nbsp;States, including in Europe, Australia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United&nbsp;States by the FDA may be subject to
certain conditions. In cases where data from clinical trials conducted outside the United&nbsp;States are intended to serve as the sole basis for regulatory approval in the United&nbsp;States, the FDA will generally not approve the application on
the basis of foreign data alone unless (i)&nbsp;the data are applicable to the United&nbsp;States population and United&nbsp;States medical practices, (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and
(iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site&nbsp;inspection</FONT> by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through
an <FONT STYLE="white-space:nowrap">on-site&nbsp;inspection</FONT> or other appropriate means. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many
foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any
comparable foreign regulatory authority will accept data from trials conducted outside of the United&nbsp;States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in
the need for additional trials, which would be costly and time-consuming&nbsp;and delay aspects of our business plan, and which may result in our product candidates not receiving regulatory approval or clearance for commercialization in the
applicable jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although we intend to explore other therapeutic opportunities in addition to the programs and product candidates that we
are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates
and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail
to yield results for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications and/or product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective products; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources than we will possess to identify additional therapeutic
opportunities for our product candidates or to develop suitable potential product candidates </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance
that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable product candidates through internal research programs, which could materially adversely affect our future growth and
prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to
commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution,
import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United&nbsp;States and by comparable foreign regulatory authorities. Before we can commercialize any of our product candidates, we must obtain
regulatory approval. Currently, all of our product candidates are in discovery or preclinical development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that
our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain regulatory approvals and
expect to rely on third-party&nbsp;CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory
authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of
manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended pharmacokinetics, side effects, toxicities or other
characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party&nbsp;contract
manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals,
both in the United&nbsp;States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval may be delayed, if
obtained at all. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidate involved. Changes in regulatory approval policies during the development period,
changes in or enactment of additional statutes or regulations, or changes in regulatory review policies for each submitted NDA, premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of
an application. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to enroll a sufficient number of patients in our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an NDA, or other submission or to obtain regulatory approval in the United&nbsp;States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party&nbsp;manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change such that our clinical data are insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we were to obtain regulatory approval, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the
performance of costly post-marketing&nbsp;clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining, or if we fail to
obtain, approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and
adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public health
crises such as pandemics or similar outbreaks could adversely impact our business. In 2020 and continuing into 2021, a novel strain of a virus named
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2&nbsp;(severe</FONT></FONT> acute respiratory syndrome coronavirus 2), or coronavirus, which causes <FONT STYLE="white-space:nowrap">COVID-19&nbsp;has</FONT> spread to most
countries across the world, including all 50 states within the United States, including Cambridge, Massachusetts, where our primary office and laboratory space is located. The coronavirus pandemic is evolving, and has led to the implementation of
various responses, including government-imposed&nbsp;quarantines, travel restrictions and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third-party&nbsp;partners, including our
preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the
severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;globally</FONT> could adversely impact our preclinical or clinical
trial operations in the United States, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure
<FONT STYLE="white-space:nowrap">to&nbsp;COVID-19&nbsp;if</FONT> an outbreak occurs in their geography.&nbsp;For example, similar to other biopharmaceutical companies, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience delays in initiating <FONT STYLE="white-space:nowrap">IND-enabling&nbsp;studies,</FONT> protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials
as well as in activating new trial sites. <FONT STYLE="white-space:nowrap">COVID-19&nbsp;may</FONT> also affect employees of third-party&nbsp;CROs located in affected geographies that we rely upon to carry out our clinical trials. Any negative <FONT
STYLE="white-space:nowrap">impact&nbsp;COVID-19&nbsp;has</FONT> to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain
regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites which could be adversely affected by global health matters,
such as pandemics. We plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic.</FONT> Some factors from the <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> that may delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic
concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on travel that could interrupt key trial and business activities, such as clinical trial site
initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed&nbsp;travel restrictions or quarantines that will impact the ability or willingness of
patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face&nbsp;meetings</FONT></FONT> and other
interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential negative affect on the operations of our third-party&nbsp;manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples,
investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on
employees working from home, disruptions to or delays in ongoing laboratory experiments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely
impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the
<FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and
approval timelines. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees,
including temporarily requiring certain of our employees to work remotely, suspending all <FONT STYLE="white-space:nowrap">non-essential&nbsp;travel</FONT> worldwide for our employees, implementing
<FONT STYLE="white-space:nowrap">COVID-19&nbsp;testing</FONT> policies for employees in certain instances and discouraging employee attendance at industry events and <FONT STYLE="white-space:nowrap">in-person&nbsp;work-related&nbsp;meetings,</FONT>
which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the SEC or FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other factors arising from <FONT STYLE="white-space:nowrap">COVID-19&nbsp;could</FONT> worsen in countries that are already afflicted with <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;or</FONT> could continue to spread to additional countries. Any of these factors, and other factors related to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related
issues could lead to adverse effects on the economy of the United&nbsp;States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face
substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the
pharmaceutical, biotechnology, and other related markets that address structural biology-guided&nbsp;chemistry-based&nbsp;drug design to develop therapies in the fields of cancer and genetic diseases. There are other companies focusing on precision
oncology to develop therapies in the fields of cancer and other diseases. We also compete more broadly across the market for cost-effective&nbsp;and reimbursable cancer treatments. Some of these competitive products and therapies are based on
scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face
competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical
companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish
collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and
commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets. Key product features that would affect our ability
to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, our ability to identify biomarkers, ability to
successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the companies that we compete against or which we may compete against in the future have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result
in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage&nbsp;companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or
less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products sooner than we may obtain approval
for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are
likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement from government and other third-party&nbsp;payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for our programs and product candidates are smaller than we estimate or if
any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incidence and prevalence for target patient populations of our programs and product candidates have not been established with precision. Our lead product
candidate, TNG908, is an oral small molecule inhibitor of PRMT5. We are developing TNG908 for the treatment of patients with solid tumors with MTAP deletion, genetic alteration which occurs in 10 to 15% of all human tumors, including many commonly
occurring cancers with high unmet need such as squamous cell lung, esophageal and bladder cancer. Our second product candidate, USP1, is a strong synthetic lethal target for BRCA1-mutant&nbsp;which are present in approximately 15% of ovarian cancer,
5% of breast cancer, and 1% of prostate cancer. Additionally, our undisclosed Target 3 program is being developed for patients with STK11
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;mutations,</FONT></FONT> a genetic alteration in approximately 20% of <FONT STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancer. Our projections of
both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our programs and product candidates, are based on our estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, the indications
for which our product candidates are approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with the cancers and solid tumors for which our product candidates may be
approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect
our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which
may prove to be the wrong choice and may adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our current product candidates or any future product candidates do not
achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never
commercialized a product candidate for any indication. Even if our current product candidates and any future product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among
physicians, patients, third-party&nbsp;payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant revenue and may
not become profitable or may be significantly delayed in achieving profitability. Market acceptance of our current product candidates and any future product candidates by the medical community, patients and third-party&nbsp;payors will depend on a
number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch, from existing therapies even when new and potentially more effective or safer
treatments enter the market. If public perception is influenced by claims that the use of certain precision oncology product candidates or immunotherapies and targeted therapies is unsafe, whether related to our or our competitors&#146; products,
our products may not be accepted by the general public or the medical community. Future adverse events in precision oncology, immuno-oncology&nbsp;or the biopharmaceutical industry could also result in greater governmental regulation, stricter
labeling requirements and potential regulatory delays in the testing or approvals of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and
third-party&nbsp;payors on the benefits of our current product candidates and any future product candidates may require significant resources and may not be successful. If our current product candidates or any future product candidates are approved
but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our current product candidates and any future product candidates
will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy of our current product candidates and any future product candidates as single agents and in
combination with marketed combination therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercial success of the checkpoint blockade drugs with which our products may be <FONT
STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse events associated with our current product candidates and any future
product candidates or those products with which they may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our product candidates are approved and the approved claims that we may make
for the products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the product&#146;s
<FONT STYLE="white-space:nowrap">FDA-approved&nbsp;labeling</FONT> or those of comparable foreign regulatory authorities, including potential limitations or warnings for our current product candidates and any future product candidates that may be
more restrictive than other competitive products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care for the targeted indications for our current product candidates and any future
product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative convenience and ease of administration of our current product candidates and any future product
candidates and any products with which they are <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate coverage or reimbursement by third party payors, including government healthcare
programs such as Medicare and Medicaid and other healthcare payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price concessions required by third-party&nbsp;payors to obtain coverage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket&nbsp;in</FONT></FONT> the absence of adequate coverage and reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and strength of our marketing and distribution of our current product candidates and any future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already
used or that may later be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to
our current product candidates and any future product candidates or to which we agree as part of a risk evaluation and mitigation strategy, or REMS, or voluntary risk management plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our current product candidates and any future product candidates, as well as
competitive products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our current product candidates and any future product candidates for sale at competitive
prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and strength of our third-party&nbsp;manufacturer and supplier support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actions of companies that market any products with which our current product candidates and any future
product candidates may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of other new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about our current product candidates and any future product candidates or any products with
which they are <FONT STYLE="white-space:nowrap">co-administered,</FONT> or favorable publicity about competitive products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to conduct our future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If
these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business
could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have the ability to independently conduct clinical trials. We expect to rely on medical institutions,
clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our Phase 1/2 clinical trial of TNG908 and any other product candidates that
emerge from our precision oncology programs. We may also rely on academic and private <FONT STYLE="white-space:nowrap">non-academic&nbsp;institutions</FONT> to conduct and sponsor clinical trials relating to our product candidates. We will not
control the design or conduct of the investigator-sponsored&nbsp;trials, and it is possible that the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will not view these investigator-sponsored&nbsp;trials as providing
adequate support for future clinical trials, whether controlled by us or third parties, for any number of reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored&nbsp;trials, including access to and the
ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored&nbsp;trials. However, we would not have control over the timing and reporting of the data from
investigator-sponsored&nbsp;trials, nor would we own the data from the investigator-sponsored&nbsp;trials. If we are unable to confirm or replicate the results from the investigator-sponsored&nbsp;trials or if negative results are obtained, we would
likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or
if the data proves to be inadequate compared to the first-hand&nbsp;knowledge we might have gained had the investigator-sponsored&nbsp;trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials
ourselves may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely and expect to continue to rely heavily on these parties for execution of clinical trials for our product
candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific
standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may
include civil penalties up to and including criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our principal investigators and our CROs are required to comply with regulations,
including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately
informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign
regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail
to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good
Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process,
significantly increase our expenditures and could also subject us to enforcement action. We also are required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored&nbsp;database, ClinicalTrials.gov, within certain timeframes. Failure to do so can
result in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we plan to design our Phase 1/2 clinical trial of TNG908 and intend to
design the future clinical trials for our product candidates, these trials are conducted by CROs and we expect CROs will conduct all of our future clinical trials. As a result, many important aspects of our development programs, including their
conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we
were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, fail to comply
with contractual obligations, experience regulatory compliance issues, undergo changes in priorities or become financially distressed or form relationships with other entities, some of which may be our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost
increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory
approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development program may be materially and irreversibly harmed. If we are unable
to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and
require significantly greater expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party&nbsp;principal investigators or CROs terminate, we may not
be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the
clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject
indication would be harmed, our costs could increase and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have entered into collaborations and
may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research,
development, commercialization and/or strategic collaborations, including the existing collaboration that we have with Gilead, are subject to numerous risks, which include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may have significant control or discretion in determining the efforts and resources that they will
apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have limited influence or control over the approaches to research, development and/or commercialization of
product candidates in the territories in which our collaboration partners lead research, development and/or commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not pursue research, development and/or commercialization of collaboration product candidates
or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus, availability of funding or other factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development
for collaboration product candidates or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit
sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not properly maintain or defend our intellectual property rights or might use our
intellectual property improperly or in a way that jeopardizes our intellectual property or exposes us to potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration activities might result in the collaborator having intellectual property covering our activities or
product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which
could impact the collaboration and us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes might arise between a collaborator and us that could cause a delay or termination of the collaboration
or result in costly litigation that diverts management attention and resources; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations might be terminated, which could result in a need for additional capital to pursue further
research, development and/or commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, funding provided by a collaborator might not be
sufficient to advance product candidates under the collaboration. For example, although Gilead provided us with $175.0&nbsp;million upfront payments and a $20.0&nbsp;million equity investment in connection with certain collaboration agreements with
Gilead, we might need additional funding to advance product candidates prior to the completion of the clinical milestones of the collaboration agreement with Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to exercise a license or other option under the
collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to either secure other funding to advance research,
development and/or commercialization of the relevant product candidate or abandon that program, the development of the relevant product candidate could be significantly delayed, and our cash expenditures could increase significantly if we are to
continue research, development and/or commercialization of the relevant product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any one or more of these risks, if realized, could reduce or
eliminate future revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of our product candidates for preclinical development and expect to continue to do so for clinical
testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our
development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own or operate, nor do we have any plans to establish in the future, any
manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of
our product candidates receive regulatory approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could
delay, prevent or impair our development or commercialization efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by
the FDA pursuant to <FONT STYLE="white-space:nowrap">pre-approval&nbsp;inspections</FONT> that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent
on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict
regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product
candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our
product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any contract manufacturing organization, or CMO, with whom we contract fails to perform its obligations, we may be
forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some
cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such
skills to a <FONT STYLE="white-space:nowrap">back-up&nbsp;or</FONT> alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO
maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product
candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize
our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a
license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies
between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our failure, or the failure of our third-party&nbsp;manufacturers, to comply with applicable regulations could result in sanctions being imposed on
us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal
prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to establish
any additional agreements with third-party&nbsp;manufacturers or do so on acceptable terms. Reliance on third-party&nbsp;manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that we may develop may compete with other product candidates and approved
products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development
or regulatory approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit
margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The third parties upon
whom we rely for the supply of the active pharmaceutical ingredients and drug product to be used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The active pharmaceutical ingredients, or API, and drug product we expect to use in all of our product candidates are supplied to us from
single-source&nbsp;suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API and drug
product for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We are also unable to predict how changing global economic conditions or potential global health concerns
such as the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic&nbsp;will</FONT> affect our third-party&nbsp;suppliers and manufacturers. Any negative impact of such matters on our third-party&nbsp;suppliers and manufacturers may also have an
adverse impact on our results of operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all of our product candidates, we intend to identify and qualify additional
manufacturers to provide such API and drug product prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source&nbsp;suppliers will be able to meet our demand for their products, either
because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in
the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Establishing additional or replacement suppliers for the API and drug product used in our product candidates, if required, may not be accomplished quickly. If
we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the
API and drug product used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API and drug product from alternate sources at acceptable prices in a timely manner could
impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have
to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our product
candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of
those product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s own evaluation of a potential
collaboration. Factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing
products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.
The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be restricted under
collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming&nbsp;to negotiate and document. In addition, there have been a significant number of recent
business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able
to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its
development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we
do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion
in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development
process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making&nbsp;authority.
Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business
reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of
the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be
impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the
United States and other countries for our current or future product candidates, including our current lead product candidate, TNG908, and our other future product candidates, as well as for their respective compositions, formulations, methods used
to manufacture them, and methods of treatment, in addition to successfully defending these patents against third-party&nbsp;challenges. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent
applications in the United States and abroad related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. Our ability to stop unauthorized third parties from making,
using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valid and enforceable patents or trade secrets that cover these activities. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation
to develop and maintain our proprietary and intellectual property position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally
is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our current or future product candidates may be
unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications that mature into issued
patents will include claims with a scope sufficient to protect TNG908 or our other current or future product candidates. In addition, if the breadth or strength of protection provided by our patent applications or any patents we may own or <FONT
STYLE="white-space:nowrap">in-license&nbsp;is</FONT> threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, in jurisdictions
outside the United States, a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported <FONT STYLE="white-space:nowrap">co-owner&nbsp;of</FONT> our patent
rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such <FONT STYLE="white-space:nowrap">co-ownership.</FONT> Furthermore, patents have a limited lifespan. In the
United States and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction&nbsp;basis;</FONT></FONT> however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or
<FONT STYLE="white-space:nowrap">in-license&nbsp;may</FONT> not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates,
including generic versions of such drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other parties have developed technologies that may be related or competitive to our own, and such parties may
have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds,
methods, formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the United States and other jurisdictions are typically not published until at least 18&nbsp;months after the earliest priority date of patent filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we
were the first to make the inventions claimed in patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;patents</FONT> or pending patent applications, or that we were the first to file for patent protection of such inventions. As a
result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the
patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent
applications covering our current or future product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may
be significantly narrowed by the time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some
circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications
may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we acquire patent protection that we expect
should enable us to establish and/or maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged
in the courts or patent offices in the United States and abroad. We may become involved in post-grant&nbsp;proceedings such as opposition, derivation, reexamination,<I></I><I>&nbsp;inter partes</I>&nbsp;review, post-grant&nbsp;review, or
interference proceedings challenging our patent rights or the patent rights of others from whom we may in the future obtain licenses to such rights, in the U.S. Patent and Trademark Office, or USPTO, the European Patent Office, or EPO, or in other
countries. In addition, we may be subject to a third-party&nbsp;submission to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from our pending patent applications. Competitors may allege that they
invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice our
technology as claimed under our patents or patent applications. Competitors may also contest our patents by claiming to an administrative patent authority or judge that the invention was not patent-eligible, was not original, was not novel, was
obvious, and/or lacked inventive step, and/or that the patent application filing failed to meet relevant requirements relating to description, basis, enablement, and/or support. In litigation, a competitor could claim that our patents, if issued,
are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent
applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary
<FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our
intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection
covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party&nbsp;patent rights. In
addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent
competitors from designing around our patent claims to circumvent patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;by</FONT> developing similar or alternative technologies or drugs in a
<FONT STYLE="white-space:nowrap">non-infringing&nbsp;manner.</FONT> For example, a third party&nbsp;may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different
composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to
impede such competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all
relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to
obtain, maintain, or enforce such patent claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for
patent protection on these inventions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The USPTO and foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be
paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to
official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment&nbsp;of</FONT> fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with
similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do
not obtain patent term extension for our product candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and
specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents or those of our future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of
1984 (Hatch-Waxman Amendments). The Hatch-Waxman&nbsp;Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may
be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product
approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our
product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.
Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors
may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing
our clinical and preclinical data and launch their product earlier than might otherwise be the case. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names for our
products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other
potentially adverse consequences to building our product brand recognition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, diluted,
circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may
be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable
agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable
agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Opposition or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. If we
are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> we seek to rely on trade secret protection,
confidentiality agreements, and license agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how&nbsp;that</FONT> may not be patentable, processes for which patents are difficult to enforce and any other elements of our product
discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that may not be covered by patents. Although we require all of our employees, consultants, advisors, and any
third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the
protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may
have or have had access to our trade secrets or proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, any of these parties might breach the agreements and intentionally or
inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant
problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or
maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is
unpredictable. If we choose to go to court to stop a third party&nbsp;from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to
protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain
access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or
information to compete with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential
information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific
circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In the case of employees, the agreements
provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are
our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our
own. The assignment of intellectual property rights may not be self-executing, or the assignment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our
intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be
expensive, time-consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe any patents we may own or
<FONT STYLE="white-space:nowrap">in-license.</FONT> In addition, any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;also</FONT> may become involved in inventorship, priority, validity or unenforceability disputes. To counter
infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be
commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;is</FONT> not valid or is unenforceable or that the other
party&#146;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35&nbsp;U.S.C. &#167; 271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to
stop the other party from using the technology at issue on the grounds that any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;do</FONT> not cover the technology in question or that such third party&#146;s activities do not
infringe our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or <FONT
STYLE="white-space:nowrap">in-license&nbsp;at</FONT> risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Such litigation or proceedings could substantially increase our
operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or
proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property
portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-grant&nbsp;proceedings provoked by third parties&nbsp;or brought by the USPTO may be necessary to determine the validity or priority of inventions with
respect to our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us
to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO
post-grant&nbsp;proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be
substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant&nbsp;challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our
inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant&nbsp;proceedings within patent offices may result in a decision adverse to our interests and, even if we are
successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect
those rights as fully as in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to detect infringement against any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> Even if we detect infringement
by a third party&nbsp;of any patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> we may choose not to pursue litigation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against or settlement with the third party. If we later sue such third party&nbsp;for patent infringement, the third party&nbsp;may have certain legal defenses available to it, which otherwise
would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or
<FONT STYLE="white-space:nowrap">in-license&nbsp;against</FONT> such third party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation and administrative patent office
patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and
could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or
investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for
development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter
into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third
parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former
employees, contractors or consultants. In addition to diverting attention and resources to such disputes, such disputes could adversely impact our business reputation and/or protection of our proprietary technology. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intellectual property landscape relevant to our product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that
we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our
ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a
substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference,
reexamination,<I></I><I>&nbsp;inter partes</I>&nbsp;review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic
partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary
technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future product candidates and other technologies that we have developed, are developing or may develop in the
future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. For example, many of our employees were previously employed at other biotechnology or
pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how&nbsp;of</FONT> others in their work for us, we may be subject to
claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual&#146;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those
related to one or more of our current or future product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While certain activities related to development and clinical testing of our current or future product candidates may be subject to safe harbor of patent
infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or
litigation by third parties having patent or other intellectual property rights alleging that such product candidates infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and
pending patent applications, which are owned by third parties, exist in the fields in which we are developing our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk
increases that our current or future product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs,
products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or
future product candidates, technologies or methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual
property rights, we may face a number of issues, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be
expensive and time-consuming&nbsp;to litigate and may divert our management&#146;s attention from our core business and may impact our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court
decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#146;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent
owner&#146;s attorneys&#146; fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a court prohibiting us from developing, manufacturing, marketing or selling our current product candidate,
including TNG908, or future product candidates, or from using our proprietary technologies, unless the third party&nbsp;licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other
amounts, and/or grant cross-licenses&nbsp;to intellectual property rights for our products, or the license to us may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which would permit third parties to use the same intellectual property to
compete with us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or
violate third-party&nbsp;intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there could be public announcements of the results of hearings, motions or other interim proceedings or
developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise
the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect
on our business, financial condition, results of operations or prospects. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may choose to challenge the patentability of claims in a third party&#146;s U.S. patent by requesting
that the USPTO review the patent claims in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ex-parte&nbsp;re-exam,</FONT></FONT><I></I><I>&nbsp;inter partes</I>&nbsp;review or post-grant&nbsp;review proceedings. These proceedings
are expensive and may consume our time or other resources. We may choose to challenge a third party&#146;s patent in patent opposition proceedings in the EPO or other foreign patent office. The costs of these opposition proceedings could be
substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party&nbsp;alleging that the patent may be infringed by our
current or future product candidates or proprietary technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without
authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#147;clear and convincing,&#148; a heightened standard of proof. There may be issued
third-party&nbsp;patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications
can take many years to issue. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not
published until 18&nbsp;months after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or
future product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> we may be required
to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a <FONT STYLE="white-space:nowrap">non-exclusive&nbsp;basis.</FONT> There may be currently
pending third-party&nbsp;patent applications which may later result in issued patents that our current or future product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not
believe are relevant to our current or future product candidates or other technologies, could be found to be infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and
claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any
third-party&nbsp;patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the
holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or
unenforceable. Similarly, if any third-party&nbsp;patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods,
the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either
case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party&nbsp;patent on commercially reasonable terms, or at all, our ability to commercialize our current
or future product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and
commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay
royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially
reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties to advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if
at all. In that event, we would be unable to further develop and commercialize our current or future product candidates, which could harm our business significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain patent or other intellectual property protection for our current or future product candidates or our future products, if any,
in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to pursue patent coverage of our current or future product candidates in all countries. Filing, prosecuting and defending patents on current
or future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the
laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our current or
future product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Much of our patent portfolio is
at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult
for us to stop the infringement of any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;or</FONT> marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have
in our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;in</FONT> foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put any patents we may own or <FONT STYLE="white-space:nowrap">in-license&nbsp;at</FONT> risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under
which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited
remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired,
and our business, financial condition, results of operations, and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not obtain or grant licenses or
sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be necessary for
us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party&nbsp;intellectual property rights is a
competitive area, and more established companies may pursue strategies to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
license or acquire third-party&nbsp;intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their
size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire
third-party&nbsp;intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms,
our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties
owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may
be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third
parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time be party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or
future product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us
and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we
have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and
could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease
our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related&nbsp;issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property rights of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our current or future product candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of any patented technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how&nbsp;resulting</FONT> from the joint
creation or use of intellectual property by our future licensors and us and our partners. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we may license intellectual property or technology from third
parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our
rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition,
results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and
commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any granted patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> covering our current or future product candidates or other valuable
technology could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO and the EPO. A patent asserted in a judicial court could be found invalid or
unenforceable during the enforcement proceeding. Administrative or judicial proceedings challenging the validity of our patents or individual patent claims could take months or years to resolve. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors or strategic partners initiate legal proceedings against a third party&nbsp;to enforce a patent covering one of our current or future
product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace, and there are numerous grounds upon which a third party&nbsp;can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that
someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, in the process of obtaining the patent during patent prosecution. Third parties may also raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT><I></I><I>&nbsp;inter partes</I>&nbsp;review, post grant review and
equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or
<FONT STYLE="white-space:nowrap">in-license&nbsp;in</FONT> such a way that they no longer cover our current or future product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we may own or
<FONT STYLE="white-space:nowrap">in-license,</FONT> allow third parties to commercialize our current or future product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or
commercialize products without infringing third-party&nbsp;patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant&nbsp;challenge proceedings, such as
oppositions in a foreign patent office, that challenge our or our future licensors&#146; priority of invention or other features of patentability with respect to our patent applications and any patents we may own or
<FONT STYLE="white-space:nowrap">in-license.</FONT> Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from
using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current or future product candidates and other technologies. With respect to the validity question, for example, we cannot
be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or
if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could have a material adverse impact on
our business and our ability to commercialize or license our technology and current or future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such proceedings also may result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved
in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to
obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the current or future product candidates we may develop. The loss of exclusivity or the narrowing of our patent application
claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the United States and
other countries, including the Leahy-Smith&nbsp;America Invents Act, or Leahy-Smith&nbsp;Act, signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs. The Leahy-Smith&nbsp;Act includes a number of significant changes
to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective&nbsp;avenues for competitors to challenge the validity of patents. These include
allowing third-party&nbsp;submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant&nbsp;proceedings, including post-grant&nbsp;review, <I>inter
partes</I>&nbsp;review, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.
Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United&nbsp;States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding
sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to
invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, the Leahy-Smith&nbsp;Act has transformed the U.S. patent system into a &#147;first inventor to file&#148; system. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file&nbsp;provisions,</FONT></FONT>
however, only became effective on March&nbsp;16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith&nbsp;Act will have on the operation of our business. However, the Leahy-Smith&nbsp;Act and its implementation could make it
more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business,
results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of
patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries
that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant
<FONT STYLE="white-space:nowrap">law-making&nbsp;bodies</FONT> in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents
and patents that we might obtain in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our or our licensors&#146; patent searches or analyses, including the identification of relevant patents, the scope of patent
claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party&nbsp;patent and pending patent application in the United States and abroad that is relevant to or
necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S. patent applications filed before November&nbsp;29, 2000 and certain U.S. patent applications filed after that date that will not
be filed outside the United States remain confidential until patents issue. As mentioned above, patent applications in the United States and elsewhere are published approximately 18&nbsp;months after the earliest filing for which priority is
claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or future product candidates could have been filed by third parties without our knowledge. Additionally,
identification of third-party&nbsp;patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to, for example, differences in terminology among patents or incomplete databases. Additionally, pending
patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future product candidates or the use of our current or future product candidates. The scope of a patent
claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may
negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future product candidates are not covered by a third-party&nbsp;patent or may incorrectly predict whether a third
party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to
develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to
successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our
current or future product candidates that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no longer infringe the third-party&nbsp;intellectual property rights. Any of these
events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not guarantee commercial success of current or future product candidates or other
business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of
future protection afforded by our intellectual property rights, whether owned or <FONT STYLE="white-space:nowrap">in-licensed,</FONT> is uncertain because intellectual property rights have limitations, and may not adequately protect our business,
provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party&nbsp;has intellectual property rights that cover the practice of our technology, we may not
be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications that we own or may <FONT STYLE="white-space:nowrap">in-license&nbsp;may</FONT> not lead to
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents, should they issue, that we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> may not
provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical
compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> should
any patents issue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a
patent application that we own or may <FONT STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors or collaborators, might not have been the first to file patent applications covering
a particular invention; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies without infringing, misappropriating or
otherwise violating our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other countries that
provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive
products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may
preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party&nbsp;may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop or <FONT STYLE="white-space:nowrap">in-license&nbsp;additional</FONT> proprietary technologies
that are patentable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United&nbsp;States have requirements for
approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs
for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable regulatory approvals, our target market will be reduced
and our ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our
product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative
effect on the regulatory approval process in others. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and
promotion of the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the
United&nbsp;States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process
involves all of the risks associated with FDA approval. In many jurisdictions outside the United&nbsp;States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price
that we may intend to charge for our products will also be subject to approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek priority review designation for one or more of our
other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement
in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.
We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such
designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval
compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT STYLE="white-space:nowrap">six-month&nbsp;review</FONT> cycle or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits
associated with orphan drug designation, including the potential for market exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we may seek orphan drug
designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United&nbsp;States and Europe, may designate drugs for relatively small patient populations as orphan drugs.
Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the
United&nbsp;States, or a patient population of 200,000 or more in the United&nbsp;States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United&nbsp;States. In the
United&nbsp;States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee&nbsp;waivers.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, in Europe, the European Commission, upon the recommendation of the EMA&#146;s Committee for Orphan Medicinal Products, grants orphan drug
designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening&nbsp;or chronically debilitating conditions affecting not more than five in 10,000 persons in Europe and for which no
satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of
a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe,
orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if a product with an orphan drug
designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing
application for the same product and indication for that time period, except in limited circumstances. The applicable period is seven years in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United&nbsp;States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is
sufficiently profitable so that market exclusivity is no longer justified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for one of our product candidates,
that exclusivity may not effectively protect our product candidate from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the
same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug
exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United&nbsp;States may be lost if the FDA later determines that the request
for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another product with the same active moiety is determined
to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or
approval process. While we may seek orphan drug designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a
faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United&nbsp;States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended,
alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening&nbsp;disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and
communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough
therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for
designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process,
review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the
FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek fast track designation for some of our product candidates. If a drug is intended for the treatment of a serious or life-threatening&nbsp;condition
and the drug demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular
product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to
conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the
FDA&#146;s priority review procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated approval by the FDA, even if granted for our current or any other future product
candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive&nbsp;regulatory&nbsp;approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek accelerated approval of our current or future product candidates using the FDA&#146;s accelerated approval pathway. A product may be eligible for
accelerated approval if it treats a serious or life-threatening&nbsp;condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA
requires that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled&nbsp;post-marketing&nbsp;clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires
as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval&nbsp;of</FONT> promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval,
we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our
product candidates, and such changes can be difficult to predict. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA, the EMA and regulatory authorities in other countries have each
expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United&nbsp;States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed
interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or
other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process,
require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant
post-approval&nbsp;limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to
delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory
approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner,
if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to
these agencies&#146; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of
the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy
changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, government funding of the SEC and other government agencies on which our operations may rely,
including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and
other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse
effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, since March 2020 when foreign and domestic inspections were largely placed on hold due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. The FDA has developed a rating system to assist in determining
when and where it is safest to conduct prioritized domestic inspections and resumed inspections in China and India in early 2021. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations,
using risk management methods, to meet user fee commitments and goal dates. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the
FDA does not determine a remote interactive evaluation to be appropriate, the agency has stated that it generally intends to issue a complete response letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an
inspection can be completed. Additionally, as of March&nbsp;18, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its
user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with the FDA quality standards. However, the FDA may not be able to continue its current pace and approval
timelines could be extended, including where a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is required and due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel
restrictions FDA is unable to complete such required inspections during the review period. In 2020, several companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their
applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other
regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future
government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to
be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative
initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changed the way health care is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, addressed a new methodology by which rebates owed
by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and
extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in
which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. There have been many legal challenges to the ACA as well as
legislative and regulatory modifications. There are also other initiatives at the federal and state level intended to contain healthcare costs by requiring manufacturers to provide greater discounts or by limiting the amount of government
reimbursement for pharmaceutical products. We expect these changes to continue between now and the time we may launch a commercial product with uncertain consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June&nbsp;17,
2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision on January&nbsp;28, 2021,
President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&nbsp;15, 2021 and remained open through August&nbsp;15,
2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver
programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In December 2018, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of the federal district court litigation
regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. We cannot predict what effect the healthcare reform measures of the Biden administration or
other efforts, if any, to challenge, repeal or replace the ACA would have on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in
the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted
deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of
Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic
Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Proposed
legislation, if passed, would extend this suspension until the end of the pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, increasing efforts by governmental and third-party payors
in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our
product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on
prices that drug manufacturers can charge for medications sold to certain health care facilities. On December&nbsp;27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing
program, and CMS subsequently altered the Fiscal Years 2019 and 2018 reimbursement formula on specified covered outpatient drugs, or SCODs. The court ruled this change was not an &#147;adjustment&#148; which was within the Secretary&#146;s
discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July&nbsp;31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#146;s decision and
found that the changes were within the Secretary&#146;s authority. On September&nbsp;14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October&nbsp;16, 2020. It is unclear how
these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals,
executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, former President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the
administration&#146;s proposals. In response, the FDA released a final rule on September&nbsp;24, 2020, which went into effect on November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada.
Further, on November&nbsp;20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price
drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S.
states and territories for a seven-year period beginning January&nbsp;1, 2021 and ending December&nbsp;31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November&nbsp;20, 2020, DHHS
finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The
rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy
benefit managers and manufacturers. Implementation of the amendments to the discount safe harbor have been delayed until at least January&nbsp;1, 2023. Although a number of these and other proposed measures may require authorization through
additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition,
individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control biopharmaceutical and biologic product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional
reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or
used. Additionally, we expect to experience pricing pressures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment
initiatives and additional legislative changes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third-party payors will be subject to applicable
anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and
future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be
subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party&nbsp;payors
play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party&nbsp;payors and customers may expose us to broadly applicable fraud and abuse and
other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain regulatory approval. Restrictions under
applicable federal and state healthcare laws and regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback&nbsp;Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment
may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are
subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment of up to ten years, and exclusion from government healthcare programs. The Anti-Kickback&nbsp;Statute has been
interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some
common activities from prosecution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims
Act, or FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment
that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government
payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback&nbsp;Statute
constitutes a false of fraudulent claim for purposes of the FCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for executing a scheme to defraud any healthcare benefit program (e.g. public or private), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with
the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback&nbsp;Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have
committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Sunshine Act&#148;
under the ACA, which require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to HHS information related to transfers of value
made to physicians (currently defined to include doctors, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective
January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made to certain <FONT STYLE="white-space:nowrap">non-physician&nbsp;providers</FONT> such as physician assistants and nurse practitioners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure
of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the
federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to
government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, such as state anti-kickback&nbsp;and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental&nbsp;third-party&nbsp;payors,</FONT> including private insurers. Some state laws require pharmaceutical
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to
payments to physicians and other health care providers or marketing expenditures. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our future business arrangements with third parties comply
with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment
or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions,
including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations,
we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of
hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot
eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the
use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage
or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any of our product candidates, we will be
subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and
labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging,
distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing&nbsp;information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for
our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing&nbsp;studies, including
Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with our third-party&nbsp;manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance
requiring remediation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings,
contraindications or other safety information, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a REMS which may include distribution or use restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct additional post-market&nbsp;clinical trials to assess the safety of the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial holds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or other regulatory enforcement action; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to
additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection
Regulation, or GDPR. The GDPR is wide-ranging&nbsp;in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the
individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches,
and taking certain measures when engaging third-party&nbsp;processors. Compliance with the GDPR will be a rigorous and time-intensive&nbsp;process that may increase our cost of doing business or require us to change our business practices, and
despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain
products outside of the United&nbsp;States and require us to develop and implement costly compliance programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we expand our operations outside
of the United&nbsp;States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business
from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist
the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United&nbsp;States to comply with certain accounting provisions requiring the company to maintain books and records
that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents
particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with
clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various laws,
regulations and executive orders also restrict the use and dissemination outside of the United&nbsp;States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security
purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United&nbsp;States, it will require us to dedicate additional resources to comply with these laws, and these laws may
preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United&nbsp;States, which could limit our growth potential and increase our development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment
from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on many of our key employees and members of our executive management team as well as the other principal members of our
management, scientific and clinical team. Although we have entered into employment letter agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#147;key person&#148;
insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high
quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and
sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to
hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, we have experienced a very competitive hiring environment in Cambridge, Massachusetts, where we are headquartered. Many of the other
pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better
chances for career advancement. Some of these characteristics may be more appealing to high-quality&nbsp;candidates than what we have to offer. If we are unable to continue to attract and retain high-quality&nbsp;personnel, the rate and success with
which we can discover and develop product candidates and our business will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to adequately protect our information
systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on information technology systems that we or our third-party&nbsp;providers operate to process, transmit and store electronic information in our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day&nbsp;operations.</FONT></FONT> In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email
addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary
information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments,
industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">malware,&nbsp;denial-of-service,&nbsp;social</FONT></FONT> engineering fraud or other means
to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential
business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material
adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#146; personal data could result in significant
liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g., the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies
and potentially disrupt our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on our third-party&nbsp;providers to implement effective security measures and identify and correct for any
such failures, deficiencies or breaches. If we or our third-party&nbsp;providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our
information technology systems, we or our third-party&nbsp;providers could have difficulty preventing, detecting and controlling such cyber-attacks&nbsp;and any such attacks could result in the losses described above as well as disputes with
physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of
operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are
unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California
Consumer Privacy Act, or CCPA, which went into effect on January&nbsp;1, 2020, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA
provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have
been proposed at the federal level and in other states. By way of example regarding foreign laws and regulations with respect to data privacy and security, the GDPR went into effect in the European Union in May&nbsp;2018 and introduces strict
requirements for processing the personal data of EU data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential
fines for noncompliance of up to &#128;20&nbsp;million or 4% of the annual global revenue of the noncompliant company, whichever is greater. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or
third-party&nbsp;CMOs, CROs or other contractors or consultants fail to comply with U.S. and international data protection laws and regulations, it could result in government enforcement actions (which could include civil or criminal penalties),
private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this
information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if
we are not found liable, could be expensive and time-consuming&nbsp;to defend and could result in adverse publicity that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2021, we had 86
full-time&nbsp;employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if
any of our product candidates receives regulatory approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our
facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances or create joint ventures with
third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully
integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from
realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive
officers, directors, principal stockholders and their affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our common stock outstanding as of August&nbsp;31, 2021, our executive officers, directors and their affiliates and our principal stockholders
beneficially held, in the aggregate, approximately 40% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would
be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. These stockholders may have interests, with respect to their
common stock, that are different from those of other investors and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely
affect the market price of our common stock by delaying, deferring or preventing a change of control of us, impeding a merger, consolidation, takeover or other business combination involving us or discouraging a potential acquirer from making a
tender offer or otherwise attempting to obtain control of us. See &#147;<I>Security Ownership Of Certain Beneficial Owners and Management</I>&#148; for more information regarding the ownership of our outstanding common stock by our executive
officers, directors, principal stockholders and their affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax
attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Sections&nbsp;382 and 383 of the Internal Revenue Code, as amended, or the Code, if a corporation undergoes an
&#147;ownership change&#148; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity over a three-year&nbsp;period), the corporation&#146;s ability to use its
<FONT STYLE="white-space:nowrap">pre-change&nbsp;net</FONT> operating loss carryforwards and certain other <FONT STYLE="white-space:nowrap">pre-change&nbsp;tax</FONT> attributes to offset its post-change&nbsp;income may be limited. We have
experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. As of December&nbsp;31, 2020, we had federal net operating
loss carryforwards of approximately $41.0&nbsp;million, and our ability to utilize those net operating loss carryforwards could be limited by an &#147;ownership change&#148; as described above, which could result in increased tax liability to us. We
have not yet conducted a study to assess whether a change of control has occurred as a result of the Business Combination. A study will be conducted in the near term. If we experience a change of control, as defined by Section&nbsp;382 of the Code,
as a result of the Business Combination or otherwise, utilization of net operating loss carryforwards or research and development tax credit carryforwards could be subject to an annual limitation under Sections 382 and 383 of the Code, as
applicable. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Moreover, our ability to utilize our net operating loss carryforwards
or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in our financial statements could be limited
and may expire unutilized. Federal net operating loss carryforwards generated in taxable years beginning after December&nbsp;31, 2017 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our
annual taxable income in taxable years beginning after December&nbsp;31, 2020. There is also a risk that due to regulatory changes, such as suspensions on the use of net operating loss carryforwards or other unforeseen reasons, our existing net
operating loss carryforwards could expire or otherwise be unavailable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to offset future income tax liabilities, including for state tax purposes. In future years, if and when a net deferred tax asset is recognized related to our net operating loss carryforwards, the
changes in the carryforward/carryback periods as well as the new limitation on use of net operating loss carryforwards may significantly impact our valuation allowance assessments for net operating loss carryforwards generated after
December&nbsp;31, 2017. For these reasons, we may not be able to utilize some portion of our net operating loss carryforwards, none of which are currently reflected on our balance sheet, even if we attain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and
bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a board of directors divided into three classes serving staggered three-year&nbsp;terms, such that not all
members of the board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken
at a meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that special meetings of the stockholders may be called only by the board of directors acting
pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for
cause and then, in addition to any other vote required by law, only upon the approval of not less than 66&nbsp;2/3% of all outstanding shares of our capital stock then entitled to vote in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supermajority voting requirements to amend our bylaws by stockholder action (unless our board recommends that our
stockholders approve such amendment(s)) and to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors
without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
anti-takeover&nbsp;provisions and other provisions in our certificate of incorporation and bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed
by the then-current&nbsp;board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders
to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our bylaws&nbsp;designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could
limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our bylaws, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any
action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (iii)&nbsp;any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, or the DGCL, or our certificate of incorporation or bylaws (including the
interpretation, validity or enforceability thereof), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. We refer to the foregoing provision in this prospectus as the Delaware Forum Provision. The Delaware Forum
Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United&nbsp;States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We refer to such provision in this prospectus as the Federal Forum Provision. Our bylaws provide that
any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot
and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware Forum
Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#146; ability to bring a claim in a
judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might
benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March&nbsp;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#147;facially valid&#148;
under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The
Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United&nbsp;States
may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us
than our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other
trade laws and regulations. We can face serious consequences for violations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other matters, U.S. and foreign anti-corruption,
anti-money&nbsp;laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel,
accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public
or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other
consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated&nbsp;hospitals, universities, and other organizations. We also expect our
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be
held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that
our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized
activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such authorities; healthcare fraud and abuse laws and regulations in the United&nbsp;States and abroad; or laws that require the reporting of financial information or data accurately. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing&nbsp;and other abusive practices. These laws and
regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of
information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We intend to adopt, prior to the
completion of the Business Combination, a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we
are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could
have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if
any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain
for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for
purchasers of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general, and the market for biopharmaceutical
companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock. The market price for our
common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advancement of our preclinical programs, such as our targeted oncology programs, into clinical testing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials of our product candidates or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United&nbsp;States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our programs and product candidates or preclinical and clinical
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or
<FONT STYLE="white-space:nowrap">in-license&nbsp;additional</FONT> product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;<I>Risk Factors</I>&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur
significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley&nbsp;Act and rules subsequently implemented by the SEC and the Nasdaq Stock Market, or Nasdaq, have imposed various
requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these
compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming&nbsp;and costly. For example, we expect that these rules and regulations may make
it more difficult and more expensive for us to obtain director and officer liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act,
we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.
However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with
Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered
public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to
a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that
information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We
believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived&nbsp;and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These
inherent limitations include the realities that judgments in decision-making&nbsp;can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by
collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business or if they publish
negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research
and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable
evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to publish reports covering our company regularly, we could lose visibility in the market for our stock,
which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to
securities class&nbsp;action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#146;s attention from other business concerns, which
could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax regimes we are subject to or operate under are unsettled and may be subject to significant change. Changes in tax laws (including in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or tax rulings, or changes in interpretations of existing laws, could cause us to be subject to additional income-based taxes and <FONT STYLE="white-space:nowrap">non-</FONT> income taxes (such as
payroll, sales, use, value-added, digital tax, net worth, property, and goods and services taxes), which in turn could materially affect our financial position and results of operations. Additionally, new, changed, modified, or newly interpreted or
applied tax laws could increase our customers&#146; and our compliance, operating and other costs, as well as the costs of our products, if approved. As we expand the scale of our business activities, any changes in the U.S. taxation of such
activities may increase our effective tax rate and harm our business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic
conditions could adversely affect our business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely
affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> has caused significant volatility and uncertainty in U.S. and international markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including,
weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our
customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not be sustained, and you may not be able to resell your shares at the price you paid.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our common stock is listed on the Nasdaq Capital Market, an active trading market for our shares may not be sustained. In the absence of
an active trading market for our common stock, investors may be unable to sell their shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the shares of Common Stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their
respective accounts. We will not receive any of the proceeds from these sales. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We have never declared or paid
any cash dividends on our capital stock. We do not intend to pay cash dividends on our common stock in the foreseeable future. Investors should not purchase our common stock with the expectation of receiving cash dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating
results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_9">
</A>DETERMINATION OF OFFERING PRICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which the shares of Common Stock may be sold by the Selling
Securityholders under this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_10"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet of New Tango as of June&nbsp;30, 2021 and the unaudited pro forma condensed
combined statements of operations of New Tango for six months ended June&nbsp;30, 2021 and for the year ended December&nbsp;31, 2020 present the combination of the financial information of BCTG and Tango, after giving effect to the Business
Combination, PIPE Financing and related adjustments described in the accompanying notes. BCTG and Tango are collectively referred to herein as the &#147;Companies,&#148; and the Companies, subsequent to the Business Combination and the PIPE
Financing, are referred to herein as New Tango. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined statements of operations for the six months ended
June&nbsp;30, 2021 and the year ended December&nbsp;31,&nbsp;2020 give pro forma effect to the Business Combination and PIPE Financing as if they had occurred on January&nbsp;1, 2021. The unaudited pro forma condensed combined balance sheet as of
June&nbsp;30, 2021 gives pro forma effect to the Business Combination and PIPE Financing as if they were completed on June&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited
pro forma condensed combined financial information is based on and should be read in conjunction with the accompanying notes to the unaudited pro forma condensed combined financial information, the audited and unaudited historical financial
statements of each of BCTG and Tango and the notes thereto, and the disclosures contained in this prospectus in the section titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and do not necessarily reflect what New
Tango&#146;s financial condition or results of operations would have been had the Business Combination and PIPE Financing occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial information also may not be
useful in predicting the future financial condition and results of operations of New Tango. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The
unaudited pro forma adjustments represent management&#146;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes
available and analyses are performed. We believe that our assumptions and methodologies provide a reasonable basis for presenting all the significant effects of the transactions based on information available to management at this time and that the
transaction accounting adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined information contained herein incorporates the results of BCTG&#146;s public stockholders having elected to redeem
their shares of BCTG common stock for cash upon the approval of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF JUNE&nbsp;30, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(A)<BR>Tango<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(B)<BR>BCTG<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PIPE<BR>Transaction<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and investments held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series&nbsp;A, B, and
<FONT STYLE="white-space:nowrap">B-1)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(156,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; equity
(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma notes </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed consolidated balance sheet of Tango as of June&nbsp;30, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed consolidated balance sheet of BCTG as of June&nbsp;30, 2021.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited pro forma condensed combined financial information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE SIX MONTHS ENDED JUNE&nbsp;30, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(A)<BR>Tango<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(B)<BR>BCTG<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(a)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(b)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,214,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, or Founder Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Founder Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma notes </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of Tango for
the six months ended June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed consolidated statement of operations of BCTG for the six months ended
June&nbsp;30, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited pro forma condensed combined financial information.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(A)<BR>Tango<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(B)<BR>BCTG<BR>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(a)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(a)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(b)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(b)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,461,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, or Founder Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,212,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Founder Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.60)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4(c)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma notes </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the audited consolidated statement of operations and comprehensive loss of Tango for the year
ended December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the audited statement of operations of BCTG for the period from inception through
December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited pro forma condensed combined financial information.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#151; Description of the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
August&nbsp;10, 2021, Tango consummated the Business Combination pursuant to the Merger Agreement. Upon the closing of the Business Combination, Merger Sub merged with and into Tango, with Tango as the surviving company in the Merger. Upon the
closing of the Business Combination, BCTG changed its name to &#147;Tango Therapeutics, Inc.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and conditions of the Merger
Agreement, the aggregate consideration paid to Tango equity holders upon the closing of the Merger was 55,000,000 shares of New Tango common stock. Subsequent to the closing of the Business Combination, BCTG consummated the private placement of
18,610,000 shares of New Tango common stock at $10.00 per share, for aggregate gross proceeds of $186.1&nbsp;million, under the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following represents the aggregate merger consideration paid to Tango equity holders upon the consummation of the Business Combination: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B></B><I>(in thousands, except share and per share amounts)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchase<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share consideration to Tango(a)(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of common stock issued to Tango included in the consideration is reflected at $10.00 per share as
defined in the Merger Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total 55,000,0000 consideration shares to be issued for all outstanding Tango common and preferred stock
includes underlying unvested and/or unexercised stock options of 6,406,197 and excludes unissued options of 1,191,103. These amounts are based on Tango&#146;s outstanding shares as of June&nbsp;30, 2021 and the exchange ratio of 0.340 at the
effective time of the Business Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the effective time of the Business Combination, the conversion ratio was 0.340. The
closing conversion ratio was calculated in accordance with the methodology and procedures set forth in the Merger Agreement, and was announced by BCTG through a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing with the SEC
four business days prior to the special meeting of BCTG&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the unaudited pro forma common stock outstanding
immediately after giving effect to the consummation of the Business Combination and PIPE Financing transactions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,635,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less redemption of BCTG redeemable shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG Sponsor and Directors and advisors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total BCTG</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,231,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tango(A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,593,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Shares Outstanding (excluding certain Tango shares)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tango-Remaining Consideration Shares(A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,406,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Shares (including certain Tango shares)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,841,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total consideration issued to Tango was $550.0&nbsp;million or 55,000,000 shares ($10 per share price). The
total shares issued included Tango common and preferred stock plus shares underlying unvested stock options. Accordingly, the consideration shares outstanding at the closing of the Business Combination was adjusted to exclude the portion of
consideration shares that remained unvested and/or unexercised at the closing of the Business Combination. The Tango-Remaining Consideration Shares reflect a conversion ratio of 0.340. Tango shares are presented as of June&nbsp;30,&nbsp;2021.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#151; Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information was prepared in accordance with Article 11 of SEC Regulation
<FONT STYLE="white-space:nowrap">S-X</FONT> as amended by the final rule, Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786</FONT> &#147;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#148; The historical
financial information of BCTG and Tango has been adjusted to give effect to the transaction accounting adjustments of the Business Combination and the PIPE Financing and certain other adjustments to provide relevant information necessary for an
understanding of the combined company upon consummation of the transactions described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is being accounted for as a
reverse recapitalization because Tango has been determined to be the accounting acquirer under Financial Accounting Standards Board&#146;s Accounting Standards Codification Topic 805,<I> Business Combinations</I> (&#147;ASC 805&#148;). The
determination is primarily based on the evaluation of the following facts and circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">pre-combination</FONT> equity holders of Tango holding the majority of
voting rights in New Tango; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">pre-combination</FONT> equity holders of Tango having the right to appoint
the majority of the directors on New Tango&#146;s board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior management of Tango comprising the senior management of New Tango; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Operations of Tango comprising the ongoing operations of New Tango. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the reverse recapitalization accounting model, the Business Combination is being treated as Tango issuing stock for the net assets of BCTG, with no
goodwill or intangible assets recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information reflects all BCTG&#146;s public stockholders
that exercised redemption rights with respect to their public shares. A total of 1,106,814 shares were redeemed for an aggregate redemption value of approximately $11.1&nbsp;million. The resulting redemption scenario still provided BCTG with cash at
closing of the Business Combination of greater than the minimum requirement of $300.0&nbsp;million pursuant to the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Tango expects to
enter into new equity awards with its employees after the consummation of the Business Combination. The terms of these new equity awards have not been finalized and remain subject to change. Accordingly, no effect has been given in the unaudited pro
forma condensed combined financial information for the new awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not reflect the
income tax effects of the transaction accounting adjustments as any change in the deferred tax balance would be offset by an increase in the valuation allowance given Tango incurred significant losses during the historical period presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Transaction Accounting Adjustments to the Unaudited Pro Forma Condensed Combined Balance
Sheet as of June&nbsp;30, 2021 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of
June&nbsp;30, 2021 are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma transaction accounting adjustments </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the impact of the Business Combination on the cash balance of the Combined Entity. The table below
represents the sources and uses of funds as it relates to the Business Combination: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(in thousands)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma<BR>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG cash held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment to redeeming BCTG Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of other Business Combination transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Excess cash to balance sheet from Business Combination</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE&#151;BCTG Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE&#151;Tango Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other PIPE Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of PIPE Financing transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Excess cash to balance sheet from PIPE transaction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total excess cash to balance sheet from Business Combination and PIPE Financing</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount of the restricted investments and cash held in the trust account upon consummation of the
Business Combination at closing of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of the redemption value for the 1,106,814 shares of restricted investments that were
redeemed by BCTG stockholders from the trust account prior to the consummation of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of the estimated Business Combination transaction costs of $9.2&nbsp;million. The unaudited
pro forma condensed combined balance sheet reflects these costs as a reduction of cash, with a corresponding decrease in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. As of June&nbsp;30, 2021, $2.0&nbsp;million in transaction
costs have been incurred, of which $0.6&nbsp;million remains unpaid. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the issuance, from the PIPE Financing, to certain investors of 18,610,000 shares of New Tango common
stock at a price of $10.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of the estimated PIPE Financing transaction costs of $7.0&nbsp;million. As of June&nbsp;30,
2021, no PIPE Financing transaction costs had been incurred or paid. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents release of the restricted investments and cash held in the BCTG trust account upon consummation of
the Business Combination (See Note 3(a)(1)). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reclass less than $0.1&nbsp;million of historical BCTG franchise tax payable and accrued income tax to the
accrued expenses and other current liabilities account of New Tango. Also reflective of the $0.6&nbsp;million decrease of accrued transaction expenses with a corresponding decrease to additional paid in capital. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following table represents the impact of the Business Combination and PIPE Financing on the number of
shares of BCTG common stock and represents the total stockholders&#146; deficit after giving effect to all redemptions by BCTG stockholders: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(in thousands)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of historical redeemable stock of BCTG to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment to redeeming BCTG Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value of consideration shares issued for all outstanding Tango common and preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical redeemable convertible preferred stock of Tango</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical accumulated deficit of BCTG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical deferred IPO costs of BCTG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of other Business Combination transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital
adjustment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the recapitalization of BCTG through the contribution of all historically outstanding common stock
subject to redemption of BCTG to Tango and the issuance of 15,712,245 shares of Tango common stock to BCTG stockholders. The unaudited pro forma condensed combined balance sheet reflects the adjustment as a reclassification to additional paid in
capital and the difference to common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of the redemption value for the 1,106,814 shares of restricted investments that were
redeemed by preferred shareholders from the trust account prior to the consummation of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the $0.001 par value impact on additional paid in capital pursuant to the 55,000,0000 consideration
shares issued for all outstanding Tango common and preferred stock and includes underlying unvested and/or unexercised stock options of 6,406,197 and excludes unissued options of 1,191,103. These amounts are based on Tango&#146;s outstanding shares
as of June&nbsp;30, 2021 and the exchange ratio of 0.340 at the effective time of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the automatic conversion of all outstanding shares of Tango redeemable convertible preferred stock
immediately prior to the effective time of the Business Combination. The adjustment reflects the derecognition of the carrying value of the Tango redeemable convertible preferred stock of $166.5&nbsp;million. The unaudited pro forma condensed
combined balance sheet reflects the adjustment as a reclassification to additional paid in capital and the difference to common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the elimination of the accumulated deficit of BCTG. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the settlement of $5.8&nbsp;million of deferred underwriting commissions incurred during BCTG&#146;s
initial public offering that were contractually due upon completion of the Business Combination as Business Combination transaction costs are shown gross within note (7)&nbsp;below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of the estimated Business Combination transaction costs of $9.2&nbsp;million. The unaudited
pro forma condensed combined balance sheet reflects these costs as a reduction of cash, with a corresponding decrease in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. As of June&nbsp;30, 2021, $0.6&nbsp;million in transaction
costs had been incurred and remained unpaid. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Transaction Accounting Adjustments to the Unaudited Pro Forma Condensed Combined Statement
of Operations for the Six Months Ended June&nbsp;30, 2021 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed
combined statement of operations for the six months ended June&nbsp;30, 2021 are as follows:<I> </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma transaction accounting adjustments
</I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reclass historical BCTG franchise tax expense to general and administrative expenses of New Tango.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To eliminate interest earned on the Trust Account which was released upon closing of the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Presentation of the pro forma basic and diluted net loss per share amounts. See Note 6 &#151; Net Loss Per
Share for additional details. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Tango is expected to be a <FONT STYLE="white-space:nowrap">tax-paying</FONT> entity in 2021 due to taxable
deferred revenue from the Gilead collaboration that is partially offset by the utilization of federal and state net operating losses and federal and state tax credits. However, the Company has historically been loss-making. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151; Transaction Accounting Adjustments to the Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended December&nbsp;31,
2020 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended
December&nbsp;31, 2020 are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma transaction accounting adjustments </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reclass historical BCTG franchise tax expense to general and administrative expenses of New Tango.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To eliminate interest income, and the related income tax expense from interest income, earned on the Trust
Account which were released upon closing of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Presentation of the pro forma basic and diluted net loss per share amounts. See Note 6 &#151; Net Loss Per
Share for additional details. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#151; Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss per share was calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the
Business Combination and PIPE Financing, assuming the shares were outstanding since January&nbsp;1, 2020. As the Business Combination is being reflected as if it had occurred at the beginning of the earliest period presented, the calculation of
weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination and PIPE Financing have been outstanding for the entire period presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared for the six months ended
June&nbsp;30, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended June&nbsp;30, 2021</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma weighted average shares calculation&nbsp;&#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,635,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less BCTG Stockholder redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG Sponsor and Directors and advisors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,231,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tango(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,593,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro Forma weighted average shares outstanding &#151; basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes 6,406,197 Tango consideration shares that will be issued upon the occurrence of future events (i.e.,
exercise of stock options). Includes 93,107 unvested Tango consideration restricted stock awards that are expected to vest prior to the effective time of the Business Combination. Total consideration to be issued to Tango is $550.0&nbsp;million or
55,000,000 shares ($10 per share price). The total shares to be issued includes all issued and outstanding Tango common and preferred stock plus shares underlying unvested stock options. Accordingly, the weighted average pro forma shares outstanding
at closing of the Business Combination has been adjusted to exclude the portion of consideration shares that will be unvested and/or unexercised at the closing of the Business Combination and are therefore not included in the calculation of weighted
average shares outstanding as the impact is anti-dilutive. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of applying the if converted method for calculating diluted earnings per share, it was assumed
that all Tango stock options are exchanged for common stock. However, since this results in anti-dilution, the effect of such exchange was not included in calculation of diluted loss per share. Shares underlying these instruments include 6,406,197
Tango consideration shares for unvested and/or unexercised stock options. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss per share was calculated using the historical
weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination and PIPE Financing, assuming the shares were outstanding since January&nbsp;1, 2020. As the Business Combination is being
reflected as if it had occurred at the beginning of the earliest period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination
and PIPE Financing have been outstanding for the entire period presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared for the year ended
December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31, 2020</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma weighted average shares calculation&nbsp;&#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG public stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,635,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less BCTG Stockholder redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG Sponsor and Directors and advisors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,231,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tango(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,593,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro Forma weighted average shares outstanding &#151; basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,435,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes 6,405,747 Tango consideration shares that will be issued upon the occurrence of future events (i.e.,
exercise of stock options). Includes 256,793 unvested Tango consideration restricted stock awards that are expected to vest prior to the effective time of the Business Combination. Total consideration to be issued to Tango is $550.0&nbsp;million or
55,000,000 shares ($10 per share price). The total shares to be issued includes all issued and outstanding Tango common and preferred stock plus shares underlying unvested stock options. Accordingly, the weighted average pro forma shares outstanding
at the closing of the Business Combination has been adjusted to exclude the portion of consideration shares that will be unvested and/or unexercised at the closing of the Business Combination and are therefore not included in the calculation of
weighted average shares outstanding as the impact is anti-dilutive. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of applying the if converted method for calculating diluted earnings per share, it was assumed
that all Tango stock options are exchanged for common stock. However, since this results in anti-dilution, the effect of such exchange was not included in calculation of diluted loss per share. Shares underlying these instruments include 6,405,747
Tango consideration shares for unvested and/or unexercised stock options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a precision oncology company leveraging
our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art&nbsp;target</FONT></FONT></FONT> discovery platform to identify novel targets and develop new drugs directed at tumor suppressor
gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be directly targeted. Empowered by recent advances in CRISPR
technology, we are now able to employ a unique functional genomics approach and apply the principles of synthetic lethality to target the loss of specific tumor suppressor genes at scale. We believe this will result in establishing a sustainable
pipeline optimized to deliver meaningfully clinical benefit to patients. Our novel small molecules are designed to be selectively active in cancer cells with specific tumor suppressor gene loss, killing those cancer cells while being relatively
inert in normal cells. We also are extending this target space beyond the classic, cell-autonomous&nbsp;effects of tumor suppressor gene loss to include the discovery of novel targets that reverse the effects of tumor suppressor gene loss that
prevent the immune system from recognizing and killing cancer cells (immune evasion). We believe this approach will provide the ability to deliver the deep, sustained target inhibition necessary for prolonged tumor regression and meaningful clinical
benefit as a result of the unique ability of synthetic lethal targeting to spare normal cells. We believe our approach also opens possibilities of histology-agnostic&nbsp;treatments for patients harboring specific genome alternations, regardless of
cancer type, in cases where a specific tumor suppressor gene loss is common to more than one subgroup of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our target discovery and drug
development process, which is clinically oriented and guided by patient-focused&nbsp;cancer genetics to produce innovative therapies, can be summarized by the following fundamental elements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A singular focus on precision oncology from target discovery through clinical development.</B> By identifying
a target patient population, defining the tumor suppressor gene loss that characterizes those patients&#146; cancers and using<I></I><I>&nbsp;in vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>&nbsp;models that mimic the genetics of those cancer cells
in our discovery platform, we concentrate discovery and clinical development paths on treatments for those patients most likely to derive meaningful clinical benefit from each new molecule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deep expertise linking cancer genetics to novel target discovery. </B>We have built a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery engine, based on multiple optimized CRISPR systems, advanced functional genomics and a proprietary
cloud-based&nbsp;computational biology platform, which we refer to as TANDEM, for sophisticated analysis of our genetic and functional data, enabling integration of target biology with specific genetic alterations in cancer cells.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A versatile drug discovery approach. </B>We employ our
<FONT STYLE="white-space:nowrap">hit-finding&nbsp;and</FONT> medicinal chemistry expertise to identify tractable chemical matter and solve high resolution crystal structures for our novel targets as the basis for designing potent, selective
molecules with the precise mechanism of action required by the target biology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>A unique ability to bring precision medicine to immuno-oncology. </B>Through&nbsp;our rigorous focus on cancer
genetics, we have identified critical links between tumor suppressor gene loss and the ability of tumor cells to evade killing by the immune system causing immune evasion. That knowledge powers our approach to reverse the tumor-intrinsic&nbsp;immune
evasion mechanisms driven by specific tumor suppressor gene loss in cancer cells. We plan to design clinical trials that combine the efficiency and success of genetic patient selection with a novel approach to reversing tumor-intrinsic immune
evasion, which we believe could mitigate the known drawbacks of clinical trials lacking a patient selection strategy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our first product
candidate, TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5, or PRMT5, designed to work selectively in cancer cells with an-methylthioadenosine phosphorylase, or MTAP, deletion.
MTAP-deletion&nbsp;occurs in approximately 10% to 15% of all human tumors, including many common cancers with high unmet need such as squamous cell lung, esophageal and bladder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancer, creating a significant therapeutic opportunity for patients. The challenge of <FONT STYLE="white-space:nowrap">non-synthetic&nbsp;lethal</FONT> PRMT5 inhibitors in treating cancer is that
they kill rapidly growing normal cells (bone marrow cells in particular) as effectively as cancer cells and therefore the dose needed to kill cancer cells often cannot be achieved without endangering patients. To address this problem, we designed
TNG908 to be selectively active (synthetic lethal) in cancer cells that have a deletion of MTAP, which is not present in normal cells. MTAP encodes the enzyme that degrades
<FONT STYLE="white-space:nowrap">5&#146;-deoxy-5&#146;-methylthioadenosine,</FONT> or MTA, an intrinsic inhibitor of PRMT5. Deletion of MTAP is not tumor-promoting by itself but occurs as a &#147;passenger&#148; with deletion of the tumor suppressor
gene CDKN2A. As the normal function of MTAP is to degrade MTA, MTAP deletion results in marked accumulation of MTA in cancer cells. This increase in MTA results in partial PRMT5 inhibition, creating a vulnerability that is not sufficient alone to
kill tumor cells but makes them more susceptible to PRMT5 inhibition than normal cells. As PRMT5 is an essential gene, treatment with a PRMT5 inhibitor like TNG908 is sufficient to cause cancer cell death without killing normal cells. However,
treatment with a <FONT STYLE="white-space:nowrap">non-selective</FONT> PRMT5 inhibitor kills cancer cells and normal cells at approximately the same exposure, markedly limiting potential efficacy. This difference in mechanism of inhibition occurs
because TNG908 binds much more efficiently to the <FONT STYLE="white-space:nowrap">PRMT5-MTA</FONT> complex, so the increased MTA levels in MTAP-deleted cancer cells make TNG908 more potent in MTAP-deleted cancer cells than in normal cells. In our
preclinical studies, TNG908 has demonstrated 15-fold greater potency in MTAP-deleted cancer cells versus normal cells. This unique selectivity of TNG908 for MTAP-deleted cancer cells allows for the near-complete and sustained inhibition of PRMT5
needed to induce tumor cell death while sparing normal cells, including bone marrow cells which is likely responsible for the dose-limiting toxicity of non-synthetic lethal PRMT5 inhibitors currently in clinical development. In our preclinical
studies, TNG908 demonstrated selectivity for MTAP-deleted tumors, anti-tumor effects<I></I><I> in vitro</I> and<I></I><I> in vivo</I>, and pharmacokinetics that, if approved, support its potential to be a highly differentiated synthetic lethal PRMT5
inhibitor. We plan to file an IND application for TNG908 in the fourth quarter of 2021 and initiate a Phase 1/2 clinical trial in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second product candidate has the potential to be a highly differentiated small molecule inhibitor of ubiquitin-specific&nbsp;protease 1, or USP1, a
synthetic lethal target for BRCA1-mutant&nbsp;breast, ovarian and prostate cancer. USP1 has the potential to treat a patient population that is comparable in size to approximately half of the patient population for poly <FONT
STYLE="white-space:nowrap">(ADP-ribose)</FONT> polymerase, or PARP, inhibitors that are effective against cancers with BRCA1 and BRCA2 mutations. BRCA1 mutations are present in approximately 15% of ovarian cancer, 5% of breast cancer, and 1% of
prostate cancer.<I></I><I> In vitro</I> and<I></I><I> in vivo</I> preclinical data demonstrate potent anti-tumor activity with a lead series compound used as a single agent. Preclinical data further demonstrate that USP1 inhibition is synergistic
with PARP inhibition in BRCA1 mutant cancer cell lines and murine xenograft models, providing the basis for the future clinical trials of a USP1 inhibitor both as a single agent and in combination with PARP inhibitors in BRCA1-mutant&nbsp;breast,
ovarian and prostate cancer. We anticipate advancing a clinical candidate and filing an IND for this program in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third program, an undisclosed
target (Target 3), exploits our platform developed to find synthetic lethal targets that reverse the immune evasion effects of tumor suppressor gene loss, in this case serine-threonine kinase&nbsp;11, or STK11, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">loss-of-function&nbsp;mutations.</FONT></FONT> STK11 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;mutations</FONT></FONT> are present in approximately 20% of <FONT
STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancers. Using our proprietary target discovery platform, we identified STK11 as a tumor suppressor gene responsible for mediating cancer cell resistance to immunotherapy when deleted
(immune evasion) and then identified a novel drug target (Target 3) that reverses this effect when inhibited in preclinical studies. We expect the clinical development plan for this inhibitor in STK11-mutant&nbsp;lung cancer to be the first to
combine the power of genetically-based&nbsp;patient selection and checkpoint inhibitor therapy. We anticipate advancing a clinical candidate for this target <FONT STYLE="white-space:nowrap">into&nbsp;IND-enabling&nbsp;studies</FONT> in the second
half of 2022 and filing an IND in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October&nbsp;2018, we entered into a collaboration agreement with Gilead Sciences Inc., or Gilead, and this
collaboration was expanded in August&nbsp;2020, or the Gilead Agreement. Our immune evasion platform is the foundation for our collaboration with Gilead. Under the Gilead Agreement, we and Gilead collaborate to identify and develop novel immune
evasion targets by leveraging our proprietary functional genomics-based discovery platform. To date, Gilead has licensed two of our programs and has research-extended two programs. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaboration with Gilead excludes our lead program, PRMT5, as well as USP1 and our undisclosed target (Target 3) in STK11-mutant&nbsp;cancers. We retain the right to identify and validate
targets outside the scope of our collaboration with Gilead, which includes all cell autonomous targets except those discovered in immune evasion contexts, and to develop and commercialize products directed to such targets on our own or in
collaboration with third parties. See &#147;&#151;<I></I><I>&nbsp;Collaboration and License Agreements &#151; Collaboration and License Agreement with Gilead Sciences</I>&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are leveraging the power and
productivity of our discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of discovery programs for multiple cancer types with limited treatment options. Our pipeline is summarized in the table
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g06w69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
pioneering novel approaches to the discovery and development of innovative precision oncology therapies. We leverage the following core strategic components, enabling bold thinking in pursuit of transformative therapies for patients with cancer:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance TNG908, the first PRMT5 inhibitor scheduled to enter the clinic that is synthetic lethal with MTAP
deletion, into the clinic in multiple indications with high unmet need. </B>TNG908, our PRMT5 inhibitor, is currently in <FONT STYLE="white-space:nowrap">IND-enabling&nbsp;studies.</FONT> We plan to file an IND in the fourth quarter of 2021 and
initiate a Phase 1/2 clinical trial in the first half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance our USP1 inhibitor program into clinical development in multiple
BRCA1-mutant</B><B></B><B>&nbsp;cancer types. </B>We discovered USP1 as a strong synthetic lethal target for BRCA1 loss of function. We are developing a potent, potentially differentiated molecule for the treatment of BRCA1-mutant&nbsp;breast,
ovarian and prostate cancer. We plan to file an IND in 2022 and expect this molecule to have both single agent activity in <FONT STYLE="white-space:nowrap">PARPi-na&iuml;ve&nbsp;and</FONT> PARPi-resistant&nbsp;BRCA1 mutant cancers and to synergize
with PARP inhibitors. As with PARP inhibitors, it may be possible to define additional sensitive patient populations based on the mechanism of action of USP1 inhibition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bring the first immunotherapy program within genetically-defined</B><B></B><B>&nbsp;patients into the clinic
in STK11-mutant</B><B></B><B>&nbsp;lung cancer. </B>Using our innovative discovery platform, we identified and validated STK11 as a tumor suppressor gene that, when inactivated causes immune evasion, manifested clinically as checkpoint inhibitor
resistance. We are pioneering the development of treatments that reverse STK11-loss&nbsp;mediated immune evasion. We anticipate advancing a clinical candidate for our first immune evasion&nbsp;target
<FONT STYLE="white-space:nowrap">into&nbsp;IND-enabling&nbsp;studies</FONT> in the second half of 2022 and filing an IND in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Discover and drug the next generation of precision oncology targets</B>. We are growing our drug discovery
pipeline with potentially innovative and differentiated discovery programs for multiple common genetically defined cancers. Based on evidence from multiple datasets that hundreds of synthetic lethal pairs remain to be discovered, we believe that our
target discovery engine will continue </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
to fuel our drug discovery pipeline for the foreseeable future. Based on the productivity of our discovery platform, we plan to file one new IND every 12 to 18&nbsp;months and have multiple
targets in discovery stage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically</B><B></B><B>&nbsp;evaluate and maximize the value of our strategic collaboration to bring
more medicines to patients, accelerate development timelines and explore combination therapy</B> <B>approaches for our product candidates.</B> Through our collaboration with Gilead, we can validate and develop multiple immune evasion targets,
producing more potential drug targets than we can independently develop by accessing the expanded capabilities and global development reach of a large company. We will consider additional collaborations that could maximize the value of our pipeline
through the evaluation of our product candidates in combination with compounds owned by third parties and/or through collaborations that allow us to leverage the existing infrastructure of other companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate History and Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled an
experienced team of experts in genetics, drug discovery and precision oncology to leverage synthetic lethality as a key principle of our strategy. Our Chief Executive Officer and <FONT STYLE="white-space:nowrap">co-founder,</FONT> Barbara Weber, MD,
is a board-certified&nbsp;medical oncologist and was a Professor of Medicine and Genetics at the University of Pennsylvania, where she was involved in the identification and characterization of BRCA1 and BRCA2, led a clinical and translational
research program in cancer genetics and developed the foundational concepts on which we were founded. Moving to industry in 2005, she led early oncology clinical development at GlaxoSmithKline and then Novartis, where she oversaw the filing of more
than 80 INDs. She also spearheaded the early development of ceritinib that led to registration of that drug from the Phase I trial. Dr.&nbsp;Weber joined Third Rock Ventures in 2015 as a Venture Partner, where she played a major role in the
formation of Relay Therapeutics and Neon Therapeutics (later acquired by BioNTech). She created and led the formation of Tango Therapeutics, Inc. and launched the Company in 2017. Alan Huang Ph.D., our Chief Scientific Officer, also played a leading
role in the creation of our company, specifically developing the ground-breaking&nbsp;concept of immune evasion driven by tumor suppressor gene loss. He brings 14 years of oncology translational research, target discovery and drug development
experience from his years at Millennium Pharmaceuticals (acquired by Takeda) and Novartis, where he led oncology translational research. Dr.&nbsp;Huang oversaw the laboratory-based&nbsp;efforts supporting the Novartis Oncology portfolio and played a
leadership role in establishing the foundation of project DRIVE, a large-scale&nbsp;functional genomics screen platform, as well as the Cancer Cell Line Encyclopedia project, a large external genomic collaboration with The Broad Institute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have world-class&nbsp;founders now acting as our scientific advisors, a skilled and experienced management team, and a knowledgeable board of directors
with deep expertise in oncology, drug development, clinical operations, and company creation. Alan Ashworth, Ph.D., a scientific founder of our company, was a leader in the discovery of the BRCA2 gene and discovered that PARP inhibitors are
synthetic lethal with BRCA1 and BRCA2 mutations. Nobel <FONT STYLE="white-space:nowrap">prize-winner&nbsp;William</FONT> Kaelin, MD, also a scientific founder, was among the first to describe synthetic lethality in human cancers and has utilized
high throughput screens to identify synthetic lethal gene pairs to known, cancer-associated&nbsp;mutations. Scientific founders Antoni Ribas, MD, Ph.D. professor of medicine, professor of surgery, and professor of molecular and medical pharmacology
at the University of California Los Angeles is an internationally recognized translational oncology researcher as was Jose Baselga, MD, Ph.D., former head of oncology R&amp;D at AstraZeneca, at the time of his passing in March&nbsp;2021. Of note,
Dr.&nbsp;Ribas was the first to discover inactivating mutations in cancer genes that result in checkpoint inhibitor resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received gross
proceeds of $352.9&nbsp;million upon the closing of the Business Combination and PIPE Financing in August 2021. Prior to the Business Combination, our operations were funded primarily with gross proceeds of $166.9&nbsp;million received through the
sale and issuance of preferred stock to a strong syndicate of investors, including Third Rock Ventures, Boxer Capital, Casdin Capital, Cormorant Asset Management and Gilead. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKGROUND </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cancer Treatment Landscape </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer is a disease of the
genome, and almost all cancers have multiple genetic lesions that must be addressed to develop curative combination therapies. One view of the hallmarks of cancer suggests that targeting oncogenic drivers, tumor suppressor gene loss and the
underlying mechanisms by which cancer cells evade immune destruction are the minimum that will be required for cures. The first wave of precision therapies for cancer focused on drugging gene products that are activated by genetic alterations
(oncogenes) in specific cancer types and has resulted in many important drugs for a wide range of cancer types. Precision medicines targeting activated oncogenes are available to an increasing number of cancer patients, but despite these very
significant advances most patients still receive treatment that includes various chemotherapy regimens and/or radiation. Although chemotherapy provides significant clinical benefit to many patients, cytotoxic mechanisms that affect normal and cancer
cells equally limit the dose of treatments that can be safely given to patients and therefore limit the efficacy of many drugs. There is an urgent need to develop precise, effective, and well-tolerated&nbsp;drugs that selectively target unique
cancer genetic dependencies without damaging or killing normal cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Precision Medicine and Synthetic Lethality </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As hundreds of thousands of human cancers have now been characterized by deep genome sequencing, it is believed that sequence-based&nbsp;discovery of oncogenes
druggable with conventional approaches has been largely exhausted, and any remaining undiscovered activating mutations occur at very low frequency (less than 1%). Many other genetic drivers of cancer have been well-characterized&nbsp;but have not
been directly targeted due to their molecular structure (undruggable oncogenes) or functional loss (tumor suppressor genes). Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be
directly targeted. Functional genomic screening provides an avenue to overcome these challenges and identify novel drug targets that may lead to the next wave of drugs needed for the large majority of cancer patients with advanced disease who do not
currently survive their diagnoses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The numerous cancer genome projects that resulted from the advances of the Human Genome Project, as well as systems
biology studies using functional genomics technologies (such as RNA interference and CRISPR-Cas9 gene editing), have enabled us to better understand and study cancer based on genetic alterations, rather than by histology and tumor type or tissue of
origin. The genetic alterations cataloged by these large-scale cancer genome sequencing efforts include deletions and/or inactivating mutations in almost all human cancer types. Activating mutations in oncogenes have been successfully drugged with
multiple inhibitors for HER2 amplification, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">BCR-ABL</FONT> translocation, and EGFR and BRAF mutations as well as many others. However, as shown in Figure 1 below, druggable oncogenes represent only a
portion of the many genetic alterations that drive the formation of cancers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g71e01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 1: Targeting tumor suppressor gene loss directly is not possible because they are deleted or inactivated, and the
immune evasion effects of tumor suppressor gene loss has only recently been described. We are using the concept of synthetic lethality to address the unmet medical need of these large groups of patients characterized by tumor suppressor gene loss
and activation of immune evasion genes. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Activated oncogenes are the &#147;gas pedals&#148; in cancer development and tumor suppressor genes are the
&#147;brakes&#148;. Tumor suppressor gene loss is a central mechanism by which normal cells lose the ability to regulate key protective cellular functions as they undergo malignant transformation. Many tumor suppressor genes have been
well-characterized, such as TP53, RB1, and BRCA1, but tumor suppressor gene loss is undruggable, as the function or presence of the genes themselves are lost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identification of druggable synthetic lethal partners is currently the only way of targeting the functional loss of tumor suppressor genes in cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synthetic lethality, initially described in<I></I><I>&nbsp;Drosophila</I>&nbsp;(fruit flies) in the 1930s, is classically defined as the setting in which
inactivation of either of two genes individually has little effect on cell viability, but the loss of function of both genes simultaneously leads to cell death. In cancer, the concept of synthetic lethality has been extended to pairs of genes where
one is inactivated by a genetic alteration and the other is inhibited pharmacologically. While genetic alterations give rise to the development of cancer, they also create a unique vulnerability that can be exploited therapeutically. Biologically,
such vulnerability can be the inability of cancer cells to respond to a specific signal, such as DNA damage or cell cycle arrest, or the inability to remodel chromatin or to maintain cellular homeostasis. The unique advantage of a synthetic lethal
approach to cancer therapy is that normal cells are not vulnerable to the synthetic lethal drug target and are largely unaffected at drug doses where the relevant cancer cells are selectively killed. The recent success of PARP inhibitors in
BRCA-mutant&nbsp;breast, ovarian and prostate cancers is the first clinical example of using synthetic lethality to target tumor suppressor gene loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the potentially large number of synthetic lethal interactions in the human genome, discovery of synthetic lethal pairs amenable to drug discovery
requires a functional genomic approach. We exploit multiple CRISPR technologies to identify synthetic lethal &#147;hits&#148; in cell line panels and<I></I><I>&nbsp;in vivo</I>&nbsp;models with loss of a specific tumor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suppressor gene and matched as closely as possible to models that retain wild-type, or WT, function of the tumor suppressor gene. &#147;Hits&#148; from these screens are potential synthetic
lethal drug targets, and the patient population expected to benefit from inhibiting these targets is defined by the genetic alteration of the tumor suppressor gene being interrogated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Synthetic Lethality and Novel Target Discovery </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumor
suppressor gene loss of function is a feature of virtually all human cancers &#151; it is a driver of tumorigenesis of equal importance to oncogene activation &#151; and synthetic lethality provides a powerful framework for developing precision
therapeutics that are functionally linked to the loss of specific tumor suppressor genes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hundreds of tumor suppressor genes have been described and
well-studied. Our internal analyses, supported by published data from the Sanger Institute and other institutions, suggests that there are hundreds of synthetic lethal partner genes for tumor suppressor genes that remain to be discovered which are
potential cancer drug targets. As noted above, the first clinically validated example is the PARP-BRCA1/2 synthetic lethal interaction. PARP inhibitors are effective in patients with inactivated tumor suppressor genes BRCA1 and BRCA2, as first
described by one of our founders, Alan Ashworth, and summarized in Figure 2 below. Notably, the first PARP inhibitor received FDA approval in 2016 and this class of molecules is now a multi-billion-dollar&nbsp;market benefiting thousands of patients
annually that is projected to become an $8.0&nbsp;billion market by 2027. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g72r02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 2. PARP inhibitors selectively kill these BRCA1/2 mutant cancer cells while largely sparing the normal cells.
Therefore, these synthetic lethality targets inherently can offer a wide therapeutic index. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By exploiting the genetic principle of synthetic
lethality, our novel molecules lead to selective killing of cancer cells, while being relatively inert in normal cells. We believe that this approach will deliver on the promise of precision medicine to bring more new treatments to the right
patients with effective, tolerable drugs for key drivers of cancer, that have heretofore of necessity been ignored in precision oncology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tumor
Suppressor Gene Loss and Immune Evasion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classic definition of synthetic lethality applies to events in cancer cells themselves that result in cell
death (&#147;cell autonomous&#148; events), but a synthetic lethal target discovery approach can be adapted to identify druggable targets that do not kill cancer cells directly, but rather attract immune cells to destroy them. While a wide variety
of mechanisms have been postulated by which cancer cells attain the ability to &#147;hide&#148; from the immune system </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(immune evasion), including immune editing, T cell exhaustion and an inhibitory microenvironment, important drivers of immune evasion likely come at least in part from the cancer cell itself.
However, the genetics of tumor-intrinsic immune evasion have only recently begun to be described, and no drug targets with the potential to reverse this hallmark of cancer have yet been publicly disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remarkable clinical activity of immunotherapies, specifically checkpoint inhibitors that help the immune system kill cancer cells, underscores the value
of identifying tumor suppressor gene loss that is linked to immune evasion, whereby tumor cells escape destruction by the immune system. We are using the concept of synthetic lethality to address the unmet medical need of this large group of
patients by identifying novel immune evasion genes that (i)&nbsp;are activated by tumor suppressor gene loss and (ii)&nbsp;the effects of which can be reversed through inhibition with a small molecule as illustrated in Figure 3 below. In the first
step, we perform an<I></I><I>&nbsp;in vivo</I>&nbsp;CRISPR-based&nbsp;screen using immune cell-mediated&nbsp;cell killing as the readout. This first step allows us to identify tumor suppressor genes linked to immune evasion. For the second step, we
repeat the<I></I><I>&nbsp;in vivo</I>&nbsp;CRISPR screen in animals with an intact immune system looking for potential drug targets that reverse the immune evasion effects of the tumor suppressor gene deletion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g73t03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 3. Discovery of novel drug targets that reverse the immune evasion effects of tumor suppressor gene loss requires
two sequential in vivo CRISPR-based screens. In the first screen, a CRISPR library of several hundred known tumor suppressor genes is transfected into a syngeneic mouse tumor model, and tumor growth is measured under conditions of increasing immune
pressure. &#147;Hits&#148; from this context discovery screen are tumor suppressor genes that are enriched in tumors that grow well even when exposed to <FONT STYLE="white-space:nowrap">anti-PD1</FONT> treatment. In the second screen, a CRISPR
library of potential drug targets is introduced in a syngeneic mouse tumor model with and without a deletion of the tumor suppressor gene of interest and genes that when knocked out reverse the immune evasion effect of the known tumor suppressor
gene are potential drug targets. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR APPROACH </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unmasking Vulnerabilities in Cancer to Deliver the Next Generation of Targeted Therapies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded on the tenet that tumor suppressor gene loss is a largely unmet target discovery and drug development opportunity. Our target discovery engine,
leveraging synthetic lethality with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> CRISPR screening, is designed to identify novel drug targets for cancer
types with specific tumor suppressor gene loss. We are using this approach to discover synthetic lethal drug targets that pair with specific tumor suppressor gene loss in multiple cancer types that have limited treatment options. Moreover, we plan
to use the tumor suppressor gene loss as a patient selection marker for clinical trial enrollment to ensure we are enrolling the patients most likely to benefit from each new drug candidate. We believe this approach should enable efficient clinical
development and increase the probability of success with maximum clinical benefit for the patient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our expertise, capabilities, and experience differentiate us from others and will enable the
rapid development of impactful new cancer treatments by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Defining the genetic context of patient subgroups with specific tumor suppressor gene loss;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identifying synthetic lethal targets that are selectively active in specific genetic contexts by using cell line
and animal models that reflect the patient genomics in our CRISPR-based&nbsp;target discovery platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discovering and optimizing molecules with superior biological and innovative chemical properties; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selecting patients for clinical trials using the cancer genetic context employed during target discovery as
patient selection biomarkers to maximize enrollment of the patients most likely to respond. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are disciplined about adhering to this
four-step&nbsp;approach to discovering novel synthetic lethal targets, rigorously validating them, discovering molecules optimized for potency and selectivity for cancer cells and designing genetically driven clinical trials. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g74y04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 4. By anchoring our target discovery in the cancer genomic profile of patients with high unmet need, we are using
our functional genomics platform to systematically identify the optimal synthetic lethal target that addresses the unique genetic weaknesses inherent to the cancer cells. Once the synthetic lethal interaction for the genetic alteration/target pair
has been validated using multiple model systems, we then develop innovative and/or differentiated small molecule inhibitors and match the treatment to the right patient using the genetic alteration as the patient-selection biomarker inherent to that
cancer type. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Target and Drug Discovery </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Step
1: Patient genomics.</U> The first step in each target discovery effort is to define the genetic background of the cancer type of interest, which ultimately becomes the patient selection strategy. For this, we prioritize genetic alterations and
tumor types with high unmet medical need. We concentrate on target classes that are druggable with small molecules (or antibodies for cell surface targets if they arise), minimizing drug discovery risk present in emerging areas, for example protein
degradation or protein:protein interaction disruption, and accelerating preclinical development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Step 2: Synthetic lethal targets.</U>
CRISPR is a powerful tool that we use for<I></I><I>&nbsp;in vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>&nbsp;target discovery and validation. We continue to refine and enhance our capabilities for CRISPR &#151; Cas for gene-editing. In our target
discovery screens, we begin with a clinically relevant genetic alteration (tumor suppressor gene loss) that confers defined characteristics, for example, enhanced growth or the ability to avoid immune cell killing causing immune evasion. We then use
CRISPR-based gene editing to systematically knock out every gene in a CRISPR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
library and, using cell viability as a functional readout, to determine which genes may be a synthetic lethal partner with the original mutation or deletion. Our CRISPR libraries vary in size
from <FONT STYLE="white-space:nowrap">200-300</FONT> genes for<I></I><I> in vivo</I>&nbsp;screening to 5,000 genes for our druggable genome library and 20,000 genes for our whole exome library. Choice of library varies by model system being used and
the specific experimental design. Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> CRISPR &#147;toolbox&#148; extends beyond optimized CRISPR-cutting
and-mediated knockdown (CRISPRi) systems into sophisticated, optimized combinatorial systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A unique feature of our toolbox is our<I></I><I>&nbsp;in
vivo</I>&nbsp;CRISPR screening capability, essential for discovery of immune evasion targets, and a T cell and cancer cell <FONT STYLE="white-space:nowrap">co-culture&nbsp;system</FONT> that markedly increases the speed and productivity of
immune-oncology target discovery and validation. Exploiting our immune evasion platform, we have evaluated approximately 200 tumor suppressor genes for their ability to induce resistance to checkpoint inhibitors when deleted using<I></I><I> in
vivo</I> syngeneic mouse tumor models with an intact immune system. Once a tumor suppressor gene has been linked to an immune evasion effect, we use CRISPR gene editing tools to generate multiple relevant isogenic tumor models for target discovery.
These isogenic models are engineered pairs of cancer cell lines that differ from each other only by the presence or absence of the tumor suppressor gene loss being evaluated. This approach allows us to systematically interrogate potential drug
targets for their ability to reverse immune evasion. Our novel undisclosed target (Target 3), a chemically tractable enzyme for reversing immune evasion in STK11-mutant cancers, is an example. This program has the potential to be the first
immuno-oncology&nbsp;program for a genetically defined patient population that currently derives minimal benefit from immune checkpoint inhibitor therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have identified synthetic lethal targets using our proprietary computational biology platform, Tango Cancer Dependency Map, or TANDEM, which brings
deep computing, machine-learning, and statistical power to our target discovery capabilities. TANDEM enables<I></I><I>&nbsp;in silico</I>&nbsp;analyses of public data for both discovery efforts and target validation and allows for strong clinical
hypothesis validation. In addition to analyzing our internally derived data, TANDEM integrates carefully curated genetic and genomic data from the massive external databases generated by the Broad Institute, the Sanger Institute, and the U.S.
National Cancer Institute (The Cancer Genome Atlas). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sophisticated Drug Discovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Step 3: Right molecule.</U> Our genetics and cancer biology expertise is complemented by deep drug discovery expertise incorporating chemistry hit finding,
biochemistry, structural biology, chemical biology, computational and medicinal chemistry to identify novel chemical space from large diversity libraries and/or with rational design. We utilize multiple
<FONT STYLE="white-space:nowrap">hit-finding&nbsp;approaches</FONT> for each target to maximize our probability of success and identify the best possible chemical space, including high-throughput&nbsp;biochemical screening of our proprietary 500,000
compound diversity library, as well as other approaches including fragment-based, <FONT STYLE="white-space:nowrap">DNA-encoded</FONT> library technology, and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the&nbsp;art</FONT></FONT> virtual screenings to identify unique chemical starting points. Of note, our drug discovery accomplishments to date include being the first, we
believe, to discover an <FONT STYLE="white-space:nowrap">MTA-cooperative&nbsp;PRMT5</FONT> inhibitor, inhibitors for a novel exonuclease, <FONT STYLE="white-space:nowrap">sub-nanomolar&nbsp;inhibitors</FONT> to a second methyltransferase with a
previously unknown role in immune evasion and selective inhibitors for a kinase with a very close structural paralog, any one of which would be a substantive achievement on its own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our novel target discovery engine and drug discovery expertise are rooted in the fundamental knowledge of cancer genetics and driven by the vision of a
leadership team with decades of experience and accomplishments in precision oncology. Our team has deep expertise in the necessary scientific disciplines of cell biology, functional genomics, CRISPR technology, computational biology, and<I> in
vivo</I> pharmacology using both conventional (CDX) and patient-derived (PDX) xenograft models. Our senior scientists lead the design and execution of experiments in close collaboration with our external partners for<I></I><I> in vivo</I> mouse
modeling, absorption, distribution, metabolism and excretion (ADME), pharmacokinetics and pharmacodynamic analysis (PK/PD), process chemistry, <FONT STYLE="white-space:nowrap">scale-up</FONT> and toxicology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our target discovery platform generates multiple targets of interest, which we validate and prioritize for
drug discovery based on the strength of the synthetic lethal interaction, tractability of the target, unmet medical need and the ability to select patients with a fixed genetic alteration. With this powerful platform, we are growing our drug
discovery pipeline with a balance of potential innovative and differentiated discovery programs for multiple common genetically defined cancer subtypes. Based on the evidence that hundreds of context-specific&nbsp;synthetic lethal pairs remain to be
discovered, we expect our highly productive target discovery engine to feed our novel drug discovery pipeline for the foreseeable future and underlies our goal of generating one new IND every 12 to 18&nbsp;months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Step 4: Right patient.</U> All
of our clinical trials will focus on selected patient populations that have the genetic alteration (usually tumor suppressor gene loss) that drove target discovery to increase the probability of maximum therapeutic impact. For example, as our lead
program PRMT5 inhibitor is synthetic lethal with MTAP deletion, we will select patients with MTAP-deleted&nbsp;tumors using next-generation&nbsp;sequencing, or NGS, or immunohistochemistry, or IHC. As there is the potential to see significant
responses across multiple tumor types, we will investigate both histology-specific&nbsp;and histology-agnostic&nbsp;study cohorts, the latter providing a path to tumor agnostic approval if supported by the data. We also will evaluate rare
cancer-types&nbsp;where there are no current approved treatments, for example malignant peripheral nerve sheath tumors, or MPNST, that may allow for an expedited orphan drug registration path. Lastly, for immune evasion targets, we will select
patients with resistance to checkpoint inhibitors as well as the genetic alteration of interest, for example STK11 mutations for our undisclosed immune evasion target (Target 3), which would bring genetic patient selection to
immuno-oncology&nbsp;for the first time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR PROGRAMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TNG908 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead development candidate, TNG908, is a potent and selective oral small molecule inhibitor of PRMT5 that is synthetic lethal with MTAP deletion. We
believe this interaction is one of the strongest and most prevalent synthetic lethal interactions in human cancers and represents a subset of synthetic lethality termed collateral lethality. Collateral lethality occurs when a &#147;passenger&#148;
gene adjacent to a tumor suppressor gene is lost along with the &#147;driver&#148; gene. In this case, MTAP is the &#147;passenger&#148; and is frequently <FONT STYLE="white-space:nowrap">co-deleted&nbsp;with</FONT> the &#147;driver&#148; CDKN2A
gene (p16). The interaction occurs because MTAP-deleted&nbsp;cells accumulate high levels of the PRMT5 inhibitory <FONT STYLE="white-space:nowrap">co-factor&nbsp;MTA.</FONT> As a result, PRMT5 is partially inhibited in MTAP-deleted&nbsp;cells,
making those cells more sensitive than normal cells to further pharmacological inhibition of PRMT5 activity. We believe this dependency provides the potential for a large therapeutic window for PRMT5 inhibitors in patients with
MTAP-deleted&nbsp;tumors, given that normal cells (without MTAP deletion) are largely spared, potentially limiting toxicity and allowing for deep and sustained target inhibition in normal cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taking advantage of this unique interaction between PRMT5 inhibition and MTAP deletion requires a specific mechanism of inhibition called MTA cooperativity.
Our lead molecule, TNG908, binds cooperatively with MTA to inhibit PRMT5 function by blocking access to the PRMT5 active site for both protein substrates and the activating PRMT5 <FONT STYLE="white-space:nowrap">co-factor</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">S-adenosyl-L-methionine,</FONT></FONT></FONT> or SAM. This <FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> mechanism of inhibition selectively
inhibits PRMT5 in tumor cells that have lost MTAP (MTAP-null) while being relatively inert in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
normal cells without MTAP deletion (MTAP WT). We believe TNG908 is currently the most advanced <FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> PRMT5 inhibitor in development and is
differentiated from all clinical PRMT5 inhibitors based on this mechanism as illustrated in Figure 5 below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g76u05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 5. <FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> PRMT5 inhibition is required for synthetic lethality
with MTAP. PRMT5 catalyzes the transfer of a methyl group from SAM to protein substrates. All clinical PRMT5 inhibitors function by competing with SAM or protein substrates and are not synthetic lethal with MTAP. TNG908 inhibition of PRMT5 is
enhanced by the presence of MTA which is present in marked excess in MTAP-null cells. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing TNG908 for the treatment of patients with
solid tumors with MTAP deletion, which occurs in 10% to 15% of all human tumors, including many commonly occurring cancers with high unmet need such as squamous cell lung, esophageal and bladder cancer. In
<FONT STYLE="white-space:nowrap">pre-clinical&nbsp;studies,</FONT> TNG908&nbsp;has demonstrated <FONT STYLE="white-space:nowrap">15-fold&nbsp;selectivity</FONT> for MTAP-null&nbsp;cancer cells over MTAP WT normal cells,
anti-tumor&nbsp;effects<I></I><I>&nbsp;in vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>, and pharmacokinetics that support its potential to be a leading PRMT5 inhibitor if approved. We anticipate filing an IND application for this program in the
fourth quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRMT5 mechanism of action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRMT5 is a protein arginine methyltransferase that modifies multiple proteins involved in essential cellular processes such as RNA splicing, cell cycling, cell
death, and metabolic signaling, by adding a methyl group to substrate proteins. The function of many of these proteins is critical for growth and viability of both normal and cancer cells. In preclinical models, PRMT5 inhibition has been shown to
cause cancer cell death and suppress tumor growth. PRMT5 inhibitors in clinical development have been shown to cause tumor regressions in some patients, and a complete response in one instance; however, none are selective for MTAP deletion, and all
have a narrow therapeutic window that limits the amount of drug that can be administered without cytotoxic effects on bone marrow cells and therefore limits therapeutic efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> PRMT5 inhibition as a novel mechanism with synthetic lethality in cancers with MTAP-deletion
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRMT5 methylates target proteins by removing a methyl group from SAM and transferring that methyl group to a specific residue on target proteins. This
methyl modification, or &#147;mark&#148;, alters the function of the target protein, thereby regulating the cell processes for which the protein is important. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The function of PRMT5 is regulated in several ways, including by the endogenous inhibitor MTA. MTA directly competes with SAM for binding to the active site
in PRMT5 but does not have a methyl donor, thus when present inhibits PRMT5 function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In normal,
<FONT STYLE="white-space:nowrap">non-cancerous&nbsp;cells,</FONT> MTA is degraded by the enzyme MTAP. When MTAP is lost in cancer cells intracellular MTA is elevated, but, importantly, MTA is not elevated in adjacent normal cells. TNG908 is a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PRMT5 inhibitor that requires a cooperative interaction with MTA to bind to and inhibit PRMT5. As a result, TNG908 selectively kills MTAP-null&nbsp;tumor cells with high MTA levels while sparing
normal cells <FONT STYLE="white-space:nowrap">(MTAP-WT).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 6. Schematic of PRMT5 and MTAP functions. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g77i06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MTAP-deletion&nbsp;frequency in multiple solid tumors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A partial deletion of chromosome 9p21, driven by loss of the tumor suppressor gene CDKN2A, is the most common homozygous deletion in human cancer. MTAP is
immediately adjacent to CDKN2A and is lost along with it in <FONT STYLE="white-space:nowrap">80-90%</FONT> of tumors, thus MTAP is one of the most commonly deleted genes across all cancer types. Based on The Cancer Genome Atlas, or TCGA, data, there
are at least 15 cancer types where MTAP loss occurs in more than 10% of patients, including 10% of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-squamous&nbsp;non-small&nbsp;cell</FONT></FONT> lung cancer, or NSCLC, 20% of
squamous NSCLC, 25% of bladder cancer and 30% to 50% of MPNSTs. Given that we believe this is a large and important opportunity for patients with cancer, we have multiple preclinical efforts ongoing to support the development of TNG908, our lead
product candidate, clinical combinations therapies, resistance mechanisms and next generation inhibitors that we are designing to be more potent and selective for MTAP deletion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 7. The frequency of MTAP deletion across tumor types as determined from analysis of TCGA </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g78o07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Existing PRMT5 Inhibitors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRMT5 has long been a therapeutic target of interest for cancer given its role in regulating multiple essential cellular functions. Initial efforts to target
PRMT5 focused on making inhibitors that compete with or cooperate with SAM, the <FONT STYLE="white-space:nowrap">co-factor&nbsp;and</FONT> methyl donor which is necessary for PRMT5 to modify its various substrates. Clinical trials of these existing
PRMT5 inhibitors have demonstrated some clinical efficacy, supporting the potential for PRMT5 inhibition to have meaningful clinical benefits for patients. However, all existing inhibitors equally suppress PRMT5 in both tumor and normal cells,
resulting in a very narrow therapeutic index with similar cytotoxic effects on cancer and normal cells. PRMT5 and SAM are required in every tissue and cell type, and we believe PRMT5 inhibition with a SAM cooperative or competitive approach is
likely to have substantial <FONT STYLE="white-space:nowrap">on-target,</FONT> dose limiting toxicity in normal cells, which limits therapeutic efficacy. Furthermore, a strategy to select patients likely to benefit from these <FONT
STYLE="white-space:nowrap">non-selective&nbsp;PRMT5</FONT> inhibitors has yet to be elucidated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 8. TNG908 has a unique mechanism of action that is distinct from existing PRMT5 inhibitors.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g79p08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our differentiated approach with TNG908 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TNG908 is distinct from existing PRMT5 inhibitors because of its mechanism of binding cooperatively with MTA. This mechanism allows TNG908 to inhibit PRMT5
selectively in MTAP-deleted tumor cells with high intracellular MTA levels while preserving normal cells. We believe this mechanism of action should give TNG908 a large therapeutic index when used in patients selected for MTAP-null tumors. While
several PRMT5 inhibitors are in clinical development, they are not selective for MTAP-null cancer cells and their ability to inhibit PRMT5 to the level needed to kill cancer cells is reduced by <FONT STYLE="white-space:nowrap">on-target,</FONT>
dose-limiting bone marrow toxicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">MTA-cooperative&nbsp;PRMT5</FONT> inhibitor discovery effort began with a
high-throughput&nbsp;screen of a large chemical diversity library designed to identify small molecules that preferentially inhibit PRMT5 in the presence of MTA. We subsequently solved the crystal structure of PRMT5 with inhibitor bound using novel
compounds we designed, enabling routine use of structure-based&nbsp;drug design to facilitate efficient design of novel, increasingly potent and selective <FONT STYLE="white-space:nowrap">MTA-cooperative&nbsp;PRMT5</FONT> inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compared the potency and selectivity of our development candidate TNG908 and the clinical PRMT5 inhibitor, GSK3326595, in a panel of 162 cancer cell lines
representing <FONT STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancer, bladder cancer, pancreatic cancer, cancers of the central nervous system, leukemia and lymphoma. TNG908 demonstrated significant MTAP-selective inhibition of
viability, while GSK3326595 showed no selectivity for MTAP-null cell lines over <FONT STYLE="white-space:nowrap">MTAP-WT.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 9. TNG908 inhibits viability selectively in MTAP-null cancer cell lines. Cellular viability was
determined in a panel of 162 cancer cell lines treated for seven&nbsp;days with either TNG908 or GSK3326595. Cell lines are color-coded by MTAP-status as indicated, and the maximal viability effect (% Amax)&nbsp;is plotted on the <FONT
STYLE="white-space:nowrap">y-axis.</FONT> </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g79s09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further validation of our approach to selectively target MTAP-null&nbsp;cancer cells was achieved<I></I><I>&nbsp;in
vivo</I>. Xenograft models differing only in MTAP status <FONT STYLE="white-space:nowrap">(MTAP-WT&nbsp;or</FONT> MTAP-null) were treated TNG908. PRMT5 symmetrically <FONT STYLE="white-space:nowrap">di-methylates&nbsp;specific</FONT> arginine
residues, or SDMA, of its substrate proteins, a modification that can be detected by specific antibodies and a direct measurement of PRMT5 activity that can be quantified by intracellular SDMA-modified&nbsp;protein levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with the inhibitory effects of MTA accumulation caused by MTAP-deletion, PRMT5 activity was reduced in MTAP-null tumors at baseline relative to <FONT
STYLE="white-space:nowrap">MTAP-WT</FONT> tumors. When tumor-bearing mice were dosed with TNG908, &gt;90% PRMT5 inhibition was observed in the MTAP-null tumors while PRMT5 inhibition in <FONT STYLE="white-space:nowrap">MTAP-WT</FONT> tumors remained
above the threshold for lethality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 10. TNG908 selectively inhibits PRMT5 in MTAP-null cancer in vivo. HCT116 MTAP-isogenic xenograft
models were generated by deleting endogenous MTAP to create an MTAP-null cell line. Tumor-bearing mice were dosed with TNG908 or vehicle at the indicated dose levels. SDMA-modified protein levels were determined by immunoblot analysis on tumors
harvested eight hours after the last dose. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g80a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical data summary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TNG908 was discovered with high-throughput screening of over 500,000 compounds using a biochemical assay designed to identify
<FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> inhibitors. The discovery of TNG908, an <FONT STYLE="white-space:nowrap">MTA-cooperative</FONT> inhibitor, was achieved through a structure-guided optimization, with over 150 <FONT
STYLE="white-space:nowrap">x-ray</FONT> crystal structures generated and good physicochemical properties prioritized during this effort. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TNG908 is highly
selective for PRMT5 against a panel of 38 methyltransferases at 10 &micro;M, showing that TNG908 does not affect other biological processes regulated by this family of enzymes at concentrations well above the predicted clinical efficacious dose.
TNG908 has excellent drug-like&nbsp;properties and is easily formulated in standard conditions for oral dosing in preclinical and clinical studies. Pharmacokinetic properties of TNG908 indicate high passive permeability with moderate clearance and
bioavailability in preclinical species. Allometric scaling was performed to predict human pharmacokinetics and resulted in an estimated effective human dose of 500&nbsp;mg twice-daily&nbsp;(BID). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the cellular potency and selectivity of TNG908 in MTAP-null tumors, we developed assays using engineered isogenic cancer cell lines that differ
only by the presence or absence of MTAP. To determine pharmacodynamic potency and selectivity, a HAP1 MTAP-isogenic cell line pair was treated with TNG908 for 24 hours and PRMT5 activity was measured by SDMA quantification. TNG908 inhibits PRMT5 in
the MTAP-null HAP1 cell line with an IC50 of 5 nM, with marked selectivity over the MTAP-WT cell line. See representative data in Figure 11 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 11. PRMT5 inhibition by TNG908 is dose-dependent</I><I></I><I>&nbsp;and MTAP-selective</I>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vitro <FONT STYLE="white-space:nowrap">in-cell</FONT> western data demonstrating dose-dependent reduction of SDMA levels after 24 hours of TNG908
treatment in HAP1 MTAP-isogenic cancer cell lines. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g81d11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For comparison, PRMT5 inhibitors that are currently in clinical development, and are not
<FONT STYLE="white-space:nowrap">MTA-cooperative,</FONT> have not demonstrated MTAP-selective&nbsp;PRMT5 inhibition, as summarized in the table below. These data show that TNG908 is MTAP-selective, and that its activity is <FONT
STYLE="white-space:nowrap">on-target.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 12. TNG908 is differentiated from clinical PRMT5 inhibitors in its ability to inhibit PRMT5
selectively in MTAP-null cells. Average IC50s from in vitro SDMA <FONT STYLE="white-space:nowrap">in-cell</FONT> western assay. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g81f12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRMT5 activity is required for cellular viability, likely due to its role as a regulator of transcriptional activity, cell
cycle control, spliceosome assembly and other essential cellular processes. As TNG908 potently inhibited PRMT5 in an MTAP-selective manner, we investigated whether TNG908 also inhibits viability in an MTAP-selective manner. In MTAP-isogenic cell
lines representing three different cancer lineages (HAP1 (chronic myelogenous leukemia), LN18 (glioblastoma) and SW1573 (lung carcinoma)), TNG908 potently inhibits cellular viability in MTAP-null cell lines with approximately 15X selectivity over <FONT
STYLE="white-space:nowrap">MTAP-WT</FONT> cell lines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 13. Inhibition of cellular viability by TNG908 is dose-dependent&nbsp;and MTAP-selective&nbsp;In
vitro assay demonstrating dose-dependent&nbsp;cellular viability effects following seven&nbsp;days of compound treatment in HAP1 (CML), LN18 (GBM) and SW1573 (NSCLC) MTAP-isogenic&nbsp;cancer cell lines. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g82g13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Though the GSK3326595, <FONT STYLE="white-space:nowrap">JNJ-64619178&nbsp;and</FONT> Prelude compounds inhibit cellular
viability consistent with their inhibition of PRMT5, none have been shown to selectively target MTAP-null&nbsp;cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Table 14. TNG908 is
differentiated from clinical PRMT5 inhibitors in ability to selectively inhibit viability in MTAP-null&nbsp;cells. Average IC50s from in vitro cellular viability assay with HAP1 MTAP-isogenic&nbsp;cell lines. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g82h14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with<I></I><I>&nbsp;in vitro</I>&nbsp;data, TNG908 also demonstrates dose-dependent&nbsp;PRMT5
inhibition<I></I><I>&nbsp;in vivo</I>&nbsp;in an MTAP-null&nbsp;xenograft model. LN18 tumor-bearing&nbsp;mice were treated with TNG908 at&nbsp;3,&nbsp;10, 30 or 60 mg/kg BID for ten&nbsp;days. Plasma concentrations of TNG908 increased with dose, and
tumoral SDMA-modified protein levels decreased in a dose-dependent&nbsp;manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 15. PRMT5 inhibition with TNG908 is dose-dependent</I> in vivo<I>. LN18 (MTAP-null)
tumor-bearing</I><I> mice were dosed with TNG908 at</I><I></I><I> 3,</I><I></I><I>&nbsp;10,</I><I></I><I>&nbsp;30, or 60 mg/kg BID for ten</I><I></I><I>&nbsp;days. Tumors were harvested at the time points indicated, and the levels of a single
SDMA-modified</I><I></I><I>&nbsp;protein were determined by immunoblot. Tumors from the</I><I></I><I>&nbsp;3</I><I></I><I>&nbsp;mg/kg group were not harvested at 16 hours post-last</I><I></I><I> dose.</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g82j15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with<I></I><I>&nbsp;in vitro</I>&nbsp;findings, TNG908 demonstrated significant and
dose-dependent&nbsp;antitumor activity in the LN18 MTAP-null&nbsp;xenograft model (data not shown). Regressions <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;-65%,&nbsp;-55%</FONT></FONT>
<FONT STYLE="white-space:nowrap">and&nbsp;-56%</FONT> were demonstrated in additional MTAP-null&nbsp;xenografts including models representing a diffuse large <FONT STYLE="white-space:nowrap">B-cell&nbsp;lymphoma</FONT> cell line <FONT
STYLE="white-space:nowrap">(OCI-Ly19),</FONT> a glioblastoma cell line (U87MG), and a patient-derived&nbsp;cholangiocarcinoma xenograft, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 16. TNG908 demonstrates strong antitumor activity with regressions in MTAP-null xenograft models. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g83k16.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 17. TNG908 demonstrates strong, MTAP-selective&nbsp;antitumor activity in xenograft models.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g83l17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TNG908 was evaluated in an engineered MTAP-null xenograft model, HCT116, a colon cancer cell line. Marked activity was
observed at 90 mg/kg BID (Figure 16 above). In comparison, TNG908 had minimal effect on the HCT116 MTAP WT xenografts. Together with PK/PD data, these data demonstrate that TNG908 inhibition of PRMT5 suppresses tumor growth in an on-target and
MTAP-selective manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Planned clinical trials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
completion of our ongoing preclinical studies and formulation work to optimize pharmacokinetics and the therapeutic index, we have designed our Phase 1/2
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human&nbsp;trial</FONT></FONT> to evaluate the oral administration of TNG908 monotherapy in patients with MTAP-null&nbsp;tumors (See Figure 17 below). Our planned indications
reflect the unmet medical need for new therapies in prevalent histologies, including both squamous and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-squamous&nbsp;non-small&nbsp;cell</FONT></FONT> lung cancer and bladder
cancer as well as indications where there are limited treatment options with no standard of care, including cholangiocarcinoma and MPNST. As TNG908 is designed to selectively work in cancers with MTAP loss, we intend to limit enrollment to patients
with MTAP-deleted&nbsp;tumors using either NGS or IHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dose escalation phase will evaluate safety and dosing regimen in patients with locally
advanced or metastatic cancer of any histology with an MTAP deletion. Following determination of the recommended dose, we will evaluate the efficacy of TNG908 in multiple separate expansion arms including NSCLC (squamous and <FONT
STYLE="white-space:nowrap">non-squamous),</FONT> bladder cancer, cholangiocarcinoma and MPNST. In parallel, we will enroll an MTAP-null, histology agnostic &#147;bucket arm&#148; to provide optionality for a registration strategy in all tumors
regardless of histology if broad-based&nbsp;activity is observed. Given that MTAP deletion occurs in 10% to 15% of human tumors, we plan to expand into other indications based on activity observed in the histology-agnostic&nbsp;cohort. We anticipate
filing an IND in the fourth quarter of 2021 and initiating the Phase 1/2 clinical trial of TNG908 in the first half of 2022. We expect to report preliminary safety and efficacy data for TNG908 monotherapy in the first half of 2023. This program is
excluded from the Gilead Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 18. TNG908
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-human</FONT></FONT> trial schema. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g84x18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next-generation PRMT5 Inhibitors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have next-generation&nbsp;PRMT5 inhibitor compounds in preclinical development that use the same mechanism of action as TNG908 but may be more potent and
appear to be at least as selective and more efficacious in our xenograft models to date. We believe additional potency may allow stronger target inhibition and thus clinical efficacy and additional selectivity for MTAP-null&nbsp;cells may provide a
wider therapeutic index. Development timelines for these compounds are approximately 12 months behind TNG908. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a set of these
next-generation&nbsp;compounds in various stages of development with increased potency, selectivity and therapeutic index. We intend to continue to advance and evaluate these compounds through preclinical testing. An exemplar of these
next-generation&nbsp;compound potently inhibits PRMT5 in an MTAP-selective&nbsp;manner (data not shown) and leads to stronger tumor regression in a LN18 (glioblastoma) MTAP-null&nbsp;xenograft model. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 19. Next-generation PRMT5 inhibitor exemplar data demonstrates strong tumor regression in the LN18 xenograft model. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g84z19.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our next-generation&nbsp;compounds have the potential to be more effective than our lead PRMT5
inhibitor, TNG908. If additional preclinical evaluation of our next-generation&nbsp;compounds supports this hypothesis, we may elect to promote a next-generation&nbsp;compound as our lead PRMT5 inhibitor, which would result in a delay to our
development timeline of approximately 12 months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our early development programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USP1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using our CRISPR-based&nbsp;target discovery
platform, we discovered USP1 as a strong synthetic lethal target for BRCA1, but not BRCA2, loss reflected in Figure 20 below. This discovery has since been independently reported and published by several other groups. We are developing a potent,
potentially differentiated molecule targeting BRCA1-mutant&nbsp;breast, ovarian, and prostate cancer with plans to file an IND in 2022. USP1 inhibitor has the potential to treat a patient population that is comparable in size to approximately half
of the PARP inhibitor market (BRCA1 and BRCA2). BRCA1 mutation is present in approximately 15% of ovarian cancer, 5% of breast cancer, and 1% of prostate cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 20. Volcano plot shows analysis of CRISPR screens performed in a panel of BRCA1 WT vs. mut cell lines where knockout of USP1 using multiple
independent single strand guide RNAs (sgRNAs) leads to selective killing of BRCA1 mutant tumor cells. The clinically proven PARP-BRCA interaction was also identified in this screen as expected. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g85c20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USP1 is a deubiquitinating enzyme that facilitates DNA damage response, or DDR, repair. Our preclinical pharmacology
studies show that USP1 tool inhibitor halt the proliferation of cancer cell lines with BRCA1 mutations, as well as a subset of <FONT STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancer cell lines that do not have BRCA1 mutations. We
are currently conducting experiments to define patient selection markers for these BRCA1 WT cell lines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead series demonstrate nanomolar potency
against USP1, as measured by cytotoxicity in BRCA1 mutant cells, and upregulation of mono-ubiquitinated&nbsp;PCNA. Consistent with <I>in vitro</I> data, our USP1 inhibitors exhibit potent anti-tumor&nbsp;activity in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MDA-MB-436&nbsp;xenograft</FONT></FONT> model (BRCA1 mutant breast cancer cell line). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 21. Tango lead series USP1 inhibitor demonstrates selective viability effect and target
engagement. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g85v21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Left)&nbsp;In vitro&nbsp;assay demonstrating cellular viability effects in exemplar BRCA1 mutant but not WT cell line
following ten&nbsp;days of compound treatment. (Right)&nbsp;In vitro&nbsp;assay demonstrating dose dependent increase in monoubiquitinated PCNA, a USP1 substrate, in BRCA1 mutant cell line following 24 hours of treatment. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 22. Lead series USP1 inhibitor demonstrates anti-tumor&nbsp;activity in vivo. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g86n22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DDR pathways regulated by USP1 are not currently targeted by any clinical stage compounds. Moreover, we performed
genome-wide CRISPR-Cas9 screens in the presence and absence of our USP1 inhibitor tool compounds and confirmed that USP1 inhibition has a differentiated and novel mechanism of action relative to other DDR-based inhibitors, including PARP inhibitors.
We expect this molecule to have both single agent activity in <FONT STYLE="white-space:nowrap">PARPi-na&iuml;ve</FONT> and most PARPi-resistant BRCA1 mutant cancers and to synergize with PARP inhibitors. Additional patient selection markers are
being evaluated in BRCA1 WT populations with or without homologous recombination deficiency, particularly in a subset of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer cell lines sensitive to USP1 inhibition. This program is
excluded from the Gilead Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 23. USP1 inhibition sensitizes PARP inhibitor in BRCA1 mutant context. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g118907g86m23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vitro&nbsp;assay demonstrating cellular viability effects in SUM149PT BRCA1-isogenic&nbsp;cell lines following seven
days of olaparib treatment, in the presence and absence of USP1 inhibitor. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reversing Immune Evasion in lung cancer with STK11 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using<I></I><I>&nbsp;in
vivo</I>&nbsp;CRISPR-based&nbsp;screens in mouse syngeneic tumor models, we identified serine-threonine&nbsp;kinase&nbsp;11 (STK11) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;mutations,</FONT></FONT> a
genetic alteration in approximately 20% of <FONT STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancer, as a tumor suppressor gene that when inactivated confers resistance to the efficacy of
<FONT STYLE="white-space:nowrap">PD-1&nbsp;immune</FONT> checkpoint inhibitors. STK11 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;mutations&nbsp;trigger</FONT></FONT> complex changes in both cancer cell
signaling and in the broader tumor microenvironment. Retrospective analysis of human clinical data by Dr.&nbsp;Ferdinandos Skoulidis, Dr.&nbsp;John Heymach and others (MD Anderson Cancer Center) subsequently identified STK11 as a marker for the lack
of durable clinical benefit to pembrolizumab + chemotherapy in <FONT STYLE="white-space:nowrap">non-small&nbsp;cell</FONT> lung cancer patients, demonstrating that STK11
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;in</FONT></FONT> lung cancer correlates with primary resistance to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1&nbsp;therapy.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated genetically engineered mouse
tumor models that consistently recapitulate the immunosuppressive microenvironment caused by genetic STK11 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function&nbsp;mutations</FONT></FONT> and have conducted several
target discovery screens using these same models. We now have strong genetic and pharmacologic validation showing reprogramming of the tumor microenvironment and strong sensitization to <FONT STYLE="white-space:nowrap">anti-PD1&nbsp;therapy</FONT>
in a STK11-mutant&nbsp;dependent manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Figure 24: Pharmacologic target validation in STK11 mutant MC38 mice </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g87b23.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A Target 3 inhibitor tool compound validates the genetic interaction with STK11&nbsp;in vivo. Mice were
treated with the Target 3 inhibitor for 18&nbsp;days after tumor implantation either alone or in combination with <FONT STYLE="white-space:nowrap">anti-PD1&nbsp;therapy.</FONT> Treatment was stopped at day&nbsp;18, and all surviving animals on study
were sacrificed at day 24. Nine out of ten mice in the Target 3i + PD1 combination arm had no detectable tumor at endpoint. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinically, <FONT
STYLE="white-space:nowrap">loss-of-function</FONT> mutations in the tumor suppressor gene STK11 are strongly associated with immune checkpoint inhibitor resistance. We have generated clinically relevant mouse models of STK11-mutant cancers and used
these models to discover novel targets to reverse the immune evasion effect of this genetic alteration, summarized in Figure 24 above. In these models, treatment with tool compounds against this target are highly synergistic combined with anti-PD1
therapy. In this experiment, mice were treated for 18 days after tumor implantation, treatment was stopped at day 18, animals were sacrificed at day 24, and nine out of ten mice were found to have no detectable tumor at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate advancing a clinical candidate targeting this undisclosed immune evasion target (Target 3) into IND-enabling studies in the second half of 2022.
The clinical development plan for this program in STK11-mutant lung cancer will combine the power of genetic patient selection for immunotherapy with a novel approach to reversing tumor-intrinsic immune evasion. This program is excluded from the
Gilead Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreement with Gilead Sciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, we entered into an amended and restated research collaboration and license agreement, which we refer to as the Gilead Agreement, with
Gilead. The Gilead Agreement expanded our 2018 collaboration with Gilead, or the 2018 Gilead Agreement. Pursuant to the Gilead Agreement we will use our proprietary functional genomics-based discovery platform to identify and develop novel immune
evasion targets during a seven-year period, or the Research Term. During the Research Term, Gilead has the option to obtain exclusive, worldwide licenses to develop and commercialize products directed to up to 15 targets validated in the
collaboration. Prior to exercising its option for a program, Gilead may &#147;extend&#148; such program, in which case we will further collaborate with Gilead during the Research Term to discover and develop immuno-oncology treatments directed to
such target(s), potentially through early clinical development and be eligible to receive research extension payments from Gilead. Gilead will retain its option rights to any such extended program. For up to five programs licensed by Gilead, we have
the option to co-develop and co-promote the lead product for such program in the United States, subject to certain exceptions, and eligible to receive milestone payments and royalties on <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Gilead Agreement, we received an upfront payment of $125.0 million in addition to an upfront payment of $50.0 million received under
the 2018 Gilead Agreement. We also received a $20.0 million equity investment in connection with the Gilead Agreement. We are eligible to receive up to an additional $410.0 million per program in license, research extension, and clinical, regulatory
and commercial milestone payments. We are also eligible to receive tiered royalties in the first decile on net sales by Gilead on a country-by-country and product-by-product basis until the later of (i) the expiration of the last valid claim of our
patents or, in some instances, certain Gilead&#146;s patents, in each case covering such product in such country or (ii) ten years after the first commercial sale of such product in such country. For those products that we opt to co-develop and
co-promote in the United States, we and Gilead will equally split profits and losses from the sales of such products in the United States, as well as development costs for such products attributable to the United States. For such products, we will
remain eligible to receive certain of the $410.0 million per program milestone payments related to clinical and regulatory milestones as well as commercial milestones and royalties in the first decile on net sales outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Either party may terminate the&nbsp;Gilead Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure
provisions, or enters into bankruptcy or insolvency proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, Gilead may terminate the agreement for any or no reason, in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT>
basis, upon specified written notice. If we terminate the Gilead Agreement for Gilead&#146;s material breach, or Gilead terminates the Gilead Agreement without cause, then Gilead is obligated to negotiate with us in good faith for a specified period
regarding the transfer by Gilead of certain assets and the provision by Gilead of certain assistance to enable us to continue the research, development and commercialization of products under any terminated programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, Gilead has licensed two of our programs and has research-extended&nbsp;two programs under the Gilead agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our collaboration with Gilead excludes our lead programs, PRMT5, USP1 and the undisclosed target for development in STK11-mutant&nbsp;lung cancer. We also
retain the right to identify and validate targets outside the scope of our collaboration with Gilead (all cell-autonomous&nbsp;targets, exclusive of those in immune evasion contexts), and to develop and commercialize products directed to such
targets, on our own or in collaboration with third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with Medivir AB </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March&nbsp;2020, we entered into a license agreement, or the Medivir Agreement, with Medivir AB, or Medivir, pursuant to which we obtained a worldwide,
royalty-bearing, exclusive license under certain current and/or future patents <FONT STYLE="white-space:nowrap">and&nbsp;know-how&nbsp;of</FONT> Medivir, to research, develop and commercialize products that are covered by such licensed patents or
otherwise modulate USP1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Medivir Agreement, we are obligated to pay Medivir in connection with development, regulatory and
commercial activities. We have agreed to make certain milestone payments of (i)&nbsp;$1.4&nbsp;million in the aggregate for the first licensed product that achieves specified clinical milestones plus $25.0&nbsp;million for the first licensed product
that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and (ii)&nbsp;$0.7&nbsp;million in the aggregate if that first licensed product achieves specified clinical
milestones plus $5.0&nbsp;million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in
either of the first two specified genetic contexts. We have the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#146;s patents or if payments are due to a third party for a
license under such third party&#146;s intellectual property rights. We are also obligated to pay Medivir a low single-digit&nbsp;royalty on net sales of any product covered by a licensed patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments in respect of net sales or sublicense in a country shall remain in force on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis,</FONT></FONT> with respect to products that are not
covered by a licensed patent or certain of our patents, for ten years from the date of first commercial sale in such country, and products that are covered by a licensed patent or certain of our patents, until the expiration date of the last to
expire of the licensed patents covering such product or its manufacture or use in the applicable country. No milestones have been achieved to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead investigational products are
small molecule inhibitors that can be readily manufactured without requiring any specialized equipment or processes. We do not own or operate, and currently have no plans to establish any manufacturing facilities. We rely, and expect to continue to
rely, on third party Contract Development and Manufacturing Organizations, or CDMOs for the manufacturing, packaging, labeling and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution of our investigational products for preclinical and clinical testing, as well as for commercial manufacturing if any of our investigational products obtain marketing approval. A team
of internal experts and consultants oversees activities at contracted CDMOs ensuring our investigational products are being manufactured under current good manufacturing practices, or cGMP. At present, we have signed manufacturing and supply
agreements for drug substance and drug product to support the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human&nbsp;study</FONT></FONT> of our PRMT5 development candidate TNG908. The contracted CDMOs have the capacity
to support registrational studies and commercial supplies, in addition to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human&nbsp;study.</FONT></FONT> We plan to continue to expand and diversify our supply chain by
identifying and contracting other CDMOs with the capacity and expertise to support TNG908 and other investigational products in our pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance
the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We
also rely on trade secrets relating to our proprietary target discovery technology platform and on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and
<FONT STYLE="white-space:nowrap">in-licensing&nbsp;opportunities</FONT> to develop, strengthen and maintain our proprietary position in the field of precision oncology that may be important for the development of our business. We additionally may
rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success
may depend in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how&nbsp;related</FONT> to our business; defend and enforce
our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to limit third parties from making, using, selling, offering to sell,
or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may depend on third party licensors.
With respect to both licensed and company-owned&nbsp;intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future,
nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent expiration dates noted in the following paragraphs refer to statutory expiration dates and do not take into account any potential patent term
adjustment or extension that may be available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PRMT5 inhibitors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We exclusively own three patent families directed to selective, synthetic lethal, small molecule inhibitors of PRMT5 and methods for using the inhibitors in
the treatment of MTAP-deleted&nbsp;cancers. One family discloses and claims first generation small molecule PRMT5 inhibitors and methods of treating MTAP-deleted&nbsp;cancers using the compounds. One U.S. patent application has been allowed in this
family and will expire in 2039. A second family is directed to second-generation&nbsp;small molecule PRMT5 inhibitors and methods of treating MTAP-deleted&nbsp;cancers using the compounds. A Patent Cooperation Treaty application is pending in this
family, with a national phase entry date in April&nbsp;2022. If granted, patents in this family would have an expiration date in 2040. A third family covers third-generation&nbsp;selective, synthetic lethal, small molecule inhibitors of PRMT5 and
methods of treating MTAP-deleted&nbsp;cancers using the compounds. This family discloses the first product candidate in the PRMT5 program, TNG908. A U.S. provisional patent application is pending. Any future patents granted in this family would have
an expiration date in 2041. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>USP1 inhibitors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own four patent families directed to several chemical classes of small molecule inhibitors of USP1 and to methods for treating cancers, including
BRCA1-mutant&nbsp;breast, ovarian and prostate cancers using said inhibitors. U.S. provisional patent applications are pending in each of the four families. If granted, patents in each of the four families would expire in 2042. Two of the families
are exclusively owned by us, and the remaining two are jointly owned by us and Medivir AB and exclusively licensed to us under a license agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory
authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval&nbsp;monitoring and post-approval&nbsp;reporting of drugs. We, along with our vendors, contract research organizations, or CROs, clinical investigators
and contract manufacturing organizations, or CMOs will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct
studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of
substantial time and financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United&nbsp;States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or
FD&amp;C Act, its implementing regulations, and other federal, state and local statutes and regulations. Drugs are also subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other
requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion,
packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#146;s refusal to
approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or
partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates must be
approved for therapeutic indications by the FDA before they may be marketed in the United&nbsp;States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a New Drug Application, or NDA. The process generally involves the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical studies in accordance with applicable regulations, including studies
conducted in accordance with good laboratory practice, or GLP, requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor
intends to use in human clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated
annually and when certain changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site
before each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled&nbsp;clinical trials in accordance with applicable IND regulations,
good clinical practice, or GCP, requirements and other clinical trial-related&nbsp;regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60&nbsp;days of its receipt of an NDA to file the application for review;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval&nbsp;inspections</FONT>
of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and
purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the NDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA, including, where applicable, consideration of the views of any FDA advisory
committee, prior to any commercial marketing or sale of the drug in the United&nbsp;States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical studies and clinical
trials for drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include
laboratory evaluations of product chemistry, formulation and stability, as well as<I></I><I>&nbsp;in vitro</I>&nbsp;and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical
studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to
the FDA as part of an IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational product to humans and must be granted and
become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes the results of animal and<I></I><I>&nbsp;in
vitro</I>&nbsp;studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of
the investigational product. Some long-term&nbsp;preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the
<FONT STYLE="white-space:nowrap">30-day&nbsp;time</FONT> period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full
or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to
commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until any safety concerns or deficiencies articulated by
FDA are corrected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the
supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed
consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters
and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved
by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves
the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at
any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries.
Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on<I></I><I>&nbsp;www.ClinicalTrials.gov</I>, a clinical trials database
maintained by the National Institutes of Health. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United&nbsp;States may, but need not, obtain
FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP/ICH
requirements, and the FDA is able to validate the data through independent analysis and an onsite inspection if deemed necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials to
evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;1</I>&nbsp;&#151; Phase&nbsp;1 clinical trials involve initial introduction of the
investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the
investigational product in humans, excretion, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;2</I>&nbsp;&#151; Phase&nbsp;2 clinical trials typically involve administration of
the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#146;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and
safety risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;3</I>&nbsp;&#151; Phase&nbsp;3 clinical trials typically involve administration of
the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical
trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and
well-controlled&nbsp;Phase 3 trials are required by the FDA for approval of an NDA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2018, the FDA released a draft
guidance titled &#147;Expansion Cohorts: Use in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-In-Human&nbsp;Clinical</FONT></FONT> Trials to Expedite Development of Oncology Drugs and Biologics,&#148; which outlines how
drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human&nbsp;clinical</FONT></FONT> trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support
the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval&nbsp;trials, sometimes referred to as Phase&nbsp;4 clinical trials or post-marketing&nbsp;studies, may be conducted after initial marketing
approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In
certain instances, the FDA may mandate the completion of Phase&nbsp;4 clinical trials as a condition of NDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progress reports detailing the
results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators 15 days after the trial sponsor determines the information
qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or<I></I><I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk for human volunteers and any clinically important increase
in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening&nbsp;suspected adverse reaction as soon as possible but
in no case later than seven calendar days after the sponsor&#146;s initial receipt of the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of
the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability
studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. marketing
approval for drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials,
together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA package requesting approval to market the product for one or
more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#146;s safety and efficacy for the requested indications. The marketing application is required to
include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among
other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval,
the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug to the satisfaction of the FDA. The FDA must approve an NDA before a drug may be marketed in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request
additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60&nbsp;days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth&nbsp;substantive</FONT> review of the NDA. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective for the indications sought
and whether the facility in which it is manufactured, processed, packaged or held meets standards, including cGMP requirements, designed to assure and preserve the product&#146;s continued identity, strength, quality and purity. Under the goals and
policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and 6 months from
the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee
waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs,
unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan&nbsp;indication.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a Risk
Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies
like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization&nbsp;tools. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and
other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the
manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is
not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA, except that where the FDA determines that the data supporting the application are
inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may
require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of
this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an
approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even
if the FDA approves a product, depending on the specific risks to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that
post-approval&nbsp;studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a product&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other
conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product
based on the results of post-marketing&nbsp;studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to
further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation and exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition
with either a patient population of fewer than 200,000 individuals in the United&nbsp;States, or a patient population greater than 200,000 individuals in the United&nbsp;States when there is no reasonable expectation that the cost of developing and
making the product available in the United&nbsp;States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the
generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though
companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to a seven-year&nbsp;period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent
product&#146;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors, however, may receive approval of different therapeutic agents for the indication for which the
orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven
years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an
indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United&nbsp;States may be lost if the FDA later determines that the request for designation was
materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited development and review programs for drugs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of
serious or life-threatening&nbsp;diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the
development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A new drug is
eligible for Fast Track designation if it is intended to treat a serious or life-threatening&nbsp;disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the
combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to
the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening&nbsp;disease or
condition and preliminary clinical evidence indicates that the drug, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development program beginning as
early as Phase&nbsp;1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary&nbsp;review, where appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional
FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA is submitted, if the product that is the subject of the
marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#146;s goal date to take action on
the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical
benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking
into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accelerated Approval is usually
contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, adequate and well-controlled&nbsp;additional post-approval&nbsp;confirmatory studies to verify and describe the product&#146;s clinical benefit. The FDA may withdraw approval
of a drug or an indication approved under Accelerated Approval if, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, as a condition for Accelerated Approval, that all
advertising and promotional materials intended for dissemination or publication within 120&nbsp;days of marketing approval be submitted to the agency for review during the <FONT STYLE="white-space:nowrap">pre-approval&nbsp;review</FONT> period.
After the <FONT STYLE="white-space:nowrap">120-day&nbsp;period</FONT> has passed, all advertising and promotional materials must be submitted at least 30&nbsp;days prior to the intended time of initial dissemination or publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or
the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the
quality of evidence necessary to support approval, though they may expedite the development or review process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information and pediatric
exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and NDA supplements must contain data that can be used to
assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The
FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a product candidate that includes a new active ingredient, new
indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60&nbsp;days of an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase&nbsp;2</FONT></FONT> meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must
include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information,
and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor
can submit amendments to an agreed-upon&nbsp;initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.
Unless otherwise required by regulation, PREA does not apply to a drug for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA for a new active ingredient that is orphan-designated&nbsp;if the
drug is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A drug can also obtain pediatric market exclusivity in the United&nbsp;States. Pediatric exclusivity, if granted, adds six months to existing exclusivity
periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month&nbsp;exclusivity,</FONT> which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in
accordance with an <FONT STYLE="white-space:nowrap">FDA-issued&nbsp;&#147;Written</FONT> Request&#148; for such a study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. post-approval
requirements for drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions
on promoting products for unapproved uses or patient populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label&nbsp;use&#148;)</FONT> and limitations on industry-sponsored&nbsp;scientific and educational activities. Although physicians
may prescribe approved products for <FONT STYLE="white-space:nowrap">off-label&nbsp;uses,</FONT> manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label&nbsp;uses,</FONT> including not only by company employees but also by agents of the company or those speaking on the company&#146;s behalf, and a company that is found to have improperly promoted <FONT
STYLE="white-space:nowrap">off-label&nbsp;uses</FONT> may be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant liability, including investigation by federal and state authorities. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters,
corrective advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products are obtain reimbursement under federal health care programs. Promotional materials for approved drugs must be
submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to
submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval&nbsp;requirements as a condition of approval of an NDA. For example, the FDA may require
post-market&nbsp;testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the
manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the
change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third party manufacturers that a sponsor may
use. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory
requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program
user fee for any marketed product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market&nbsp;studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions
under a REMS. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications
containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval&nbsp;clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation
of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or
mandated modification of promotional materials and labeling and issuance of corrective information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of companion diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk
for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.
Companion diagnostics are regulated as medical devices by the FDA. In the United&nbsp;States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design
and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market&nbsp;surveillance.
Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a
medical device are clearance of a premarket notification, or 510(k), and approval of a PMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance for a medical device, or for
certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a <FONT
STYLE="white-space:nowrap">pre-amendment&nbsp;device</FONT> that was in commercial distribution before May&nbsp;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the
device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and
other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway
generally takes from three to 12 months from the date the application is completed, but can take significantly longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A PMA must be supported by valid
scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA
typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval&nbsp;inspection</FONT> of the manufacturing facility or facilities
to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#146;s review of an initial PMA is required by statute to
take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval
letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny
the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be
withdrawn by the FDA if compliance with post-approval&nbsp;requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#147;In Vitro Companion Diagnostic
Devices.&#148; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product,
the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a
drug cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in
July&nbsp;2016 setting forth the principles for <FONT STYLE="white-space:nowrap">co-development&nbsp;of</FONT> an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and
contemporaneous marketing authorization for the therapeutic product and its corresponding<I></I><I>&nbsp;in vitro</I>&nbsp;companion diagnostic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once cleared or approved, the companion diagnostic device must adhere to post-marketing&nbsp;requirements
including the requirements of the FDA&#146;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at
any time during which the FDA will conduct an audit of the product(s) and the company&#146;s facilities for compliance with its authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other
regulatory matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or
commercialization are also subject to regulation by numerous regulatory authorities in the United&nbsp;States in addition to the FDA, which may include the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the HHS, the
Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local
governments and governmental agencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other healthcare laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians, and third-party&nbsp;payors will play a primary role in the recommendation and prescription of any products for which we
obtain marketing approval. Our business operations and any current or future arrangements with third-party&nbsp;payors, healthcare providers and physicians may expose us to certain liabilities and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United&nbsp;States, these laws include, without limitation, state and
federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback&nbsp;Statute prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have
actual knowledge of the federal Anti-Kickback&nbsp;Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the
remuneration involved, imprisonment, and exclusion from government healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and
formulary managers, on the other. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback&nbsp;Statute constitutes a false or fraudulent claim for purposes of the
civil False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims
Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if
they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or
remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable by
Medicare or a state health care program, unless an exception applies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting
to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or
falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback&nbsp;Statute, a person or
entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information
including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to
business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing
federal civil actions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available
under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, for certain payments and &#147;transfers of value&#148; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors)
and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made in the previous
year to certain <FONT STYLE="white-space:nowrap">non-physician&nbsp;providers</FONT> such as physician assistants and nurse practitioners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities
that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback&nbsp;and
false claims laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and
relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of
marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are
not <FONT STYLE="white-space:nowrap">pre-empted&nbsp;by</FONT> HIPAA, which may complicate compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scope and
enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently
increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental
authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government
funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance&nbsp;with</FONT> these laws and
the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar actions,
penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming&nbsp;and can divert a company&#146;s
attention from its business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insurance Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United&nbsp;States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed
services generally rely on third-party&nbsp;payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party&nbsp;payors,
including government health programs in the United&nbsp;States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the
United&nbsp;States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors
tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party&nbsp;payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor.
The process for determining whether a third-party&nbsp;payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved.
Third-party&nbsp;payors are increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness&nbsp;of medical products and services and imposing controls to manage costs. Third-party&nbsp;payors may limit
coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness&nbsp;of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally,
companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party&nbsp;payor
not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party&nbsp;payor&#146;s decision to provide coverage
for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the
product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a
priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment&nbsp;programs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment&nbsp;measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a
company&#146;s revenue generated from the sale of any approved products. Coverage policies and third-party&nbsp;payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future healthcare reform legislation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United&nbsp;States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes
and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March&nbsp;2010, the
United&nbsp;States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. The ACA includes provisions of importance to our potential product candidates
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
rebate for both branded and generic drugs and revising the definition of &#147;average manufacturer price,&#148; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discounts&nbsp;off</FONT></FONT> the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created a new Patient-Centered&nbsp;Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous
judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically
ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage
through the ACA marketplace, which began on February&nbsp;15, 2021 and remained open through August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that
limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage
through Medicaid or the ACA. In December 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to
the outcome of the federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. The implementation of the ACA is
ongoing, the law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the ACA may
continue, with unpredictable and uncertain results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United&nbsp;States since the
Affordable Care Act was enacted. For example, in August&nbsp;2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
April&nbsp;2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The CARES Act, which was signed
into law in March&nbsp;2020 and is designed to provide financial support and resources to individuals and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> suspended these reductions from May&nbsp;1, 2020
through December&nbsp;31, 2020. In January&nbsp;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer
treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and
delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional
inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for pharmaceutical products. For example, at the federal level, the former Trump administration&#146;s budget proposal for fiscal year 2021 included a $135&nbsp;billion allowance to support legislative proposals seeking
to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket&nbsp;drug</FONT></FONT> costs for patients, and increase patient access to lower-cost&nbsp;generic and biosimilar
drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket&nbsp;pharmacy</FONT></FONT> expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket&nbsp;expenses,</FONT></FONT>
and place limits on pharmaceutical price increases. Further, the Trump administration also previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase
manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has
already implemented certain measures. For example, in May&nbsp;2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January&nbsp;1, 2020. However, it is unclear whether the Biden
administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions. In addition, individual states in the United&nbsp;States have also increasingly passed legislation and implemented regulations designed to
control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things,
provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients
can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result
of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the
United&nbsp;States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can
extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness&nbsp;of a product to other available therapies. The conduct of such a clinical trial could be expensive and
result in delays in commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries
provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness&nbsp;of a particular product candidate to currently
available therapies or <FONT STYLE="white-space:nowrap">so-called&nbsp;health</FONT> technology assessments, in order to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems
provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the
company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in
the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by
many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e.,
arbitrage between <FONT STYLE="white-space:nowrap">low-priced&nbsp;and</FONT> high-priced&nbsp;member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for
pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance
with other federal and state laws or requirements; changing legal requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any products that we may develop are made available to
authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant&nbsp;packaging requirements under the U.S. Poison Prevention Packaging Act.
Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and
security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory
requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal
healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including
government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our
business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling or packaging; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional recordkeeping requirements. If any such
changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other United States environmental, health and safety laws
and regulations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological
materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be
held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees, but this insurance may
not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future
environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation of drugs outside of the United&nbsp;States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To market any product outside of the United&nbsp;States, we would need to comply with numerous and varying regulatory requirements of other countries regarding
safety and efficacy and governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales and distribution of our products. For instance, in the United&nbsp;Kingdom and the European Economic Area, or the EEA
(comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Centralized procedure</I>&nbsp;&#151; The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological
processes, products designated as orphan medicinal products, advanced therapy products (gene therapy, somatic cell therapy and tissue engineered products) and products with a new active substance indicated for the treatment of certain diseases,
which includes products for the treatment of cancer. For medicines that do not fall within one of the mandatory categories, an applicant still has the option of submitting an application for a centralized marketing authorization to the European
Medicines Agency, or EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public
health in the EEA. If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, the EMA&#146;s Committee for Medicinal Products for Human Use, or CHMP, is responsible for conducting an
initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit/risk ratio. Under the centralized procedure the maximum timeframe for the evaluation of a marketing
authorization application, or MAA, by the EMA is 210&nbsp;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of
evaluation of a MAA considerably beyond 210&nbsp;days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing
authorization, which is issued within 67&nbsp;days of receipt of the EMA&#146;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest,
particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150&nbsp;days, excluding clock stops, but it is possible that the CHMP may revert to the standard
time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>National authorization procedures</I>&nbsp;&#151; There are also two other possible routes to authorize
products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Decentralized procedure</I>&nbsp;&#151; Using the decentralized procedure, an applicant may apply for
simultaneous authorization in more than one EEA Member State for a medicinal product that has not yet been authorized in any EEA Member State and that does not fall within the mandatory scope of the centralized procedure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Mutual recognition procedure</I>&nbsp;&#151; In the mutual recognition procedure, a medicine is first
authorized in one EEA Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EEA Member States in a procedure whereby the countries concerned recognize
the validity of the original, national marketing authorization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both cases, as with the centralized procedure, the competent
authorities of the EEA Member States assess the risk-benefit&nbsp;balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e.,&nbsp;innovator products) qualify for eight years of data
exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from referencing the preclinical and clinical trial data contained in the dossier of
the innovator product when applying for a generic or biosimilar marketing authorization in the EEA during a period of eight years from the date on which the innovator product was first authorized in the EEA. The additional <FONT
STYLE="white-space:nowrap">two-year&nbsp;period</FONT> of market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EEA until ten years have elapsed from the initial authorization of the
reference product in the European Union. The overall <FONT STYLE="white-space:nowrap">ten-year&nbsp;period</FONT> can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is
considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on a MAA with a complete
independent data package of pharmaceutical tests, preclinical tests and clinical trials </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#147;orphan medicinal
product&#148; in the EEA are similar in principle to those in the United&nbsp;States. Under Article 3 of Regulation (EC) 141/2000, in the EEA a medicinal product may be designated as orphan if it meets the following criteria: (i)&nbsp;it is intended
for the diagnosis, prevention or treatment of a life-threatening&nbsp;or chronically debilitating condition; and (ii)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the EEA when the application is made, or
(b)&nbsp;it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EEA to justify the investment needed for its development; and (iii)&nbsp;there exists no satisfactory method of
diagnosis, prevention or treatment of such condition, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of
fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this <FONT STYLE="white-space:nowrap">ten-year&nbsp;orphan</FONT> market exclusivity
period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication, unless (i)&nbsp;the second applicant can establish that its product, although
similar, is safer, more effective or otherwise clinically superior than the authorized product; (ii)&nbsp;the marketing authorization holder of the authorized product consents to a second orphan medicinal product application; or (iii)&nbsp;the
marketing authorization holder of the authorized product cannot supply enough orphan medicinal product. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. The <FONT
STYLE="white-space:nowrap">ten-year&nbsp;market</FONT> exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. The application for orphan drug designation
must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing
authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United&nbsp;States, the various phases of <FONT STYLE="white-space:nowrap">non-clinical&nbsp;and</FONT> clinical research in the European Union
are subject to significant regulatory controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national
implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the national competent authority, or NCA, of the
EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee, or EC, has issued a favorable opinion. The clinical trial
application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and the provisions of the
individual EU Member States&#146; legislation implementing the Clinical Trials Directive. Under the current regime (the EU Clinical Trials Directive 2001/20/EC and corresponding national laws) all suspected unexpected serious adverse reactions to
the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
April&nbsp;2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. It is expected that the new Clinical Trials Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the
Clinical Trials Information System (CTIS), the centralized European Union portal and database for clinical trials foreseen by the regulation, through an independent audit. The regulation becomes applicable six&nbsp;months after the European
Commission publishes notice of this confirmation. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the
European Union will continue to be bound by the Clinical Trials Directive and the Member States&#146; national implementing legislation until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be
governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the
Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European
Union. The main characteristics of the regulation include: a streamlined application procedure via a single-entry&nbsp;point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as well as simplified
reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&nbsp;I is assessed by the competent authorities of all EU Member States in which
an application for authorization of a clinical trial has been submitted (Member States concerned). Part&nbsp;II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial
applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials
Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation of data collection outside of the United&nbsp;States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event we conduct clinical trials in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health
data in the European Economic Area, or EEA (being the European Union plus Norway, Iceland, and Liechtenstein), is governed by the General Data Protection Regulation, or the GDPR, which became effective on May&nbsp;25, 2018. The GDPR applies to the
processing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to
data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects,
expanded disclosures about how personal data is used, enhanced requirements for securing personal data, requirements to conduct privacy impact assessments for &#147;high risk&#148; processing, limitations on retention of personal data, mandatory
data breach notification and &#147;privacy by design&#148; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries
that do not ensure an adequate level of protection, like the United&nbsp;States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and
Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#146;s global revenue for the preceding financial year, or &#128;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the
right to claim material and <FONT STYLE="white-space:nowrap">non-material&nbsp;damages</FONT> resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will
require significant time, resources and expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There has been limited enforcement of the GDPR to date, particularly in
biopharmaceutical development, so we face uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in
interpretation of the new law. Further, the United&nbsp;Kingdom&#146;s decision to leave the European Union, means that it has in force its own legislation which is aligned with the GDPR, known as the Data Protection Act 2018. The requirements are
similar except that the United&nbsp;Kingdom is now regarded as a &#147;third country&#148; for the purposes of transfers of personal data from the EEA. Transfers continue to flow freely from the United Kingdom to the EEA; however, as part of the
agreement between the United Kingdom and the European Union, the United Kingdom intends to obtain an adequacy decision from the European Commission to ensure personal data can continue to flow freely from the European Union to the United Kingdom.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data protection authority activity differs across the European Union, with certain authorities applying their own agenda which shows there is uncertainty
in the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will
wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should we utilize third party distributors, compliance with such foreign governmental regulations would generally be the
responsibility of such distributors, who may be independent contractors over whom we have limited control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face direct competition from pharmaceutical and biotechnology companies leveraging the principle of synthetic lethality as well as companies developing
therapies for the same target pathway. Well- established companies that are developing or may develop therapies based on synthetic lethality include AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Merck KGaA and Pfizer. Smaller and
earlier-stage&nbsp;companies focused on synthetic lethality include Artios Pharma, Cyteir Therapeutics, KSQ Therapeutics, Ideaya Biosciences, MetaboMed, Mirati Therapeutics and Repare Therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related to our PRMT5 inhibitor program, TNG908, we face direct competition from companies that have advanced preclinical-stage,
<FONT STYLE="white-space:nowrap">MTA-cooperative&nbsp;PRMT5</FONT> inhibitors that are selective for MTAP-deleted&nbsp;cancers. We are aware that Mirati Therapeutics, Inc. has a preclinical
<FONT STYLE="white-space:nowrap">MTA-cooperative&nbsp;PRMT5</FONT> inhibitor program, using the same mechanism of action as TNG908. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indirect competition may come from <FONT STYLE="white-space:nowrap">non-MTAP&nbsp;deletion</FONT> selective
PRMT5 programs or MAT2A inhibitor programs that are uniquely different than the TNG908 mechanism of action. Several <FONT STYLE="white-space:nowrap">non-MTAP&nbsp;deletion</FONT> selective PRMT5 inhibitors are in clinical development, including
GlaxoSmithKline (GSK3326595), Prelude Therapeutics (PRT543 and PRT811), Johnson&nbsp;&amp; Johnson (JNJ 64619178) and Pfizer (PF 06939999). These PRMT5 inhibitors are not selective for MTAP deletions, do not have a patient selection strategy based
on MTAP deletion and we believe TNG908 may have a wider therapeutic window than these <FONT STYLE="white-space:nowrap">non-selective&nbsp;competitor</FONT> candidates. MAT2A is an enzyme upstream of PRMT5 essential for the metabolism of the PRMT5 <FONT
STYLE="white-space:nowrap">co-factor&nbsp;SAM</FONT> that acts on the same pathway as TNG908. Agios Pharmaceuticals <FONT STYLE="white-space:nowrap">(AG-0270)</FONT> and Ideaya Biosciences (IDE397) are the two companies we are aware of competing in
the MAT2A space. Agios announced the divestment of their oncology portfolio to Servier Pharmaceuticals, including the MAT2A program in December&nbsp;2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competition for our preclinical&nbsp;USP1&nbsp;inhibitor program comes from KSQ Therapeutics, which has a USP1 program in preclinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face competition more broadly across the oncology market for safe, efficacious, and reimbursable cancer treatments. The most common methods of treating
patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, biologic therapy (such as monoclonal and bispecific antibodies), immunotherapy, cell-based&nbsp;therapy and targeted therapy, or a combination of
any such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing
drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and
others are available on a generic basis. Insurers and other third-party&nbsp;payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market
for, any of our product candidates that we successfully introduce to the market may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as our product
candidates progress through clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with their collaborators, have significantly greater
resources, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and
retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller
or early-stage companies may also prove significant competitors, particularly through collaborative arrangements with large and established companies. Additionally, mergers and acquisitions may result in even more resources being concentrated in our
competitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2021,
we had 86 full-time&nbsp;employees, of which 42 have M.D. or Ph.D. degrees. Within our workforce, 69 employees are engaged in research and development and 17 are engaged in business development, finance, legal, and general management and
administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional
employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based&nbsp;compensation awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate headquarters is located in Cambridge, Massachusetts, where we lease and occupy approximately 22,383 square feet of office and laboratory space.
The term of our lease expires on June&nbsp;30, 2026, with an option to extend for one additional three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our existing facilities
are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially
reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to
time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.
Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with the section entitled &#147;Unaudited Pro Forma Condensed Combined Financial Information&#148; and our financial statements and notes thereto included elsewhere in this prospectus. Certain of the information contained in this discussion
and analysis or set forth elsewhere in this prospectus, including information with respect to plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those
factors set forth in the section entitled &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should
carefully read the section entitled &#147;Risk Factors&#148; to gain an understanding of the material and other risks that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled
&#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a precision oncology company leveraging our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss
in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be directly targeted. Empowered by recent advances in CRISPR
technology, we are now able to employ a unique functional genomics approach and apply the principles of synthetic lethality to target the loss of specific tumor suppressor genes at scale. We believe this will result in establishing a sustainable
pipeline optimized to deliver meaningfully clinical benefit to patients. Our novel small molecules are designed to be selectively active in cancer cells with specific tumor suppressor gene loss, killing those cancer cells while being relatively
inert in normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse the effects of tumor suppressor gene loss that prevent
the immune system from recognizing and killing cancer cells (immune evasion). We believe this approach will provide the ability to deliver the deep, sustained target inhibition necessary for prolonged tumor regression and meaningful clinical benefit
as a result of the unique ability of synthetic lethal targeting to spare normal cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program, TNG908, a protein arginine methyl transferase 5,
or PRMT5, inhibitor that is synthetic lethal with MTAP deletion, is being developed as a treatment for cancers with MTAP deletions, which occur in 10% to 15% of all human cancers. In preclinical studies, TNG908 demonstrated <FONT
STYLE="white-space:nowrap">15-fold</FONT> greater potency in cells with MTAP deletions than those without. We plan to file an IND application for TNG908 in the fourth quarter of 2021 and initiate a Phase 1/2 clinical trial in the first half of 2022.
We are also developing a ubiquitin-specific protease&nbsp;1 (USP1) inhibitor that is synthetic lethal with BRCA1 mutations, which are present in approximately 15% of ovarian cancer, 5% of breast cancers, and 1% of prostate cancers. <I>In vitro</I>
and <I>in vivo</I> preclinical data demonstrated potent anti-tumor activity. We plan to file an IND in 2022 and expect this molecule to have both single agent activity in <FONT STYLE="white-space:nowrap">PARPi-na&iuml;ve</FONT> and PARPi-resistant
BRCA1 mutant cancers and to synergize with PARP inhibitors. Our third program, an undisclosed synthetic lethal target (Target 3), reverses the immune evasion effect of serine-threonine kinase 11 (STK11) <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations, which are present in approximately 20% of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. We plan to file an IND for this program in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2021, we completed a business combination transaction with BCTG Acquisition Corp., or BCTG, in which BCTG acquired 100% of our issued and
outstanding equity securities in exchange for $550.0&nbsp;million worth of consideration in the form of BCTG common stock, or the Business Combination. See &#147;<I>&#151;</I><I></I><I>&nbsp;Business Combination</I>&#148; below for additional
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have focused primarily on organizing and staffing our company, business planning, raising capital, discovering
product candidates, securing related intellectual property, and conducting research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and development activities for our programs. Since our inception, we have funded our operations primarily through equity financings and from the proceeds received from our collaboration agreement
with Gilead Sciences, Inc., or Gilead. Since inception we have raised an aggregate of approximately $166.9&nbsp;million of gross proceeds from the sale of preferred shares, approximately $352.9&nbsp;million in gross proceeds through the closing of
the Business Combination and PIPE Financing transactions and another $202.1&nbsp;million through our collaboration with Gilead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have
incurred significant operating losses. For the years ended December&nbsp;31, 2020 and 2019, and the six months ended June&nbsp;30, 2021, our net losses were $52.0&nbsp;million, $14.1&nbsp;million and $16.6&nbsp;million, respectively. We had an
accumulated deficit of $119.7&nbsp;million and $103.1&nbsp;million as of June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future,
as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio, as well as hire additional personnel,
pay for accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the SEC, director and officer liability insurance, investor and public
relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our preclinical studies, our clinical trials and our expenditures on other research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any product candidates approved for sale and have not generated any revenue from product sales. We will not generate revenue from product sales
unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates, if ever. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party
commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial
additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity
offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on
acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a negative effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to the ongoing global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including any novel variants such as the &#147;Delta
variant,&#148; we established a cross-functional task force and have implemented business continuity plans designed to address and mitigate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees and our
business. Our operations are considered an essential business and we have been allowed to continue operating under current governmental restrictions during this period. We have taken measures to secure our research and development activities, while
work in laboratories and facilities has been organized to reduce risk of <FONT STYLE="white-space:nowrap">COVID-19</FONT> transmission. The extent of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business,
operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our clinical trial enrollment, trial sites, CROs, CMOs and other
third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. While we are experiencing limited financial and operational impacts at this time, given the global economic
slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, our business, financial condition and results of operations ultimately could be materially adversely affected. We
continue to closely monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as we evolve our business continuity plans, clinical development plans and response strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, we executed a definitive merger agreement with BCTG and BCTG Merger Sub memorializing the terms of the Business Combination. The
Business Combination was approved on August&nbsp;9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of our issued and outstanding equity securities on August&nbsp;10, 2021. The Business Combination was accounted for as a &#147;reverse
recapitalization&#148; in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. Under the reverse recapitalization model, the Business Combination was treated as Tango issuing equity for the net assets of BCTG,
with no goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#147;acquired&#148; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the
Business Combination, our stockholders have a majority of the voting power of the combined company, we comprise all of the ongoing operations of the combined entity, we comprise a majority of the governing body of the combined company, and our
senior management comprise all of the senior management of the combined company. In connection with the Business Combination, BCTG was renamed Tango Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received gross proceeds of $166.8&nbsp;million upon the closing of the Business Combination. Upon the closing of the Business Combination, the PIPE
Investors purchased an aggregate of 18,610,000 shares of our common stock at a price of $10.00 per share, which resulted in gross proceeds of an additional $186.1&nbsp;million upon the closing of the PIPE Financing. Total transaction costs and
redemptions approximated $27.3&nbsp;million, resulting in total net proceeds of $325.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the merger agreement, at the
effective time of the Business Combination, each share of Old Tango redeemable convertible preferred stock issued and outstanding immediately prior to the effective time of the Business Combination was converted into a share of New Tango common
stock. At the effective time of the Business Combination, each option to purchase Old Tango common stock became an option to purchase shares of New Tango common stock, subject to adjustment in accordance with the exchange ratio. Completion of the
PIPE Financing and merger transaction were subject to approval of BCTG stockholders and the satisfaction or waiver of certain other customary closing conditions, all of which were satisfied or waived prior to closing on August&nbsp;10, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the next several
years. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as
to when we will generate such revenue, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Gilead Sciences </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October&nbsp;2018, we entered into a collaboration agreement with Gilead, or the 2018 Gilead Agreement. Pursuant to the terms of the 2018 Gilead Agreement,
we received an initial upfront payment of $50.0&nbsp;million. The upfront payment was initially recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July&nbsp;2019, Gilead licensed a program from us, and also separately contracted for additional services related to the program through a letter
agreement. As of December&nbsp;31, 2019, we had substantially completed our required obligations under the license and side letter agreement, and as a result, recognized $9.4&nbsp;million of revenue. As of December&nbsp;31, 2020, all remaining
obligations under the license and side letter agreement were completed, resulting in the recognition of the remaining consideration of $0.7&nbsp;million of revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the 2018 Gilead Agreement was expanded into a broader collaboration via an amended and
restated research collaboration and license agreement, or the Gilead Agreement. Pursuant to the terms of the Gilead Agreement, we received an upfront payment of $125.0&nbsp;million. Consistent with the treatment of the previously received upfront
payment, this upfront payment was recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December&nbsp;2020, Gilead elected to extend a program for an additional $12.0&nbsp;million fee which was added to our estimate of the transaction price to
total $187.0&nbsp;million. Certain portions of the payment related to this research extension remained outstanding at June&nbsp;30, 2021, however, we determined that achievement of the entire research extension fee was probable and that a
significant reversal in the amount of cumulative revenue recognized would not occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April&nbsp;2021, Gilead licensed a program for an
$11.0&nbsp;million fee. The $11.0&nbsp;million license fee was received in May&nbsp;2021 and recognized as revenue in the second quarter of 2021 since we have no continued involvement in the advancement of the program, Gilead can benefit from the
license on its own and the license is separately identifiable from the research services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, $37.8&nbsp;million has been
recognized as collaboration revenue related to the upfront and research extension payments from the agreement with Gilead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended
June&nbsp;30, 2021 and 2020, we recognized $20.7&nbsp;million and $13.8&nbsp;million, respectively, of revenue associated with the Gilead Agreements based on performance completed during each period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 2 and Note 3 to our unaudited condensed consolidated financial statements and related notes and our audited consolidated financial statements
and related notes appearing in elsewhere in this prospectus for additional information regarding our revenue recognition accounting policy and our collaboration agreement with Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, Gilead elected to extend a program for a research extension fee of $12.0&nbsp;million. Consideration pertaining to the research extension
is paid to us in equal quarterly installment payments over an agreed upon payment schedule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, other related costs
for those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development expenses incurred under agreements with CROs as well as consultants that
conduct our preclinical studies and development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing material for our preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and research materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to fulfill our obligations under the collaboration with Gilead; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent,
utilities and insurance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific
tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end
of any reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our direct external research and development expenses consist primarily of fees paid to CROs and outside consultants in
connection with our preclinical development and manufacturing activities. Our direct external research and development expenses also include fees incurred under license agreements. We track these external research and development costs on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis once we have identified a product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not
allocate employee costs, costs associated with our target discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as
such, are not separately classified. We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. We use internal resources primarily to conduct our research and discovery activities
as well as for managing our preclinical development and manufacturing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TNG908 direct program expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USP1 direct program expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery direct program expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and other related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and
development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the
timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and
preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to
each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#146;s commercial potential. Our
clinical development costs are expected to increase significantly as we commence clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing
product candidates, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies,
clinical trials and other research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile with IND enabling studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our product candidates show safety and efficacy in our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our collaboration with Gilead; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profile of products following any regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could
mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our
clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the FDA, European Medicines Agency, or EMA, or another regulatory authority were to delay
our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to
expend significant additional financial resources and time on the completion of clinical development of that product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense consists primarily of employee related costs, including salaries, bonuses, benefits,
stock-based compensation and other related costs. General and administrative expense also includes professional services, including legal, accounting and audit services and other consulting fees as well as facility costs not otherwise included in
research and development expenses, insurance and other general administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will
increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory,
compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income consists of income earned in connection with our investments in money market funds, U.S. Treasury bills and U.S. government agency bonds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income, net consists of
miscellaneous income and expense unrelated to our core operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benefit from (provision for) Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our benefit from (provision for) income tax consists of an estimate for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable
credits, deductions, uncertain tax positions, changes in deferred tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets and liabilities and changes in tax law. We have recorded an insignificant amount of income tax provision or benefit for the six months ended June&nbsp;30, 2021. There is no provision for
income taxes for the six months ended June&nbsp;30, 2020 and for the years ended December&nbsp;31, 2020 and 2019 because we have historically incurred net operating losses and maintain a full valuation allowance against our deferred tax assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months
Ended June&nbsp;30, 2021 and 2020 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the six months ended June&nbsp;30, 2021 and 2020:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration revenue was $13.5&nbsp;million and $9.1&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively, which was derived from
the Gilead collaboration. The increase of $4.4&nbsp;million is primarily due to incremental costs incurred under the Gilead Agreement during the six months ended June&nbsp;30, 2021 as compared to the six months ended June&nbsp;30, 2020 as well as an
increase in the total transaction price allocated to the combined performance obligation under the Gilead Agreement during the second half of 2020, which resulted in greater revenue recognized during the first half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration revenue was
$11.0&nbsp;million and $0.7&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively, which was derived from the Gilead collaboration. The increase of $10.3&nbsp;million is primarily due to the incremental revenue recognized
during the six months ended June&nbsp;30, 2021 from Gilead licensing a program for an $11.0&nbsp;million fee as compared to residual 2019 Gilead Letter Agreement revenue of $0.7&nbsp;million recognized during the six months ended June&nbsp;30, 2020.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense was $34.1&nbsp;million for the six months ended June&nbsp;30, 2021 compared to $22.0&nbsp;million for the six months ended
June&nbsp;30, 2020. The increase of $12.1&nbsp;million was primarily due to a $9.1&nbsp;million increase in external CRO expenses and lab supplies primarily relating to our lead product candidate, TNG908, and the advancement of our other drug
discovery programs. Additionally, personnel-related costs increased $2.3&nbsp;million primarily due to additional headcount to support our research and development activities as well as a $0.8&nbsp;million increase in IT spend, consulting and
professional fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $7.1&nbsp;million for the six months ended June&nbsp;30, 2021 compared to $4.3&nbsp;million for the six months ended
June&nbsp;30, 2020. The increase of $2.8&nbsp;million was primarily due to a $1.6&nbsp;million increase in personnel-related costs due to additional headcount and a $0.9&nbsp;million increase in consulting and professional fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income was $0.2&nbsp;million
for the six months ended June&nbsp;30, 2021 compared to $0.1&nbsp;million for the six months ended June&nbsp;30, 2020. Interest income was not significant for the six month periods primarily due to low interest rates in each period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other (Expense) Income, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net was
$0.1&nbsp;million for the six months ended June&nbsp;30, 2021 compared to other income, net of $0.1&nbsp;million for the six months ended June&nbsp;30, 2020. Other (expense) income was not significant for both the six months ended June&nbsp;30, 2021
and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provision for Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provision for
income taxes was less than $0.1&nbsp;million for the six months ended June&nbsp;30, 2021 compared to $0 for the six months ended June&nbsp;30, 2020. The increase of less than $0.1&nbsp;million is primarily attributable to taxable deferred revenue
partially offset by the utilization of federal and state net operating losses and federal and state tax credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended
December&nbsp;31, 2020 and 2019 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration revenue was $7.7&nbsp;million and $24.7&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively, which was derived from
the Gilead collaboration. The decrease of $17.0&nbsp;million was due to the majority of the obligations under the license and letter agreement being substantially completed in 2019, which resulted in greater revenue recognized in 2019. Additionally,
a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustment was recorded during 2020 due to executing the Gilead Agreement resulting in a reduction of $11.3&nbsp;million of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expense was $50.0&nbsp;million for the year ended December&nbsp;31, 2020 compared to $32.3&nbsp;million for the year ended December&nbsp;31, 2019. The increase of $17.7&nbsp;million was primarily due to a $13.7&nbsp;million increase in
external CRO expenses primarily relating to our lead product candidate, TNG908, and the advancement of our other drug discovery programs. Additionally, personnel-related costs increased $3.6&nbsp;million primarily due to additional headcount to
support our research and development activities as well as a $0.5&nbsp;million increase in consulting and professional fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $9.9&nbsp;million for the year ended December&nbsp;31, 2020 compared to
$7.5&nbsp;million for the year ended December&nbsp;31, 2019. The increase of $2.3&nbsp;million was primarily due to a $1.0&nbsp;million increase in personnel-related costs due to additional headcount and a $1.2&nbsp;million increase in consulting
and professional service fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income was $0.1&nbsp;million for the year ended December&nbsp;31, 2020 compared to $0.7&nbsp;million for the year ended December&nbsp;31, 2019. The
decrease of $0.6&nbsp;million was primarily due to a decline in interest rates in 2020 as compared to 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income, net was $0.1&nbsp;million for the year ended December&nbsp;31, 2020 compared to $0.4&nbsp;million for the year ended December&nbsp;31, 2019.
Other income was not significant for both the years ended December&nbsp;31, 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have
generated recurring net losses. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception, we have funded our operations primarily through
proceeds from the issuance of preferred stock and from the proceeds received from our collaboration with Gilead. We received gross proceeds of $352.9&nbsp;million upon the closing of the Business Combination and PIPE Financing in August 2021. Prior
to the Business Combination we raised an aggregate of approximately $166.9&nbsp;million of gross proceeds from the sale of our preferred stock and another $202.1&nbsp;million through our collaboration. As of June&nbsp;30, 2021, we had cash, cash
equivalents and marketable securities of $198.4&nbsp;million, not inclusive of the $325.6&nbsp;million in net proceeds received upon the closing of the Business Combination and PIPE Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the gross proceeds of approximately $352.9&nbsp;million from the Business Combination and the PIPE Financing, together with our existing cash,
cash equivalents and marketable securities on hand as of June&nbsp;30, 2021 of $198.4&nbsp;million will enable us to fund our operating expenses and capital expenditure requirements at least into the second half of 2024. We have based this estimate
on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to incur significant expenses and
operating losses for the foreseeable future as we advance our product candidates through preclinical and clinical development, seek regulatory approval and pursue commercialization of any approved product candidates. We expect that our research and
development and general and administrative costs will increase in connection with our planned research and development activities. In addition, we expect to incur additional costs associated with operating as a public company. Because of the
numerous risks and uncertainties associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements will depend on
many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, costs, progress and results of our planned clinical trials of TNG908;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of preclinical development and possible clinical trials of our current and future earlier-stage
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of our research programs and preclinical development of any additional
product candidates that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development requirements of other product candidates that we may pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development and establish a commercial
infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under
our current or future collaboration and license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing,
prosecuting, defending and enforcing our patent claims and other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by
third parties against us or any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we partner our programs, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other
product candidates and technologies or enter into additional collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of TNG908 and any future product candidates for which we
receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a
combination of equity offerings, debt financings, collaborations and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible securities, the ownership interest of our stockholders will be or could be diluted,
and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common shares. If we are unable to raise
additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if
we would otherwise prefer to develop and market such product candidates ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the six month periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing
activities. Operating cash flow is derived by adjusting our net loss for <FONT STYLE="white-space:nowrap">non-cash</FONT> operating items such as depreciation, and stock-based compensation as well as changes in operating assets and liabilities,
which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $21.1&nbsp;million for the six months ended June&nbsp;30, 2021 compared to net cash used in operating activities of
$23.1&nbsp;million for the six months ended June&nbsp;30, 2020. Our net loss drove our net cash used in operating activities. The largest <FONT STYLE="white-space:nowrap">non-cash</FONT> items reconciling included in our net loss were stock based
compensation expense of $2.1&nbsp;million for the six months ended June&nbsp;30, 2021 and $0.8&nbsp;million for the six months ended June&nbsp;30, 2020. The decrease in net cash used in operations was primarily due to higher <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses, including stock-based compensation and depreciation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities was $14.0&nbsp;million for the six months ended June&nbsp;30, 2021 compared to net cash used in investing activities
of $16.5&nbsp;million for the six months ended June&nbsp;30, 2020. The increase in cash provided by investing activities was primarily due to increased sales and maturities of marketable securities partially offset by purchases of marketable
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $29.7&nbsp;million for the six months ended June&nbsp;30, 2021 compared to net cash provided by financing
activities of $29.9&nbsp;million for the six months ended June&nbsp;30, 2020. The net cash provided by financing activities in both periods related to net proceeds from the issuance of shares of redeemable convertible Series B preferred stock, which
occurred in April 2020 and March&nbsp;2021, respectively. The decrease in net proceeds provided by financing activities was primarily due to merger related transaction expenses incurred in 2021, partially offset by greater proceeds from the
exercising of stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2020 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the years presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(146,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net
cash provided by operating activities was $70.1&nbsp;million for the year ended December&nbsp;31, 2020 compared to net cash used in operating activities of $24.8&nbsp;million for the year ended December&nbsp;31, 2019. The increase in net cash
provided by operations was primarily due to a net increase in operating liabilities driven by a $125.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment received from Gilead that was recorded as deferred revenue in
2020. It was also due to higher <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses, including stock-based compensation and depreciation, partially offset by our net loss as a result of higher operating expenses, primarily related to TNG908
and our other discovery programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $145.5&nbsp;million for the year ended December&nbsp;31, 2020 compared to net cash provided by investing activities
of $0.8&nbsp;million for the year ended December&nbsp;31, 2019. The increase in cash used in investing activities was primarily due to increased purchases of marketable securities and was partially offset by an increase in sales and maturities of
marketable securities, as well as a reduction in purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $80.9&nbsp;million for the year ended December&nbsp;31, 2020, consisting of net proceeds from the issuance of
shares of redeemable convertible Series B preferred stock in April&nbsp;2020 and net proceeds from the issuance of shares of redeemable convertible Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock in August&nbsp;2020. Net cash
provided by financing activities was $11.0&nbsp;million for the year ended December&nbsp;31, 2019, consisting of net proceeds from the issuance of shares of redeemable convertible Series A preferred stock in January&nbsp;2019 upon the achievement of
specified development milestones in connection with the third tranche of the Series A stock purchase agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations at December&nbsp;31, 2020 and the effects that such obligations are expected to have on our
liquidity and cash flows in future periods: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;&#150;&nbsp;3&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;&#150;&nbsp;5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table above reflect the minimum payments due under our operating lease for office and laboratory
space at our 100 Binney Street, Cambridge, Massachusetts location, which expires June&nbsp;2026. These commitments are also recognized as operating lease liabilities in our balance sheet at December&nbsp;31, 2020. The table does not include the
minimum payments due under our new operating lease for office and laboratory space at the 201 Brookline Avenue, Cambridge, Massachusetts location, as this lease is yet to commence as of December&nbsp;31, 2020. Commitments pertaining to the 201
Brookline Avenue lease will be added to the table above, and also recognized as operating lease liabilities on our balance sheet once the new lease commences. The fixed annual rent payable under the lease is $5.1&nbsp;million, increasing by 3%
annually from the rent commencement date. We will also be required to pay the remaining security deposit balance of $1.7&nbsp;million for the 201 Brookline Avenue lease on the delivery date notice, which is expected to occur in the second half of
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, our remaining obligations associated with the operating lease for office and laboratory space at our 100 Binney Street,
Cambridge, Massachusetts location totaled $9.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, we enter into contracts with third parties for preclinical studies and research and development supplies. These contracts
generally do not contain minimum purchase commitments and provide for termination on notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of
December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no material changes in our contractual obligations since December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into
license agreements under which we may be obligated to make milestone and royalty payments. We have not included future milestone or royalty payments under these agreements in the table above since the payment obligations are contingent upon future
events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. As of June&nbsp;30, 2021 and December&nbsp;31, 2020, we were unable to estimate the timing or likelihood of achieving these milestones
or generating future product sales. See Note 8 to our audited consolidated financial statements and notes included in this prospectus and Note&nbsp;7 to our unaudited condensed consolidated financial statements and related notes appearing elsewhere
in this prospectus for a description of our license agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us
to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these
estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected
in the consolidated financial statements prospectively from the date of change in estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in
more detail in Note 2 to our audited consolidated financial statements and related notes appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the
preparation of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of our collaboration agreements may include consideration such as <FONT STYLE="white-space:nowrap">non-refundable</FONT> <FONT
STYLE="white-space:nowrap">up-front</FONT> payments, license fees, research extension fees, and clinical, regulatory and sales-based milestones and royalties on product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize revenue under ASC Topic 606, <I>Revenue from Contracts with Customers</I>, or ASC 606, which applies to all contracts with customers, except for
contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services
is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of
the new revenue standard, we perform the following five steps: (i)&nbsp;identify the promised goods or services in the contract; (ii)&nbsp;determine whether the promised goods or services are performance obligations including whether they are
distinct in the context of the contract; (iii)&nbsp;measure the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the performance obligations; and (v)&nbsp;recognize revenue when (or
as) we satisfy each performance obligation. We only apply the five-step model to contracts when collectability of the consideration to which we are entitled in exchange for the goods or services we transfer to the customer is determined to be
probable. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods
and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. We then allocate the transaction price (the amount of consideration we expect to be entitled to from a
customer in exchange for the promised goods or services) to each performance obligation and recognize the associated revenue when (or as) each performance obligation is satisfied. Our estimate of the transaction price for each contract includes all
variable consideration to which we expect to be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize the transaction price allocated to license payments as revenue upon delivery of
the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not
be distinct from other performance obligations, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&nbsp;at a point in time, but only for licenses
determined to be distinct from other performance obligations in the contract, or (ii)&nbsp;over time; and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. We evaluate the measure
of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We evaluate whether it is
probable that the consideration associated with each milestone payment will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction
price until they meet this threshold. Milestones tied to regulatory approval, and therefore not within our control, are considered constrained until such approval is received. Upfront and ongoing development milestones under our collaboration
agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of a significant reversal of the cumulative
revenue recognized for the milestones, and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues
from collaborators in the period of adjustment. We exclude sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty
has been allocated has been satisfied or partially satisfied), because the license to our intellectual property is deemed to be the predominant item to which the royalties relate as it is the primary driver of value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 606 requires us to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or
service separately to a customer. If other observable transactions in which we have sold the same performance obligation separately are not available, we are required to estimate the standalone selling price of each performance obligation. Key
assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we determine that multiple promises to a customer are not distinct and comprise a combined performance obligation that includes services, we
recognize revenue over time using the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method, based on the total estimated cost to fulfill the obligation. Significant management judgment is required
in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred
revenue in the consolidated balance sheets. We have recorded short-term and long-term deferred revenue on our consolidated balance sheets based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of
amounts that are expected to be recognized as revenue in the next 12 months. Amounts that we expect will not be recognized within the next 12 months are classified as long-term deferred revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain instances, the timing of and total costs of satisfying these obligations under our collaboration agreement can be difficult to estimate.
Accordingly, our estimates may change in the future. Such changes to estimates would result in a change in revenue recognition amounts. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount
of revenue that we will recognize and record in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC 606, we will recognize revenue when we fulfill our performance obligations
under the agreement with Gilead. As the required performance obligation is satisfied, we will recognize revenue for the portion satisfied and record a receivable for any optional fees that have not been received. Amounts are recorded as short-term
collaboration receivables when our right to consideration is unconditional. A contract liability is recognized when a customer prepays consideration or owes payment to an entity in advance of our performance according to a contract. We do not assess
whether a contract has a significant financing component if the expectation at contract inception is that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. We
expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This
process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for
services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; however, some require advance payments, which would be recorded as a prepaid expense in other assets, or if there is the
right of offset, offset against our liability balance with the counterparty. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time.
At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record the expense
and accrual related to research and development activities performed by our vendors based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of
the research and development activities; invoicing to date under the contracts; communication from the vendors of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase
orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and
timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to
our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the consummation of the Business Combination, we estimate the fair value of our stock option awards using the Black Scholes method utilizing the
&#147;simplified method,&#148; for determining the expected life of the award, which is based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term as all options granted after becoming
a public entity will be granted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-money.&#148;</FONT></FONT> We determine the volatility for options granted based on an analysis of reported data for a peer group of
companies. The expected volatility of granted options has been determined using a weighted-average of the historical volatility measures of this peer group of companies. We will continue to apply this method until a sufficient amount of historical
information regarding the volatility of our own stock price becomes available. Our board of directors determines the fair value of each share of common stock underlying stock-based awards based on the closing price of our common stock as reported by
Nasdaq on the date of grant. The risk-free interest rate utilized in our calculations is based on a treasury instrument whose term is consistent with the expected life of the stock options. The expected dividend yield is assumed to be zero as we
have never paid dividends and do not have current plans to pay any dividends on our common stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the consummation of the Business Combination,
we measured stock-based awards granted to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and directors based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference
between the purchase price per share of the award, if any, and the fair value of our common stock for restricted common stock awards. As there was not a public market for our common stock prior to becoming publicly traded, the estimated fair value
of our common stock was determined by our board of directors as of the date of grant of each option or restricted stock award, considering our most recently available third-party valuations of common stock and our board of directors&#146; assessment
of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as
Compensation</I>. Our common stock valuations were prepared using either an option pricing method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and preferred stock as
call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes. Under this method, the common stock had value only if
the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method was a probability-weighted expected
return method, or PWERM, where the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimated the fair value of common stock based upon an analysis of future values for the company,
assuming various outcomes. The common stock value was based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future
value of the common stock under each outcome was discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of
marketability of the common stock was then applied to arrive at an indication of value for the common stock. The Black-Scholes option-pricing model also uses as inputs the fair value of our common stock and assumptions we make for the volatility of
our common stock, the expected term of our common stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options, and our expected dividend yield. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation expense for awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees
and directors and the period during which services are performed for <FONT STYLE="white-space:nowrap">non-employees.</FONT> We use the straight-line method to record the expense of awards with service-based vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our methodologies are reasonable based upon our internal peer company analyses and further supported by transactions involving our preferred stock.
If different assumptions had been made, equity-based compensation expense, consolidated net loss and consolidated net loss per share could have been significantly different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, by grant date, the number of shares subject to options granted from October&nbsp;18, 2019 through June&nbsp;30, 2021, the
exercise price per share of the options, the fair value per share on each grant date and the estimated per share fair value of the options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Common<BR>Shares<BR>Subject to<BR>Options<BR>Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price<BR>per&nbsp;Common<BR>Share(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value<BR>Per&nbsp;Common<BR>Share<BR>at Grant<BR>Date(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR><FONT STYLE="white-space:nowrap">Per-&nbsp;Share</FONT><BR>Fair&nbsp;Value<BR>of&nbsp;Options(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;18, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">534,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;22, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,171,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;2, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,251,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,697,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">596,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;28, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,805,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;18, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;19, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise price per share of common stock and fair value of our common stock represents the fair value of
our common stock on the date of grant, as determined by our board of directors, after taking into account our most recently available contemporaneous valuation of our common stock as well as additional factors that may have changed since the date of
such contemporaneous valuation through the date of grant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The estimated per share fair value of options reflects the weighted average fair value of options granted on
each grant date, determined using the Black-Scholes option-pricing model. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the time of the option grants on January&nbsp;28, 2021, our board of directors determined that the fair
value of our common stock of $1.19 per share calculated in the third-party valuation as of December&nbsp;14, 2020 described above reasonably reflected the per share fair value of our common stock as of the respective grant dates in that period.
However, as described below, the fair value of common stock at the date of these grants was adjusted in connection with retrospective fair value assessments for accounting purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing for the issuance of our financial statements for the year ended December&nbsp;31, 2020, in March&nbsp;2021, we performed a retrospective fair
value assessment and concluded that the fair value of our common shares underlying stock options that we granted on January&nbsp;28, 2021 was $1.81 per share for accounting purposes. We applied the fair value of our common shares from our
retrospective fair value assessment to determine the fair value of these awards and calculate stock-based compensation expense for accounting purposes. This reassessed value was based, in part, upon a third-party valuation of our common shares
prepared as of December&nbsp;14, 2020, inclusive of a retrospective valuation prepared as of January&nbsp;2021 reflecting the initial BCTG merger offer. The third-party valuation was prepared using an OPM, which used a market approach to determine
our enterprise value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed
within the unaudited condensed consolidated financial statements and related notes appearing elsewhere in this prospectus and also in Note 2 to our audited consolidated financial statements and related notes appearing elsewhere in this prospectus.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualitative and Quantitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to certain market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position
due to adverse changes in financial market prices and rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had cash, cash equivalents and marketable securities of $198.4&nbsp;million and $190.3&nbsp;million as of June&nbsp;30, 2021 and December&nbsp;31, 2020,
respectively, which consisted of cash, money market funds, U.S. Treasury bills and U.S. government agency bonds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an
immediate 1% change in interest rates would not have a material effect on the fair market value of our investment portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Exchange
Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our reporting and functional currency is the U.S. dollar. We currently do not have significant exposure to foreign currencies as we hold no
foreign exchange contracts, option contracts, or other foreign hedging arrangements. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effects of Inflation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that inflation
has had a material effect on our business, financial condition or results of operations. Our operations may be subject to inflation in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; under the JOBS Act. Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage
of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting
standards as private entities. As an emerging growth company, we may take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may present only two years of audited financial statements and only two years of related Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations in our periodic reports and registration statements, including this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may avail ourselves of the exemption from providing an auditor&#146;s attestation report on our system of
internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may provide reduced disclosure about our executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not require nonbinding advisory votes on executive compensation or stockholder approval of any golden
parachute payments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;December 31, 2025, (ii)&nbsp;the last day
of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the
second fiscal quarter of such year, provided we have been subject to the Exchange Act for at least 12 calendar months and have filed at least one annual report pursuant to the Exchange Act or (iv)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. We may choose to take advantage of some but not all of these exemptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated Registration and Shareholder Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, we entered into an Amended and Restated Registration and Stockholder Rights Agreement, or the Amended and Restated Registration and
Stockholder Rights Agreement with BCTG Holdings, LLC, or the Sponsor, certain persons and entities holding securities of New Tango, and entities receiving Common Stock pursuant to the Merger Agreement (the foregoing persons and entities, together
with other persons or entities who become party to the Amended and Restated Registration and Stockholder Rights Agreement collectively referred to as the Holders), pursuant to which we (i)&nbsp;agreed to register for resale (1)&nbsp;certain shares
of Common Stock held by, or issuable upon exercise of options held by, the Holders and (2)&nbsp;any warrants, shares of capital stock or other securities of our company issued as a dividend or other distribution with respect to, or in exchange for
or in replacement of the shares specified in clause (1) (the securities in clauses (1)&nbsp;and (2)&nbsp;collectively referred to as the Registrable Securities) and (ii)&nbsp;granted certain other registration rights to the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the Amended and Restated Registration and Stockholder Rights Agreement provides for the following registration rights: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Shelf registration/demand registration rights</I>. No later than 30&nbsp;calendar days following the Closing
Date, we are required to file with the SEC, a shelf registration statement registering the resale of the Registrable Securities, and use our commercially reasonable efforts to have such registration statement declared effective by the SEC within a
specified period. At any time and from time to time when an effective shelf registration statement is on file with the SEC, a Holder may request to sell all or any portion of such Holder&#146;s Registrable Securities by means of an underwritten
takedown off of the shelf registration statement, except that we are only obligated to effect such underwritten shelf takedown if such offering will include Registrable Securities proposed to be sold by the requesting Holder, either individually or
together with other requesting Holders, with a total offering price reasonably expected to exceed, in the aggregate, $20.0&nbsp;million. Additionally, we are not required to effect more than one underwritten shelf takedown in any <FONT
STYLE="white-space:nowrap">six-month</FONT> period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Piggyback registration rights</I>. Subject to exceptions for certain offerings and registration statements, if
at any time, we propose to file a registration statement under the Securities Act in connection with an offering of our equity securities or securities or other obligations exercisable or exchangeable for, or convertible into, our equity securities,
either for our own account or for the account of our stockholders, the Holders are entitled to include their Registrable Securities in such registration statement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expenses and indemnification</I>. The fees, costs and expenses of registrations pursuant to the registration
rights granted to the Holders under the Amended and Restated Registration and Stockholder Rights Agreement will be borne by us, except that underwriting discounts and selling commissions, brokerage fees, and certain other incremental selling
expenses will be borne by the holders of the shares being registered. The Amended and Restated Registration and Shareholder Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to us, and holders of Registrable Securities are obligated to indemnify us for material misstatements or omissions attributable to
them. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our securities shall cease to be Registrable Securities when (i)&nbsp;a registration statement with respect to the sale of such
securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration statement, (ii)&nbsp;such securities are freely saleable under Rule&nbsp;144 under the Securities
Act without any volume limitations or (iii)&nbsp;such securities shall have ceased to be outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amended and Restated Registration and
Stockholder Rights Agreement shall terminate on the earlier of (i)&nbsp;the 10th anniversary of the date of the agreement and (ii)&nbsp;with respect to any Holder, on the date that such Holder no longer holds any Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Amended and Restated Registration and Stockholder Rights Agreement does not
purport to be complete and is qualified in its entirety by the full text of the Amended and Restated Registration and Stockholder Rights Agreement, a copy of which is attached hereto as Exhibit 10.3 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, on the Closing Date, we entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with our directors, officers and
certain of our stockholders, or collectively, the Lockup Holders. The terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements provide for the Common Stock held by the Lockup Holders as of immediately after the effective time of the
Business Combination to be subject to transfer restrictions for a period of 180 days after the Closing Date, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
description of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements does not purport to be complete and is qualified in its entirety by the full text of the form of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, which is
attached hereto as Exhibit 10.2 and incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships and Related Person Transactions &#151; BCTG </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Founders Shares </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;4, 2020, BCTG
issued 3,593,750 shares of common stock to the Sponsor in exchange for a payment of $25,000. We refer to such issued shares in this prospectus as the Founder Shares. On September&nbsp;2, 2020, BCTG declared a dividend of 0.16 shares for each
outstanding share of common stock (an aggregate of 575,000 shares), resulting in an aggregate of 4,168,750 Founder Shares outstanding. The Sponsor had agreed to forfeit up to an aggregate of 543,750 Founders Shares, so that the Founders Shares would
represent 20% of BCTG&#146;s issued and outstanding shares after BCTG&#146;s initial public offering, to the extent the underwriters&#146; over-allotment option was not exercised in full or in part. On September&nbsp;8, 2020, the underwriters
exercised their 15% over-allotment option in full; thus, the Founders Shares were no longer subject to forfeiture. The Sponsor currently owns an aggregate of 4,493,450&nbsp;shares of our common stock, and its independent directors and advisors
collectively own 208,800&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial stockholders have agreed not to transfer, assign or sell any of their Founders
Shares (except to certain permitted transferees) until the earlier of (i)&nbsp;one year after the date of the consummation of the Business Combination or (ii)&nbsp;the date on which the closing price of our common stock equals or exceeds $12.00 per
share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading&nbsp;day</FONT> period commencing at least 150&nbsp;days after the Business
Combination, or earlier if, subsequent to the Business Combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares of
common stock for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Private Shares </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of BCTG&#146;s initial public offering, the Sponsor purchased 533,500 Private Shares, at a price of $10.00 per share, in a
private placement for an aggregate purchase price of approximately $5.3&nbsp;million. The Private Shares are identical to the shares of common stock sold in BCTG&#146;s initial public offering, subject to certain limited exceptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Related Party Loans </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2020
and June&nbsp;10, 2020, the Sponsor agreed to loan BCTG up to $25,025 and $274,975, respectively, for an aggregate amount of $300,000 to be used for the payment of costs related to BCTG&#146;s initial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public offering pursuant to a promissory note, or each, a Note, and collectively, the Notes. The Notes were <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured and due upon
the date BCTG consummated its initial public offering. BCTG borrowed approximately $127,000 under the Notes and repaid the Notes in full on September&nbsp;10, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to fund working capital deficiencies or finance transaction costs in connection with the Business Combination, the initial stockholders, officers and
directors and their affiliates could have, but were not obligated to, loan BCTG funds as may be required, or the Working Capital Loans. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the
Business Combination, without interest, or, at the lender&#146;s discretion, up to $1.5&nbsp;million of the notes may be converted upon consummation of the Business Combination into additional private placement shares at a conversion price of $10.00
per share. If BCTG did not complete a business combination, the loans would not be repaid. Such private placement shares would be identical to the Private Shares. BCTG did not have any borrowings under the Working Capital Loans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Administrative Support Agreement </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on September&nbsp;2, 2020, BCTG&#146;s prospectus, BCTG agreed to pay an affiliate of the Sponsor a total of $10,000 per month for office space and
certain office and secretarial services. Upon completion of the Business Combination, BCTG ceased paying these monthly fees. For the period from May&nbsp;21, 2020 (inception) through the completion of the Business Combination, BCTG incurred
approximately $110,000 related to these services. As of the date hereof, no amounts are payable related to this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Share Purchase
Commitment </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor entered into an agreement to purchase an aggregate of at least 2,500,000&nbsp;shares of BCTG&#146;s common stock for an
aggregate purchase price of $25.0&nbsp;million, or $10.00 per share, prior to, concurrently with, or following the closing of the Business Combination in a private placement. The funds from such private placement could be used as part of the
consideration to the sellers in the Business Combination, and any excess funds from such private placement may be used for working capital in the post-transaction company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PIPE Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Closing, PIPE Investors
subscribed for and purchased an aggregate of 18,610,000 shares of Common Stock at a price of $10.00 per share for aggregate gross proceeds of $186,100,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships and Related Person Transactions &#151; Old Tango </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2018 or any currently proposed transactions to which have been or will be a participant, in
which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers, or holders of more than 5% of our capital stock, or any member of the
immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described in the section titled &#147;<I>Executive Compensation</I>&#148; or that were
approved by its compensation committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the terms obtained or consideration that we paid or received, as applicable, in
connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Preferred Stock Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;7,
2020, Old Tango entered into a Series&nbsp;B Preferred Stock Purchase Agreement, or the Series&nbsp;B Purchase Agreement, pursuant to which Old Tango issued 45,372,050&nbsp;shares of its Series&nbsp;B Preferred Stock for a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per share price of $1.3224, for aggregate gross proceeds in the amount of $60.0&nbsp;million in two closings. The first closing of the Series&nbsp;B Preferred Stock financing occurred on
April&nbsp;7, 2020, and the second closing of the Series&nbsp;B Preferred Stock financing occurred on March&nbsp;11, 2021. The following holders of more than 5% of Old Tango&#146;s capital stock participated in the Series&nbsp;B Preferred Stock
financing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name of 5% Tango Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Series&nbsp;B<BR>Preferred&nbsp;Stock<BR>Purchased&nbsp;&#150;<BR>First&nbsp;Closing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price&nbsp;&#150;<BR>First&nbsp;Closing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Series&nbsp;B<BR>Preferred&nbsp;Stock<BR>Purchased&nbsp;&#150;<BR>Second&nbsp;Closing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price&nbsp;&#150;<BR>Second&nbsp;Closing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC and affiliated entities(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,507,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,507,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casdin Capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,890,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,499,999.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,890,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,499,999.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Asset Management and affiliated entities(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,781,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999,999.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,781,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4,999,999.70</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hillhouse Capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,726,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,249,999.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,726,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,249,999.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes Boxer Capital LLC, which purchased 8,417,650 shares at the first closing and 8,417,650 shares at the
second closing; and MVA Investors, LLC, which purchased 89,610 shares at the first closing and 89,610 shares at the second closing. Aaron Davis, a member of our board of directors, is Chief Executive Officer of Boxer Capital, LLC. Boxer Capital, LLC
and Mr.&nbsp;Davis are each affiliated with BCTG and the Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes Cormorant Private Healthcare Fund II, LP, which purchased 3,027,828 shares at the first closing and
3,027,828 shares at the second closing; Cormorant Global Healthcare Master Fund, LP, which purchased 707,048 shares at the first closing and 707,048 shares at the second closing; and CRMA SPV, LP, which purchased 46,128 shares at the first closing
and 46,128 shares at the second closing. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;17, 2020, Old Tango held the closing of its Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock financing, pursuant to its <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock Purchase Agreement, or the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Purchase Agreement, at which Old Tango issued 27,152,255 shares of its Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock for a per share price of $1.885, for aggregate gross proceeds in the amount of $51.2&nbsp;million. The following holders of more than 5% of Old Tango&#146;s capital stock participated in the <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock financing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of 5% Tango Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Series <FONT STYLE="white-space:nowrap">B-1</FONT><BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC and affiliated entities(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,511,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,519,684.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casdin Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,957,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,551.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Asset Management and affiliated entities(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,560,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,942,081.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hillhouse Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,950,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,677,602.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,610,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,999,998.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes Boxer Capital LLC, which purchased 3,392,141 shares; and MVA Investors, LLC, which purchased 119,628
shares. Aaron Davis, a member of our Board of Directors, is Chief Executive Officer of Boxer Capital, LLC. Boxer Capital, LLC and Mr.&nbsp;Davis are each affiliated with BCTG and the Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes Cormorant Private Healthcare Fund II, LP, which purchased 1,235,518 shares; and Cormorant Global
Healthcare Master Fund, LP, which purchased 325,268 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gilead Collaboration Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October&nbsp;2018, we entered into a Collaboration and License Agreement with Gilead Sciences, Inc. which collaboration was amended and restated on
August&nbsp;17, 2020, concurrently with the closing of the <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock financing in which Gilead Sciences, Inc. participated. Gilead Sciences, Inc. holds 5% or more of our capital stock.
See the section titled &#147;<I>Business</I><I></I><I>&nbsp;&#151; Collaboration and License Agreements</I><I></I><I>&nbsp;&#151; Collaboration and License Agreement with Gilead Sciences</I>&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the initial closing of the Series B Preferred Stock financing, Old Tango entered into an Amended and Restated Investors Rights Agreement, or
the Investors Rights Agreement with certain of its investors, including its 5% stockholders. Pursuant to the Investors Agreement, the investors were granted certain demand and registration rights as well as certain information rights. In connection
with the Merger, the Investors Rights Agreement was terminated at the closing of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the initial closing of the Series B Preferred Stock financing, Old Tango entered into an Amended and Restated Voting Agreement, or the
Voting Agreement with certain of its investors, including its 5% stockholders. Pursuant to the Investors Agreement, certain investors were given the right to designate certain members of Old Tango&#146;s board of directors. In connection with the
Merger, the Voting Agreement was terminated at the closing of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to indemnity agreements with our directors and executive officers. These agreements, among other things, require us to indemnify these individuals
for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such persons in any action or proceeding, including any action by or in our right, on account of any services undertaken by such
person on behalf of our company or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Policies for Approval of Related Party Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
board of directors reviews and approves transactions with directors, officers and holders of 5% or more our capital stock and their affiliates, or each, related party. Prior to the transaction, the material facts as to the related party&#146;s
relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are
not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction are
disclosed to the stockholders, who must approve the transaction in good faith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Policies and Procedures for Related Party Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification
of related person transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;Related Person Transaction&#148; is a transaction, arrangement or relationship in which we or any our
subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest. A &#147;Related Person&#148; means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any person who is, or at any time during the applicable period was, one of our officers or directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any person who is known by us to be the beneficial owner of more than 5% of our voting stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent,
stepparent, spouse, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law</FONT></FONT> of a director, officer or a beneficial owner of more than 5% of its voting stock, and any person (other than a tenant or employee) sharing the household of such director, officer or beneficial
owner of more than 5% of our voting stock; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any firm, corporation or other entity in which any of the foregoing persons is a partner or principal or in a
similar position or in which such person has a 10% or greater beneficial ownership interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have policies and procedures designed
to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time.
Specifically, pursuant to our charter, the audit committee has the responsibility to review related party transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_14"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning our directors and executive officers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Weber, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Class&nbsp;III&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Huang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexis Borisy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;III Director and Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lesley Calhoun</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;I Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;III Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reid Huber Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;I Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malte Peters, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;II Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Class&nbsp;II Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Barbara Weber, M.D.</B>&nbsp;has served as our President and Chief Executive Officer since March&nbsp;2017. Dr.&nbsp;Weber has been a Venture Partner at
Third Rock Ventures since March&nbsp;2015. Previously, Dr.&nbsp;Weber served as Senior Vice President, Oncology Translational Medicine, Novartis from 2009 to 2015, Vice President, Oncology, GSK from 2005 to 2009 and Professor, Medicine and Genetics,
University of Pennsylvania from 1994 to 2005. Dr.&nbsp;Weber has served on the board of directors of Revolution Medicines, Inc. (NASDAQ: RVMD), a biotechnology company, since April&nbsp;2018 and Fog Pharma, a private biopharmaceutical company, since
October&nbsp;2018. Dr.&nbsp;Weber received a B.S. in Chemistry and an M.D. from the University of Washington, was a resident in internal medicine at Yale University and fellow in Medical Oncology at the Dana Farber Cancer Institute. We believe
Dr.&nbsp;Weber qualifies to serve on our board based on her position as our President and Chief Executive Officer, her leadership experience and her extensive experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Daniella Beckman</B>&nbsp;has served as our Chief Financial Officer since September&nbsp;2019 and served as our interim Chief Financial Officer from
October&nbsp;2016 to August&nbsp;2019. Prior to joining us, she provided consulting and interim chief financial officer services for early-stage biotechnology companies since November&nbsp;2015. Previously, Ms.&nbsp;Beckman was the Chief Financial
Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June&nbsp;2011 until it was acquired by Merck&nbsp;&amp; Co., Inc., a pharmaceutical company, in August&nbsp;2014. Ms.&nbsp;Beckman has served on the board of directors of
Translate Bio, Inc., a clinical-stage mRNA therapeutics company, since October&nbsp;2017, on the board of directors of 5:01 Acquisition Corp, a special purpose acquisition company, since October&nbsp;2020 and on the board of directors of Vor
Biopharma Inc., a cell therapies company, since July&nbsp;2020. Ms.&nbsp;Beckman holds a B.S. in business administration-accounting&nbsp;from Boston University. She is also a certified public accountant in Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alan Huang, Ph.D.</B>, has served as our Chief Scientific Officer since April&nbsp;2018. Before being appointed as Chief Scientific officer, Dr.&nbsp;Huang
served as Senior Vice President, Head of Biology. From 2016 to 2017, he served as a consultant at Third Rock Ventures. Previously, Dr.&nbsp;Huang was Senior Director and interim Global Head of Oncology Translational Research at Novartis Institute
for Biomedical Research. Prior to joining Novartis, Dr.&nbsp;Huang was a senior scientist at Millennium Pharmaceuticals, Inc. Dr.&nbsp;Huang obtained his B.S. in biochemistry from Fudan University and his doctorate in biochemistry&nbsp;&amp;
molecular biology from the University of South Alabama. He completed a postdoctoral fellowship at Schepen&#146;s Eye Research Institute of Harvard Medical School. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alexis Borisy</B>&nbsp;has served as a member of our board of directors since our founding in 2017. Since June&nbsp;2019, Mr.&nbsp;Borisy has served as
Chief Executive Officer and chairman of EQRx, Inc., a biotechnology company. From </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2010 to June&nbsp;2019, Mr.&nbsp;Borisy was a partner at Third Rock Ventures, a series of venture capital funds investing in life science companies. Mr.&nbsp;Borisy
<FONT STYLE="white-space:nowrap">co-founded&nbsp;Blueprint</FONT> Medicines Corporation (NASDAQ: BPMC), a biopharmaceutical company, and served as its Interim Chief Executive Officer from 2013 to 2014 and has served as a member of its board of
directors since 2011. Mr.&nbsp;Borisy <FONT STYLE="white-space:nowrap">co-founded&nbsp;Foundation</FONT> Medicine, Inc. and served as its Interim Chief Executive Officer from 2009 to 2011 and served as a member of its board of directors from 2009 to
July&nbsp;2018, until its acquisition by Roche. In addition, during the past five years Mr.&nbsp;Borisy has served as a member of the board of directors of various public companies, including Relay Therapeutics, Inc. (NASDAQ: RLAY), Revolution
Medicines, Inc. (NASDAQ: RVMD), Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Editas Medicine, Inc. (NASDAQ: EDIT). Mr.&nbsp;Borisy received an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from
Harvard University. We believe Mr.&nbsp;Borisy&#146;s extensive experience as an executive of, and working with and serving on the boards of directors of, multiple biopharmaceutical and life sciences companies, his educational background and his
experience working in the venture capital industry provide him with the qualifications and skills necessary to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lesley Ann Calhoun</B>&nbsp;has served as a member of our board of directors since March&nbsp;2021. Since June&nbsp;2020, Ms.&nbsp;Calhoun has served as
Executive Vice President and Chief Financial Officer at Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company. From August&nbsp;2016 to June&nbsp;2020, Ms.&nbsp;Calhoun served as Senior Vice President of Finance&nbsp;&amp;
Administration and Chief Accounting Officer at Global Blood Therapeutics, Inc. From January&nbsp;2013 to September&nbsp;2015, Ms.&nbsp;Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial pharmaceutical company,
which was acquired by Horizon Pharma plc, a biopharmaceutical company, in May&nbsp;2015. Prior to Horizon Pharma, Ms.&nbsp;Calhoun served as Senior Director of Finance and Corporate Controller at Theravance, Inc., a biopharmaceutical company, from
August&nbsp;2005 to January&nbsp;2013. Prior to Theravance, Ms.&nbsp;Calhoun held various senior finance positions of increasing responsibility where she oversaw all aspects of finance and accounting operations for U.S. and multinational,
publicly-traded&nbsp;and <FONT STYLE="white-space:nowrap">pre-IPO&nbsp;stage</FONT> technology companies and in the biopharmaceutical industry. Earlier in her career, Ms.&nbsp;Calhoun was a member of the audit practice of Deloitte&nbsp;&amp; Touche
LLP from 1989 to 2001. Ms.&nbsp;Calhoun holds a B.S. in business administration with a concentration in accounting from San Francisco State University and is a Certified Public Accountant (inactive). We believe that Ms.&nbsp;Calhoun&#146;s financial
and accounting expertise and her experience in the finance and life sciences industries qualify her to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aaron Davis</B>&nbsp;has served as a member of our board of directors since April&nbsp;2020. Mr.&nbsp;Davis has been the Chief Executive Officer of Boxer
Capital, the healthcare arm of Tavistock Group, since 2012. He <FONT STYLE="white-space:nowrap">co-founded&nbsp;Boxer</FONT> Capital in 2005 and, prior to being appointed Chief Executive Officer in 2012, served as Portfolio Manager. Prior to the
Business Combination, Mr.&nbsp;Davis was the Chairman and Chief Executive Officer of BCTG Acquisition Corp., our predecessor company. He has also served as Executive Chairman of CiVi Biopharma Holdings, Inc. since 2016, as a member of the board of
directors of Odonate Therapeutics, Inc. (NASDAQ: ODT) since December&nbsp;2016; as a member of the board of directors of Mirati Therapeutics, Inc. (NASDAQ: MRTX) since December&nbsp;2018 and as a member of the board of directors of iTeos
Therapeutics, Inc. (NASDAQ: ITOS) since 2020. From 2000 to 2004, Mr.&nbsp;Davis worked in the Global Healthcare Investment Banking and Private Equity Groups at UBS Warburg, LLC. Mr.&nbsp;Davis holds an M.A. in biotechnology from Columbia University
and a B.B.A. degree in finance from Emory University. We believe that Mr.&nbsp;Davis&#146;s experience serving as a director of multiple biotechnology companies and his knowledge of funds specializing in the area of life sciences makes him qualified
to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reid M. Huber, Ph.D.,</B>&nbsp;has served as a member of our board of directors since July&nbsp;2019.
Dr.&nbsp;Huber has served as a Partner at Third Rock Ventures since December&nbsp;2018. From April&nbsp;2014 to December&nbsp;2018, Dr.&nbsp;Huber served as Executive Vice President and Chief Scientific Officer at Incyte Corporation, a
pharmaceutical company. From 2002 to 2014, Dr.&nbsp;Huber held various roles of increasing responsibility at Incyte. Prior to joining Incyte, Dr.&nbsp;Huber held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers&nbsp;Squibb
from 1997 to 2002. Dr.&nbsp;Huber has served on the board of directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) since October&nbsp;2014 and also currently serves on the board of MOMA Therapeutics, Asher Bio, Insitro
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and The American Cancer Society Dr.&nbsp;Huber received his Ph.D. in molecular genetics from the Washington University School of Medicine and held <FONT STYLE="white-space:nowrap">pre-</FONT> and
post-doctoral&nbsp;fellowships at the National Institutes of Health. We believe that Dr.&nbsp;Huber&#146;s extensive background in the pharmaceutical industry and senior management experience qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Malte Peters, M.D.,</B>&nbsp;has served on our board of directors since September&nbsp;2018. Since March&nbsp;2020, Dr.&nbsp;Peters has served as Chief
Research and Development Officer of MorphoSys AG, a biopharmaceutical company, and prior to that served as its Chief Development Officer and member of its management board since March&nbsp;2017. Prior to his time at MorphoSys, Dr.&nbsp;Peters served
as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. From 2004 to 2015, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine
at Novartis. Dr.&nbsp;Peters has also held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany, served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer
Research at Merck KGaA and as Medical Director at Micromet AG. Dr.&nbsp;Peters received his Doctor of Medicine from the Freie Universit&auml;t Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany.
After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany. We believe Dr.&nbsp;Peters&#146; extensive knowledge of the biotechnology industry&nbsp;makes him qualified to serve on our
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mace Rothenberg, M.D.</B>, has served on our board of directors since March&nbsp;2021. Dr.&nbsp;Rothenberg was previously at
Pfizer, Inc., a pharmaceutical company, where he served as Chief Medical Officer and Head of Worldwide Medical and Safety from 2019 to 2021, Chief Development Officer for Oncology from 2016 to 2018, and Senior Vice President for Clinical Development
and Medical Affairs for Pfizer Oncology from 2008 to 2016. Prior to joining Pfizer, Dr.&nbsp;Rothenberg spent 25&nbsp;years in academia, serving on the faculties of the University of Texas Health Science Center &#151; San Antonio and Vanderbilt
University Medical Center. Dr.&nbsp;Rothenberg is a fellow of the American College of Physicians and the American Society of Clinical Oncology and is board-certified&nbsp;in Internal Medicine and Medical Oncology. Dr.&nbsp;Rothenberg received his
B.A from the University of Pennsylvania, his M.D. from the New&nbsp;York University School of Medicine, completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute. We
believe Dr.&nbsp;Rothenberg&#146;s industry experience and life science expertise make him qualified to serve on our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family
Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is divided
into three staggered classes of directors, with each director assigned to one of the three classes. At each annual meeting of our stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class
whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the year 2022 for Class&nbsp;I directors, 2023 for Class&nbsp;II
directors and 2024 for Class&nbsp;III directors. Lesley Calhoun and Reid Huber currently serve as our Class&nbsp;I directors, Malte Peters and Mace Rothenberg currently serve as our Class&nbsp;II directors and Alexis Borisy, Aaron Davis and Barbara
Weber currently serve as our Class&nbsp;III directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that the number of directors shall be fixed
solely and exclusively by a resolution adopted from time to time by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The division of our board of directors into staggered classes
may delay or prevent stockholder efforts to effect a change of our management or a change in our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules of the Nasdaq require that a majority of our board of directors be independent. An &#147;independent director&#148; is defined generally as a person
other than an executive officer or employee of our company or any other individual having a relationship which, in the opinion of our board of directors, would interfere with the exercise of independent judgement in carrying out the responsibilities
of a director. Our board of directors has determined that each individual who serves on our board, other than Dr.&nbsp;Weber, qualifies as an independent director under the rules of Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of
directors has established three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operates pursuant to a written charter adopted by our board of directors. The
current members of our audit committee are Lesley Calhoun, Mace Rothenberg and Alexis Borisy, and Lesley Calhoun serves as the chairperson of the audit committee. The current members of our compensation committee are Malte Peters, Mace Rothenberg
and Alexis Borisy, and Malte Peters is the chairperson of the compensation committee. The current members of our nominating and corporate governance committee are Reid Huber, Aaron Davis, and Lesley&nbsp;Calhoun, and Reid Huber is the chairperson of
the nominating and corporate governance committee. The composition and functioning of all of our standing committees comply with all applicable requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules and regulations. Each of our standing
committees&#146; charter is available on our website at https://www.tangotx.com. Information contained on or accessible through such website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive
textual reference only. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
audit committee currently consists of Lesley Calhoun, Mace Rothenberg and Alexis Borisy. Our board has determined that each member of our audit committee is independent under Nasdaq listing standards and
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1)</FONT> under the Exchange Act. The chairperson of the audit committee is Lesley Calhoun. Our board has determined that Lesley Calhoun is an &#147;audit committee financial expert&#148; within
the meaning of SEC regulations. Our board has also determined that each member of the audit committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, our board has
examined each audit committee member&#146;s scope of experience and the nature of their employment in the corporate finance sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary purpose
of our audit committee is to discharge the responsibilities of our board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee our independent registered accounting firm. Specific
responsibilities of our audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement and qualifications of a qualified firm to serve as the independent registered
public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping to ensure the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end&nbsp;operating</FONT> results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing policies on financial risk assessment and financial risk management; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that
describes our internal quality-control&nbsp;procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving (or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving)</FONT> all audit and all permissible
<FONT STYLE="white-space:nowrap">non-audit&nbsp;service</FONT> to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee
currently consists of Malte Peters, Mace Rothenberg and Alexis Borisy. Our board has determined each member of our compensation committee is a <FONT STYLE="white-space:nowrap">&#147;non-employee&nbsp;director&#148;</FONT> as defined in <FONT
STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated under the Exchange Act and an &#147;outside director&#148; as that term is defined in Section&nbsp;162(m) of the Code. The chairperson of the compensation committee is Malte Peters. The
primary purpose of our compensation committee is to discharge the responsibilities of our board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers,
directors and other senior management, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our compensation committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending that our board approve, the compensation of our executive officers and
senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending that our board approve, the terms of compensatory arrangements with our
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our stock and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting independent compensation consultants and assessing whether there are any conflicts of interest with any
of the committee&#146;s compensation advisors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, approving, amending and terminating, or recommending that our board approve, amend or terminate,
incentive compensation and equity plans, severance agreements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other
senior management, as appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our overall compensation philosophy. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
nominating and corporate governance committee currently consists of Reid Huber, Aaron Davis, and Lesley&nbsp;Calhoun. Our board has determined each member is independent under Nasdaq listing standards. The chairperson of the nominating and corporate
governance committee is Reid Huber. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, evaluating and selecting, or recommending that our board approve, nominees for election to our
board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our board and of individual directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the adequacy of our corporate governance practices and reporting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing management succession plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board regarding corporate governance guidelines and matters.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Our Board of Directors in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. Our board does not have a standing risk management
committee, but rather administers this oversight function directly through our board as a whole, as well as through various standing committees of our board that address risks inherent in their respective areas of oversight. In particular, our board
is responsible for monitoring and assessing strategic risk exposure and our audit committee is responsible for considering and discussing our major financial risk exposures and the steps our management will take to monitor and control such
exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and regulatory requirements. Our compensation committee assesses and
monitors whether our compensation plans, policies and programs comply with applicable legal and regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Conduct that applies to all of our employees, officers and directors, including those&nbsp;officers responsible for financial
reporting. The Code of Conduct is available on our website at https://www.tangotx.com. Information contained on or accessible through such website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an
inactive textual reference only. We intend to disclose any amendments to the Code of Conduct, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_15"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, our
executive compensation program has reflected our growth and development-oriented&nbsp;corporate culture. To date, the compensation of our Chief Executive Officer and President and our other executive officers identified in the 2020 Summary
Compensation Table below, who we refer to as our named executive officers, has consisted of a combination of base salary, bonuses and long-term&nbsp;incentive compensation in the form of restricted common stock awards and incentive stock options.
Our named executive officers who are full-time&nbsp;employees, like all other full-time&nbsp;employees, are eligible to participate in our retirement and health and welfare benefit plans. As we transition from a private company to a publicly traded
company, we will evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances merit. At a minimum, we expect to review executive compensation annually with input from a compensation consultant. As part of
this review process, we expect our board of directors and our compensation committee to apply our values and philosophy, while considering the compensation levels needed to ensure our executive compensation program remains competitive with our
peers. In connection with our executive compensation program, we will also review whether we are meeting our retention objectives and the potential cost of replacing a key employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation awarded to, earned by, or paid to during the year ended December&nbsp;31, 2020 to (i)&nbsp;our principal
executive officer and (ii)&nbsp;our two next most highly compensated executive officers who were serving as executive officers at the end of the fiscal year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers for fiscal year 2020 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Barbara Weber, M.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniella Beckman, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alan Huang, Ph.D., our Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name and Principal<BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary(1)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards(3)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation(6)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Barbara&nbsp;Weber,&nbsp;M.D.(5) <I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,788</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Daniella Beckman <BR><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323,447(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,323</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,776</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">834,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Alan Huang, Ph.D. <BR><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">373,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,376</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Salary amount represents actual amounts paid during 2020. See &#147;&#151; <I>Narrative Disclosures to the
Summary Compensation Table</I> &#151; <I>Base Salaries</I>&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Beckman earned a base salary of $288,000 for the period between January&nbsp;1, 2020 and June&nbsp;30,
2020, which reflected her part-time status. Upon her appointment to full-time on July&nbsp;1, 2020, her salary was increased to $360,000. Her base salary and bonus were prorated to reflect her partial year of full-time employment from July&nbsp;1,
2020 through December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards
granted during fiscal year 2020 computed in accordance with ASC 718 for share-based compensation transactions. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock
options, the exercise of the stock options or the sale of the shares of common stock underlying such stock options. We provide information regarding the assumptions </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
used to calculate the value of all stock options made to our named executive officers in Note 11 to our audited financial statements included elsewhere in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reflected include an increase to Ms.&nbsp;Beckman&#146;s stock options to reflect her appointment
to full-time status, effective on July&nbsp;1, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Weber also serves as a member of our board of directors but does not receive any additional
compensation for her service as a director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects performance-based cash bonuses awarded to our named executive officers. See
<I>&#147;&#151;</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;Non-equity</FONT></I><I></I><I>&nbsp;incentive plan compensation</I>&#148; below for a description of the material terms of the program pursuant to which this compensation was
awarded. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported reflect $4,320 of commuter benefits, $2,865 of health benefits and life &amp; disability
insurance and $5,603 of expenses for phone services and home office expenses that we paid for on behalf of Dr. Weber. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported reflect $4,320 of commuter benefits, $1,684 for life &amp; disability premiums and $4,772
of expenses for phone services and home office expenses that we paid for on behalf of Ms.&nbsp;Beckman. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported reflect $4,320 of commuter benefits, $1,684 for life &amp; disability premiums and $3,372
of expenses for phone services and home office expenses that we paid for on behalf of Dr. Huang. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosures to the
Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors reviews compensation annually for all employees, including our named executives. In setting
executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, historical compensation level of our executives, individual performance as compared to our expectations and
objectives, our desire to motivate employees to achieve short- and long-term&nbsp;results that are in the best interests of our stockholders and a long-term&nbsp;commitment to value creation for our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual base salaries of our
named executive officers are generally determined, approved and reviewed periodically by our compensation committee in order to compensate our named executive officers for their satisfactory performance of duties to our company. Annual base salaries
are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed
necessary to attract and retain individuals with superior talent. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020&nbsp;Base<BR>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021&nbsp;Base<BR>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Weber, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">526,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Huang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">373,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">411,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Beckman transitioned to full-time employment on July&nbsp;1, 2020 and her salary was adjusted to
reflect her employment status with our company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2021 Base Salary is effective as of August&nbsp;10, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bonus program is intended to recognize and reward associates for achieving established objectives that are linked to our growth and success, thereby
allowing them to share in our performance based on corporate and individual accomplishments. Early in 2020, our board of directors determined a number of company performance goals for fiscal 2020 pertaining to (i)&nbsp;Early-stage target discovery
efforts of 30% (ii) Drug discovery efforts, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including the development efforts for our TNG908 program of 55% and (iii)&nbsp;Corporate Strategy and organizational objectives of 15%.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020<BR>Bonus<BR>Target&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021<BR>Bonus<BR>Target&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Weber, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Huang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2021 Bonus Target is effective as of August&nbsp;10, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weber, Ms.&nbsp;Beckman and Dr.&nbsp;Huang all earned bonuses as set forth in the 2020 Summary Compensation Table. Theses bonuses were based on
specified company and individual performance metrics which were approved by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our equity-based&nbsp;incentive awards granted to our named executive officers are designed to align our interests and those of our stockholders with those of
our employees and consultants, including our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have historically used stock options as an incentive for long-term compensation to
our executive officers because the stock options allow our executive officers to profit from this form of equity compensation only if our stock price increases relative to the stock option&#146;s exercise price, which exercise price is set at the
fair market value of our common stock on the date of grant. We may grant equity awards at such times as our board of directors or compensation committee determines appropriate. Our executives generally are awarded an initial grant in the form of
stock options in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving corporate goals or to reward certain performance. Our stock
options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in 36 equal monthly installments over the following three years, subject to the holder&#146;s continued employment with us. From
time to time, the board of directors may also construct alternative vesting schedules as it determines are appropriate to motivate particular employees. All options are granted with an exercise price that is no less than the fair market value of our
common stock on the date of such grant of such award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, we granted all stock options pursuant to our 2017 Plan (as
defined herein). The terms of our equity plans are described below under &#147;<I>Equity Plans.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Compensation Arrangements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initially entered into an offer letter with each of our named executive officers in connection with such officer&#146;s employment with us,
which set forth the terms and conditions of such officer&#146;s employment, including base salary, target annual bonus opportunity, initial equity awards and standard employee benefit plan participation. Effective upon the closing of the Business
Combination, we entered into an employment agreements with each of Dr.&nbsp;Weber, Ms.&nbsp;Beckman and Dr.&nbsp;Huang that replaced the offer letters and provide for specified payments and benefits in connection with a termination of employment in
certain circumstances. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the named executive officers will focus their full time and attention on the
requirements of the business rather than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the named executive officers, rather than negotiating severance at
the time that a named executive officer&#146;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain
circumstances are appropriate because they encourage our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
named executive officers to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally. The employment agreements with our named
executive officers will require the named executive officers to execute a separation agreement containing a general release of claims in our favor to receive any severance payments and benefits. The material terms of the employment agreements with
Dr.&nbsp;Weber, Ms.&nbsp;Beckman and Dr.&nbsp;Huang are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Barbara Weber, M.D. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Business Combination, we entered into a new employment agreement with&nbsp;Dr.&nbsp;Weber. Under Dr.&nbsp;Weber&#146;s
employment agreement, or the Weber Employment Agreement, Dr.&nbsp;Weber will serve as our Chief Executive Officer on an <FONT STYLE="white-space:nowrap">at-will&nbsp;basis.</FONT> Dr.&nbsp;Weber&#146;s base salary is $526,000, which is subject to
periodic review and adjustment, and she will be eligible to earn an annual bonus with a target amount equal to 50% of her base salary. Dr.&nbsp;Weber is eligible to participate in the employee benefit plans available to our employees, subject to the
terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Weber Employment Agreement, in the event that her employment is terminated by us without &#147;cause&#148; or
Dr.&nbsp;Weber resigns for &#147;good reason&#148; (as each term is defined in the Weber Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i)&nbsp;she
will be entitled to receive base salary continuation for 12&nbsp;months following termination, (ii)&nbsp;she will be entitled to receive a prorated portion of her target annual cash incentive compensation for the year of termination, payable over
the 12&nbsp;months following termination, (iii)&nbsp;subject to Dr.&nbsp;Weber&#146;s copayment of premium amounts at the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we will cover the portion of the
premium amount equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Weber had she remained employed with us until the earliest of (A)&nbsp;12 months following termination, (B)&nbsp;Dr.&nbsp;Weber&#146;s eligibility for
group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of Dr.&nbsp;Weber&#146;s COBRA health continuation period, and (iv)&nbsp;acceleration by 12&nbsp;months of the unvested portion of all stock options
and other stock-based&nbsp;awards subject solely to time-based&nbsp;vesting held by Dr.&nbsp;Weber. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In lieu of the payments and benefits described in the
preceding sentence, in the event that Dr.&nbsp;Weber&#146;s employment is terminated by us without cause or Dr.&nbsp;Weber resigns for good reason on or within 12&nbsp;months following a &#147;change in control&#148; (as defined in the Weber
Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i)&nbsp;she will be entitled to receive a lump sum in cash equal to 1.5 times Dr.&nbsp;Weber&#146;s
then-current&nbsp;annual base salary (or Dr.&nbsp;Weber&#146;s annual base salary in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to 1.5 times Dr.&nbsp;Weber&#146;s
target annual cash incentive compensation for the year of termination, (iii)&nbsp;subject to Dr.&nbsp;Weber&#146;s copayment of premium amounts at the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we
will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Weber had she remained employed with us until the earliest of (A)&nbsp;18 months following termination,
(B)&nbsp;Dr.&nbsp;Weber&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of Dr.&nbsp;Weber&#146;s COBRA health continuation period, and (iv)&nbsp;100% of all stock options and
other stock-based&nbsp;awards subject solely to time-based&nbsp;vesting held by Dr.&nbsp;Weber shall be accelerated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Daniella Beckman </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Business Combination, we entered into a new employment agreement with&nbsp;Ms.&nbsp;Beckman. Under Ms.&nbsp;Beckman&#146;s
employment agreement, or the Beckman Employment Agreement, Ms.&nbsp;Beckman will serve as our Chief Financial Officer on an <FONT STYLE="white-space:nowrap">at-will&nbsp;basis.</FONT> Ms.&nbsp;Beckman&#146;s base salary is $390,000, which is subject
to periodic review and adjustment, and she will be eligible to earn an annual bonus with a target amount equal to 40% of her base salary. Ms.&nbsp;Beckman is eligible to participate in the employee benefit plans available to our employees, subject
to the terms of those plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Beckman Employment Agreement, in the event that her employment is terminated by us without
&#147;cause&#148; or Ms.&nbsp;Beckman resigns for &#147;good reason&#148; (as each term is defined in the Beckman Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in
our favor, (i)&nbsp;she will be entitled to receive base salary continuation for 12&nbsp;months following termination, and (ii)&nbsp;subject to Ms.&nbsp;Beckman&#146;s copayment of premium amounts at the applicable active employees&#146; rate and
proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Ms.&nbsp;Beckman had she remained employed with us until the earliest of
(A)&nbsp;12 months following termination, (B)&nbsp;Ms.&nbsp;Beckman&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of Ms.&nbsp;Beckman&#146;s COBRA health continuation
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In lieu of the payments and benefits described in the preceding sentence, in the event that Ms.&nbsp;Beckman&#146;s employment is terminated by
us without cause or Ms.&nbsp;Beckman resigns for good reason on or within 12&nbsp;months following a &#147;change in control&#148; (as defined in the Beckman Employment Agreement), subject to the execution and effectiveness of a separation
agreement, including a general release of claims in our favor, (i)&nbsp;she will be entitled to receive a lump sum in cash equal to 1.0 times Ms.&nbsp;Beckman&#146;s then-current&nbsp;annual base salary (or Ms.&nbsp;Beckman&#146;s annual base salary
in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to Ms.&nbsp;Beckman&#146;s target annual cash incentive compensation for the year of termination, (iii)&nbsp;subject to
Ms.&nbsp;Beckman&#146;s copayment of premium amounts at the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to
provide health insurance to Ms.&nbsp;Beckman had she remained employed with us until the earliest of (A)&nbsp;12 months following termination, (B)&nbsp;Ms.&nbsp;Beckman&#146;s eligibility for group medical plan benefits under any other
employer&#146;s group medical plan or (C)&nbsp;the end of Ms.&nbsp;Beckman&#146;s COBRA health continuation period, and (iv) 100% of all stock options and other stock-based&nbsp;awards subject solely to time-based&nbsp;vesting held by
Ms.&nbsp;Beckman shall be accelerated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alan Huang, Ph.D. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Business Combination, we entered into a new employment agreement with&nbsp;Dr.&nbsp;Huang. Under Dr.&nbsp;Huang&#146;s
employment agreement, or the Huang Employment Agreement, Dr.&nbsp;Huang will serve as our Chief Scientific Officer on an <FONT STYLE="white-space:nowrap">at-will&nbsp;basis.</FONT> Dr.&nbsp;Huang&#146;s base salary is $411,000, which is subject to
periodic review and adjustment, and he will be eligible to earn an annual bonus with a target amount equal to 40% of his base salary. Dr.&nbsp;Huang is eligible to participate in the employee benefit plans available to our employees, subject to the
terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Huang Employment Agreement, in the event that his employment is terminated by us without &#147;cause&#148; or
Dr.&nbsp;Huang resigns for &#147;good reason&#148; (as each term is defined in the Huang Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i)&nbsp;he
will be entitled to receive base salary continuation for 12&nbsp;months following termination, and (ii)&nbsp;subject to Dr.&nbsp;Huang&#146;s copayment of premium amounts at the applicable active employees&#146; rate and proper election to continue
COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Huang had he remained employed with us until the earliest of (A)&nbsp;12 months following
termination, (B)&nbsp;Dr.&nbsp;Huang&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of Dr.&nbsp;Huang&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In lieu of the payments and benefits described in the preceding sentence, in the event that Dr.&nbsp;Huang&#146;s employment is terminated by us without cause
or Dr.&nbsp;Huang resigns for good reason on or within 12&nbsp;months following a &#147;change in control&#148; (as defined in the Huang Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general
release of claims in our favor, (i)&nbsp;he will be entitled to receive a lump sum in cash equal to 1.0 times Dr.&nbsp;Huang&#146;s then-current&nbsp;annual base salary (or Dr.&nbsp;Huang&#146;s annual base salary in effect immediately prior to the
change in control, if higher), (ii) he will be entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive a lump sum in cash equal to Dr.&nbsp;Huang&#146;s target annual cash incentive compensation for the year of termination, (iii)&nbsp;subject to Dr.&nbsp;Huang&#146;s copayment of premium
amounts at the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Huang
had he remained employed with us until the earliest of (A)&nbsp;12 months following termination, (B)&nbsp;Dr.&nbsp;Huang&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of
Dr.&nbsp;Huang&#146;s COBRA health continuation period, and (iv)&nbsp;100% of all stock options and other stock-based&nbsp;awards subject solely to time-based vesting held by Dr.&nbsp;Huang shall be accelerated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2020 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; "><B>Name and Principal <BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commence<BR>ment<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>(Exercisable)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>(UnExercisable)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Shares&nbsp;or<BR>Units of<BR>Stock<BR>That<BR>Have&nbsp;Not<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value<BR>of<BR>Shares&nbsp;or<BR>Units&nbsp;of<BR>Stock&nbsp;That<BR>Have&nbsp;Not<BR>Vested<BR>($)(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares,<BR>Units&nbsp;or<BR>Other<BR>Rights<BR>That&nbsp;
Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market<BR>or<BR>Payout<BR>Value&nbsp;Of<BR>Unearned<BR>Shares,<BR>Units&nbsp;or<BR>Other<BR>Rights<BR>That<BR>Have
Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Barbara&nbsp;Weber,&nbsp;M.D. <I>President and<BR>Chief Executive
Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/30/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/13/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">403,208</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/24/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336,007</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/24/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">645,132</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Daniella&nbsp;Beckman <I>Chief&nbsp;Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/10/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334,813</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/18/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,490</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,615</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/1/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Alan&nbsp;Huang,&nbsp;Ph.D. <I>Chief&nbsp;Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/16/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/16/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,709</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,334</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/24/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,167</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/24/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the awards in this table were granted under our 2017 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the option awards listed in the table were granted with an exercise price per share that is no less than
the fair market value of our common stock on the date of grant of such award. The fair market value has been determined by independent valuation experts and determined in good faith by our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These shares represent the unvested amount of restricted stock awards granted in July 2017. The total award
grant was 3,225,660 and vested 25% after the first anniversary and monthly over the next 36 months. These shares are subject to Dr.&nbsp;Weber&#146;s continued employment in our company and the unvested amount is subject to repurchase by us if no
longer employed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There was no public market value for our common stock as of December&nbsp;31, 2020. Market value as of
December&nbsp;31, 2020 was determined as $1.19/share, as determined by an independent valuation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% vesting after first anniversary and monthly vesting thereafter for 36 months assuming continuing employment
with our company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Monthly vesting for 48 months assuming continued employment with our company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares represent Ms.&nbsp;Beckman&#146;s transition to full-time status and are vested over 48 months assuming
continued employment with our company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Elements of Compensation; Perquisites </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health and Welfare Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During their employment, our
named executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental benefits, life insurance&nbsp;&amp; disability benefits, to the same extent as our other full-time&nbsp;employees, subject
to the terms and eligibility requirements of those plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Retirement Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. The
savings plan is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. Participants may make <FONT
STYLE="white-space:nowrap">pre-tax&nbsp;and</FONT> certain <FONT STYLE="white-space:nowrap">after-tax&nbsp;(Roth)</FONT> salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the
Code. Participants who are 50&nbsp;years of age or older may contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up&nbsp;contributions.</FONT> Participant contributions are held in trust as required
by law. Under this plan, we do not currently offer any matching contributions but will reserve the right to evaluate changes in the future. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other
full-time&nbsp;employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe
that our ability to grant equity-based&nbsp;awards is a valuable compensation tool that enables us to attract, retain, and motivate our employees, consultants, and directors by aligning their financial interests with those of our stockholders. The
principal features of our equity plans are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tango Therapeutics, Inc. 2017 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tango Therapeutics Inc. 2017 Stock Option and Grant Plan, or our 2017 Plan, was initially adopted by our board of directors and approved by our
stockholders in March 2017. The 2017 Plan was amended from time to time, and was amended and restated in December 2020 to increase the number of shares of common stock reserved for issuance under the plan. The 2017 Plan provided for the grant of
options to purchase shares of our common stock, as well as for the award of restricted stock and restricted stock units. Our 2017 Plan is administered by our compensation committee. Subject to the terms of the 2017 Plan, our committee has the power
and authority to, among other things, prescribe, amend, expand, modify and rescind rules and regulations relating to the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the 2017
Plan, we were permitted to grant incentive stock options, which are intended to qualify for tax treatment as set forth under Section&nbsp;422 of the Code, only to our full-time or part-time employees (including officers and directors who are also
employees). We could grant <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options and all other types of awards to our employees (including officers and directors who are also employees),
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants. The maximum permitted term of options granted under our 2017 Plan is ten years from the date of grant. In the case of an incentive stock option that is granted to a ten
percent stockholder, the term of such stock option cannot exceed five years from the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2017 Plan also provided for the issuance of
restricted stock awards pursuant to which the holder may purchase restricted shares of our common stock. Among other terms and conditions, we may retain an option to repurchase the unvested restricted stock for defined periods of time following the
holder&#146;s termination of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our compensation committee, awards granted under our 2017 Plan generally may not be
transferred or assigned in any manner other than by will or the laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the coming into effect of our 2021 Plan (discussed
below), our 2017 Plan was terminated and we will not grant any further awards under such plan, but our 2017 Plan will continue to govern outstanding awards granted thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan, or the 2021 Plan, became effective upon the closing of the Business Combination and replaced
our 2017 Plan. The 2021 Plan allows us to make equity and equity- based incentive awards to officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants. Our board anticipates that providing such persons with a
direct stake in our company will assure a closer alignment of the interests of such individuals with those of our company and our stockholders, thereby stimulating their efforts on our behalf and strengthening their desire to remain with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initially reserved 9,498,725 shares of common stock for the issuance of awards under the 2021 Plan, or the Initial Limit. The 2021 Plan provides that
the number of shares reserved and available for issuance under the 2021 Plan will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2022, by 5.0% of the outstanding number of shares of common stock on the immediately preceding
December&nbsp;31, or such lesser amount as determined by our board, or the Annual Increase. . This limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split
or other similar change in our capitalization. The maximum aggregate number of shares of common stock that may be issued upon exercise of incentive stock options under the 2021 Plan shall not exceed the Initial Limit cumulatively increased on
January&nbsp;1, 2022 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase or 4,749,362 shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
description of the 2021 Plan does not purport to be complete and is qualified in its entirety by reference to the text of the 2021 Plan, which is attached as Exhibit 10.6 hereto and incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares we issue under the 2021 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards
that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, or are otherwise terminated (other than by
exercise) under the 2021 Plan will be added back to the shares of common stock available for issuance under the 2021 Plan. The maximum aggregate number of shares of common stock that may be issued in the form of incentive stock options under the
2021 Plan shall not exceed the Initial Limit. The grant date fair value of all awards made under the 2021 Plan and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director for services as a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan will be administered by our
compensation committee. Our compensation committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the
specific terms and conditions of each award, subject to the provisions of the 2021 Plan. The administrator may delegate to a committee consisting of one or more officers the authority to grant awards to employees who are not subject to the reporting
and other provisions of Section&nbsp;16 of the Exchange Act and not members of the delegated committee, subject to certain limitations and guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons eligible to participate in the 2021 Plan will be those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors, and consultants of our company as selected from time to time by our compensation committee in its discretion. As of August&nbsp;31, 2021, approximately 122 individuals will be eligible to participate in the 2021 Plan, which includes
approximately 3 officers, 83 employees who are not officers, 6 <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and 30 consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. Options granted under the 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plan will be <FONT STYLE="white-space:nowrap">non-qualified</FONT> options if they do not qualify as incentive stock options or exceed the annual limit on
incentive stock options. Incentive stock options may only be granted to employees of our company and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiaries. <FONT STYLE="white-space:nowrap">Non-qualified</FONT> options may be granted to any persons eligible to awards under the 2021 Plan. The exercise price of each option will be
determined by the administrator but may not be less than 100% of the fair market value of the common stock on the date of grant or, in the case of an incentive stock option granted to a ten percent stockholder, 110% of such share&#146;s fair market
value. The term of each option will be fixed by our administrator and may not exceed ten years from the date of grant or, in the case of an incentive stock option granted to a ten percent stockholder, may not exceed five years from the date of
grant. The administrator will determine at what time or times each option may be exercised, including the ability to accelerate the vesting of such options. The exercise price of a stock option may not be reduced after the date of the option grant
without stockholder approval, other than to appropriately reflect changes in our capital structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercise of options, the option exercise price
may be paid in cash, by certified or bank check or other instrument acceptable to the administrator or by delivery (or attestation to the ownership) of shares of common stock that are beneficially owned by the optionee free of restrictions or were
purchased in the open market. Subject to applicable law, the exercise price may also be delivered by a broker pursuant to irrevocable instructions to the broker from the optionee. In addition, <FONT STYLE="white-space:nowrap">non-qualified</FONT>
options may be exercised using a &#147;net exercise&#148; arrangement that reduces the number of shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the
recipient to cash or shares of common stock equal to the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100% of the fair market value of our common stock on the date of grant. The term
of each stock appreciation right will be fixed by the administrator and may not exceed ten years from the date of grant. The administrator will determine at what time or times each stock appreciation right may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. The administrator may also grant shares of common stock that are free from
any restrictions under the 2021 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. The administrator may
grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator may grant cash-based awards under the 2021 Plan to participants, subject to the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2021 Plan, an acquirer or successor entity may assume,
continue or substitute outstanding awards under the 2021 Plan. To the extent that awards granted under the 2021 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, such awards shall
terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based vesting conditions or restrictions shall become fully vested and exercisable or nonforfeitable as of the effective time of the
sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and exercisable or nonforfeitable in connection with a sale event in the administrator&#146;s discretion or to the extent
specified in the relevant award certificate. In the event of such termination, we may make or provide for payment, in cash or in kind, to participants holding options and stock appreciation rights equal to the difference between the per share
consideration payable in the sale event and the exercise price of the all such outstanding options or stock appreciation rights (provided that, in the case of an option or stock appreciation right with an exercise price equal to or greater than the
per share consideration payable in such sale event, such option or stock appreciation right shall be cancelled for no consideration). We shall also have the option to make or provide for a payment, in cash or in kind, to grantees holding other
awards in an amount equal to the per share consideration payable in such sale event multiplied by the number of vested shares under such award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or discontinue the 2021 Plan and our compensation committee may amend or
cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2021 Plan
require the approval of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2021 Plan after the date that is ten years from the effective date of the
2021 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tango Therapeutics, Inc. Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a special meeting of the stockholders of BCTG held on August&nbsp;9, 2021, BCTG&#146;s stockholders considered and approved the Tango Therapeutics, Inc.
2021 Employee Stock Purchase Plan, or the ESPP. An aggregate of 949,873 shares is reserved and available for issuance under the ESPP. The ESPP provides that the number of shares reserved and available for issuance under the plan will automatically
increase each January&nbsp;1, beginning on January&nbsp;1, 2022, by (i) 1.0% of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31, or (ii) 949,873 shares of common stock or (iii)&nbsp;such number of
shares of common stock as determined by the administrator. If our capital structure changes because of a stock dividend, stock split or similar event, the number of shares that can be issued under the ESPP will be appropriately adjusted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
Merger, on August&nbsp;10, 2021, we entered into indemnification agreements with each of our directors and executive officers. Each indemnification agreement provides for indemnification and advancements by us of certain expenses and costs relating
to claims, suits or proceedings arising from each individual&#146;s service to us as an officer or director, as applicable, to the maximum extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the indemnification agreements is qualified in its entirety by the full text of the forms of indemnification agreement, which are
attached hereto as Exhibits 10.11 and 10.12 and incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. The
savings plan is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. Participants may make <FONT
STYLE="white-space:nowrap">pre-tax&nbsp;and</FONT> certain <FONT STYLE="white-space:nowrap">after-tax&nbsp;(Roth)</FONT> salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the
Code. Participants who are 50&nbsp;years of age or older may contribute additional amounts based on the statutory limits for <FONT STYLE="white-space:nowrap">catch-up&nbsp;contributions.</FONT> Participant contributions are held in trust as required
by law. Under this plan, we do not currently offer any matching contributions but will reserve the right to evaluate changes in the future. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other
full-time&nbsp;employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_16"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Business Combination, we adopted a compensation program for our
<FONT STYLE="white-space:nowrap">non-employee&nbsp;directors</FONT> under which each <FONT STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> will receive the following amounts for their services on our board of directors. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An option to purchase 80,000&nbsp;shares of our common stock upon the director&#146;s initial election or
appointment to our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An annual option to purchase 40,000&nbsp;shares of our common stock on the date of the annual meeting for such
year. Directors who were elected in the 12&nbsp;months preceding the annual grant are <FONT STYLE="white-space:nowrap">pro-rated&nbsp;on</FONT> a monthly basis for time in service. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An annual director fee of $40,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the director serves on a committee of our board of directors or in the other capacities stated below, an
additional annual fee as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-executive&nbsp;chairperson,</FONT> $30,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lead independent director, $15,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Audit committee chairperson, $15,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Audit committee member, $7,500 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation committee chairperson, $10,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation committee member, $5,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nomination and governance committee chairperson, $8,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nomination and governance committee member, $4,000 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted to our <FONT STYLE="white-space:nowrap">non-employee&nbsp;directors</FONT> under the program will have an exercise price equal to the fair
market value of our common stock on the date of grant and will expire not later than ten years after the date of grant. The options granted upon a director&#146;s initial election or appointment will vest in 48 substantially equal monthly
installments following the date of grant. In addition, all unvested options will vest in full upon the occurrence of a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not, and
do not expect to, provide separate compensation to our directors who are also our employees, such as Dr.&nbsp;Weber, our President and Chief Executive Officer. Dr.&nbsp;Weber&#146;s compensation as our principal executive officer in 2020 is reported
in the &#147;<I>Executive Compensation</I>&#148; section of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Director Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexis Borisy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cary Pfeffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malte Peters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Pellini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reid Huber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of
December&nbsp;31, 2020 by each <FONT STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> who was serving as of December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>outstanding<BR>at&nbsp;2020&nbsp;fiscal<BR>year end</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexis Borisy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cary Pfeffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reid Huber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malte Peters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Pellini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of certain provisions of our capital stock does not purport to be complete and is subject to our certificate of incorporation, our
bylaws and the provisions of applicable law. Copies of our certificate of incorporation and our bylaws are attached to this prospectus as Exhibits 3.1 and 3.2, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized and Outstanding Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate
of incorporation authorizes the issuance of 210,000,000&nbsp;shares, consisting of 200,000,000&nbsp;shares of common stock, $0.001 par value per share, and 10,000,000&nbsp;shares of preferred stock, $0.001 par value, all of which shares of preferred
stock will be undesignated. As of September 28, 2021, there were 87,474,258 shares of Common Stock outstanding and held by approximately 132 stockholders of record, and no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation
provides the following with respect to the rights, powers, preferences and privileges of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Power </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock
possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to any preferential rights of
holders of preferred stock then outstanding, holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. In no
event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation, Dissolution and Winding Up </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of our voluntary or involuntary liquidation, dissolution, distribution of assets or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of common stock will be entitled to receive an equal amount per share of all of our assets of
whatever kind available for distribution to stockholders, after the rights of the holders of then outstanding preferred stock with preferential rights have been satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive or Other Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock has
no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our stockholders, or Holders, hold registration rights pursuant to the Amended and Restated Registration and Stockholder Rights Agreement.
Stockholders holding a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest&nbsp;of</FONT></FONT> such registrable securities are entitled to make a written demand for registration under the Securities Act of all or
part of their registrable securities. Additional information regarding such registration rights is set forth in this prospectus under &#147;<I>Certain Relationships and Related Person Transactions &#151; Amended and Restated Registration and
Shareholder Rights Agreement</I>.&#148;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Amended <FONT STYLE="white-space:nowrap">By-laws</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other things, our certificate of incorporation and bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to 10,000,000&nbsp;shares of preferred stock, with any rights,
preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed
only with cause by the holders of at least 66 2/3% of all of our then-outstanding&nbsp;shares of the capital stock entitled to vote generally at an election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to fill director vacancies, all director
vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called by our board of directors pursuant to a
resolution adopted by a majority of the total number of authorized directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors will be divided into three classes of directors, with the classes to be as
nearly equal as possible, and with the directors serving three-year&nbsp;terms, therefore making it more difficult for stockholders to change the composition of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of our company by replacing our board of directors. Because our board of
directors has the power to retain and discharge its officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred
stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and our policies and to discourage
coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the
effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have opted out of
Section&nbsp;203 of the DGCL. Section&nbsp;203 of the DGCL prohibits a Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; (i.e. a stockholder owning 15% or more of company&#146;s
voting stock) for three&nbsp;years following the time that the &#147;interested stockholder&#148; becomes such, subject to certain exceptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Liability and Indemnification of Officers and Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation limits the liability of our directors to the fullest extent permitted by the DGCL, and our bylaws provide that we will
indemnify them to the fullest extent permitted by such law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. Under the terms
of such indemnification agreements, we are required to indemnify each of our directors and officers, to the fullest extent permitted by the laws of the state of Delaware, if the basis of the indemnitee&#146;s involvement was by reason of the fact
that the indemnitee is or was a director or officer of our company or any of our subsidiaries or was serving at our request in an official capacity for another entity. We must indemnify our officers and directors against all reasonable fees,
expenses, charges and other costs of any type or nature whatsoever, including any and all expenses and obligations paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or preparing
to defend, be a witness or participate in any completed, actual, pending or threatened action, suit, claim or proceeding, whether civil, criminal, administrative or investigative, or establishing or enforcing a right to indemnification under the
indemnification agreement. The indemnification agreements also require us, if so requested, to advance within ten days of such request all reasonable fees, expenses, charges and other costs that such director or officer incurred, provided that such
person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful
third-party claims against us and may reduce the amount of money available to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Jurisdiction of Certain Actions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole
and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to
us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (including the interpretation, validity or enforceability thereof), or (iv)&nbsp;any action
asserting a claim governed by the internal affairs doctrine. We refer to the foregoing provision in this prospectus as the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act
or the Exchange Act. Our bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting
a cause of action arising under the Securities Act. We refer to such provision in this prospectus as the Federal Forum Provision. Our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital
stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws
and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of
Delaware law and federal law, as applicable, such provisions may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these provisions may limit our stockholders&#146; ability to bring a claim in a judicial
forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our
stockholders.. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Lock-Up&nbsp;Restrictions</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our stockholders holding 46,646,053 shares of our common stock are subject to restrictions on transfer until February&nbsp;7, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing of Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;TNGX&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent for our common
stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_18"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our
outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, which generally provide that a person has beneficial ownership of a security if
he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of warrants or
stock options or the vesting of restricted stock units, within 60 days of August&nbsp;31, 2021. Common stock issuable upon the exercise, conversion, vesting or settlement of options, warrants, restricted stock units, restricted stock awards or other
rights to acquire common stock that are currently vested, exercisable, convertible or subject to settlement, or that will vest or become exercisable, convertible or subject to settlement within 60 days of August&nbsp;31, 2021 are deemed to be
outstanding and beneficially owned by the person holding such warrants, options or restricted stock units for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the
percentage ownership of any other person. Except as disclosed in the footnotes to the table below, and subject to community property laws where applicable, based on the information provided to us, we believe that the persons and entities named in
the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. Unless otherwise noted, the business address of each of our directors and executive officers is 100 Binney St, Suite 700,
Cambridge, MA 02142. The percentage of beneficial ownership is calculated based on 87,474,258 shares of Common Stock outstanding as of August&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Weber, M.D.(1).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,614,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexis Borisy(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lesley Calhoun(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Huang, Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">397,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reid Huber Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malte Peters, M.D.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Directors and Executive Officers as a group (nine individuals)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,396,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Five Percent Holders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Funds affiliated with Boxer Capital, LLC(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,973,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG Holdings, LLC(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casdin Partners Master Fund, L.P.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,487,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,854,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures IV, L.P.(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,363,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,367,592 shares of common stock and options to purchase 246,558 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 63,867 shares of common stock and options to purchase 133,889 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists options to purchase 73,947 shares of common stock exercisable within 60 days of August&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 12,384 shares of common stock exercisable within 60 days of August&nbsp;31,
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 144,380 shares of common stock and options to purchase 252,665 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 89,171 shares of common stock exercisable within 60 days of August&nbsp;31,
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 12,384 shares of common stock exercisable within 60 days of August&nbsp;31,
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;with respect to Boxer Capital, LLC, or Boxer Capital, 6,871,642 shares issued as Merger
Consideration, and (ii)&nbsp;with respect to MVA Investors, LLC, or MVA, 101,524 shares issued as Merger Consideration. Boxer Capital, Boxer Asset Management Inc., or Boxer Management, and Joseph Lewis share voting and dispositive power over the
shares held by Boxer Capital, and Aaron Davis has sole voting and dispositive power over the shares owned by MVA. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except to the
extent of any pecuniary interest therein. The principal business address of Boxer Capital, MVA and Aaron Davis is: 12860 El Camino Real, Suite&nbsp;300, San Diego, CA&nbsp;92130. The principal business address of Boxer Management and Joe Lewis is:
c/o Cay House <FONT STYLE="white-space:nowrap">P.O.&nbsp;Box&nbsp;N-7776</FONT> E.P. Taylor Drive Lyford Cay, New Providence, Bahamas. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A board consisting of Aaron Davis, Christopher Fuglesang and Andrew Ellis makes voting and dispositive
decisions with respect to securities owned by BCTG Holdings, LLC. Each of Aaron Davis, Christopher Fuglesang and Andrew Ellis disclaims any pecuniary interest in BCTG Holdings, LLC except to the extent of his beneficial interest in the securities
owned by BCTG Holdings, LLC. Holdings presented includes 4,488,450 shares held prior to the Merger and 2,500,000 shares issued in the PIPE Financing. The principal business address of BCTG Holdings, LLC is: 12860 El Camino Real, Suite 300, San
Diego, CA 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 3,987,910 shares issued as Merger Consideration and 1,500,000 shares issued in the PIPE Financing.
The general partner of Casdin Partners Master Fund, L.P. is Casdin Partners GP, LLC, or Casdin Partners GP. Casdin Capital, LLC is the investment manager of Casdin Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital, LLC and makes
the sole voting and investment decisions with respect to shares held by Casdin Master Fund, L.P. The address of Casdin Capital, LLC is 1350 Avenue of the Americas, Suite 2405, New York, NY 10019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 3,604,443 shares issued as Merger Consideration and 1,250,000 shares issued in the PIPE Financing.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 19,363,975 shares issued as Merger Consideration. The general partner of Third Rock Ventures IV,
L.P. is Third Rock Ventures GP IV, L.P. The general partner of Third Rock Ventures GP IV, L.P. is TRV GP IV, LLC. Abbie Celniker, Ph.D., Robert Tepper, M.D., Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV GP IV, LLC who
collectively make voting and investment decisions with respect to shares held by Third Rock Ventures IV, L.P. Dr.&nbsp;Huber is a partner at Third Rock Ventures, LLC, and a member of our board of directors. The address for each of Third Rock
Ventures IV, L.P. is 29 Newbury Street, Suite 401, Boston, MA 02116. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_19"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the Selling Securityholders from time to time of up to an aggregate of 68,175,412 shares of our common stock,
consisting of up to an aggregate of 18,610,000 shares of our common stock that were issued to the PIPE Investors in the PIPE Financing and up 49,565,412 shares of common stock issued to certain former shareholders of Tango Therapeutics Sub, Inc. at
the closing of the Business Combination. The Selling Securityholders may from time to time offer and sell any or all of the securities set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the
&#147;Selling Securityholders&#148; in this prospectus, we mean the persons listed in the table below, their permitted transferees and others who later come to hold any of the Selling Securityholders&#146; interest in the common stock other than
through a public sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of the date of this prospectus, the names of the Selling Securityholders, the aggregate number
of shares of common stock beneficially owned, the aggregate number of shares of common stock that the Selling Securityholders may offer pursuant to this prospectus and the number of shares of common stock beneficially owned by the Selling
Securityholders after the sale of the securities offered hereby. The percentage of beneficial ownership of after the offered securities are sold is calculated based on 87,474,258&nbsp;shares of common stock outstanding as of August&nbsp;31, 2021.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership
for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table below have sole voting and sole investment power with respect to all securities that they beneficially own, subject to community
property laws where applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such common stock. In
addition, the Selling Securityholders may sell, transfer or otherwise dispose of, at any time and from time to time, the common stock in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus.
For purposes of this table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling Securityholder information for each additional Selling Securityholder, if any, will be set forth by prospectus supplement to the extent required prior
to the time of any offer or sale of such Selling Securityholder&#146;s common stock pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of
each Selling Securityholder and the number of shares of common stock registered on its behalf. A Selling Securityholder may sell or otherwise transfer all, some or none of such shares in this offering. See &#147;<I>Plan of Distribution</I>&#148; for
additional details. Unless otherwise noted, the business address of each of the persons and entities listed in the table below is 100 Binney St., Suite 700, Cambridge, MA 02142. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Being Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Huang(1)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Life Sciences Fund LC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Bain Capital Life Sciences(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,921,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">921,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Baker Bros. Advisors LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barbara Weber(6)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,614,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,367,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Being Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCTG Holdings, LLC(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benjamin Cravatt(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Boxer <BR>Capital(10)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,973,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,973,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casdin Partners Master Fund, L.P.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,987,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,987,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles M. Baum(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd.(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant(14)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,099,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,099,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman(15)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with EcoR1 Capital, LLC(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Farallon Partners, L.L.C(17).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with FMR LLC(18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fifth Avenue Private Equity 15 LLC(19)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund V, L.P.(20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harvard Management Private Equity Corporation(21)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hillhouse Capital Management, Ltd.(22)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,373,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,373,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.(23)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,854,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,854,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jamie G. Christensen(24)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Biotech Innovation Master Fund Limited(25)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey H. Hager(26)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logos Global Master Fund, LP(27)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Varney Advisors(28)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners II Limited Partnership (29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners Limited Partnership(29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners SI, LP(29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCP QR LP(29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCP RFM LP(29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NexTx Insights, LLC(30)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with The Pellini Family Trust(31)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Olson(32)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PH Investments, LLC(33)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Being Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Portland Investment(34)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.(35)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Heyman(36)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.(37)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SCubed Capital, LLC(38)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi(39)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Silver Creek CS SAV, L.L.C. (29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sobrato Capital(40)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Southpoint Master Fund, LP(41)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures IV, L.P.(42)*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,363,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,363,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Wilson(43)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodline Partners LP(44)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These shares are subject to a contractual lockup for 180 days following the Closing Date as described under
&#147;<I>Certain Relationships and Related Person Transactions</I>.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 144,380 shares of common stock and options to purchase 252,665 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. Dr.&nbsp;Huang is our Chief Scientific Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P. (&#147;Alyeska&#148;), has
voting and investment control of the shares of common stock held by Alyeska. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr.&nbsp;Parekh, however,
disclaims any beneficial ownership of the shares held by Alyeska. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, <FONT
STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Behzad Aghazadeh serves as the portfolio manager and Managing Partner of Avoro Life Sciences Fund LLC. The
address of Avoro Life Sciences Fund LLC and Behzad Aghazadeh is 110 Greene Street, Suite 800 NY, NY 10012. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Number of Shares of Common Stock Beneficially Owned&#148; before the offering,
consist of (i)&nbsp;the following shares of Common Stock purchased in the PIPE Financing: (a) 1,713,138 shares of common stock and 208,652 shares of common stock purchased by Bain Capital Life Sciences Fund II, L.P., or BCLS II, and BCIP Life
Sciences Associates, LP, respectively, or BCIPLS, and together with BCLS II, the Bain Capital Life Science Entities. The shares reported under &#147;Number of Shares of Common Stock Being Offered&#148; consist of 891,428 shares held by BCLS II and
108,572 shares held by BCIPLS. Bain Capital Life Science Investors, LLC, or BCLSI, whose managers are Jeffrey Schwartz and Adam Koppel, is the manager of the general partner of BCLS II and governs the investment strategy and decision-making process
with respect to investments held by BCIPLS. As a result, each of BCLSI, Mr.&nbsp;Schwartz and Dr.&nbsp;Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by the Bain Capital Life Sciences
Entities. The address of the Bain Capital Life Sciences Entities is c/o Bain Capital Life Sciences, LP, 200 Clarendon Street, Boston, MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 55,202 shares of common stock held directly by 667, L.P. , or 667, and (ii) 694,798 shares of
common stock held directly by Baker Brothers Life Sciences, L.P., or Life Sciences, and together with 667, the BBA Funds. Baker Bros. Advisors LP, or BBA, is the investment adviser to the BBA Funds and has the sole voting and investment power with
respect to the securities held by the BBA Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC, or BBA GP, is the sole general partner of BBA and thus may be deemed to beneficially own the securities held
by the BBA Funds. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
principals of BBA GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the BBA Funds. The business address of BBA, BBA GP, Julian C. Baker and
Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. The BBA Funds&#146; respective general partners relinquished to BBA all discretion and authority with respect to the investment and voting power over securities held by the BBA
Funds, and thus BBA has complete and unlimited discretion and authority with respect to the BBA Funds&#146; investments and voting power over investments. Therefore, the BBA Funds should not be deemed to be beneficial owners of the securities
directly held by them. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,367,592 shares of common stock and options to purchase 246,558 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. Dr.&nbsp;Weber is our President and Chief Executive Officer and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A board consisting of Aaron Davis, Christopher Fuglesang and Andrew Ellis makes voting and dispositive
decisions with respect to the securities owned by BCTG Holdings, LLC. Each individual above disclaims beneficial ownership over the shares owned by BCTG Holdings LLC except to the extent of their pecuniary interest therein. The address of BCTG
Holdings, LLC is 12860 El Camino Real, Ste 300 San Diego, CA 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Benjamin Cravatt, Ph.D. is 5751 Chelsea Avenue, La Jolla, CA 92037. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registered holder of the referenced shares to be registered is the following fund under management by a
subsidiary of BlackRock, Inc.: BlackRock Health Sciences Trust II. BlackRock, Inc. is the ultimate parent holding company of such subsidiary. On behalf of such subsidiary, the applicable portfolio managers, as managing directors (or in other
capacities) of such entities, and/or the applicable investment committee members of such fund, have voting and investment power over the shares held by the fund which is the registered holder of the referenced shares. Such portfolio managers and/or
investment committee members expressly disclaim beneficial ownership of all shares held by such fund. The address of such fund and such portfolio managers is 60 State Street 19th/20th Floor, Boston, MA 02109. Shares shown include only the securities
being registered for resale and may not incorporate all shares deemed to be beneficially held by the registered holder or BlackRock, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 6,871,642 shares of common Stock held by Boxer Capital, LLC and (ii) 101,524 shares of common
stock held by MVA Investors, LLC. Boxer Asset Management, Inc. and Joseph Lewis hold shared voting and dispositive power over the shares held by Boxer Capital, LLC. Each individual and entity above disclaims beneficial ownership over the shares
owned by Boxer Capital except to the extent of its or their pecuniary interest therein. Aaron I. Davis is the Chief Executive Officer of MVA Investors, LLC. Mr.&nbsp;Davis disclaims beneficial ownership over the shares owned by MVA Investors, LLC
except to the extent of his pecuniary interest therein. Mr.&nbsp;Davis is a member of our board of directors. The address is 12860 El Camino Real, Suite 300, San Diego, CA 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reflected as beneficially owned by Casdin Partners Master Fund, LP in the above, are owned directly
by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i)&nbsp;Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii)&nbsp;Casdin Partners GP, LLC, the general partner of Casdin
Partners Master Fund LP, and (iii)&nbsp;Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except
to the extent of their respective pecuniary interest therein. The address of each of Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin is 1350 Avenue of the Americas, Suite 2600 New&nbsp;York, NY 10019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Dr.&nbsp;Baum is 6960 The Preserve Way, San Diego, CA 92130. Dr.&nbsp;Baum was previously a
director of BCTG Acquisition Corp. prior to the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are directly held by Citadel CEMF Investments Ltd., or Citadel CEMF. Citadel Advisors LLC, or
Citadel Advisors, is the portfolio manager of Citadel CEMF. Citadel Advisors Holdings LP, or CAH, is the sole member of Citadel Advisors. Citadel GP LLC, or CGP, is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP.
Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote and/or shared power to dispose of the securities held by Citadel CEMF. This disclosure shall not be construed as an admission that
Mr.&nbsp;Griffin or any of the Citadel related </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
entities listed above is the beneficial owner of any securities of the Company other than the securities actually owned by such person (if any). The address of Citadel CEMF is c/o Citadel
Advisors LLC, 601 Lexington Avenue, New York, NY 10022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 31,341 shares held by CRMA SPV LP, or CRMA, (ii) 590,894 shares held by Cormorant Global
Healthcare Master Fund LP, or Cormorant Master Fund, (iii) 10,000 shares purchase by Cormorant Master Fund in the PIPE Financing and (iv) 2,476,949 held by Cormorant Private Healthcare Fund II, LP, or Cormorant Private Fund. Bihua Chen serves as the
portfolio manager of each of CRMA, Cormorant Master Fund and Cormorant Private Fund and is the natural person who exercises voting and dispositive power over the shares. Ms.&nbsp;Chen disclaims any beneficial ownership of the securities held by
CRMA, Cormorant Master Fund and Cormorant Private Fund other than to the extent of any pecuniary interest she may have therein, directly or indirectly. The address is c/o Cormorant Asset Management, LP, 200&nbsp;Clarendon Street, 52nd Floor, Boston,
MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 63,867 shares of common stock and options to purchase 133,889 shares of common stock exercisable
within 60 days of August&nbsp;31, 2021. Ms.&nbsp;Beckman is our Chief Financial Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 57,743 shares held by EcoR1 Capital Fund, L.P. and 442,257 shares held by EcoR1 Capital Fund
Qualified, L.P. (together with EcoR1 Capital Fund, L.P, the &#147;EcoR1 Funds&#148;). Oleg Nodelman directly or indirectly controls the EcoR1 Funds and as a result may be deemed to have voting and dispositive power over the securities held directly
by the EcoR1 Funds. The address for the EcoR1 Funds is 357 Tehama Street, Suite 3, San Francisco, CA 94103. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 5,000 shares purchased by Farallon Capital (AM) Investors, L.P., 23,700 shares purchased by
Farallon Capital F5 Master I, L.P., 15,900 shares purchased by Farallon Capital Institutional Partners II, L.P., 95,000, shares purchased by Farallon Capital Institutional Partners III, L.P., 82,400 shares purchased by Farallon Capital Institutional
Partners, L.P., 113,300 shares purchased by Farallon Capital Offshore Investors II, L.P., 39,000 shares purchased by Farallon Capital Partners, L.P. and 11,200 shares purchased by Four Crossings Institutional Partners V, L.P (collectively, the
&#147;FPLLC Entities&#148;). Farallon Partners, L.L.C., or FPLLC, as the general partner of each of the FPLLC Entities and may be deemed to beneficially own such shares held by each of the FPLLC Entities. Farallon F5 (GP), L.L.C., or F5MI GP, as the
general partner of Farallon Capital F5 Master I, L.P., or F5MI, may be deemed to beneficially own such shares held by F5MI. Farallon Institutional (GP) V, L.L.C., or FCIP V GP, as the general partner of Four Crossings Institutional Partners V, L.P.,
or FCIP V, may be deemed to beneficially own such shares held by FCIP V. Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew
J. M. Spokes, John R. Warren and Mark C. Wehrly (collectively, the &#147;Farallon Managing Members&#148;), as a (i)&nbsp;managing member or senior managing member, as the case may be, of FPLLC or (ii)&nbsp;manager or senior manager, as the case may
be, of F5MI GP and FCIP V GP, in each case with the power to exercise investment discretion, may be deemed to beneficially own such shares held by the FP LLC Entities, F5MI or FCIP V. Each of FPLLC, F5MI GP, FCIP V GP and the Farallon Managing
Members disclaims beneficial ownership of any such shares. The address of each of the entities and individuals referenced in this footnote is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, CA 94111.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 215,400 share purchased by Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund, 1,200
by Fidelity Capital Trust: Fidelity Flex Small Cap Fund&#151;Small Cap Growth Subportfolio, 1,059,748 by Fidelity Growth Company Commingled Pool, 1,006,711 by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, 210,485 by Fidelity Mt.
Vernon Street Trust: Fidelity Growth Company K6 Fund, 223,056 by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, 499,400 by Fidelity Securities Fund: Fidelity Small Cap Growth Fund, 113,500 by Fidelity Securities Fund:
Fidelity Small Cap Growth K6 Fund and 670,500 by Fidelity Select Portfolios: Biotechnology Portfolio. These accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman, the Chief Executive
Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment
Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the
Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. Fidelity
Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bessemer Trust Company, N.A., or BTNA, as the sole Advisor to Fifth Avenue Private Equity 15 LLC, or PE 15, has
the power to dispose of the securities held by PE 15. BTNA&#146;s principal office is located at 1271 Avenue of the Americas, New York, NY 10020. BTNA&#146;s decisions regarding such securities will be made by a consensus of its five private equity
team professionals, or the PE Team. PE 15&#146;s board of managers, which consists of five individuals, has power to vote the securities reported in Item 1(a) on behalf of PE 15. The power to vote the securities cannot be exercised by less than a
majority of a quorum of the board members consisting of at least three of the members. Under the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;rule of three&#148;, if voting and dispositive decisions regarding an entity&#146;s securities
are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity&#146;s securities. Accordingly, neither the
individuals comprising the PE Team nor the individuals comprising the board of managers have been listed here. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are owned directly by Foresite Capital Fund V, L.P., or Fund V. Foresite Capital Management V, LLC,
or FCM V, is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these
shares. Each reporting person disclaims the existence of a &#147;group.&#148; Each of FCM V and Mr.&nbsp;Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report
is not an admission that FCM V or Mr.&nbsp;Tananbaum is the beneficial owner of these shares for purposes of Section&nbsp;16 or any other purpose. The address for Fund V is 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94930.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Harvard Management Private Equity Corporation is a wholly-owned subsidiary of President and Fellows of Harvard
College (Harvard), a Massachusetts corporation. Harvard has delegated investment authority over the securities being registered for resale to Harvard Management Company Inc. Narv Narvekar, Chief Executive Officer of Harvard Management Company Inc.,
located at 600 Atlantic Ave, Boston, MA 02210, may be deemed to have voting and investment power over the securities held by Harvard Management Private Equity Corporation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 16,100 shares of common stock purchased in the PIPE Financing by YHG Investment, L.P., or YHG,
(ii) 483,900 shares of common stock purchased in the PIPE Financing by HHLR Fund, L.P., or HHLR Fund, and (iii) 3,873,982 shares of common stock held by HH <FONT STYLE="white-space:nowrap">AUT-IV</FONT> Holdings Limited, or HH AUT. Each of YHG and
HHLR Fund is a Cayman Islands exempted limited partnership. HHLR Advisors, Ltd., an exempted Cayman Islands company, acts as the sole general partner of YHG and acts as the sole management company of HHLR Fund, and is deemed to be the beneficial
owner of, and to control the voting power of, the shares held by YHG and HHLR Fund. HH AUT is an exempted company with limited liability registered in the Cayman Islands. HH AUT is ultimately managed and controlled by Hillhouse Investment
Management, Ltd. Only shares held by HH AUT are subject to a contractual lockup for 180 days following the Closing Date. The registered address of HH AUT shall be at 89 Nexus Way, Camana Bay, P.O. Box 31106, Grand Cayman, <FONT
STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(23)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 3,604,443 shares issued as Merger Consideration and 1,250,000 shares issued in the PIPE Investment.
The address for Gilead Sciences, Inc. is 333 Lakeside Drive, Foster City, California 94404. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(24)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Dr.&nbsp;Christensen is 12780 Via Vieve, San Diego, CA 92130. Dr.&nbsp;Christensen was
previously a director of BCTG Acquisition Corp. prior to the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(25)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are held by Janus Henderson Biotech Innovation Master Fund Limited, or Janus. Each of Andy Acker and
Dan Lyons, acting as portfolio managers as delegated by Janus Capital Management LLC, who acts as investment adviser to Janus has the ability to make decisions with respect to the voting and disposition of the shares held by Janus. The address for
Janus is 151 Detroit Street, Denver, CO 80206. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(26)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Mr.&nbsp;Hager is 133381 Benchley Road, San Diego, CA 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(27)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arsani William is the managing partner&nbsp;&amp; Chief Investment Officer who exercises voting and dispositive
power over the shares held by Logos Global Master Fund, LP . The address for each of Logos Global Master Fund, LP and Mr.&nbsp;William is 1 Letterman Dr., Ste <FONT STYLE="white-space:nowrap">D-700,</FONT> San Francisco, CA 94129.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(28)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Mike Varney Advisors is 709 N Granados Ave, Solana Beach, CA 92075. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(29)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nantahala Capital Management, LLC is a Registered Investment Adviser and has been delegated the legal power to
vote and/or direct the disposition of such securities on behalf of the Selling Securityholder as a General Partner or Investment Manager and would be considered the beneficial owner of such securities. The above shall not be deemed to be an
admission by the record owners or the Selling Securityholder that they are themselves beneficial owners of these securities for purposes of Section&nbsp;13(d) of the Exchange Act or any other purpose. Wilmot Harkey and Daniel Mack are managing
members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the Selling Securityholder. The address for the Selling Securityholder is 130 Main St. 2nd Floor, New Canaan, CT 06840.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(30)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Steven L. Bender has the power to vote or dispose of the shares held by NexTx Insights, LLC. The address of
NexTx Insights, LLC is 1759 Oceanside Blvd, Ste C, #1267, Oceanside CA, 92054. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(31)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 84,929 shares of common stock held directly by Michael Pellini, (ii) 20,000 shares of common
stock purchased in the PIPE Financing by Dr.&nbsp;Pellini, and (iii) 67,943 shares held directly by The Pellini Family Trust, of which Dr.&nbsp;Pellini is the trustee and has voting and investment control with respect to these shares. The address
for each of Dr.&nbsp;Pellini and The Pellini Family Trust is 33841 Niguel Shores Drive, Dana Point, CA 92629. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(32)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Peter Olson is 4763 Robbins St, San Diego, CA 92122. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(33)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PH Investments LLC managed by managing members Amos B. Hostetter, Jr. and Barbara W. Hostetter and managing
directors Melinda E. Barber, Benjamin A. Gomez and John W. Vander Vort, The address for PH Investments LLC is Pilot House, Lewis Wharf, Boston MA 02110. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(34)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 159,386 shares owned by Portland Investment &#150; EP, LLC, or Portland EP, and 194,806 shares
owned by Portland Investment &#150; PIA, LLC, or Portland PIA. William Kane, the Corporate Director of each of Portland EP and Portland PIA has the power to vote or dispose of the shares held by Portland EP and Portland PIA. The address for each of
Mr.&nbsp;Kane, Portland EP and Portland PIA is 101 Merrimac St Suite 800, Boston, MA 02114. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(35)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RA Capital Management, L.P. is the investment manager for RA Capital Healthcare Fund, L.P., or RACHF. The
general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. Each of Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah may be deemed to have voting and investment power over
the shares held by RACHF. Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the persons and entities listed above is 200 Berkeley Street, 18th
Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(36)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Heyman was previously a director of BCTG Acquisition Corp. prior to the Business Combination<B>. </B>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(37)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are registered and held by Samsara BioCapital, L.P. Dr.&nbsp;Srinivas Akkaraju, MD, PhD is the
reporting person and the managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital, L.P. The reporting person disclaims beneficial ownership of this securities except to the extent of the reporting person&#146;s
pecuniary interest therein. The address is 628 Middlefield Road, Palo Alto, CA 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(38)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mark Stevens, as Managing Partner, has the power to vote or dispose of the shares held by SCubed Capital, LLC.
The address for each of SCubed Capital, LLC and Mr.&nbsp;Stevens is Apres Ski Way #701, Steamboat Springs, CO 80487. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(39)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Dr.&nbsp;Gujrathi is 1395 Rancho Santa Fe, CA 92067. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(40)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Sobrato Capital, a DBA of Sobrato Family Holdings, LLC, a California limited liability company
is 599 Castro Street, Suite 400, Mountain View, CA 94041. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(41)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares reported herein are held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves
as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons
disclaims beneficial ownership of the shares reported herein. The address for Southpoint Master Fund, LP is 1114 Avenue of the Americas, 22nd Floor, New York, NY 10036. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(42)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The general partner of Third Rock Ventures IV, L.P. is Third Rock Ventures GP IV, L.P. The general partner of
Third Rock Ventures GP IV, L.P. is TRV GP IV, LLC. Abbie Celniker, Ph.D., Robert Tepper, M.D., Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV GP IV, LLC who collectively make voting and investment decisions with respect to shares
held by Third Rock Ventures IV, L.P. Dr.&nbsp;Reid Huber is a partner at Third Rock Ventures, LLC, and a member of our board of directors. The address of Third Rock Ventures IV, L.P. is 29 Newbury Street, 3<SUP
STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor, Boston MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(43)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Mr.&nbsp;Wilson is 5 Ponderosa Ln., Rolling Hills Estates, CA 90274. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(44)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Woodline Partners LP serves as the investment manager of Woodline Master Fund LP and may be deemed to be the
beneficial owner of the shares of common stock. Woodline Master Fund LP disclaims any beneficial ownership of these shares. The address of Woodline Master Fund LP is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_20"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our shares of
common stock, which we refer to as our securities. This discussion applies only to securities that are held as capital assets for U.S. federal income tax purposes and is applicable only to holders who are receiving our securities in this offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is a summary only and does not describe all of the tax consequences that may be relevant to you in light of your particular
circumstances, including but not limited to the alternative minimum tax, the Medicare tax on certain investment income and the different consequences that may apply if you are subject to special rules that apply to certain types of investors (such
as the effects of Section&nbsp;451 of the Code), including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions or financial services entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mutual funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retirement plans, individual retirement accounts or other <FONT STYLE="white-space:nowrap">tax-deferred</FONT>
accounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governments or agencies or instrumentalities thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that actually or constructively own five percent or more of our voting shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders subject to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting with respect to the securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding the securities as part of a &#147;straddle,&#148; hedge, integrated transaction or similar
transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. holders (as defined below) whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of
such entities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the
date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state,
local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have not sought, and will not seek, a ruling from the U.S. Internal Revenue Service, or the IRS, as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by
a court. Moreover, there can be no assurance that future legislation, regulations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You are urged to consult your tax advisor with respect to the application of
U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or foreign jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our securities through such entities.
If a partnership (or other entity or arrangement classified as a partnership or other pass-through entity for United States federal income tax purposes) is the beneficial owner of our securities, the United States federal income tax treatment of a
partner or member in the partnership or other pass-through entity generally will depend on the status of the partner or member and the activities of the partnership or other pass-through entity. If you are a partner or member of a partnership or
other pass-through entity holding our securities, we urge you to consult your own tax advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES. EACH PROSPECTIVE INVESTOR IN OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX
CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY UNITED STATES FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME,</FONT> STATE, LOCAL, AND <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section applies to you if you are a &#147;U.S. holder.&#148; A U.S. holder is a beneficial owner of our shares of common stock who or that is, for U.S.
federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any
state thereof or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of
its source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if (i)&nbsp;a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&nbsp;it has a valid election in effect under Treasury Regulations to be treated as a U.S.
person. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of Distributions</I>. If we pay distributions in cash or other property (other than certain distributions of our
stock or rights to acquire our stock) to U.S. holders of shares of our common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits,
as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. holder&#146;s
adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described under &#147;<I>U.S. Holders &#151; Gain or Loss on Sale, Taxable
Exchange or Other Taxable Disposition of common stock</I>&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. holder that is a taxable corporation generally will
qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and
provided certain holding period requirements are met, dividends we pay to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder may constitute &#147;qualified dividends&#148; that will be subject to tax at the maximum tax rate accorded
to long-term capital gains. If the holding period requirements are not satisfied, then a corporation may not be able to qualify for the dividends </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received deduction and would have taxable income equal to the entire dividend amount, and <FONT STYLE="white-space:nowrap">non-corporate</FONT> holders may be subject to tax on such dividend at
regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain or Loss on Sale, Taxable Exchange
or Other Taxable Disposition of common stock</I>. Upon a sale or other taxable disposition of our common stock, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S.
holder&#146;s adjusted tax basis in the common stock. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder&#146;s holding period for the common stock so disposed of exceeds one year. If the holding period
requirements are not satisfied, any gain on a sale or taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term capital gains recognized by <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the amount of gain or loss recognized by a U.S. holder is an amount equal to the difference between (i)&nbsp;the sum of the amount of cash and the
fair market value of any property received in such disposition and (ii)&nbsp;the U.S. holder&#146;s adjusted tax basis in its common stock so disposed of. A U.S. holder&#146;s adjusted tax basis in its common stock generally will equal the U.S.
holder&#146;s acquisition cost for the common stock or less, in the case of a share of common stock, any prior distributions treated as a return of capital. In the case of any shares of common stock originally acquired as part of an investment unit,
the acquisition cost for the share of common stock that were part of such unit would equal an allocable portion of the acquisition cost of the unit based on the relative fair market values of the components of the unit at the time of acquisition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information Reporting and Backup Withholding</I>. In general, information reporting requirements may apply to dividends paid to a U.S. holder and to
the proceeds of the sale or other disposition of our shares of common stock, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number, a
certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amounts withheld under the backup withholding rules generally should be allowed as a refund or a credit against a U.S. holder&#146;s U.S. federal income
tax liability provided the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section applies to you if you are a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> holder.&#148; As used herein, the term <FONT
STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> holder&#148; means a beneficial owner of our common stock who or that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual (other than certain former citizens and
residents of the U.S. subject to U.S. tax as expatriates); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate or trust that is not a U.S. holder; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition. If you are such an
individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of Distributions</I>. In general, any distributions we make to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder of shares of our common
stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not
effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s conduct of a trade or business within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is eligible for a
reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E).</FONT></FONT> Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holder&#146;s adjusted tax basis in its shares of our common stock and, to the extent such distribution exceeds the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s adjusted tax basis, as gain realized from the sale or other
disposition of the common stock, which will be treated as described under <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holders &#151; Gain on Sale, Taxable Exchange or Other Taxable Disposition of common stock&#148; below. If we are unable
to determine, at a time reasonably close to the date of payment of a distribution on our common stock, what portion, if any, of the distribution will constitute a dividend, then we may withhold U.S. federal income tax on the basis of assuming that
the full amount of the distribution will be a dividend. If we or another withholding agent apply over-withholding, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be entitled to a refund or credit of any excess tax withheld by timely
filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding tax does not apply to dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holder who provides a Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s conduct of a trade or business within the
United States. Instead, the effectively connected dividends will be subject to regular U.S. income tax as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder were a U.S. resident, subject to an applicable income tax treaty providing
otherwise. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> corporation receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax&#148; imposed at a rate of 30% (or a lower treaty rate). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances. The certification requirements described above
also may require a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder to provide its U.S. taxpayer identification number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain on Sale, Taxable
Exchange or Other Taxable Disposition of common stock</I>. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or
other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30%
tax (or such lower rate as may be specified by an applicable income tax treaty) on the amount by which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s capital gains allocable to U.S. sources exceed capital losses allocable to U.S.
sources during the taxable year of the disposition (without taking into account any capital loss carryovers); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes at
any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder held our common stock, and, in the case where shares of our common stock are
regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period
preceding the disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s holding period for the shares of our common stock. There can be no assurance that our common stock will be treated as regularly traded on an established
securities market for this purpose. Generally, a corporation is a U.S. real property holding corporation if the fair market value of its U.S. real property interests, as defined in the Code and applicable U.S. Treasury Regulations, equals or exceeds
50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property
holding corporation for U.S. federal income tax purposes, or that we are likely to become one in the future. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless an applicable treaty provides otherwise, gain described in the first bullet point above will be
subject to tax at generally applicable U.S. federal income tax rates as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder were a U.S. resident. Any gains described in the first bullet point above of a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that is a foreign corporation may also be subject to an additional &#147;branch profits tax&#148; at a 30% rate (or lower treaty rate). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder, gain recognized by such holder on the sale, exchange or
other disposition of our common stock will be subject to tax at generally applicable U.S. federal income tax rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information Reporting and Backup
Withholding</I>. Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of common stock. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder may
have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding
under a treaty will satisfy the certification requirements necessary to avoid the backup withholding as well. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder will be allowed as a
credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FATCA Withholding Taxes</I>. Provisions commonly referred to as &#147;FATCA&#148; impose withholding of 30% on payments of dividends (including
constructive dividends) on our common stock to &#147;foreign financial institutions&#148; (which is broadly defined for this purpose and in general includes investment vehicles) and certain other <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied by, or an exemption applies to, the payee
(typically certified as to by the delivery of a properly completed IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E).</FONT></FONT> Foreign financial institutions located in jurisdictions that have an
intergovernmental agreement with the United States governing FATCA may be subject to different rules. Under certain circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder might be eligible for refunds or credits of such withholding
taxes, and a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder might be required to file a U.S. federal income tax return to claim such refunds or credits. Prospective investors should consult their tax advisers regarding the effects of FATCA
on their investment in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of material U.S. federal tax considerations is for general information only. It is not
tax advice. You should consult your own tax advisors regarding the particular U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common stock, including the
consequences of any proposed changes in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_21"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the possible offer and sale from time to time by the Selling Securityholders, or their permitted transferees, of up to an aggregate of
68,175,412 shares of our common stock, consisting of up to an aggregate of 18,610,000 shares of our common stock that were issued to the PIPE Investors in the PIPE Financing and up to an aggregate of 49,565,412 shares of our common stock issued to
certain former shareholders of Tango Therapeutics Sub, Inc. at the closing of the Business Combination. We are also registering any additional securities that may become issuable by reason of share splits, share dividends or other similar
transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale of shares of common stock by the Selling Securityholders pursuant to this prospectus. The
Selling Securityholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Securityholders in disposing of the securities. We will bear all other costs, fees and expenses incurred in effecting the registration
of the securities covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities beneficially owned by the Selling Securityholders covered by this prospectus may be offered and sold from time to time by the Selling
Securityholders. The term &#147;Selling Securityholders&#148; includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling securities received after
the date of this prospectus from a Selling Securityholder as a gift, pledge, partnership distribution or other transfer. The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each
sale. Such sales may be made on one or more exchanges or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise, at prices and under terms then prevailing or at prices related to
the then current market price or in negotiated transactions. Each Selling Securityholder reserves the right to accept and, together with its respective agents, to reject, any proposed purchase of securities to be made directly or through agents. The
Selling Securityholders and any of their permitted transferees may sell their securities offered by this prospectus on any securities exchange, market or trading facility on which the securities are traded or in private transactions. If underwriters
are used in the sale, such underwriters will acquire the shares for their own account. These sales may be at a fixed price or varying prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to prevailing
market prices or at negotiated prices. The securities may be offered to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. The obligations of the underwriters to purchase the
securities will be subject to certain conditions. The underwriters will be obligated to purchase all the securities offered if any of the securities are purchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth in any applicable registration rights agreement, the Selling Securityholders may use any one or more of the following
methods when selling the securities offered by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this
prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer so engaged will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> distribution
in accordance with the rules of the Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through trading plans entered into by a Selling Securityholder pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the
basis of parameters described in such trading plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the date of this prospectus; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agreements with broker-dealers to sell a specified number of the securities at a stipulated price per share or
warrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market&#148; offerings, as defined in Rule 415(a)(4) under the Securities Act, at negotiated
prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar
offerings through sales agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers, including through a specific bidding, auction or other process or in privately negotiated
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of the above methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a Selling Securityholder that is an entity may elect to make a pro rata <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of
securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely
tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the
distributees to use the prospectus to resell the securities acquired in the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Selling Securityholders will
sell all or any of the securities offered by this prospectus. In addition, the Selling Securityholders may also sell securities under Rule 144 under the Securities Act, if available, or in other transactions exempt from registration, rather than
under this prospectus. The Selling Securityholders have the sole and absolute discretion not to accept any purchase offer or make any sale of securities if they deem the purchase price to be unsatisfactory at any particular time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Securityholders also may transfer the securities in other circumstances, in which case the transferees, pledgees or other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> will be the selling beneficial owners for purposes of this prospectus. Upon being notified by a Selling Securityholder that a donee, pledgee,
transferee, other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name
specifically such person as a selling securityholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to a particular offering of the securities held by the Selling Securityholders, to the
extent required, an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is part, will be prepared and will set forth the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific securities to be offered and sold; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of the selling securityholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the respective purchase prices and public offering prices, the proceeds to be received from the sale, if any, and
other material terms of the offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the date of this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of any participating agents, broker-dealers or underwriters; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable commissions, discounts, concessions and other items constituting compensation from the selling
securityholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with distributions of the securities or otherwise, the Selling Securityholders may enter into hedging
transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with Selling Securityholders. The Selling Securityholders
may also sell the securities short and redeliver the securities to close out such short positions. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction). The Selling Securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged securities pursuant
to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters or
agents, as the case may be, involved in the offering of such securities may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. Specifically, the underwriters or agents, as the case may be, may over-allot
in connection with the offering, creating a short position in our securities for their own account. In addition, to cover overallotments or to stabilize the price of our securities, the underwriters or agents, as the case may be, may bid for, and
purchase, such securities in the open market. Finally, in any offering of securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allotted to an underwriter or a broker-dealer for distributing such
securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market
price of the securities above independent market levels. The underwriters or agents, as the case may be, are not required to engage in these activities, and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may solicit offers to purchase the securities directly from, and it may sell such securities directly to, institutional investors
or others. In this case, no underwriters or agents would be involved. The terms of any of those sales, including the terms of any bidding or auction process, if utilized, will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that one or more underwriters may make a market in our securities, but such underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the Nasdaq Capital Market under the symbol &#147;TNGX&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may authorize underwriters, broker-dealers or agents
to solicit offers by certain purchasers to purchase the securities at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The
contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we or the Selling Securityholders pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Selling Securityholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in
privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
sale transactions. If so, the third party may use securities pledged by any Selling Securityholder or borrowed from any Selling Securityholder or others to settle those sales or to close out any related open borrowings of stock, and may use
securities received from any Selling Securityholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable
prospectus supplement (or a post-effective amendment). In addition, any Selling Securityholder may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In effecting sales, broker-dealers or agents engaged by the Selling Securityholders may arrange for other
broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission, fees or other items
constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the gross proceeds of any offering pursuant to this prospectus and any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If at the time of any offering made under this prospectus a member of FINRA participating in the offering has a &#147;conflict of interest&#148; as defined in
FINRA Rule 5121, or Rule 5121, that offering will be conducted in accordance with the relevant provisions of Rule 5121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To our knowledge, there are
currently no plans, arrangements or understandings between the Selling Securityholders and any broker-dealer or agent regarding the sale of the securities by the Selling Securityholders. Upon our notification by a Selling Securityholder that any
material arrangement has been entered into with an underwriter or broker-dealer for the sale of securities through a block trade, special offering, exchange distribution, secondary distribution or a purchase by an underwriter or broker-dealer, we
will file, if required by applicable law or regulation, a supplement to this prospectus pursuant to Rule 424(b) under the Securities Act disclosing certain material information relating to such underwriter or broker-dealer and such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents may facilitate the marketing of an offering online directly or through one of their affiliates. In those cases,
prospective investors may view offering terms and a prospectus online and, depending upon the particular underwriter, broker-dealer or agent, place orders online or through their financial advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In offering the securities covered by this prospectus, the Selling Securityholders and any underwriters, broker-dealers or agents who execute sales for the
Selling Securityholders may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. Any discounts, commissions, concessions or profit they earn on any resale of those securities may be
underwriting discounts and commissions under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters, broker-dealers and agents may engage in transactions with us or the
Selling Securityholders, or perform services for us or the Selling Securityholders, in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the
securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been
registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Securityholders and any other persons participating in the sale or distribution of the securities will be subject to applicable provisions of the
Securities Act and the Exchange Act, and the rules and regulations thereunder, including, without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of any of the securities by,
the Selling Securityholders or any other person, which limitations may affect the marketability of the shares of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will make copies of
this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any agent, broker-dealer or underwriter that participates in
transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the Selling Securityholders against certain liabilities, including certain liabilities under the Securities Act, the Exchange Act or other federal or state law. Agents, broker-dealers and underwriters may be entitled to indemnification by
us and the Selling Securityholders against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments which the agents, broker-dealers or underwriters may be required to make in respect
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_22"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common
stock offered by this prospectus will be passed upon by Goodwin Procter LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Experts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of BCTG Acquisition Corp. as of December&nbsp;31, 2020 and for the period from May&nbsp;21, 2020 (inception) through December&nbsp;31,
2020 appearing in this prospectus have been audited by WithumSmith+Brown, PC, or Withum, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere herein, and are included in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Tango Therapeutics, Inc. as of December&nbsp;31,
2020 and 2019 and for each of the two&nbsp;years in the period ended December&nbsp;31, 2020 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm,
given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Registrant&#146;s Certifying Accountant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<I>&nbsp;Dismissal of Previous Independent Registered Public Accounting Firm.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2021, the Audit Committee of Tango dismissed Withum as the Company&#146;s independent registered public accounting firm, effective
immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The report of Withum on the financial statements of BCTG Acquisition Corp. (the Company&#146;s legal predecessor) as of December&nbsp;31,
2020 and for the period from May&nbsp;21, 2020 through December&nbsp;31, 2020 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the
period from May&nbsp;21, 2020 through December&nbsp;31, 2020 and the subsequent interim period through August&nbsp;10, 2021, there were no (i)&nbsp;disagreements (as defined in Item 304(a)(1)(iv) of Regulation
<FONT STYLE="white-space:nowrap">S-K)</FONT> with Withum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Withum, would
have caused Withum to make reference to the subject matter of the disagreements in its reports on the financial statements of the Company, or (ii)&nbsp;&#147;reportable events&#148; (as defined in Item 304(a)(1)(v) of Regulation <FONT
STYLE="white-space:nowrap">S-K)</FONT> within the period of Withum&#146;s engagement and the subsequent interim period through August&nbsp;10, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have provided Withum with a copy of the disclosures we are making in this prospectus and requested that Withum furnish a letter addressed to the SEC stating whether it agrees with the statements above, and, if not, stating the respects in which it
does not agree. Withum previously provided such a letter and has advised no changes need to be made. A copy of Withum&#146;s letter dated August&nbsp;13, 2021 is filed as Exhibit 16.1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<I></I><I>&nbsp;Engagement of New Independent Registered Public Accounting Firm.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2021, our Audit Committee appointed PricewaterhouseCoopers LLP, or PwC, as the Company&#146;s independent registered public accounting firm
for the fiscal year ending December&nbsp;31, 2021. That engagement was effective immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PwC served as the independent registered public accounting
firm of Old Tango prior to the Business Combination. During the period from May&nbsp;21, 2020 through December&nbsp;31, 2020 and the subsequent interim period through August&nbsp;10, 2021, neither Tango nor anyone on its behalf consulted with PwC
regarding either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company&#146;s financial
statements, and a written report or oral advice was provided to the Company that PwC concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii)&nbsp;any
matter that was either the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> or any reportable event within the meaning of Item&nbsp;304(a)(1)(v) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc118907_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We have also filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> including exhibits, under the Securities Act, with respect to the common stock offered by this prospectus. This prospectus is part of the registration statement, but does not contain all of the information
included in the registration statement or the exhibits. Our SEC filings are available to the public on the internet at a website maintained by the SEC located at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain a website at http://www.tangotx.com. The information contained in or accessible from our website is not incorporated into this prospectus,
and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. You may access, free of charge, our annual reports on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendment to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc118907_24"></A>INDEX TO FINANCIAL STATEMENTS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BCTG ACQUISITION CORP. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_1">Unaudited Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_2">Unaudited Condensed Consolidated Statement of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_3">Unaudited Condensed Consolidated Statement of Changes in Stockholders&#146; Equity
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_4">Unaudited Condensed Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_5">Notes to Unaudited Condensed Consolidated Financial Statements</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_6">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_7">Balance Sheet as of December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_8">Statement of Operations for the period from May&nbsp;
21, 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_9">Statement of Changes in Shareholders&#146; Equity for the period from May&nbsp;21,
 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_10">Statement of Cash Flows for the period from May&nbsp;
21, 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TANGO THERAPEUTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_12">Unaudited Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_13">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_14">Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred
 Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_15">Unaudited Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_16">Notes to Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_17">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-52</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_18">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-53</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_19">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-54</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_20">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-55</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_21">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-56</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin118907_22">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-57</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_1"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">582,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">734,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,549,316</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168,312,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,191,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,950,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock; 15,635,785 and 15,736,221 shares subject to possible redemption at $10.00 per share
as of June&nbsp;30, 2021 and December&nbsp;31,&nbsp;2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,357,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,362,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of
June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 30,000,000 shares authorized; 5,741,465 and 5,641,029 shares
issued and outstanding (excluding 15,635,785 and 15,736,221 shares subject to possible redemption) as of June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,126,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,122,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,127,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,549,316</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168,312,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_2"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Three<BR>Months<BR>Ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Six Months<BR>Ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The<BR>Period<BR>From<BR>May&nbsp;21,<BR>2020<BR>(inception)<BR>through<BR>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">924,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(770,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,036,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(764,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,003,830)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(764,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004,355)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding, of Public shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, Public shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding, of Founder shares (1)(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,702,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Founder shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>For the period from May&nbsp;21, 2020 (inception) through June&nbsp;30, 2020, this number excluded an
aggregate of up to 543,750 shares of common stock subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. The underwriters fully exercised the over-allotment option on September&nbsp;8, 2020;
thus, these Founder shares are no longer subject to forfeiture (see Note 4). </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>On September&nbsp;2, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of
common stock, resulting in an aggregate of 4,168,750 shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend (see Note 5). </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_3"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three and Six Months Ended June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,641,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,122,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(123,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(239,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(239,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; March&nbsp;31, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,665,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,362,242</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(362,800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(764,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(764,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; June&nbsp;30, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,741,465</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>574</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,126,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,127,401</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The Period From May&nbsp;21, 2020 (inception) through June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholder&#146;s<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; May&nbsp;21, 2020 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock to Sponsor (1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; June&nbsp;30, 2020 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,641</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(472</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,528</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>This number included an aggregate of up to 543,750 shares of common stock subject to forfeiture if the
over-allotment option was not exercised in full or in part by the underwriters. The underwriters fully exercised the over-allotment option on September&nbsp;8, 2020; thus, these Founder shares are no longer subject to forfeiture (see Note 4).
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>On September&nbsp;2, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of
common stock, resulting in an aggregate of 4,168,750 shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend (see Note 5). </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_4"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six<BR>Months<BR>Ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For The<BR>Period<BR>From<BR>May&nbsp;21,<BR>2020<BR>(inception)<BR>through<BR>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(763,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest released from Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from note payable to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(731,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash &#151; beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash &#151; end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>582,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,993</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in note payable &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value of common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_5"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#151; Description of Organization and Business Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BCTG Acquisition Corp. (&#147;BCTG&#148; or the &#147;Company&#148;) was incorporated as a Delaware corporation on May&nbsp;21, 2020. The Company was formed
for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination (a &#147;Business Combination&#148;) with one or more operating businesses or entities (a
&#147;target business&#148;). Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus on businesses that have their primary operations located in North
America and Europe in the biotechnology industry. The Company has neither engaged in any operations nor generated revenue to date, other than searching for a target business and the negotiation of the transactions related to the Proposed Business
Combination (as defined below). The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), as modified by the Jumpstart our Business Startups Act
of 2012 (the &#147;JOBS Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, BCTG entered into an agreement and plan of merger (as it may be amended and/or restated from
time to time, the &#147;Merger Agreement&#148;), by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of BCTG (&#147;Merger Sub&#148;), and Tango Therapeutics, Inc. (&#147;Tango&#148;). The Merger Agreement
provides for the merger of Merger Sub with and into Tango, with Tango continuing as the surviving entity. Tango is a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines. See &#147;The
Proposed Business Combination&#148; described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Company activity for the period from May&nbsp;21, 2020 (inception) through June&nbsp;30, 2021
has been related to the Company&#146;s formation and initial public offering (&#147;Initial Public Offering&#148;) described below, and since the Initial Public Offering, the search for a prospective initial Business Combination and the negotiation
of the transactions related to the Proposed Business Combination. The Company will not generate any operating revenue until after the completion of its initial Business Combination, at the earliest. The Company generates <FONT
STYLE="white-space:nowrap">non-operating</FONT> income in the form of income earned on investments on cash and cash equivalents in the Trust Account (as defined below). The Company has selected December&nbsp;31 as its fiscal year end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is BCTG Holdings, LLC, a Delaware limited liability company (the &#147;Sponsor&#148;). The registration statement for the
Company&#146;s Initial Public Offering was declared effective on September&nbsp;2, 2020. On September&nbsp;8, 2020, the Company consummated its Initial Public Offering of 16,675,000 shares of common stock (the &#147;Public shares&#148;), including
the 2,175,000 Public shares as a result of the underwriters&#146; full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of approximately $166.8&nbsp;million, and incurring offering
costs of approximately $9.6&nbsp;million, inclusive of approximately $5.8&nbsp;million in deferred underwriting commissions (Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with
the closing of the Initial Public Offering, the Company consummated the private placement (&#147;Private Placement&#148;) of 533,500 shares of common stock (the &#147;Private Placement shares&#148;), at a price of $10.00 per Private Placement Share
to the Sponsor, generating gross proceeds of approximately $5.3&nbsp;million (Note 4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private
Placement, approximately $166.8&nbsp;million, representing the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (&#147;Trust Account&#148;) in the United States maintained
by Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee, and will remain invested only in U.S. government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule <FONT
STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act of 1940 (&#147;Investment Company Act&#148;) and which invest solely in U.S. Treasuries, until the earlier of: (i)&nbsp;the completion of a Business Combination and
(ii)&nbsp;the distribution of the Trust Account as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to stock exchange listing rules, the Company&#146;s initial Business Combination must be with one
or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of any deferred underwriting discount held in trust and taxes payable on the income earned on the
Trust Account) at the time the Company signs a definitive agreement in connection with its initial Business Combination. The terms of the Merger Agreement satisfy this requirement. However, the Company will only complete an initial Business
Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment
company under the Investment Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds
of its Initial Public Offering and the sale of Private Placement shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Furthermore, there is no assurance that the
Company will be able to successfully complete a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of Public shares (the &#147;Public
Stockholders&#148;) with the opportunity to redeem all or a portion of their Public shares upon the completion of a Business Combination either (i)&nbsp;in connection with a stockholder meeting called to approve the Business Combination or
(ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be
entitled to redeem their Public shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released
to the Company to pay its tax obligations). The <FONT STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Stockholders who redeem their Public shares will not be reduced by the deferred underwriting commissions the Company
will pay to the underwriters (as discussed in Note 5). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority
of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to the
amended and restated Certificate of Incorporation which was adopted by the Company in connection with the Initial Public Offering (the &#147;Amended and Restated Certificate&#148;), conduct the redemptions pursuant to the tender offer rules of the
U.S. Securities and Exchange Commission (the &#147;SEC&#148;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transactions is required by law, or the Company
decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public
Stockholder may elect to redeem their Public shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Founder shares
prior to the Initial Public Offering (the &#147;Initial Stockholders&#148;) have agreed to vote their Founder shares (as defined in Note 4) and any Public shares purchased during or after the Initial Public Offering in favor of a Business
Combination. In addition, the Initial Stockholders have agreed to waive their redemption rights with respect to their Founder shares and Public shares in connection with the completion of a Business Combination. In addition, the Company has agreed
not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company holds a
stockholder vote or there is a tender offer for shares in connection with an initial Business Combination, a stockholder will have the right to redeem such holder&#146;s Public shares for an amount in cash equal to such holder&#146;s pro rata share
of the aggregate amount on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest not previously released to the Company to pay its franchise and income taxes. As a
result, such common stock has been recorded at redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standard Board (&#147;FASB&#148;), Accounting Standard Codification (&#147;ASC&#148;) 480,
&#147;Distinguishing Liabilities from Equity.&#148; The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company&#146;s Amended and Restated Certificate provides that a Public
Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the shares of common stock sold in the Initial Public Offering, without the prior consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, executive officers, and directors have agreed not to propose an amendment to the Company&#146;s Amended and Restated Certificate
that would affect the substance or timing of the Company&#146;s obligation to provide for the redemption of its Public shares in connection with a Business Combination or to redeem 100% of its Public shares if the Company does not complete a
Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Business Combination has not been consummated within 24 months from the closing of the Initial Public Offering, or September&nbsp;8, 2022 (the
&#147;Combination Period&#148;) and stockholders do not approve an amendment to the amended and restated certificate of incorporation to extend this date, the Company will (i)&nbsp;cease all operations except for the purpose of winding up,
(ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public shares and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the
remaining stockholders and the board of directors, dissolve and liquidate, subject (in the case of (ii)&nbsp;and (iii)&nbsp;above) to the Company&#146;s obligations under Delaware law to provide for claims of creditors and the requirements of other
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder shares if the Company fails to
complete a Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with
respect to such Public shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account
in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the
Company&#146;s Public shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the
Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will seek to have all third parties (other than the Company&#146;s independent registered public accounting firm) and any
prospective target businesses enter into valid and enforceable agreements with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account. Nevertheless, there is no guarantee that
vendors, service providers and prospective target businesses will execute such agreements. The Company&#146;s insiders have agreed that they will be jointly and severally liable to the Company if and to the extent any claims by a vendor for services
rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any
claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under our
indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the
Company&#146;s insiders may not be able to satisfy their indemnification obligations. Moreover, the Company&#146;s insiders will not be liable to the Public Stockholders and instead will only have liability to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proposed Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, BCTG entered into an agreement and plan of merger (as it may be amended and/or restated from time to time, the &#147;Merger
Agreement&#148;), by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of BCTG (&#147;Merger Sub&#148;), and Tango Therapeutics, Inc. (&#147;Tango&#148;). Pursuant to the Merger Agreement, at the closing of
the transactions contemplated thereby, Merger Sub will merge with and into Tango (the &#147;Merger&#148;) with Tango surviving the merger as a wholly-owned subsidiary of BCTG (the &#147;Proposed Business Combination&#148;). In addition, in
connection with the consummation of the Proposed Business Combination, BCTG will be renamed &#147;Tango Therapeutics, Inc.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Merger
Agreement, BCTG has agreed to acquire all of the outstanding shares of Tango common stock (including any options or warrants exercisable therefor) for $550,000,000 in aggregate consideration, comprising 55,000,000 shares of BCTG common stock, based
on a price of $10.00 per share (such shares being referred to herein as the &#147;Merger Consideration&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time of the Proposed
Business Combination (the &#147;Effective Time&#148;), by virtue of the consummation of the Proposed Business Combination and without any further action on the part of BCTG, Merger Sub or Tango (after Tango causes each share of Tango preferred stock
that is issued and outstanding immediately prior to the consummation of the Proposed Business Combination to be automatically converted immediately prior to the consummation of the Proposed Business Combination into a number of shares of Tango
common stock at the then-effective conversation rate as calculated in accordance with Tango&#146;s organizational documents), each share of Tango common stock issued and outstanding immediately prior to the Effective Time shall be canceled and
automatically converted into the right to receive a number of shares of BCTG common stock equal in value to the quotient of the Merger Consideration divided by the fully diluted capitalization of Tango (the &#147;Exchange Ratio&#148;) without
interest. Each outstanding Tango option shall be assumed by BCTG and automatically converted into an option to purchase such number of shares of BCTG&#146;s common stock, as adjusted based on the Exchange Ratio. If any shares of Tango common stock
issued and outstanding immediately prior to the Effective Time are shares of Tango restricted stock, then the shares of BCTG common stock issued in exchange for such shares of Tango restricted stock shall to the same extent be unvested and subject
to the same repurchase option or risk of forfeiture as in effect immediately prior to the Effective Time, and the certificates and/or book entries representing such shares of BCTG common stock shall accordingly be marked with appropriate legends. No
certificates or scrip representing fractional shares of BCTG&#146;s common stock will be issued pursuant to the consummation of the Proposed Business Combination. Stock certificates evidencing the Merger Consideration shall bear restrictive legends
as required by any securities laws at the time of the closing of the Proposed Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Proposed Business Combination is
subject to certain customary conditions of the respective parties, including, (i)&nbsp;stockholder approval; (ii)&nbsp;no Material Adverse Effect (as defined in the Merger Agreement) with respect to Tango since the date of the Merger Agreement;
(iii)&nbsp;expiration or termination of the Hart Scott-Rodino waiting period; (iv)&nbsp;a minimum of $5,000,001 of net tangible assets immediately following the closing (after giving effect to any redemptions); (v) proceeds, net of BCTG expenses, at
the closing of at least $300&nbsp;million (subject to certain shortfall provisions); (vi) satisfaction of any applicable listing requirements of The Nasdaq Capital Market; (vii)&nbsp;delivery by certain Tango stockholders of <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements; and (viii)&nbsp;BCTG and certain Tango stockholders having entered into an amended and restated registration rights agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of the execution of the Merger Agreement, BCTG entered into subscription agreements (the &#147;Subscription Agreements&#148;) with certain
institutional and accredited investors, pursuant to which, among other things, BCTG agreed to issue and sell, in a private placement to close immediately prior to the closing of the Proposed Business Combination, an aggregate of 18,610,000 shares of
BCTG common stock for $10.00 per share for a total of $186,100,000.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;20, 2021, the Company filed with the SEC a Registration Statement on
Form <FONT STYLE="white-space:nowrap">S-4,</FONT> which includes a proxy statement/prospectus, which was declared effective by the SEC on July&nbsp;16, 2021. The Company filed a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
definitive proxy statement and final prospectus to hold a special meeting of the holders of BCTG common stock on August&nbsp;9, 2021 (the &#147;Special Meeting&#148;). The holders of the majority
of the voting power of BCTG&#146;s common stock present in person or represented by proxy at the Special Meeting must approve the Merger Agreement, the Proposed Business Combination and certain other actions related thereto, as provided in the
Delaware General Corporation Law, BCTG&#146;s certificate of incorporation and applicable listing rules of The Nasdaq Stock Market LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger
Agreement may be terminated by BCTG or Tango under certain circumstances, including (i)&nbsp;by mutual written consent of BCTG and Tango; (ii)&nbsp;by either BCTG or Tango if the closing of the Business Combination has not occurred on or before
September&nbsp;30, 2021; (iii) by either BCTG or Tango if BCTG has not obtained the necessary stockholder approvals; or (iv)&nbsp;by BCTG if Tango has not timely delivered written consent of the Tango stockholders to the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement, Subscription Agreements and other support agreements have been filed as exhibits to and described in the Company&#146;s Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;14, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, the Company had $0.6&nbsp;million of cash in its operating account and approximately $0.4&nbsp;million of working capital, not taken
into account tax obligations of approximately $36,000 that may be paid using investment income earned from Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through June&nbsp;30, 2021, the
Company&#146;s liquidity needs were satisfied through a payment of $25,000 from the Company&#146;s Sponsor in exchange for the issuance of the Founder shares (as defined in Note 4), the loan under the certain promissory notes from the Company to the
Sponsor of approximately $127,000 to the Company to cover for offering costs in connection with the Initial Public Offering, and net proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the
promissory notes on September&nbsp;10, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Company&#146;s officers, directors and initial stockholders may, but are not obligated to, provide the
Company Working Capital Loans (see Note 4). However, in the Merger Agreement, the Company has covenanted not to enter into any such arrangements. Accordingly, as of June&nbsp;30, 2021 and December&nbsp;31, 2020, there were no amounts outstanding
under any Working Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity
to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating
prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the
Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#151; Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation and Principles of Consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) for financial information and pursuant to
the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which
include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June&nbsp;30, 2021 are not necessarily indicative of the results
that may be expected through December&nbsp;31, 2021 or for any future interim periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company,
and its wholly owned subsidiaries. All significant intercompany accounts and transactions are eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated
condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on
March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to,
not being required to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and
proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth
companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#146;s financial statement with another
public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of
June&nbsp;30, 2021 and December&nbsp;31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers
all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents held outside of the Trust account as of June&nbsp;30, 2021 and December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investments Held in the Trust Account </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that
invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#146;s investments held in the Trust Account are comprised of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. government securities, the investments are classified as trading securities. When the Company&#146;s investments held in the Trust Account are comprised of money market funds, the
investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of
these securities is included in interest earned on investments held in the Trust Account in the accompanying unaudited condensed statement of operations. The estimated fair values of investments held in the Trust Account are determined using
available market information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company&#146;s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term
due to one or more future confirming events. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the
Company&#146;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#147;Fair Value Measurements and Disclosures,&#148; approximates the carrying amounts represented in the balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as
the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3
measurements). These tiers consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the
fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offering Costs Associated with the Initial Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting and other costs incurred that were directly related to the Initial Public Offering and that were
charged to Stockholders&#146; equity upon the completion of the Initial Public Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Subject to Possible Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 &#147;Distinguishing Liabilities from
Equity.&#148; shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. shares of conditionally redeemable common stock (including common stock that feature redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary equity. At all other times, shares of common stock are
classified as stockholders&#146; equity. The Company&#146;s common stock features certain redemption rights that are considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events. Accordingly, at
June&nbsp;30, 2021 and December&nbsp;31, 2020, 15,635,785 and 15,736,221 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders&#146; equity section of the Company&#146;s balance sheet,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
complies with the accounting and reporting requirements of Financial Accounting Standards Board Accounting Standard Codification, or FASB ASC, 740, &#147;Income Taxes,&#148; which requires an asset and liability approach to financial accounting and
reporting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or
expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained upon examination by taxing authorities. The Company recognizes accrued
interest and penalties related to unrecognized tax benefits as income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Common Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s condensed consolidated statements of operations include a presentation of net income (loss) per share for Public shares subject to possible
redemption in a manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of net income (loss) per common stock. Net income (loss) per common stock, basic and diluted, for Public shares is calculated by dividing the interest
income earned on the Trust Account, less interest available to be withdrawn for the payment of taxes, by the weighted average number of Public shares outstanding for the periods. Net income (loss) per common stock, basic and diluted, for Founder
shares is calculated by dividing the net income (loss), adjusted for income attributable to Public shares, by the weighted average number of Founder shares outstanding for the periods. Founder shares include the Founder shares as these common stocks
do not have any redemption features and do not participate in the income earned on the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2021, the Company did not have any
dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the
period presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects the calculation of basic and diluted net income (loss) per share of common
stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Three<BR>Months<BR>Ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Six Months<BR>Ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Public shares</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Income allocable to Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Company&#146;s portion available to be withdrawn to pay taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: Weighted average Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,675,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,675,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Founder shares</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Net income (loss) minus net income allocable to Founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(764,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,004,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income allocable to Public shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(764,601</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,004,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: weighted average Founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,702,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,702,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting standards update (&#147;ASU&#148;)
<FONT STYLE="white-space:nowrap">2020-06,</FONT> <I>Debt-Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging-Contracts in Entity&#146;s Own Equity (Subtopic <FONT
STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I>, which simplifies accounting for convertible instruments by removing major separation models required under current
GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for
fiscal years beginning after December&nbsp;15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&nbsp;15, 2021 and adoption must be as of the beginning
of the Company&#146;s annual fiscal year. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on
the accompanying financial statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;8, 2020, the Company consummated its Initial Public Offering of 16,675,000 Public shares, including the 2,175,000 Public shares as a result
of the underwriters&#146; full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of approximately $166.8&nbsp;million, and incurring offering costs of approximately $9.6&nbsp;million,
inclusive of approximately $5.8&nbsp;million in deferred underwriting commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;4, 2020, the Company
issued 3,593,750 shares of common stock to the Sponsor (the &#147;Founder shares&#148;) for an aggregate purchase price of $25,000. On September&nbsp;2, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of common stock
(an aggregate of 575,000 shares), resulting in an aggregate of 4,168,750 shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend. The Initial Stockholders agreed not to transfer, assign or
sell any of their Founder shares (except to certain permitted transferees) until the earlier of (i)&nbsp;one year after the date of the consummation of the initial Business Combination or (ii)&nbsp;the date on which the closing price of the
Company&#146;s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period
commencing at least 150 days after the initial Business Combination, or earlier if, subsequent to the initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results
in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement
shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Initial Public Offering, the Sponsor purchased 533,500 Private Placement shares, at a price of $10.00
per share, in a private placement for an aggregate purchase price of approximately $5.3&nbsp;million. The Private Placement shares are identical to the shares of common stock sold in the Initial Public Offering, subject to certain limited exceptions
as described in Note 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors have agreed, subject to limited exceptions, not to transfer, assign or
sell any of their Private Placement shares until 30 days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2020 and June&nbsp;10, 2020, the Company&#146;s sponsor agreed to loan us up to $25,025 and $274,975, respectively, for an aggregate amount of
$300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to certain promissory notes. These promissory notes were <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured and due upon the date we
consummate the Initial Public Offering. We borrowed approximately $127,000 under these promissory notes and repaid them in full on September&nbsp;10, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Initial Stockholders may, but are not obligated to, loan the Company
funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the &#147;Working Capital Loans&#148;). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of
the initial Business Combination, without interest, or, at the lender&#146;s discretion, up to $1,500,000 of the notes may be converted upon consummation of the Business Combination into additional private placement shares at a conversion price of
$10.00 per share. If the Company does not complete a Business Combination, the loans would not be repaid. Such private placement shares would be identical to the Private Placement shares. However, in the Merger Agreement, we have covenanted not to
enter into any such arrangements. Accordingly, to date, the Company had no borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Support
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on September&nbsp;2, 2020, the Company agreed to pay an affiliate of the Sponsor a total of $10,000 per month for office
space and certain office and secretarial services. Upon completion of the initial Business Combination or the Company&#146;s liquidation, the Company will cease paying these monthly fees. The Company incurred $30,000 and $60,000 of such expenses
during the three and six months ended June&nbsp;30, 2021, respectively, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included as administrative expenses&#151;related party on the accompanying condensed statement of operations. As of June&nbsp;30, 2021, no amounts were payable related to this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Purchase Commitment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
Sponsor entered into an agreement to purchase an aggregate of at least 2,500,000 shares of common stock for an aggregate purchase price of $25.0&nbsp;million, or $10.00 per share, prior to, concurrently with, or following the closing of the initial
Business Combination in a private placement. The funds from such private placement may be used as part of the consideration to the sellers in the initial Business Combination, and any excess funds from such private placement may be used for working
capital in the post-transaction company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151; Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Founder
shares, Private Placement shares and shares that may be issued upon conversion of Working Capital Loans are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to
make up to two demands that the Company register such securities. The holders of the majority of the Founder shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common
stock are to be released from escrow. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the
expenses incurred in connection with the filing of any such registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters in our Initial Public Offering were entitled to an underwriting discount of $0.20 per share, or approximately $3.3&nbsp;million in the
aggregate, which was paid upon the closing of the Initial Public Offering. In addition, the underwriters will be entitled to a deferred underwriting commission of $0.35 per share, or approximately $5.8&nbsp;million in the aggregate. The deferred fee
will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to
evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results
of its operations, and/or its efforts with respect to an initial Business Combination, the specific impact is not readily determinable as of the date of these financial statements. The financial statement does not include any adjustments that might
result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#151; Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred stock</I></B>-The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. As of June&nbsp;30,
2021 and December&nbsp;31, 2020, there are no shares of preferred stock issued or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B>-The Company is authorized to
issue 30,000,000 shares of common stock, par value of $0.0001 per share. On September&nbsp;2, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of common stock (an aggregate of 575,000 shares). All shares and associated
amounts have been retroactively restated to reflect the share dividend. As of June&nbsp;30, 2021 and December&nbsp;31, 2020, there were 21,377,250 shares of common stock outstanding, including 15,635,785 shares and 15,736,221 shares of common stock,
respectively, subject to possible redemption that were classified outside of permanent equity in the accompanying unaudited condensed consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#151; Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s assets that are measured at fair value on a recurring basis and indicates the fair value
hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;30, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Prices in<BR>Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money Market Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Prices in<BR>Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities maturing March&nbsp;4, 2021(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,811,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Excludes approximately $4,000 of investments held in cash within the Trust Account.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers between
levels of the hierarchy for the six months ended June&nbsp;30, 2021. Level&nbsp;1 instruments include investments U.S. Treasury securities with an original maturity of 185 days or less. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#151; Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated
subsequent events and transactions that occurred up to the date unaudited condensed consolidated financial statements were issued. Based upon this review, the Company determined that, except as disclosed in Note 1, there have been no events that
have occurred that would require adjustments to the disclosures in the unaudited condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_6"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BCTG
Acquisition Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of BCTG Acquisition Corp. (the &#147;Company&#148;), as of December&nbsp;31, 2020, the related
statements of operations, changes in stockholders&#146; equity and cash flows for the period from May&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;financial statements&#148;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020, and the results of its operations and its cash flows for the period from May&nbsp;21, 2020
(inception) through December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for
Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an
opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect
to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement
of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our
audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our
opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WithumSmith+Brown, PC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_7"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,815,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>168,312,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,950,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock; 15,736,221 shares subject to possible redemption at $10.00 per share</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,362,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 30,000,000 shares authorized; 5,641,029 shares issued and
outstanding (excluding 15,736,221 shares subject to possible redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,122,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>168,312,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_8"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period from May&nbsp;21, 2020 (inception) through December&nbsp;31, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses&nbsp;&#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(181,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding, of Public shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Public shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding, of Founder shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,212,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Founder shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_9"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF&nbsp;CHANGES IN STOCKHOLDERS&#146; EQUITY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;&#150; May&nbsp;21, 2020 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,168,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of common stock in initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,748,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,624,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,624,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of private placement shares to Sponsor in private placement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">533,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,334,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,335,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,736,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(157,360,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(157,362,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;&#150; December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,641,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,122,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(123,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_10"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF&nbsp;CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period from May&nbsp;21, 2020 (Inception) Through December&nbsp;31, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(183,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(327,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from note payable to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,335,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of note payable to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,591,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,391,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;&#150; beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;&#150; end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,314,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in note payable&nbsp;&#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial value of common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,484,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value of common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_11"></A>BCTG ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1.
ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BCTG Acquisition Corp. (the &#147;<B>Company</B>&#148;) was incorporated
as a Delaware corporation on May&nbsp;21, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination (&#147;<B>Initial Business
Combination</B>&#148;) with one or more operating businesses or entities that it has not yet selected (a &#147;<B>target business</B>&#148;). Although the Company is not limited to a particular industry or sector for purposes of consummating a
Business Combination, the Company intends to focus on businesses that have their primary operations located in North America and Europe in the biotechnology industry. The Company has neither engaged in any operations nor generated revenue to date,
other than searching for a target business. The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), as modified by the Jumpstart our
Business Startups Act of 2012 (the &#147;<B>JOBS Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had not commenced any
operations, other than searching for a target business. All activity for the period from May&nbsp;21, 2020 (inception) through December&nbsp;31, 2020 had been related to the Company&#146;s formation and the initial public offering (&#147;<B>Initial
Public Offering</B>&#148;) described below, and since offering, the search for a prospective Initial Business Combination. The Company will not generate any operating revenue until after the completion of its Initial Business Combination, at the
earliest. The Company generates <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of income earned on investments on cash and cash equivalents in the Trust Account (as defined below). The Company has selected December&nbsp;31
as its fiscal year end. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is BCTG Holdings, LLC, a Delaware limited liability company&nbsp;(the
&#147;<B>Sponsor</B>&#148;).&nbsp;The registration statement for the Company&#146;s Initial Public Offering was declared effective on September, 2020. On September, 2020, the Company consummated its Initial Public Offering of 16,675,000 shares of
common stock (the &#147;<B>Public shares</B>&#148;), including the 2,175,000 Public shares as a result of the underwriters&#146; full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds
of approximately $166.8&nbsp;million, and incurring offering costs of approximately $9.6&nbsp;million, inclusive of approximately $5.8&nbsp;million in deferred underwriting commissions (Note 6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#147;<B>Private
Placement</B>&#148;) of 533,500 shares of common stock (the &#147;<B>Private Placement shares</B>&#148;), at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.3&nbsp;million (Note 4). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, approximately $166.8&nbsp;million ($10.00 per share), representing
the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (&#147;<B>Trust Account</B>&#148;) in the United&nbsp;States maintained by Continental Stock Transfer&nbsp;&amp; Trust
Company, as trustee, and will remain invested only in U.S. government treasury bills, notes and bonds with a maturity of 185&nbsp;days or less or in money market funds meeting certain conditions under
<FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7</FONT> under the Investment Company Act and which invest solely in U.S. Treasuries, until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the Trust
Account as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to stock exchange listing rules, the Company&#146;s Initial Business Combination must be with one or
more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of any deferred underwriting discount held in trust and taxes payable on the
income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the Initial Business Combination. However, the Company will only complete an Initial Business Combination if the post-transaction company
owns or acquires 50% or more of the outstanding voting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of
1940, as amended, or the Investment Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific
application of the net proceeds of its Initial Public Offering and the sale of Private Placement shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Furthermore,
there is no assurance that the Company will be able to successfully complete a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will provide the holders
of Public shares (the &#147;<B>Public Stockholders</B>&#148;) with the opportunity to redeem all or a portion of their Public shares upon the completion of a Business Combination either (i)&nbsp;in connection with a stockholder meeting called to
approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its
discretion. The Public Stockholders will be entitled to redeem their Public shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in
the Trust Account and not previously released to the Company to pay its tax obligations). The <FONT STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Stockholders who redeem their Public shares will not be reduced by the
deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note&nbsp;6). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such
consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other
legal reasons, the Company will, pursuant to the amended and restated Certificate of Incorporation which was adopted by the Company in connection with the Initial Public Offering (the &#147;<B>Amended and Restated Certificate</B>&#148;), conduct the
redemptions pursuant to the tender offer rules of the U.S.&nbsp;Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder
approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and
not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection
with a Business Combination, the holders of the Founder shares prior to this Initial Public Offering (the &#147;<B>Initial Stockholders</B>&#148;) have agreed to vote their Founder shares (as defined in Note&nbsp;5) and any Public shares purchased
during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Stockholders have agreed to waive their redemption rights with respect to their Founder shares and Public shares in connection with the
completion of a Business Combination. In addition, the Company has agreed not to enter into a definitive agreement regarding an Initial Business Combination without the prior consent of the Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company holds a stockholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a
stockholder will have the right to redeem such holder&#146;s Public shares for an amount in cash equal to such holder&#146;s pro rata share of the aggregate amount on deposit in the Trust Account as of two business days prior to the consummation of
the Initial Business Combination, including interest not previously released to the Company to pay its franchise and income taxes.&nbsp;As a result, such common stock has been recorded at redemption amount and classified as temporary equity, in
accordance with the Financial Accounting Standard Board (&#147;<B>FASB</B>&#148;), Accounting Standard Codification (&#147;<B>ASC</B>&#148;) 480, &#147;Distinguishing Liabilities from Equity.&#148; The amount in the Trust Account is initially
anticipated to be $10.00 per Public Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company&#146;s Amended and Restated Certificate provides
that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as
amended (the &#147;<B>Exchange Act</B>&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the shares of common stock sold in the Initial Public Offering, without the prior consent of the
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, executive officers, and directors have agreed not to propose an
amendment to the Company&#146;s Amended and Restated Certificate that would affect the substance or timing of the Company&#146;s obligation to provide for the redemption of its Public shares in connection with a Business Combination or to redeem
100% of its Public shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Business Combination has not been consummated within 24&nbsp;months from the closing of the Initial Public Offering, or September, 2022
(the &#147;<B>Combination Period</B>&#148;), the Company will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the
outstanding Public shares and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, dissolve and liquidate, subject (in the case of (ii)&nbsp;and
(iii)&nbsp;above) to the Company&#146;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder shares if the Company fails to complete a
Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to
such Public shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&nbsp;6) held in the Trust Account in the
event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company&#146;s
Public shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to have all third parties (other than the Company&#146;s independent registered public accounting firm) and any
prospective target businesses enter into valid and enforceable agreements with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account. Nevertheless, there is no guarantee that
vendors, service providers and prospective target businesses will execute such agreements. The Company&#146;s insiders have agreed that they will be jointly and severally liable to the Company if and to the extent any claims by a vendor for services
rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any
claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under our
indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company&#146;s insiders may not be able to satisfy their indemnification obligations. Moreover,
the Company&#146;s insiders will not be liable to the Public Stockholders and instead will only have liability to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Basis of
Presentation </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statement is presented in U.S. dollars in conformity with accounting principles
generally accepted in the United&nbsp;States of America (&#147;<B>GAAP</B>&#148;) and pursuant to the rules&nbsp;and regulations of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Emerging Growth Company </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to
other public companies that are not emerging growth companies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley&nbsp;Act of 2002, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new
or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to
comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to
<FONT STYLE="white-space:nowrap">non-emerging&nbsp;growth</FONT> companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or
revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#146;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Liquidity and Capital Resources </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had $1.3&nbsp;million of cash in its operating account and approximately $1.4&nbsp;million of working
capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2020, the Company&#146;s liquidity needs were satisfied through a payment of $25,000 from the
Company&#146;s Sponsor in exchange for the issuance of the Founder shares (as defined below), the loan under the Note of approximately $127,000 (see Note 5) to the Company to cover for offering costs in connection with the Initial Public Offering,
and net proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the Note on September&nbsp;10, 2020. In addition, in order to finance transaction costs in connection with a Business
Combination, the Company&#146;s officers, directors and initial stockholders may, but are not obligated to, provide the Company Working Capital Loans (see Note 5). As of December&nbsp;31, 2020, there were no amounts outstanding under any Working
Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity
to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating
prospective Initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the
Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2. SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Use of Estimates </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Making estimates requires management
to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating
its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Cash and Cash Equivalents </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There
were no cash equivalents at December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Concentration of Credit Risk </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution
which, at times, may exceed the Federal depository insurance coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant
risks on such accounts. The Company&#146;s investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185&nbsp;days or less or investments in a money market funds that comprise only
U.S. Treasury securities, or a combination thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Investments Held in the Trust Account </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth
in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185&nbsp;days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company&#146;s investments held in the
Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in
interest earned on investments held in Trust Account on the accompanying statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Fair Value of Financial Instruments </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction
between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In
those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the carrying values of cash, prepaid expenses, accounts payable, accrued expenses, accrued income taxes and
franchise tax payable approximate their fair values due to the short-term nature of the instruments. The Company&#146;s investments held in Trust Account are comprised of investments in U.S. Treasury securities with an original maturity of
185&nbsp;days or less or investments in money market funds that comprise only U.S. treasury securities and are recognized at fair value. The fair value of investments held in Trust Account is determined using quoted prices in active markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Offering Costs associated with the Initial Public Offering </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting and other costs incurred that were directly related to the Initial Public Offering and that were
charged to stockholders&#146; equity upon the completion of the Initial Public Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Common Stock Subject to Possible Redemption </U>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480
&#147;Distinguishing Liabilities from Equity.&#148; shares of common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. shares of conditionally redeemable common stock (including
common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary equity. At all
other times, shares of common stock are classified as stockholders&#146; equity. The Company&#146;s common stock features certain redemption rights that are considered to be outside of the Company&#146;s control and subject to the occurrence of
uncertain future events. Accordingly, at December&nbsp;31, 2020, 15,736,221 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders&#146; equity section of the Company&#146;s balance
sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Income Taxes </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company complies with the accounting and reporting requirements of Financial Accounting Standards Board Accounting Standard Codification,
or FASB ASC, 740, &#147;Income Taxes,&#148; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial
statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FASB ASC 740 prescribes
a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT
STYLE="white-space:nowrap">more-likely-than-not&nbsp;to</FONT> be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Net Loss Per Common Share </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net loss per share of common stock is computed by dividing net loss applicable to stockholders by the weighted average number of shares of
common stock outstanding during the periods. Weighted average shares were reduced for the effect of an aggregate of 543,750 shares of common stock that were subject to forfeiture if the over-allotment option was not exercised by the underwriters.
The underwriters exercised their over-allotment option in full on September, 2020; thus, these Founder shares were no longer subject to forfeiture (see Note 6). At December&nbsp;31, 2020, the Company did not have any dilutive securities and other
contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s statement of operations includes a presentation of loss per share for common stock subject to redemption in a manner
similar <FONT STYLE="white-space:nowrap">to&nbsp;the&nbsp;two-class&nbsp;method&nbsp;of</FONT> income per share. Net loss per share, basic and diluted for Public shares is calculated by dividing the investment income earned on the Trust Account, net
of applicable income and franchise taxes of approximately $26,000 for the period from May&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, by the weighted average number of shares of Public shares outstanding for the period. Net loss per
share, basic and diluted for Founder shares is calculated by dividing the net loss of approximately $123,000, less income attributable to Public shares, by the weighted average number of shares of Founder shares outstanding for the periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Recent Accounting Pronouncements </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a
material effect on the Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3. INITIAL PUBLIC OFFERING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September, 2020, the Company consummated its Initial Public Offering of 16,675,000 Public shares, including the 2,175,000 Public shares as a
result of the underwriters&#146; full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of approximately $166.8&nbsp;million, and incurring offering costs of approximately
$9.6&nbsp;million, inclusive of approximately $5.8&nbsp;million in deferred underwriting commissions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4. PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 533,500 Private Placement
shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
portion of the proceeds from the Private Placement shares was added to the proceeds from the Initial Public Offering to be held in the Trust Account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5. RELATED PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Founder
shares </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;4, 2020, the Company issued 3,593,750 shares of common stock to the Sponsor (the &#147;<B>Founder
shares</B>&#148;) for an aggregate purchase price of $25,000. On September, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of common stock (an aggregate of 575,000 shares), resulting in an aggregate of 4,168,750
shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend. The Sponsor agreed to forfeit up to an aggregate of 543,750 Founder shares, so that the Founder shares would represent 20% of the
Company&#146;s issued and outstanding shares after the Initial Public Offering, to the extent the underwriters&#146; over-allotment option was not exercised in full or in part. The underwriters fully exercised the over-allotment option on September,
2020; thus, these Founder shares were no longer subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Initial Stockholders agreed not to transfer, assign or sell
any of their Founder shares (except to certain permitted transferees) until the earlier of (i)&nbsp;one year after the date of the consummation of the Initial Business Combination or (ii)&nbsp;the date on which the closing price of the
Company&#146;s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period
commencing at least 150&nbsp;days after the Initial Business Combination, or earlier if, subsequent to the Initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which
results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Private
Placement shares </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Initial Public Offering, the Sponsor purchased 533,500 Private
Placement shares, at a price of $10.00 per share, in a private placement for an aggregate purchase price of approximately $5.3&nbsp;million. The Private Placement shares are identical to the shares of common stock sold in the Initial Public
Offering, subject to certain limited exceptions as described in Note 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors have
agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement shares until 30&nbsp;days after the completion of the Initial Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Related Party Loans </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2020 and June&nbsp;10, 2020, the Sponsor agreed to loan the Company up to $25,025 and $274,975, respectively, for an aggregate
amount of $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (each, a &#147;<B>Note</B>&#148; and, collectively, the &#147;<B>Notes</B>&#148;). The Notes were <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured and due upon the date the Company consummated the Initial Public Offering. The Company borrowed approximately $127,000 under the Notes. The Company repaid the Notes in full on
September&nbsp;10, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to finance transaction costs in connection with a Business Combination, the Initial
Stockholders may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the &#147;<B>Working Capital Loans</B>&#148;). Each loan would be evidenced by a
promissory note. The notes would either be paid upon consummation of the Initial Business Combination, without interest, or, at the lender&#146;s discretion, up to $1,500,000 of the notes may be converted upon consummation of the Business
Combination into additional private placement shares at a conversion price of $10.00 per share. If the Company does not complete a Business Combination, the loans would not be repaid. Such private placement shares would be identical to the Private
Placement shares. To date, the Company had no borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Administrative Support Agreement </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the date of the Company&#146;s prospectus, the Company agreed to pay an affiliate of the Sponsor a total of $10,000 per month for
office space and certain office and secretarial services. Upon completion of the Initial Business Combination or the Company&#146;s liquidation, the Company will cease paying these monthly fees. For the period from May&nbsp;21, 2020 (inception)
through December&nbsp;31, 2020, the Company incurred $40,000 related to these services. As of December&nbsp;31, 2020, no amounts were payable related to this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Share Purchase Commitment </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor entered into an agreement to purchase an aggregate of at least 2,500,000 shares of common stock for an aggregate
purchase price of $25.0&nbsp;million, or $10.00 per share, prior to, concurrently with, or following the closing of the Initial Business Combination in a private placement. The funds from such private placement may be used as part of the
consideration to the sellers in the Initial Business Combination, and any excess funds from such private placement may be used for working capital in the post-transaction company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Registration Rights </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the Founder shares, Private Placement shares and shares that may be issued upon conversion of Working Capital Loans are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these
securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founder shares can elect to exercise these registration rights at any time commencing three months prior to the date on
which these shares of common stock are to be released from escrow. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the consummation of a Business
Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Underwriting
Agreement </U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted the underwriters a <FONT STYLE="white-space:nowrap">45-day</FONT> option from the date of the
prospectus to purchase up to 2,175,000 additional shares at the Initial Public Offering price less the underwriting discounts and commissions. On September, 2020, the underwriters fully exercised the over-allotment option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to an underwriting discount of $0.20 per share, or
approximately $3.3&nbsp;million in the aggregate,&nbsp;paid upon the closing of the Initial Public Offering. In addition, the underwriters will be entitled to a deferred underwriting commission of $0.35 per share, or approximately $5.8&nbsp;million
in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Risks and Uncertainties </U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has concluded that the
specific impact is not readily determinable as of the date of the balance sheet. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7. STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred stock </I></B>&#151; The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per
share. As of December&nbsp;31, 2020, there are no shares of preferred stock issued or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B>&#151; The
Company is authorized to issue 30,000,000 shares of common stock, par value of $0.0001 per share. On September, 2020, the Company declared a dividend of 0.16 shares for each outstanding share of common stock (an aggregate of 575,000 shares). All
shares and associated amounts have been retroactively restated to reflect the share dividend. As of December&nbsp;31, 2020, there were 21,377,250 shares of common stock outstanding, including 15,736,221 shares of common stock subject to possible
redemption that were classified outside of permanent equity in the accompanying balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s financial assets that are measured at fair value on a recurring basis as of
December&nbsp;31, 2020 by level within the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Prices in<BR>Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets held in Trust:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities maturing March&nbsp;4, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,811,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money Market Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>166,815,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers
between levels for the three months ended December&nbsp;31, 2020 and for the period from May&nbsp;21, 2020 (inception) through December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generates taxable income primarily consisting of interest income earned on the Trust Account. The Company&#146;s general and
administrative costs are generally considered <FONT STYLE="white-space:nowrap">start-up</FONT> costs and are not currently deductible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The income tax provision (benefit) for the period from May&nbsp;21, 2020 (inception) through
December&nbsp;31, 2020 consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s net deferred tax assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Start-up/Organization</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net
future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information
available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the period from May&nbsp;21, 2020 (inception) through
December&nbsp;31, 2020, the valuation allowance was $31,362. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the statutory federal income tax rate (benefit) to the
Company&#146;s effective tax rate for the period from May&nbsp;6 (inception) through December&nbsp;31, 2020 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory Federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26.91</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.91</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no unrecognized tax benefits as of December&nbsp;31, 2020. No amounts were accrued for the payment
of interest and penalties at December&nbsp;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax
examinations by major taxing authorities since inception. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have
required adjustment or disclosure in the financial statements which have not previously been disclosed within the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_12"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A redeemable convertible preferred stock, $0.001 par value, 55,700,000 shares authorized,
issued, and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; liquidation preferences of $55,700 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.001 par value, 45,372,050 shares authorized at
June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; 45,372,050 and 22,686,025 shares issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; liquidation preferences of $60,000 and $30,000 at June&nbsp;30, 2021
and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, $0.001
par value, 27,152,255 shares authorized, issued, and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; liquidation preferences of $51,182 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value; 166,000,000 shares authorized at June&nbsp;30, 2021 and
December&nbsp;31, 2020; 14,817,103 and 13,301,649 shares issued and outstanding as of June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(103,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_13"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from (provision for) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,485,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,193,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,214,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,913,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive (loss) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (loss) gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_14"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income&nbsp;(Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,301,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(103,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of less than
$0.1&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">895,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,196,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">620,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,817,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,334,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,259,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred
stock, net of issuance costs of less than $0.2&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,279,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_15"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(86,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of merger with BCTG and PIPE financing transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger with BCTG and PIPE financing deferred offering costs included in accounts payable and
accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_16"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Nature of the Business and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tango Therapeutics, Inc (&#147;Tango&#148; or the &#147;Company&#148;) is a precision oncology company committed to the discovery and development of novel new
drugs in defined patient populations with high unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to early-stage companies in the biotechnology
industry. Principal among these risks are the uncertainties of the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology, dependence on key personnel, compliance with
government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including
extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.
There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s technology will be obtained, that any products developed will obtain necessary government
regulatory approval, or that any approved products will be commercially viable. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the
Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations. The Company expects to
incur substantial operating losses and negative cash flows from operations for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Company has generated
recurring net losses, including net losses of $4.5 million&nbsp;and $16.6 million&nbsp;for the three and six months ended June&nbsp;30, 2021, respectively, and net losses of $8.4 million&nbsp;and $16.3 million&nbsp;for the three and six months ended
June&nbsp;30, 2020, respectively. The Company had an accumulated deficit of $119.7&nbsp;million as of June&nbsp;30, 2021. Since inception and through the issuance date of these unaudited condensed consolidated financial statements, the Company has
raised an aggregate of approximately $166.9&nbsp;million of gross proceeds from the sale of preferred shares, approximately $352.9&nbsp;million in gross proceeds through the closing of the BCTG Business Combination and PIPE Investment transactions
and another $202.1&nbsp;million through our collaboration with Gilead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects operating losses and negative cash flows from operations to
continue for the foreseeable future as it continues to develop, manufacture and commercialize its products. As of June&nbsp;30, 2021, and with the additional gross proceeds of approximately $352.9&nbsp;million received on August&nbsp;10, 2021 from
the consummation of the BCTG Business Combination and PIPE Investment transactions, the Company expected that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements
for at least 12 months from the issuance date of the unaudited condensed consolidated financial statements. The future viability of the Company beyond that point may be dependent on its ability to raise additional capital to finance its operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may seek additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry
out all of its planned research and development and commercialization activities. However, there is no assurance that the Company will be able to obtain additional funding under acceptable terms, if at all. If the Company is unable to obtain
additional financing, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger with BCTG Acquisition Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, the Company and BCTG Acquisition Corp. (&#147;BCTG&#148;) signed a definitive merger agreement memorializing the terms of BCTG&#146;s
acquisition of 100% of the Company&#146;s issued and outstanding equity securities in exchange for $550.0&nbsp;million worth of consideration in the form of BCTG common stock (the &#147;Business Combination&#148;). The Business Combination was
approved on August&nbsp;9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of our issued and outstanding equity securities on August&nbsp;10, 2021. The Business Combination was accounted for as a &#147;reverse recapitalization&#148;
in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Under the reverse recapitalization model, the Business Combination was treated as Tango issuing equity for the net assets of BCTG,
with no goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#147;acquired&#148; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the
Business Combination, the Company&#146;s stockholders possess a majority of the voting power of the combined company, the Company comprises all of the ongoing operations of the combined entity, the Company comprises a majority of the governing body
of the combined company, and the Company&#146;s senior management comprises all of the senior management of the combined company. As a result of the Business Combination, BCTG was renamed Tango Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tango received gross proceeds of $166.8&nbsp;million upon the closing of the Business Combination. Tango continues to operate under the current Tango
management team. Subsequent to the closing of the Business Combination, an aggregate of 18.6&nbsp;million shares of common stock (the &#147;PIPE Financing&#148;) were purchased, resulting in gross proceeds of an additional $186.1&nbsp;million upon
the closing of the PIPE Financing. Total transaction costs and redemptions approximated $27.3&nbsp;million, resulting in total net proceeds of $325.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the merger agreement, upon the closing of the Business Combination (the &#147;Effective Time&#148;), each share of the Company&#146;s
redeemable convertible preferred stock (the &#147;Preferred Stock&#148;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#146;s common stock. At the Effective Time, each option to purchase the
Company&#146;s common stock became an option, respectively, to purchase shares of common stock of the surviving entity, subject to adjustment in accordance with the exchange ratio. Completion of the PIPE Financing and merger transaction were subject
to approval of BCTG stockholders and the satisfaction or waiver of certain other customary closing conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the end of 2019, a novel strain of a virus named <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes <FONT STYLE="white-space:nowrap">COVID-19</FONT> has spread to most countries across the world, including all 50
states within the U.S., including Cambridge, Massachusetts, where the Company&#146;s primary office and laboratory space is located. The coronavirus pandemic led to the implementation of various responses, including government-imposed quarantines,
travel restrictions and other public health safety measures. The extent to which the coronavirus, including any novel variants such as the &#147;Delta variant,&#148; impacts the Company&#146;s operations or those of its third-party partners,
including preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning
the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could adversely impact the Company&#146;s preclinical or
clinical trial operations in the U.S., including its ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19</FONT> if
an outbreak occurs in their geography. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on
its business and financial statements. To date, <FONT STYLE="white-space:nowrap">COVID-19</FONT> has not had a material impact on operations, and the Company has not incurred significant delays related to its research and development programs.
Additionally, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specific related event or circumstance that would require it to revise its estimates reflected in these condensed consolidated financial statements. The extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact the Company&#146;s business, results of operations, financial condition and liquidity, including research and development costs, will depend on future
developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, and the duration and intensity of the related
effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The <FONT STYLE="white-space:nowrap">year-end</FONT> balance sheet data was derived from audited financial statements, but does not
include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect the operations of Tango and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.
The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of management, all adjustments necessary for a
fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and six months ended June&nbsp;30, 2021 and 2020 are not necessarily
indicative of the results for the year ending December&nbsp;31, 2021, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements for the three and six months ended June&nbsp;30, 2021 and 2020
have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December&nbsp;31, 2020 included in the Company&#146;s effective proxy statement/prospectus, on
file with the SEC on July&nbsp;16, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than policies noted below, there have been no significant changes from the significant accounting policies disclosed in Note 2, <I>Summary of Significant
Accounting Policies</I>, of the audited consolidated financial statements and notes for the year ended December&nbsp;31, 2020 included in the Company&#146;s effective proxy statement/prospectus, on file with the SEC on July&nbsp;16, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December&nbsp;2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Simplifying the Accounting for Income Taxes,</I> (&#147;ASC&nbsp;740&#148;). The ASU enhances and simplifies various aspects of the income tax accounting
guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis <FONT STYLE="white-space:nowrap">step-up</FONT> in goodwill obtained in a transaction that is not a business combination, separate financial statements of
entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law,
and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after
December&nbsp;31, 2020; however, early adoption was permitted The Company adopted this standard as of January&nbsp;1, 2021 on a prospective basis. The adoption did not have a material impact on the Company&#146;s condensed consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT> <I>Debt</I><I></I><I>&nbsp;&#151; Debt with
Conversion and Other Options (Subtopic</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;470-20)</FONT> and Derivatives and Hedging</I><I></I><I>&nbsp;&#151; Contracts in Entity&#146;s Own Equity (Subtopic 815</I><I></I><I>&nbsp;&#151; 40)</I>.
The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#146;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting
models for convertible instruments. It also amends the accounting for certain contracts in an entity&#146;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies
how particular convertible instruments and certain contracts that may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
settled in cash or shares impact the diluted earnings per share (&#147;EPS&#148;) computation. Early adoption is permitted, but no earlier than fiscal years beginning after December&nbsp;15,
2020, including interim periods within those fiscal years. The Company elected to early adopt this guidance on January&nbsp;1, 2021. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March&nbsp;2021 at
an original issue price of $1.32 per share, which would have resulted in the recognition of a beneficial conversion feature of $28.4&nbsp;million prior to the adoption of ASU <FONT STYLE="white-space:nowrap">2020-06.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that
are not yet effective will not have a material impact on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Gilead Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
October&nbsp;2018, the Company entered into a Research Collaboration and License Agreement (the &#147;2018 Gilead Agreement&#148;) with Gilead Sciences, Inc. (&#147;Gilead&#148;). Pursuant to the 2018 Gilead Agreement, the Company performed target
discovery and validation activities in accordance with an agreed-upon multi-year research plan. During the initial three-year research term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to five
validated programs (&#147;Gilead Program License&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, Gilead paid the Company a $50.0&nbsp;million
<FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment upon the execution of the 2018 Gilead Agreement. The Company was eligible to receive milestone payments of up to $1.7&nbsp;billion across all programs and royalties on future
sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> certain programs licensed by
Gilead in the U.S. and was eligible to receive royalties on <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed this arrangement
in accordance with ASC 606 and concluded that the contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering
committee and the research and development services provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the
Company and the interdependent relationship between the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This
option will be excluded from the transaction price until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company
determined that the single combined performance obligation is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company&#146;s performance. The future milestone payments represent variable consideration
that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended Gilead Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, Gilead made an equity investment of $20.0&nbsp;million into the Company as a participant in the Company&#146;s Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred stock offering. At the time of the original investment, as well as of the December&nbsp;31, 2020 balance sheet date, Gilead maintains an ownership of less than 10% of the Company and is thus not
considered to be a related party to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the Company and Gilead also entered into an Amended Research Collaboration and License
Agreement (the &#147;Gilead Agreement&#148;), which superseded and replaced the 2018 Gilead agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the
2018 Gilead Agreement. Under the Gilead Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company received upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> consideration of
$125.0&nbsp;million from Gilead upon execution of the Gilead Agreement in 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement
has a research term of seven years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gilead expanded its option to license up to 15 programs for which Gilead may obtain exclusive, worldwide licenses
to develop and commercialize therapies, subject to applicable license fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to exercising its option to license a program, Gilead may &#147;extend&#148; such program, in which case
Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For up to five programs licensed by Gilead, the Company has the option to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> sales. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive up to $410.0&nbsp;million per program in license,
research extension, and clinical, regulatory, and commercial milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Gilead Agreement was accounted for as a modification of the 2018 Gilead
Agreement under ASC 606 as both the scope and price of the contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation
identified under the 2018 Gilead Agreement which was only partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research
services and continued participation on the joint steering committee during the research term. As a result, the Company&#146;s progress towards completing its research services to Gilead over the seven-year term of the Amended Gilead Agreement was
lower than its progress under the three-year term of the 2018 Gilead Agreement and a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustment was recorded during the third quarter of 2020 resulting in a reduction of $11.3&nbsp;million
of revenue previously recognized through the date of the Gilead Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December&nbsp;2020, Gilead elected to extend a program for a research
extension fee of $12.0&nbsp;million. The Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the <FONT
STYLE="white-space:nowrap">on-going</FONT> research plan. Consideration pertaining to the research extension is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment
payments are not payable in the event of scientific failure, the Company determined that the variable consideration of $12.0&nbsp;million should not be constrained as the potential for a significant reversal of cumulative revenue recognized at the
contract level is remote, and therefore the research extension consideration was added to the transaction price under the Gilead Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
April&nbsp;2021, Gilead licensed a program for a $11.0&nbsp;million fee. The $11.0&nbsp;million license fee was received and recognized as revenue in the second quarter of 2021 since Tango has no continued involvement in the advancement of the
program, Gilead can benefit from the license on its own and the license is separately identifiable from the research services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Revenue
Recognized </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $187.0&nbsp;million at
June&nbsp;30, 2021. The total transaction price was comprised of the $50.0&nbsp;million upfront payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the 2018 Gilead Agreement, the $125.0&nbsp;million upfront payment pursuant to the Gilead Agreement, and the $12.0&nbsp;million pursuant to the research extension fee in
December&nbsp;2020. During the three and six months ended June&nbsp;30, 2021, the Company recognized $7.2&nbsp;million and $13.5&nbsp;million, respectively, and during the three and six months ended June&nbsp;30, 2020, the Company recognized
$4.7&nbsp;million and $9.1&nbsp;million, respectively, of revenue associated with the Gilead Agreements based on performance completed during each period. During the three and six months ended June&nbsp;30, 2021, the Company recognized revenue of
$11.0&nbsp;million, associated with the payments received in the second quarter of 2021 pursuant to the April 2021 program license. During the three and six months ended June&nbsp;30, 2020, the Company recognized revenue of $0.3&nbsp;million and
$0.7&nbsp;million, respectively, associated with the payments received in 2019 pursuant to the program license and Gilead Letter Agreement. The consideration allocated to the Gilead License was recognized upon delivery of the underlying license in
2019 as Gilead could benefit from the license on its own and the Gilead License was separately identifiable from the Gilead Letter Agreement research services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each
reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur. As of June&nbsp;30,
2021 and December&nbsp;31, 2020, the Company had short-term deferred revenue of $24.5&nbsp;million and $32.0&nbsp;million, respectively, and long-term deferred revenue of $118.7&nbsp;million and $120.8&nbsp;million, respectively, related to the
Gilead collaboration. The remaining long-term revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately 6.1 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as
revenue are recorded as deferred revenue on the Company&#146;s condensed consolidated balance sheet. As of June&nbsp;30, 2021, $4.0&nbsp;million of the total research extension fee amount of $12.0&nbsp;million had been received, $2.0&nbsp;million
had been recorded as accounts receivable and the remaining $6.0&nbsp;million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. The contract asset balance is presented net of the
deferred revenue contract liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs incurred pursuant to the Gilead Agreements are recorded as research and development expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following tables present information about the Company&#146;s financial assets measured at fair value on a recurring basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value Measurements<BR>as of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value Measurements<BR>as of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value levels during the six months ended June&nbsp;30, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Marketable Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At
each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s marketable debt securities, classified as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale:</FONT></FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company holds investment grade marketable securities, and none were considered to be in an unrealized loss position as of
June&nbsp;30, 2021 and December&nbsp;31, 2020. As a result, the Company did not record any reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $0.1&nbsp;million in accrued
interest at June&nbsp;30, 2021 and December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Supplemental Balance Sheet Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net
as of June&nbsp;30, 2021 and December&nbsp;31, 2020 consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.2&nbsp;million for each of the three months ended June&nbsp;30, 2021 and 2020 and
$0.4&nbsp;million and $0.3&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses and Other Current
Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities as of June&nbsp;30, 2021 and December&nbsp;31, 2020 include the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of both June&nbsp;30, 2021 and June&nbsp;30, 2020, the Company maintained a restricted cash balance of $2.3&nbsp;million, all of which was related to
security deposits associated with the Company&#146;s facility leases. The cash will remain restricted in accordance with the lease agreements absent the event of a lease termination of modification. The reconciliation of cash and cash equivalents
and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
September&nbsp;2017, the Company entered into a Research Collaboration Agreement (the &#147;HitGen Agreement&#148;) with HitGen Ltd (&#147;HitGen&#148;). Under the terms of the HitGen Agreement, HitGen would use its
<FONT STYLE="white-space:nowrap">DNA-encoded</FONT> library technology to screen up to three targets and deliver to the Company the structures of certain compounds that bind to the targets. The Company would provide certain materials containing each
target for purposes of the screen. The Company could have been obligated to make certain milestone payments. The Company and HitGen mutually agreed to terminate the HitGen Agreement in March&nbsp;2021. No milestones were achieved or paid upon the
termination of the agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords and
clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#146;s activities. These indemnification
provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not
incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company, from time to time, may be
party to litigation arising in the ordinary course of business. The company was not subject to any material legal proceedings as of June&nbsp;30, 2021, and no material legal proceedings are currently pending or threatened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March&nbsp;2017, the Company executed a stock purchase agreement to sell 55,000,000 shares of redeemable convertible series A preferred stock (&#147;Series
A&#148;). This agreement was subsequently amended in July&nbsp;2017 to increase the authorized capital to 55,700,000 shares of Series A. The Series A stock purchase agreement was structured to close in three tranches, each contingent upon the
achievement of certain specified milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the initial closing of the Series A stock purchase agreement, the Company issued an aggregate of
18,700,000 shares of Series A convertible preferred stock for $1.00 per share, resulting in net proceeds of $14.0&nbsp;million after deducting $4.7&nbsp;million related to the settlement of the convertible notes and accrued interest that were
previously outstanding. During the year-ended December&nbsp;31, 2018, the Company issued 26,000,000 additional shares of Series A preferred stock at a price of $1.00 per share upon the achievement of specified development milestones in connection
with the second tranche of the Series A stock purchase agreement. Total proceeds from this issuance was $26.0&nbsp;million. In January&nbsp;2019, the Company issued 11,000,000 additional shares of Series A preferred stock at a price of $1.00 per
share upon the achievement of specified development milestones in connection with the third tranche of the Series A stock purchase agreement. Total proceeds from this issuance was $11.0&nbsp;million. The aggregate issuance costs associated with the
issuance of all three tranches of Series A preferred stock was less than $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April&nbsp;2020, the Company executed a stock purchase
agreement to sell shares of redeemable convertible series B preferred stock (&#147;Series B&#148;). The Series B stock purchase agreement allows for the issuance of up to 45,372,051 shares. In April&nbsp;2020, the Company issued 22,686,025 shares of
Series B at a price of $1.32 per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share. Proceeds from this issuance totaled $29.8&nbsp;million, net of $0.2&nbsp;million in issuance costs. In March&nbsp;2021, the Company sold 22,686,025 additional shares of Series B redeemable
convertible preferred stock at a price of $1.32 per share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled
$30.0&nbsp;million. Total issuance costs associated with the second tranche of the Series B preferred stock was less than $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August&nbsp;2020, the Company executed a stock purchase agreement to sell shares of redeemable convertible series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">B-1&#148;).</FONT> The
Series <FONT STYLE="white-space:nowrap">B-1</FONT> stock purchase agreement allows for the issuance of up to 27,152,255 shares. All 27,152,255 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> were issued at a price of $1.89 per share in
August&nbsp;2020. Proceeds from this issuance was $51.1&nbsp;million, net of $0.1&nbsp;million in issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021 and
December&nbsp;31, 2020, redeemable convertible preferred stock consisted of the following (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,538,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,538,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights, preferences and privileges of the Company&#146;s redeemable convertible preferred stock are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Par Value Per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The par value of all
preferred stock is $0.001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Tranche Right Feature </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined that the future tranche rights under the Series A and Series B preferred stock purchase agreements (the &#147;future tranche
rights&#148;) did not meet the definition of freestanding financial instruments because, while separately exercisable, they were not legally detachable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future tranche rights were evaluated for any beneficial conversion features or embedded derivatives, including the conversion option, that could require
bifurcation and receive separate accounting treatment. The Company determined that the embedded future tranche obligations did not require bifurcation for accounting purposes as they did not meet the definition of a derivative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the convertible preferred stock are entitled to the number of votes equal to the number of shares of common stock into which each share of
convertible preferred stock could be converted on the record date for the vote or consent of stockholders, except as otherwise required by law, and has voting rights and powers equal to the voting rights and powers of the holders of common stock
voting as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of any liquidation event, deemed liquidation event, dissolution or winding up of the Company, the holders of preferred stock then outstanding shall receive a distribution prior to any distribution to the common holders, an amount equal to the
greater of a) original issue price per share plus any noncumulative dividends declared but unpaid, or b) the amount per share that would have been owed had all preferred shares been converted into Common Stock immediately prior to the liquidation
event. In the event that assets are insufficient to pay the full amount, distribution will be on a pro rata basis. After payment of all preferential amounts required to be paid to the preferred stockholders, the remaining assets of the Company
available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A deemed liquidation event is
defined as either a merger or consolidation, or the sale, lease, transfer, exclusive license, or other disposition, in a single transaction or series of related transactions, of all or substantially all of the assets of the Company, unless the
holders of a majority in voting power of the outstanding Preferred Stock elect otherwise by written notice sent to the Company at least ten days prior to the effective date of any such event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of convertible preferred
stock is convertible at the option of the holder into a specified number of shares of common stock based on a conversion ratio subject to adjustment under specified terms and conditions. The initial conversion price and conversion value of Series A
convertible preferred stock is $1.00 per share. The initial conversion price and conversion value of Series B convertible preferred stock is $1.32 per share. The initial conversion price and conversion value of Series
<FONT STYLE="white-space:nowrap">B-1</FONT> convertible preferred stock is $1.89 per share. Certain terms exist to protect the conversion rights of the holders of the convertible preferred stock in the event of the issuance of additional shares of
common stock or a merger or reorganization of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a firm commitment underwritten public offering of the Company&#146;s common
stock with aggregate proceeds of at least $60.0&nbsp;million and the Company&#146;s common stock is listed on Nasdaq, all shares of convertible preferred stock will automatically be converted into shares of common stock at the then effective
conversion rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or after
March&nbsp;31, 2023, upon the vote or written consent of the holders of the Series A, Series B, and <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> preferred shares then outstanding, each preferred share shall be redeemed, to the extent
permitted under law, for the price equal to the original issue price per share plus any noncumulative dividends declared but unpaid in three annual installments commencing no later than 60&nbsp;days after receipt by the Company. Distributions shall
be made out of sufficient funds legally available. Upon and after the date of redemption of preferred shares and payment in full by the Company for each redeemed preferred share, all rights of the holder of such shares, except the right to receive
the redemption price without interest upon surrender of the certificates, would cease and terminate. All preferred shares acquired by the Company through redemption would be cancelled and eliminated from the pool of preferred shares authorized for
the Company to issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a stock-based compensation plan under which stock options, restricted stock awards (&#147;RSAs&#148;), unrestricted
stock awards, restricted stock units, or any combination of the forgoing may be granted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. The Company recorded stock-based compensation expense in the following expense
categories in its accompanying condensed consolidated statements of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Activity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock option activity of the Company&#146;s 2017 Plan for the six months ended June&nbsp;30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Options outstanding as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,952,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,625,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,625,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,515,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(158,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Options outstanding as of June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,903,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,555,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,864,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,973,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, total unrecognized compensation expense related to stock options was $13.7&nbsp;million, which the
Company expects to recognize over a remaining weighted-average period of 3.1&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2021, 739,618 RSAs vested. Stock-based compensation expense attributable to RSAs during the six months ended
June&nbsp;30, 2021 totaled $0.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,485,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,193,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,214,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,913,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potential dilutive securities, which include convertible preferred stock, common stock
options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to
calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of
diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,386,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,903,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,475,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,143,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,625,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s effective income tax rate was (0.3)% and 0.0% for the three months ended June&nbsp;30, 2021 and 2020, respectively, and was (0.3)% and 0.0%
for the six months ended June&nbsp;30, 2021 and 2020, respectively. The benefit from income taxes was $21&nbsp;thousand and $0 for the three months ended June&nbsp;30, 2021 and 2020, respectively, and the provision for income taxes was
$53&nbsp;thousand and $0 for the six months ended June&nbsp;30, 2021 and 2020, respectively. The change in the benefit from and provision for income taxes for the three and six months ended June&nbsp;30, 2021, respectively, compared to the three and
six months ended June&nbsp;30, 2020 was primarily due to taxable deferred revenue partially offset by the utilization of federal and state net operating losses and federal and state tax credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective income tax rate for the three and six months ended June&nbsp;30, 2021 and 2020 differed from the federal statutory rate primarily due to the
valuation allowance maintained against the Company&#146;s deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger with BCTG Acquisition Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;13, 2021, the Company and BCTG Acquisition Corp. (&#147;BCTG&#148;) signed a definitive merger agreement memorializing the terms of BCTG&#146;s acquisition of 100% of the Company&#146;s issued and outstanding equity securities in exchange
for $550.0&nbsp;million worth of consideration in the form of BCTG common stock (the &#147;Business Combination&#148;). The Business Combination was approved on August&nbsp;9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of our
issued and outstanding equity securities on August&nbsp;10, 2021. The Business Combination was accounted for as a &#147;reverse recapitalization&#148; in accordance with U.S. GAAP. Under the reverse recapitalization model, the Business Combination
was treated as Tango issuing equity for the net assets of BCTG, with no goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#147;acquired&#148; company for financial reporting purposes. This
determination was primarily based on the fact that subsequent to the Business Combination, the Company&#146;s stockholders possess a majority of the voting power of the combined company, the Company comprises all of the ongoing operations of the
combined entity, the Company comprises a majority of the governing body of the combined company, and the Company&#146;s senior management comprises all of the senior management of the combined company. As a result of the Business Combination, BCTG
was renamed Tango Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tango received gross proceeds of $166.8&nbsp;million upon the closing of the Business Combination. Tango continues
to operate under the current Tango management team. Subsequent to the closing of the Business Combination, an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate of 18.6&nbsp;million shares of common stock (the &#147;PIPE Financing&#148;) were purchased, resulting in gross proceeds of an additional $186.1&nbsp;million upon the closing of the
PIPE Financing. Total transaction costs and redemptions approximated $27.3&nbsp;million, resulting in total net proceeds of $325.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject
to the terms of the merger agreement, upon the closing of the Business Combination (the &#147;Effective Time&#148;), each share of the Company&#146;s redeemable convertible preferred stock (the &#147;Preferred Stock&#148;) issued and outstanding
immediately prior to the Effective Time was converted into a share of the Company&#146;s common stock. At the Effective Time, each option to purchase the Company&#146;s common stock became an option, respectively, to purchase shares of common stock
of the surviving entity, subject to adjustment in accordance with the exchange ratio. Completion of the PIPE Financing and merger transaction were subject to approval of BCTG stockholders and the satisfaction or waiver of certain other customary
closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation of the consolidated financial statements, the Company evaluated the events subsequent to the
balance sheet date of June&nbsp;30, 2021 through August&nbsp;13, 2021, the date the unaudited condensed consolidated financial statements were available for issuance, and determined that all material transactions have been recorded and disclosed.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_17"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholders of Tango Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Tango Therapeutics, Inc. and its subsidiary (the &#147;Company&#148;) as of
December&nbsp;31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders&#146; deficit, and of cash flows for the years then ended, including the
related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of
December&nbsp;31, 2020 and December&nbsp;31, 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United&nbsp;States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United&nbsp;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance
with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&nbsp;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;12, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_18"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A redeemable convertible preferred stock, $0.001 par value, 55,700,000 shares authorized,
issued, and outstanding at December&nbsp;31, 2020 and 2019, respectively; liquidation preferences of $55,700 at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.001 par value, 45,372,050 and 0&nbsp;shares
authorized at December&nbsp;31, 2020 and 2019, respectively; 22,686,025 and 0&nbsp;shares issued and outstanding at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively; liquidation preferences of $30,000 and $0 at December&nbsp;31, 2020
and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, $0.001
par value, 27,152,255 and 0 shares authorized, issued, and outstanding at December&nbsp;31, 2020 and 2019, respectively; liquidation preferences of $51,182 and $0 at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value; 166,000,000 and 80,800,000 shares authorized at December&nbsp;31,
2020 and December&nbsp;31, 2019, respectively; 13,301,649 and 13,334,856 shares issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(103,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_19"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding&nbsp;&#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;11,461,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;8,985,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_20"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income<BR>(Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,700,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,522,360</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,601</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(35,426</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repurchases of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,187,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,700,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,334,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,311</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,129</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of
$0.2&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred
stock, net of issuance costs of $0.1&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repurchases of restricted common stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,700,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,686,025</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,761</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,152,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,083</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,301,649</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(97,944</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_21"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(207,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,581</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock, net of issuance costs of $0.3&nbsp;million and $0
during the periods ended December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin118907_22"></A>TANGO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tango Therapeutics, Inc (&#147;Tango&#148; or the &#147;Company&#148;) is a precision oncology company committed to the discovery and
development of novel new drugs in defined patient populations with high unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to
early-stage companies in the biotechnology industry. Principal among these risks are the uncertainties of the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology,
dependence on key personnel, compliance with government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional
research and development efforts, including extensive preclinical, clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and
extensive compliance-reporting capabilities. There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s technology will be obtained, that any products
developed will obtain necessary government regulatory approval, or that any approved products will be commercially viable. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will realize
significant revenue from product sales. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or
terminate its operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has generated recurring net losses, including a net loss of $52.0&nbsp;million and $14.1&nbsp;million for the
years ended December&nbsp;31, 2020 and 2019, respectively. The Company had an accumulated deficit of $103.1&nbsp;million and $51.1&nbsp;million as of December&nbsp;31, 2020 and 2019, respectively. Since inception and through the issuance date of
these consolidated financial statements, the Company has raised an aggregate of approximately $166.9&nbsp;million of gross proceeds from the sale of preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects operating losses and negative cash flows from operations to continue for the foreseeable future as it continues to
develop, manufacture and commercialize its products. As of April&nbsp;12, 2021, the issuance date of the consolidated financial statements for the year ended December&nbsp;31, 2020, the Company expected that its cash, cash equivalents and marketable
securities, and the $30.0 of additional proceeds from the closing of the second tranche of the Series B convertible preferred stock purchase agreement (see Note 14) received in March&nbsp;2021, will be sufficient to fund its operating expenses and
capital expenditure requirements for at least 12 months from the issuance date of the annual consolidated financial statements. The future viability of the Company beyond that point may be dependent on its ability to raise additional capital to
finance its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may seek additional funding in the future, from one or more equity or debt financings,
collaborations, or other sources, in order to carry out all of its planned research and development and commercialization activities. However, there is no assurance that the Company will be able to obtain additional funding under acceptable terms,
if at all. If the Company is unable to obtain additional financing, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could
adversely affect its business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Merger with BCTG Acquisition Corporation (Unaudited) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, the Company and BCTG Acquisition Corp. (&#147;BCTG&#148;) signed a definitive merger agreement, which will result in
BCTG acquiring 100% of the Company&#146;s issued and outstanding equity securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The proposed merger will be accounted for as a &#147;reverse recapitalization&#148; in accordance with U.S. GAAP. Under the reverse recapitalization model, the Business Combination will be
treated as Tango issuing equity for the net assets of BCTG, with no goodwill or intangible assets recorded. Under this method of accounting, BCTG will be treated as the &#147;acquired&#148; company for financial reporting purposes. This
determination is primarily based on the fact that subsequent to the merger, the Company&#146;s stockholders are expected to have a majority of the voting power of the combined company, the Company will comprise all of the ongoing operations of the
combined entity, the Company will comprise a majority of the governing body of the combined company, and the Company&#146;s senior management will comprise all of the senior management of the combined company. As a result of the proposed merger,
BCTG will be renamed Tango Therapeutics, Inc. The boards of directors of both BCTG and Tango have approved the proposed merger transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BCTG is expected to receive net proceeds of approximately $156.9&nbsp;million upon the closing of the proposed merger transaction, assuming no
redemptions are affected by stockholders of BCTG, and will operate under the current Tango management team upon the closing of the proposed merger. In connection with the proposed merger, BCTG has entered into agreements with existing and new
investors to subscribe for and purchase an aggregate of 18.6&nbsp;million shares of its common stock (the &#147;PIPE Financing&#148;) that will result in net proceeds of an additional $179.7&nbsp;million upon the closing of the PIPE Financing. The
closing of the proposed merger is a precondition to the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the merger agreement, at the effective
time of the merger (the &#147;Effective Time&#148;), each share of the Company&#146;s redeemable convertible preferred stock &#147;Preferred Stock&#148; issued and outstanding immediately prior to the Effective Time shall be converted into a share
of the Company&#146;s common stock. At the Effective Time, each option to purchase the Company&#146;s common stock shall become an option, respectively, to purchase shares of common stock of the surviving entity, subject to adjustment in accordance
with the exchange ratio. Completion of the PIPE Financing and proposed merger transactions is subject to approval of BCTG stockholders and the satisfaction or waiver of certain other customary closing conditions. The approval from BCTG stockholders
is expected in the third quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of 2019, a novel strain of a virus named <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT>
(severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes <FONT STYLE="white-space:nowrap">COVID-19</FONT> has spread to most countries across the world, including all 50 states within the U.S., including Cambridge,
Massachusetts, where the Company&#146;s primary office and laboratory space is located. The coronavirus pandemic led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health
safety measures. The extent to which the coronavirus impacts the Company&#146;s operations or those of its third-party partners, including preclinical studies or clinical trial operations, will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The
continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could adversely impact the Company&#146;s preclinical or clinical trial operations in the U.S., including it&#146;s ability to recruit and retain patients and principal
investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19</FONT> if an outbreak occurs in their geography. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its business and financial
statements. To date, <FONT STYLE="white-space:nowrap">COVID-19</FONT> has not had a material impact on operations, and the Company has not incurred significant delays related to its research and development programs. Additionally, the Company has
not incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these consolidated financial
statements. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact the Company&#146;s business, results of operations, financial condition and liquidity, including research and
development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the
actions taken to contain or treat it, and the duration and intensity of the related effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United&nbsp;States of America (&#147;U.S. GAAP&#148;). The accompanying consolidated financial statements reflect the operations of Tango and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated. The
functional and reporting currency of the Company and its subsidiary is the U.S. dollar. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the
reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to,
the revenue recognized from collaboration agreements, the valuation of common shares and stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies.
The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and
the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the
carrying value of any assets or liabilities related to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results
in the period in which they become known. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief
operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment, the business of discovering and developing precision oncology therapies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All highly liquid marketable securities purchased with an original maturity date of 90&nbsp;days or less at the date of purchase are considered
to be cash equivalents. Cash equivalents consisted of money market funds and U.S Treasury bills as of December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investments in Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketable debt securities consist of investments with original maturities greater than 90&nbsp;days. The Company classifies its investments
with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of
marketable securities to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and
losses are reported as a component of accumulated other comprehensive income (loss) in stockholders&#146; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses and declines
in value determined to be other than temporary are based on the specific identification method and are included as a component of other income, net in the consolidated statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its investments with unrealized losses for impairment. When assessing
investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or <FONT STYLE="white-space:nowrap">non-credit</FONT> loss. For credit losses, the Company reduces the investment to fair
value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair
value. For <FONT STYLE="white-space:nowrap">non-credit</FONT> losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss)
in stockholders&#146; equity. No such credit losses were recorded during the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the early adoption of ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT><I>, Financial Instruments &#151; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,</I> on January&nbsp;1, 2020, the Company evaluated its investments with unrealized losses
for other-than-temporary impairment. If any adjustment to fair value reflected a decline in the value of the investment that the Company considered to be &#147;other than temporary,&#148; the Company would reduce the investment to fair value through
a charge to the consolidated statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with
U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed
in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 &#151; Fair values are determined utilizing prices (unadjusted) in active markets for identical
assets or liabilities that the Company has the ability to access. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 &#151; Fair values are determined by utilizing quoted prices for identical or similar assets and
liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 &#151; Prices or valuations that require inputs that are both significant to the fair value
measurement and unobservable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s cash equivalents and marketable securities are
determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company&#146;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these
assets and liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk and Significant Suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and
marketable debt securities. The Company&#146;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit
the amount of credit exposure to any one financial institution. Substantially all the Company&#146;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at
December&nbsp;31, 2020 and 2019. At times, the Company&#146;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to
significant credit risk beyond the normal credit risk associated with commercial banking relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies, and expects
to continue to rely, on a small number of vendors to perform research activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related
processes of these vendors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the
restrictive obligation. As of both December&nbsp;31, 2020 and 2019, the Company recorded restricted cash of $2.3&nbsp;million, all of which was related to security deposits associated with the Company&#146;s facility leases in Boston, Massachusetts
and Cambridge, Massachusetts, and is recorded as long term in its balance sheet because the deposit is required for the duration of the lease which is greater than a year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized
using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. The estimated useful lives of the Company&#146;s property and equipment are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Asset</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated useful life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Shorter&nbsp;of&nbsp;remaining&nbsp;lease&nbsp;term&nbsp;or&nbsp;10&nbsp;years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes
in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group
is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs for assets not yet placed into service are capitalized as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">construction-in-progress</FONT></FONT> and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and
accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for leases in accordance with ASC Topic 842, <I>Leases</I>, which it early adopted on January&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and
circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the
balance sheet. Lease expense is recognized over the expected term on a straight-line basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease payments are discounted at the lease
commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate
at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as initial direct costs paid or incentives received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected to account for lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components as a single lease component, however
<FONT STYLE="white-space:nowrap">non-lease</FONT> components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#146;s lease terms often include renewal options. The
amounts determined for the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions,
if any, are exercised, unless it is reasonably certain that the Company will exercise such options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808,
Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the
commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first
determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method
is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 3, &#147;Collaboration
Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2017, the Company early adopted ASC Topic 606, <I>Revenue from
Contracts with Customers</I> (&#147;ASC 606&#148;), and related amendments using the retrospective transition method, which had no impact on the Company&#146;s financial statements. This standard applies to all contracts with customers, except for
contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services
is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the
scope of ASC 606, the Company performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will
collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or
services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is
identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes
the associated revenue when (or as) each performance obligation is satisfied. The Company&#146;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the
constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company
must use its judgment to determine: (a)&nbsp;the number of performance obligations based on the determination under step (ii)&nbsp;above; (b)&nbsp;the transaction price under step (iii)&nbsp;above; (c)&nbsp;the stand-alone selling price for each
performance obligation identified in the contract for the allocation of transaction price in step (iv)&nbsp;above; and (d)&nbsp;the contract term and pattern of satisfaction of the performance obligations under step (v)&nbsp;above. The Company uses
judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a
relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to
estimate. Accordingly, the Company&#146;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the
course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the
collaboration agreements are recorded as accounts receivable in the Company&#146;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#146;s consolidated
balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance
sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusive License Rights</I>&nbsp;&#151; If the license to the Company&#146;s intellectual property is determined to be distinct from the
other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront fees allocated to
the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general
marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied
promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess
the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time
and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#147;IP&#148;),
revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services</I>&nbsp;&#151; The obligations under the Company&#146;s collaboration agreements may include research
and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance
obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The
Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to
estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as
<FONT STYLE="white-space:nowrap">co-development</FONT> activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Customer Options</I>&nbsp;&#151; The Company&#146;s arrangements may provide a collaborator with the right to acquire additional goods or
services in the future. Under these agreements, fees may be due to the Company (i)&nbsp;upon the exercise of the customer option or (ii)&nbsp;in equal installment payments over an agreed upon period. If an arrangement is determined to contain
customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those
included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time
in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire
additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company
allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material
right are not recognized as revenue until, at the earliest, the option is exercised or expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>&nbsp;&#151; At
the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most
likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the
Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At
the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded
on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#146;s efforts to
satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue
reversal would not occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>&nbsp;&#151; For arrangements that include sales-based royalties, including milestone payments
based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance obligation to
which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries,
employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development activities and the allocable
portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#146;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs
associated with research and development are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management estimates the Company&#146;s accrued research and
development expenses as of each balance sheet date in the Company&#146;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from
the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the
awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service
period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and
recognizes the cumulative effect of current and prior period changes in the period of change. The Company also has the right and option to repurchase an individual&#146;s shares of common stock or vested stock options to acquire common stock
subsequent to employment termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of common stock underlying stock-based awards is based on an estimate at each grant
date. The valuation provided by the board of directors is derived from a recommendation by an unrelated third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valuation firm. The Company determines the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporate objective
and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable
convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#146;s stock. The estimated per share fair value of the Company&#146;s common stock is determined in accordance with the guidance
outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. The fair value of each restricted common stock award is estimated on the date of
grant based on the fair value of the Company&#146;s common stock on that same date. The fair value of each stock option grant is determined using assumptions discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>:&nbsp;&nbsp;&nbsp;&nbsp;The expected term of the stock options is estimated using the &#147;simplified method,&#148; as
prescribed in SEC&#146;s Staff Accounting Bulletin (SAB) No.&nbsp;107, as the Company has no historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its
stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected
Volatility</I>:&nbsp;&nbsp;&nbsp;&nbsp;Since there is limited historical data for the Company&#146;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on
an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free Interest Rate</I>:&nbsp;&nbsp;&nbsp;&nbsp;The risk-free rate is based on the U.S. Treasury yield curve commensurate with the
expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rate</I>:&nbsp;&nbsp;&nbsp;&nbsp;The expected dividend was assumed to be zero as the Company has
never paid dividends and has no current plans to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in estimating the fair value of stock-based awards represent
management&#146;s estimate and involve inherent uncertainties and the application of management&#146;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different
for future awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive
loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital are credited to share capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Classification of Convertible Preferred shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares are classified outside of stockholders&#146; deficit because the holders of such
shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. Further, the Company&#146;s convertible preferred shares are redeemable at the option of the holder
after March&nbsp;2023. The Company records convertible preferred shares at fair value upon issuance, net of any issuance costs or discounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share Issuance Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering, either as a reduction to the carrying value of the preferred exchangeable shares or convertible preferred shares or in shareholders&#146; equity (deficit) as a reduction of additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should an <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs would be expensed immediately as a
charge to operating expenses in the consolidated statements of operations and comprehensive loss. As of December&nbsp;31, 2020 and 2019, the Company had no deferred offering costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it
is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years
that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the
taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not
likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as
necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss as well as other changes in stockholders&#146; equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company&#146;s only element of other comprehensive loss for the years ended December&nbsp;31, 2020 and 2019 was unrealized gains on investments in marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of
common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are
considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and
stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net
loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#146;s convertible preferred stock and unvested restricted stock entitles the holder to participate in dividends and earnings of the
Company, and, if the Company were to recognize net income, it would apply the <FONT STYLE="white-space:nowrap">two-class</FONT> method to calculate earnings per share. The <FONT STYLE="white-space:nowrap">two-class</FONT> method is not applicable
during periods with a net loss, as the holders of the convertible preferred stock and unvested restricted stock have no obligation to fund losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">two-class</FONT> method of computing net loss per share
would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss
per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available
to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Commitments and Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is
probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent Events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide
additional evidence relative to certain estimates or to identify matters that require additional disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth
Company Status (Unaudited) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business
Startups Act (&#147;JOBS Act&#148;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&nbsp;107 of the JOBS Act provides
that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying
with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions
up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting
standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13</FONT><I>, Financial Instruments &#151; Credit Losses (Topic
326), Measurement of Credit Losses on Financial Instruments</I>. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and
certain other instruments that aren&#146;t measured at fair value through net income. For <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities, entities are required to recognize an
allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be
recognized. For public entities, the guidance was effective for annual reporting periods beginning after December&nbsp;15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard
as of January&nbsp;1, 2020 on a prospective basis. The adoption did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> <I>Changes to the Disclosure Requirements for Fair
Value Measurement</I>. The amendments become effective for the Company&#146;s fiscal year beginning January&nbsp;1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair
value measurements is permitted. Adoption of this standard on January&nbsp;1, 2020 did not have a material impact on the Company&#146;s consolidated financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-15,</FONT>
<I>Customer&#146;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</I>. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to
capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the
hosting arrangement is ready for its intended use. The new standard became effective for the Company&#146;s fiscal year beginning January&nbsp;1, 2020. Early adoption was permitted. The early adoption of this standard on January&nbsp;1, 2020 did not
have a material impact on the Company&#146;s consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting
Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December&nbsp;2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Simplifying the
Accounting for Income Taxes,</I> (&#147;ASC 740&#148;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis <FONT
STYLE="white-space:nowrap">step-up</FONT> in goodwill obtained in a transaction </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">that is not a business combination, separate financial statements of
entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law,
and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after
December&nbsp;31, 2020; however, early adoption is permitted. The adoption is not expected to have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT> <I>Debt</I><I></I><I>&nbsp;&#151; Debt with
Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging</I><I></I><I>&nbsp;&#151; Contracts in Entity&#146;s Own Equity (Subtopic 815</I><I></I><I>&nbsp;&#151; 40)</I>. The amendments in
this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#146;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible
instruments. It also amends the accounting for certain contracts in an entity&#146;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular
convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December&nbsp;15, 2020, including interim periods
within those fiscal years. The Company elected to early adopt this guidance on January&nbsp;1, 2021. Adoption of the ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> guidance as of January&nbsp;1, 2021 has no impact on its consolidated financial
statements for the year ended December&nbsp;31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March&nbsp;2021 at an original issue price of $1.32 per share, which would have resulted in the
recognition of a beneficial conversion feature of $28.4&nbsp;million prior to the adoption of ASU <FONT STYLE="white-space:nowrap">2020-06.</FONT> As such, the adoption of this guidance is expected to have a material impact on the Company&#146;s
financial statements for the year ending December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new account pronouncements are issued by the FASB or
other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the
Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Gilead Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2018, the Company entered into a Research Collaboration and License Agreement (the &#147;2018 Gilead Agreement&#148;) with
Gilead Sciences, Inc. (&#147;Gilead&#148;). Pursuant to the 2018 Gilead Agreement, the Company performed target discovery and validation activities in accordance with an agreed-upon a multi-year research plan. During the initial three-year research
term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to five validated programs (&#147;Gilead Program License&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, Gilead paid the Company a $50.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment upon the
execution of the 2018 Gilead Agreement. The Company was eligible to receive milestone payments of up to $1.7&nbsp;billion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
across all programs and up to low double-digit tiered percentage royalties on future sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the
option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> certain programs licensed by Gilead in the U.S. and was eligible to receive milestone payments and royalties on <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed this arrangement in accordance with ASC 606 and concluded that the
contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering committee and the research and development services
provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the Company and the interdependent relationship between
the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This option will be excluded from the transaction price
until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the transaction price at the inception of the arrangement was equal to the total upfront payment received in the
aggregate amount of $50.0&nbsp;million. The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company determined that the single combined performance obligation
is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company&#146;s performance. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement
as the achievement of the milestone events are highly uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2019, Gilead licensed (the &#147;Gilead License&#148;) its
first program under the 2018 Gilead Agreement and paid the Company a $7.5&nbsp;million license fee. Gilead obtained a license to develop and commercialize therapies associated with the nominated program. At the inception of the 2018 Gilead
Agreement, the Company determined that the licenses provided to Gilead through the 2018 Gilead Agreement did not include a material right as the license fees were not priced at a discount. At the time of the exercise of the license option by Gilead
for the specified nominated program, the Company&#146;s obligations for the nominated program were completed. As such, the Gilead license of the nominated program was determined to be distinct and accounted for as a separate contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2019, the Company and Gilead also entered into a letter agreement (the &#147;Gilead Letter Agreement&#148;) whereby the Company
would perform additional research services on behalf of Gilead associated with the first program licensed under the 2018 Gilead Agreement. Upon execution of the Gilead Letter Agreement, Gilead made a $2.6&nbsp;million payment to the Company as
consideration for the performance of additional research services as stipulated in the Gilead Letter Agreement. The Company concluded that the Gilead Letter Agreement should be combined with the Gilead License and accounted for as a single contract.
The Company determined that the Gilead License and the research services included in the Gilead Letter Agreement were each distinct as Gilead could benefit from the Gilead License without receiving the additional research services from the Company.
As such, the Company allocated the transaction price for the combined agreement between the two distinct performance obligations in proportion to their relative standalone selling prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended Gilead Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, Gilead made an equity investment of $20.0&nbsp;million into the Company as a participant in the Company&#146;s Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred stock offering. At the time of the original investment, as well as of the December&nbsp;31, 2020 balance sheet date, Gilead maintains an ownership of less than 10% of the Company and is thus not
considered to be a related party to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the Company and Gilead also entered into an Amended Research
Collaboration and License Agreement (the &#147;Gilead Agreement&#148;), which superseded and replaced the 2018 Gilead agreement. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company received upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> consideration of
$125.0&nbsp;million from Gilead upon execution of the Gilead Agreement in 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement
has a research term of seven years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gilead expanded its option to license up to 15 programs for which Gilead may obtain exclusive, worldwide licenses
to develop and commercialize therapies, subject to applicable license fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to exercising its option to license a program, Gilead may &#147;extend&#148; such program, in which case
Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For up to five programs licensed by Gilead, the Company has the option to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> the lead product in the U.S., subject to certain exceptions, and eligible to receive milestone payments and royalties on <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> sales. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive up to $410.0&nbsp;million per
program in license, research extension, and clinical, regulatory, and commercial milestones. The Company is also eligible to receive up to low double-digit tiered royalties on net sales by Gilead, if any, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until the later of (a)&nbsp;the expiration of the last valid claim of the
Company&#146;s patents or, in some instances, certain Gilead patents, in each case, covering such product in such country or (b)&nbsp;ten years after the first commercial sale of such product in such country. For those programs the Company <FONT
STYLE="white-space:nowrap">co-develops</FONT> and <FONT STYLE="white-space:nowrap">co-promotes</FONT> in the U.S., the Company and Gilead would share equally in the development costs as well as the profits and losses in the U.S. For such products,
the Company remains eligible to receive certain clinical and regulatory milestone payments as well as commercial milestone payments and up to low double-digit tiered royalties based on net sales outside the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Gilead Agreement was accounted for as a modification of the 2018 Gilead Agreement under ASC 606 as both the scope and price of the
contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation identified under the 2018 Gilead Agreement which was only
partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering
committee during the research term. As a result, the Company&#146;s progress towards completing its research services to Gilead over the seven-year term of the Amended Gilead Agreement was lower than its progress under the three-year term of the
2018 Gilead Agreement and a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustment was recorded during the third quarter of 2020 resulting in a reduction of $11.3&nbsp;million of revenue previously recognized through the date of the
Gilead Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December&nbsp;2020, Gilead elected to extend a program for a research extension fee of $12.0&nbsp;million. The
Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the <FONT STYLE="white-space:nowrap">on-going</FONT>
research plan. Consideration pertaining to the research extension is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of
scientific failure, the Company determined that the variable consideration of $12.0&nbsp;million should not be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore
the research extension consideration was added to the transaction price under the Gilead Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Revenue Recognized </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $187.0&nbsp;million at
December&nbsp;31, 2020. The total transaction price was comprised of the $50.0&nbsp;million upfront payment pursuant to the 2018 Gilead Agreement, the $125.0&nbsp;million upfront payment pursuant to the Gilead Agreement, and the $12.0&nbsp;million
pursuant to the research extension fee in December&nbsp;2020. During the years ended December&nbsp;31, 2020 and 2019, the Company recognized $7.0&nbsp;million and $15.2&nbsp;million, respectively, of revenue associated with the Gilead Agreements
based on performance completed during each period. During the years ended December&nbsp;31, 2020 and 2019, the Company recognized revenue of $0.7&nbsp;million and $9.4&nbsp;million, respectively, associated with the payments received in 2019
pursuant to the program license and Gilead Letter Agreement. The consideration allocated to the Gilead License was recognized upon delivery of the underlying license in 2019 as Gilead could benefit from the license on its own and the Gilead License
was separately identifiable from the Gilead Letter Agreement research services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reevaluates the transaction price and the
total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the
Company is responsible for, are resolved or other changes in circumstances occur. As of December&nbsp;31, 2020 and 2019, the Company had short-term deferred revenue of $32.0&nbsp;million and $19.6&nbsp;million, respectively, and long-term deferred
revenue of $120.8&nbsp;million and $14.1&nbsp;million, respectively, related to the Gilead collaboration. Of the total short-term deferred revenue at December&nbsp;31, 2019, $18.6&nbsp;million related to the 2018 Gilead Agreement and the other
$1.0&nbsp;million related to the Gilead Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts due to the Company that have not yet been received are recorded as
accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company&#146;s consolidated balance sheet. As of December&nbsp;31, 2020, $2.0&nbsp;million of the total research extension
fee amount of $12.0&nbsp;million had been recorded as accounts receivable and the remaining $10.0&nbsp;million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. The contract asset
balance is presented net of the deferred revenue contract liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs incurred pursuant to the Gilead Agreements are recorded as
research and development expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s financial assets measured at fair value on a recurring basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value Measurements<BR>as of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value Measurements<BR>as of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value levels during the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Marketable Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each
balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s marketable debt securities, classified as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale:</FONT></FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements<BR>as of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements<BR>as of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable debt securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company holds investment grade marketable securities, and none were considered to be in an unrealized loss
position as of December&nbsp;31, 2020 and 2019. As a result, the Company did not record any reserves for credit losses related to its marketable debt securities during the years then ended. Marketable securities include $0.1&nbsp;million in accrued
interest for each of the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Supplemental Balance Sheet Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net as of December&nbsp;31, 2020 and 2019 consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.7&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2020
and 2019, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities as of December&nbsp;31, 2020 and 2019 include the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2017, the Company entered into a lease of office and laboratory space at 100 Binney Street in Cambridge, Massachusetts for the
Company&#146;s corporate headquarters. The lease commenced in March&nbsp;2018 and rent commenced in June&nbsp;2018. This lease has a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of eight years with an option to extend for one
additional three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon commencement of the lease, the Company recorded an operating lease liability in the amount of
$9.5&nbsp;million and related operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset in the amount of $9.8&nbsp;million. Upfront payments totaling $0.3&nbsp;million for rent and tenant
improvements were included as a reduction in the calculation of the lease liability amount upon the commencement of the lease. There were no tenant obligation payments made for leasehold improvements for the periods ended December&nbsp;31, 2020 and
2019. The fixed annual rent payable under the lease is $1.7&nbsp;million, increasing by 3% annually from the rent commencement date. The minimum rent payments to be paid over the <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of this
lease totaled $15.6&nbsp;million. The additional rental payments associated with the renewal option are not included in the calculation of the operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and associated operating lease liability as the renewal is not considered probable of occurring. The lease agreement required the Company to provide a
letter of credit for $0.6&nbsp;million that is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2019, the Company entered into a new lease for office and laboratory space
at 201 Brookline Avenue in Boston, Massachusetts. As of December&nbsp;31, 2020, the space was undergoing construction and the lease is expected to commence in 2022. The Company is not deemed to be the accounting owner of the construction project due
to the nature of the work being performed and the Company&#146;s lack of control over the project. In conjunction with executing the lease, the Company provided the landlord a letter of credit for $1.7&nbsp;million. The letter of credit is
collateralized with cash that is recorded as restricted cash in the accompanying balance sheet as of December&nbsp;31, 2020. Upon delivery date notice of the lease, which is estimated to occur in the second half of 2021, the Company will be required
to provide an additional letter of credit in the amount of $1.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon commencement of the 201 Brookline Avenue lease, the
Company will determine the appropriate classification of the lease, the amount of the associated lease liability and the amount of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset that will be
recognized on the balance sheet. The lease has a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of ten years with an option to extend for up to two five-year periods. The fixed annual rent payable under the lease is $5.1&nbsp;million,
increasing by 3% annually from the rent commencement date. The Company is entitled to a tenant improvements allowance of up to $12.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s rent payments for the lease at 100 Binney Street are classified as operating lease costs in the chart below. The lease is a
net lease and therefore the <FONT STYLE="white-space:nowrap">non-lease</FONT> components, such as common area maintenance, are paid separately from rent based on actual costs incurred; therefore, the <FONT STYLE="white-space:nowrap">non-lease</FONT>
components are not included in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and liability and are reflected as an expense in the period incurred. The
<FONT STYLE="white-space:nowrap">non-lease</FONT> components are classified as variable costs in the chart below. As of December&nbsp;31, 2020 and 2019, assets under the operating lease totaled $7.5&nbsp;million and $8.4&nbsp;million, respectively.
The elements of lease cost were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Operating leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Other information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows used for operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases that have commenced as of
December&nbsp;31, 2020 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity&nbsp;of&nbsp;Lease<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research Collaboration Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2017, the Company entered into a Research Collaboration Agreement (the &#147;HitGen Agreement&#148;) with HitGen Ltd
(&#147;HitGen&#148;). Under the terms of the HitGen Agreement, HitGen would use its <FONT STYLE="white-space:nowrap">DNA-encoded</FONT> library technology to screen up to three targets and deliver to the Company the structures of certain compounds
that bind to the targets. The Company would provide certain materials containing each target for purposes of the screen. The Company could have been obligated to make certain milestone payments. The Company and HitGen have mutually agreed to
terminate the HitGen Agreement in March&nbsp;2021. No milestones were achieved or owed upon the termination of the agreement and the Company is under no obligation to make any payments upon termination of the HitGen Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2020, the Company entered into a License Agreement (the &#147;Medivir Agreement&#148;) with Medivir AB (&#147;Medivir&#148;),
pursuant to which the Company obtained an exclusive license to all patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property associated with a preclinical-stage research program. Pursuant to the Medivir Agreement, the
Company made an upfront payment of $0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir
in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $1.4&nbsp;million in the aggregate for the first licensed product that achieves specified clinical milestones, plus
$25.0&nbsp;million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $0.7&nbsp;million in the aggregate if that first licensed
product achieves specified clinical milestones, plus $5.0&nbsp;million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development,
regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#146;s patents or
if payments are due to a third party for a license under such third party&#146;s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The
Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront fees paid pursuant to the Medivir License Agreement were recorded to research and development expense. No milestones have been
achieved to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These
typically include agreements with directors and officers, business partners, contractors, landlords and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or
incurred by the indemnified party as a result of the Company&#146;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required
to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these
obligations is minimal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company, from time to time, may be party to litigation arising in the ordinary course of business. The company was not subject to any
material legal proceedings as of December&nbsp;31, 2020, and no material legal proceedings are currently pending or threatened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Redeemable
Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2017, the Company executed a stock purchase agreement to sell 55,000,000 shares of
redeemable convertible series A preferred stock (&#147;Series A&#148;). This agreement was subsequently amended in July&nbsp;2017 to increase the authorized capital to 55,700,000 shares of Series A. The Series A stock purchase agreement was
structured to close in three tranches, each contingent upon the achievement of certain specified milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the initial
closing of the Series A stock purchase agreement, the Company issued an aggregate of 18,700,000 shares of Series A convertible preferred stock for $1.00 per share, resulting in net proceeds of $14.0&nbsp;million after deducting $4.7&nbsp;million
related to the settlement of the convertible notes and accrued interest that were previously outstanding. During the year-ended December&nbsp;31, 2018, the Company issued 26,000,000 additional shares of Series A preferred stock at a price of $1.00
per share upon the achievement of specified development milestones in connection with the second tranche of the Series A stock purchase agreement. Total proceeds from this issuance was $26.0&nbsp;million. In January&nbsp;2019, the Company issued
11,000,000 additional shares of Series A preferred stock at a price of $1.00 per share upon the achievement of specified development milestones in connection with the third tranche of the Series A stock purchase agreement. Total proceeds from this
issuance was $11.0&nbsp;million. The aggregate issuance costs associated with the issuance of all three tranches of Series A preferred stock was less than $0.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2020, the Company executed a stock purchase agreement to sell shares of redeemable convertible series B preferred stock
(&#147;Series B&#148;). The Series B stock purchase agreement allows for the issuance of up to 45,372,051 shares. In April&nbsp;2020, the Company issued 22,686,025 shares of Series B at a price of $1.32 per share. Proceeds from this issuance totaled
$29.8&nbsp;million, net of $0.2&nbsp;million in issuance costs. In March&nbsp;2021, the Company sold 22,686,026 additional shares of Series B redeemable convertible preferred stock at a price of $1.32 per share upon the achievement of specified
development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled $30.0&nbsp;million. Total issuance costs associated with the second tranche of the Series B preferred stock
was less than $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2020, the Company executed a stock purchase agreement to sell shares of redeemable
convertible series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">B-1&#148;).</FONT> The Series <FONT STYLE="white-space:nowrap">B-1</FONT> stock purchase agreement allows for the issuance
of up to 27,152,255 shares. All 27,152,255 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> were issued at a price of $1.89 per share in August&nbsp;2020. Proceeds from this issuance was $51.1&nbsp;million, net of $0.1&nbsp;million in
issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020 and 2019, redeemable convertible preferred stock consisted of the following (in thousands,
except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon&nbsp;Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,372,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,686,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,152,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,224,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,538,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,538,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock Issuable<BR>Upon&nbsp;Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights, preferences and privileges of the Company&#146;s redeemable convertible preferred stock are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Par Value Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The par value of all preferred stock is $0.001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future Tranche Right Feature </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the future tranche rights under the Series A and Series B preferred stock purchase agreements (the &#147;future
tranche rights&#148;) did not meet the definition of freestanding financial instruments because, while separately exercisable, they were not legally detachable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future tranche rights were evaluated for any beneficial conversion features or embedded derivatives, including the conversion option, that
could require bifurcation and receive separate accounting treatment. The Company determined that the embedded future tranche obligations did not require bifurcation for accounting purposes as they did not meet the definition of a derivative. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of the convertible preferred stock are entitled to the number of votes equal to the number of shares of common stock into which each share of convertible preferred stock could be converted on the record date for the vote or consent of
stockholders, except as otherwise required by law, and has voting rights and powers equal to the voting rights and powers of the holders of common stock voting as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the event of any liquidation event, deemed liquidation event, dissolution or winding up of the Company, the holders of preferred stock then outstanding shall receive a distribution prior to any distribution to the common holders, an amount equal to
the greater of a) original issue price per share plus any noncumulative dividends declared but unpaid, or b) the amount per share that would have been owed had all preferred shares been converted into Common Stock immediately prior to the
liquidation event. In the event that assets are insufficient to pay the full amount, distribution will be on a pro rata basis. After payment of all preferential amounts required to be paid to the preferred stockholders, the remaining assets of the
Company available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A deemed
liquidation event is defined as either a merger or consolidation, or the sale, lease, transfer, exclusive license, or other disposition, in a single transaction or series of related transactions, of all or substantially all of the assets of the
Company, unless the holders of a majority in voting power of the outstanding Preferred Stock elect otherwise by written notice sent to the Company at least ten days prior to the effective date of any such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of convertible preferred stock is convertible at the option of the holder into a specified number of shares of common stock based on
a conversion ratio subject to adjustment under specified terms and conditions. The initial conversion price and conversion value of Series A convertible preferred stock is $1.00 per share. The initial conversion price and conversion value of Series
B convertible preferred stock is $1.32 per share. The initial conversion price and conversion value of Series <FONT STYLE="white-space:nowrap">B-1</FONT> convertible preferred stock is $1.89 per share. Certain terms exist to protect the conversion
rights of the holders of the convertible preferred stock in the event of the issuance of additional shares of common stock or a merger or reorganization of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a firm commitment underwritten public offering of the Company&#146;s common stock with aggregate proceeds of at least
$60.0&nbsp;million and the Company&#146;s common stock is listed on Nasdaq, all shares of convertible preferred stock will automatically be converted into shares of common stock at the then effective conversion rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or
after March&nbsp;31, 2023, upon the vote or written consent of the holders of the Series A, Series B, and Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares then outstanding, each preferred share shall be redeemed, to the extent
permitted under law, for the price equal to the original issue price per share plus any noncumulative dividends declared but unpaid in three annual installments commencing no later than 60&nbsp;days after receipt by the Company. Distributions shall
be made out of sufficient funds legally available. Upon and after the date of redemption of preferred shares and payment in full by the Company for each redeemed preferred share, all rights of the holder of such shares, except the right to receive
the redemption price without interest upon surrender of the certificates, would cease and terminate. All preferred shares acquired by the Company through redemption would be cancelled and eliminated from the pool of preferred shares authorized for
the Company to issue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Certificate of Incorporation, as amended, authorizes the Company to issue shares of common stock with a par value of $0.001
per share. The holder of each share of common stock is entitled to one vote in respect of each share of stock held. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment of all
preferential amounts required to be paid to the holders of shares of Convertible Preferred Stock, the remaining funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common
stock, pro rata based on the number of shares of common stock held by each such holder. The holders of Common Stock are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors,
subject to the prior rights of holders of all classes of redeemable convertible preferred stock outstanding. No dividends have been declared as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company increased the number of shares of common stock authorized by 2,800,000 to 80,800,000 during 2019 and by 85,200,000 to 166,000,000
during 2020. As of December&nbsp;31, 2020 and 2019, there were 13,301,649 and 13,334,856 shares of common stock issued and outstanding, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Founder
and Advisor Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, the Company issued 4,690,000 shares of restricted common stock outside of the Company&#146;s 2017
Stock Option and Grant Plan to nonemployee founders and advisors (the &#147;Founders and Advisors&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s Founders and Advisors restricted common
stock activity as of and for the years ended December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant-Date<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested restricted common stock outstanding as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,221,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(987,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(109,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested restricted common stock outstanding as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(950,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares are issued under the terms of the respective restricted common stock agreements and are subject to
repurchase by the Company at the original purchase price per share upon the termination of the grantee&#146;s service relationship with the Company. As the restrictions are released and the awards vest, the value is recorded as common stock and
excess of par value is recorded as additional paid in capital on the accompanying balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the
unrecognized compensation cost related to shares of unvested founder and advisor restricted stock awards (&#147;RSAs&#148;) expected to vest was less than $0.1&nbsp;million, which is expected to be recognized over an estimated weighted-average
amortization period of 0.22&nbsp;years. The aggregate fair value of awards that vested during both years ended December&nbsp;31, 2020 and 2019 was $0.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2017, the Company&#146;s stockholders approved the 2017 Stock Option and Grant Plan (the &#147;Plan&#148;), under which stock
options, RSAs, unrestricted stock awards, restricted stock units, or any combination of the forgoing may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are
subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors (&#147;Board of Directors&#148;). Upon approval, the maximum number of common stock shares reserved and available for issuance under the Plan was
10,000,000 shares. The Company increased the number of shares available for grant under the plan by 6,700,000&nbsp;million and 2,800,000&nbsp;million during the years ended December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31, 2020,
the maximum number of common stock shares reserved and available for issuance under the Plan was 30,600,000 shares. As of December&nbsp;31, 2020, there were 11,783,597 shares available for future grant under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of stock option award agreements and RSAs, including vesting requirements, are determined by the Board of Directors at the time of
issuance. To date, options granted generally vest over a period of three or four years with 25% cliff vesting upon the first anniversary of the issuance date and monthly vesting thereafter. Vesting criteria for awards vary by grant as determined by
the Board of Directors. Options and RSAs generally have a <FONT STYLE="white-space:nowrap">ten-year</FONT> term from the date of grant but may be less in the event that the award is granted to a 10% shareholder. The exercise price of an award
generally shall not be less than 100% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors. The exercise price of an award granted to a 10% shareholder shall not be less than 110% of
the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the RSA activity of the Company&#146;s Plan as of and for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant-Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested restricted common stock outstanding as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,888,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,744,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,078,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested restricted common stock outstanding as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,066,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,370,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested restricted common stock outstanding as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSAs represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting.
RSA recipients are not entitled to cash dividends and have no voting rights during the vesting period. The RSAs are issued under the terms of the respective RSA agreements and are subject to repurchase upon the holder&#146;s termination of their
service relationship with the Company. The award restrictions are released as the awards vest. Upon vesting, the value is recorded as common stock and excess of par value as is recorded as additional paid in capital on the accompanying balance
sheets. The common stock is subject to the Company&#146;s right to repurchase at the original purchase price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2020, the unrecognized compensation cost related to shares of unvested RSAs expected to vest was $0.2&nbsp;million, which is expected to be recognized over an estimated weighted-average amortization period of 0.43&nbsp;years. The
aggregate fair value of RSAs that vested during the years ended December&nbsp;31, 2020 and 2019 was $0.5&nbsp;million and $0.6&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the stock option activity of the Company&#146;s 2017 Plan as of and for the years ended December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Options outstanding as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,902,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">420,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,716,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(586,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Options outstanding as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,952,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,625,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,611,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,466,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the
options and the fair value of the Company&#146;s common stock for those options that had exercise prices lower than the fair value of the Company&#146;s common stock. The total fair value of options vested during the years ended December&nbsp;31,
2020 and 2019, was $0.9&nbsp;million and $0.3&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total intrinsic values of options exercised totaled less than $0.1&nbsp;million for the
year ended December&nbsp;31, 2020. There were no options exercised for the year ended December&nbsp;31, 2019. The weighted-average grant date fair value per share of stock options granted was $0.49 and $0.34 for years ending December&nbsp;31, 2020
and 2019, respectively. Substantially all options outstanding as of December&nbsp;31, 2020 are expected to vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option
Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes
option pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected option life (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.0&nbsp;&#150;&nbsp;6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.0&nbsp;&#150;&nbsp;6.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">67%&nbsp;&#150;&nbsp;72%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">70%&nbsp;&#150;&nbsp;75%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.4%&nbsp;&#150;&nbsp;1.4%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.6%&nbsp;&#150;&nbsp;2.6%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;%</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the
vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was approximately $3.3&nbsp;million of unrecognized stock-based
compensation expense, which is expected to be recognized over a weighted-average period of approximately 2.84&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2020 and 2019, the Company recorded no tax provision or benefit due to the losses incurred and the
need for a full valuation allowance against its deferred tax assets. All of the Company&#146;s operating losses since inception have been generated in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective income tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit at U.S. federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondeductible/nontaxable permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant components of the
deferred tax assets and liabilities are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had U.S. federal and state net operating loss (&#147;NOL&#148;)
carryforwards of $41.0&nbsp;million and $39.1&nbsp;million, respectively, which may be available to offset future taxable income. The federal NOLs include $3.3&nbsp;million which expire at various dates beginning in 2035 and $40.5&nbsp;million which
carry forward indefinitely. The state NOLs expire at various dates beginning in 2035. As of December&nbsp;31, 2020, the Company also had U.S. federal and state research and development tax credit carryforwards of $3.4&nbsp;million and
$2.2&nbsp;million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2030, respectively. During the year ended December&nbsp;31, 2020, deferred tax assets, before valuation allowance, increased by
approximately $15.0&nbsp;million mainly due to the operating loss incurred by the Company during that period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilization of the U.S.
federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&nbsp;382 of the Internal Revenue Code, and corresponding provisions of state
law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In
general, an ownership change results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has performed an analysis of ownership
changes through August&nbsp;17, 2020 and determined that on February&nbsp;6, 2017 and August&nbsp;17, 2020 ownership changes had occurred. Based on this analysis, the Company&#146;s ability to use its
<FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset federal and state taxable income are subject to annual limitations and a portion of the attributes generated prior to February&nbsp;6, 2017 will expire unutilized, which
could potentially result in an increased future tax liability. The Company has adjusted its deferred tax assets and valuation allowance balance for the affected tax attribute carryforwards to reflect the expiration of the attributes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported, if based on the weight of the evidence, it is more likely
than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#146;s
history of cumulative net losses incurred since inception and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize
the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&nbsp;31, 2020 and 2019. Management reevaluates the positive and negative evidence at each
reporting period. The Company had a net increase in the valuation allowance of $15.0&nbsp;million during 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards, as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted on March&nbsp;27, 2020. Among the
business provisions, the CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property.
Additionally, the Consolidated Appropriations Act of 2021 was signed on December&nbsp;27, 2020 which provided additional COVID relief provisions for businesses. The Company has evaluated the impact of both Acts and has determined that any impact is
not material to its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020 and 2019, the Company had not recorded any amounts for
unrecognized tax benefits. The Company&#146;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&nbsp;31, 2020 and 2019, the Company had no accrued interest or penalties related to
uncertain tax positions and no amounts had been recognized in the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions, as prescribed by tax laws. In the normal course of
business, the Company is subject to examination by federal and state jurisdictions, where applicable. The statute of limitations for federal and state tax authorities is generally closed for years prior to December&nbsp;31, 2017, although
carryforward attributes that were generated prior to 2017 may still be subject to change upon examination if they are utilized to offset taxable income in subsequent tax years. There are currently no federal or state income tax audits in progress.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net Loss Per Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and
diluted net loss per share attributable to common stockholders was calculated as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands, except per<BR>share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common <BR>stockholders&nbsp;&#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock <BR>outstanding&nbsp;&#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,461,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,985,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common <BR>stockholders&nbsp;&#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s potential dilutive securities, which include convertible preferred stock,
common stock options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares
outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the
computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,538,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,951,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,902,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">755,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,028,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,245,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,631,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Stock Options under&nbsp;2017 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2021, the Company granted options for the purchase of 6,805,312 common shares, at an exercise price of $1.19 per share, to
officers, employees, and consultants of the Company. The aggregate grant-date fair value of these option grants was $8.8&nbsp;million, which is expected to be recognized as share-based compensation expense over a weighted-average period of
3.8&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2021, the Company granted options for the purchase of 1,010,000 common shares, at an exercise price of
$2.57 per share, to directors, employees, and consultants of the Company. The aggregate grant-date fair value of these option grants was $1.7&nbsp;million, which is expected to be recognized as share-based compensation expense over a
weighted-average period of 3.8&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Redeemable Convertible Series B Preferred Stock Tranche </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2021, the Company sold 22,686,026 additional shares of Series B redeemable convertible preferred stock at a price of $1.32 per
share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Each of the tranches under the Series B stock purchase agreement maintain the same rights and features.
Gross proceeds from this issuance totaled $30.0&nbsp;million. Total issuance costs associated with the second tranche of the Series B preferred stock was less than $0.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Waiver of Preferred Stock Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2021, the holders of the Series A, Series B and Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable preferred stock
irrevocably waived their right to redeem any shares of Preferred Stock until March&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Collaboration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2021, Gilead licensed its second target under the Amended Gilead Agreement and is required to pay the Company a
$11.0&nbsp;million license fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the preparation of the consolidated financial statements, the Company evaluated the
events subsequent to the balance sheet date of December&nbsp;31, 2020 through April&nbsp;12, 2021, the date the consolidated financial statements were available for issuance, and determined that all material transactions have been recorded and
disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events Subsequent to Original Issuance of Consolidated Financial Statements (unaudited) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events through April&nbsp;19, 2021, the date of the initial filing of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Merger with BCTG Acquisition Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2021, the Company and BCTG Acquisition Corp. (&#147;BCTG&#148;) signed a definitive merger agreement, which will result in
BCTG acquiring 100% of the Company&#146;s issued and outstanding equity securities. The proposed merger will be accounted for as a &#147;reverse recapitalization&#148; in accordance with U.S. GAAP. Under the reverse recapitalization model, the
Business Combination will be treated as Tango issuing equity for the net assets of BCTG, with no goodwill or intangible assets recorded. Under this method of accounting, BCTG will be treated as the &#147;acquired&#148; company for financial
reporting purposes. This determination is primarily based on the fact that subsequent to the merger, the Company&#146;s stockholders are expected to have a majority of the voting power of the combined company, the Company will comprise all of the
ongoing operations of the combined entity, the Company will comprise a majority of the governing body of the combined company, and the Company&#146;s senior management will comprise all of the senior management of the combined company. As a result
of the proposed merger, BCTG will be renamed Tango Therapeutics, Inc. The boards of directors of both BCTG and Tango have approved the proposed merger transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BCTG is expected to receive net proceeds of approximately $156.9&nbsp;million upon the closing of the proposed merger transaction, assuming no
redemptions are affected by stockholders of BCTG, and will operate under the current Tango management team upon the closing of the proposed merger. In connection with the proposed merger, BCTG has entered into agreements with existing and new
investors to subscribe for and purchase an aggregate of 18.6&nbsp;million shares of its common stock (the &#147;PIPE Financing&#148;) that will result in net proceeds of an additional $179.7&nbsp;million upon the closing of the PIPE Financing. The
closing of the proposed merger is a precondition to the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the merger agreement, at the effective
time of the merger (the &#147;Effective Time&#148;), each share of the Company&#146;s redeemable convertible preferred stock &#147;Preferred Stock&#148; issued and outstanding immediately prior to the Effective Time shall be converted into a share
of the Company&#146;s common stock. At the Effective Time, each option to purchase the Company&#146;s common stock shall become an option, respectively, to purchase shares of common stock of the surviving entity, subject to adjustment in accordance
with the exchange ratio. Completion of the PIPE Financing and proposed merger transactions is subject to approval of BCTG stockholders and the satisfaction or waiver of certain other customary closing conditions. The approval from BCTG stockholders
is expected in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g118907g01q37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 68,175,412 Shares of Common Stock </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September
29</B><B>, 2021 </B> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g118907g01q37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g01q37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &72^918X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            80   3H          0                         !
M          $Z    80                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    80    !29VAT;&]N9P   3H    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &$
M    4F=H=&QO;F<   $Z     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      [\     0   *     Q   !X
M6^    [@ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MKZ"R+:WO._KO7V7EHWG'H>_+=/\ H]M7IXE3U*8@8R35U>^K-@B"=0#]#/\
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M_N)G?YE7_O2NBROJYT#-R7Y67T[&R,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-3=3L;7!T1HE.4-B8V=T=7>BL^'P&2=&1U57A9.7LM;_Q  = 0$  04! 0$
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MZ#G5W)D#^:*G0'"NKCR%K_-J0MQ#KBTE6Z$-AQ:>D[G/X_/134R)$D@K6.[
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M( F3%*.8!]"IKV'4$CFUS)F=X'-B";/J '=P!UY&WK$V4;!1&VP*]B>Q\U*
M$CI';I*4GKW/8]C]#QRU)_,^RB YVM\.4?6(GOC>^,WKSRJ\P&-\OW*7G%+B
M]YAV.L6VK-C88IB67==QD+,.QIJ1EO)J6Z9A&MIGHLN6Y$0U(6]8+9<V+&_&
M_P#"G"DC&I"YM0E:7G$(5G,L%.1*@07#OF-Q;;8Q:3Z@RE) N"F[:#Q;_"V_
MRAOGDF]H)YUKCF>TDQSF8U,Q_)M%\ERF%CF6PX6F^G.-OQ&[MU,&%9,VE+CD
M"P0W7SW6'7P):?,96M2MPGH&:QS@.GH*29/ILZEH22 9BEDD%W"0IF8@=#Y1
M,FI"S<6=N3<G8_0\K/K/&K9,>;&;G17$/1IC;,EA]LA2'67FTN-.(4-PI"VU
M)<01\)2L%( /?E!2I*E!6H+->S6W][Q=1D.$(C:>T!^(GS5\AT[E=9Y:<ZJ\
M,;U,AZN.9>FRPO#LM,]S%96F[=(IE65TEP8 BHR"V\Q,(QQ)#R3(#I89+>Z<
M'</4V/S*M%2[2#("2%E#&:)SNQ#_ -V .3WZVU1.5)*,H)S9G #_ )<NNO/3
M<MRAF#E+]HUYQ:+7?"U<UN;5&HFB%A._!<PKJC3S \:M::-8K9:9R:!88OCU
M1/?=IG0F0["<DF-*BE\'HD",XG:<8[/*:DIYLRC4H+0DJ#S,[FQ "75I<$L]
M]#%$JJ*G"@6L[ACY^;7MT&A,3NL(RW'<ZQFCS'$K6%=8ODM7#NJ*U@2$2(DV
MNL&$OQWX[J"4K:<0L*0=QT@AOI'1QR*;)FR)ZI<T$*22"D@@I87!?:X:+L*"
MAX2".8Z]?2-D=;3\@5[]1[*VV(V(!V4 >X[$@['TVXI42&(]1TW/I_6)B$%X
MGGC1>(-RS<\>N^BND>K-#0Z>8'D=?6X[33-,--KQ^)&F4E=-<2]:W.+3K5X^
M?*=(4J:X1N 5!(VXZ?P]PA18KA<NNFI5WBAHF8I+^(L2' .O2QZ!_E.FB7DN
M+Z[M9[MU.]S8.(>:\!7GDYC^>31S6O+^9#,JW,;[#<ZI*#'Y-=BF,XHF)6RZ
M>3+D,KC8Q5U464I;[*%AY]EQ\!.WF;;CC6^+,%I\$J94FG!:9*4M1*\[LS,7
M.CD6+<A%:%9TA3-]/H^KZOITA]Z2H!M2NI("&RI1)&R=BI22H]2=AN =^M [
M?$H(ZN-43HD,7):P)NYBK]#[O9_>L1O?$F]H(TLY7;S(-&N7"E@:Q:NU*GX%
MUDK[Z3IYB%BE )9:DQU%W)I[#P*9;$;RJ^,XRXRJ3(((&^8!P+5XNA-3/*I$
MJY2#F2HW# N0 ]R #L+AR!\YDU$L N"78I>_PUMJ3U L8BVZH^--XDVI]S/L
MYW,_G.*1I4A:V:W3QV)A-=!86?@BLLXW'K.M# V0AQT.R%>KKRE?%QTFDX,P
M:@0G\31RJ@ 9,ZDA:L[.'.I.KD[;[Q:BJ45,D\P2 ?L+GZ;6C#8)XR'B3Z?6
MD6QKN:W4V[7%=0[[EF=FWFM;(2@[AJ3 R9JTB/I> Z2B0A3:02>D$#B:WA/A
M^H0I,FBDR2;!24!*@]RQ>W4V/G$_BEG6[7N!I;F3]#ZQ(GY O:1J'4&VH-+N
M<O&X^(9!;3(5;7ZL8C'/Y.2)<QY##8R/'X[9D594XM*G)]4%,I!*683:0%<<
M[QW@N902UU%*H*EHU1XE$O:Q<D-N;IYD1]94[.6.XUMJ-0S?'EL\2O83[<IE
MB3'6A;$EIA^,X%*"'$NH\QIU!/\ 2=86A74K8NH<;41UI6..?D!R"V9)8\P1
ML>3'VT7$$;S+\S6CO*9I3?ZR:W95$QC#\>8(6XL(>M+N8M;:6*F@K4K2[96<
MUU:&HT9D; *+\ER/$:>D-7M!AU3BD]-/2I4I1/B4/R(#*(*E: '*0'-R& =H
MI6L2TE2F '.UW9KQ"[YQO:4>9/4R[L:/E4KH.B&#-N%B-?V4"KR'/;B.4JZ9
MC[]E#DP*9QQ(0L,U2&EL[%LRY))4>HX/V>)RIG5Q"]RE19.FF5V(?<N=;O:+
M0U?)C;9CO?DQ/PO#4MCXK_B.6,\SY'.-KDS(<=#GDP,[O:R#TE?40FOB2&8;
M8_J^4TA""/A(*"4G8O\ 5+ I'AF4TM?/P@N>@.NW,_.(55+8Y0;?X0Q >YL[
M=6 'E"N^7+V@;Q!=%+R YG.H:=<<.9?3^(8WJ'75LJ<^SU)ZA&RR-"&0Q7>C
M<(;,QQCJ(*F%@;&QKN!<*JD*532Q*7EME)07-G*0V8Z&X('-HA-6IP% AR-1
M<^IN/56C-S,R?P[/%0T \0W&W3A$B5A>J%$RR]E6F&12(YM8Z.GI>G44I"DM
MW5(E8*A(:2U)8!Z)49(&YY/CG#E=@TY/>E2I.9PO*<K/_-KE)&FS\M(O4+"P
MX'/K;W?T!&\.C[CUW&WIZCUWVV_?V_7V]>,+%45X0A'/,QSS\KW*#'KAK]JO
M1859V\5V94XZXIR9D-I'94XTJ1#J(H<E+86ZRZVP\_Y;3CC2T(45(6!?4.%5
M^)KR4,DS%@[AD\S?ZW&L5)25E@'<Z,_4EAL&ABWF$\>CD?M+K\0T_P"7I_6S
M*:T!FGR[,L>IJJ)'>0LE"BF>U(MGHJ%$EAMEYOI!W '&_P"%<!X\0!45JJ"0
MMS,1+4K-<,P&CMSY1G\.PVKG'^&M:07T)!&C ^9.K#3E"!LW\=/FVS)B15:>
M5^"Z-4CP*&&</HF5V34=SX4=$V=YPCJ22-C&"% ['Y';:CV>X134)J*E=543
MDNQFK*4$W-P;%[EW#]!KTO!N#\&FSD3J^7.J56!2I3W:_A4"2 S:^@A.T?7K
MF.UXM0]F&H6I.?SG@I:XZ[&VG(2GJ*E$18"NE+8.Y3NT=D_/L>.%<?2)]%05
M(I):4R4A08,[!P X)]027/HW:^'L,X1I)E.$R*2EG!3()2D*M_+XM5,+[ZG1
MH^.LQ'.,CNY$AZFGMLM/>[1USD*CNK"%!#N_FJ\U06X"K=8ZCU)*AW&_A+'N
M(*)-=,H533.J9DZ8E/B!$M6<A2"78!)\(OM8[1[;X+7A^ X?35E1+132!3&:
M3+ !6E<K,A9  NL$*#L"Y)+F'%LKY4K#1'EXH<_SC,J2GOM1A -9B["R;IN!
M:Q'99?EK=4&VVXE:G=0+6[4B2VA1"ND\?#$N )LF5A_$-17RIO?ID34T_>))
MERYTL+0A@7\ (20W(@G;0L-[79G%W:'6</X'@M3685A$Q2)F)E"A+,^5/[M4
MM]%@JS#4 A)$$ERTLZ.4&M&%7F5O2[7'\5M&LCMD1H[LE;ZZI!>A1$-*/E]$
MB>B-'*-NDLB0.R2>.F<+\6<*<)(3/Q+.NI4ONTA"#,R-8  /86 V  .EQOW;
M'(XOQ/@VMPG T4\B;BG>4J4"84F6A;HS%K#*E0(L&(U:X,KG7YEZ[F:U8L\D
MQIV6G#<<B1<=QFME,>4N.Q#9!=4]'2HH2I^8Z\\"C<J;+2%=D]/'K7L]XIP_
MB&C-7AI>6M(U;,H* -P[ADDACH-WCD'9?V:5/9CPR48TE(Q"K[RLK9TNX*I@
M"E',=0&(?S>T*RG3#R,>&CDEZ[YM5J[S(%^'7)40S:0X%C$6RV=OA6RBNK!Y
MBRGX>M\$[GC8)<K\;C!2%=Y)I9CVNFQ<#_>OKUVN8\U\231VD]J_X>D)F8+P
M\/S.2A4R6H$L0Z227TNWQAFKPU>61[FKYML/QBRC.RL1QN6[FF<R5;J1^$T[
MR)3,9U1!_.6$SRXS*E=UNN*"OEQMV/5APW#4SI9_B3I>1(+:J<:.^CDD.1LT
M9?M.QQ. X1.,IA,*1(E)&I$U(06#YF#%RFXUT>)_L%42+&CPHGDH;CM(8::;
M" A#;2 A*6T)V"4!*1T)2 E*=DI[ <<C+DDG4W<W=^OUZQXMFIG&8N9,!(6H
MJ)(+^(N'/KOJ6YQET'=(.P'KV'R()!XI%_B?D2(^4(,YY_#TT$\0*DP7'->&
M<F>K=.[6WN,?3C=[*HG/?+N'!BS?>78NQ>06ZZ,4)5^BI.X/;C*85C55@\V=
M,I@G,L(25*#E@Y#7YDZAOO! 4"#H?Z_I>&T9OLV7AU1XLEY$#58KBQGG6UG4
M&V'QM-J<27=CLM&X"E!05U;GZD<9]''.,*5+05H\:TAF5IU8\GO\SM\13I!<
M$WZ?HWRZ.\0+=5<;KL.U/S_$*A#HJ<:S+(Z:O\YU2Y!B5=K*BQ _)5NIY88:
M0'5J[N$]Q\N.X44Q53A\JHFD9U2$J;<L'L^H&PUY: "U7+\;:<_DVNECKTB6
M7X6'@C<E_.!R9:<:[:L1M1',URB9?,6CE'F4^LKRF!,#;'E1(Q#:#TK(4K;=
M6PW[ ;<JXAXLQ+#L0F4],4"6):5,H$',5+!OY -9_6/M+D)9R2+GD_QOT_00
M\9RR^!QR5\I^MN&:\Z41M1&\ZP.1.F4:[S,K*UJTO6-584\DR83RNAT*A3Y*
M!OZ%7W[ZC7\5XCBLDTM21D)<@ A_70@WLS^D7*4)1H+GS<>[_&'.==-6<9T'
MT>U)UDS60(F-:;8=?9C;'=+:WVZB _):@,*4H#WNQDF/ @(WW=F2&&CN5)3Q
MAJ:2JHJ),@7[V8A&CLZ@YY$!+DORB5%@3R!,<I3F'UCR3F'UOU1UJR^0N5D&
MI6:7V63"M2G$QS<V+\N/ CJ43M$AL.-Q8;8)2Q&9;91\#0 ]*T&'T^%8;3=T
M  F6A^1)%KOOIZ6 C&A6<KON0;-ML[GHQ_J4K\>QHYODRF9=;8PG4N);>;>B
M38;Z=E-]3;J6W65^B@I24K1^;6G8@'C(3.YQ"GF22Q44*#!G9O-[M^CO$(29
M:MREP>NV@?;Z/'2Q\$[F\8YM>1[ +*VLQ.U"TP9:TZSP.K!DN2Z=HBHL7$E1
M<+4^J\D-NK +BHSBCN>Y\Y\2X<O#,3F2RED3E*6@C0>)B-  VW2[1DDK"PX>
MUB_R^4.[*6 4CZGN?D!_K/RXP$51#6]K'W_%>1[;_P"'\P'[O>-(M_X<=1[-
M%$3<3 W_  I-M@*E_K%M4@$)_P"IO.S1#TV2I.Q/^()]0G^C"#UD=_*3UA2T
MCNK;L-P..P2Y")DA><"Y5E>Q#C6^SF_I&/S$$9=;OTT_7KRB6)[/KXJ;^!Y#
M6\D^O.3N+Q'(WW&M%<AMY9+&/73LAUR1A;DM]?4FOL7'''JA*STQY0=B-E*
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MD@$E24A (2+%AFUTU.XM%TF3+!<#JSD;7Z"W7;XL9^*;[/E3Z2X%D&O7)O\
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MC2(S[V-R,A;R3/9#3>[<'!\<*;6T4\?T6TV"HT*GCN$@[V32MBIQ0XZ-Q/B
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MZ@SYE'%; 0S$KKZ-%NS':0GLF/$<G.-,(_JM-H3WX])\*3%S\.IYBBZ>Y25
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ME5&]TRVCA(4-U2+&M;BVR=ECX:4]B2.-([0,(R*1B,H!BI86&V*D@&SV!YD
M!V#Z54\P$E-WMKS;X,W0=!&8]J_)_$^2$$DI%?K^4]0.X'FZ/IZ5*_K.!6_5
MZC90/S'#LT!*\64VLNF8#6Z:HL;_ ##Z=8JJFR)\S\B/U$-E>SH]_$VP,?\
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MS+)*!R((< DM<!B '.VT>#N ^+L/Q7M%Q/B3'9LM*ITR<9 F&Z0M; 222+L
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M./95DV<1KB/,LGVYV475A&J\"L8+,NWD,0(#;<>?)0F'7QB%G<CC8^&.*).
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M;N5-C0Z.JB A3LM1B%U;AV;0R'UK)2D\(1A59[S$.MJMX&CM U3+'G,U4S+
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M*[*=;;6L[*VW0\KW;]?A"*-3]3H&0<TO+KC]*KWVDPS)LT1?Y$A:/PAO);3
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,'[^O"$7<(0.$(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g118907g06w69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g06w69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $LR^2!(X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            B@   E0          0                         !
M          )4    B@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    B@    !29VAT;&]N9P   E0    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   (H
M    4F=H=&QO;F<   )4     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      A3     0   *     E   !X
M16    @W !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X   $$ P$! 0             ! @,$!08'" D*_\0 >A
M 0,"! ($!@H&#A,)# L  0(#! 41  8'(1(Q"!-!4105(F%Q@0D6%S*1DJ&Q
MP=$*(R13E/ 8&24S-4)%4E155W*3TB8G-#=#5F)D<W2"A)6BLK/"T]5'=H.6
ME[3AYO$V.$1&8V=UA;6VP]0:2&5F=X:DQ<;6Y?_$ !L! 0$! 0$! 0$
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M-M#]0DKWWMT*4+UU/*G40^C,*3\U(PGB-Q\TE@=X\D]"M=^(?F?0TCMXZ\%
M^;:ANV[>?".^XY)XC=\4E=QGT"J3INN,0!;T"B$*)">KK@VX>=[TR%>]QR+O
M:0E(W-G<U)R<77/+N>.2U_-OG7'9A1&8-9K#\S:-_AU/\7!XOP_D'FJT/XOS
ME'C_ %F/ZF4;_#J1\R<'BQA_*/-&APB_.?).;K>LRR1XNHXL+_HZ#] P>+\/
MY!YJ$"X';&1T*E\<:S#]3Z/_ (<!^?!XL8?R#S1A@?\ ,/\ 2E\<ZS#]3J(?
MW]="1ZB!S\V'K&4MD/D73U14$?QOSA1X[UG[*90/^,%_I&&C'W"?-72AN/\
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MMP&D),[,)PS.LN[R+S!0L""=9_O 94HS83*E-;UGMO2J !VD5ZY \U^9P(B
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MYNHK5:;4.HDMQU-;_KF4K6;\(OQ%05Z[W-\+GS(W-YJ7D:CO?R5'/_Z+Y/\
M/F>C@^<%QVX]![1B'J.86AT/(KJF*HL ]6J5&J*::]4X,:HOE:V83TN$U.=0
MFY4MJ(O[:MFVX=(N1O<D[$38]>HTV4Y$AU:F2I;!6F5!@SX,B8P4WXNO;;?#
MC)&_&E20I/;RP1669\&0EPQIT9UN.ZMMUQF0S(3'6@76'E<2@P4@V4"38[C!
M%CWLS4"'&9F2ZW2F(LAPMQY<JI1&FWE<9;X([BC9\%8*>=[@I!L-J 30$[$6
M3,Z$E,90DQAX40(BRXC@DN*%PE"T>2H*20H<(Y;]^#&<C*N,\D[SW*KXZI*2
MI9J,%+;4@0EN)D EJ>H@^"<.XN2JX2;$\5KXNC%@:/WGE5.2SB""D$<-M_>F
MZ;W-['TWVY#D.6,HM%KWZ)N_VL?\TUBW#6>04O.H<RL9%22D$ %9+9;OWI8N
M3\(5ON?5C4 >1<#$9RVWMMQ1G( N:6J<ANE?*]E\BX_3/Z1CG2FU R-&H].K
MNE&0L[2J)FGP?32JQX66<HTRD,U1W,4S4M&8&X<FI,[HE4KQ4I+1L.#F#]"R
M\'9QB%X@"9!RTR,"9F3@ ;Y*B\U9GQ($N!DVZ]M4TQ]D*U3UVR-TEUY4S5IE
MEG.NFQGYPTZ>1EUS,U-GZ?Q5R?!8U;I<Y=#4[6W515*==@O\'EHX5FQQUC]'
MP0$ S!+$N7#T)&9D9AKZA.^W/+<M1S+T[NE5DS(LB34ZYDK,F:*ED7(.;(-5
MRYIG]V-O9JJ<.)+@1\K.9H?%5>89EK\7^$U%A)=3P%83:W3[.@(<&>'+)FJW
M&BMXF-N5,<,)K)Y\]D*Z0NBDW+;N<J2W6<K5K(=6K=>S'FO3(9'S!E/,$JJ1
M:5E235:%1LV56-&H3BY*V70[4'@\ZZ726U.=2WJS]&6=H 06+D>J=(2-'/%Q
M*CR0N#0C6/-Y737JC0O5WI.Y]Z1-(RG7M2]/']-96C^5M47LOTO3'P.K.MU]
M+0-+;S0O,DA+:&%J<6P504DL*:X@I0*E>;Q?A+*QA)FX)ADY<NSX,8C<,4UX
M"EUV6I?4R+<%">)1"5%(XTH2;)<X4CA;\C8  *'O@ HW))Q\I3O;?1DRM?S"
M]_94?YO%AJ-8YK,?LG9S"Y_*E18,=V1/J$6!&*D)Z^7)C4Y#9.Q DO$%\J/)
M)MPD\ (MC41.D1JOD)#8I" P.#DXUWX_)7&9D)U+;R),!:0T5M.)G4XJDL >
M7(05*NJ,T04NK-QQ VQ"YFQ+Y':T[J>2K48"5#)]=,)ZY45H3J:&!*-1BIBJ
M6E'A0G1V8KKJMFTL/LGJW4IV'"FY!V)OB'.M^.U6C.UU^K!M5QR5@S(D=QIE
MZ3%;=?)+;3LF,@SP;DJ1UIXE!D6/& 0?,,&)H"=BMSF7+/O6Z>*C3VVE.KGP
M41D*4E4@SZ<TP%) *@7%WL4[<6]@+=F&B<#N*KD&1U&XY8W49L:*NUFW*? X
MZ,SY;<C-*2A]:J_3'4)639+?VL\(6"0;$7W%^RS1B-QW%,*<.+=9E; W5Z4X
MA3R:E!=CMMH=<6B6RMMIAP\+3B%->3P%0-N(W%E$]EHQ%0RBDF.)=ITEUM2%
MMK0A;3K:^-+R%))2[?>Q.X(N;<."+4&_>)]&.L58=?4+E#2+5YI^,Q]>D/F5
MJ#IUB\@K-P$\.UR=O0+?]/RX\\436D,.(!XF2Z"AU@\W/+7)>4NE7TAJYT?J
M3D:=0LL4C,SV:JW4*6ZU6)S\-F'X%353DOM!D$+?6I(;;"N:B1OCZG@O"0^)
MC$!B9V-'E.6V]") F^XW[,)5S7SNR][*GGO.M-8I^3=+LD4C454:C1*IEW.5
M6K[T6B5JMUYNE1G9,.DAB9)HL]I:9,1"9;!4XM)LL"X^M:^@X88!$(X@TZ7;
MKJ.-11G-XU.Y:<YSU4R7O?H\]*P9WK&8],]8I^GF2-8LN9I7EAJAY=S-4%T3
M-;AALU!F7E:)64F<VVS&D)8F1%2)*FY2N%11<7^);^'%B/5<@S<@.!<XDP,K
MG&83AO\ DU],%[>;<#BD+;*N7 BX*%!+9"2DMC9*4KXN%6Y6"=[#'E[[W)<:
M9ZGW5;@UZS$8DN;\^WS>2KL_'Y,%%83[P'MZMW_*&"+6,T?S+&] ^=.**1:N
MH4-8=?0K7TA)2GB-M]N\^2/FWQV%!J"XFIUGFAX[$6L!:QMZ.6*HIDCR1V;#
M'(^T9/)FPD*8?%=1[(FTW?&9KC\$N'W2=)Y"6$QRI0)/2$FF7-QD<MK/K3E&
MS:=B=^S?OP@J=74)'%H@39S@ZCXAV@CTCY,=6!J'7,6A-(N'P4C8"@3V<O7_
M -'P;XSHPF[IR5TXL> \D\V190!)N  '.K*O,%&^]MP.\ ]F&C#J=L3>*AZ8
MY*&TB$P>0XY5V)B9L ((,^GE4=887UDM)D)6HD=7+!.TA!!!!L2?.,8C#%YS
M)Z3"W9QF)](@F[%BXGF]<"E7+A(6IDSX+;@(^UO2V6G%@V((#BAY/=8WY]EL
M9 >Y^*Z'(_'@4],ZG*<+)FQ0H-E3B6IL9? A()+C@:)/"GF;C:W,8:,6!W%7
M6\^]M.V3DR8BXXF(E11"-T^',R6G(I V+A+AX0X+6V5L+C87PT2[-,3;'=W=
M52[7JEG,2EMXA2!^(\X6D/QG'^!M7@Z'64E"+7:?)9-^%^]_MGD>2-[VP9JN
MV+>;3"82NO(F=@D#A5E4=S%08<D0IM=HT.=NEV*Y5Z/&=4![U)2L]=V'B0O8
MV)(N$X,YDYV3W?%+GEO#<GG*;;U)&K=$G-K=@5N@24MO)9<$*?">;960JR7E
MQE%?7WL$CWOEW-B4V:)P.4E7RPO->"M^&P$K6TN?$9<C6+_W4D2F$JL0J4#[
MWB\G@!L"G<6WP$)- 9TDF/61875U2FS*=Z9$99;?D3(L>,X4I:FO34H;?4OW
M@"MK%?GN=CVC @BH(UAD[H/@K@4FW"5K6LI"@A;G7H"#NEQIT6/"L$$@[D ;
M[8BGSJK3%^K)"CL1^/JY?-@BDN>\_"<$64;]XGT8(GX(C!$8(D5R/H/S8(M:
MK?YW%]?TXU![0V\BLQ^R=G,+7%#B21WC'9<@2"&F4TV2.'R3?F%#B2?.I/:#
MR([>6.-K$VC#[Q#;92U[\%J 3)H!*?65U]%XZZ;72E;Z)^EL3.L"FY=K&:JQ
MF*F4+*E S3F%O+-,J#K]G*RX[4';HB-L4D25Q6E<7&X!>PWQ[/"V M8F-" Y
M.S1 K2>Q="VC$UX.#/-R]9SQ!JO)6H_LH_M(S+0FH&1J)/R+G+0Z@ZA92SJ]
M4IS]&5GK,51FT^!D2IJIBD!B-/:A/28DUMU*W:C 5P$7)'N^S(2_K%Q,D .0
M"#>*U%XF21>N<-0*BHO(K+?,XR)97-1^F]TI-,LQ:QJJF2]":GE72F%HM/91
M!<S]%KM:A:XYEI>6*"RACQBFG-KH J?5EY2PY)6 H%)-\<X? 646B!%&T4<4
M E"6B@TM)ZUT#PD)MV((P<!Z3RPQ(KB'6VU3IH:\JR/J7K51M-M)SHIE,:L4
MW+#%6S;6:=GQ[,&FU8=H[M3J5)++E%ET.O5FE3V85,@<55I+2.%594XYPIA]
M'00V@@,46D(830Z!<D%R ?6>&;L&B!#N0ESRPP-:M?@_"3KDR_9/<^4W6C.^
M7JWD;)3NG6G]9S- S:*!&SXYG7+]"R]D09L8SQ5ZG4$NZ>,TFHS!&H(ITQ]J
MM&3+:LX.)*AO[,@#^N:/-@"<B-$FAD& D9S3B:-,F<GO%2!Y&:;0?9)M<M1-
M&,F:BZ>Y/T*9S>O6BDZ*ZAY/K&8,S9GIV7ZAF.9,10*]3:YE.<4SHKE+C19+
MT<I2I+LWJTD]5OS/@;,%GB+@Q.T+2$P\B)S  V@.EU17;.^E.VFNG4OIRZZS
MM6]9<CS<O:;0Z1HQ(S'$GL1LD:P5)[,K^7<ON5A;\7/;$SVAT)J3-X8[,6I7
MJA;V]_B#P5G$Q$1&DVC"=$1 O>P'4!W8W4U,J5:@F<N)?R[-T3.E/JMK%FM&
M1M7LJY(RW5JQI?0-8LMU33^?7IE*>RW6YIA.9?KD',\5Z<Q58TE3:7GHTQ##
MZ>-R* BQQY?$^&^J)%P)!! ?&@<;V,B;EEIUD]U^]N\E]'6E+#!"KJ</5MFY
M-MD]O?WD_#:V/(BR;?YVC]XGYA@BXCTC]M"=4[;?R'9@Y;?^!R/J&"+4.CR
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M[7WMROO@B+LW)LBY !/"+D)OP@FUR$W-AV7-N>")>)KO3\ \WF\P^ 8(D!9
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M$G>_FR+CK(%D*/?=LCYDXR8WQ&H_!:AA,W VSZI$L.#FVKS62KZAB@@N\_\
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M:E)^5WZ:7).M72A)-@HG66>20GD#^9&X%S8$[7-L0>EG('U5E/\ Z4']*SH
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M2+* %S8C<;%/9>$!AZH+D R%.9D[BE"4%^KJ,F%TZF8DLXG3'(A2DG+D=PD
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M<-=JVDW\14_NWFR?I3@HXSW'R3SKW6K>50J>0.SPU\V]12!^/+#:W>HK,41
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M;YJ=K^YIQERBYRC9/J^;<FU"! J4ROPIU,B.1HTYUMN&S"@+"9-;K4QIXO\
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M&KGZ(O\ ]@3_ )M&.EG?LZKG:7;>BQ:5)"4W%SPI[!W#'3'7/<%PB,(,P\L
M>:Q=<K4?+E KM<DJ<7&I-.E3WX;'4-RW8[#)D/--N2D/(4J2;);X0 VV?)2!
M?'"(#2)(!F9L#,:\)+K#'"(9!I"4H:RD0;[FG7"7B#,O3E<R?1Z75:AIS2W9
M,U(J#%&I&HD3,U1B9=EJ!;JE0H] R_4)M/G=2J[C=5%,H[)%DUEP!83ZK/P4
M-K (Q:$:0G"-,7S9B(2!-VD^"ZREG[.IL)]&VN7T;IQS:R_3(431J2&\USI%
M-R,_)U!R^U$J$^FJ0I8KLF-$?3EJ,E"RM#P:K;@-DF(@?;,;_4(?WI8!ZD\-
M)S,&<V:XL$!VWR(H]>^*%]/EIJN5^AQ]'LR55>7F51:@_0LPQ:W0D5^.V9*:
M<QF:-0UY4:A]85-JFRZ^NI$I6GVNLVX4[A]&@P@_7-I>R"8@7!F[Q/L.B:#%
M5GI208 5&$KL!*E[%=ET\Z3=5S7J3&TVS5I^_DF;/HK5<BU!S,BJY'ER5(0[
MX) ?AT15'FN1^-+,A3.8')K<AIULY7C(2'U<+3P8LPXC)84,1<4>I#0M(!Q,
M.[,315IS!$@#6_(BX8RU>MVT'JDE1)58$\2>$V4 H@I*W.$@&W"%6%K!*!9"
M?(1" 16$>\\6]Y]LLFDV+92QD"O)O38Z.SO2HZ/V<M&XF:&LENYD;@I3F-=,
M9JR("8+XD%*J>W/C//WW6E*D) "R4W!"E>_T9XO]0\3#X@"( 0D"&$Z,0TF)
M:0A^ZQ!B$R]R^KZ&\=^I6T,;F$.VD"1,FCAB[9B[,CX"L?8]M=>:2Y^2GC*"
MN(A2])IJBL<1LL$YF0>%0\I/DVL1;:V/T*P_21XCPEE#8006QA@<O]="9Q$Q
M&\XX[J#^_A^G,-C"+,Q$F$#VHB^-Y?IA)6D?8\U=*01TJ(PY[)TDGV_Q<SD?
M3CM_:GX@5L8R<[6!]LU(OT@0PE@ <_7.XB)FZNID_8\-=6+GI3LGLVTDG6^7
M- .+_:E;G_DQ_P"=9#FY6?V]TIBS)%'&DW&-T[_Z._6NWI3L7\^DL\'Y,TVQ
M?[4_$BEE$W_?L^A X(?IX1_RVU@D_P"M/3]CN5DB_P"2MA(WY.:33>+T^5G5
M@V[O(_NCV/[5/%BE@2,3:PGB(F4_;P^YN ZQ'FIV_L=2KN;_ )*V"3YM)I(&
MW>59_2;^KM&^']JOC'__ )S_ )GQ;?U3]NW_ .63_"#LKK4I^QT:MM?I60!M
M^Y.^.T_^<+&?[5?&7^'.RT)' A/VZ/[H_D'FHG/L=6M-(=6GI54]:0V/?:3R
M2 JZKG^> L#8B]M[<@3;&A^E;Q@E^KN31[5IWU,VED9ZUN'Z<N&-G$)U8 "6
M B=\P*M.2QA^QYJP D?DJH2C;<HTDGD ]UTYOE>KRT;?I-^)3^U7Q)]JQB>[
M0MH &N>L\=@0_3Z&"0#R>>D0-6B0!2FYD#['FKA%D=*F,-[W&D=0OZ/^Z88A
M_2IX@_\ )CVVL!ZJ?V@B;"(?X1$VUXP>PI$_8\U?/+I71D6%C_*FJ:;\]_)S
M1:_RXH_2GXJ[PT46+VD+C*3J']($1/JPQY^T)_YHZR;)W#['DKIW/2NB*/*Z
MM**GM\.9[]N-#]*?C&EX4C_R0CR6#]/8XJPQG7/G:E2M_8\%:5=1Z5451%@.
M#2F>#Y_?9HN>SE\Y&,Q?I1\69Q>&8BA^M@,G#WO*JL/Z08K,MHQC2HSU$ONQ
MG%MH6=RU]CR*;S#1IF9NDO(JE!@5.-,JE*BZ8SX+]4C,**UQ&JB<S_<9= +9
M<M8I4H'R;W^=X[](OBO%6>B;., 0D-%:!CI,)L7;87PDZX>/^F\7B++0T2Y$
M7WG9V!<$RI<"V3,ON%D;HQY>RC0*3D_*U712J-EF!&I<*GQJ&$I8CM(*6NM;
MB37P'UEM3CJW.%;JU*45+(61_!>,](Q>D;0QQ0B$P$LPKID.:@_=E2N+O^?^
M)\9%XVUBCBA T20&9QI5=L0'K)Y7MN2NC\X3OFET#LM09E_7PNC\>['E7G
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M 9^6Z;,C/NMO=1("'PVMQ" ;^L1"9H< 06))FY<@S.MYAV75P["D\+F<2P<
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M!C(6ZTZ[&2EV31H\8I>#*^J4F2H.( 62+V$^JCP[Z;6*G??=ZWB%KGD>=J)
MTUILFHS\P5&#/JCDB+2IBJ-%CTI$3PIB34'%*99><5.:4A#8! +84FX4,#91
M0PZ18.Q:^]WP(82GKN6@'>_U7$Z-C<[.<3(575*G<TQ:SQBY3Y5F[E)!L"H
M<TVW.YO=6Y)QS8Q.(20;B#0]]NRYF&.TBT(09WAA(MCA.FI:4VH*4"E178V!
M46R=C;:_<.7E;<K6Q!''9C1BL3:$%S&Q)+SJ)L 6PW*VGA?$P1&$0QZ($-9E
MC""==>BOH+@M;@MOS6A)]! ('9C,5O&/_K'6QGL+S!SUA06'BA]TM_A8[ &
MWOP5@*7;<;^9QJWSXA\1&?\ ZYW :Z#%7ZBU^]9VC_A!;B3S4B>*W.W]VG_1
M-L6&WC;_ (#3OA!YH+*,2^HC.9T@>$E8:<*#Y:P$';WZ0;GF;$^BQY]V+IVL
M3Q,(100TF)DL)7\UVL;&/2)-C& !1B0^HWR%_"C9$Y3#S24H4I"R/*%C?<WL
M=QN.8VMV;''"*TM1$'@+!GBF:R8SG.AJ97UXV\?U<;:#"NB0Q;/YX9K/Q5.
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M$ C$&C@/S1#HD6EHF9IA#T+I'8L9Y*4.QFG4H"DH2['9<2E*T=6M("D$!*T
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MR4OM U_'+4*J#^]F<)X#>?)&B][^4)1D+I C8:AU3\&9PG@-Y\D:+WOY0@Y
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M/:-TA!RU%J@_O5CZL6=W-NA58W1'<#T"#D;I"'GJ+5?P9GZL2> W_!1C?%P
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M@BE"$FZ0A'DWW*;#;SE/P>ON.")@#9O]K;O?A2.!*B5=I/D^][03ZL$3N!L
M#R0#MLTGF#<F]NWYL$1=H!(#:5<2B@*"4'<<R2+@=I)[/.;X(DNV=QU5@2"0
MVE2!8D>^'H(/G![C@BG#;=O>(/.Q*4FXOMN!W<O-@B"RT3<MH^*/JP11+2T/
M)2E""%)2;H'Z;?8D=@W/9S'/!$O"D&W @I%DE7"GB!WWV';MV?7@BD#38 '
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A$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g118907g71e01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g71e01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2DB4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ !>     0 " %X    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            $-   !9          !                          $
M           60   $-                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   $-     %)G:'1L;VYG   !9     9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !#0
M    !29VAT;&]N9P   60    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     0X0DE-! P     'HT    !    H    'D   '@
M#BX   'G$ &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G
M1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M           0  ]M8  0    #3+4A0("
M                                   !%C<')T   !4    #-D97-C
M !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%
ME:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (
MAV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M   "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8V
MMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M           !)S4D="($E%0S8Q.38V+3(N,0
M                                          6%E:(        /-1
M$    !%LQ865H@                     %A96B        !OH@  ./4
M.06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V
M,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:
M                        !D97-C         "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14
M,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                          9&5S8P         L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F
M5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                           '9I97<      !.D_@ 47RX $,\4  /MS
M $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                       H\    "<VEG(     !#4E0@8W5R=@
M0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &
M@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0
M#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6
M !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"#
M(4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ N
ML"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[
M/Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2
ML%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C
M:=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#
M((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^P
MH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!
M(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20
MYD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-
M<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q
M.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H
M\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQ
MG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4
M<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"
M$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0
MDE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."
MEK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>
M$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS
M+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]
M<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](C
MUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O
M=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UT
MD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3T
ME/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE
M8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-
M9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV
M1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z
M=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77
M.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\
M)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'8
M2 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3
M&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-)
M:?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_
MJ@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:
MH<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"
M6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+
M[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;
MG*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $3 6P# 1$  A$! Q$!_\0 'P !   & P$!
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MUQ"CFJW+&N<]N0S8QF&:QW%A)(V7SV$!WW"ZGE2STN(<(4KA)Y"7>/E)Y_K
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M(FB*! /G5FN+9(,2(-@;:[@\E! .O>H\?Z_X^=5F?\ ?16#B!$VT]G52*0%
M^1SY[G@_7@@'@CGCL01^FH(!UYSJ1]%B?3:[F#,V<X==B-U3*2D?;@<)(/'
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M5X_CEC"]/N?V)5364UX8%<SG"55<MU+CRL==6M:O;A2U^X[6HY"&Y!+2  \
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MZ\>>W.H].JIV8S!TND3%Q%[&T*5QI/0> >3PD'CJX*B$]1']X#GJ(/D ZH1
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MA(X^9"E 'D\)6CCOX[@E0/'?L.WG75:S0&:G?4B- -K\YWLO)_XE4L_P7Q4
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M9&G*"[?2.AB?&ZJZWS;C[VNLJ[*WW[!W$H5N.^S'GNKJI"N2E*DSFRRV5'D
M!MY3;O)Y * 2.VN.XC3%6@YT?,T$@#4VL.\D 3RFRTL12;58<VTF;::[@[@
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M1W5(X4%]3;)"0.DZZ?\ $&%-5AJM:0:?S<K$P=C.VEOOZI_"WB(PN.JX4O\
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M9:;V[.@S'+;Q-_*9"] ?39>"UP9JM<65R*"TD0>5$DAB8]\9&ZN>2![DB8D
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MJ08,Q/HH(!$>Y6R?IDOU0<PL*!;O#5[7..L-J("3/KW$/(4/^X15R2."#\O
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M*"DC@I5PH#N0/&L3JC"&]B^G5<9+@'@96Q8@WF?!59B&5FSARVJ03F;G#2T
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MR\9"^BZG4 )DE^6"?F(T=-B(CO,(M1;5TN(+14?ZM#A2%K2%%"PGI*TE;:@
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MW(B8/TMUW'(KDN'X 8YQ>VI&&:W,ZO&@Z-S $S8?. LU8OZ:H6X$RHEX)N#
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M7*P20+"/E/.\G-)UV(Y\BM*G\24FX@/90JN$NS-J508:;2R*#0TC:0\'Y9!
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MHH,?0#G" VGEEH^8YLQ-[0,MYN8)([#G/H^W&H[I['WMS,*R?=1G(\7Q7-L
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M]/ZY/<GMKWK^'/$AC>&4<* >TP;32<3%V@S-KZ.CNC0+VOX'Q@Q>#[$$@TV
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MLS2;OF#T%[^)^_18ZI (L8[.IFTN):V/_N!OI!E=F)!;C\<=H[0[>.R$I_\
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MY3<-I$6:8C25.)*7' CE)UMX>I3:RM2JSD>PEL99%0?I=<M^_*+W>_?)9?\
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MM)6XC3K8<AKG BPZR9T%A!-YFTWMHMMG$&"Q;5,D-L&S+K D%P$21))F- (
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MVDI:2$H0VE/2E"4E24)X2/S<\C@@)UY>]SGU'/.CI.NY/=L!N2OKNDP4Z;&
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M\9WQV;2Q'W[V5E2+K%$.+3'B9YC;S*TY5MA?OI*"JJRNL]QB&MU1;K;U%59
M<QU<[>%JM!-&J?Z-4PZTY2?TN Z.@Z;((!F))B=B=M1K ,^@ZY;V,WGQ3?\
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M \Z_BTE]]^;F^W5:VZJ&ER1D.-PW%KFUJ-QCVXA@IO;EK"<M3=PS& =C:!M
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M+\IKZTB"U@&Q+/FSZF ")<5Z9P?XZH/8W#8Q@#W//]1Y,1E %XF 6F\VF=9
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M1R)CW$]._P"&WZ4_38($W$-M*NZRF(VV#F>7-#(\A6^>$J>9DV/OB"5D\AJ
MB.PCMP@)2..K8SC.*QGR/JN:S,'908AS06Z^)/[0O8^#?!?!>#AG982G6JL9
ME[6JT/)(+2'00((RB\<R;K?&,TQ&2EM"4--)3TMI;2&T):1ST_(GA"2>%=P
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M+:<9A6L.0H+^"; *5EW)7+U6"[RX4Y0Y+^WKG,7+6K2BHF3H#E<NZIY3YC2
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+T1-$31$T1-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g118907g72r02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g72r02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1]\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'V"^@#(X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            \    2H          0                         !
M          $J    \                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    \     !29VAT;&]N9P   2H    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /
M    4F=H=&QO;F<   $J     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    '.$))300,     !3H     0   *    "!   !X
M\>   !3, !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M4NGYVF'DUW._<!A__;3]MG_05E$2^JJ=($$2.Z=9E-SL9XUFAQ@@_F$_N_\
M!K2&HE/!M#__T/4;[1567GX >:YKZP=?Q.AX7VW+FVRQ^RJAC@U]COS]F_\
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M[ 1WG[PO/O\ &=TVMMF%U0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( /4!, ,!$0 "$0$#$0'_Q  ?   ! P4! 0$
M            !@<( 0(#!0D$"@O_Q !0$  ! P,# P(#!04% @H'"0 ! @,$
M!081  <A"!(Q$T$)(E$4%6%Q@2,R0I&A%K'!T? *4A<D*#AB<G6"I>$E-6:B
MM+;Q&3,V0T5C982U_\0 ' $!  (# 0$!              $" P0%!@<(_\0
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MGCZ:0BN3]3_/4N=SYPBY))4,DGS[_@=2C]P\?8Q.@ZG[19*B-3&%M/("D$@
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MZ\Z@ FK!M?)H_3FV]+\^C?Q7G#QV7\6[J1MY]G^U$.T[U@((+S#]/329#HR
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M@HZ4<@/RJP?45W>[?>O2:O3;@I5-KE'F-SZ56($6ITN:P4J9FT^:PB3$DM%
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M2HH. 4?+V_*2%H 8<22V5-A*/01Z8"LD*45#.=>8Q92M8_[%_([;,&^-M++
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M 'RC'&NA@EE)J2P+TV]Q5]8!S2+5+))()'D CA0!/LH84#CC((4 2 <$@[!
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M?XZO+U\/O"+RKMSXXPL\_P " I;A.> $]J3G\_RU.(N:$EAT9O.)8%^0<=7
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M'?1B6 [PJU2!XT>MG)<.PIMQPW7^'?U1[5R9!78,B\Z0TI916K)=^_&%(1R
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MNM.>YZC]*C9_> $=!P?!.?Q/M@8T#5I4\VMX&)C%%VEM!AP+:I<5*PKNR8R
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M"#2$&D(-(0:0@TA!I"#2$4/C]4_WC2$10V3/_*"ZJQ__ #&V!_G;-5_RU)#
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6E*4 22$@D#CSXYXR>"=;$3'ITA'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g118907g73t03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g73t03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2..4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (W*^D'0X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0%?\F\         *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           ! 0   ET          0                         !
M          )=   ! 0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ! 0    !29VAT;&]N9P   ET    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0$
M    4F=H=&QO;F<   )=     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !CY     0   *    !$   !X
M?X   !C= !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M          $  /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4WU]F7>VNUBT.YK\(Q 'YH (YLS!$TG@9@KI^U]ZNUYVW;WBZ/#KL^VM7!Q
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MYHB*FO;[+N5N<0NH Q DP*QJ8S@ 029-.<( 7I;/VR]KKEL\"XWRU%W8PM8
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M#0M)$2,SAD\W(T)6&P_Q'?9;%NNR/<L5I=;<$/EH:_\ UGO8=&$RZ + Q @
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MD+3;:VTQ5U02<3APU:).8H>"V#QMQ.\1V&XZL.Q'GO,&+HIUYP36,P#)DPB
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M"'3#'68>]K+,NP,Y5I82YU""YG-Q/-HS"6N7:YV1-!(KGB@$NB3A(, F:2)
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M0[3.QK>\#:<[0<UA.SC<F2PO+6C#:'" UL6C0VT:YSWCFO :6NQLV==>5(B
M"X!SIK )F"21B!;,$ 0209EM[">"+@[<$9-*6F* $K#6>$'%^9(\1A)'BAGF
M$Y'*)SG5W%E.XX91@ZO$4:9,H4\;AI*#D24EH]-A):HJ($!Q72JU;'VB]I[1
MEFQUI:,<;\;,%XL>4:\;/+BU_-=9 NPX@6,P&Z&RP S*V#LZ[ R&B(Q'"7$
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MS<C_  'L9(0ER#2T7C\K[;3/$&&0NFJV2$1T[*"QT54,*2>0#"B;EJZZNC"
M*NJ'9-#Z:S+FR8R&0PY# >5,P3V]1X:=Y.9F%EOAZFW$9*LVQJ]DV[F)C"0U
MW.L6#U$X$=$1R:-[T5X:);$3,VOO<'XI1H[8$B>78]&S:1*&B:*HP\BPR_(R
MRE"L@K;MNX$60$0TFM09<#\SZ  0))EQDD1 "UI.*G#NDP-3F1!C14DG*>(@
MSDBX1ZAE@@2$'K(<Q$G.(I"-QS$QUSBYPH*95PZ6(# ,<CM*L1CI#)U,)(9
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MHQQE,WP69XQP5X&4S\;(IAA$I%9 YI+4F)LG:T(%0RQNQ)!MJ D8CA$\P'$
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MBUH:<)(.$&&N(!#8$$2'@Q%*FLA4??77EHOMXMR3>*ESCB<Z "9)S$" 1&H
M@B+<8\?,*=CU>7\<SEBR;3V_!I(6(OX/8B,>J2+XXF3$F2G[B4>(MA@;"9-#
M(+4A(6C,J6$2T6**/*A0A3.9VS7LF"*"00'$G.D1,T%!O%#FJ65HVTM+*SY8
M223(RH!$:QG6N1U5U1/B]#FSAD3=B,J?B(QFF088E$\9-8R+CT9ESC-4IQ'
MPC@$YG!*6FD=OA 129X,-42OC$(+JS$=&7"8-KF[86LM* O:"W.2*3!@@9B
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MWKT7-2TP!.Q9U)D1/%N4R !=?/*FR#QK52(M&A)':5U5"EI*UZCK%P( @R7
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MRS_XKOMGU3W6Z_RUW_VS/PJ'8(?W&&?!K?\ 6U/*6G\1_P!IWJGNMU_EKO\
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M)&9!.K)UW4Z=L)#8>P8T2R"*I+K6PJ .W<S1R45>UW9!:C;6]"&@OX:_+&9
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M!,I%LJ.HIV6@GLI1&;]HAL 6$QA@\T& [$<K.),D$P'#-L.J8-@,P<L@9@4
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M#=]\^,GK)ZS0>1'D.2[J*V[DU9S???WN8X$5 UI-=]-T3-:NFW.LSF=QTIJ
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M/?"G'\8QF4.LA4"LBY'R:RL,LDEB0EM?C]\-LZ5KCT((?*^1G! R/'"(-?\
M6^U7;LH6*HZ)E7:Z\-M+:=K>K;$PEK1(8&D[H)) ZP(RF<XGENAT@UFIF"#K
M'9EN--%HSG+&.1^#6?XXC/!1D-(U9XF9X3A++ <X&WY7CB%E'0MR9/94@EVM
MS2\A0Z&,J5(D8]:[4$.T<[]E$EZ(O7I=GWVX[8N=^O7M%8%S=BW1MI^T+(ML
M[1T1@L;0.H_E!C;,BA(;R;H><#6DVK;%IG%B(LSI2KI) @&)!))D"N2Q&3QU
MB.V;<6,@Y<XKLK3.AW<L$\MLLVF(:Z;%_ED=.H'%@]21X&)9O-D&#7SM4I7?
MUZ=_X@]HO_7K[.; ]M[?V5V1[/W2\[!%Z%S??&X2 74< TL:7@'+%&( 8FLJ
MOI5T_P +[Y>;@-H^_-:Z,0:7..O-#G#+FQ.$/#23#G@"?2[!&3;8";B.&9R8
ME,][!PA'<FQK+DU/-2<KGH8W(GH=Y>,V&(I@EMX,?*VL(2\,BDZ51>BB\]?J
M+9^T;K[0["NOM'LUS!8;2CDK-K, L^9((K!!@C"&@ Y&*GS=ZV%;W39UE>[:
M\8[P+[>[E>V15KKJ 9<9R(+349 $U!G=14JM?*])%V[ZE5-D5.2;ISY;JJJB
MKW=Z>1,W-D @1I]1PX;UYW-KW8QCU[*#.#P2^Y:M*:[CBY19MT[]);EWP5O?
M=-]D7[Z[KMMOY-M0X-UCA)^HKK^2R6;'VA :TN.N$>L>,*FM3P8CM;8DAKNJ
ME.5NP\;7DV[O]Q$Y>3S<^?/;5!:V>4BFDC33,UZUEM;K>K(2ZQ<!Q:[K_P"9
MCNRKJ4JJ;VT\'Y%Z2<ZN2;<EWY)LFR\^^I>_?I95@7#:KI[>$3S]+9/S?9]_
M;W]^6BIS/U/5EO\ '7BN25I<15\%OLFWG^XE6W)>?V4[TT4N);!'_&Y0N<J*
M/E$[T^Y[R;+O\MS\J^_\MLJ%(((D?KR4QHI31$T1-$31$T1-$31$T16=.OK2
MDG\T$?T1-$6"(%],M_:_[M6EE\O;]4M?F[/HMAQ7TJS_ "U_/HBN'1$T1-$3
M1$T1-$6A_$9P@V\BF7&4,5F&L R]4UL,B;IRT5_$I\/:;=5:3F/MU8(0>,UI
M2D898D!1@2J[4E>RD)BBO7V;MBUN7[IY)L]-2T<)S$99EHD01$2"6D$'+S.9
MC*>.>HA>;4T6=P:Y?"9SP?+@=NS>\#</QD,1R=#'M.^Z.1MV.M$ER<^[M&("
MUY?OJBT_*^PL-H7:_6=(KI+9D4,SOKF#P%2MYE^+#EY=\F!,R#N&L0M='X?@
MV*/+Q4H#AJ$NG\T;DXP[:$NL<]E0:\!];3NV7NV5=MTVY6=9NM(D]58&^E1G
M W<1JL[=H":R.MI\#30T@G3A.9H2Y9/5LB<&84GDN>I\[MT%P0A#@=O?_P"+
M<R"=M8^S5@J=Z1_M5=NX2B(FL)O=WNHBVLH)J*MU!(&61TDFHW1.&TO_ '$4
M<21(RXD@B!3QJM_\'<&,A>F@^1>)&^)*$@CEL5A^)8[></8)&2S9UUYL<DK@
M@UI6=29D\3885(CA0L3M44$1\68:(57SFT-M6EN#96)(;4%U:@B*:TI&@C62
MM)UH7$$D4W F#EK,'+AD="O2U+5KH):6BA+*65H6A;?S/H<U[MTYJGO]W/;7
MG0]Q=N.^LCM\-%1?/[$(-CV%YEXS,^Q;'<7"R:$\0%O"V-05L(P[$QPHV' 2
M4CR($ )908QDDX>VVKH>3;L*5%)3MO4B7-OG'_JK_P 7?:__  L_P?N%_P!@
M6Y]^VI=0!?7CWF,9< '1!(8)HZ0"0XD.+2O3^P>P+CM_;?N%[M\-A=\3H B
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M[%O[-O=ZN5]L+:QO!NIQ >\M!EH<0V<P,+0"29,$3!(I@6" ^(0,1=DL.\(
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M3:\V;+*T%L#+",37 0,)(@9D@M^$S!BLY1CL'M>;1O)F0Z(.<QGN(<*B)$
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M*M8J8KJ:F-1$?3/[U8,NUYN=V]P'NHNN0RKE'6 !UC@ OB%7E_K[/O<U[O\
MUU]FM>7L[,Q$CKKVS0:037?,K>MIL[.),4XY&I[@(''3)>M,FX1ADIR%8Q?&
ML$.87BBUD,<$QIQ*B3\@>2+-D!:8ZG<O\9!T8ELG\4\C$<@QB+MIQ=]2P<'6
M#WWM$22*R M(@ I.-:6KL,D0Z&DMD$-.HH*P9'&(U7&M;Y:V<:D#6" #'#K(
M%,R!H%SE_P CRQ;&"UJ*7<RR ;(9)>,/XT2D,8M"(O&0$=PIPS9H,.)Y05>
M)8T(-&V?G\9I3L$46%%H,I8H*%U.%%"[V=^O))EI !IEF"YN1)$0T.#IR)XQ
MKW?:-J3,94[1)XR0 ,C$$ 3 *EW/R/"#6X9DN6$IIEB /(D*G%UA%,@8K)WI
M#;2# <C&64HE3>!W)?XM0R850ND=&R$O2&+LDL404D J&6RD@E^T+6A FL9]
MFL4.<30F*DF8M]HVQFA)$$ :S!(.4&*'.I!B,M83$L>\$W%W(+_#[-)*^?83
MR"?A;HY(F8L1XWWX@>>1Z4CG(\.Z(,:H7)$#.%[-Z^I11&VWT43?4WRZW>_7
M'E2,)@$@28--:&A$@P*]B[>S_P#561#LX%0.T'*)J8R%*Q5?<W"Y2QG,-B,U
M$I4@N71>/R<8E:?-^SY$*9&6J(N_/9D\1%W3WUY]_P .OK;.POUXW$2.V-(U
M[>HE7Q"SM:FIB=.LG/7A3+);*\/@DP2R<&=#4O6FHCP[DNXH3YA2Q5JZ:HU<
MHN_U<B+_ "4\N^R:V-E-D[X SI29T[,MPDQ5>+]M;>S==FM%), 36:D90,XK
M!K4+TTWHY5^]X.CR>?N5.:;I[_)$Y\^[T!.$=0IY!?)P,3SN%>T#Z05W:E73
M1$T1-$31$T1-$5G3KZTI)_-!']$31%@B!?3+?VO^[5I9?+V_5+7YNSZ+8<5]
M*L_RU_/HBN'1$T1-$31$T1-$31$T1-$34$@"2BU;SAAY[,;)F3P4E1'IN0BC
MJ+'EOD24?$3N)+UIRW 'C(=L^)@2()XZ<$8'/AK H7@Y=V\KMBSPHI((^6Q7
MP.M;A;V0<"' N@D4H9(F#49C(YT,@[>S;S:77:MRMVV<NL'@  361I$D34B9
M))C#3#YL<$>29;F;, $#E3)[FAO@ "3#X\B]\UU8AEITIXP%6:'W;,J^#33Q
M5#"&S7=B_+?16ML7WI^>>T_G7L[?KQM':#FWB"-G-(NDDPZ06DR)!+0,P3GK
M!G]!_P")7L_<O9/85A;[)N,#VF&*_G""=DAK6Q9"<)8+X))#Q/\ ]MO-);'N
M6BHJ;HJ*B]RIS1?NZ^EK\XIHBU[XCG];#%Y2BQ7MVB^&L%7_ .GUE7-Q._9-
M^I\^>^W+ESUHWQXLK MSF !7(2>K/2=.-/1>RUDRVVO=@X3F0>L1V$B:UZLU
M\5/_ +0)<N('X6^_P?:>7+O<NWU/CM=OLKSW1$W3FN_DUZ'_  _L18WCE1-9
MG,P!2NA(@@#>OLM@^RL[R;&LFDP,SAX;S3JWY^#?#3+X1 \[8YEV1V]B]$0Y
MEY?(7W M#[0([=A2K4'*[H+=_P",;6*21XPE#\-U$FI0<*I%=EDT3E]&O%C>
M"*&14F*$Q%)XQ6*#,2L=M8V@/"(@\-:9Y2*BLTW;ZXQEG#7(,FQMQQC<1D2X
MAA(0 +8/#)>+9J<4-0+S*2/#PAKD!F%CTYD<A"0U7!$9;E43+!! XI9C$9)"
M^S$[,Y5I8WT/=A;6I:* 3H!74YS .I!)7+M?>02 )SF.-!]9F2)ZXL<9(>!=
M_:;!KH"#"R4=CN/V\7D19GFFH%*YD4X>3-W)!#**"GK][=$ <YM8XT&I$1P"
MXG6EN)43A"%2"9;1U^C_ .#49Q->'":5KUE6Y':M:G(;\S&M:Q2.JL@$9,[=
M^1FC(T"=U1J&GI"P<SA\:;V'6?AP\K)&H7+K@ )H / ];M<4/S->*6(!]7+1
M,UH&(,22U*3MY!WQ-9M6TR)->,'/?I3LX56+D=K&*32"!F3K-(CZ:FA6KO ;
MELOCGC;P=+@%#8"UE.40\+*"!-;JD6D:R$=ICSH%L_=$7KP<TI+V'XY'Y$IL
MHIHNR*FGM!=;.WN0)BF<=Y-/^#$[BN^P8&P14@YTR-8,@\8@3XK[KMTVZ2+R
MY*FR<OS;]_O?8Y=_PNT9R=YO%C3,B!,P#QUX=R@6LN(B@U![_P EN]PLQ'JH
M\Q,[USI]J_0EG95.26&CGK#ESY46I':JG?ZUKWHNVNULEF&R+@<SV]\Z0(/7
M35?*O;2^"WOC;&/AEVX5&$"1OK2*3OHMR?E43WJ/L\MJ?C^57W_OZZR\4N6B
M)HB:(FB)HB:(FB)HB:(M:II_"&_^U,?_ -M:ZC4]0\W*=!UGR:LL /66_M%.
MKN^7^D?54;\W]1^BOW5592;SUE/]+\R:(L*3/ZDJ^VI_:35C\+?[O-5'Q._M
M\E<&)?K4O_SR^_0VNJ#+M=YE7.?8WR"ROJ5"ZUJK5%3P??\ ^>GT:@@'/?*+
M7S*V*"&0I'#S#8W2):@V%\>5L6JR+5T6'NLJ8;G)$<KD=4BJP)QS&Q^/$6R]
M*DI3(-JE08A*FK/=[S;7>2TP[0T,'"YH<!6H#JY@1D*1@M;)EI0D:C.)J#$Y
MBM8ZHU6%J>%F4^+[<%5D(E7<L0!N$ZQV[-/"+D2U&Q(=<@==4WUU7RO!*O=U
M7FJ[[=I;UT]<;4L(/[FI,S#9C$XAA@5#08WS,FIG3]V)@2(@@"3\1 &*=]!.
M8@ 9"%V$^'#*MYM(P W)74(\9?3QV.NV3<M8E0+61ALQ 8]'Q*L7'SD/ ,9Y
M$B%#@>_:]F%813V6+IW&$AE#M.P>;%UK82Y@ >6AO[PXK-SC%.<0QP$S <*B
M"K^[&L.&$R8Q9"' #/(XAD1E$;[C&\/LT%Y%CTE:3XIXJ!'UYRTCMHPYL6 ;
M.F:3>5HR:M7 A\Z,,#XJ3@8N3&U'P+46+BC-*4.T]F#1F!]]LGV)LN1:"X#&
M^(<XAK6@B"0V"TF T#G4BI==EA:L=(=S9, .)PB32'5K(FN5<XB0?\/V4;I6
M?G!.62(PL:,NBT2*WW=YZW877\K:&;35_&6PP=12R Q[KT'&(^.RA2(@I435
M0=71&4WLK_=VV5C9NNX(88?0$N;AB)<34NPN,-;5L&A!!]A;N)(?!J09BL@Y
M"D#G:]U0;:)\-&3W+N34M)]>H&$:K[<6QMRPI:N7&C22M7,9<OW!6)'E5^"C
M6X9^AM)VI9RSW&W "NFJQK99M>RAN.[LQ-DAP8,W XR (PE[B2<) APF8=BQ
M&ZVPGG4)%"XU$B)-/A;09Y4S4V3X<<LD*S%V]DJBX]+!*&C(Y9)2X8_B9%%E
MUXA=CK"DB_H=-)3XQ"6!*E^_0D,% 6OS0Z24:HL-JV P@6 #6B"S"R'$%I:X
MN(!!86R  &XB,@T)[K;15P-9D.)(%:#*09$SD 8#CGE9WB U8B$AC(0PEQHZ
MF<9E H01+R.RPOB!+2*H<BQ$DCA^8:,)"9$'BI%;%1'=2U2DAA2ET1&W.:;V
MVUMS;.H2'"0&R"9PF(:"0,(R D$3 6<W?"P"/F!B3,&-3HZ2:5RUJL0Q?A<G
M45A[,.)R/<8200.!5!G]HC+'0BP1AD+QP(B8^\.<$$58AXS0TV1,A:>147)R
MB5;%"9-5W[7:;+5KK,V ]W(@-AH+27O+R").(M<P&M2P1F":&[L$03(@YG,8
M8W:S2#$F94^XX8YIXS]9<90D)&.^%QU159('W]ET[&1!<9M34=)M6HJIV]:R
M%(?)#I%SXVT#")2:/AEV,54N290E4;5:VQ-D+%I,O<UQ ECW&T(<#D2 YK&@
ML!AIQ.<'0#;H*'2 ,S40!#I),&)-3F($RKBFW#[)Y  QR)&R-JA2$1V91VT>
M?EI);?"JY8U%CP\J'.;%[KA8M%$%-WXUJ7>IVF4:M/HF+6GM1MCL-H6=E:WA
MW)$!_)X0 ",+"2]A:Z1#P2'&) ).<*S[ D-FL!U3\LBD3.6$&F9$9%9#PU$9
ME&[V0GTM)%W-LA,B;.$M"C^Q>OC($U(%289JY;,RA-EUOMN0R!F+(=>[4)0N
MS#[1=!A1FHL9IWVV;:82S"7!LO<V8+X#<0! B0T.< !SL4[UEL@03- 28G09
MS05@R,R2*[U6Y?AR*R@U5+&ETQ"I\MNPWM9 @A"R$D_@;52=5:F*G;8@$F8Q
MITE[."3<#*0XRIS54-&4+4JZP,M[; ;.?W+JACJ@'*6C0F721AD&:F"MB8UW
MCOW]?"3([5;K5CQ)16U6W;$,6Y=:47TI;N9!</8ED%MG1SMTD7 43DP#(2J[
M(JN6(R%C*>:H+;<UU,V9B0YO577KK(SH*Y4HL)-IP(KI!RUIORX::"<3)V5&
MB]!_PY3]_=Z:45N8O-,-OAO16FE>LV[\FR-$2:V5V]STZ**J;<EVES+/Y;85
M_P"UP/\ ^WZ=4TF9?J-YBA[,^[6@XJ[B]\K*,<':[\<+1@J7C1UJD=.7@CDP
MSO*U=M6[9S>CA,^&J7=$WZ@0*;([]ENBZULW%8V@SEI%<I(, TS,4_4;ES=%
M[L)I^\;,[B0*P>/>-PKX!\;N$7W$5PLYCQ")5;9V0QJR\CW3^=^G)HF;%2^.
M-JD1%5$>$0+0?OW;.UWY+SYFQ;T=E7R!GE S&5-W$5KI25]ZNO)7BYW<D4WR
M-Y)$S0B ,P*'>O@M+"B8,J3 G![L88#/W(DJP?6W-ATS?LG2M';9TWW^<WS)
M[S14Y;+W+Y?N=A;6=^LIK%(I$SEO&>=13=DMREXI- )!H),0.&@SRX 0:M#X
MU(IU+8G!XO8<$I-*9&'C$3'4N&S;K4@DA1B&%-F[EYNT9=<?/6_2V3N3O\NE
MJ1=0.NFIK/Z X[\J/Y.[TJ.$UK4YTC4 <!O6TX'@7S-,XM/9W G<0R##($V(
MWR$KB!0F8"D"(:/EYC(P-EPH7<(=CP2.OB%"R_L%"ZOPJ"BI59N"4IJOO<;@
M3IKV17_G0KEOVG[N0.0$Q,Z@9G4"),:FE *%6EQ7\/J\-&2?4_MS)U,TO7,G
MLKA:Z+0!5>L8YX@LP8*9IU?MH^OS[3B)K(JMWZ]EJ6[*1"O5>U2F2QM>78U\
M1+6N@5 Q,!()(;,$D33?20!LV-^-ZPQ=PZ6@D-)'55X93<!V\=8-7M&_Z.\1
MN,=Q)] N@OOSX-W-YWPC\,CF_P#3KN \3U<E7O6" ^7YT^QKX7MYLWV<H)TF
ME3/F?#B<<9&-8&4Z@&#$F>K++=ZF<)KQ;9F6C^?2<#!;GR[_ #HZ=-41.]5^
MJZM]]N2)NB[KJVS,S$1&ATK%-U.O=25\Z]NK+![N=^6>45G29)KUYYC>_H4>
MQI_X4]&NROG"Y:(FB)HB:(FB)HB:(K.G7UI23^:"/Z(FB+!$"^F6_M?]VK2R
M^7M^J6OS=GT6PXKZ59_EK^?1%<.B)HB:(FB)HB:(FB)HB:(FB+'4_AS'(4.D
M$+)OR@UC)1]\60>@G:L2EIE?1;;FVU=^#<*SZW:WL=-$I7;=45%IWUK7JP;>
M;*ULI(QTIG BE=X/5D#K.]LR_P!MLR]W>_,#7/NS\3,;<30\5:[>7-,$$5!,
MB#"U_.\&6 C;;$C1_"F-;7#5I!\0:UMF+YNX$HBTN1DF;%FC]F?'O;OAGSCM
M"Q434JY=%AI-D4=+<7GW?9-WNWNYI_I0(@QKGD=TY G%0Z+NN]LMM.N^U[O:
M6O+MVZ6&^A[29Y&8PP1!$@2[$ & 8"XDG(*X$'"Z:_$3).8L<HORURV)G-<U
M'56.:]6;BLQB\H!@[9?EE^@ \5OWJJHB:[G*.S(:2<R14Q$91E'ZJO(<DT9%
MP[?4?KL"EDQUG=E?6D3Q#T/FO?0DTQ3&SK_951%\(YB)F -$[]]U'KW+LNK\
MI9_P6_:*G WBIS/H)V7Q832CY[=AJF)._7;M]!:^J7=G[CJR+LFS*ZY<;;JF
M^_?MKG7QG+7=PX2:$\(@:<:1$9&1W-AWKW*_,>)J" =9)F9SB=!/62)/S:_)
M0.$QYQ5<.3IM%6R.,DXR?N)K";'_ ,06J1JC60QG?=-J9 R6I%WWV*BFG+?E
MJOLQM']E6XY69G? @P)@BN6\")F2OMUF;,78VO:2*R*QEW \!D#*^*%XS<,'
M=\>0;.&CMFY<M73-S0EAQ8OLEZJZ:N&R=[[>GR<E55V[EV^TV-Z]YLYLZ ^9
MW[]:\*F*+9LIM )IF:>9J8] %F;A_P 7,\P9%IAKQR=M4TQF92:T)B@]J6F4
MD<Q6-ES[2)1<>^=;/3A_LGJ";K2@P6KLF@TFK5!I/#>;>\74?3/4',=<:[J
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MO2Y:LR+Q$C[PIB0.24CR<U 9#35VL*V*R#IMMKE9V9_<L>]SF3B:Z &BS;:
M"=8>X;B0' Q75_?.(IA%=0,Y+9H*9 D[R087?(8/Q--W1%I&961OM+9(1<AQ
M)Q(V"UB+%!0"]FCB96GH]5DC0\&60B(D/2DKV Z5-JQ*H+*1^UE;[- ;RC1
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MW]1^BOW5592;SUE/]+\R:(L*3/ZDJ^VI_:35C\+?[O-5'Q._M\E<&)?K4O\
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M)OSYJJ>]OW?'OY-81=;2TJ9,TI.O:)XZ5[^^R_7!\AM9I0".Z<\M1I)R4M<
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M/6NB52BKI:JVRM'SA;,9U&^-Z8QO\.^F?>.(D*BG.*?!D>J%VGTM)N+YM'U
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MV5E8P;A;=A"[SJ7P\T(@DO(#YM'.UH2C2.O54NB(TT-A:5.$<V<56\V!)!K
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M@L$9Q*RC@=<(EY>3,R4C)_#CGX<2L@1F3*BRG9$?077WZVAL8<30X3AT)$
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M%7WMO-J477X.W0GRZ[JOG54^\B+OYM]U7[F^H) $E%SI6W3NB+2GGW7GW?\
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M,;\B-,R867;QQ2WT5G*ENR!"8N,+GLG[/Y)H<W$^6@XLP7%N-T@.,-$D"8I
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M^J(Z$%^UNQ_&,M'<PN3R2 X&,0) H"TM!$SIB!.5 [<5.-HJ9&5-:R)S)K'
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MYP%),_VFCH:VC$C<,A#&+PLV/(D]GA>DN\CM(@.5#ERYB-[MIL^P#L/O.9?
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:$T1-$31$T1-$31$T1-$31$T1-$31$T1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g118907g74y04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g74y04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@P4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ !>     0 " %X    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            #)   !6@         !                          $
M           5H   #)                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   #)     %)G:'1L;VYG   !6@    9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    R0
M    !29VAT;&]N9P   5H    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     4X0DE-! P     '9P    !    H    %T   '@
M"N8   '8  &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G
M1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M           0  ]M8  0    #3+4A0("
M                                   !%C<')T   !4    #-D97-C
M !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%
ME:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (
MAV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M   "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8V
MMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M           !)S4D="($E%0S8Q.38V+3(N,0
M                                          6%E:(        /-1
M$    !%LQ865H@                     %A96B        !OH@  ./4
M.06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V
M,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:
M                        !D97-C         "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14
M,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                          9&5S8P         L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F
M5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                           '9I97<      !.D_@ 47RX $,\4  /MS
M $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                       H\    "<VEG(     !#4E0@8W5R=@
M0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &
M@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0
M#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6
M !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"#
M(4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ N
ML"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[
M/Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2
ML%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C
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M6TG+43L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(T*1%R0S4J&QT?!BP1DE0W+Q&"8W1$93<W:"DK*UXO_$ !L! 0 " P$!
M           ! @,$!08'_\0 .!$  @$" P8% P,$ 04! 0    $1 B$#,4$$
M$E%A<? %@9&AL2+!T083X3)"4O$5%"."HM)BDO_:  P# 0 "$0,1 #\ S^-
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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M?OO1>OR_B_KVO,F-T$;=]4FWV^W1-?Y9D_43:U>87_7AM]O77[BY+DM_CD3
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M?3OS'??#J7X&0H-I[CW'E7)Y)Y^I7DDI1YX^1VC@^ 2!W$#DT T T T T T
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M<TIF7%PU332U3P;NVUID\W>?;.Y=@["" 1SRD<*X!4 !SR2CM3W$'^\!'"2
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M^HGR>3\'7:P,*G P*:*4DJ::5QFR4]S]B4DE"4(]8> /Y#6Q3DNB^"374@:
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MN#^7"%$GP -/V*]H:5"=E+76(\^O0*F7]#SSUA>D^K7XF-C6V.17X1(=9-1
M64D/V*%(<=2I0 2U&!2I:' ?H>+K0\\A*CPD]K8O \6NI.JETJ$VZMY)RU$7
M5^'FGQ-K"PIEUJ5DG>F=;*SRC2,N1!@ZD>F;;7/Y^!V2L\GRJ#,*+;G)]SO]
M%^X-KM%BNX>4.T+=!AV2[D5V/R<&HK29(R3'F7I$FT374SMW":OK6L_$(0KU
M^Q^#[/@PWAIUI/-N\7_IJJJ5HG-MOJ9UAT4Y)Z9N4]9B6I5K7CD5[H);;2E
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MB3\3VF7@,K&[JE#[TS*ZG--J,8W)1)_"22$HE>[D#T*"VWPB2&XZ74M/*<)
MDI@OJ*[;7^S. ;P91M]NAB\?,J!_);JNB8TJUAX-CK%Z]CXO;^Z<DUD)50]-
M;!:->F7:.(*GQ3H807B!&]]U^; TN36&'UZ,]S&_@6511M1,/P^3:HMLBR*'
M%L:/'JJ7(E08<VXLZJ2BU;93(2RQ7MOR)\F$E 20.NQZ@.Q4ZIA66/0=R<MM
MWK;-*B7AV-X/-FYC0?Z/#6,Y]:WE3,EQ6X59BDJX@0)\H27OQ$M]$*H:LO<8
M6X!&6P?5WC74%N]O%MOB&/6_[ VPQ_:K*J?<-2DN8WGM#NMCDS(Z:?3!3$>3
M$1^":CNQDO\ O*F,*D.D1E,*:(%8&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@(2SC,*K <5R#,K]Y]BBQFGG7EL[%B.SI+<"M
M8<DRUL1&$J>?=2R@E#3:5+<4 E*23JKJ2SX3Y7_ [[]"QWL;ZQV&=;'5'N[T
MW[-X7D-5@FVVWM3E@W"RJNGX[>Y)83;<5<R#&QR<E+L2J;+C;L6<YPN4._Z4
MA/!X'C6U.G9GNN-YNF$Y>4Z<D],[743@QZMU)2DG9RK\;?Q<K5)/)'/*B>">
M>2#VI*BI1)''U E7DGD#GQY^:?N[17BNE)N:DJ7&]QGDDE#Y+-FIONNJV63;
MR]WKUXMKA,;#=M[;*%MS'>Z#5ESAR2ZE0><1]Q'2H#O21S]9/W''SKT_AO@>
M+CU4XN(H3W6VU"><VC36?1I&SAX4J6H4WGBI=EYWGB55XYB5/C<8,5D5+!4$
M)>><Y7(?*.[A:UGR!]2^U/P.3SS]O<[-L6!LR^BF[2EN^4OGJV^IGIIIIF%$
MY]]Q-B*"VD\<\^.#\_E_U^_YZW"R4&J4A//'CD\__#0&[0' _P =@!/;R?D'
MA0/YI)\<_P _GX&@+1^XOIF1\@S'_2#095B5EEQRK>F<Y%W!QNPM\91CF\=S
MA^0SHL>)4V5;,9O*"SPNJ=JYWO+B2FE2HDUI;+RP#4YD1GSZ=^I$.(^G0UA.
M8T4FFSV WA>/9ATGY^S3)QUN'-7DO3-0W&..-M_AG170J'*ZNVC2TQF&4KJ[
M*),#*S%++2!/#E^&ON0MNAZ:5GGMWE\B/N77/T6<9+U!7-CC^44$JQK,9<WQ
MRQ%^K),3BQID9I6;T3#:ZO\ $W29E3(C^P^(@<.A'&/+OK?S*K>E/I@G].\'
M,_VMED;*+7-JO;&#-<@5BZVOAN;=[88SMT78C3SCK_M6?[NBU"'%J6P9)9!(
M0"1/4HCOO2YS+(<+QS [7=C$K6DQS;*QVMIY-MB=E-D8Y5JR:=D55D=!#%BW
M7')I0EIK;UZ>P_$<CM^[":9=*5: B_/NE+-]D\%@9SA,B]SO<VAW7V^SVF=Q
M'%D7;=0_0XC!P2V,G&)$Z))NJ:96,OO3&6;"//C(>]R.]RT!H"26VOIU;F;D
MXU$WAW$DXO5[NY'E.^$RSI=RL-E.08^&[H9#C$Z#)7C]1:17*/*:MS"H%E B
MO3)D1,*8F+;_ (M:WEZ=]^X[[_DN.]-W2LCIRS_,;7'LBA3\+RS:_9/"(]&:
ME-?85=MLU27^-(L(RHBA ;J;NIM8SYKT-!4*PBO^PK\*XTVV[[[L-8Z^T?DK
M/T T T T T T T T T T T T T T T T T T T T T T T T T T T!Q.+4D
M^".WM)/CDCM/)/Z\@\ ?F-8VZJ9;?TJ^F7I/I/F"36Z^;-T]<JGAE#MC9QW6
MU=R4*;AQUI(4Z_W@IX<1WH2"#R?D'G7$\7\4P]EH6Y4M]J;J4E-GP=\ED_(Q
MXF)N0INU,:QH_P &,=T[5Z1ZWW5]%KH2$B1TT;;N-1XT=ME!+N3NE1"64I;Y
M)_C( [N?JX^W'QOW-KV"BNCZJJL6JIS=75W$M1RT]37KWL14WF\-)=PLKV;M
MY9)F";1H2AFRR5H*/*%M5B>"$GDE(E*3RDD )Y0"1X\GG6YX9X+A?M[^/AIU
MMIJ^6;RO$OCEDHDOA8"IEU7>BGAQB%S7OG!4)&B,QFD,M(2AIM(0EM/ 0A(^
M$!(  2G_  @?')^W&O48>'1ATJFA0EDN^!L_'#1'8[$^/D<>?!.K1=N7?NP-
MP''W)_F>=2#70#0&U:$K'"OCD'^H^#_30'%^':_W>?J[O/GCCX )\]H/)">>
M.2>>02- :_AVN5'M\KX[_//=PDI //(X')(3\!1)XY)T +#9"D_4 H\GA1!Y
MX !!^1VA("?/@<_F= :^RCDGSR0!SSY 'Y?ES]_N= :".T/A)']3_3[_ &'@
M<\Z >PWSSQYYY/Z_I\?'\OS.@-?9;X([>0?L?(_+^OCQYY\<CX)T #*$J2H
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M.?.@.!I]2U *[1X4>>1P0E7'<D\^>TJ2VOP EP$ GYT'G.?L<Z5$]O/^($\
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M>NXW#G]S8T]A+@24<.QY#C:@K0$?: : : : : : : : : : : : : : : :
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M5K^ZETJI?*$W6,&Z>GV"8:PHL2&GK*P#4UF0T9:BG0%8O5WOW8]+_3+O9O\
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M!<=D,GE#BVBT0 ^KN C#U:'42<1Z@WFPE2'O67]0)Q"T$<*9D83T[.<I ^H
MI*"H#GEP^/J4> )0^F8M25]/:>/;*_4$VE6$J 6LAO'JL >3X3V\\GX1XY\\
M: FOZHNZ"LQQ[J[S/\0IZ7O;ZC67NL+<45.O8MMOAS]:PRDCZ51HE]_"@<)0
ML_3Y\Z MW]#_ .)N\FWOVY865+W$Z;]X8$!@K4!+R?'<5EY9B*.U/RIK)*>
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MP<MD_0'B+'K6*V$]P ]P!'>$]W!"5>1[;I0!]*G;;_Z/,%__ "ACG_\ 40]
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MQL1H+C%L9S._QNJM<@H\=R!+B+NFKK&9%=D1J^S0\^F7';4$+3(D@!(DR/=
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G:C1H[20AIB.PA+3++:!P$MMMI2A"0.$I  \#0'/H!H!H!H!H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g118907g76u05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g76u05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %@R^5D0X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            H    AL          0                         !
M          (;    H                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    H     !29VAT;&]N9P   AL    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   *
M    4F=H=&QO;F<   (;     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      N4     0   *     O   !X
M6"    MX !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MM[0\,M.X!Y$P9.UVW\[:@-;DAX+LNHLW EOHP2W]W=ZOTOY>U0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( *,")P,!$0 "$0$#$0'_Q  ?   ! P4! 0$              0('! 4&
M" D#"@O_Q !D$  ! P," P,%"0H'# <$"P$! @,$!081  <2(3$($T$4%B)1
M80D5%S)257&!DR,V0G21DJ&QT=(D,S2RL\'P"C4W0T535G64M+73)6)R@H.B
MX29$1F,8&2=4<X2CI*7"\>+_Q  = 0$  @(# 0$              0(#! 4&
M!P@)_\0 1Q$  0($! ((!0($! 4# P4  0(1  ,$(042,4%18083(G&!D:'1
M!S*QP? 44A4C0N%BTN+Q""0S0W(6@I(E4Z)$5*.RPO_:  P# 0 "$0,1 #\
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MA2CQ* !X5!"3U_"4/K(QI$_GY^-&;^;M<_TQJ?V4?_GZ0@\W:Y_IC4_LH_\
MS](0>;M<_P!,*F?86HX'Y0_G\FD(:JWZ[X7=41X?Q*#ZNI$C\G0^WQU(4 ""
MD.; GGPV/A]8A(93DY@X.4V##;QW@\WZY_I=4\GQ[E  /A@%_&/I./6=1%W&
M;,$A@0<NUMCWZ&$-!KB2 ;NJ><@X[ICF,^H/?^I& ,<CINWCM_OMON;1C*59
M5J!+J+<0E[6 L&OH;%K6AOO%7N/A\ZZEPD9X@TGD>?+!?Z]/ #V=204EC<%[
M#0W[_-F^T645.F7E &4DK [18<;'FY#=Y#P_S?KI_P#B^I_0&&\_TWZ<?7GG
MI$9D@9;/^XDNWFS^L+YOUW_2VJ?[.C_FZESR\A[17(/W+_\ FKWA@M^OA7";
MOJ:CTP([77..H?/Y/'ZM1$J!(8**3QN]O$0OO!7CG_VPGCIC*&.7('F ^.HZ
M=#ST\?I[1D0I*$A*DYSLHD@]VA_'A?-ZO?Z7U7_9VO\ F:11QQ'F(/-ZO?Z7
MU7_9VO\ F:0<<1YB#W@K@_\ BZIGE_F6OT_=A^3V<](HI!404K4D<GNW"X'I
M]H3W@KO7SOJ?3IW#?7KG^.S]/A[=%NK3LZ:/]B-?'N)BX9LKN0 '>^FIY[O
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M#,$Y3N[L&)!+W((#!G+D=XX"JZ;88@+R32"G*<IEJ&K!2-B%)<&Y:QVLJ^;
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M *8/@T?'^7U^/^(3^$,'\/Q'+Z-&/$^GM!O\*1W$CZ"#X-9  'O^Y@# '<C
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MT?)/YFD(.-'R3^9I"#C1\D_F:0A"M&#A.#@X)3R!\,^SUZ0A@7RR>1Y\PWQ
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MVT58]!MMQ:0!Z.$D$+Z 9ZDG.D(KV8C*!Q% *R<\63Z@/7^OF.FD(J@E(Z)
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MTNB6#/0M,YTDDE(!%AHQ.I\38QZ/C>)RIN%T29:DYD*4M0.I!0P !O8C8[W
MLW=R-LQVG-JXT>U=CMSK G[>0TN-T:D[KT6ISZ_:D-Q>8]+IM7I;3KM3IT)
M B,U/#[;26V^)3:01YD*S#BHKK9$T+4'_E3#+2I0+.K4 J#GB#>.FIQ*AJ'1
M/23,&B@2@!K %M/ V-HE_:+9*39%=K.XU^7%Y][MW33XE)JMS&(W!I=%H<<M
MNBVK0IB4@T>A/2F6YLQE1+LZ8VA]]1* E.M45*)J2B0%(D)!4B6HYB2WS+.B
ME#0$'^VC5U$T#*A2>H*NRD@%0(! )/(.#S+\(Y0_W1A<0HGN>*J=QX7=N]NW
M] ;3GA[]UJCW9<X:41U'#;'$D8/-M/TCG_AX42L80LN;357+A\\OCLSQPT\Y
MI4Q1=R3H6#NJY'*_C'SR?W/CNC"V[]T'H=!J523"B;H;<WE8\5IY10Q-KJ7:
M9==.8R2!WQ8HL]E@DDE3I0D KUZ+T\IS.PN4J4A2DF:F8LER0,JLQ!X)!).^
MIUCC*.<E,U68@=DI;=W21S.[>5V:/ODFH<9=1)9<+:DE#C:BDC"LA1.1E2B.
M@ &" K)QSUX0.K54&67 0E5WWM:_??\ #'+J6A,O,00<P;_QN[[=Q#>L:_;I
M;_[IVS?CD*E0YZ+<C4BWWZ'3Z5;\:K3[QK$ZHB+68#$R4L-L+IS 2X8C!3*4
MTI3K><8UP=5/KI=3."%#J$H'5,@%6<JNZMPVEM>\1W;#<'PFHH*>?.F--F3B
M)JE3F3U03;*&9*BK>PU>(=K_ &E.U3%ES*195ML7M7&KM8IR2];S=*MUJ%*\
MXB83D]93)CS(342FKE"2D.+6/N*E)?...178NJ8D)R$%0#F58IN>-CH!WZ:Q
MW*GZ*="U4TV=45^529&9*!495"8TLZ =L *5<!B69[QTIVON&=<]D6K6Z@\\
M_-JEO4V;.7)@&ERC/=CM&:B333_()#,DN,OQ.C#J%-I*@DG79Y)69:3,+K(!
M+!KM>VS&/)<2D2J>NGRJ<O3H6L2R59B4A3).;<$!^\M=K2'K)&E!I"#2$&D(
M8Y\17T:0B -Q_O@;_P!6Q?Z21I"+MM9_+JI^+M_STZG8]X^BHC<=Q^J8FS41
M,&D(-(0:0A#T/T'2$>/&I7$$J Q^$0 ,^OGZO[#UB&_/SRBF8E3!B.-^?YSX
M\-:=R4N5-J\6H3"GY#]'J<)AEOFM]]5+?9:0C&0I:U% QRRHXUI8@@KHJA(!
M[4F;9KET*L-W<\+1SV G]-CF%3IJTHDRJNFFK41\I3-3F)Y!(-CL7MO\N/80
MV1W9H';NH4^K[?W52H-N7/7)U;F3J4\S'I,2I"4["D5!9&&FY32T+CD$\:%)
M5T(.O$>C>$XE*Z1S)@E*3)ZS,,R2K4]I]+7)T/FXC[\^*W3/HG.^$0IY.)T]
M76S:22B73R2D*"P 38.^AYAV.\?5[GJ2#S^D#)]>/#F3CK[=>^J!R2TI+3$$
M:@EMS8@:N=7;72/SL4A=0A<Z=V$%S*1\I(XEM;:<KVU+=5C'"'E^4?I(&LB$
MA2D@Z$%_#-["$?F']LW=N;=?;OWWW?@.CRAS?ZY+EI"P2I*&:1=LJ734).2"
M$-QHRAA7,ISQ<QCZ,PJ3+E=%E4,L*!7(SJ<YE%1#/NPT+7YQPH5GG#.3J6:S
M<>>I.W"]@8_1^V>O6G[A[3;7;B4"0F13[LLFUKDI\A"N\2IJ92HDI*^($@\8
M*SPA1Y'A^CY]KJ55/4U$E+B8DK!S:DA1&FCC@S'R,<J I09^SX=[?FGI&X%O
M5QNLPFGD*2'4)"9+1 "FU 8SC/B1G ]?U:T;BQU&O?O&6,CTA!I"#2$&D(-(
M0:0@TA&NFX'WRS_Q9C^:WI"+MM?_ 'VJ'XHW_3M:0B<F_B)^C2$/TA!I"#2$
M&D(\7>?$DG&4@ YQGB/,YS^"$Y^O2$0-<,AJ77IKS+B>#O4-)6?BE2$!!&$Y
M)]($<0!'+VG%DGM"Q.I8"[,?:WB='BDV4LRE3\R0A)""";W+NVK,=M^+,?E.
M[6^Q^[E9]T'K-2I>W=TU"'7MSZ'5Z3+B4I]R-/I5,J-+>GSF'2 A4:$TDNO.
M G!!)Z:^><>P.NK>F)J) 6)2:E,P@N24@@$CD-.0/-X_2/X<=.>BN'?!3]-,
MKJ9%7)P6;33$DI?K5REI1+U^:X8$A1LPCZLZ?';1#@J>81Y4U"CLK4IM)6V$
MM-A;*B<D%+B M2>6%A/,8U[_ ",DNBD*6#FE24IRC11(&HL[$,7C\ZZV8F=B
M$RL4<\B;43BH<A.6P#6 4"'U!(U$<(/=WK'WKKVT>W=S68]6)6TUJ5"N.[JT
M>D.N#O%244U=OU:KQVN3U)IODM30XI86VS)E1E+ 22I/HW0BKI)2\U2F6)LW
M*4!0#CY@&<OH0>-@-'?P3XRRJ^93?J:!"_X:@JZY,E*@KM!! S V^5;VCDGM
MKVDMJ=L[-9I/9VVH%9O2Z*',IU(I$F%)J.YM&N6FS(;-TRZ]6J:ZMZ=1+BMY
MVC7E:3E+9?=H=TVG-C!*(+2UN=XJ<*G39ZL0GU 1(E*S90K*"A1*DA(=A9+$
MW!W,>,85CE)(3(D890)55U"2)84CK)P6A*$K$PJOE45Y@EG"S:UQ8]SNS=>U
MG[9/;V[B;NSJ/OU9]6CU*@QF7V$T"-08!:E,T:AUF"U%;B7/ J,WRM,1#*&7
M&Y3;ZRLU)E;N"57T5:M5&B4M:6"2H$\P^A#%CH^EW3:,&+X56T#X_.FF1B$I
M762J?K2@',RE,D&Y'9+:"QN3'>?W,3W0J#VIK(8LB^JE%IN^5C,,&<ROAB)O
M"E,@M1J_3@M>79((#=3AH]-#Q[U"5-.)4>B]*NC<[#3^L0 N1-S94H8J24@'
MM-?=N!U'&/?OAGT\E](,,30U:Q*Q*7E ,Q79(=BHN;NUSJ-6#O'=:A5INJ0T
M/(6"^A"4R6_1):=."I) ))QCD?;C)UT5U%&9(8EPQV(V+M^/WQZ\D@N"7*6"
MBD6=MB;$?C",@:<4LD$<@.1QCU?MU""HCM6+_FFW-[\HEP=';\_ =Q'OJ\(-
M(0:0@TA!I"&.?$5]&D(@VL_?]4OH8_X7'TA&3R\_"93O5[WJQ]/DLK/]7Z=(
M1)7$<DD@ 8P!Z1/7F<9(&>GT'2$.!2K.,''+V@^H@CEI"&K:0LDD'.,9"B/5
MZB#U']ARU0!0-F8F_%OP^\(IBR,**\(RKF#@ DXR<X5@>B.0'#UR.>=7B" =
M1#'%L,MK4ZM##:0 '5J2$H'#PY0I>22 D*!4"I*B2<\1&D1E3P%HP:L77%:S
M%H[(D2BH(0]A7<HXQ@N)6<!:D\.$DJ)0 !TY"%.6+]D.5;\"/,N>;&)9(<LS
M7=O/G9AMI81#-UW-1+'MRX+[O:L1*)0*#!FU>NUN>M#<2+'B-+>?45$]5(:X
M&VF4\;KI2VA*G%I2<\@5=?4(IY*5**BA,I*0Y47 8.[V<DN0D:[F-NDHIU9.
M2F7>Z2&=W<.XU)Y7U+<N!_9M]UT[-5K[\;^IN^)<MNVENIN6Q7[;O-Z J7 8
M@QJ:S242:I"BAZIPVY!;,KO7(H9CL*"GE)!SKT_$?A_C*<-I*NG"9\Q$DHF2
MDN5)5=5G8%(T8W?0L([K6=',0G4<E*<R2D:#4@C30]V^E[.8[X[<[I[;;NT6
M-<>V5[VS?%$?9[SWPMRK0JLP M(4A3RHCSQ;4V% +0^EM+6 E8"\)UYG7T.)
M4\_J:VF7*5I_,09>4@LX?47)!!(/UZ9B&'3\.(2N4O9BH$%QJ26&NH<7U$2*
M(RR0.'*CZ2UD%*E+22.AR#R((*,-CGUR#K6")\E*D]@I*"S E3VMJQ</H!H"
M>>B,P0)DQ5E'* XR@D$@L;V V\W,<K_=DNR+>?:^[$5Y6-M]"-5ORQK@H^Z]
MH4- /?U^I6K3:Y39E%A8 "JE.H-P5=NELY!EU),2$G[I*0#V3HG6RJ"LDS9P
MLK,DDV *IB2%$';LM;1W-@3%)K&6I']3OKJP)ML'?<ZE@[1^>YMY>]\]GW>&
MTK_HT>90[\VHO:FUV/!J+,F'(9J5NSF7)%/G1E--R4-O=Q,AU-H(#ODBGD''
M&%:^@9_Z#%\*ZE$Q+F2<K=MW2R@PYD[LUN_KX"Y=0DGY3, 5Q%W\B+;>8C])
M_L3]L7;'MP;%6CN=8M<I3E?D4R,U>-HMU**]6K0N2.REFH4RK4]MT2(H#N7X
MKSC9CRHSK;K3CC:PK7SEC6#5&'5-2A*5E6=T+6DH"TV-B;6W8\> CL2PA:4(
M!)40"0&>S@MHUPV@Y"-M8JJE2'S(A@*!X0^WPCNW@D\RL('=E>.I01G\('EK
M@4RYA0TY(2L$ON2]^/D=M-HVDSU(E_IU*.5(S(#W>PU?>SMX1(U-NBDOI0)B
M?)'3PG[J@\(X0,!*TI  XN>#E1Y\1(/*Z42TV2Q(ULQ!\=N>EN0C!GF.1F4$
ME]S=VUORWMWQE<63$=4I^/(9=#@X04.IX".6!@ 97D$\P3Z2N>"!J\0!<J)4
M2;7+BWM]^Z+L#G \<$Y&<<B/'Z_UZ1,(GBZ**2?9U_)I"':0@TA#'/B*^C2$
M0!N/]\#?^K8O])(TA%TVN)$VJ$9SY.UT&3_&(SR\>6=3L>\?141N.X_5,36D
MJ(/@03Z6.HR<$#\F=1$P\>WGI"#2$,*^O#S.0.AP/7DXZ=<GP^K2$4TB4U';
M6J0\VRD!6%.*"00 K/",Y41RP.1/3KI$%F+Z;Q'-=N]QY+D.CH"R 6ERBD\(
MXQPGNT#GGED*!/+'7F#9(!+$M8GR;\V[Q%TE$I"IC%1 =M#8.6X*;0LP)TV.
M$,M)C)?GSG6V8[(5)D.R' @- -J<=\H>^*"&4*>R@DI:4"HI4,:PSZF7*01,
M^4!R3J$@$DG8N ;>+\8HY=773)$N2E9F3IA2B6D$K479" >*B 'T<GN/*>UO
M=#.S+0>UGN_;U7OB)3*36T6]2*?>3K;IMB56:! ;I\U@UAM"X[49*T*;1,DE
MN,M2%<"UJ&-=#D=,\'1C*Z5 EI((3G(9R[&X( U<>MG)^DJOX+=-<0Z%X=B%
M-A]0N<G^9,HP%&:)8!4G,@D.2 ' O=@"XCJK;5RV[>5,C5JT:]1[EH\QM+D6
MI4B>Q/BOI=YMK:>B..I4V %$K5C*<<A@Z[S+G4U:OK*:I2KBD+2I]@6X'F=3
M<ZM\^XWAN-8=6RZ/$J&=2S95ETW5+ESD$ ?.E6C:G?ZQDODCWL/L P?TJUN]
M6-SZ@_0$QQ2Y@"21<]Q_M]8%17<9X3U'(#GR.?6?[?7JZ D3=\J00D\21Q-M
M28H)ALY!O?1V\#[^WY5W:CVRNW9[M$;P[:7PQ(BW+:.X%QTVIH>0H*DK;J;P
MCSFN,)4MBJH6W)B.JX>]BNMOI2I*M?2V!3Z:KITJEJ04=4$!BELA;[:'GY<.
MM*I1!8V4]WV?DS[EKZOQC[</<$^U;;._'8WM_9F346$;D]GYD6C6*4[*1Y=+
MMGOWO-BK1FGEI<=CIA<$*4MOB:;EQGXZ2"D$^*].L+G4^)KJI259)A)# $.E
MG (O<!W/, WCE:><"G9P18_EAL.!Y7CN/%<J-#F)DP^11_&-*&6WD8YJ6A)&
M58Z'.!RR.6NE!V#V+#UC:B2J?>L"44HDA4-W !+B3W)..9[SHGGX<\#IS&D/
MSA&4QY\:2,L2([PQ_BG0KZ^>.77GI"*D*63G&1Z@,9\,A1P"/'(ZC!'+2$>B
M3D XQGGC(/Z02#]1TA"Z0@TA!I"-=-P/OEG_ (LQ_-;TA%WVPP*I4/7Y*V?9
MP]^U^H@Z0B;4=X4C!"1CH1GE]/32$>R<XYD$^L=-(0ND(8M13CXH!\5$CGZA
M@'2$4TB='BMER0ZTP@'!6ZL)!Z<TCJ>HQZ](1'-=N]<E#\.E)/I!3:Y2D*'"
ME60>Y.1SX<'O!Q).0,<CE",/A4UU2DK<](<UJ& %+(!PE2C@$NK)/$%#!0KB
M*>-.4L_ST@V"D%R> ?0<7 T<\BT54B6L$+6L$E@D'L\B0 [W.XMZ\N^TAVVM
MAMH.UQM#1KJNE>;.H]WP+TDP(\BIQ[;DW/"C1Z6W4?)$OK4ZRXCCD-M\?DZ"
M%.E&-="Q;I!A.'XVB3GEF8E"DJN" 2K0_P")]]1OI'TCT0^&G2W&_A_B*<-H
MITQ-354]13'(K--E29:BHH<CLF]S8NX;?HSMUNOMSNU1F;@VWO2W;PI;R,B1
M1JC&F%M9 4I+Z(Y4ZP\@J"7FGT)<;5Z*AD$:[718O05R9:4349"$Y@"[J%QJ
M='>QYW9X\0Q_H[CW1V?.IL9P>IIDA:DH)EK2E0S$9DEB" 3<AW>UHR^NVU2[
MEI%4M^OTN)6J/6:;*@5>E5",),.=!EM.,28C[;C:VE-/MK'&ET\)0HA:3T/+
MHJ%HGIJ):BE,G*H,[6)-V)#  /Q<#73K$^325=,O#ITE,Y%0E07F2.RXRI#D
M6/:4#Q^GQ]]N?LA[A^YI[^T7M!;*LON[37#6*H;?J/=./-6E4ZQ'=$^QZK)9
M2[*A1YM-E9MZIO=VM4%EQ*G'7:7*8<]HZ.XQ0](:!5+6S^KJ"A"$I2H("F"]
M4J"G8@9N9/&/DGIOT-Q'H9BZL9HD']#,GK,E902)&7)F"@E@G-UC)-W2BP?3
M7^S=M]]NW_=%9W4W(K<JU-BK5NJ1[YW1*:2NAT%^MO1'W[0LF'PLR+AN9VGT
M^(W'AM]\Y'APH*'C$IXBL(8GB^%]$Z">%24KJAG*5LZB$6"F%W[1[R'XF+=!
M>BO2/XJX_3T1"E4AFF6N>4+*%!1 2$JS900E#JU?L"S7WD;V,M2#MP=RNS-1
M(FSEY=F*V$[D4/<NK5N2@[A,-U>=#K=LWM-JGD=*549RX"YD!#!;9*)3U. )
M1&6?/<#Z;(Z4U\^A5*G*3,*$LI)")86I270X<$L'U)-][?1WQ*^"%)\+< H<
M1I:^5*K:9*YT\)F(3-6 E"@)@%CJ0E("6%G<M'<'L#]M"A]K+:B%?M!4Q3KT
MH/DM'W!M;C2?>VK]T5=XT!@K@5$-KEPGCQ%2%<(6H)R=3I1@<[":AY"G0LG*
ME3*;=] UCPL-.>ET&Z7RND>$NA"3.DD2EL""HI#9C?5P;GB?#I+2[RIT@ 2R
MJ&Z4X6EU)#9<R,\"^8Y\R!ZAUUUX;))&;*"H:,=#ZQW="DJ2&!!!90.QY<N)
M/I&4LSXSXXF)+#HY'DH9((Y<AD]?'&IB\5?'CFLI .<$<1YCZ4@:0A^>F!R(
M)SZNF/RYTA"Z0@TA#'/B*^C2$0;6?O\ JE]#'_"X^D(R:<3\)-/ /I>083ZA
MQ1I0)R.8P<8Y^W!TA#E.U5$AU3<YY"0ZOA0HA2< XQS3G!QG&?V:N$VNH![M
MR\XH5%R "6WY\--HN3-<J[6$N-Q'D^*DI4AP_P#:RYPD^ QC'C[:E(?5^#&P
MYD:/X_:)<ZL0VH._<SGQRF*WSE?X<>]ZN+D.+O4E.<=>'&<?20-3E+^#[/X
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M0V_/K +2;. =6+OSY6WO%9[X174*X76^AP"H\9P,_%X?JZZK%H@W<?[X&_\
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M4C]'.27/:RD);F>6[!G<.[QSM?T^Z$85+E5-9TDP>G2$C-_STM(<W^=9$O\
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MJF(Q4IKZWUU%F%,C]]P_IBF?DD8G-F2$[S9>8IS  !W4XS!W.51=GL2VLNE
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MHU%^3-E2Y#REOR7GWEN./.*42!@#SJIGS*J>JHFJ!6LE18 "^C#@VY<_6-\
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M8<5&IT9N,R7BPTVE2RA'&HI0D<:E<(&<:^D:7#::3329/5 ]6@!U %18%W(
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MU95H4.W.\4@*"%K-*A15<:0H\*N+*,DIX23F)M75SP/U%3.G)39'63%+"00
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M @_3UA]N0E3Y$AL(*N[CI4"!G!*DX)//"1D\6!GAS@9QFJ&*B!<YF(XDOP'
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M4]S^+6\138J@V0_&X'PDM$2&%)<XDE:.%Q*N%7>)2HHX<^DE2#Z0(U=533I
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M5%5TL-+\C:XBCMNHVG=E'C7!;5PTFMT24%*9JM.F,R82@A1;5F2@EM)4YA"
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M@GR4S$]:I3E3*9KG1PYT&SZ]UZ8[TGPW%%X8N7AYI_TLV6J:!D4)B$97978
MS%S<:'9WB 8G98WPH*MH[2GW95+AIZKZK;%\56F5:8[#I^S:Z+:-5G4*K3U-
MT"34[LK%UV-1Z=3)L"AQ3&H]PW#&+,EU<^<]A&%30"E4Y;KFE94$@$ A(*0,
MP>X=P ;GC',U/3'"*I-2J3029"Y=+(E2"LYC^HDS)RS.R!*4D3DS42U%2K!
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M$0$@:!M[$B_'6 VS;YZTB ?I81HPX#R$6%M"?,^\ MJ@#I2((^AA(_5HP&@
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C'M6]0V%<;-+AM+SGB0RE)R4E)YC_ *I(^C4P8=_>2?K'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g118907g77i06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g77i06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CZ^9Q@X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            Z0   B           0                         !
M          (@    Z0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    Z0    !29VAT;&]N9P   B     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .D
M    4F=H=&QO;F<   (@     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      _&     0   *    !%   !X
M@6    ^J !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MA^['><V@<T6D"T#_ (#).UMG_%Y7T_\ N6KZ=)2#$S*,N@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( .X"+ ,!$0 "$0$#$0'_Q  >  $   8# 0
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M1-$31$T1-$35+_RGY?J$4*@.Y)^I/!_4!*R ?T\G52+31OT>-X,\\D#\\=\
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M*RJK=2XYF/4MRP$MK2HL&.J0B;%G!8/'#:VN/E*=4LL*9N#3'Y?$=B.@)D?
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MC8.R[-U4ALA;'J0U,E("DE*P4^/(U50NJ-*I4) EQ)G'4DN\I^&9ZG<SX;<
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M;HSR05D(94I('<>01QVCHE @Y&?-V._U^'ZF8\<F)F!Y-GMV[=22N#T<[8(
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MWY"DI1W.RI+<5,B2^HI"G'W7%K6L%2EDDG1%? LMGV3P/ X3\HX2  G@>.T
M>$^PY/CSHBB+:2 ".>/OY/OSQS]O^K1%P&D#^SXXX[?[(_DGV'U_OT1$M(1R
M$I[0?MXX_P#)_P!7GW/'UT11)0A')2D JX[C]5$?4GZGSHBBT1<$ _W$<_7@
M^^B+@H2?! (/N.!P??W_ +_/\AHB@4RVK@%/RI\A/)[0?HKM]N1]#]-$0,MC
MGA/!5SW'D\D\<<D_4@>.??C1%R&D <=OCCC@^QY'!)'U)!\DZ(K0[I;"[+[Q
MT<C'=TMK,"SZEFGLEP,JQBHMV7$E#B0HJF1G%(4@K)0ODE)/@<D'1%A3'^'Q
M8[0RW+CH_P"H_=WI_CH]1;&V=K;JW5V/=?604QX^VV<BRA8I Y"62G"7**0V
MPIU$:0QZKBB1#U0]5_3VMYOJGZ=XN=8)$46E[Y=+2IV11(D1I:4,6.5[.Y%+
M=RZI9>0?4DKQV_RMUM2QZ%?V* :).WQ_I_99B[,]1FS?4%2KO=H=PL?S.-'(
M1908CSD2_HI (#D/(<:L&XE]0RVEDLKBV]?"?#B3P%CR2*]+3Y<<*> !P3QY
M*O!]SX1V\^W:4DGW!(T156B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N#X!
M(^Q]_ T1=?,LHM?$?G3YD.%$BM+>DR9C[<5B.RV@K6Z_(?6EEAM"05*<=*4!
M()) \Z(L \R^(AM[)O96!=..$YIU8;D1WG(3]1M-%8:P:FE)X259/NK>*C8A
M7QHY),M-*_D=@UV* KU+'IDB\NO:SK\W\BK&[>]N-=*6(3BHIP7IK@"_W%3"
M/"F8%UO#F+4D1Y:>?3E2\)QS%G I)*)00H $^W:?Z_+Y^05Q]I/AW=*^TUPG
M,&MNT;C[E.O,RI6ZN\UE8;K;D2):7/5F/_MAFK]Q<QVG5K)$1J6EA! [4>
M3IWV[>OI^RS@B5E? :0Q!AQH;"/X&8K+;#22?=0;:2A 4?JKCDZ(JOTT\<<>
M.>0"?;]!]A]QHBY[$\ =HX!YX^G(/(_GP?;GVT10AI )*4]I)Y)3X)^OD_4<
MGV.B*,I2?H/;CP!R!^A^FB+D#@ ?8<:(FB*$H2>[D#YO?]?]SYT10>BWR"$\
M%*>U)!/R@GD@?;1%&$ ??C@CCD\>22?']?[M$4(:; "0GA(Y^4>$^>?H/!\D
MG^9T1=;94-+<QUP[BJK[6*XE:7(UE#CS6'$.#M6A;4EMQ"D*3X*2../'&B+
MC<+X:O3?D5_(S7;*!E735N2ZI;O^4+ISRBSVHNI<@A*_7R"+C+\&IRIL.!/?
M7Y#"L8+R0$NLJ25 D7GGXWQ$^GIEIVHNMONM+ JY/;(J<HBQ-HM\DPF1P#7Y
M)11G<"R&=V@A+-IC5:]+<3R]<(6LNE\_V^/?[HKB;4?$ V3W R&'MYFW[2[
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MYQ$]?Z?N"CBX-:>_7]<?V50/('\AJ!/7S52YU*)HB:(H"A)//L>".1[^>/\
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MK6[ZE/WN8. K%S#)!Y6R,DG>F<$Z+8:33T]KW5&#5:.JTJE*!4\:DYCZ;:A
M>US"&-YVAK<G#HW@K>AS%,NS-=O4NY=<;MY#O2QNA69! EVLFQ:MU6[+\#'X
MF.1[%=0[4-4D96)_C9$-<U-6CEV8F.M+"-DT[V@<1:I;V_"MCIUM7MKBR.AB
MUIV[:K6AU,TW7/. 'MJ?B^:^@N<QM<Y:1$:O?\"<.Z;4N^(=1O;JS_"78U2I
M6JW7AM<&^\^FQSVLH\L?R!3$U6TH9SEV5]D72;M#9;([,8QAENIM=V4/VURE
M!!;;L+:2Y*>BM/E* Z(Q>+*3V E#:.0-?8GLWX7N>%>&[:SO7\UT:=.I6I@"
M6UG-:7MY6@ &<0 (.%\5>T;B2VXIXJO;^R;%GS\EO4AQ#J-*6TW3+C[P$Y$D
M&8!VR:2M1X''CM[>2./;QSR3_/\ 3Z^VM]:X1R\CV@=2(@?0Y^P6CEID.YFN
MF<#<R=C)GIU G(WA5#:U!LGQ\H\ CS[\>>#_ +_4ZEKFN!#3M.3^OG_7HH)C
M+@9W(Z]ST^^R@0^5*(/CCGGY3[?<>>> //ZCVYU/+4$$EL3&QG]?+.!\E2'M
M)@ CIE3E+44%2!['^T/<?I_L_O\ '/C4DP)/15+A#BE'A0 !'CW')\> 2?//
MD@>^@,B1MF)W[>BGE()C/^.G2?-3AS]?\-2H$]8GR312FB)HB@4VE?)4//
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MM.I5MPZF?=):.6!)!)+X<3(<"5NMUP1[)M6>-,IT>&[>JVESOJ4:M&E7YR(
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M0SR"7&_4; )X'KW^H3AS3KYUOIHJ:E28\M=4I^ZPD;\C\B)QD2")B%W?0?\
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M:?1K5;ZC;.?4-6K:5J]6E2>SPZC6OK/8UK!,<I)<6@B-FNN#]:-?B"\T_36
MW55]O;NK4V\AI/'@^*QWB!X>UDO<26@N!@&9.57PI-I-\-L=_&-J+/&ZN'21
M\XI,TPNRQ"783L8CP[%LR\JJ83EBPU9-N1)/XA^:_-CLQD/2BVW*=2I).?\
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MJ;21L6I>VO@C6K,Z%K.F71TRK:A])QH?D+',IL+9EK2!!$C><Y6MZ?["N/\
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MZRP>.[?VU(S2V5YCV0O*35(AAR:B?C<N;7^@[(?=CA@NB0R]%>#J$\H*HZ#
M'P]?T"9DDN+I/7T3]^ZR,8\]Y\\DCGGCC[\C^_SS]=%.?KM\/4J?HB:(FB)H
MB:(K7[R[@UVU>W.3Y_: KBXW6NS T#PI^2M3<>$PGR/F?FO1V1Y'^D(Y\ZU_
MBC61H&A:AJ<CFMZ#G,#H@O@AFY&.8B<[%9KAS1JFOZWIVE4P2;NX93,"2&'+
MR/,,:Z.D_0_&OU'_ !,[',]U]YZ//F\G?_R9443)6ZR-/:;HK%F<F&MFEI(
M4$)F16Y\/UUR>\J+O<>4Z^0-8MN+>-[?3=4.J^!:ZM>7-+\-2>X?AJ5&HZFZ
MH3T!:V<_\3&8C[.T%G!W E6^TG^&,N+[2K2SJU*]:F#4KU+@!S6F/S$$Q[H$
M'?98_0NKZSM)NW4.HV1S&<K<^MD6N,/B]HFD.-UX*[%+C:D][2J]*>7T>/4'
M ;\<\:@/9M1I6^I7%QJK75]->TU:CO'<X4ZM7PJ-1G(1[S\XB!$[%;U4X_\
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MPUM>EI+:%6M4%!ULPUA5!>3S!X9R$$F'$1'7WO>-KNQN-.M^6A=6U9M"A?\
MCAC.<UW"F9 ((<.;FY8@@0<+[(^A*_IM]MFYT#<FKJ<MFX5:?E,:UMH$:<_*
MJ)4<R*Q#DIU#CC[D9#;B$NEQ14T&RLJ'!/6O8_=6O&G#UQ;:U;,O:^DW#K'G
MN*0-1X:7>]4<X<[G# $]-AA</]LEI>\$<26]UH]Y<:=;:Q;_ (P4+6IR4J3F
M<C7AC&&&ASCS.@2223DXS_H=K-OL=5^(H\/Q^J>40H.PZN&TZD\@DH>#7JI\
MCP0L'CQXUU^WX6T*V=S4]+M&\I!9_*:>2(@-QC8GY]Y7'+SB+7-0C\;JEY=
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M);4-5?Q'"YP%(?::M/P,IHC@R8;[K!7&<9<5/P,_!/E"N-HB@<'*%?R_W_\
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MV.1KW-G=Q)<[("^L]/T'A/3KZUNK-]DY[16Y32K"KFZ#17<"USO^\+6N($@
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M:(FB)HB@6COX\\ <'C@'D@\CGGW'W'UT1:T/B=5TO"]G]N^IRC0_^?=)&]6
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MI<_$)WIC>1K6?\6@?01_1?(U]6-S>7%RX%CJU6I4<PN!ASWN<[(# 9DX:P-
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M5-0%.&WU/AJIP]PSIO$FC6ES9:E3N;6]N6B\MZC&VMR[GH-+1X3@X,!%8N)
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M)  ';P5>5$I! (*OD !/T23W<<$@<\:\UGYR!W7#B@X@@I'!Y"? 6HD>Q /
M !XY[N>?;Q[Z*5YG*,5QS-Z"XQ;+Z:JR?&<BK9=+>4%U!BV=1<54]HLSJZ?
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M3)4EW'*?#\QY2@K++>"[BXAF$E]0Y3PAF'3.NK5SPVE*G#R$<*(LP-NK07V
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MW<>+!?=><5W*2D-H:2LK6H_*//GCC11\5AQ\+^BE8_\ #SZ.8DYD1["QZ?\
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MY*O U;UJ[:#:E6I[M*C3=4>XF! $D;8B-\[[+TI4JE9[*=,%U2H]K&-B)+S
M&/W^87S4]9?Q0G+O>6%L+C>2W&&0+J-D<ZG75N283^20L93VV+UA;Q)$=V.R
MZXI34*O0%-R^4E[N]0)3\H<>\9<9<36M\.&8IZ/:WPL*U5M;EJOJ/>YHY.6#
M  ,@ QRDR.OUY[/. .#N'3;7'%196UBO:-OK:D]A\-C6AI(<UP>"YO,,\PDG
M PM2ECU[[3_LY'S9,_<FTH9E_88XFXAX]8R4(N8TJJ83&EN":&HWYD_>5PK2
MI2!*7(]-E'C@\EM^!N,S7KVWXVI^*-L;ZJ^IJ#_$90>QU=S@.?\ *U@)?!!;
M'+!.%URMQ9PC3;1?3M+0VKKAMHTLLJ88RJUPIM:X>'+W%T $0'&3/596;$_$
M2J\?W,Q3;%BSN;N5E>(HS!W;'/JN0NKF4*K"; <@3(-B^^FKOU,U\J<PPAL2
MTUR6I22ZPM*3E=$_ZMX:IMU[6&,U;0+6Y&G7#'U&W-1IHB"]AJ$DTA1#7BH6
M<H+FB08*PW$-EPEQ61H]B6:;Q":!N[&_LVNLZ[14'.QH?28UH:<'P^<N+9GF
M()'TE;/[1]+N\&$8YN?CNTN$-1[QDS?PSV.U'J09[;JFYL9]*(O87XTI#S2U
M@>2WW#P=?4G#7#?!?$NFVFO6VG6Q9>L_%<KJ=-W(YWO.:6AH ,GL8CME?)?$
MNO<;\,ZK?:%=ZWJ#GV55UOXK+FJ!68TPRHPEYP\ $9@3 Z+27\43XA$?93*L
M>VEPO'I--MX_G3.W,IO%'XU%^(L''&6)=A8I9CD/U<)QTH3&1Z06RDR%N=Q4
MH<AXIU*ZXMU;6>&.&7T]!M=";<TZU2A_+=<_AB&D!U,,Y>;,22"!!@PNT<':
M)9\*Z-I7%W%+3KVIZY6M#;T[EPK&THUS[K_YG.2YH(+CB9Z0M1M[UH*;D[N*
MQC:VYS*#M%+"+VV;RBJKF9E08HD&\@E^%(==:]9?X81TN/.K4%.!SM'&N5_^
MS*I5;IK]2XDY+G4:52I1#Q7J%CZ=0L+:AYVAQD$R)W$+L1]I5G3K7U*EPXS\
M+8N%(UJ18P.'AM<"6MID'$S):O65G79<[63MG;NRQ#*]O;W<6ZA.PGJS*(DY
M>+8Q+>I6(F86\N!':5^7.2[B+'<B."*I/SJ,CM[NS,Z1P?Q+ICKVOHG$U4_P
MBG4JU &U*;+BI1!K"VI--5QYWTV%S/$(#BTB)(6)U7B_AS5:5M;:SH5,VNJ$
M4J?,*9-$5'^#XA]P.Y0XB7 R">C9!^OGHDZAYV_NW4I60!*<OPN6U6WJV7"$
MV*)+)<A6:F^#Z?XP)>86E16M4J(\^5?O>Q'TM[)..:O&&CUZ=]_,O[!QHW)>
M 'ES7EHEHD @  @3.\F<_*?M<X&M^#M>I?PX/IZ9J+/Q-FPN)# :=-]1@DR6
M\]0N;)@ P( SFHEON/<" 4@\_<<@#GR?/(^W' (^OD]8+0WE? ,   8D3&\D
M@9^JY27 \[(@R1/D#C:/1A304I^4J/(\'Y?^P@:J&<F03TDC[ ^NP4#&.WKU
MNH>6^?<GG]/ /''E/U_3S]^?II'Q^I_7=,YVCIC[^NG7=8'SNFC*W^N^#U."
MWK!AT3:Y6%KIU-O*M56*@ZD20M/+88!<'".TJ/GR..-8,Z6XZZ-3#H M? (.
M3)F#,C \^VZZZ/:%8L]D/_L^-&I^,=KE75'U6L 86%]-U-LC)/NF=HZ!9U)C
M AQ:5%*CX)Y/*? )(/Z<D'P.0.W@>1K--9RN<X'\T8[0 -^LQU7(P0#)$^1.
M#D].YD3^IQ$!CEQWD$):24J(^W8"0!S_ &"XAEQ20/)1PKGN/,CE]Z(R9/F<
M GSQUV/Q5)-0. )/+(=U&0"#YC)D9B9[E<EE(^;D!:D^5A/U"EE/"5<@^F5
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M09 A?6_ VJ67M0X4K>S_ %EK3K5C0=3X>N3RR&AI<:-5M3WGO?4+0SD,.+@
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M</I5X#ZI8^F\\HD;%I)(]X#:=R3&Q6'U>A5JL]P@<H.#,]=B!.3/;IG*^/\
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M4]FNJ4R(SCT:2MA!<">5CGFOL=JE-O#.FVSKWG?%U6AM1M(. #N=S27!QEV
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MN</\17=_>7]O<.U<W-!ANKBG-*I;406TP"/==S'E:#RM!$000NVW/R_)<)W
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M!_LU F,^?6>N,_!5F)QMC]%,U*A-$31$T1-$31$T12EO(;4E*N05>WC@$^?
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MR(D;3M/2=\3Y%=>(*BD]X05\!/\ &2"D*!!)4VI7"?;TR5)4!\Q\\"EM)C7
MB>8?EJ3-0"(Y03(B,=O)'$N:9 )($M_V!P@X[R1,D#ZY548Y/@D'GGDDJ_N"
M4]H_W]M5<N9WGN=O(8^/Z=2FX ('G'7Y[IZ+H( *0E(^7YE\\\<<> $@<?\
M1Y\_W2! CLHR29CE(CS\_4_3KT+.+UD:VF9!&K:]F]L84.OGVJ66OQ\J%7NR
M'H4-Z8EE,A<6([*EN16%N*:85,?[6R#P?+P*;JK;A[?YP$.(,B!)PX@$F3U
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M(NGNJ6!>Q7(%M7U]O6O)3Z];:1(\V$^IM8=94Y&E-.L.*;>0VX@N(5V*2%(
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MZ?-EML7XW(9G8+MGA^,VH'O^\MJNGCV3A)'*E&4%*/E2E'SHI5_DL >_  !
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L2221HBGI3VCCQ[D^ 0//Z<GC^0\?;1%%HB:(FB)HB:(FB)HB:(FB)HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g118907g78o07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g78o07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'C"^=R@X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !]0   AH          0                         !
M          (:   !]0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !]0    !29VAT;&]N9P   AH    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ?4
M    4F=H=&QO;F<   (:     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !.X     0   *    "5   !X  !
M%V   !.< !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M" "5 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5)))
M)2DD+)?>RESL=@MM$163MD2-XW'^0J0R.M@ NQ*S,Z-?J($]_;[_ *+?<DIT
MDEG9V1U6G"8_&I9;F.LVFJ8:6^_N7_Z-N[Z:H?M'ZV_^5M?^>/\ TL@95W^Q
M?'&9"[B/.0B[S]VT[?I08^*YC%P?K2UC'9EMEKJ740QES6[VU,N;:+' -]V5
M:W%==_T%9_:/UM_\K:_\\?\ I9,WJ7UM+01TVLR.=P'_ *-2&2NA^Q/LG]Z'
M^/%?I6!]8VYE;^HY4UXS8.UV]MY=]H>[VAM/I>GZV.W>^CU/U7]%_.6JOB4?
M6YF.REQ]KF?I'76-?<VP5UBS]*QSF^C;DBVRC^=_X3TOT==5C]H_6W_RMK_S
MQ_Z63?M+ZVS'[-KF)C</_2J/N?U?^:KV3^]'_'BH#ZVN+++-@=MEU;-@:T@Y
M ?LW/W6VNK?C?9VVV?9_9^G]'](IV-^M%F+E,<:V6VX[A0:B&EEVVK86V%SO
MIO?D;_\ 1^BSTU']H_6W_P K:_\ /'_I9,[J7UL#23TVL =]P/\ Z-2]S^K^
M"O9/[T/\>*4U_6:BQM6,:;:6N< ^W<20*JW,<\OMLOVV93LEO\Y;;7Z>-_@_
M506Y'UM?0_TZ6;QOV.M#6.AMAJ;^C;86>LZIOK,]_P!F_P"$4OVC];?_ "MK
M_P \?^EDOVC];?\ RMK_ ,\?^ED/<'[OX*]D_O0_QXI"[ZSM=^D-0K+B7/J8
M'%@FUC8J-FZVIM;*+_;^L^I9Z+/Y&CTJW-NP*;L]@JR;6^I94!&S<2YE/]>I
MFVM_\M9(ZE];23'3:S!@^X::#_A4_P"T?K;_ .5M?^>/_2R1F.Q^Q7LG]Z'^
M/%Z!)<\>I?6P%L].K$F -PUT)_TJO=*RNM7V6#J6*W&8T UN:09))W#1]B0E
M?0_8B6,@7<?I*)=-))#QWN?2USM7$:HK'__0]50'YV'7=Z#[F,MT]CB =1N'
M*.AOQZ'NWOK8YVGN+03I]'5)2,]1P 0TY%4NX]X\)\?Y*HY HNN=8.J&EKG1
ML:\-@QZ6T2[][W,5C,JIQZ0:,%F07.#36UK1H[Z3_HGP58Y!W@MZ2\R/<[:P
M'ET_]3[=R2F'5&4LZ34VWJ+ZF>KKFM)+I)L.V:C^]^A]JQO\G_\ SQW_ /@G
M_DEN=1-K>FU?9^GMM?Z@C">&Q!WRXM'Z/_A5E[^J?_.]C_YK$R>__HS9PGT[
M]>^,?]-K_P"3_P#YX[__  3_ ,DF:.G[1_V0W-T^B/4T_P"DK._JG_SO8_\
MFL3-?U/:(^K]!$:':W5-_E^DR7X_\[#_ -Z@_P G_P#SQW_^"?\ DDT=/W3_
M ,XK^.?TGW?25G?U3_YWL?\ S6);^J;O_$_1QQM:E_+:2K/?_G8?^]:_^3__
M )X[_P#P3_R29PZ>6D?\X;G>1]2#_P!)7L7[?9DU5W]!QZJ7O LLVL]K>[D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;6S(BF0:T*;?UFDMBX]OMY:5S-BN<_J='$=F#H/+L1,H&O5:*7E .@D#U>A
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M;J\T%?)XXCLPX1X;K5PNGC^.%2[;)N6Z7U\HM6UI(&MQ5".?<S#MW2A&(O\
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MIEY0\6M  =/]= /W_P *%-MQ4LZ]EU\J(7@&@T%; 5H!0"@% * 4 H!0"@%
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M5;&$WJ@%/J CNBTE@G3^W@OE<KX*Z?3_ /;<0[*OU5GM6:RZ..IE(<5_#F(
M(YFQUOZJ(P/O=L/X1J^$<'Y^#I(^"VGT_P#VS$OCU5UE/CK>'0-ZS1CGJ.^M
MSQH^]_= 5'I'!9/$2^1M#Q6T_P#=N(]4N#BNX<_'F?'6_:NB-#[W;#^&GA+
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M*8E^I.?+ V>A6*T?Y^#U9Z]\)3M$?*7[)O\ NU>ZKS<W\-E[ZT?Y^#HG?*5
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MO9EWY@(;:DF*GZT4J8V]MVX&^+BR+O4!RF]4(B501 2CS=F< 3$@Z_>B8G,
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M'?S%3(8@")A*GM13F $*F :%(@% 1,1(-B&S 8HF$1*!^42Z*  GR$T ;$
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M0[QLNV,NKE>9'M")\[W4-.R'@B4>XD&A'Z"JL0\?L2 W>KL3)F6 .<P\XB-
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M70CY"W6***_UHG%?C=>@YZI!0"@% * M-WD^B'\0U 0!BSUQ\^?5W%?F;;E
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M2^H8O='F<G$A9[2+=S$;:A&\M.Q5NLNSN1HJ)I*8<"W8E-I,"E)VP")N4 $
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M0"@% * 4!PG0(<X'V)3=-B7EZ\O=O91WT$Q0'O*!A$HE-HP 4!N0-!LXE !
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M(?Q#4! &+/7'SY]7<5^9MN4!L#0"@% * 4 H!0&OEY?NA</?4]?/P<>@-@Z
M4 H!0"@% * 4 H!0"@.NN(!RB.@ /&8W(78CH [AYAW^]$!#K[>Z ^!^<[CN
MJ'S]GF[&TL9@G8V5\9D0F4,BR<1>$1#21#%?1-J6(FF:+N5G*=S_ ,+?M!0
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M1.&)-VI1IK.JJ]RYJ\EUEKI@.Q;-DL:PKV1M>"=O'+VYUEW;F,9.7#@YKJF
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M_A\;_P!,5#S._C* =^@R^^[/'G^F(T\7M+[OY7UE7TI\%$ZK2\"?%(QJ?_\
MK%1\SQXRA#7H,O\ [L\>?Z85/%W2_'ZK+Y5."KL],IK=W'&_],6^EW\97L,O
MONRQ[_IC5\7M+;OY8NLQ\J7!/[W@_A\;_P!,/2[^,KV&7WW98\_TQIXO:6W?
MRQ=8\J7!3[W@Y\/C:<_^3%WI>'&3[##[W[RQW_I?1\'M+[J_W7UE?TJ<%-NE
MI36VF$QK=.)=PSW<94/,[^,O8?V&7G>'_GECH?O?%CUK'Q?TP[:E*VK>W2S'
MRJ<#]FE/_P#"QJ]O<;&/O^!7BMBY.#AY'$CA&2N$[XD*T&[[ 4/(^ ))+.^Q
M.2[%$2]DDN01!VJV$-CR%4Z5DN#VEE$G'#]2M72C^JOTOUE2JV-\A8?I5X)0
MM1PZ2EQ10?6AA6&Q:<44+JDFY*K>R;JE6]JGW3\SSP[D;"^%W=K9+M@;5GSW
M/)/RQQY"&DCF9N1(**W;P3V0:>K$#!RBX P:[AV(![?1&&BPTARW#JTIS6I\
M.+.]S\_\/=/X?A#I-8K#-Q2U+BAJTU5N)O)PPTV6SO<^@8'$#%()>\ Z[]KW
M/%7;GACEH!0"@% * @'B'#FMZP0WK^S%C<?^F1J.Z:WI@GZJ!0"@% * 4 H#
MP[D^8<M]+7_Y*K0$=</_ *Q&&OK96'^;L90$PT H!0"@% * M-WD^B'\0U 0
M!BSUQ\^?5W%?F;;E ; T H!0"@% * 4!KY>7[H7#WU/7S\''H#8.@% * 4 H
M!0'$HL5,0 >\0WWAW^(-!LPB/BT4: L\( =Z((@ B #XA$ V(AH!T :$/5<I
MN8-<NQ"@';^IV!=B/RH"(@(^K[/>N43 4%! #&Y=%(('#8;  +#&YC%/T#12
M\H ;Y?F$IC%ZZ$3%Y0,4.790T8-\^B@6 4>8.8VP -@83F-SE#0#ZE03#OY8
MO7H&S#O8[  4#!T.(CLW>/( %'H)!$@_(]^V4"]1WZKJ- 4$ 'H.]@83B41$
MXB?NY^\.8 'J4!WH=Z   * M,F!/5;$P&'8B ?+%ULQ= 80$1 NC%Y0*;0;V
M/6@+NS#0 !!*&@,'[[E,!.S$ V8 *0I2" &*8#<IM (")N8"U0@<Q3 4G*4J
MHFV&BCW&/V@:*'JNIPT0!'D#U92B8#@  !#E#6N<3B4P%,81*/B#6Q+S<ZA!
M'8F'Y02D)RB!R% "@IT$PG$1Y]@;741 #=1,!MB)AV(AH?4B = $O57Y5O.N
M\-SLG :Y2E06V)C"41 $S#T,'+KKXA$-[U16_*Q$M?ZM*.M%RY)V_,U.PAF?
M$L#CJ)BY_)=BQ,FPDKI:NF$C=D"S>-%"73+G!NNFZD"K$.4AP,)#AO1@'0 %
M<69C,/*B:CF0PWVM5KN:L]COQ'<^!-+3(8(I>#G38'!"TY4J*).M;NB>5*.N
M5B6_C@,%>R[C?W[YMD ^](B-8>$<'Y^#I(] Z9V:.QG-(C^,)<&?\%CW9;QL
M/N7S;@_@D!JK2&#?[1+7*Z$\ ::^[L;SR6O?"4'/^# ZCEK&_OWQ;@??-( %
M7O\ P?I$I_WE\:%\ ::^[L9^"W[H2GQP&"Q_ON8W+[87S;)OO#)A^&IW_@_/
MR_6AZR> -,_=V-7^XB^$+ Y_P7XLO8W]^][8 /O2@C]ZGA#!^?E^LNLO@#3/
MW?C/P(OD*>C_ (,]E[&H_P#+FVOTR(5/"&#?^G@]9+WLG@'3/W=C?P(OE*>C
M]@TWJ0RWC<V^@@%[VR?U/[[90DA$0UO?0>G7NH](8-?Z>7ZR?N9E#H#35531
M^,3WN3$ETJ&W%=$(V-FW#R&:<SR;G)MA(1\G#8O3CW2UXV^1LY4CT+S(\3:G
M/)\@F;F=) J*92;!0H"'3J\(X/S\&W;V_,V1\']-)7P.(BR24,$442K^[J\5
M>//94G,<_8,#J.6L<![8WQ;0![X^>5/".#\_!TFGP#IG[NQOX$7REOQP&"O9
M<QK[U]6UO[\B'X:>$<'Y^#I'@'3/W=C?P(OE*AG_  680*7+>-Q$>X/BXMH?
MO!)"/V &GA'!^?@Z0M :9?\ J[&KED1?*7CGO!X (^BSCCI_^-[>#\+\ ^R-
M/".#\_!TF7B_IK[OQ?X+^4L]'[!OLLXX^[FV_P"D:>$<'Y^#I,? .FON[&_@
M/Y1Z/V#AZ!EG' ;_ /QQ;8__ +C1:0P;:2GP7=,]X\ ::V:.QO/(B^6U=^P#
MGO!Y1 !RWCD?'\^MNA[W]WCXO\_=6<.-PT;U5.@K_M+F^&60>@M+P+6BP.)A
MI=UE/)7;_1R6TQR^GK%]D_!#R.>(/&3QQ>:R3ILL55H[35C(4452*H',W<D$
MFNS,4X]P& 1 :Y%4TFJ1)VJG:CMF=9$XH(XI<>M#$JU335U6SR:S>S:;" AH
M0]6.@WT ! O3Y7U/-K8!O8]_B#55))45DC&K>=*YOE]]#F @;YAZCXA\GN5(
M8=6MZU[;P75D!0"@% * @+B%^=^P?KPXW^&1H"?: 4 H!0"@% * \.Y/F'+?
M2U_^2JT!'7#_ .L1AKZV5A_F[&4!,- * 4 H!0"@+3=Y/HA_$-0$ 8L]<?/G
MU=Q7YFVY0&P- * 4 H!0"@% :^7E^Z%P]]3U\_!QZ V#H!0"@% * 4!KUQ43
M$I;W#[EZ;A)%W%2T;8\P\82+%91N[9N4$.=-9NL0Q3)*D[R'*(#OVPH"&H'B
M$?6W!\+4$L]AY8,B8N;2%Q3DA(D,[1EHC&:=P%!9?MQ3[5_(-A!\HX'M3&44
MY0$P@% 1'&<8&:+YM_#JE@VO8@3N3+&S7=[TTXM)#&QQ,67>ZAFJ#<K)P51<
MLDR8)(&$%1(5T[!<Y@2+RC,JUR[=NL+FRYN;X&.L..S)5\3V)(&P[7MQ&5OV
MU\)7"YBGS28DW"R>457"]U/DWK-RBRAF%E1[;PT$)(3.)!-RDDV4WH*OP_+?
MGS<>ZTK=97JMN>SV5?+O-I.)S-]YX4:6-,1,9&!:LE(.27U>4DT?2C.T&2*;
M15HNO%L739[X _6<+HN9-,'"<<FDEVK=45"@(IKM>W&GDJ)N&Y7MM1%@/K%M
MO,-DX?52D7<FG<TD_N46AWMP1R/;$2-'$3<#X B=(QQ*!3G4UTH#/H'B]FI1
M[C2/686XBYO+,5]8ZETBO5@5BXBUFKA=O)]B545TUU3(Z="HD!.4=$#>AH")
M7/'A>K>:OMBQC;5N:(C\9WS?UI34;'S41'JN+2E$XWP+MWKQ0\LQ5YU"JNFZ
M3< 624*0I@Z@[4[=LN=\.W;J.G<7&-Q(VG$Y(G9FSL6FC,:V)C3+$JBQ7G55
MWEHY#=>"I6^R34<@'GHS1;NW"CM001[9%(J:!^U]2'Y)<^^M%VXZ$FON+S(B
M=U2\RQAK-4QE;O$E;/#L\A'3I^.09%]<4A!0BMT,2E<>"*-V+V?2719&;\[J
M,:/'':%!#J]U<^KLB5Z=W;WGH.^,"YT$K01:0=N.YBX.(;)6'#Q1I!9)P6+L
MP+F\ZWYB]J)T'[I2)8(N5U2%:HHN!5$ *(;%)7X7,ZW3EU"\XZ_F\3 7S:S]
MHC-66TC9!E(6T@]2%5FF[<NG#EI*MW1 %9K(LC)D7*)A[$@:H3;S/ES7;C-K
MWVQ9+B'00;+#H!ULPIF -AW"/C 3 .AZZ\FN:VI<;6>J^RXS;(IW6#=W1-UW
MIWS^!^,#*P!Z*>1@Y@*<+VN?8E  YA&9>"<XFZ%.(FT "4>G*/?L1#Y;I*/$
MO%S%'K:EW"TXKMNBR=,E?C/VAP5P^B9F@<$H(\.L0H%W11J!-PTNZQ)U>M1<
MA@6O*J)?=T/XNZZ]N8_.1=+][/0=Z8)?Z3"<SE?! >7_ !@']H2@.O;Z@'^H
MU4INQ3%TKXE6$P;RFX7IE]13IXA$OME*4!]SIXJKAG/[?3UU+WGA/MX5\\OX
M)#J/^V'_ .:'X1J:LR&[UZ<M/<@\'@]L>$2Y9;]]BNA_QAOLD_ST;C?V^=M_
M!$[SP*RFX2O^Y0UY51 /*(EU]X1J4C=EK5Y_C8=ZX-?Z7"/GE_!5 @&A^3<^
M@$1 !ZZ -B/0/WO?[U74FJ]8^G?;9</#8%*\>#:VIZK7.J%3"(]1.8!'0 )A
M^5 H#RB( &]!S*%( ATYC:Z!L;$IM*J*-NEJ5;S54KWVU?%R&/>VCW1:^#=:
M[(4[<>[.]GLV%H;_ ,< ^T&]^]L #[(UA_;[7-IMJJ+GN583 UM'A$]]8?C8
MKH?\8;[)/\]7Z_[WM+WI@_.X3UI744]5XS]/'L2B'O@ "/WJ+766M792H>$P
M?G<)S12Z^Q5*[+XE$P]O0]/;^4JMSFJ4F*NVF7'9U,>],%YW#/\ O0]1;U_Q
MY?\ G?\ =K'5G;8YO\_69+"8)M+NF%NZ?I+K*;'QK%$/& ] U[8B&M5E"INM
M#29-;JJ*]WLSB:SXC9#A,%!$HU'A(W U$H71J)PNNJU6]:4IQEIN4V]B30@8
M $NMZZZ'H B ]X@.N\>@5E*BQW?$"I&EKP;6_P!95K7VMI;5N.MG+"S7BM>3
MA5#W*=5J7#1-RXJTSI3W+/(_5M9@F\$X0A.77];4KRFZ==VW;_, AUWH^^\
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M89I;Q<56]YS,9%&69,A4E#D:OV[91HBL@H>0,LB4C54[<4$E2-U$1Y#HF#N
MSN'P3BJWDK?2@[&M^,+:L+<MNV]X(W51+$0EX.!?7+&LTRJB1-K-/M+OD]#V
M@B8Q3$$0  [,U1NG@'MEY>HS5I72K9=LF1Q\T90T/&\DG:D3C9PD[B(:TI@K
MI-1C'O\ L#(/R.P=&[%9<J8B4Y2E#MV[9&V%\X;QSE!K$-K_ +=:W,A"J'-'
MI/W+TJ>U2I@N1PDU<HI.D'1T&ZRK=T19(YDTS&)L!"@[=NW(0KF'@PQ5E5W&
MS[*(8VE>4?=EH7*K<\:U-X4]):CHBZ;!9H*P,=N$4TFAGIFPN2))% A]=* D
M=IPSX,C+M6OIGC>W4KK7E7$X>9(BX%8DLZ(=)T^21,X%LBY=)G,58R:12J;$
M3;WN@.G&<*?#Y'*R:[+&-O)J2[&4BI+?AJA%HJ;5\(DXY%,[LZ+5D\<!VZK9
MH1%(5>8P ',.P,MD\#8FF6LXRE+%@GK2YK>MVTK@;KHK&2EK;M-<5[<AW8 L
M45&<28RAVJ8:$%%#B<Y@'5 >:;AQPR>_$LFGL" />Z+QK)%F12<%$)5BB1NS
MF19E7\ 4F&R"9$DI)1H9V0H%$%0,4!$#I+\,.#7%VO;Z6QQ;BEV2$LXG'<R*
M3L%U)=TT69.I%)(KD&S9XZ1<K^%+((E.Y.J8RPG$"B &76%B''.*PES6-;#&
M!6GW*3F8=(J/'3R15;D[-'PEX_<NG)R)$V5!+M011*/(F0A>E";5R._1^1G;
ML=-7&M" HKB #W@'9'  ZCK>^H;T'EJ.]4U:BSVI_"G:@AJKUO6JRLZ^_?T&
MGV%L X:N?'D3-W!C:TY:8D)"YUWTB]BT%G+I7XJIHH*J*" B<1* !S;'NUON
MKAS-'X6;$XHI<+;SJJW[;-E;69W4.G]+R8()<K&3I<$,*2A@CBARVNZSVWW<
MTKEX8\ @/K2V3W>*&;_I+6"T7@EG(@?-0/A'IM_M^*YYK^,3*CPR8"\6)K)]
M^%;?H+5\&8)92(%TD7"+3>W'8G\5]:*?&R8#]B:R/M*W_P"[5\&X+S$/MZR^
M,6FO3L3^*_G*#PQX#'OQ-9'VE;_]VH]&8)K_ #,/O]X\8]->G8G\6+YRGQL6
M ?8ELC[3-_\ NUCX+P?F8/5_,OC)IOT_%?BQ?.5+PQX! =^A-9(:\80S??WR
MU5HO!;9,#YJ$?"/3>S'XK\:*W\S]Q<;AEP&(:#$]E#OIUAFP!H?+T =>7OV&
MPT.ZO@S ^CP= 7"/3E;Z0Q2S_P!-$R#;'X><+O,U9FBW>,K07CXJ)QDO'-#P
MZ!D&9I1K=YGQD Y= *ZC)OS; !TF(#W!3P7@-DB';5;%E1*F5%[S.+A'IMI+
MPAB4K.O=(JO.[=;US=J5I0G,W#'@+0_V);*]^%; 'OCRT>C,#YB!<QAXPZ:5
M_".)_$B7Q7O.+XV/ /L36/\ :9O_ -VL?!>#\S!ZOYE\9--^GXK\6+YRX.&+
M (" ^A+9'O0S?]):+1>"VR8'_=(^$>FZ?_K\5^+%\S]Q</#-@ H";T)K*Z=?
MF,U#[_+T]VLO!F!]'@,?&+3>W'XE)7KW5VZ"SXVK (B)0Q-98B'_ *F;"'>4
M.OJ0Z>J =]V@$=]*+1F!V8>!WW5ON_(RBX1::2OI+%4?_P"[%OIO]WO*EX9L
M!".@Q-9'-O6AA&W3IWCT\7>(5DM'8)--8>6FKKZN[DOVN%PATW"U'#I+%III
MPQ*;$Z/8[NELSE#A?P$&Q#%%E;$!Z!"M@*/M?*[ .[>NH>*JL!A5'KJ3"GGE
MDTZUKV]BIN?"GA X'!%I3%-1)J+^TBNG9K/)JSWHZ-[Q3*,R=@./CT$V;)DO
M>;9HV0*":+=!&)@P3233* %*0I0 H 'B"N6DH51));%NY.W(=!-<4Z8YLR.*
M*-O6BB;O$[7>]O;[MVQ-4"@% * 4 H!0$!<0OSOV#]>'&_PR- 3[0"@% * 4
M H!0'AW)\PY;Z6O_ ,E5H".N'_UB,-?6RL/\W8R@)AH!0"@% * 4!:;O)]$/
MXAJ @#%GKCY\^KN*_,VW* V!H!0"@% * 4 H#7R\OW0N'OJ>OGX./0&P= *
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MA4+@=+M:RJJK96ZMQ*IYGIC/%C[(K?[2Q/ZJM'C!I+TJ'H9V/DMX)^BQ]/\
MW#TQGBQ]D5O]I(L?P(B-1\(=)[,3"^E#R6\$_18^G_N*^F,<6/LBM_?@XP/P
MH %1<(=*-T[XAZ7\*CR6\$_18^G_ +BGIC/%C[(K?[218_@1$:KX0:45^^(?
MYE[TAY+>"?HL?3_W%?3&.++V1$!_]A1GZ4 J>,.E/2(5SOX5'DMX)^BQ]/\
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M$F8?4F$1$![NHT<6JM;=>_$74[HU!]IJ%4WMTZ+H^.UI^:8XBQ-&N,=3MGY
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M>[EI*)(U4DV9&)!69%? J9F*X=KHOA)45C)=1 P)'Z^IU3P-B_0YG1^0\>-
M?>&%XGWS"D]Z3;2JMOYH]3XTKB5#NPS>8CY!8)Z^^L ??"G@;%^AS.W,1\-]
M 4_]PPBY,5+?_,5^-+XEO89O(._J$>D AT\6G C]X:G@;$_K86;"ML56Z<SZ
M/=<L'#C@\HDX](X;5O7_ "F!YIK8T\\]R!>$OB5 =^@U>HAL.Y@GW#H.HBL
M:#O[^[NZZK=)T+BH8TTHH8=9/ZS:MLK;X5WG'AX:\&I,&*@F:0D1Q3Y<<,KN
M<^&8E$ZTUTXH6DUL5=BO2_ZF>'J)DH##.,H689KQ\I&6E%-'[%P4"+MG*2 )
MJ)*E 1 #E,([ZCX_<KZ1@('+PLN6ZUA2K7H^'$?DK3\R"?IC'S9<:F2X\1,B
M@CAR<+B;3KMSKF[[:DW5S3IQ0"@('R-Z[6#?X]?/P3"4!/% * 4 H!0"@% 0
M!Q#F MO6"([UZ,.-^[Z<C0$_T H!0"@% * 4!X=R?,.6^EK_ /)5: CKA_\
M6(PU];*P_P W8R@)AH!0"@% * 4!:;O)]$/XAJ @#%GKCY\^KN*_,VW* V!H
M!0"@% * 4 H#7R\OW0N'OJ>OGX./0&P= * 4 H!0"@% * XE%DTM\Y@+HAE.
MH@ <I1 ##L1  Y=EWL0 .8.M !72 W*)@ >43Z\?*&]CH-CK8"&]:$0$ '=
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MT[XD>>E^NNL>#-(^@XK\"9\H"^K*#NNNU_MU&?M-.^)'GI?KKK'@S2/H.*_
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M1O7:P;_'KY^"82@)XH!0"@% * 4 H" N(7YW[!^O#C?X9&@)]H!0"@% * 4
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MPN?XR^ON:9?TW3P_@M\7L'DOX4>BP_BQ_(4'S5#A=#N4OO?M6VS+]\)NGA_
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MU)=%B'#JK5;4=U2SKNH[<6UV)I\\83_=L=_*FOZVKK2GDI3Z/E,.YXO[,_\
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MGC3\TSS!B)_.X[@+'QR_B;4N2YHUD[E&EQ*2"J0W!)..9=1I=#5,1[14X?*
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M<R3'+^M-A@;:EX>!NBB;2UTLF[*D7TLQYR>CSG30Z,6%Q,! ZE Q#M+Y 3"
MAU. HZ[]@7O#NKU2>LE$J9++DZZ5X\[GQ%5I2DRB5M:&)0\;AJDJ5JJY.RS1
ML35 H!0"@% * 4! ^1O7:P;_ !Z^?@F$H">* 4 H!0"@% * @+B&$ M^P1$0
M /1AQQW]/_+(T!/M * 4 H!0"@% >'<GS#EOI:__ "56@(ZX?_6(PU];*P_S
M=C* F&@% * 4 H!0%IN\GT0_B&H" ,6>N/GSZNXK\S;<H#8&@% * 4 H!0"@
M-?+R_="X>^IZ^?@X] ;!T H!0"@% * 4 H!0"@% :P<5&/I;)EBM;78XNM;*
MC-P\44>1-Q7&\M5S%KE1$K"9A)AE&R:K9\S5,<3B1))7D,445B&W3MVS!J1C
M_A.S19]VV--3KN#NIPZPQ/XSN.X7,JX4G+.<.W:KJ$7C574<J:X_.QLH1B#M
MRJP=JD RBAC".A P$O!GG";MJ*M]];]A6HKCO#=[XRCI&)N!TY4R;)7.8$VT
MK+"2$9##-2I@+YTFOY[+>'>H(<R8\U"-)IKM7>99?7 W=,K;N:6=L0%D,)6\
M<(8>LVSWQEQ:':WC9LBX>W2^761BE#1J3L4(Y5)V@FY5=JMTUU$4CI$ TOVV
M=MMQ3+B[>VG493D/A[XBKWSS;=QN?B<5L*U<T8BR'#O6LR6+.E;=K,8=M=+"
M5@T8!1[.3ZK]!^Z:R;FX$T#1Z+.-\#32YQ&E_/L\OZ\E3'H[A9S.3AQR-P]N
MK,L%1^HB^:0623W"Y\]KV(_OUO<YU)INI"+*1"9V!5_"R^%2?,],D5 B1"B8
M'L5ELXJTY[+++C(U7/8ZKIMOYS:C"^%)C&N9<RW65A"Q-EWI!8U:04?#F.D(
M2]M6TC&3SE=B#=)!L59XF()JD54.ZY>V4 @FY06H^UKU^!;U5&J7O6G1E3G>
MTVB<Z%FX$>4!!%;O'0@44C;'J4>H?A\O=6,4.M"X:5UDU3?7EZ/S+*BU9D,4
M==51IO-O53OS4^+/SGK^9N9JRO)W!D.WYRT4(FZ+HNF08IOGKTCPK;XH9)$@
M+%29\@" IFZ;V',&@UH:\7C.#V)GSHHY#A@;SUZI4J\JJB?OOQGZ!T)]*6C-
M%8"1@XX)D:EP)654G1<:OFMM;9;:>E-<0G\(;(_ETE^R5Q?%C2/G)/2CM_+'
MHCS$WU?S*AYDUQ"?PBL</=?20_\ 8QIXL:1\Y)Z45?3)HF%U4F:GE^C^97TI
MKB$_A%8W\MDOV*GBQI'SDGI1EY9]%^:G>JNL#YDUQ"?PBL;WGLD _D04\6-(
M^<D]*(_IFT5$J.5.:_V?S+?2FN(0.ZX;']]])?L8U5P9TBG>9*IMI%_0Q\L>
MB5E)FK^[_P!Q4/,FN(,W0]Q6*4OE%]):WW!W,@'Q]/P#63X,XR)-38X(H'FH
M75US5JO:9P_3)H5NDZ3B7!1_H0IQ:V4--9M9YVKN)^X8/,Y\R89SE8>2;EF[
M/=PMLOG;EZWCG;]1XJ1Q&O&B8(IK-DDS""BY14V8!Y ,8H"(  ]GHO0?>LR"
M8W^@W;BI3X[[JO%7R_#+Z2M%\(-"S]'8=8R&.;# H89BAU5JS(8W6C;K16_>
MXJL^H&/->CSG4>4 U"8G+TW_ +GO@Q!#?D*8Y?=V'0=A7JDDH4E2W;X5M57/
MAD;3B@<,3:<N&JSHZQ.[V5L]C=JFQ%""@% * 4 H!0$#Y&]=K!O\>OGX)A*
MGB@% * 4 H!0"@-?N(L!&W+"T C_ &8L;]W7_P LC0&P- * 4 H!0"@% >'<
MGS#EOI:__)5: CKA_P#6(PU];*P_S=C* F&@% * 4 H!0%IN\GT0_B&H" ,6
M>N/GSZNXK\S;<H#8&@% * 4 H!0"@-?+R_="X>^IZ^?@X] ;!T H!0"@% *
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M2.7E+D=,3; 0YHUV ;#VQ3UOR!X^ZGAW Q44$RL3R5*+CJZ94W7'D^X3+]/
MN&&N;B6>Q*E;[K&S^-LC6CE:THV][)DPEK<F?"18/NR.D"QF;A9LN $. &(
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MN\GT0_B&H" ,6>N/GSZNXK\S;<H#8&@% * 4 H!0"@-?+R_="X>^IZ^?@X]
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MHC_(\5KR^=[4?O AL/L4[C+^RFMU%3ELD5XS%O.?/I_^>8_8XVO=UOB>A_\
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M;*P_S=C* F&@% * 4 H!0%IN\GT0_B&H" ,6>N/GSZNXK\S;<H#8&@% * 4
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M"3,#C7([A,>M$I<#A;BI%#=U=8:1156VJW'T  "E$NA'1/4" :UL-B/+_A:
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M371?WYG8*02B3V@, ^,.O7\-4IRT H!0&O5@>OYGCZ38F_F+]H#86@% * 4
MH!0"@('R-Z[6#?X]?/P3"4!/% * 4 H!0"@% 0%Q"_._8/UX<;_#(T!/M *
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MUJ6IS4XE2AV4_E"^Y61"^@% * UZL#U_,\?2;$W\Q?M ;"T H!0"@% * 4!
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M!H#DT'D#Q^(/&.Q^R/4?*/4: M$ YB] Z[$=@&Q$  -^Z :#?DV'=0'"<Y#
M DT([$N]=1]S6A_2%".F3=*Y7HSIO2&(U7,/<*"XF#KL-)G'J;N#W1Z>(*97
M[6"3<22UHM:R5W?*E..R6;J:38=XGL!6=8T?;=RY6M"'G8F1N9M)1KV7;).V
MC@;HEU#)K)\XB4P%.0=& !#?MUU\[2F#E3(H)LQ0)9-5I7=;BZ:,]%)X)\(,
M1*AGR-&SYL$>44,.2=U6BW)6=7R$J%XP^&8=_P!F>QAZ>.:;_>]5OW_\]:UI
M?1SRQ"=+YOXNAL\3N$[LM$8FKLOJ[^8R>T.(C"F1)MO;-DY'M:YYY1%P\2BH
MJ12=.SMFB8JNUNR3,)@322'8G[BF,3QB%;I6-PV)B<$B8HXU#KM*K^JJ0UYF
MU?,XF,X/::T;*[MI# S<-*<:EJ.8J0N9%5PP73JWJQ-K<F]A,:0 E[9N0-FZ
MB43"4I=  ZT  4##Y1,(]XC7*@;JT^-\=;5N=.TLU7.ROEEO>ZG54[X:$ ,'
M=KIXN_VO>K88E: 4 H#7JP/7\SQ])L3?S%^T!L+0"@% * 4 H!0$#Y&]=K!O
M\>OGX)A* GB@% * 4 H!0"@("XA?G?L'Z\.-_AD: GV@% * 4 H!0"@/#N3Y
MARWTM?\ Y*K0$=</_K$8:^ME8?YNQE 3#0"@% * 4 H"TW>3Z(?Q#4! &+/7
M'SY]7<5^9MN4!L#0"@% * 4 H!0&OEY?NA</?4]?/P<>@-@Z 4 H!0"@% *
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M1O7:P;_'KY^"82@)XH!0"@% * 4 H" N(7YW[!^O#C?X9&@)]H!0"@% * 4
MH#P[D^8<M]+7_P"2JT!'7#_ZQ&&OK96'^;L90$PT H!0"@% * M-WD^B'\0U
M 0!BSUQ\^?5W%?F;;E ; T H!0"@% * 4!KY>7[H7#WU/7S\''H#8.@% * 4
M H!0"@% * 4 H!0"@.%38F "B(")3=P=0Z#H0'Q#O0>+OH#4&T+WNJ0XN\V6
M*ZF7RUHVWB?&\[#09E!!FREI28NA.37;B)#!VKM-B@BX$1Y@2 0('?0)7SZM
MF?;\M9+-XV/B"QNW?WA#2CN-DK"SE==DRUP7"]N&>N>^,=Y-D;>&P#.G2&W
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M :_\1'SO6#]>+&_PR:H\GR,&P%4"@% * 4 H!0'AW)\PY;Z6O_R56@(ZX?\
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M::JR5E3I'\C+R"PP#,Z#:69@/8,F30Y&AC@S(D5!$IQ%-S<4X3E["S+EZ_\
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M(LJWHK*^>:/Q3IS_ -YTE>%KOW%.L/Z+_MFTU:B33K1665"6JY9U8H!0"@%
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M[\0T)NH#O8T!:1DS(4Q2-&I"G 0.4C=(I3@(B80, $ # )A$1 0$!$1'O$:
MP6Z\;6A=]Q6=<L[%D>S-C.7[VVEC**ID9N)%!-L[.9(A@27 R*92]DJ4Q1#?
M0>FG;MV^!*?'H9EXM&W*1(Z")BH@ )IJ))'(0@!_M?,0 ()@'?* = #6PZ (
MIA<3C.S(F];AO]C#I$NFYVL7'S3X555"N&L,5<D<5-NN)DD"MRN#Z*@4A!,)
M3CHQ2Z=ND&>D:H<QA,@B)P,40,*1!,/9@)4SCT^6*&RE,'770->,"IV+)3DY
MVC8_9"<4^9!(W9BH;F4$FRCRB<P<Q^77,/4VQH#A=,T#H*HE2!--P14C@4"B
MBHH11,R9B@LCR+)*&Y]D63,4Y!+L#%'5 87C;']I8NM!A95D198JW(GMQ9-.
MU5<G,L\74=.UW"ZXF<*NG#E9154ZIQ$QC;'J(U'D^3/+^@,P?<I63@VMF!NL
M70;US"F;0CKO]_\ 35ANE?9MV[&GR[:VH81ND+S==W;\]V]0)@*$A'&+X)9Q
M%13AT=[<QEEE&3<RRAOBHF0VH<Y#&'H !S&'IH.O=7'4O"QQQ?V<IQ+/ZL*V
MTVYW7/QG/>,QT,$M.?B8(-5*!*.91*]$E5-+8EQ<A,9;=MLP\AX2)-H! =1[
M4VC&Z&'F%'E'U(CO6AT/BJP8:0FXH8(&U5-45+[DZY4Z+Y92+'XR"/56)Q,+
M:HVYDR%M)U577ZUTFEOOG=Y(W211*5-$A2$*0I2@4H$*4I0 I2%*4  I2@
M4 Z &@#H%;51/55J7HN;K.*VXHG%$VXHFW%$[MMNK;>;;>;VG8K(@H!0"@%
M:]6!Z_F>/I-B;^8OV@-A: 4 H!0"@% * @?(WKM8-_CU\_!,)0$\4 H!0"@%
M * 4!K_Q$"(6]8.AU_9BQO\ #)JCLGR,&P%4"@% * 4 H!0'AW)\PY;Z6O\
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M<P==@(; :%.3T<,1['FOZV^;Q[?  Z#N =$ZB'EH"H9KQ&8!$+^MH '8?W8
MB(#U'8\N^H_8H2JX^AOW(#F[$1/4C?UM#W=[T Z!W!\H/=J@3KVI[R@9NQ"(
M:"_+:UUZ>'EZ;T(Z]1TWT[J!Q)9OWEP9KQ&(\P7];0#T#^[2FWK>MCR]=;'0
M#W#U[QH-9/*KYGU%0S=B4@<H7];8AW_W<4O?[7+_ *]WBH362S=.9]0'.6)
M[[^MO^7A_P!RA4T\CKGSMB/MD4@R';)3GYA*EYX%YU *&QY2\NQ*76SB #HO
MC"A3D1S?B@W-O(-MCH>O]7 80-L=E'U'30<O3RB/=0E5_1-^XO/F[$I2[-D"
MV]=0 1>@  8?4EV %V/,(\N@\0C057'SIKWKB,4X<9)E,6M?$K&NDWT=(YGR
MZ]8O$C"*3ALXOB6.@JEL"B*:R/9+E-K1NV$0$0J*^7];*Y>MY<OQ-@ZH% *
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M#A#'UA   %DVCH.@?UMPWZ65"46Y=!0V/[#V3^LFTNAQ'YW(?OY#?^A^U0I
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M@% * 4!X=R?,.6^EK_\ )5: COA_$0P1AK7L8V('O#;D8 _>&@)@     .X
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M^+ERF7EWZM0H@!![P'[% 2M0"@% * 4 H!0'D2S=1['OVA3%*99JX1*<P:(
MJ(J$$51#J4GJRAS%ZAH1[Z QG%]L/;,QO8-GR"J2[VU[1MN >+([[%5Q#0[-
MBNHEOKV:CAN8Y-]>0P;H#/ WH-]^@W[OCH"M * 4 H!0'&<1WT_>\@ATZ=3&
M*;_FC[W?0$6V;:$A;=V9-G':R2R%XW(PF(]-+^W)((0,3$G!4/E>J[%10H_X
M!@\E 2FF;G(!O+][KX]>/_704!?0"@% * 4 H"+;@LQ_)91L2]4ED"L+9BKB
M8ND#"/;J*R[44$3)_O>4@CZH1\?35 2<F<3!U#Q /76^N^\ ]R@.2@% * 4
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MA3&U6-P043*-(R?0@#))C'DEF[K0$(1P*Z9"D #:)!!-LBF@B4"))$*FF0H
M4I2$ "E*4I0*4I2E   I2E*     !0'+0"@% * 4!CMV6I 7Q;LS:=T1Z<K;
M\_'N(N6CE3J)INV3HO(NB91 Z:Z8F+\JHDJ11,P%42.10I3 !K:VX(>'5M;T
MC;PVI-.B2+R(?!.O[UN][=\:O;V@@0@[N<3*EPP:,.4I2,$(N0:I))AR"0Y1
M, E1>WV@G;&N,;+Q':S>S;#B1B(-!T[?G35=NY%\^DI!7MG\I*2<@LYD)*2>
6J:,Y>O7"RZG(0HGY2%* &?4 H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g118907g79p08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g79p08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V"^< @X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5X            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              V    @D
M         0                         !              ()    V
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    V
M  !29VAT;&]N9P   @D    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,     !#*     0   *    !"   !X   >\   !"N !@  ?_8_^T
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M^G^D_P"#1F'KM6/6VQF%;<&EME@.CK"YOI-:W]7V[Z'>QG[_ /HU)O1>G^D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC[X_1_PX0B[PA!PA!PA!PA!PA%#GWB_/[T^1V/Z"/+Z>$(:K5+3#!M9L-M,
MU&QZ!E.(VSM>[;4UFA:HDA=7/C6L!92A:%A<>PAQ9&X4$J2D[[I4>*T*4A3I
MLK;1G?=_!_%HNTU09$Q:@6LI]+C+E(+[,Y\<INT?.MRYX_@.@&B/-7KQ@T'$
ML.UBPGGNU4T(T=S"^H;++IU)16>18YC-5AV-8[%E(=N;!%#:W$7'Z5U:&2^^
MX77&VRMQ.VGO.G2Y)(*3(23<#O9C<E@0' +![@. "8[;$$R9]1ATI3=FO"94
MZ8!=QVI)=[W2D"VK,;$@NXQ\H%S84&":_P!+838$_.M+=7M"\0QG(LZP"HQB
MR?J]6$URWF,HQ3';!VIC"*))]#]$+,Q,>2VY*<0^0F/4:&G,R4'.5<E:U,HD
M9DY2#F+.^8Z:@:;Q85A.%IG2I>RL.,XD*<Y\P(OS8&_+=@Q5F:\\'-5H/*YH
MM-LZR+#M1,TTWKM%++!\Y8P]C'*.A7K.N0VE[(:N$\AMZHQ=MA2W9DAQ#KSC
MB!)DNI5T&PBFD3B@I"DA1F%0)<]T@:N!<W#'0_6S3X5ATU-(LA1_ES%+3?OE
M"F >WS?*+#R+ VLDYZ.:#0#)=6\5U SC376QS ^7JJU2IKC&,9A4*'K^_M8T
M%AO(&JB0MEB#6ID>(%-.1$S&$!YT(]I7%^3A\B>@*#RSG8A2E.0DWR@M\PTL
M>AB])P;#YZ,P0J2>W6"%+)[KZ,68ZW_Q#^:#\Q/,S0\QFBFCVMF?X+JS3\P^
MDM[J33S\2Q6#C$[3Z735,:\-9(-<\ZS:T<V.\N%#F2TF2N2D+,MT?<CA3I4@
M(64!2%2UE'>)90!9[A^K,_5HUU50T29,Z9*EJ3V"BDDDDJ+L=39BVG*QWB(W
M.A<R\"^53Q/6Y5N[64^B&B>@>19(HON"&,0S[7BYTES&;)9"O",:KQS/)]@I
MU2=T)AA0.Z!QF4"$3:69(8=K-5,1+&@?LBH G4!T'3_6PPB1)J:"9+*1^H4H
MI2EG=@2;\\J5%M#OI">Y"M*L:UTYG.8Y&K5(<LQOF&T9QO7>TQZ_=E28+L'-
M->-1<FP/9EQP>"F%AL?#U1$M](6AM742-]\C$^SI9<I%.H'(4R\P8_*A25 ]
M<R6(V(W(89&,IDT-'3]A<9F)L1J=;$:ACHV[FT6N6RFT=Y:.7+G8YH(V(54?
M4#1[7#7S =,[_P"ZR+.HZY\+&\-H:@//J5X#-A9Q%M1HZ5+,-M]21V/%JK(F
M55-(! 0I"%*#!R<Y)T:Q  /4O<:4UTR745=/1@D22$NS%V?,IVT(#68$-N8T
M_P F!KG1Z!:C:BZ71;?,-1X6?:18UK0FI9IKU-S.U6KHS-?J334,7*(M*93\
MEY^O=K8<13L=;#;G3(V;)%W$Z1Y,F=W4'M%R[!OY8?*HW8.&)N&)\Q.-8<B=
M2RJE@,BU)!%W0"R<VK$ 78VV&YG/J3SC:[ZKZHZ.:)Z'0;/EON]1:#4',KC)
M=:\%K9-O"K< \!H5U?22YTRJ'KEU\.&>ZX^MN*VXIMEL@*XUB)$E$M4Q:NT*
M2D (.ZCN.@\HU,K#J)$HS)BA4 972@W#_-F#N /#G&FMN9?FPS#/-!^7+$]2
M]&\0U%RW!<ZS/-]8<>K:_.,1MDX3*=AM5^)0)4A=29%@DMNW# 3(=IGFWPVM
M*$)"),BG2E4UIBDND!!=*@[ FVHW%[AQ:T7?T6'(3-69:YJ<TMD$J=()#6U(
MNQWM9G>&RQGGRYE]67=!]"L9N\&P?5S4'6SF!TBRK6=>-LW.(/L<O\)J?(O<
M3Q^?+D52[#,8TN*W4QICEC%$UB6TPRI);81D*I)$M,Y9$PI1)E342P;A4P'4
M@.&(=CH')T:+]7A&'R_U4R6Z0:&5-0ER<BYA *>;@&]V#.0-L&!SR\U]S:8/
MHG#RO36)J:WSDYQRNY+JDYBS4C#LFJ:+ 8V3P<G@4J9B(U??QWIJH\NCB/MQ
M'+:/717(ST69)2JH4=,A)F*EK4G]*B:$YBE05D*C<-8EF^;^H !@(REX)A\J
ME3/"NU[3#.WR ]Y,U9!4#S+$)!^9P1HS:7).?_FLPFLRK0^;8TV9:QX_S5/:
M#1M8\5P2HE1IN.(Q.%ERY<?#'+6IQAW/"N6:ANL>>AUB4M%3L%^P#BN*TX9)
M4B7/"\J%2DS!+)N%$9@ZSHEF!+/NVT)&!8=-E]L72^'KG=F272LDFY)U!<;E
MF<;%0SN=/G;KL"Q#&9C&.T>I=[S,C1>MS',\-I8;5]C%A1&RAW]SAM!>V+6/
MV]:^Z&Y%:U*CJE.QMC'#"UJ-A5'3@DYB1V87E<D.<UPI@XL&L6-S&)_",/0J
M4HJ.15$N802== <PU&A%NM@836M_/%S6:49#EB:K4V@SYG2',<#P+-X>,Z20
M$X=-N[B8S$NEY3E-C81YM%<.![KBT^,-R&X_2@J405;9$B@IYPENE2>UDS9M
MU]Y.7Y2 '[MC<L2-0["+])@U+/,L 65339P.9E6#C34?2^HW"<RG4/6&ELOE
M0,HRG+,<S_%<29P)^%I[EN-Q[;'43;>HASZXLPI:W6FJ^%$4[#G0/ +5A(<9
ME.K\9&XJ1*DDT*0% *DJNDD$,I=W#$NSCD]AM$RZ6G2,+)%CVP4+7 "A<F^H
MU#ZVT8O1EO/)KII<[FNCL2+BOVQ<RQ'EGG<IM7'H&68$B%JE)IL.R>%-C-]#
M$YO#K9U^Q:8 #C56W'2\/ 2-K HI,T]HE3(2N<F<ZBZ2DJRER=NZ2[:G5K6E
MX5A\R3)J=#VE2)X)+]T$H(T# 92=KD,=80SG/CSEVVJNIEMAU%(O, T9YD&=
M"K? HF"XC%I,II\:LZ.HS:[G:B7&25EQ0Y?9-6[M[BE5!@.52FT0XO1-]+=1
M"E5'3=@A=PM<HS'*R[JN!E9CE!!*M+!PYNF83A:*1,Q!)*I(6Y4Q!86 86)>
M]A9];Q]!E>ZIZ%'>4@MJ=:2X6SN"@K'5T[%2B.G?;;<;;>0\N-+??W_K2..4
M %*"?E!('@_2,SA$0<(0<(0<(0U&F'X2U9_.G/\ Y-PGB!JKQ_80CS2K\&99
M^=34K^=;O@-/-7W,(=CB80<(0<(0<(0<(1R[SWGGUV5S2ZX<LV@?*5*UKG:!
M46E.09ME4G6+%-/(C;.KU#9WF/,0:^^K94F2XRS37$9UQITMEQEM72 I(X0B
M8>DFIV4Y-C.,_;GPRJT0U7R07DA.E+^?T&9V"(--9O1FYE;;U2(<:W:D5P@V
MLI$*,KU:;!#,I0<;*E(>_=A%Q>M51)S?%\>HG\9N\/NL9RV\G9[#S?'U1Z>5
MB<F,S)A"H2\J591U)>=,^RB.IBU*V"W-4DN) 0A$ZA<Y?+MI[I9J-J](U1Q#
M(\9TLK%6>6)QO(JJTDQ&UOMQX[(CQI2B9$MYP-1MMTR7-VVE*5VX0C88CS,8
MIF%DBQ9E8U5Z76&F&(:C4FI$[.<=98E)RR6(D>KFT"WTS:]$;Q6F_6LEX094
MTN0&CZ0VH<(0XF,:SZ39LQD\W$-3L)R*'B'4YE$JGR>JG1\>::\5\S+A]F4M
MBO@J88D]4N4IN*8\9YQ+W2TX4H17A>LNE.I3J86!:D89F$QR+82A#QS(ZNTE
M>C5TB-#L)*X<24[)$*)*GUK$B0IOP$"=#2'")#2EH1#W7[G(U:P+F;H>5K1'
MEN=UUS6ST8BZU6MA)U1QK3:LJ:%[,LBP]%<%Y! F&?,3-HC*6J,6^AN2D[$)
M5NA#&Y#\JA?4FG,Z<GEIR'[?6/<S.&\K&3:&3]0L<BBKSO.:BPOJ.T9U!,%5
M%,I)53!;EH?;C I3)2'.E22.&WO[/[YQ#AQ=W?3\WAY<+YV=5(&LN(:*\R/+
M%9Z$9%J5C&:Y%IO=5VJ&,ZG8[DLO ZE=W?4,N3CL"(JGL$5;;DF.N6%-2$@H
M;V5WX1,9_)I\H5@G-QH5JIK=]C%GIG'TAS'4'&LIH<CM(LJ6S680].;8RAN6
MPRPTFHR)%=/77%2"ILP)+:UK4RHA"(TZ6?*KZMZ^<KCO-5H7R8Y!F&$8_?:R
M5N>UU_JYB>&7F+5>E4.AMH]MZ-:U:U62LLIK*PG1(,9#;]2Y6(B3.M<QOI0A
MR\#^4/U?L.6QSFJU4Y1+[3W3+(\%T<RK2F-4ZL8GG.4ZDV>O6481C&FV,1L?
MJJ^,]16UE*SV@,A4]3K;3SJXI0E2"2A$NN737?476QG()&;\NFH^@[=,J$*T
M9].J))R9,I+Q>=KS5@>&(B4#Q4ND]2G6]B.DCA#W[_S"T&LE/399J!29O+QG
M"<=PZ9BM=593=9I1L(R&7DF-M7CD:75NO,2:&5$47XT*-8J+UHS&78Q4F,L;
M(0TVK_.CI+IMI;&U7QR_QW4['7-2<*TYM'\5RJH,>DE9C:"L1-LYP<?CPDUZ
M>J0XU(#*WVDE32DI]KA"%SD7,9@Z=-\HS72:_P )U9D8I,A09]75Y]CM5%BR
MYD]J*VS874R0[!K2A+JG6#*"1.+1;C*6M8(0AOM*N=O2'4/+]8M/\AR+&].\
MHTNY@KC06%2Y+E=-&L<QL:G!]/,T;O:F$MZ/)9@6GV>(I8D5])=D3JZ6TTX[
MUH:2A%G5[G6T_P"7Z\NHFL1JL3Q_[<FBNC&(7_V744N3>WVLD:F]'LK6E#K<
M_&*S&I]FX;9^W/2[4Q7+EHMP'$KX?X'UTA9R+OJ VW/UZP_TW6G2:KS*'I_9
M:GX/$S:S6R(>+2<HJ6;F09;/I,%+=<Y+$E3TN,MEZ*STI=E,O(<8;6UT$H1D
M7.LVE&/W$C'[[4O"*>]A,2I<VHL,HIHUC!CP&V'IK\R(_+2]&;CHDL*<<D(;
M2GQFQOW&Z$;C3_4W3W4Z',LM/<VQC-8->^(<Z5C5U N6X4H@J]'EF&\ZJ,Z4
MCJ0V\$]:=U(ZDC?A"'"X0@X0@X0@X0CQ7D?H/\.$(BS4?V TI_.K5?YO9<(1
M*)'F?H_U'"$7>$(.$(.$(.$(.$(.$(M.H2I"P1MV)W !)['W>_M[O?P\(#4;
MQ$V]Y-.7F^T_S73&;@$1O$M0=3+'67)8<.5)BRW]2K*8Q92\PA3VG _ NQ81
M8[K#\=2 PEH%L ;\7$S9@6E8+J  !Z N![^\9B*R;+4E8)S(2R2;@ *<)N;)
M'3P9HT5-R*\LE%77]5"T\CKCY3<8ED61^E39LV1<W6"2!)QFSG/R7W')$N$^
MTV^A:U?=%;)/L)"1=-7.4SJ#@*2X&RF<'8. .3;=;TS%:E:RHJ26E*2&#'(1
M=-MF9(UZ:0:X\L&'YQ3:O66'5&%5.INL&'X_B.0W6:4YOJ2]IL40I%%6W=4I
M]HO0HK2WFV'(ZFWH[JDN)62D<4RII0I#N4RU%7=)!N1F+C8CGTA1ULQ"1,R$
MA"TD$ VN"1KTO9VYQ%/E=^3QBZ89WFV=:I56F#%1F&FS&F36G6$1KEZ@DUZI
M?I-I;7<[(I\Z5/D672E#,%MQ,:N:3TLI'L\9U5B"YZ$RY;V5F)RA)&6X#!K"
M]]R7UM&QK\;G3@O( #V\M686-AHS;D^#=;Q+W1#DUY=^7N^GYCICAK-=?38+
ME2F[L;6;;/P*9]]I\T]9(GR'A65B'&FTI@Q>A(0V&]RD[' 7.F37"B[WL-2-
M-/>\:NJQ*JGHRG^H@D) #[<@^KOJYZ/"GU%Y8]"M4;O,,ISW"JF^ML_T[B:3
MY/.ER%)-K@D*]&1Q:(D+"$LL7/\ UBVZC9U*P-E  ;0B9,01D40Q*@SD@D%-
M_(W8;Z/%N16UM.QE!0,DDL ;.X)4&8ZG6[ZG6-Q@^@^CVE^4_9;AV-U-)D;>
M 8GI<;!F00ZU@F%-.,XYC_@K60(U87E%K8>*X3L5';@N;,F)99) 4I6FZBI1
M)+[E1VL(JG5-?5)R*2I4N8MTEBV8DGNV:SEFM?:$XYRC<O<O$;+"W,!K'\6O
M=4?MRVM.IQY<*PU$$QN>+^2WXA2\M4QMM:F3O'6E*04';BDS%YLQ)S ,^X'[
M<_'2*%5D\J6H_-E =B"&9F.HT UU/U5N1Z&:/W698'J1<8E2L99IG(F.XC>-
MI:KG*E=BV(LEE:F/!:D,O-)2$,O]:0H=03[^';3"#+*U%*F+$DAQR?=F<<FB
M15U)2N49ZE)(;*5$B_(6 ?>QL''1/:[\KVC/,FQ0LZH8SZYDXR]*=HK6#.FU
M-M6IF(#<IF+90'67FX\QH]$MCK+3R/,=P>)D5$V4"0P<D$,""QL2"#>T12U<
MRE)R,0K5P_2[]-MX169\C7+/G6#85IW<:>0(U'IRPN)ARJ*9+IK.AC3$NIL&
M8ME7O-3DM61>=5-2ZZH2U+4MWJ*NU4JMG)F*4"Y-U!0!!:P[I! ;1M!?>\9"
M,4J:>::A+.L%)"D@@L3H#:WII%O).2CECR73#%]&9N 4\'$< D.W>*0ZJ<_5
M7N.6$QR09]U"MXK[=G%G6+DF4)\];A$H/+\52BD;7$5U2F=,F9G4M(220"%!
MF;+HP!8,-2[C>I.*5:JE50HA2EI[,I(=+,S92&8,]KG4=6+U9^3=THR>LY=,
M1PJ)28;I5HWJADNI&<8_(]8JFYDJ]Q2;3R+)R\;E-26LBBS'X]EZZE/.'H8
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M\/Y*/E%L)3A=CC[]OS!<^JL(QPUCL5<_'+EF;#P]=)"4 %5]C'9C-UH:ZT!
M;;2HG<"8G5_RWNWG&TN,)QEOY)ODWPW6[3#5W*\3Q;2;DAE:I8SIDX["SC"D
MX%3Z<W#^46D)@*MYE/@>34D"SRJ!2(5="OKI<R&6E0EOMH1E<@44'F/UYL]
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M3$MH2 Q+D$[\;C?PLXSP4+GJPI>(T*"0FMPS-64ZT@%1F9I)*T):[S$RR+6
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MIPWQ 4R>-^!<$G2RD2YN(X%3HH<54SGM$S"4$DE1)EBI1*)<]F"ZCC?TQOE
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MOQ-6--BEM0:=M[2,P[#M,3KNI DH:ES[JP3&4AGT=3J%A5*,9JY5L1PV;)2
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MQ4;#+FL >EBQ9M8T''? 6-\ XS/PG%I*P9:4JDSLBA*GRRD+"Y:R %* 4TP
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MY(()8MN.4>+\9\&4W#^%8)CN&XA_$<,Q[];^EF*1E7FH9QD5(8:I3,"D)/\
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MD3 5]BM22@.]@P!+ @'=_"/5N(L2X/5BN*<*2.$),@4TP4E%B5!V\VO7.0R
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ME!V!#@FYY6N-H]DX?I<&P+@<<55N"4N/5M1B@HDT]8N8B13R$HF.H*ELZUE
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MJ7SL5_-;GTZUTWSS4-\:6Y3#II^!V>/85G3U2JE=<1%8L6U2*5MUF.I#A69
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MQ1.H,LHK"CMHA W=A6##D=TI)2OI=;"_$844J2EU*5*! (-N9)1/243$A25
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M:9;H;D/OE;@0%K;'L?WB0/9 &I1A5:FIGS)-6J5+5-*C+"4L4OI=WS#5G9R
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M:F!PO)4IH=P4=(W/8*)/&=(P\TU3,J432$S+KEL#F.ER?J+N_I*4)!)?5N;
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MT;$[4W=WLUM.F_+VVD7,Q=FT +@ ;EM!KU=_I%Y,9I"NH!6_3T]U*VV[#R!
MWV&V^VX&X'8G>>8O?6Y]CRB" 5!1 *@&!Z.^FFMW9XO)2E._2-M_G)_B3Q
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M.-,JBC< $Y% V%@;LS?(?&/PWQGA;&J3"U),^5B4Q4NE6$&RD %68@$LRP7
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M&M:J<PN!?4TXCO"N:>4U'E0)+??K2IM2'-OZNMQ/MD"]X0O&5*6@%1W.YWW
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MX @-E]20>MH@J3ZA\+^.L+X)Q5,J?VDR4I)E]H5+2'>RLI4L#P#W/T\D^*?
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M!4Y6)"&$=1W](,@14H'B%8;!4.;1QUPN9IDKQ64)@.4(TS%V8%BY'B'CHO\
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M*NR6E144J)[JW 8;W.H:/9OAGP[)3A.,<6U,B75JPN65T\A;J&8+"2Z!J&4
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M40Q8.OKFQDAF&5^'Z0M'B!P-%S9MM:D)0HD'<[\(AQ[]/KM&P3DU.\G=FVK
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M7%='HS"GDOI2'&T*3Z!P1QK)X(Q?MI4RHG)3:<I2LTJ8 H?(DNI*2 Y!)Z6
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MRJ&:[.(UU[I%?90AN59Y/&BVL")2P:Y-5#2U7FNIF[?9JQ,EE_THR7;I]YQ
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M2T+![[!:]DCMN&SOYD<?I=2]KV85-24K4E!(=@#ENZ;L7+=&(ZG\QY[&=,*
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M9(&G6H61XY!;(/W*GG-P<GI&DD__ "(U=D+4-@  )9C)0/O.*R222H@\F#6
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M$D^(/V>._*&4J0E02$K'NW(Z=C]Z% !>P]P)\O, ]AI 7#\XSHT%A=5E?*1
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M_P"16#5-*L4'#^*HQ9$G*HSI0[,3%):6&0K, ]KJ+NX+QUNY.^5/ .72':Y
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M=KDU-@%BRY"2PY>T\*K6U(A1VO"M4LCB03I2)B91%,"A"BB:"H3 I9S@S2'
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M60Y24?\ X%N55-OE:Y3;KR$/Z77205!(1T[[H&ZB H@G91W"=AN@IZRYOTA
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M/XE+X?J)M5Q9A0DXA*IJFEI9^&RE3Y=/3E"*G%2*AY\F:SSUI*29IS H#I*
MNN6;G7D(S6$QIZRY6:FXSA6,Y0AQ-R^[*CX=C>/Y P;5T!M<AQQ%#+PR2O[J
MVY8V[\;8,N!UJU.H>(,RB,J.VEHDJ,KM0$I1E59UK8DI8DAC=DB-]A7&/P$?
M#$S:FOD+P[&ZZOE%:J26)J9ZZB4E%3,,]2>Q2:CMI9ED*R(0M14RLTA'^5CF
M(&1#)X6A6AJ<I8Y354\/((>, 7J,ZCMTT&+Z/;3XD5'VVHL-IR-%L9UC!AMM
M%Z.[8)A*6M&3/HL7G) ,BG2O](9':($Q*RZD*SJ>:H=H"@$*8!BJVXX<\9_"
MY<@(J<9XFF2D?$6972I)K*1:9>'*$Q0"D&<I)P-TI$LRY9G%12$J#D1,[Y.7
M$==L%PC-*+5K%<:QJF3D<%_$);-;9464Y$C['<>1:VF14LRSN#!::GH730W)
M$F+.=?K),E4!V#(B3)&_P&37R)/9524]FA#(60H35*<#ONM0&BK,'[I%GCR[
MX\8AP'B7$5#4<%U-3."J"6*M':R:BA21-GJ*J>:@2UYR9B<R5(6SE)FNCO2H
MPT'-=:LYS-*O%I,&K8^F-(\D@M/WK+OKG-I4=9ZDN!B=-A8[-#>W@6>/S6%K
M=\-*D]!'A$2$*0-R"1LD@)_NCM[AMPA$6ZC^P&E/YU:K_-[+A")/[;]MM_+]
M'<;']![^_P"CA"(_9G)=P?673[,%)2U29Q7R=*L@E$$LQ;R1(%K@3[X2I&R)
M%JFPH(Y=64KG9'%;2IHN*46_OZ>WWZ0VA_5/*4TK9(*@$]6P40E1)!2.WW4)
M6A22M'<G;H0I6R32IF+AQ9QYB O[]^]81N;ZBX/IEB]EFFHF78U@V(TK)D6N
M2Y1=5])3P6E!10I^QL7X\9"W2"W&:+OCRW"&X[*G"AI=<N2N<4HE2U*6JR0A
M+J=Q<,+ 6<Z 7) B%J2@$J4  ]R0+=+[DZ<SN\<3->?^D+?)SZ9.V5%C5SGN
MODQ++L%]G37"V7<7<4X%H5&DW>;6>*1),5WJ6VM==#MF-E'H0XE1WZ"CX=Q.
M<J6K*)+FRR5YTM<$ !GY=Y[_ $UL[$:49T%693639E=#O<Z'3R,?+?S#\_7+
M!;ZC6^K7)UH_S!\GFHU^ZY)NKS2;F!9Q#&KF2^^X\X[8X-6XE+:V6\OQ/0J+
M)ZND2^I1<K.LE:^TH,"JU(,NI--5(!NF;*6I2P&L5"8 !U(?6YUC4JKDRU9I
M4R<@D_+F"@/ $!M;AR+!@UH:^D^4+R[4F>U2<WFOW.WJ?IPM!8NL3P37*#B*
M+.* -XEE"LZFPJ[6/(;ZH\P3(C:EH47%*<!V.P& *DIF?IZ&AES5 IEO+5D"
MNK3 K7_L[NP=HJ_52Z@H,XS#E+@@A/3->SC9DZ%P8^B[Y.[Y67Y&70/&HVG6
MFN#9QRNR;=R(W?Y+J'B$C+)N66"$>"B;>9_B-OF]_-07%;M1[.NHZ:N47U5E
M;!CJ#:.,Q3A[&U+F+6B6M"05)ER24C_XA!41LX*EDN2'9HV4FHID$)25%1(#
MDBYS<["[_P!(&CL^OTKZ;:H:;ZQXI5YUI3GF)ZA8=;D&NR3#KZNR.H?4E*5+
M91.KY4IA$MIEY*9<!XL3X*7@W*9:>\-M7'SI$^1-*)B5RU#YDK!Y[!P&.Q#O
MSM&S2I*PX(/-M-O,:_80OY(>*%; 'V2?8!W[#?8>_P#3VW]Q![#$G(F+! _M
M5IKH19WO?3[[5BS'6^GOG'.>%H#ES.GE_;/UE2Q<RJ:;51L>JL85 L;A4[((
MDHRLLGBP>3>N,LL[L=+$-265O(45]84CFZB@JU.03:X;4G,"'-QI_F,8RE$$
MFQ8@)N'#N'L[AK%W9AS,>V&BV8I$VJ.+P6659%@=@TG"Z,XSC2V*^+)E2GT5
M2Y\U2;)F6VRS8S"^2^5C[F@<82\.KE$D%27*2<I(%G)MU)W?IRBE4N82+#H0
MX# /=[YG=]&M:+1TBRC(L8U3MLDP)<C)<M&,W<6)954"7*:MNN7%G-0WGT/%
M+K$1J.EU3:TLEITJ\,C?:M%!7*,PJS/,4@DN0W>!+.=QM?DQ+P2A9!=)S$NY
M;5^C$G7HVH)AYK'![*EUBQN?B>+2FZ.*]CT 1VJ*%"P^GQUD9!*M9M7*@V\%
M,:Q9E2D.-LFL4'G'V$M1WT*(9VQ1/DSPB6'1F![P)MJ[I(=O!G/E&9J;"QUT
M)T<LQ#&UK,;C8B'3UTR"=4:?6U+0+3]EN>.QM/,/0DJ+IO\ ,$2JQF8A"5H6
MMJABNV.2V+B% 1*:LE3W#T1RESH &%W/C=SR>S;Q3RZ_;GX>#GI#FXM10L9Q
M^DQRO2&H5%50*J(TCIZ$QH$5J.VDE*$)4=D^T0$@J&X2!VXF$*/A"&RU3Q7[
M-]/\IQA*PB1/K5J@.;'=,^,M$N&M)V/2M<IAML$?>!1W WWX0BK2W,SFF"8_
M>+ 3.,--;=QE;^-#R"K5ZNN(DC=1\%UJQCOD-KW6IEQIX**5 E"%TX\&@XIU
M:4-H\13CBE)\-"$DJ4X05!*6P >MQQ3:6SN#OY\4I 40$N2%:7)S$Z<R7VU=
MM8$6-_/1O/[?7:(N:B<X6@.G,B3!L,R1?7493Q>JL.CKR24P\V5,NMR)\'_J
MF&^WTJCN-39K!;*2E?20H\;&1A%54K"TR,I+,H@@L0UA<N0=VZ!A;'F52)8R
ME94SB]REB>@#.Y>Y.AUOR\YG.<OEJRM$;+YNE6<5MTU+@0:[46FO:K$LBKWG
MGO AR;?U:S?LOU,50;VFS6WTL.)3%C+8+8<.WGTM9@M-(FU,Q)I9DQ"5RI@S
M  J *GS)5E%TJ%AF=MWWO#F 3^**RKHZ%*$SY="JK)-IE20G-V$MG!G3+%-B
M>8,1TO>;O+,9@0DW>K&L0QR?/B5];7U66//Y#,<E+2@ICVFS5H\IMI2@X\H]
M#825AIMLA VM?5X+2TU+/ETU*M544)2 @*4G.Q<=XM>[%_$AXL\/\"<3XUB%
M=22)-332<,I9\^M-4Z3*,A3+EJ.5(S!BP <L'U<S)T#Y@.4G [AJ_N<*U%?S
M1]0<>SS-7:S.+")(?;ZG7TOMV$:5#6[N1XT2H7+()"G%=P<.LPW%)Z5=DO\
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M'E+!.5DY5-:Q!%@D; L7;:/SYG3[V &92E%Q=RHNSDW)!)]1O#58UDEYAUY
MR+&;*547E:\B5"G5KRXTAET*2""4H3UI6=VWFW%E+R.H!"2 %7\1IZ9<H]JE
M%TDEMQX$$-]];1,E<Q4QTDZO9W8?U>MM_.\?37HW?WF7Z58%DN0Q40KR]QVO
ME6C(2M/5(<0>N0$N)2XD34A,Q)4D*Z9'=*2=AY?6RY<JKGHEDJEI4R7(+ I!
M9Q8Y22 UF '4])*S*E(%DJ_KU<WU;J/ ZPY:HR%>)UKZ24EL=*B-DK *TC<;
M@**4]QW!3U)V423B9P"'8L78AW\6^S_>+I2"+9DZAP2YV4+N+LVCMOO%*(K(
M4=U*ZMR0>L['K(4K91[^ULD*2=PHCJ(*BH\25*4'!'+0"SZ6 Y<C$A(3\H;S
M)8[FY)!.[,[G:T>J8#:4(W5LC[W<A?WI]E14H%14!N-R23U'<GMM2,V[>KZ]
M&'NXBHDDOIN& 8'H&.O^FBVXA(V&X"0@=2=B-@=P.DIVZ"D^UN$[#S!2H=ZO
M?OV8$@AK@\P6+'\W'AYQ&VVDG6O,VL8K=G=,,%M8\S*K)MPK8S#)ZYP.Q,<C
M.E*F9-54RDMR;V0@K#K["*X$+4[X=2"$!3"Y! LS/N_O2*0HI+) 4IF=0=@W
M,$7N[WN?*)/Q]TH2.YZEGL04])*.H@ DG8*!V!4H@'8DD'BVE.5[DN2;]=HF
M&PTP_"6K/YTY_P#)N$\2-5>/["$>:5?@S+/SJ:E?SK=\!IYJ^YA#L<3"-'>X
MY3Y+53J2\@L6558L.1YD*4A+K#S3@(5U)5_?W/4AP;+0H!25 @$(E)*2X-P7
M'XB ?,%R]8?FFF][H]KYA*];N7>T!7%>>:=EYMINID=,29'EM$6<N+6@CT.R
MKW_7,$)Z07VB4C(IJJ=231-DK*5!F:P\^;^FQBS.DIGI*%.'NXUM=_J7_P /
M'S@:Z_\ 1K;/)5V68\F^O>.93BM@XN14XEJ VY$L(7B.*=$-625X=2R(S*@R
M$V=:;#V-Y1+Y63W%#QNDRTRZB6ETIRE4LDDE(8V)L7OHWUMIYF$,29:E%R[%
MGO=[#?RU$<R\Y^0H^4QPR:[%BZ&'-&VR$B;@^54UC!?2%$EQHV<FH<[))2 I
MG<@]>P<4KC=R>*,'=*E3#F(N"D&]G!</L;N;,^CG 5AU6DG*26)&H'AIKOKI
M>P$-I%^1J^4SDR/1SRFZ@MI\;VG7K+%$1RE'L I/V1J4$$#K"DA*NI16"%*)
MXS)G$V" 9A,<D.>X+$W+[=-?(F*$T%2IAWM=^3:=[]B1] #);2__ *//\HKJ
M"[&7D6*8=II"=4VW*DYME;)L(T=QQ*G7$UE2S8MR%)02/1T3&0H@DK"CU#73
M>,<-EAY:%*+[ &VE@P8&[L7%XOHPN>JY</J"P%Q?3?1]#KKK'=KDH_Z.+HCH
MAD5%J!S%YH=<<LI9D2R@8Q&K%5&GT>5%>](09T!Z0],O%(=2@EF<X[");0L1
MQMQS&)\6U%:E<F1+1+07 F!2L^4@@6<@&Y?TYQM:?#)4K*I145@!QW<K[[&W
M*XCZ5:^OB0(46%!9:B0X<=J+#BQFT-1XL9A :98CM(2E#;3;:$H0A*0$I2 D
M;;<<>H*4HK6M2B3FNVKOY_>-F& 8  <O?NP>,T-(  (!^<^_B8194$A2ATC8
M *.QW*4@=SL/=Y]M]SV/EVX@@\VYZ7^L(UEM=5-%!E6=Q81*RKAM*>DSIS[4
M:(PT$A1=6\XI"2G;=(2"5E>Z0DGI"@#!B7ZQ! +6N-_?^HCS.RW+=8B:G3E,
M_%\&<<<C7&H\UM<2PLH^Y0]%PJ"^T)"/''W--[,;9#22I<%E#G2\J;6<.Q?W
M[_:+B%!!)*$J<$7=M -CMN-_(0^.&X708511:+'H:(<*,E?61U.ORI+BNN1,
MFR'BM^7+D.$N//R%K=6M2BI6YXDDDN8M)2$A@&#D_4O"O0CH&VY/??<^??X_
M'B(JBOA"#A"++C(<4%%6Q *?($%)W)!W]Q(0?_[=O)2@:2DD@YB.@\_?D/-$
M?\]TLM(MM/S?3<P&[NRBKCYCB-IVQC4"O4VXVXS8QTI4W"NE-*4Q%N662Z4[
M1Y0>8/0+B592"-4EP06/2(4,R2G1]XY]Y3RAZ7ZO6U@=/K63I'J"V5.W6FN2
MQ5.1([^Y)54E+K8?A+)"6':Y]40(V!CLK"DCHZ+B.;(EB1/EIFI!LLDA0#,0
MVANQM?>,"90H5F92BE3NBS Z.#KI;<C6^D1KS'D%YD*>+/:IJJGMW%-2&X<Z
MGLVWUMK(*&GE0Y:8@2M)/7T>*OI._MD;GC:3^(:6II)DA'_IUS$Y.U2/YH!#
M'*#F3SU )<L+F+V!R9>%XI35\Y'ZR32SDSDTTTO*4I))9924J((U+L UX9#&
M>0C7[',:D8U.TGOKEZV5)?R*:MRH7ZYFS.D3)#Z%6)("E*)9]HEMML $ G?3
MT<G!I5#-I9B^V5-+S9\P#M9BBY!4PR.D$@,!U/+T+B#XB8OB7$.'XW3)-!_#
MERU4=)2K6*:1+E97DA*E%?9S,HSN7_M:PA9:4?)[<S556)QR7CP3 B3Y"::1
MD-A"C*BT3BD*A5CTAEV>[)]!1ULEUY)=#090%J2A(3FX=B&&X73FGE3%S4.%
M#,$NG*]@P 93[/'/\:XU.XSQ&?BU1(E4554)EB8*8*((EIRI;.Y!^91!)NLW
MUB;&F/R:TL38TW5',6%1$%MR50XTT^IZ4I#O6J.]:OE/W!24MH_J[;"D]"5M
MD+2D\*SB92R332V"TY5!>;NY7RLQ!/S*)!<.VT<?*PX%05-65E( !M?6YMM9
MAK<W:XZG8#@6+:;XY Q7#ZJ-44]<PAMJ-&3TA:]O:?D*)*WY3NW4_)=4MUY7
M=Q:B-^.6G3IE1,,R874HD_4O:-K+EIEC*FPA:_IV_5_J#Q8()9B1[\8KC'4V
ME/<D[%6Y.V_T#;W[^_B0&W)\??TY7YPC&==;1UE72VA&ZE+4H)2A"=MRHDE*
M0!NI2BI(2!U$; \3"&&R'5J;D%C*P[1R QEF1MN^AV>2OK4C"\/6HJ0](GV*
M.GUM/CI/]6JJM;BGY!0A^3&2"%"'U^P_U$#NV&GW>Q?WNT+'3;3B!A;%C)ER
MWL@S'('3-R[+[ !=C?34I;;;2D$=$&GAMI3&JJ>(EF!7QV@RPQN'%J1,.FAD
M-K*PHDJ 2K<#N!W'EMML2H_0=O(#A"+JO(_0?X<(1%FH_L!I3^=6J_S>RX0B
M42/,_1_J.$(K4D*24GR/90V!!3O[22#[E#=)]^Q[=^$(;'4;3.KSF#"DB;,H
M<KH'A-Q7,:M0;NJ&>5#J4AWL)=?*!\*RJI0=@SXV[+[#@"0(()! +'G$@@$.
M'&XCDGSN\@_+WSH1H&.\TN-#3?66OABFPOF)PF.B-!R*)#6KT2):/K1Z,V1X
MRPY19$A^-%>=<743D..)"-MAF+U.&$!![1!8%*B;; AC;PT>[.S8=33RYP)(
M*7>Z0'<:"[6L;_2/GNUD_P"C3\W6)R79NC&H.F>KN/\ 0X_$<ESI6(WCL=1Z
MF&D,.,VL69(4WV+S4F.R3OT]]AQW-)QE1K2E%7**'<*(!*1IS+MS+1J%X:M
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M0-M_,[^\\:F,L #32 G8$_ $\(F+/CIV[=SW'8^1'F#N$G]7GPA"&S?4K%<
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MV:7:I+$5+2@EV$HMV2%.1)+0"5MJ&Q "M@0#QKZZCPB;+I5)F&5.I2DRS*2
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M *M@1][N1[QW&]4(0UIK]I-5*\)W,JN9()*&XM67[22\Y_L-,P67BM7<#;J
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M82;.SAN4%47:^K6AM:)\I":13C<4(DPEN/\ 0IA*);2DNK!WXK.(UB;!2R
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M0PTTX[9QH;*R9$9Q@J;=6D.#;?N-[<N?C2BH*(4P<:!F-QM<[/RZB"I2&!L
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M L.\P#DDERF]]CSV$2Q#W<GZ_AG;<\F#AWQ3F](MIS&198\C&G])'%N0W55
M;.2MM-^C(??:CHDN639\1( 62=ALE.^W&6F?+9U$)S).XU8-J?,[A][0=3@
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MEIL27T'LVC(*7L%$E_[!H7LQ('FP#0]JEZ=9'2X0])72&#=7>09!(H;*>B)
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MF+EK:D]&&G6_UO$N6-W!<,0S/<'F=B 'M&0QCU])$U<>FLU)KE/-S5"JDJ1
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MP,2DL0>3_;VT<*<B1TW]RDJ&XLYN_P 1O(</?;?;Z-^//ZMQ-6#W7)U?1[L
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ML5A+@EP-;L=0.7@'^@\(\E.P))[ ?[)/;W^8'&#F0 0.1YZL6V<Q"4D*!*G
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M)]_1M\R-O\>H_P .$(JV'P'ZAPA!L/@/U#A"*>D_[G_D/_KX0@Z3_N?^0_\
MJX0BOB"^S>9;]C"#B80<(0<(0<(0<(0<(0<(1X-^^^WS;?#Y^(#N79MF=_.$
M>\3"/-A\!^H<(124GW=&WSHW_P >H?PXB_(?4_B$5 ;#W?H&P_5N?X\3"/>$
M4E()<CU,4](WZ@!U?'Y]MN!?;7K%0#6@]KW])'O\_P#7BGO?]?6$5<50@X0B
ME8*DD#S(]_"$>[$)V&VX';?RW^?W[<(1;"^C=*AW"5+)3N$[#8;;J/WQW^CM
MWX0AK-+R#9:M;>[52>#V([_8;A/EN!OY[;C<;[C?<'B!OX_L(1@Q<!RBCFW)
MQ[.TU\&XR/(+\0I>,1;(PY-_-7<S&FI!LXJUM"6^X4]2$GON0#ON:VOG_M_>
MC0]W_P -;EZDQLO4&I'Y28?[$Q?KS@QYGT_$2XY#U_,'J#4C\I,/]B8OUYP8
M\SZ?B#CD/7\P>H-2/RDP_P!B8OUYP8\SZ?B#CD/7\P>H-2/RDP_V)B_7G!CS
M/I^(..0]?S!Z@U(_*3#_ &)B_7G!CS/I^(..0]?S!Z@U(_*3#_8F+]><&/,^
MGX@XY#U_,'J#4C\I,/\ 8F+]><&/,^GX@XY#U_,'J#4C\I,/]B8OUYP8\SZ?
MB#CD/7\P>H-2/RDP_P!B8OUYP8\SZ?B#CD/7\P>H-2/RDP_V)B_7G!CS/I^(
M..0]?S!Z@U(_*3#_ &)B_7G!CS/I^(..0]?S!Z@U(_*3#_8F+]><&/,^GX@X
MY#U_,'J#4C\I,/\ 8F+]><&/,^GX@XY#U_,'J#4C\I,/]B8OUYP8\SZ?B#CD
M/7\P>H-2/RDP_P!B8OUYP8\SZ?B#CD/7\P>H-2/RDP_V)B_7G!CS/I^(..0]
M?S!Z@U(_*3#_ &)B_7G!CS/I^(..0]?S!Z@U(_*3#_8F+]><&/,^GX@XY#U_
M,'J#4C\I,/\ 8F+]><&/,^GX@XY#U_,'J#4C\I,/]B8OUYP8\SZ?B#CD/7\P
M>H-2/RDP_P!B8OUYP8\SZ?B#CD/7\P>H-2/RDP_V)B_7G!CS/I^(..0]?S!Z
M@U(_*3#_ &)B_7G!CS/I^(..0]?S!Z@U(_*3#_8F+]><&/,^GX@XY#U_,'J#
M4C\I,/\ 8F+]><&/,^GX@XY#U_,'J#4C\I,/]B8OUYP8\SZ?B#CD/7\P>H-2
M/RDP_P!B8OUYP8\SZ?B#CD/7\P>H-2/RDP_V)B_7G!CS/I^(..0]?S!Z@U(_
M*3#_ &)B_7G!CS/I^(..0]?S!Z@U(_*3#_8F+]><&/,^GX@XY#U_,'J#4C\I
M,/\ 8F+]><&/,^GX@XY#U_,'V.ZC. I5J1"(V)/_ &)C ^SW]DB]!2KW!7?;
M?R/!NI]/Q GD +];CEK&I5IB^WAN.8W$R5UBPQJZAY)'O5U;3ZI$N+,=E^$Y
M ,MM*&G%OJ!Z91Z0!V5Y"??OV8C\^G*S1M!C>HR-B=2814LE:2G"(J.E(W 1
ML+TA6P5]\=NXWVW/$-U/I^&AOH&;2_U=_P 15Z@U(_*3#_8F+]><&/,^GXB7
M'(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'
MK^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ_F
M#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@]0
M:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8/4&I'
MY28?[$Q?KS@QYGT_$''(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F
M'^Q,7Z\X,>9]/Q!QR'K^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@]0:D?E)A_L
M3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8/4&I'Y28?[$Q?
MKS@QYGT_$''(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X
M,>9]/Q!QR'K^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@]0:D?E)A_L3%^O.#'F
M?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8/4&I'Y28?[$Q?KS@QYGT_
M$''(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!Q
MR'K^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@]0:D?E)A_L3%^O.#'F?3\0<<AZ
M_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8/4&I'Y28?[$Q?KS@QYGT_$''(>OY@
M]0:D?E)A_L3%^O.#'F?3\0<<AZ_F#U!J1^4F'^Q,7Z\X,>9]/Q!QR'K^8I&-
M:D.. _;+@))!"5?8+%*TD=R23?[*![;)Z1TD;[GR!NI]/Q!^@]?S&]P/$GL3
MAW?I=PY>3\BR"1D=A.<AMP4^ER*VKK%-,QFWY"6VDM532TCQ2>IQ8VV )F(C
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g118907g79s09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g79s09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1584&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3R^5#8X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5X            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              V0   DT
M         0                         !              )-    V0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    V0
M  !29VAT;&]N9P   DT    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    '
M.$))300,      JE     0   *     [   !X   ;J    J) !@  ?_8_^T
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M05%A<2(3!3*!D12AL4(CP5+1\#,D8N$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1EAD96=H>)6CI*:VPL-#1U5C9H.$AK?_Q  = 0$  04! 0$
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M#T#6K5&MSF*9)B)-A<WYWF1<=5/##?Z??R*<1HM0"8$3; 04I4%D/+05!:7
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M3+ZK"YK2 ;-U/'*&@Z1/:.*\NRMF;U-I5SC6XA]!E4-H9*E6DXOAQSES7AY
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MKE9?N"WC"89J4N\J+84*+.$]I$MFOQ9%=;5%:92)SL="68AVIR4+] H5Z=(
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M:N7,NF3GWE LU>+6[JBH3 T4\^&^+0"_(C-N2=F.&LC7G%A,Z'AIXCE/VIG
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M5K6JE6KE:AW'=5 J=U+N9JY'(#]-=%5H%V2Z1/JE!095.E-PXZ9U$@R(DYM
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M7:J*:;W@I2=K:UWI!T4E: "5D+(;"U[))).H"BO80$K^XZ".,\YT]VHOU09
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M*@D%&J0HE("1IM$J!UT._$@ S<-[<WA /BI53';4E22 H*U*]4C4J(4-O5*
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MMB4,=O51"DME6UN"?>[:]M6@4VH;SL\^N@0@#30ZP9X"W:WS'P"D$Q]RJ_\
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M>.B%$_0-X(H%ME@.O54C7<ZV/EV^4@@CS:[B-/.3NQ=:*9XNT-K<1&OO5+C
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M#&*;:!:UKH ,/%1M61)X%LR(/%;*]+NZ]+T?[2V1A,":E6GM ?PSJA8:C 2
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M[H&]6I3&U*B0LJPG;VW&[+VM4P%(M>QK9S5<Q?) @$M<P<@1D!O.EEM;=/\
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M PDAU-K^C,R[_JR ^VI:6B18KYVU-SJ."V;4QK>E=49N^=K!KW4S3-<-+LA
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M(7?+8MBVMEO:M(LFS*4Q1+:H++K-+I<8JXB(B3)?FOH;*B5;*Y,EYT DZ%9
MT&[&,X<4\,P86B(%$ "!87F\6GN7SMI[2Q6VL2=H8^HZIBZSG/Q#C;.XD1,0
M3$$7D_G>&[4:C=KJ4@D C30CIT/E]NHU!OAQF3^75/#D%X V.)[^W2(C54
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MZ8TONY4;2WCV=2+\TXX GBT.<)XF_JVX<;775V^E3"MW*VT6%]]D56@ "/\
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M1H!>+1:57BTCFU _K^?%?JYB[*)=!/6183PTZK^"@DG7\N*; \_]?FQ)(,0
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M](_581N^V/2OMN^KJQ[F JY+MW(OH=:Z;D/R:(X4GY]KYM/+C77^BQ'6*/\
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MP$IT3M;D ;5&#:S[P]'H:+C6I8S;@6CA)DZ1*Y<QKJ;S5Z1SFTSZ7:H<^):
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M;E;"/M;+HCLBB+^.GBN-S 3I1KIW\U3I(^F\,WS_ /3]OFW^_<<_Q_$CG2^
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M1LH2-P20II2".8Z(XLZ)W@$@#Q=V*+F9^KE><'*(:3';:X,_$CO6G=N
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M^2?1_P ?KLLJV*VW&S&S8CQVT,LL-V"PRRTD(:898IE=0A#+:0$H2AH):;0
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M4]2U7[4K<BNRG;8M&J1[WH4RO3GPS*CTV*Q)J<.,),U#<4/R$)UVE;1SO9V
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MZ&[1(V$&WG[90?'"# $=9CX\("W/Z1G!N_$5H#!LS'5!Q]332-9DG4<SK/H
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MZZ#&[=J8IF PE.O4S96X<@AHDYLKH %A![9(O<S/&@HNQ..Q%%OWNG+B9(;
M>>8/6!S(BP 7Z*V3]@S,M,J\N+ D2XU2DV58]LVI)FL-J88FOT*CQ:<Y,:;<
M4XM"'W(Y=0VM9*$J *BH:XT#B:@KUZ]6\5*CWB;&'.D QU+.:5/HFL8V0P-
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M>5=:[YZY<MM7W5+:]WX](:FTN/28$Z(ERD-2VHSD=3SB%LE8F.)>T\792D)
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M/#R3H^OP^:>#_,+\+]:_)ZD?ML,P]@>'DG1]?A\T\'^87X7ZU^3U(_;89A[
M\/).CZ_#YIX/\POPOUK\GJ1^VPS#V!X>2='U^'S3P?YA?A?K7Y/4C]MAF'L#
MP\DZ/K\/FG@_S"_"_6OR>I'[;#,/8'AY)T?7X?-/!_F%^%^M?D]2/VV&8>P/
M#R3H^OP^:>#_ #"_"_6OR>I'[;#,/8'AY)T?7X?-/!_F%^%^M?D]2/VV&8>P
M/#R3H^OP^:>#_,+\+]:_)ZD?ML,P]@>'DG1]?A\T\'^87X7ZU^3U(_;89A[
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D:[\2BER(R8\6-'40I3$=EDJ',2TVE!(W#<2G4;AN\@P1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g118907g80a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g80a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '["^@1(X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0%>            *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !3    :X          0                         !
M          &N   !3                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !3     !29VAT;&]N9P   :X    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4P
M    4F=H=&QO;F<   &N     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !4W     0   *    !\   !X
MZ(   !4; !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M224I0LJKM;LL:'MD':X2)!WM_P US5-))36;T[ :P5MQZVL!D-#0 #L-$_\
M;+O3_J*5>#A5V"VNBMEC0&M<UH!  V-:-O\ )]J.DA0[)XI=S]J&S#Q;7%]M
M+'N, ES0=&ESF_YOJ6?YZA7TWI]6ST\>MIK.YA#1(/[TJRDE0[*XI;65)))(
MH?_1Z?J&2RCZYXM=E^V^T5A]50O:#3NO;C'(VYE>/?\ IG^EO^QW_3_T=5GH
M$ZI3E'ZW8XQZK;X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MI/G8DVSMFV%P3A2^,V2D/+7- 6-;P7.^B[?334E7D>"B13G9@L )' B*P.1
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M-V2#Y:#Z]F19AE9]Y6C;$ZL[=$CH=O/78NZ-;<<K*R4.S9&)<(,GY&3Y)S\
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MT!,JD   Z#7@@?J!,F@_5L: JT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M[;+U,@K(6.V-YXAO+&"Q!6CKCL&:LP/6$HG!-] +P[=8=AH3IF,FL!M#VJ%
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M H!0"@% 0R<[_P"$\Z-_\X?*C_3_ #% 3'G\%*H)A*!/(CW]A?*:8@!Q$#
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M C]:F+;5WU!K50% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ;!33-^<F0?
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MQRSQ.\H<T<@<C<H.0#^RFV-+:O?(1VHFM&PV;=NU1C8QJU;MR%>*)-4 4<G
MQB%*IZ8 9581 [5&=+BT;DXRYXXP\@LP9(SO;.9[YD+W;S]W/4!N"PG*H&^R
MVUHN4DBIM4X97O.R Q3" J*$,82G'8'@.&.BXM;67\)Y'Y%<KLP<GK9XTJ^K
M@;'M]J1R4%:3A(H(QKI^#5FBM(N(QH5)$@"H)% 3(0W<0OD-.^I.XU(( IW@
M'<)P,80V "(D* ]OD1[-%#MV(B ]WTU0$./.X.WJ>='  \;R'RHW_P#U_F/K
M[T!,B*::A0342*H0X=ABF*!BB04B@8IBCLHE,!C 8!#0@(AH=U%DVG;6-[/F
MK[V]0>6N,%84$!,;$>-C"8#]QALFW!$>[O..S#'".S&,)A-[B([W43U<F]7*
M+N]+R<=5?K:[_4EMNR;;LK+TVMYZ<B-O*/3OXQ\N)3D%CZ_K&CH!"!R-;+ZV
MYZS&3&WYFWW;FP8@%Q8J,VZ:)V[DP][EFJF=!8Y2G$G=L1WV!S_'91[B6%K<
M"="*X).3BWQ.7$M='>^J=^MRTZ5*7XJ<';FU=VVMZ:'HO!GI7<:N"LQ.75CM
MM.W3?4TP-&JWC>3E%Y*LHPYP%5E%HMDTFD>DXT .544RJN"AVG$2EU4YQXHS
M'.H1IXFJG3@U+@C>TG;X7.[;:6Z6R;TL5*G".L8I<KI;^N_75<B3@@![]H (
M^/'W>_\ C7/P;=V_K;?_ $5&^JP* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M_:JP5* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MF4*K3D^%2UZ>KLO/[(EX;J*+=Y3'*H(% 2'*8-"(#H1(8FP$OTWW ;Q\R9/
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MRR4!4H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M][ U(81\#Y$-^0#0"&_%2IINR^O??D#?50% * 4 H!0"@% * 4 H!0"@% *
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MJ2:FH\+2BWS;6ZE9K5.3OR:+.#G6E?C2:=US:OIJGKSU:]?)F=>@!BF IMZ
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M &:9CY\23L6SY),SXY)"UK=?$-)E LD8CR%8N2&D *!2_'&(J47?: %!P*@
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M&:A>*>MMK<2]-U;;:YZ)[*_%&!\(>.<BS_,<.ZV$PN,C*NDK\$9QE%S?PO\
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M3#K>BZ ?Q\F$I0  \CLV_P * T!4!$0U] ,  ("([]@^[8ZV  )OKY#QL#>
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MS*H[[P$0+H"B'RB(:'ZEU]0UH0-L!'8UQU-WA'K;^?U+KW_F_P!SEU60* 4
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M?38_\WC7W %6XII)-IV5GYOZ=M@K54!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0&TP; / #H=^?:H=^5OG_  #:)!, E'0![_+X\_2BXN=OE?\
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MT.Q_K\?KU4-VY-^BN0FGIL^C_B]_57-HN4RAL>X $1#8@&MA^("(!X\^=
M.]5*U5^7/R]>A4TTTN;5U;6_H;/C$0#N$1 H" "8>TH!L=;V8P; !]Q+O7ZA
MU2IQE>SV=M;6OY.^I#LE=M+UTM\W9???8WHN$UP*9,1$#!L-"4P![^!$AC%
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MHE$0(:N=OS]3WHX  _\ [A\JO?8 (EX^32@AO6M]A#" "(;UH/(@ GI]ON[
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M_P C^]0#M_D?WJ =O\C^]0#M_D?WJ =O\C^]0%!PGWIB7M[>X=";8FT&AWX
M?80\#]V]AYU0$./1I*53#O)PFBB0.:F?RZULH:FV6BB(#LQ@#P?N$!]MCL*A
MKBNI:WMOK;T;_P!]=+(F+<'Q1?"[\M_V[V)45<;V*:9&X0M.W!G.\5"RIX=B
M:0*KL.U4'8H"OZH:\+=_J%#0 .JPO^-P7O?>^XA[R]^+AC=7W>V[[MI;:2S[
M._[9X2.98I8=I+W*KS4&E:R<+\-KZ].:5]3N:21B")>TH?*!2&'6] (]O@?
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M Z79E@6382,DPLBUX6UF4O-2%Q2S6"8H1R#^=EC K(RSM%N0A%7SXY .Y<'
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M"@% * 4!3.<G:;8AK6O/L._;0CH!WOZ#0%I7,GE-:'#7 MTYPN^WYV\RQ#R
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M>+7F2Y##C6^[;<93B8-E<TG824BD>YF-OR(&%C,.8PNUDH]UV']%R8 3-VB
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M;_QUPXN9VU_)&Q[)QA<KJ3QA:/Y-'* MKU<0)6\F#IUJ-G%7DDV(4DHJ\=%
MDAQ_BS"_6UM#&'*NV$KYXB\X^-&0H*ULF71;\0Z@[HB9JV'C5W=EGNEW+8&L
M]&/$G;DT0J^^)=1HKBTD"';BNBL!*_F;IN<<\YYZPCR:O" E6V:,'NFSB+O*
MW9-6W9*[4VB1"MFEY*QGH#,M4%@.L5NN)DS&.9,0]+M*4"0! BA0 3Z =" E
M !T([#0AO8@&O&M^_P!: Y% * 4 H!0%$ZB8D'YR@ AX$1\>_P#T'\!U0'CN
M=,J&PKB/(.52VC<M]IV);,K<JEI6>V*^N6=+$ME')X^):G$ .X422$2@3O./
MN!##L! PZBX\Y.=72R\D]0_CCR<NL^<,#<@F5WXJX<7 [9-[9LNW,12\)=U@
M0;^W3HAVWB]DXP\F1V^#[,DYA%=LH1-<YCHAZ\NO+R)"K)L##W7*QW8>?X=O
M>_#OG_Q&R/:EJ9'N^VHAS!W/:EQ0[]G)79:GQ3AN9&?M^69EEGUN-GJCB0MR
M5,5"1(+%P^+) 2X9KZ;O'+/>:L#<A[]@I,N9<"2\7+0U_P!N2)[=F[J+$HK"
MUB[Q<Q8-U9N,"05"1,U7-V]Z9F@#\"Z<-SB+?ITY=_L7_E+V!V:V0I2E#ZF'
M7^/_ '^-"2I0"@% 8D/7R^-#J,])HK#""/))V93-/H8,/]G@ADHY3V4*UOJ?
M;1@BR@9 QG*8/1 I?@0V83CH0/%<5),K1ZP7#>],I\,_W,2*?6A=UK61;L8Q
MBG$?GJ])1*6:DA9F5M1Z:%:D:%E4O33=-S.5G";(AO3^);*4'77RM];Z]W/*
M,N 8<N_LG,FP I<:X[+HP"8OG(TR(=Q3:$WYI@*<-$*<"B41$-4!><MP$XAW
M1T(;-S&XPQ8-KY=A>+<)DB,R]!Q#"$OEE><<0J[>;-<38B;E=VL?::HN3* Y
M[@ P; - 33])/)]Z9?Z<?$W(60W+^1NR6Q>U;R\E(F,=[($A9.1A6+QR)A%1
M4ZL;'M %503**&VH<1$=B!&(?EUU&N866N>,UQFO;#N/N.?#BYKLQ3^UW>UB
M-I^X<SW):L9,!=B;VY._[4M<BKN)?HQCF+<-4?1<1:AD_6(\,L[Z LNX4<U\
MV8 Z5G2[X\\7F5JAR1YJYFS7CFP+HOAE]J6I8,+;F6)Q[>-T/X\YRIR"[(ER
MPBS!@N5=-SWO^X@G*D!(Z^H[[[_B2/"?-/G#QVYO&X%<UI?'6?[KR)@B?S?@
MK(V-;39V&ZEW4$>X47=CS< Q*C'-U';ZVY-C'OA0]50S<BYEO3=H$3GOO[]!
M\N_X([<"=7KF5D3,5L,,E<I\#86NY]EH]OW-Q'S5A-QC_P"S[13FUHY,D#E8
MS TI(RBS$$%VRJ[]L15PY23%8Z13@8"0.^^2%UVGU7^7%M0%MXY;KV%P$MG)
MT%>K6S8-S>J\P$+)OF[5_>/PXR<O;:*R*9F<0Z74:IIB/83L.(4!8DWZD'5C
MCN 6$.I-<>2L%CBY]>ME6C=^)6F+X[[?O:+NF_4K+"Y%[@* ?8:RSE^D1..A
M 9)H),/5+M98QJ D,Y%\R^96:N>.-^#?".\[ PNNWX]1G(W*V2\AV:TOA4D'
M<"ADX.V(J$DS*MM@<$47ZP(@X TB8Z:I"MS@('MW2DY;\H>1V1N>N-N4+JR5
M[DXO9NM'%,,E8<,G%P8%_)B14G)!LJ8RC]TVG'\:E,M$I%=9>-(\.Q*8 3,%
M!R^OIR[?R)E: 4 H!0"@% * 4 H#:8Y2ZV/N( 'Z1]OU4!TZ_<A6=C"S+GR%
M?D\QMFSK-AW\_<L[)J@@QB8F,0.Y>O'2H^")(HIF./U'P !L: L3Y-=2C >#
M>&$1S3MY\?*UEWPC;+/#<%;2WI2&2[OO1ZE'6Q;<:*A!!J_%\+@)4CDH#'-X
MZ6!<H*M3 4.^_IW<@VRIER7ZD>4[FZ>O4>X80/'[(TQCU?*%C9XQO=#.YG^#
M2I(/BP,ADB>4 IX%"3=+DA?L5\\(U?#*A'?#B=\W4H"[[@98')2]('+_ $R^
MH]@P,OX\Q-:J<=CCDDZ8(.(2_<?2Z(,;>;-I9P15RC=#-LV!9I+,'"3YL+=%
M%\/K(%[P[[^Q.5AC#%BX$QS:V*L9QCF*LZS8XD7"L7DB\E7*3<GYPK2,BNN\
M75.;RH8ZHAOP4"@ % #UI(AB".P]P#V$- /U#[Q$?<3#O>OZP*U * 4 H#03
M 7R/MO7Z/T_AXH"@HH0Q0*!OF,(:*/@VM_C[>X:W0&*!+\E>J;S+SAS'N7AO
MG''N. X:Y+>65;G%N:M]%W/95CH9-T#R9FW;E1+?VPHU,C%F4!) H.D$2F$Y
MR"($H/2VZFL/SPMJ]<9Y4L\<1\L<++&ALTX@E2*-G)CMETV#BZ(1B\(FY/".
M7O\ PSML(*FCUCH@8PMG38Q@[_8^YDWI46#*<S<-\T,!7Y/<=;QM.XTGF9[7
MQ\FFPM#-]JH1#QBWBYF!1]&);2JY3I1#N3!H/J03IYV"E((-EC@2E0EMP]OF
M=##Q$5%!(.5W\D,9'LV R$DX$!7D'H-$4OB7BX%(55RN*BZO87U%#=I: [!0
M"@% * 4!H(@4!$=^/N\C0%%0Q3IF* Z$P:T.P'R.AW]WUV/N'N'F@,4";Y0]
M4+F[R&Y?DX;9MQ[B,G#F]SVM;O&NY+?1=W!E1G'**"YE9YRZ.B )O_2%!B*G
MIH)KG(F!Q$X; DSZ7/4_8\Y(R[,-YFM(F(>76'Q<Q.6L3RA%&@O_ (!8(]]<
M4 Q>$(NI$K*J)?$-B@K\*=0 $QFIDS4!V?-'2CL:[N7F%.8V"L@S_&S(-BW9
M#2&5(O'29&-M9EM.*362/"7' ("C$&D7K-9Q"N9-1J<YXE^Z, E?)HKT!*5$
M6S!P"[]>%@8>(4EY \K+J14>S8'DY-1/TE))^=JBD=Z^42,":SMT*KE0J1"F
M.(:H#L5 * 4 H!0$6G/?I:8[YZY$P?E*Y\J9+Q3>V V5U-+(G\;O&C.00-=:
ML6J]=&7<@)TG*81)4B*H_-V.CAO1* \NP=T5<(XNS?8G('(V8<Y<B[_Q<NN[
MQU^VY=QY.#M5^NF9(LBUAD@^%4>MR&,=!<>TX+BDH<3@W1  .W7)TA<(W/<O
M/>YGUYWPF[Z@4!!V]D]%([ $;=;0<VYGFZUL[#N354<N3D5*XV42^2ZV- 6T
M6K^Q],&1T/;-CWSR0Y.9(Q);!6*#3$LK?0Q%FKL(TX';13IK%B4Z\4&@(=B?
MN2.3N*<!V @!.K9UDVYCVU;?LBRX5A;UJVI#,8* A8U$C9C'1<<@1NT9M4"
M!2$322*!C&V90PF.<QCF,(@149)Z.6(;TSIE/,5GYBS;AJ#SX)%<\8IQI<J,
M1963GAD1;/GTB4R9G44M*MQU*FC!35=JJ.%?6*9P>@-JG1=XUGX=X?X@?;E]
MMX[C]>4UD/#&6H>53ALFV'=TU<4M<3UU&RK4 +\"Y<294G#$1!%X1FS%U_\
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M?H#F*F4PB4HB!MCK?@)!]5(ABB(F -Z  $H[  #Z (_,/GYA$0#R/B@*U *
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MFX!DFH[[[T\P92R"9D];#QV:$3"!C_\ +VE$0'M+V_/LI $OYNC:#5 <B@%
M* 4 H!0"@*:I1.F8I?<P:]Q#?GR&P$!+L/'<&Q+[@!M=H@0&<JNB[9$KD_*_
M)O G(C/_ !</D.&E)3/V,\!1YY=KF%JV9KKR3*#@VLI&'BK@G$O6;)*IM)LJ
M3ERI\(S22753H"RCIMX>/E_J(8KY \?.(F:.(_'CCCQ[G</7E.9B@U+6G,OW
M.X4,PB4"QP@0DP^9@"[^4DU#J& [LZKA%!4I$Q RQ")*"8!/HO:8#%[1[MZ'
M\TQ@[#>W_*(&*'U,</% <J@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@-! !$!$/(;U^&_ T!K0"@% * 4 H!0"@% ;%"E,40,
M " " AOZ" ^!#[A#Z"'F@-I2%!4Y@#0F -B'UUK6P]AU[ (^P"(!H!&@*M *
M 4 H!0"@% * 4!H( (" @ @/N AL!_2 T!QTTR?*.A$0.80$QCF'8?F_G&'P
I7_E#V+_R@% <F@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g118907g81d11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g81d11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 &4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '^J^@7 X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !,    ;L          0                         !
M          &[   !,                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !,     !29VAT;&]N9P   ;L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   3
M    4F=H=&QO;F<   &[     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !5Q     0   *    !N   !X
MSD   !55 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M7+;\G&]"AK69#@RYQ!<[Z%%L;V[/YIV393[_ ,^I;B2-']Y8)P_S8OS/Y/\
M_]'JW7,_YY5U?8,*AI>[]>:RN[)ML%+7,:]]3F7]/_1.M9OR*K=]='I_]J%U
M2X6JS$'^,%UOK-WF]U 8QM5;]_V?=LNJHR*\S*KV_0S<S&O]_P"BKK93^LKI
M_K!B9F7@"C"?;5>^VH>K19Z3F,<\,R+MTMW^C0^VYM7^$M96DI)US_DK(^#?
M^J:O,\[_ ,7[_P#TY5_EJ78OJZVRCJYRB_T'Y#7TOR=2:R]^ZC&JHR;JZZJJ
M_LWH7N]%]WZ3[3B;UQV=_P"+ZS_TY5_EJ4V#]/\ NE1Z>;T/U$UZI0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-CETL\,8)"4F)R@T4J6FT? 956;A0U978F>"A96CM_%%1D=35&62HJ3"_\0
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M,92\7'--:5%0;JTQWNJZ]1 ["_>Y<.=.(0X0W,("(%$=C;%'8-Q$0\4 #?D
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M<@V]ROT!;/;A1B(Y.<=MQ(DF*+F6*V!^ND8C=N!DU7!TS W0 Q1*BF!2+L8
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M*(E$2B)1$HB416UVL",>,]7^HC+$.)R2N%5=/%Z"X02$[DD4+16-G&Y5"['
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M'=JCSWV33 1V$-Q!,@"([\]Q'K68X=[&G6 =Z[ ;FI:&1B#%B$8%[B-XDD?
MA?%A'=7QA*($ 2\PX0'Q@ XB.X &W%N40W';<-]ZG7FK,RQ-)6K6Z\@)6'H2
MU9:2[_P+C]QJ+Q_:$C<CMHODO']NY^N!JYR+ 7G;1REEYRY8%=F*$>[(S<$2
M5$#"JL(\R*Z[THX)8:9=.N(\#1LLO/-L8V=&6N,TY*!%91=F01=/13 I 2*N
MX44.FD!2]VF)2[ (;41>\N7:;4JBBYDTD4R <ZRJA4TR%#UYCG.(% I0W,(B
M(   (B-$6R;S3!XR1D63QD]8+IG61?-'2"[)5$@B!UTW::AFQD2"4X&."HE
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M]4V2;#PK+7YI*U ::H"[,?-9^XKSALE/FUR+W#"Q<>)TH2W&,6Z45;3HO$U
M'PH$TS )2"8! 0'[72$^UF<Z2F;VAU1"=FT.)!(O &H'J4 YITCBI44UC^&M
M.SQU39%OS!UOW[JPS]IMG[QR0RMVY+0A<;2#:W5+=A9F,3<! W#'R;LBBT\B
MZ6(14S4#I#L) ,)M@H^0GF,+C*1PT-SLYT-P%--X%+KZZN6D&O:XD5 IK/5C
MCN:E5/2<=Z!3$ #$. F(<H[D.781W*(;[[[<AZ& 0$.5?&"[-)<*$5NWE,M<
M#;^YOOL'G -MQ_.-&DD5.OZ(OU4R)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1%%.X](>,+IO#,=YRP2JTCF^UH2TKO0\,#P/U-@&G@<>>.1%,0:K
MI)@!^\#<>] %.O2C1[#DX[[0>\'^<H<.''&:"*0S7CK?6OQ60+,V1[?LF2R?
MDI)T.&,FYR/.R$4%V>(DQG;8TZ&@Y[B2V\DFJZS;FAG#]JPV&8.'";19X0N)
M[<]J ,@(J+RD@10CM254X \,!7O3B;B !W\OEKS@Y/R4"%)PH8HR1BNBP0&C
MPG"E^\*T(UD87+[)O95RFGIC**9F(D.)%RDDH<C.N<7$M@PP ,ROA&@'A7;Z
M]-R[IRLC-%PXRN2Z5I4CW%5SDNRVPCGG@R(RJ9.[ 'I (;PA#A  $@B'+I7U
MS-ERLV9=T9N<Z6C&/#<1>''170-ZERH.3F6=JY,RELRDAF;7;<H9.:+J@B&:
MWBF)O-QH%M&&F''C;-4YG=Z61F+TF[:2M0I)9PF]BHF)2<@Y D0Q42$K-0YA
M6*<Y3#Q$76*(;'&I663+B==//I%B.9F-#V-(8* 5:<:T%+]!7L_+NW?]FH&2
MT&.9:SH$ZZ?_ ).XPXD2,]@8=L+:9V =4DG. T7+9W=I5QQ=F7[$S69-]#WG
M84?*1+%S"+DCV\I$RS=1JXCYE!)/A>MB).'?<$.&R9GBYB^,8HEA,6/)S$ZR
M?+ R8;"$'/:UM3#!)S2<2.^.]HHO22R^MN3R?G<FWN;-V=.339TLF71(FTS3
M YHC0@XD!]'"_6*KEM.VFZQ]-%B+X]L%654@EKAD;BXIAUX>[![)$;)K%[X2
MD-W)?!$3)D'<2^,41'B&HV394&R)9TK >Y['1'Q*O !!>2<T4P K=?5?%E?E
M?:66<_*VC:C8;8TI(0;.A;474," Z(YA>30N<=L(<3C3=*]X.P1.(',!14 !
M #B0HB&X[B',-MAY@8-O&#KT#:IT!%#WPJ3> :5T88?0*U<Y]" XM!(/>DMP
MPK3&G:^]>#1>FRQ8C.%V9\:*2?V9WC;T3;4HD=V(Q0,(=N1LU.W9\ @DX$A
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MCRLLP-'VB!$;$#L[-!.<YMY.@FE*KC":!L-EAVD,1Q<H-&F>$]0R9@E3@O\
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MO7'S(<<5* !A\1@\$0,'(P"T6W*/G >0CL/(0Y@(5"'4QH(AN +8K"ZZXC.
M K4 XFNBZNH*!P(I6ZZ_G_CQA8H7/I)Q>[\B,H6++*+2-X7@@X%1Z1L* &F7
MY2JB=7?O=_&+P!ML !XP5L];,O/PK,D7P):7B'[)  :&MJ06!P<2&F^_&Z[5
M<51FQRV(65[TW5._>0+\>+>6ZTW)S3>_,7,9J-+&JQU\6:S2,F\1<]^D2:8E
M[P.YX13-S';8!*&^QCB.X#\VU3,>Q9K[=)0H1AR9+"W'.  )O8VE!6['#?4S
M7_K32\$BE^ QNIIX]&\LKS" 4(V/V'<? &?D#<-FR6W38-MAV+L ;  ]=]ZU
MOBD;=& ]6(X?$D*KM-0#N+EMN8#Y@$ #;SB B/Z KS H***^U%$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB;!YNG3W*(E$7P V\WR!M1%]ZT1?
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MFG9HXN&'F\76@UB9%J^7B[CN-M*(I 8RC55U?$U*L4^ 2E!'O8]\T=(E,4%
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MN_ <Q@4$2$[!02L/L9.SWQMFB/SG:N#TVUR0-U.[\M.T75UW2]Q79U\O%4G
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M+2;_ *4U8J#Z.<TT%0<3B:5-;J:OSHLI%ID+OISP(/+9/#F-=_=_Q-AAY?\
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M _?>)]]&/[4C50BD"2FB<,Q_6I#XUGLE7$&L/V4K<^)G"?\ \NH&N5VRF?\
MQE;/"Q!QWFG("5V;[E$4V)+"WXQ__-'45B]4_2'S#6-9;"7X1G36R!\5']AW
MRRKSSLZ_:7X#^"AOI=]6U^1/HW97 1?FKBKL]?>UEA[_ "__ &Z54VE/6&]%
M74,'>WUA8B6,;U_>W>U3_'CD+Z?>5M7DSYDE?=X?1:K<C^/;OE1,9?Z<T'S.
MD.?F^Z)[?IZ>6JO-U^SN&G:7CX'L5$D M)P#A592'3&.^G7 ?C![#>-A'W0&
MSH?;KY__ *<JU,M+RZ=SO^)C5QTQ'77<F[QJOPR"QI H,T4"]S!9,3B3< -M
MN'G, =1#R^3Y=J^.X4&%U>+M?7=40:DBO%JX^U"A^ ^X[[F ! -O/Y _/Y/3
M13+2()R& H\N(0W ?=';?_GS418Y?M@_YQ34M\,W7S#6RV1/HW*>[RO2<K?M
M'QW+S-5,\>IO0;YBU<[\'^P>9RAZC=\?N+)UZ%O:<::_BALOZ+0K53*#SQ:/
M#.YVJM2WB6;PY@I7FZ+^DGSU35[K7)ZPOXI?F"B+]41*(E$2B)1$HB41*(E$
M2B)1$HB41;%<P"<Q!'< X!$AN$0, @<H&$=_%3 1 P_^$V(8VP !1$BL \>N
MNRI!_E-;6=G;7:34:YS)E-6_Y_%3;*\?8=VG-><N,//0;.W['DT2HNX@&)W
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M5LOD,7.R8LLOO<8;JG$USCCJW-P@4HN4_=$T_P!ZV48:QL,;=#HUES1^K8:
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M-:\FX9AT'0'5P4I-&M!QJ+O_ &_0K)UZ%^6CC37O_P"2&R_HM ?)[G.M5LH
M?TS: TF.X<8S2?@JW+M(A-!%" *X;@YU+$2&$%=@]>)1+S#F #N/EY?+M5,7
MLM8H"!2@/4"@ ^D HB^T16FG:F]M5JLTU9OS+IIP5;V.+=DK9&'3MS(\U%.)
MZ=8+2+9I+/%EXN86D[7?$[M19DBF[@%P(50%@*54A5 R-8.0K;6LUDXV,]IB
M@9@SKBX@$BAOJW DFE-)H%\3YES'$&E 3>,2,!3'CJ, J7>#_P"$"=IO95VJ
MR^8+MQAF&V#1CALE:S^P+8MALC(''9O(IOK)@+6E>-L4.13/C("8VYFY^6U1
M@;&+FQ8ICQWL;04.<'4&Z ]_?&E]VNA%05()UAKFN!IB*'Z-(IVPOO9]&N:;
M@U&:9,-YON:,C8B<R-9R-PR,;$BN,>R77?/&XMFBKQ9TZ$A :E,(J&$1$VW$
M//?&EI2[9*>F)0$_J8KH0J:DYIN-:>L*''Z+[VN#FM<-(%=_3H&//6Y2F(("
M4.8CL&PB/7<.0[^[7Q5%0->'$HK]5%%I"LD41 3@ EVW#8>6_0>G01W* ]!.
M D 1. E B^F62*(@8Y0$NPF#?F7BW$-P#F'(!'GT !$>0;T1"JD/MPFW$=AV
MV$#;"&X")1 ! -O*( %$7[ 0$-PZ>@0_0/.B+[1$HB410WUKL=8C_&$2EHEG
M\8VWE9.\XIQ-2&6(XDE;9K#3BYT)=%! Q3%"5]6C6ZLS6,&R:"3T#B4#!N3M
MV[:5:3Y^U7]I*QU-VWC.TH;1'J[U2D=M$W26)<'V[>TG8^ZQR)/[JO<[(\7"
M]P8IC* X?'.T*)@.HFN44:(KS33@IF)7!.*U=03>":9K4LZ(/DMK;!$4[?;W
M69'>20BB-TTFY6B1Q!-,$$DT@$I@(4 ZD7ME$2B)1$HB414LNSJEHN"[.Z E
MYJ09Q,5'1&473^2D7"3-BR;)34X*B[ITN8B*"1 ]<=0Y2ARW'F%3PP3&@ ?^
MM#Z04OJG]KG*QYV1):,=9 O=9M(,UTG5Z7&HW43<)'37(\F7ZS4R1@,)5._2
M,55("B83D$#@ E'>MK;/=F65)ZRUAIIIF-U$:,-Q4":OC$B\$B\:@*GF%5SV
M$YF);9AQ>Z<2+)%LA?=M.%G"KI$J*2#6;: Y644$_"FF@/\ 'G,(%3 -U!*
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MW.&,<N=0\3;T3FDUK19<BQ]GNSN[9"YBH$"14B5E"$.*"BH&4(D %3)Q"0@
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M3O2=IX!S;%O.04P584*H56'9&XXE>(8R"\>8%$#;QR[OB>*L5.(GA9S*"47
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M[2KN7LOK/M9UHWQ6NO;<(LLX-*).%%8QFH8Z=K9&GY:V$U3]S]U) 2)U7<&
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M9(O;.S+N:X[PTB8\G[IF9&X)AW(W81W*S#M=Z^5(SNR7:-R*+.5%%C;((I)
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M8NFXSIF,^-%:'1'G.<6BZI.<3<:5J2=_&^I7[/V?$?ON&K36V8 W Q39IAC
M8#>N "EL(!\8-@,(* &P  !N.XPH<X$&E+QACVW/BI+J :KJ7G7S5NXZ[L()
M#^#F]G],/WLK(RVHQS(2+IP_>N5\JL#K.'SQ8[ETX6.:SQ 5%UU#J'$NP<0C
ML'FKT#*>V):&(,*.6PVB@[TDT%P(O [:UY&$PXM!U5 --ZY1_P!2G8$Z'\,X
M)RME6QYC/K*\,?V5,W5;3QYDQ@Z:M9F'0\,8+KHIV@0ZJ::Z93'(18@G . I
M1,(5ZNRHME['PWS3BR(TM<!4$UTX\Z\HLHR*P!I#'->'5%&U NH;@"+\,5(B
MP>QGTX9LQ]CK+.2,IZHYV^,@8XL&YKFE3Y6CTQ>2\G:$,LX.5/[#SF213#NV
M[9%10ZB#=%-(X 8IM\>3F3%F3\S'FIR'MT6.X.+B22#?6EUPO%U;M!IADZQ]
ME/+7)^1@V59-K19.2@"C(4)[F@:3@0*DU)-!>3Q]F5[!71WP[EOK5 ._BB7[
M;C'GN("!3%"RS!P[CZ_D!>'F/.OE_P!C+$H,V7H1?7"I&%].U!2MP55=LX[)
M.:Z&^WIB+#(IFO?$=2ND4?JQIIH2;KI)VKV9]H67;\3:ML:H-:$);T!'M8N'
MBF&9H=)HQ8LTRHH-4B'L8XBFD4H 4P=0'EN ;A<DO 9*2S9>$"&L;FXDXW77
M"X5K@;\5C&U9^;MBT)BTIZ*8LQ-.:^(=9:"*FM34ZR:T  T%<XKV>D6L0Z:V
MK'6THFH04U$QS5$\*B9P$ITS"6Q2!PF*80, [\N@==_49X:W-.:6N!T7TW-&
MB^@.*^1P8Y]:4[T"M_74FFYRXJ#;O^#C]G[)O7K]]+:B5W;]RJ\=NU<IQYEW
M3I=0RJZRPC92>ZJBAS'.;<0,(B/E&KBA946S #&0YDAK&YH%#0 "ZM"/@1NK
MQ,&&<6[VYVW:KIU]_P 'FT&6'95V7M;DSJ#:7#:5M3MQP+H<G1YBMIB#C'4E
M&.#%"SQ$12>M4% $.?B^6I7936O%A1(428)9%J'M(-X.J^E.)1;!A")#?FT+
M'9P+;B#Q8T7W3GV0^G[4W@;#^?,OY4U-S^3,J8ZM2[KSF4LIQ[8DA-OXAL59
M5-$+-.9%,B2:2)4E"E-P$)_JC5B3N3=DVA,.F9J7$6*XU+G7[_;5Q+)5D;*F
M6U@2S9*R+8CRTJQM&PP]S6@77 9VOFKB37V8_8):.-OY>:H3!L.X&RVR, AT
MV$I;* QN?, V'SB(;;U\<7)*Q"QPAR@8[-Q:TBI!!I7=W":@:*W50[-^R0ZK
M7V]&+7=Z[OGFK2+P>_%U3774:E)BW.S8M2T8&'MFW-46M2'@("-8P\1&,\SQ
M!6S"/8-D6S5NV3&Q3&(DFDB0H$-ZT" 7R" 7% @MEH$O A-HR$UK0 #4 "G?
M5%WP.&ZL8SL],6A-34[./,:8F8CHL1YQ+B2:XFIXS6^_2N:_Z/B/$/%U:ZVP
M-S]?FF% NX["'(; -R';8>0;;[[AT'Z*]]G"XBF &B@P-= IO$A?$:N<'DFY
MM*5.Y>0:WW<1^$(IG^#L:";EF)2>GIO4=(S$T_<2DI(.<J,3N'S]VH99RZ<F
M"S4TSJJK&,H(D(&QC"/+>JU RDMB58(4&8<(;11HH30#"^M;M2E="8X@D5-^
M('PN/QTUW5U^9_@Y/9\Q41)R3*0U!D=Q\>\>MC?;1C]DW#5LHNB<X%L\1,4B
MB93&*',P!M7H_*BV7-(=,.<' @BAK>#?X5!U?!2&!#)%0<0<=1KN<ERZEIA[
M(S3]J2P1C_+.5\HZF9N])E*YH1V^;Y38M&Y(RR+XN:R;<9M6PV:)TB,K?MZ/
M;FXB;&,F90!$358MI9/V9;$<S,[!,2*XDEQ%":FI%#3'=)Y:K(MB;)F6&3DO
M"D[$M:-)RT$$,AL>YK;P033. !OT7XUJ:D^]!V"6CCRW[JAZ\@^VXQV$ VVW
MVLD#<@$>H[#T'<-Z^1V2-A4:UDF&N!!#VB\9I!O-*#. (QTXE5U^SELE1&EL
M2WH[A[3JD5OQ??IKAN :)%VAV9-E6';\1:5GZG-9\!;4&V\$BXB-S-$H,F27
M&=90$B*V.8_W1=941WWWXA$ Y;U7I25AR4$0(-0P:*[F&]]=TUQG:]J3EMVC
M$M.T(FVS4<ET9YQ>:4&=C4T %:X@4T!=C-V?$<81_P [;6]ML&P?;IB-MPV$
M=]K" =N70-]PW#;8=J^AP)%&FAUZKQSWJFD%T1SKP*4 K=0[^/+=JIA"ZZ_X
M//H6OFYYR[;ON/4C/W)<LF\FIR9?Y5CUG4G*OE1<.WSE4+)(45555#B(#S$1
M$>H56X.4EKRL.'"@S#@U@  ;47"@OH:4^EV 4KX3'FI;N8UQW]>G1O+@P_@W
MO9XI#WA)#4.)BB!PWR?'APB4=P, C9H &P^[T]%>\;*RVXC0'3!( -0T$:*7
MT<:G=^JE,"'H%-6Y_#=7D^EKLH<%:F[!F;VRYE/4S-W#:F3\CXFAG2&4635-
MG9.-;D=6W9\64AK1^Z> 1*"*0J@404V,8NX@-6):E@6=;$Q]KGH(BQW$.SB!
M4$DG"ATWG43N+(V3NR;EEDO9\2S;(M2)*RS@>]8YU;QH(- :UX[]P265[!/1
MV(#_ (^:G#<A 2_;98B4=QVY@6S>(0V'8>'F(;^Y7PNR1L-[',^QMSLTYKW"
M\'01WMQ&[S*KP]FS9%A,S&V],DN=4ESWD@G"ISJ7;U-!!"D#9?9?V!CBVX^S
M[$U*:S;8MJ),N#"'BLR1:+)IX4]7?NS)%4L@YS>$.G2R@B <S&,8>HU7965A
M2,NR7EV9K(8S6@"O;#EQ6.;8M6T+>GHEH6I,&8F8C@][W&I>:^L<:T)%YJ-9
M%R[@;L^8X2\M6NMX!Y#RS1#_ */\0^+?Y=P'S#T^AX+F@7@U%]+]=^X-["XJ
MG.[^FC-O%#J-=-<<*#0HA9![ '13E6\9B_<AWAJ6NV[Y]P+R9N&6RPQ6DG[H
MP;&564&Q@*<3%$0'A-U$0#;G59EK>M62EVP)>.6L;3O6U%:8:;Z4%*@W7$Z5
M(Z&UY%1S?'\UTT/X-WV> ")@D-0VXAT-D^/V 0Y[[_8:&W3?KS]-?5$RKMN)
M#S73+J8$"M:$4_K'DI=O*7:(=:YHY!3DIVPP7E&F#LF\$:B;$N:;RCD[4I*/
M,?92R!B*U!0RBQ01CK&L.4)%VO%%3^Q$3G,@W64V4X>$3#RV  WL:T;%DK5F
MC-3L/;WNQ,49SN4U-=1J:4%^K(63VR3E9DK*F0L"U)BSI2+7;X4%[F-B&OK9
MKA=AK/$%)0G8+:.C"(#?>J(H;!L(Y:8=1]-F>3RC^<*^*'DG8D*)M@D8,0G'
M;&AP!TW'JUXBEU>&SALD-?G&WYESX9HQ[GO<:;ASP#\!6]>^6)V7&/\ &=M,
M[2L/4EK*M>VV!G)V4/%YFBB,TCNUUG2YN!6P>,HG=.#*";R^,8>?(:_*0(-G
M2PEY6"QK *4#;ZU)N-2&W75 WM:L*V\IK8RBGYFT[:C-G)Z9-8D9UY.DT=4F
M^^^O+?7NX]GS&[FVU:ZW>7+<<T0NQMO*'^(8;^YR$?T[>KFW=[WIT4H--2,-
M/.J!2HS221UZ]]1#R-V!>C/,%Y2V0LFWGJ=O&\YT4S2]P3.6(I:2>BBF"* +
MJA9'"<$TBE( %'D ; &WBU5Y;*&UI*39+2\9P8"#0 YX-#IK2["E!J*@8,/4
M-PCKJ;N,$'7I73 _@W/9X>O]4-0H>42CE"/'GY]OL.W$?0 >@.@?:[*RW(D/
M-=,D"E*4(/+G=M&@KS$"&#4 UOTZ]6KBO7/Z0M#,84^=,6Q.IK5S;=BX,S!)
M8SQS;]OY<C6+6%M!G$1DHU;'%:RG *K)/)%VL!@+N8#@7;8H!5"F(IF'ESZ%
MSKWD#PG&]Q..)UT.A>PP&@"ZE?SYKN6^:@=GU'B&_P#=;ZW>?/EFN#$/D'[
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MB?7>6R[Q?G3%LLK9^;\,39NZF[)NEL?P=9RV25(5VYM^26(<[!X<0.D4026
MYA345(JE9!$2$$>0B4HCZ=@WZ 4.OF*'H#I1%] Q1Z" \]N0AU\WI]SK1$XB
M[<7$'".P@;<-A =MAWZ<]PV\^X;411AN[5YIGLG-$)IXNW,=E0>:KF!LK!XX
MD'ZJ5P2:;YHX?L#-VXHJM1\+;I++$$RZ2IB@00*'$4!(M._M8.F;%F6+9P;?
M^:++M7+=YECQMFPI225"XY8DJJ=..!JU217('A2Q#@@54Z1SI<(E#@$!HBD^
MD.Z91VVW >7(/*/D 3;;]>OIV'D!%J41*(E$2B)1$HB41*(E$2B)1$HBVS@N
MXEY"(" AL &W,(] W ?)U#IL//>B*@GK&[.?4+C_ %(FU^=FQ<,-;.>)?NF^
M8L*72X*QQAG&+ I472THF)0;LIT[9)-$'0(BHJH0BZ!T7A2. (O3NRYTG:A,
M697U<:I]1%BV1A6[]5EQ6)(!@_&DHM+VI;*EGP;EG(7,^<J',!YNYY%\X<.B
M$(!DA5<&4.J*XF BK1)  $Y"/"8>(@#U H@&P#N #[O/F&^WDHBU:(O"-1FH
M7%FEW%MQYDS)/DMRR+:;I%<NBHJ.W\C(.SJ)L(2'8(AW[^7DEB@BP:)<1US\
M90*  (T10RTG]JOI/U?WK(XAMI_=F.LM-FWA26+\QVJ[L2YYV)5**A7L#'S)
M2!,-E$!!0R2 <8D-]S*H4#& B]4UD/+]L'%D9)Z==->--0N5;:E47ULXON1Y
M"P"3"(?KF87'<$.@= %#.$VSQP@(M ;D44<B"ZIN(Q#$4;NR>T?Y:T\L]36:
M,XVW;&.<CZM,N(9.?8<L=PF[M3&<9'Q[UC'1;=VB!4UI60"2<O)L2$(0KLA0
M* B)C"15?4P$NY1$! -MM@V\IMP'ST1:E$6T=G$H$ "B;BX]PV$0$  !X-P$
M-C&ZE 0\;A$NY1$!HB@_I2[0+3;K$N7*ME8DNPRE[8<O"7M*\+/GFWJ3<*!H
MQVHR&::1ZQS*N(ARLF<J+M+C*4P<*H%W 1(H#=JIV52NIZ[K%U4:>KIA<6ZO
ML8R4&M:S^;7;IVID\MO/0?P=K7:U7.DBY63=D*:.<F(X.B("F=%4@\($6EHU
MTLZVL@:W(W7'K<L?#N'+MQ_AM_B&"M3"\FXER9">RINZDKNO%\IP[)-T165B
MXP2"FW6$HMQ22(5.B:?R[?DJ\:0&V#B'F!1W+MS 3&$1Y]!#B W#Y@HBUJ(E
M$6FJ B7D&X[[AR$>F_,-A ?TT147^U2[.-IJ6L(F6L"XMQBZU96%>UDWW!7%
M<4)'MW-\L;*E$))6RIN8%,JJK22;I&:$[X3B!CAQ&-L&Q%Y=H8TL:ILC:WG.
MOW5'A>P]*\M;N(!Q%;V(\;OD7H7B[<@[1D;HNU1(1*1LT1>G"&;&%17O4T51
M4 J1BF(J^M$2B+35V[LV^^W(1V';8 , []!Z;;[>7IY:(J#7;L7]JLQ9C72Y
M?>E&_GMF7>UU$Q5ONV0KI(6[=+ZXHAZ6VH2YDU"BFXCWSIB_8H(*;)"X> 8_
M,I1HBIF7?E.QNT>R;B:Z,03L]I'[:?":,K$25E/(F20@;E<60F*TQ;][/TT"
ML5[6FB%4&(?O"G3305(S4%5OPT15%-%&E36Y?6O-GKEUBXWQ7@BY;-Q ]Q,\
MA<33;B8'-DR\2<LCWC=(F.4C5G'HG,[BT3D, +'*5(J*1$TR.W;MJ4,0.+MH
M5P1112B+3.8!(;8Q0W*.P\6P!N4=AW 0V#D([@(<@$0'E1%01[334/J"2U8Z
M6]'.)=0#;2?:^=+2NZZ2YS&(:2+F=OJ"=^#P6-V3UXHFPC2ODR&>.C)J$<.0
M,5N83BL@!2*EUD.$SSJ0SC;>B_6S,M,*]HKB4[B[]$VL^S6?J1!9D;LU3NV=
MN3167<,W/JHD107;-)P79;O 41%8%#'(IR8$TA=HSG36MIDU"ZT[#Q)C"1TD
MQ%P0DEE3&<V=]=6H(CU 6C%M,,$A2;LHE4O"X> 4O 1118I$P$YC"17*=$2B
M+YQ%#J8 ZCU#H4=C#\@B #YA'8:(K<S67G76#F#M&)[1%@O4LRTA?8AA"#RK
MBQXYMQH_4SW=\B0%Y6'<R4BHF12'A%C%8+QK$XF6$KAP9/=%:B*FI;$?JAU"
MZJYN;A%XG3%VS&G"/;H73 +B,5B36%BV&!-(DP\:;%9%7=,3I@JL@9PAW IJ
MIID'@ I,>U%6"[/'2AJQ2U?9LURZI\>X]P+=>3<=6OC97$V*)I26A+GE+>76
M6DK^N1PJ(F+(R)SD%J@/'L!$CBH %X:(J[A?6AUZ!U#8>GE#R#[E$4=-5][W
M'C33+J+R-:3I-C=-@X3RG>MKNU6Z;I)O/VO9$_+Q;DR"A127*@]9('.DL IJ
M '".^]$X]?;C5K>OV@?:=V'HIT*=HS>>?+"GK3S5F['V)[KPBRQE",V<O:MR
MR5V,'ET/;A#B<HW#(HV1(K*(,4V[:*]5F:;$A!CEC+NW:J=M6FNBG\.-1Z[8
M"VYA3M/<S:B;:(X3NK2QA'2MG^.5;'4(X&)C[HMV$N-B8$A 1:NH^=%)V4.(
M3-D5!.'"(B!%YMD>YVFKCM%<>Z[VC\LM:[O6_A[3]C=\@8PQZT'95D0<B_=Q
MH"(E!)5X]6;KF)N!G"9S&-Q".Y%?T%#8H!T_1UYT1?JB)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(J?7::Z0)'6[I0O+#-N3GV-WTRD8;(.-YE0W"R:W]9
MYW;JWBR("4Y3LUE5UD5"B42D44154 2$$*(K6'5#J5QKG3!SI#4S%OM(?:TZ
M*1CTL;S;.&=Q2V:7UN+M8]JTMM1-)%2X&UQD3,H,>EX0LU$PJ-A,@H8 (KGC
M33I^991G].NN_*!;\@M0SW3? VC<MHJ7!(-[.3<3T4R=23]Y;!N%J24.85'&
MW=@9)5P4Y@[QL6B*I,D&V_(0\4@;#RZ;CN'GZ["/E$-^5$6K1$HBV,@0YT!*
M0YDSB \)P ! H^0P\7(1*;8P%'UQ2F+Y=P(K9:_.Q/R7IWMT=3>C7*KT=;]C
M9#O[([N:<HGCK>S9;5V3:\VMCVY8H%#MD3M&JAVD4H!%$S' I1$HB4PD50S#
ML,T[3C!.GK,6?L=9>P/D7#F3TKH?62$A+6@#B_+)75C) ITMDC3MGOG7>J-C
M*I]V?\ 1 FXD56!N42G. @(!MN!1 >0F,)C\QYFW'80$>8!L%$6[HB41*(E$
M2B)1$HB41?D^PE$! 1 0X1 .NQN7+\]$4!NTBTJW1K!TK7;B7'UP1]IY+93E
MJ7]C6XY,BAV$1?%ES2<I#N71TBF433$OA*1C%*8"]Z!C?<^(*(H+Z3^Q,Q[A
M?(^)]4.0\M9(N[5] 3\C>66<C1\T9M$Y$DK@9&3>VN]C#)\);78'4!%NGXJK
MI)N3C!,IMZ(J[9 '?F(@!> NPAXWB@&VX^7?R^0=]Z(MQ1%^3[\!^'UW";;K
MUV';ISZ^;G1%1Y[71#4[=UI::<(8#1OR/LK/6H. L#4->V,VZZMY6;BU9L=V
M^/'.T2<<*QD$$I)9Y-E,15@6-(0AP[[F14=[6T78ROS*O:$]G/G',-Z#A[2_
M'XMU Z?\Z7]<ZCV\\(3-]QCYZ\%*\951%RZC$0CFQI!LLN0C@PF61!(W=EJ
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8\Z(OU1$HB41*(E$2B)1$HB41*(E$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g118907g81f12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g81f12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '6R^=3(X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0%>            *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            T0   4<          0                         !
M          %'    T0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    T0    !29VAT;&]N9P   4<    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -$
M    4F=H=&QO;F<   %'     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !+T     0   *    !F   !X
MOT   !+8 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M" !F * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#JL_)R
M6YV0UMUC6BP@ /< /AJ@?:\O_3V_Y[O_ "2GU#_E#)_XQRKK,G(\4M3N5A2_
M:\O_ $]O_;CO_))?:\O_ $]O^>[_ ,DA)(<4NY5:7[7E_P"GM_SW?^22^UY?
M_<BW_MQW_DD))+B/<JM+]KR_]/;_ )[O_))?:\O_ +D6_P#;CO\ R2$K&,[#
M :,ALD/F8/T2-I:_;_VXQ$$DUQ5YE3#[7E_Z>W_MQW_DDOM67_I[?\]W_DE-
MCL0FD6B&^G%VP$'U"7-W_P KTF[+$.UU194UC1N:T>H\2)= W#:?Y0W)&ZOB
M_%7U7^U9?^GM_P"W'?\ DDOM>7_I[?\ MQW_ ))1H-0N8;M:@??,D1\D1K\1
MKAN:'5^FW37>'AH]37Z+O4LW?ZL2%G]*OJKZL?M67_I[?\]W_DDOM>7_ *>W
M_MQW_DDLDXYL!QA%>T3SS)\?Y&Q"0)(-<5_527[7E_\ <BW_ #W?^22^U9?_
M '(M_P"W'?\ DE"MAL>VMI +C W&!)\T3['D^[V:M['0G78=';?H_P M$<9V
MLJU6^UY?^GM_[<=_Y)+[7E_Z>W_MQW_DD[<3(=^9M/@2 9@V;=O]5J0Q,@B0
MS74%LC<"-WMV_O>QR7K_ *RM5OM67_I[?\]W_DD7$R<HY>.TWVD&U@(+W$$%
MPT/N55&P_P"FXW_'5_\ 5-2C(\0U.X4__]#INH?\H9/_ !A5=:N7T;/NR[K:
MPS98\N;+H,?YJ%^P>I_NU_Y__F*SIXLG%+TG<K:+GI+0_8/4OW:_\_\ \Q2_
M8/4OW:_\_P#\Q0]G)^X447/26A^P>I?NU_Y__F*7[!ZG^[7_ )__ )BE[.3]
MPJHN>BX]E#'$W5FS@M\H^EN'YVY6_P!@]3_=K_S_ /S%0NZ/F45NMO=354WZ
M3WV;6B=/<YS4ABR WP'[%44;;<$-:TT./&\SJ2 X';[_ &^XL0;75.<WTFE@
MV@.!,^[NY6G=(RVL]1[Z&L#MA<;(&Z?3V3M^GO\ 8I,Z)U"QC7L])[' .:YK
MY!!U#FG:B<>0_H?@FBTJRUKY=Q#@#X.+7!C_ .P_:Y';D8K#[*#L.TEIU]S'
M%[7RXN_,]CV?X1'_ &#U+]VO_/\ _,4 X%@<&F_&#B'$#UAQ6=ESOH_X)_LL
M2$,HV@?L5117OK>X.8(T.[M)+GN;_FUNKK0U?;T/J+FAS16YKA((?((/]E/^
MP>I_NU_Y_P#YB@<60F^ _8BBT 2#(T/]ZF,C(!!%KI B9[3NV_U=RN?L'J?[
MM?\ G_\ F*7[!ZE^[7_G_P#F*0Q91M&2J+2]:Z-N]T1M(G\V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" #5 4X# 1$  A$! Q$!_\0 '@ !   ' 0$!
M      $" P4&!P@$"0K_Q !E$   !@ #! $-"P8'# D!"0 ! @,$!08 !Q$(
M$B$Q$Q05%A@B05%689&5T=074E-78G&!DI2AU0DC,K'!TR0E)C,T-D(U-T14
M<G5V@K*TX?!#<X2%EK.UQ/%T)U5D98:3I-+B_\0 &P$! 0$! 0$! 0
M      $" P4$!P;_Q !1$0 ! @($" D(" 0#!P4!   ! !$"(0,Q05$$$F%Q
M@9'1\ 43%%*2H;'2X14B,E-48K+!!A87(W*4XO$',T*3-#7")$-C=(*$LT1D
M<X.B)?_:  P# 0 "$0,1 #\ _4AMH9W9J9=9J1T%3[C)P,4K5(QX9@T1CSH"
M[/)RK=57=<-%E0%1%%$0T$ ,4@F* %#A^!_Q$^DW#' _",-%@N$1T<) =B8;
M*A4&N)%3O-BO+X0PFEHHP((C,.P+3(F2Q#NSE[7G8.20VK]H30=,SIS0.?\
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M#70M,V#),$AIV+8B^0R2M=8R[2P&!V^RT;9EE0=,4B1Z+ [M1!2+4?E$2IO
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M!(ADA#>4$ $-"ZC<#^AM+%@E(8(\6D&*8!*LO)G>>MPMP8,#!2&+&$0AABA
M8N23+,P<2#N)+$U,F<P$7:#(8I,5%QD %8':0MFBD8D520))/AT!JNQ*H7J@
M#\$M>Y$1 <>33?1#A&"G$,1))$1 _J:$.217)W)(ED9<^3QD2A,P2'NAKJSY
MWTK(661-C)'HR\R[8,V9K;&511LD^04<NUW[=%V*K,.Z#51NH4R1##O*E/TA
M1 "Z8]'!OHAA$4!CCI!%!"1#% ""08@X-<KWKJ=7DU( (HI 1"$B1),0)< 6
M,!/6+J5SR3LD#*/E&#<35PMHE:TP>2#EHBY*ZCF#B5=I2:92[K(O4;!5=41
MHF1 @)\%=<<,)^B)HHHXR###!'BF*,>@7Q3C38>D.IKTCP:(&(PB+%QC"#$
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M.8O U!C%@]13Z95% #JE35/N@=8PJI%,B4 ,5%-5R.HE* ?TU/\ 1+#,$P+
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M/]G='CH.H^;_ .,'%XUHHE$XCW0  >0=1UQ44V")@B8(@B <Q /GX8(I#'(
M#J8 #37]( '3EKKJ'#7AJ'?X8(L:L%KK-8217L4S&PZ;D3 D>2>MVA1*D&^L
M<!753$2(D**BZA=2HI%,HJ)4RF-@BO[=5)PDFX153716*19%9,X*IJH*D Z2
MB*A3&*=-0A@,4P"(&*.H:@(#@B].")@B8(F"*!N0_,.,Q>B=[46$-0#L^GM
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MO:#Y./>QWQ! ,6UY_(7-74MP"9(J9K)FVJKKSJMB+:8(F")@B8(H&TW#ZFW
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ME??@]-[^H[$:#)K\4[OY7WX/3>_J.Q&@R:_%.[^5]^#TWOZCL1H,FOQ3C_:
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M'I>K#D-%SH^D=J.<FH;$]Q_+CQ-K_H]+U8<AHN='TCM1SDU#8GN/Y<>)M?\
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MZB"I4P1U$HX##<#G]Y"1:S#(*V KW97%-8LN(-]W[]:TOLX46G9-L\T2QSB
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M^8<2*HYCV(L'9_U]G_+6J]KZ3L6/,I/\;2?_  P=H5L&<_+:=961-?Z=)_\
M7M__ "F^/5-4.;YE9%<6?Y!7?$57SYV^MF/-[:NR@O>2U&S)KM2I69^7EBR_
MND788QV[Z)Q,/8QRPM,<^8IJJG=Q*#-RCUJ532;.CN"*"N7=, -]2*O);%=<
MO>50[.N;3"LW;)-7(BJY0K)'4D4;0Y?UU!DD,]T8M18QZG3,4GD<Y9OC/6RX
M!^B4N\)%Q9<OR7.>DILE0>Q?";146_R8;U.0I\T-OA7[RSD F;K"]5VU-IA
M72C^5B*>T5J*K%VHDV66,1[T^Z!A(2R<K\BZ<VG_ ,FOEKM)Y=9X4U]F%FO
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M;@HHR3M66]OF*59#1BZNAE8M27A71XXRI"N#M1246$1, !B.@H P%#16G^5
M*ZK/#L72 .[@&JP;[5N[<)[TOU0]6,<10>IHO[<&Q;87#4$W">]+]4/5C4-!
M13Q:"B/_ -,$7;"61H;AJ"CN%]X7ZI1_6&*:&C%>#T(SX/1#M@0PPW#L[$W2
M^\)]0OJQ.*H?4T']BB[BF)#=UG:FZ7WA/J%]6'%4/J:#^Q1=Q,2&[K.U-TOO
M"?4+ZL.*H?4T']BB[B8D-W6=J;I?>$^H7U8<50^IH/[%%W$Q(;NL[4W2^\)]
M0OJPXJA]30?V*+N)B0W=9VINE]X3ZA?5AQ5#ZF@_L47<3$ANZSM3=+[PGU"^
MK#BJ'U-!_8HNXF)#=UG:FZ7WA/J%]6'%4/J:#^Q1=Q,2&[K.U-TOO"?4+ZL.
M*H?4T']BB[B8D-W6=J;I?>$^H7U8<50^IH/[%%W$Q(;NL[4W2#S*0 \.X7]@
M8AHZ*R@H#DXFA'^A#"!5"YN?:I@33U#3=U[W<:<>\/T#C,5' 00*"AA)#8T-
M%1 C*"(00<H(.59(+'S ,KB2VKD80@6B[ !" '6:J]R!0  $'EE#D' - Y?3
MX<<J*A,.&#&!_P %1R(!GQE<WF;Z[+%D@,XMQ>R(:[U0S9 .RU0-.'6YEP[W
M$JXCYQY^''V4D,+^C#5<+SD6H ""X!G=F6L,1=$QK'CYT72.U$PQX^=%TCM4
M87#4%\:-JC;EVA,H]K^\9"9;,Z7-QT'LL2.>=.KDA0[3<;;<;^TEEHJ.R^:I
MU*?BW9V4VJ1'HED(YQ)1RRQ7+A5Y'$5:!UA,6+,FJ^(^+YM"XQ5FR>24ZM_%
M=DU7;-K#J4J>768%(S!JF=SK+/)K,;,>@Q=2>6)EENRS;%>)<O;#9HUPG#,*
MY2K+&RL;:9IPJVZT-(]>1.R,F;IU+C13:(W5FNYW%[9[4NDVO1ERFNX7KFC:
M1_*5U6'R71ONSC-Q,Y9PL&SI8$X^W0;M>.G\FL^KPE3H>ZQ"+5Y&/4D)-B22
MDH]N^6C)^'<L6:M@K+5G))*2!XGK.3SCUSU5AKK986ZP[RLNLM$]8Z<A]NG(
M.0L<?3W4W+,9UUF3F'E"X,]A5V\2PO65D G8;LV>235VJ5"*C8Y0SYI+""C!
MPD4J"CPYQW!@,5D19J\8E\K&6GJG*ODN-0 S2G5D&>_FR&_*.0EMVHJ+7:P_
M:([,-DV<,SLZ)*]V*K2L=*+CE[/DBC3-<<G>HK+U9VS*NL<SVOA)"N4@M$-Q
M5(JAXF]*)Y6SS7&5]:/.H9IMM&]BVEF+MIN;-EY*.]F2M2%TNZ:U8;=!*Q4F
MHM L+NP7D:?:!K\4QF>R*)EVS1;?25F:TI&%.FM-.XU44VBB8<F.)K/..<R#
M9:K+%<:J0&1@7[3/>N7:&65EG;C0*G:;-7PJTW/0S:3>P(.7#HS#JH#*-@4,
M[81CMNLX:"@[7CG;))U%++J1CDZZS0[A7G%%&"1C1=([5TA (!(#Y@LZQ,>/
MG1=([56%PU!,,>/G1=([487#4%'B)0T+J.\ :\3:#S#>(0Q5!+WM-0U\.G+0
MCBD,:(VSB/579-B[W7YB G4)282TDR=Y2F*S*JSJST<@H=)0LCTB9A*IT5?G
MUD]\!X[BB+!TF8O@W5A / 7ECYZ:G$$9!$<<@7KK#KB20;=!B&2J$-9GO5(;
M'&:AJG+B4 $PF"NV,O<@/= !QB$TTQ\ G5'>[P!SQS&$PVP1]GR.]DG.3%$)
MO$S%P\?42)9Y+1=MRRJN8#S->/S .-DHN:M6K]=7K)J):V;V," Z[@VE F3N
M53*.$33)W+5Y'HQKB/?-&CIHZ!8H:;.%PAF@CKF[FR=8)%SY:IJPSA,WKOSU
MD3.<-D=ESI:]D1W*Y:IY7UW."TLH^0V?\XMGJXSMIRUG+?;[+7\U')'2UF+*
M M%-6=K8R!CJSS]W%2+2?9/II4(Z!D#,)>.<L!JH:0UD2DXD]6:NX2DM5/5,
M,=!OV:YK(Y?9RFI:4S"DD\SB)EOF9&SEF(8JV3=O<"T-L^C1UT8U8[>=9'=H
M6AY1H<[YPB>+5BVKZ31;=,'4CQ ,+@-<%(^3&D"1:!8X%TJY2Q&[AC*4@_X7
MDQF=,S*;KMLEBCRD*50LKTA2E!3^35C#N]TN^.X$29-,HFU$A4] W-T3;QA$
MQL'"8;*./5/2Y[$$43>E$3^*.0-504_9'&#R),#_ )-9L8A]/\2FQ.40&N&D
M&@_(A"8[(HAIC/R0;'&!S)+A_E5FQAYOXF+^W#E$(JAC.@_,H#&*XHCIC'R5
M):P,E$SE;C)E7$AP2,>MV/=24,0Q"*[@PPE7T,8I3(&,D!RF$2*=*"91U#A,
M$W@I)W.+[BH8C*9$C_5$3D8$7BNSK'&M>RQVCH97,62>[344I,W&/ES1<FQV
M873<:U/.7!6T9-.DG-BE'-@CZ?!F=Q59@%'\;#C('2DIM"3(6<86#7*H&]"D
M<FIS;5I.1W)TJ8Q+^=*H5NV=C9*=LU2KV0-G+6J.-VS5):,P<J\Q%,P<M+1'
MY,2U>B820E*Y/UNWMIR&0DW4M='-U87.UK6J:>V])Q(SLNE()G2EF:C]1RJC
M$\2DGEBFWA9^ZCQ%A-K 22+ 9W/ETNN@<G*74<F*0A2H0\X\ \Q/V>;EG57G
MB.YVUV^8>V2T3[Q-*.43:NIN;DWDFJR;IHMFXN0(D7GIF+"83_1&3I,K*]WZ
MM@D. 8CF,8 -TGZUM,+)&:Z;DJ8.(B(5NR@( ''^S"F#C\H2A\_'1#2\890Q
M0M,N+-!WK<+<$1?^J^N(@9\89;-8DKL@X1=(D60!;HS\2BLV<-3B'E2<I(J%
M^82!RY8^D$P@,2'#R)?,6)!JSKL&)+V6-?;,.,S[54QHTD1 #Q BUS,:U!"
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M/0LD0FL/4SL[3<5'Y5NTUVP.@\C%$. ZZ% NA@W@W +J0"!KW(% H@&@'#?
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M7M+C5RRJTM"S 03:,J#^>=SBRR$E(+OQ"1AG#1!R<3_E$"HN)U@$W![M-2K
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MME5>6&:A30]M<6\\PHF#4[ADZ D#UE44W!%PH9-PBLF0 3*D4BBQ@U ,'?\
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M>SMF^\^I9-ET[?O6EB"0>.GIF=VM3% [I3>42:-I Y&C<@AI_!D$="(EX[H
M741$,,8\P]>Q%L;<+X/O'UX8QYAZ]B)N%\'WCZ\,8\P]>Q$W"^#[Q]>&,>8>
MO8B;A?!]X^O#&/,/7L12F* %,(!Q !'F.#DRQ2'D]VL#>J:+!D" :\393!J4
MM8K.A1#@ ]7V/C\_$0Q\<'^/(LY%!_Y2V5:/HY7!)TQ66+)FW%]) /+IT/O2
M;@./N,$,BTVO-A(%JP*SG^05TZ)/CW :".NG>U#EPY:=_3337CIKB8HRUO6:
M[ZZU5@L51(&!4D2PQ'4<QDG[B4>1C-T",6+YVITCE<K<Q1.ATQPWU$FQDD1,
M(Z$#>-KI%YT<O*RW,XZ%!8K9>1=R_4?3ZM4I%\AT#ATU3,43I+')R[O<(/$A
M2F$1P1>%'*JHMVJC1-NY*V5K)JDH07(B/6$5B+"U$1Y@*Q  3!^<'3@?0=<$
M6/0>6N]8<PW]J;IO8^;OL7;X1@JX26;*%AZG4H)LY>-^BW.G:R-?5D"%$-T%
M'")QU$O!OOO\DWJRN3IWK60+94U-Q$-()5L[591T1'P$6"[M8ZD/&Q;^.DX]
MJP5( "F1LZAXQ0JBAU%3@Q03655* E$BFC\L*U'N>JT"O0<=?W5GZ5=R<RAI
M5ZQZWN'*H F5, 42W@33*0$BZ[Q4P,.N"*V,LF:3'H*,V"+]BV5BF4.Y00?*
M 5XP8.A>,D7:)RB03(+#^953W%3%#<4.<H  $68S-1B;$>"4E$ECJUR4;2\2
M=-44Q1D&G]&<&$Q Z0R8^3HQ'>#='E@B]LM7XZ8=0SYYTI7-?>K2,>H10$S(
MKK,W+!54XF 1,0[9XND)=!#101  ,!3 16(<OZX!(71%4KNMS,M8H=^18 ?,
M92;&8":<)*&+NBF\).R15DCD,4R;D  @&21,F16]KE72XXT@+)BJ@,Q&P\7(
M DX-^?;1<S)3K0Q-\#""AI68E)!RIKTCA9Z?I#'#HR$(V3]_W62PU9BH-Q-O
MV(JD7L+I*1E5@6$Y5'B;!M&)KI 8@Z'*U:(%#@!=" 80$VHF(O RHE>CJHO2
MFZ"Q(%9%R@9!1RH*A$79S**E37*;I":G,)DPU'3]$P"7A@BLD?E=4&"@+(MW
M1E#OF\D=11T*N\]:->HRJF'< FXHS $50W>ZU "@ @.I%!KE;464:XBD"2"<
M4=V5XE&&DEUFC$XRB4MT;-,VHMVBK\B;I5(PF$HB*:(II")!(KBURWK*4NE/
M(HO"225CDK/U41WKNS$M$-H>2,<FX =&I'-$&8I"4P 5/>#=.;> EMA:K<J\
M6*LP=I;QB-@8-Y(L1,1EBCP4,.C6:BE.D9.4AT 0_.&4(H4PB04U52G 4Q$
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M@5W_ &R9K5FJ.8UQ-(FKCFL1[&?=$D'T"Y/+M5X>;C&3-NJ4Q7"0BZ9JKO7
M1A$WB+<XE2/( "B)#I"4?-F);)G9[6G8IFN:$RHO)-GD(P;.8NV9?5YPBG*]
M.!$;JA (O%1<(H&154A9.;<()B14Q7B3 RZ0IB!R$*G>W19KJR7X50;U/1M7
M&N0,:O9)UI,9N2:*<K(KI+.HR%SBN-?BHE%^_P"D+U89LR!J91XX(1DBW;J*
M@<%P-AIU^#J/96;AU-?-QJOEM>Y7&PU]]2(V'BHIR[MLHXBES2DFY:EC5TXI
M:2*H0&K!\#U,G1&24*"J0  DW3B(B %5KU#/20DH1Q)L:\R%Y$4UA<)I@X?J
M%*=-Z_7:&9QJ@HE%=5%%LJZ!44A24$2H!HJ ZD68Y=WV5LY+M*R8-0CH>=7:
M1*+9!5)VA&IQK60#JLBPE.LKT;C45$R:")1 $B"7B3/?9=?9J6F'%YF[!;&5
MH1;;\/*Y+7^88P"4Q+HIO 862 :LA>G9)@F@\4;&.H1TU*5XT!TJ@8V]N& .
MIMWNL4)9G G(NU6]VNU9Z]SJ0KJUE;RL8HP0JU0=VEBQ7ZOZX6V'BJFVG7;^
MKNG#8S.=5;/%G,1*,R.#R40LT:2$JBFUD$5"JFZM"M;U9L[V7*M.S=K<3>7?
M71)JP;#F7&DCG</+K+(SD.]RVM[]PE(M4@(JF5G-)K,?X4@9LNK&(R IMTE!
M*W(K8.>4D#"NRK:L+R<;<("5F8-&,%R[F6I8=:.Z5F^AQ1Z95R9C)%DBHMSG
M=G43.S(BHKU/TJO?]FS6)5N>O1677NBLY)*Q[[6HLXNQODF"DJL5)V,80&Y)
M=6+-&N$Y0K5Q&S")4%E7:#M,#-#E(14-3]P1[F-T\TQ+?LLJ%YD[A=\KY1J4
MT?"*6:Z0YFG7!R5VZZWU]82'?MBBE'J$Z<#C_27@E.D19NIN&P3>Z2ZD2$JG
M=@<3 8-0$IA$ARFTT.4P&, @8!U#0VG,=,$5<"E =0 -=-->_H'#SZ<->>G?
MP138(F")@B8(H&Y#\P_JQF+T3O:BPEJ !?I[3Q8KH_2,C81'[QQYE)_CZ3_X
M(>V':B]SN)?+KJ.VL_(QX*D 3H-F\6HF)@+P,)G3!=01#0  1,(AH&@Z  !]
M9AB)?'BMDY-><_O4731O*W0.P,K*-0,9X,B:85-(F3Z$S\T-6Q>F2 @)]$9T
M,/TXI]& )[@GW=P-W3=X88L7K*36-BLKCK&Q>1I26S YU&#TC)15N#50[2!J
M[8ZC4-[1L<R,(0QVX;QM$3"*?=&[GB.MY/%ZZ/KVJXPN^'NKSER_C2M%V!56
MI6+I(B#IF6MU,&CE!,3&(BNW""Z%9(ACG$B:A#$*)S"  )AU<1%ZZ/6=J8PN
M^'NKU'IB*@-RGD-\K1FI'-2G@JP8&T>L0$U6+<!A1!%FJF4"*-D]U$Y  IB"
M4 ##B(O74E35FJ[TJDQA=\/=7D2R]BT"MB(':(D9*M5V9$JU4DRM%F1=UDLV
M*2" $%6A>Y:J) 0[<O!(2!PQ>(B]=2:SWDQA=\/=7O2J0(2+F80E%$9=XBBV
M=RB4+6DY%TW;@0$$'+XD,5RNB@"9 1255,1,"$ A2[H:3B(O74FL]Y,87?#W
M44J0+2",LK***RC9(&[>24AJT>000 QS@BB\-#"X22 RBA@3(H4@&4.;=U,8
M1<GB]='U[4QA=\/=46E3%@FZ28RRK-)Z<ZKU-I#5MNF[45 2J*.B(PQ"N#J%
M$0.=4#F. B!A$!PXB+UU)K/>RG6F,+OA[JHHTM!NP6BF[\$(QP)Q<1J,%5TF
M"XJ:"H*S,D*5NJ)Q*7?$Z9M[0-[70,7B(O74FL]Y,87?#W5%2FI*FC3JR'2G
MAC@K#G4@ZP<T4H4@IE4C3&A1%B<J8BF!VHI& @B4!W>&'$1^NI-9[R8PN^'N
MJ0](:J 8%'A#@:0)+& \!5C :53W-R3-O0@ZR!.C)N/!_A)=PFB@;H:.(B]=
M2:SWDQA=\/=5 ^7\:J9F=15JH:.0,UCS'K=3.9BV.<%#MV8F@A%L@90 .9%
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MA[J=;9GQKE_LL)^%X<G/K8^O:F,+OA[JB6+F#F HVN7T'@.C6$U^^+'$-!$
M3QL>LVRO1P9,TC9#8'YH[5/%UQ5C)OI=Q-R4DZD6,<R/U4G'IE128*/ED^BZ
CE9(#W9GZF^!M2]P0=!-QQB&BA?'))B( QBSM6SW/9(+*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g118907g82g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g82g13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %:"^538X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5]0(0         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              C    ED
M         0                         !              )9    C
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    C
M  !29VAT;&]N9P   ED    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   (P     4F=H=&QO;F<   )9
M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%
M6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-
M3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N
M=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y
M<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T
M<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U
M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,      L*     0   *     E   !X   16    KN !@  ?_8_^T
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MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:S/612/%8K,'Y(2,=2?PQ78(O#M#.BMA1(J+1T"9C <R9@V7A.LU&KCO[6O
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MB.)B%.G^V76\8G6)*V99:HV7(#DSFVRJ1WDVH,B:67545!*8,Z9-S"<S-JF
MZX3K^%TMVZ..GR^-;D6Q4Z0^(OMW;Y&L,K"7*[U:=4M[*+-")S<38:[.Q<Q
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M7?-!5"+>5YS*N7:0HM5!YZ78V!V?BL+6.+J-IU&XJGNO<!(IC=<6Y^ZX%S7
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M]W(!!R4J\X]H=WS^@F$ U\QUL \!^GZ\AS@!ST1:AEP[@ IQU\S=PFT(E[A
M=?V92 70E,<_N/\ (8<'%EC!C3/RRYY> 4]<HO/7BLW>?NT(:'7G0CK0#L!
M/EL=!O8[#0:#DNL#>%"Y%[/R3.S0\&E'(N&DH@[<*R"LF=!5L#!5#XA(K(K%
MT5R?T'*1T]O&7?I3O 1#7+TVN?2?4TIN:UV>;B0)X9<R>2D\O+K\^9S79]Y=
MB'G8;\?/_P /YZ_/F,/:20.O+/HJ%=VE\CVAY]_ >=;'S_,1_J/+HK/23\?A
M#P)3!Y$0V7^'WW[;\?3Y<BQR/H?AU]45P%*7P4H  ;$-  :V(B/]YA'^8_7D
MH@I"%UVE*7M#M#0 &@\> U\O <(KN$1PB.$0(Z 1^@;X4$P"> E:AS&^1C
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MCIFH7F6IL"G1Q&(I/Q8-.C2PM2G4EL5&UGAM0EQ !+ '&!?W229@Q6K"DT.
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MWI)>J0-%4],G>!NTNK/I4ZD;]-CXRWF@QX2%2EB:]"U&M4IB0Z&/<T;S9W3
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M $Y8AJ]B+:(&F1T9(DD'<F5-F*Z,6C)/XE.'?OD(<J_W>FY>,4&Z#AR1 %E
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MHDWUY\/!8Q*4P@!4P\C^(!\]P^?R#?S]_K^@\J2YEP"X3(!.64W.D=6,S#7
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M=")62G4?2>'TW%CQDYI@CS6DU9L(],K9JV2;MBB($023*FF CL=%(710#Y:
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MWX\>X;_PX(!%QO#41,\O/)+Y [I-IRB=?)(O.8O;%D5+31WYZ;:502,NJQ2
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M$15?[3VV&0<7  Q CF OH#L 'Z@ \WUP,L\]57A%@%,JGJ$.F4R9RF*("4!
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M_H!Q_P!P<RK2R_*S\(K3@ E, ^0$H@(:WX$!^7S_ $X1-<ZO>G*%ZL>GK(N
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MX04$#)JH*D,8ATQ 0$IB&,4Q3 )1$IMA4@@P1?6>BB]CA$<(CA$<(CA$<(H
M_M<8JSPETKUX=':I4F7B*Q5V+9RQIB_WA9XQ7(;]V[25G<A5:5.$/'R+))^F
ME%J1[5O+-GBSY3L53;.NM/JD:P+?G/U(_BTT.(A41Q5C(AE&YS!1:D':T5:K
M(&*$''%-Z"S!W(L5"B?M!$6K]VU%$P^BZ<$,*PD7@ONHG"$8YNK.0RG36SC'
M*S)I>4U9ML16LN9&1"(:MI-,#B9-5S, :- Q"*&3?IGCS]CI,Y.$7/9OGXVQ
M85;S\*_1EH>8MV%9*+E&@F,B\8.\NX]4;N6YA#:B"B*O>*AB%WX'TQXZZS4$
MV.=N7QTMZ:IS!/X"?/\ "7S_ "#A2KN$1PB.$1PB.$6D8A2F'8^_<(@'U]O8
M?K]=?K\^4WP'AAU%C)Y=7GCJ%!XZMO\ "_KQXW41>5.G_(,-U\4?J!3RK]U8
MZ?O*['S5+;24TW[#-"J,FII!J@J6,5:OGKM IE'!#I-R *JPD(41YXO';/Q3
M.T5#'-K/91>0PTFU'BF8 ]IS00V#D+&XOFOT=L+MOL%WZ/[9[*8CLW1QFUQ0
MJ-P>U*E.BZK2-0O>ZI2<YAJ-?3#;$$&]CHI?R>2%_,H>WZ!]/]W/;^*_.1@3
MPYH\% //@/'G\_\ 'A0"#<*HZT/TU_=_+E?\O_'ZJ4VK,"@TNS8\S(V]-%A7
MY$U+OIP*8YEJ%=G+1J#U0W@I$JW:6M9LCQRML6L+'3*9#%%RJ!\S 7@T\P?:
M:#<!P\=2)$\]4GKQL>O1.6YC1'"(X1'"(X1'"(X1'"(X14-[#^@_X<(OG.QC
M#WNM?:&T6&M4E/M7[N<7E A5H_($>52O"PD@C5)0KRUJP[IPD@<B:J[Z,637
M+Z9DBCVE[2+Z)':[5JW<.7:R+=JV245<N'"A$D4DDTQ.<ZRA^TA$DR 8QSG,
M!2% 1$0 -\(N$;Y+QRY;Q;M"^TU5K,NU&$0LG9X8R,D^0$"+,XQ8'HIO7")S
M "B+4RZH&,!3% 1 .$2>9*_]O733_P#UF5?_ /GKWA1J/ _-J<9PI1PB.$1P
MBIVE_P!$/;7L'M]/TX14[">?PE\ZW^$/.O;?CSKY?3Y<(H\NJ/J-J/1S:86\
M6B249U7+JR,6_:(1+J35:6RO*,TC3J+=B4RPG?UATHP?]VB%4K=>;E /B'2A
MO/[2VG3V37HM>0&XDD-$2)#A?E8G*3[-^?U3L-V(VA^H6 VGA\$PU<1L"@[$
ML (#G,Q#';K),DP_#D"3#14>1FGWP\FC+Q\7*-C@9O)-F;U 1 Q1.BY0!=(V
MO_Y*I3?F.M^W.W1JBJP.&M^%NLXMP7S/&89^%Q-?#F[J%9]%UYNPP[QB"..:
MZ#F5:Z.$5AP+HP^ 'M'\6@$0T Z'\]?+SR" <P#XB43:W*@XVSFWD3@9*IYJ
M:MH]ZL<X @PR76&9$(XRHCHI5+35$$FR8$ J97%66$>]P]V;*1WE,#5D_P#J
M;R#>"#IYHG+\QHCA$<(CA$<(CA$<(CA$<(N"RG%RDWC:]0\(@=U,2=5FV,8V
M3(V446?.6"Z39,B;QVP:',94Q0 KEZU1,/A1PD79P(H+_LW&LS#=8N5:S.N(
M]S-UNL62.EW""-*:K.7K:?BFSP4P@,BVETLFV=I^F[(C'Z9.#)M':Z"H&3-'
M4Z_+5%.M<KG4<=5^0MMWL$76:U#@@,A-3#@C9BV,Y51:M/45/L1<.7:R;9%!
M(IE5UW)"$(8QP#DHN4A\WXDL=D@JG!Y$K,S9;56V5LKL3&2B#QS+UIZ225:3
M3(B'>4[!R2)DQ(L<Q1,,>X3* *(J 4B\J*_]YJ]__P!C,5__ +]S!PB7?A$<
M(CA$<(J:#Z!_0.$@91;@J"4-"&@ -?3Q[<(M=1),J8[\_A$H#XU\]>->P#^0
M_IQ%Y@3QUL/LA=NQ<B3:Y'"_DD1FJ/-UF2<6C&RK=!=RH9U-5%R?T8.>4 14
M4=L3!HL--+&'M4<$*+5X(E%P4AB&4/@-*'AXM%S$7\1Q\/*%V*&-IXIK:.,=
M+3[ K&75&-L ))EP$0-0,M%U%/O\7:55F9#NHN?8J>E+5R3**$HP. ;.)D#Z
M!9N<XB+=V@*B*I  0'R&C'TR9WCO"T$DQH !E^>$K#B=FUL-3-<--7"O,4\2
MT.[MQ$$M&<. -YB^9*40P@4 #N$1,;>A$>[_ +H"'C7]WO\ /WS&X! !%I/R
M^/YU(Y;0&R";FX\? GQO]EG(!3%$-&+^HCL?Y_S_ %^G!$D'*.'70LK(,F4
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M<@F*8ARF 1 0'G%<#3+@9+YAP)R@P;:1EG<H<^&>OUZE>F4H: =" A]1'?\
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MBM[" &@*76M:[0UKZ>WMPBQ+IE%(^B$$1#QLI1\^ \[ ?&O'MX#E7SND@!Q
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MFKLCJ%R?>;HS41?(%D([O^XC*)A"E03==>&GR4?3PZN,Q C0G21L"E >X"E
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)A$<(CA$<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g118907g82h14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g82h14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1E@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &42^9&@X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5X            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             !!    @4
M         0                         !              (%   !!
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !!
M  !29VAT;&]N9P   @4    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,      ZM     0   *    !0   !X   E@    Z1 !@  ?_8_^T
M#$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,
M# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!
M_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$!
M 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#I<BZ\9-P%M@ L? WN_>=_*0_7
MR/\ 2V?Y[O\ R2?)_I5__&V?]4Y#67(FSKU6,_7O_P!+9_GN_P#))>O?_I;/
M\]W_ ))020L]U,_7R/\ 2V?Y[O\ R27KW_Z6S_/=_P"24$DK/=3/U[_]+9_G
MN_\ ))>O?_I;/\]W]ZASHK!SKB. #[M02"=S!C[G?O/:QK40>\B%(OM%_P#I
MK/\ /=_Y)+[1?_IK/\]W_DE,Y3_2=6UH9N8*RX<EH+X!_E;;-F]2&8!'Z"OV
MP6Z<'VF?[6Q'3]Y7U1>O?_IK/\]W_DDO7O\ ]+9_GN_\DGLN;8T-%3*XCW-Y
MT!'_ $D- GL;4S]>_P#TUFG\MW_DDO7O_P!-9_GN_P#)(GVM\5B(-6W:08)V
MM:SWR'-=]!)V6YSFN?6P[01'8RYC]9_>]/9_;L1T_>*OJC]>_P#TUG^>[_R2
M7KY'^EL_SW?^21AFN&GIM#)G:-(&]E_IC_@]]?T?^$L58<($]I$J9^O?_IK/
M\]W_ ))+U[_]-9_GN_\ )*3+]E?IEC7MDD;NQ(VRW_S)3=F;GE_HL#B221P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8Z2F@RFGHF+&<)8SD&8[:I:Q6X=4UDU.:ME<]DP1X> 7 H!;P6M83 4!UOH
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MC9LC),$0*":K^(7:$$IP!1J<'(#<P"..%O)S):#R9X.X2 ]?*"<^)PS.&!U
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M6"4.ZRTKA]+R#96)E7!Y!DHS.T2<L@;,E@524,J!U1URG @?F"-RX[<">5'
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M4=#D^7T$<0BHC1TL,(,B'AB  >3C6TG!(<L_T:.G$ I(,\QT)$69(N7'JL"
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M29.3QE&W&PU%AT#4Q\,U:V8'J!JF[;*B/YU%1#6N(]P;[PL(\6[B 1'B#C$
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M=;?W1ONWWW6W]WY]Q4F4TL5'1:J*($G6T.X 62V"I!%46Z*P7/1/\/JFHAN
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MLX;][LQ=Y-'4E@^9.P=SW^!XOR_\+AZ+.&_>[,7>31U)8/F3L'<]_@>+\O\
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M^%P]%G#?O=F+O)HZDL'S)V#N>_P/%^7_ (7$]%?#5A[![R:.I+!\R=@[GO\
M \7Y?^%Q?19PW[W9B[R:.I+!\R=@[GO\#Q?E_P"%Q/17PU8>P>\FCJ2P?,G8
M.Y[_  /%^7_A<7T6<-^]V8N\FCJ2P?,G8.Y[_ \7Y?\ A<3T5\-6'L'O)HZD
ML'S)V#N>_P #Q?E_X7%]%G#?O=F+O)HZDL'S)V#N>_P/%^7_ (7#T6<-^]V8
MN\FCJ2P?,G8.Y[_ \7Y?^%P]%G#?O=F+O)HZDL'S)V#N>_P/%^7_ (7#T6<-
M^]V8N\FCJ2P?,G8.Y[_ \7Y?^%P]%G#?O=F+O)HZDL'S)V#N>_P/%^7_ (7#
MT6<-^]V8N\FCJ2P?,G8.Y[_ \7Y?^%P]%G#?O=F+O)HZDL'S*'809[_ T1YQ
M-[+B>B[AWDGL_E:T=%8=ZCV#N>X_]#Q?T/QM]'^"XOHLX;UYP_PQ=Y9T=26#
MYD[!W/?X'B_+_P +AZ+.&_>[,7>31U)8/F3L'<]_@>+\O_"X>BSAOWNS%WDT
M=26#YD[!W/?X'B_+_P +AZ+.&_>[,7>31U)8/F3L'<]_@>+\O_"X>BSAOWNS
M%WDT=26#YD[!W/?X'B_+_P +B>BOAJP]@]Y-'4E@^9.P=SW^!XOR_P#"XOHL
MX;][LQ=Y-'4E@^9.P=SW^!XOR_\ "X>BSAOWNS%WDT=26#YD[!W/?X'B_+_P
MN'HLX;][LQ=Y-'4E@^9.P=SW^!XOR_\ "X>BSAOWNS%WDT=26#YD[!W/?X'B
M_+_PN'HLX;][LQ=Y-'4E@^9.P=SW^!XOR_\ "X>BSAOWNS%WDT=26#YE'L'L
M]_@:*\O'V;%']%O#0U1=D_=TT=26#YEO?1HT>,QLH\YZ7EZR8LFK&0;SK!L9
MNZ,L<7HT[,+IA84DP !00<B-KB&K?<&/V'D7Y%9=P+PO!'E((CBHZ5B0 T)H
MXQ4]H(=FWKUY'D\634CQAA$"*R 9&WH\3!^@M&@ YE9TW#_I^DO[!T\'[-WS
M8_KV2?\ -N%-@R5MGJKZ2W$D "F6X!W>YX1Q]M%4L'('0&")8.0.@,$2P<@=
M 8(E@Y Z P1+!R!T!@B6#D#H#!$L'('0&")8.0.@,$2P<@= 8(E@Y Z P1+!
MR!T!@B6#D#H#!$L'('0&")8.0.@,$2P<@= 8(E@Y Z P1+!R!T!@B6#D#H#!
M$L'('0&")8.0.@,$2P<@= 8(E@Y Z P1+!R!T!@B6#D#H#!%YUP&Q0  L(C<
M+<86XA[@%W[Q'BX@X\$7R@TC]+;-G1)TH:==UJDG5FB!4%*LQS"FV\6F6HLD
M9Z5G6\1"54^<MCJN)>C7[A=-G,"HBF>)()71#&(!L$732>=1:=S"STJ>I*Q4
M?9,Y=Y69;5\Q+%QJ+TK6/JI&KWLM,)OFJIUI!DFP@6CAMJ%$I$3G4*8P#AX\
M>/LCU#I/T\?9;)B<_LMJMJ6B\OJ>J55*JLT<IW><67ZBD<J+>7H<H4VDI430
MREDG!8]>LJ;5>,U!(=,T@@ AJB82O'C%/%4OST+YS9!:1N?56T'[E/4E4UT6
M2<Y]U+FA3>="98ENW&K5H7*K-BI81ZF=-4QXU-E)T@R5%H3:)KI_EC'*9( $
MF]?99(0$0N4  Y0$"VOJ"4  0$?"%K#W>7!%7L'('0&")8.0.@,$2P<@= 8(
ME@Y Z P1+!R!T!@B6#D#H#!$L'('0&")8.0.@,$2P<@= 8(E@Y Z P12F -4
MVX/S1XK /%RX(N+]*'-/,/+.MM$MO1DO&M*<S1TBH?+"N6#Z+([<2D!,9>9B
MU(F+%\90BL:JV?TPQ,91,BFWVATQ  WX(L,KK.VOZUTG,P='3+.8)2?6?R2B
MLUZCGEH]*24F:FJIW*(4G38I+*)E3BDFL<1_**IB)ERO"HEU12 1(M#Y+Z<5
M6Z6%49)Y:4&X3H2<J/)NM\TLT9M%B1^I%25'U0%!,H2(27.5)-"2J4/?!8QQ
M,(1P"W)<^\"/AN?Z+L/0WS_D-(K*!2K9UDBQJJDLP,P\JZS3:D%-DM4V6U62
M5-/7[$HZQ4VLVT:1\L5N43<$4?KMM<P-BF$BZZL'('0&")8.0.@,$2P<@= 8
M(E@Y Z P1+!R!T!@B6#D#H#!$L'('0&")8.0.@,$2P<@= 8(E@Y Z P1+!R!
MT!@B6#D#H#!$L'('0&")8.0.@,$2P<@= 8(E@Y Z P1+!R!T!@B6#D#H#!%K
M&M0 *PRN$  !ZH)W> ;]U%U);HN-N2X\HX^7ETLJR B1-. 2)$AQ(G6-BHKZ
MC]"K)1O^DS.C_7U(^FA:=OCSY+_S?A7_ /I;X(7O46YDO\F7Z?\ :''W$53!
M$P1,$3!%QEI/:4%3:.T5F35S?)>KZ\H7*3)F:SJK6JX>6I>,9M(N +4SF0IZ
M);3\W&.INH"Q5,OI [1@@L@W3=1Q'2Z*CU(I2C^/OT3;I7/V2WNB=4YXY$TG
MI%4GHSY@ERUK?*&N<V*>DG5140=8Z%%M&KTU-R3=M42QXV:FVBSKWC.\,BP=
M+L7"!G93% </ 5\8*CHD>ZB99Z9N3^:=>Y:T=5E/YD9+R#]I7^1-:N(>"S!B
M@8)'<)K';GDE60LY)$-=FZ%Z1L90HIJ.$S@!!D]E_P"$E;*U;1S>T]:*RKJW
M(G)IO3,Y6^D5I#Q2<S0N3U+KQRDFRB 9(OI&>J:7=O6\1"042DJ4'<B\>))J
MG(<C,'(B4#5/'B4_$ULEGI 5S 9C4GESF;D]45,%JN-JB3;9B0TI%5%ETS+2
MM.R%2/8I_(MWOOLPESLXY0K5N^BD2NP37.U47314.!%R)EI[KEDCF'7&CZQ&
M$J"'RMTKLS\T\GLA<TGIV01E3U]E/,&A%F4NP3='>P3&MI!N\1H95TB"LH[2
M2;NT6AGC(BY%D*?NJF2JM<LH\L?+$RMDM+]]H*Q>:0.(XT8\TA6$.XD#QB;#
MAG#>I=>89O:-85!L3%5J-H<RB(1;IF^6(K(W]UER>E2RE80E.3DKE+ :4#/1
M(EJP9OXH91',R2>%C6<V6ECO0F!HQ:5,5F60.S*_.02/DX[WO$'!B+ZSM5BK
MH$5)K:APN37*)3:HV$!$INV 1X[' IM^\H#@B]&")@B8(F")@B"(!QB ?/B.
M!60.M%"X<H=(8.+1>$2X<H=(8.+1>$2X<H=(8.+1>$2X<H=(8.+1>$2X<H=(
M8.+1>$7G<".J % HB(& 1$; 4-V\1 #" =S<4;^##.%HO1<IS67LS6V=M=-Z
MVRW1E,GZFR?+0SR2EY&FI"+G5W4N1R_BG-.ED%9@4#,BF$B[F,30 U@VI3;L
M,X6CQ_+Q)&)J#KCS)S05S0R=HO3'R>:5J%7Y99CY?Q-':.0U _V\I1E,##UN
MEUNYEX(F=JQ%*R,\@C!O%RFO"N46Q%SBQ,4&<+1>D^KQ^5X<A,H])R.SCT-L
MP:YR1&D(3(G0]S"T?*U;K5Y0\I*C6"Z&298N7AB0\X_:O8"HE<MI1G%*'<HR
M+8CANYFV4:51(#3.A$\YJM;S:S:3JWLHY=M[2 <[9GQ(563(S1OTCJ*R\]R_
MINI<K!8R>C;7V:$KG*DG7%!O4J9B*BR^S5HF!=-%VE0*$J SMQ6L6]5;0 R2
MK9))VDY!,Q03%G0G6/I]56Q7V5;GN8;V*(% 1"]K (!JW*-C:P!;6UBA;< ;
M@Q<Z&T7CQJ3:O7<.4.D,'%HO")<.4.D,'%HO")<.4.D,'%HO")<.4.D,'%HO
M")<.4.D,'%HO")<.4.D,'%HO")<.4.D,'%HO")<.4.D,'%HO")<.4.D,'%HO
M")<.4.D,'%HO"*4XE$AP$0L)3 /=W" WW -Q^;NX9PM%Z+B'2URZS+S JW10
M=T!1RU41N66DK3V:=;N0J"FX4(NFHJA<P*574;I3DHP4E'QGM5LERM6)5% :
MMW6J0ZVH0T,4)_>KL(!_G=58Z5:EC59Y,9D4;I-9AZ0V6=/EK N<F1T9E;4<
M%[[Q,6YI^KZ3=2:M*3HKRSMDW5@UFDB5G)\%5<N&YV0J$04%8A1N=#:+U9L1
M*V9:I\=I6A\D-"*M-$^J<D\Q,OXXM?S,-DQ6>5>:D*WE8N*<2$K5%4C7["?B
M5IQS&-56D94P^][@@K)K#&F%R@BH8=G@\-HGM"DV<#Q8\UV%H9Y!R&CIDV>C
MIYXW>5?5>8&86:U9';*@LT;U-F554A4CR,:+@4I%VT0U>,H8CH@;-X$>*Q #
M:B89G0VC5OJ1==W#E#I#%<6B\(EPY0Z0P<6B\(EPY0Z0P<6B\(EPY0Z0P<6B
M\(HXJ)@B8(F")@B8(M8YLU\;*_+VM,P?>&5JA.CH&2J%:!B%6:$I((Q311TJ
M@R4DG#)@"ADTS"GPEVBF(@-SCQ8)X\6]2U<PTF*07T8Z:TH)-L^A*4J;+&E\
MR6$0_=1J,F):N@F,K$TUKJ/"1ZDVY6D6L4BF5X*"TBHDFBN<#;R&VQ7?1^S6
MS'S<IF0J"OLEY_)A1)^@A"1T[5M!5<>H&"[5-8THSD*#J2HX]%%!=0Z)@<.4
MU5!3$Z*2B9BF%X\> A\/XU^'70B(&!,H'_. !OO$>Z-KB-A$;6WB #R@'$!%
M4P1,$3!$P1:TK/\ SORO_P#$,Y_8RI,?,RW^U<'_ /G^R"L?XOX8E9*+-;,O
M.C< _P"/J3#> #N"A*>'N@/=&_HXAQYLD8\+\*BP9&_3F-]O!3[K<27^3+]/
M^T./N(JF")@B8(F"+A'W2^2CHWW/O33/)R#5@F]T:,[X=L9R\;,0=2<KE[43
M6-CFRKDX@=\_751:-42E55<+*%302*(E*!/'3X8K@OW+^KJ8I_W$#+*1FZBA
M(IC3VCE64;4#J0DVS1O#R0PT^D,=*J*F;\">:RJ"7!% *\*LH1$I!L "4):T
M]"YGT]=$;,VA*GRW]TR]S\78R513U)TM16DQE[3(HS5/9N9:2Q&#!U639G&+
ME2E9B"05VK]1@59WJD!\B<ZG#K-ZMGXWLK]FWEQ56C][L-HG:;V8Z#X-&JK]
M&AODG)U^NF=:DLJJV4IA=G%C5TH6S*FHZ?</R<%EI K=B*K<47+T%#)$$EEO
MW79_9KYC9F>Z4MM#&C8O+;,31ID,BGV8E5YM4LPEJA>4[).F<XP&DGM1Q<V[
MI"-6D!1:H(.7QV;E0)($DX]<!L<E=6JLC;:OFW3GN;$BVTL]"W1YR!S+E,S-
M$O0MTFZZTP*PJB1I=FU0RAJ4)5M/T=D0SS,;R:D/F54$M5L<_-+Q$4RB9:B(
M=19_4^T,ZA]0C[K/'1T+B*#T9,TD\G\M-"P["0-GO1/N]RN8$Y3@$<%FV^3\
M#!RU9+9UIL!!K(FR\6I"0CZC;U;OBEB2K1A[YDF'*;("/MJG^=VY5E,FZ[8Y
MXTQIMY/0+>B-(:<]T6/EEFUH&*1+V2IN3A(J4>PC/-!:B)8Z3QM5K6F2/<PW
M57),VL2R"HFC^$"-8H$;N7C!%^WQ@==1FW.Y2*BX.DF9=$FL)45C$**B13F*
M45 3.(D!0  #VN%PP1>S!$P1,$3!%YU[CVMQ #%,4# 82@%_S[B4;@.H':B&
M\!N(#C$8)A(%?BR_J3Q@M:*97P*ZJJJDE5IA44,>Y*OJ$"W..L8"D)))D3*
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MRS_,4N*9@M.[!.M73P?])5?]-85);_>IOV#\V&C:'5E.5OMRBE(WE.+%IO\
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M$4IT4E2F*HDFH4P !BG(4Y3 '$!@, @(!W $! ,$4VH01UA(43;^VU0OVP
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M3;22KMVVA()1:4D'J1E9#@P*DUBE,"#I$X!80'%SXI>H1JFVS9U VV@*+8=
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M8'UJYWMK%7A]D.I-P&_JLJX/#PR("W_\5C4/!N7 _P!MC+BK-HC_ /Y[%J"
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M(")1U0N4PA8-<!N!P_HF 2]S'**1(\-JW+K#4.OZE38BTF")@B8(F"*\4?\
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M&CZ1;SRU5-Z8I]&IW"(MUZC2A(TDZN@9-LB**TN5 )!5,46;1+4.X,4$VZ)
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M!;\72V3\U2W4BT,X@%G?7FB>VI0X4]YNU>'_ ,*3GL X:6R?FJ6ZEQ*QG16
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MZDER\"<.:$.T=C,"_5.5T0R*Q"AVU%%1:J* 2 _9!\?0:K4=];^/Y3UKZD(
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M.+H^;@[,."+6U9$(6K\K[$+_ )Q38\7)1E2>O?RV"_$&/FY9!",JR!@ #3S
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MK*#,7-2/HNH,PW-!TQ*5*A1M*II+3]2!&I;08V)374334>+!?4*)@ 0*([@
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M&(X7#AW%0K%=BHLE/6=7C6;%JD]#5NJJJ<F9LJB0RAS$1+"LQ(D4PW*F0YG
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M8HZ@D$HZJXBN41 3%5,8P" &, D584$S6U@$UBB6PV$-4;7 0$+#N  N("(
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M:-^";$G<1)XJ?V<3B\DY$5_X1A:-^"EX.E^A)T)_9Q<S)>0=W=1A:-^"FV)
M_P#8D\5/[.)Q>2<B*_\ ",+1OP39$_0D\5/[&'%Y)R(K_P (PM&_!-D3]"3Q
M4_L8<7DG(BO_  C"T;\$V1/T)/%3^QAQ>2<B*_\ ",+1OP39$_0D\5/[&'%Y
M)R(K_P (PM&_!-D3]"3Q4_L8<7DG(BO_  C"T;\$V1/T)/%3^QAQ>2<B*_\
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M3 !VKE;5X<?=<XP7D]32Z=:Q,\;6 &,"=0Q^S QA(!H<#G IA$0*80<!>W$
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M^T3(8M$0 9RTY,*CUOU[EDPQ$O)Y6ZNI;-   +!_=\XC8   N/<* %#B*
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MZ81@JYU$WK*UUXQ!OPH4F9&@E$R;O;(ILQ.(!LBJ+@(D$BQQ*5-0"F+?7*<
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MU]0I3B!M4RHD4"QAN(%, 7U;[@L(C@B@HFBL-Q*0YB%LDH8@#<IR]J3:"41
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2')C<L )R%PL1R07+S'_R7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g118907g82j15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g82j15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/*^8X8X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5T            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              W    98
M         0                         !              &6    W
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    W
M  !29VAT;&]N9P   98    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   -P     4F=H=&QO;F<   &6
M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%
M6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-
M3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N
M=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y
M<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T
M<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U
M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,      Y;     0   *    !7   !X   HR    X_ !@  ?_8_^T
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ME/\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME9>DI:;$X?#_Q  = 0$  04! 0$              0(#!0<(!@0)_\0 41$
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MNU_@+O::3-,H*>87V8=E@7\BC6XBXN?D,(J$%<6Z803Y\U('K:@@!+ <H\%
M"F$GM"8"E,;DI0["  (G4,/2(I^\Q#F+WZ #0&/=1<)XCVLY_P#%57M&)+=;
M<"O,686L4E#/V]BM;_*LPZI[65L$<@]%19[.2;^Q*BBX1:*%1:J&$#D2;I&
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M;UL<QF/?]F%*541%K[(_L@ %'L/M]AT!XZZ9&I%%JMGO%ELD4QK=0A7$]8I
MKI%P$9$M41<*OUTD#J'!(J0]8")>%2 42=0#H#T==LL%9XF+EH*3:2+&6B8^
M:8J(+$,=:,DVR;MB\%'J]*FDY05(HF)R% 0-P'EH#P^8KS8,<4:7MU7QS:<K
MS$4HS.VH],!K]D4P#ERDV4%EZ\HDVZ6A%!=+=2@"9)(P>_0%CL3X@EM;9(Q%
M0LG[.\_8@99HR"WQE6[G<OL<&O(6MY6[1;FD:Z]2=JN"*.HRK3/HQ!/CH1*'
M/8.8GX^4\.Z76"39,! @<CSR(B'8 X*(B)2]O,2@( (^\0YU(-^@&@&@+5]Z
M8Y8)M:S@?!LK\B96&C2H4Z2"1B8ITE(B=N"Z,/)SG$1'V!['@[CZVZD3%9)3
MCEB#HQ2\& "*'PNIO<K)Y85@+W1MY&/L?5*N9*2?_JMW4>1[<E)[(DA.TE[6
MT7DBYE9^1AHAV+.8LK$@UP60L6+$3IHIB =>-5AW;J/O*G>+4IM@CZ46*ML#
MM'LF=\I3F,\>E:;F\BH5:MPM+=W1@HUN-PB8R=;6MQ4:H]$9@[J+9@7TK82K
MNT6OI3%9K?SSUCMIA]E>OFI]CPCL-US$4!G!M7YW8%,%G)2@+/E-AUBL4W$M
M!CD+@9(V25;#9+ HW<JD<JC7@079@**5A)RX$4QT!,ZF @F0!Y$0(4!$>.1$
M #GG@I0YY\^"E#GR*'EH#?H!H!H".*O_ 'U[-G\@K:__ &\;NM2\(>'FR%C%
MQ\D2-$\A^O\ N#4$F_0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0&@^0\_ ?I_)[] 1-^,7B;)&8]FECIF+*78,@6MS<*2];5ZK
M1;J4F%&D=/M73QRBW:%.?ANW#D3<<>?/''.O;>CO2UQT+T@@O^D'##=E!$FX
MFE6:EBUL;Q?P=CIC])7:*\V*@A4Y1)M88K&>]8;ZX4-?!RQ)DG#.S&$I.5Z7
M8Z!;VM^O;]>O69@ZC)(K1])(N6CP&SLI5_5'8#R B4.>! /HI](&E;CIGI%>
M+_H]PQ7:."&44#3FTXWBJ8-.CDU7 :/L([O9.&)-.;=9J3<L.QTRD2R!Y!_=
MY?BUXM52>TR!!EXN+^V7&LV#!E8VU;H+A8[O58E]0\CX-QTI=J#=K.PG6RC7
M%.:IB!CWLE5*,FND21F/LBDZY$O&IE3MY(O2<V@/9;O,+95RXAX8M)GZ7?DX
M1IDZ#0W)1&)'=UC:Q780, W!A/PMGF:.X26B,>*V-1*N'7=RS%HMZTQ:E>F.
MNCZ2,^K93M\%QGD3*F6,L:_AO(P<7;;\[8;Q)CK(SVL;E:[:V#7Q7J1D68N\
MEF-XWKN$*]$9)3VY-+&C:W"K"L59)I UR7QM-/&<8>;4D$WD,Y=MI1-0TD<7
MV[ENYZB@6&J1F;+^ \/3&W+$.[IK/3NQ.^H[HKCDB+S',XZS5-3]>@1QPGCE
MY8S2U:R!-.Y )%U!)8Z1,,9!K%C7J;!TDHQ3BO5+KGY=H>7?SV<U)F/"0QAN
M&PH^S%C_ '55^_V#+KZ-HMOBLX/X>WM,<V;'TG!M6\-CBNHRJ*==J-DQXNB:
M.G*>RZ9%,YA?/DB"/&I!-VE_FR?@ASP)1[^\.2^SV'D/9[=NV@(Z-_O^FWAZ
M?R]*3_8/N'T(>'7#XHD8+Y#^$?\ WS:$F[0#0#0$:?BLXEP-E'9QE=_N&7RF
ME0\<1(W15/$%UE:/;I*0;+-VD5! [8. CIAM-2KEG'FBK0RDZZ@HX;S*\8H\
MBF3I$NW'GJ!8KX8^.(G%.X;Y&R5M:R?A#*%KPP6R8IM=VWEY)W5M)G&H/D"R
MD4HTO+SU&@S:*IV:SUK"L31KP3 DS5220)IU\\[6QU;^WNXTG,NG\6 *%1,
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M5!KD289C(1M-<3L:G8Y!@<@B9VTBSKE>*HG22%4#)D$52)F A3"FIH"JI>#
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M*19X%QNFV:6F.LVW5:>';PDBO=&S-U!54)L32'V5M1 '5C$ (D9$$Q.GU=]
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MU.%W#I>RQ-)K4;8%G3M0ZKIRM,LXQ&147<JG.JX6.Y,HLH<YU#&,81$"H8
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M/3+^A]'?^O\ 5V9@- _"MN+^G&96Y?,/P _/K0IZ/]_^GS-^A4- - - - -
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MS)<"@ %  Y^8IYCW$>_<?>'/P$ 'XAJ(?WOXF2Z=W>IF&-3_ +^PX_E+*_\
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M*T=T$Z3O0>CK>^V]G972QCC=]BL8[37CFVYV2AQEFJ[2_G5HUJ- - - - -
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M$0 B9>0.<1$>!* AU ')0*0!'D Y#0'RTYM@J195*39+)-RF4<JI/&YP;$(
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M==BP[)3,]ZTNK_M0O+A@@@UM'71M0))-I1*LL^MSQ)3=63F\: : : : : :
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MI">B[<#WT!AVFA93;Y1K;@N-R+3,G4^Z(;7K!F+<3B>\7AU'OL:WK*\-$VN
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MQU9I\)'U^$9J.%?3.%48Z,0;-BK.%A](X6]&*JY_:5.<>^@+&:X4I?%=S84
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M    &L4?G8Y3<E)3<EL4\"X70@: : : : : : : : : : : : : : : : :
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MQGU85E6DS)#H]L97.H5BWQJ"S=E;(&(L+%LN0/66[69CF\@DBL0! /2(IJD
MXE$P&.!^D.DNK)S>>P3.8P\&X]X!QW^;T^UR   =0& >._UZ YM - - - -
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MJ$FT1*LQ544 3=)AT!T]L>QM3 >7JK;X_)D5.8PQ%@V"P1A2B1T.V:24/&)
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M)XE6?;/=\)7K LDQV7;9X5"IY$4CE)F3CR9FW6OD["S&,.= 8QTX>+L4>O\
M9 NV+H#E @!H4M89SB3[*<K9/BICNH1*41#@?1F 0YY !Y[@ ^\._GJB!4XM
M_9Y%1@]78H#XOV40'WYAL_/_ -RCKIVR<_1A;;M&RZI,="X5#T^T+:*>M:7R
M[PQ5I**U2<EMK1^5"H^-UO0X,W)*@DX7.E7\=J%3:I'6<G ,B013IMDB (J*
MJ)B<.D $?9*4/G:YPO'?7J]_%N\]O7WKZTME#9]#.CVI-2M[KBYU5FVL:XK*
MA-=X'J;EML\<-G;5VP>L+NFP=LWZ!V[IN[8X]Q\Q<)JHJ#UD %6Y_1E-W*0"
MAY!KY.>>:'!;;;<W/W\>W_.ZJ:PRZFZ$S)!$0Y$0'OVX#R^@?IT(-V@&@&@&
M@&@&@+:MY?[DK<O_ !$98_J+.ZRN@OCG1?S^Z_70%NV_-6OR<?T680FT/@<+
M[A $.0&R8F[#_P#3+?P/UAYA].MY^E=RNO1S^"W^JL'Y&]/5 _7I?PWOZRR+
MELM-)E[@';\6'C#R9VF2K/*/0*ND@#9C&6"&<N7!A5,4#B5,INDA/:$P=M:
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M,=*/\.O1_P#TWH+QNI=5X.<;'QV8\H^I,FK/TU/:K*^KH)H^F6/+N!.LKT%
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MTBNMHH8OWITJO''?U83+P]?*?"- - - - - - - - - - - - - - - - -
M1Z^)?6*TYVEYHR(YQ?CC(M]Q909NRXY=Y!PE5LZHUB3]88!*2+2GVAH\3=L4
MF#<CN<(S1*JBQ:*/P0ECL?43@8X>#=S]ZP9F&DS^WO<5LEW!1DPWQ=%7J+P%
MX>-4Q#)O)G(5L&&=XME<@XZEV4G 331DD[FXUP]-(E<^I.B2T+'%*F*H$RGB
MY8 V\RM"A<W6W:/AW<5FUW9*9BBDR&79BXUVIPB-IL#9@@:P2=/$\JA%-E')
ME$4F#559=V)&ZBR"*JBA$Y?@WX HWX%U@QX_;[E:]2,%;6,'OXZ,P)8K(PVN
M3-[L4<+RUQ.1C&J^1Y&YR\C\FY QVZ8RL'(UF.1;! O7$GZV[?(/&*P!SM,A
M1,0$A!   !(40 ..  0 > Z1$O >0<"(? 1#OH#=H!H!H"..O??7LV?R"=L'
M]N^[O4O"'AYLH>/]</@B1,_D'X!OSZMP8/CY(K,'FZ_??\H?QPVC_DQM=.67
M[,+;^7+P95T-_7O07SZZ_70E4<3_ +36XC_L?&_Y,C5[C\X_SZYPM_A1+9!"
MUQ=K&GW([W]:G]3NC:VWF[I[TK)?:SI7:[9.JVU?&C/'%HME?5DL_P!VDY5O
M5[+)5WY1+56& 9ADH]^3W38CM2-$KI>..N!SLW2PJMA(HH81])T5N-UOL=M#
M>;)6JALH8JN)-.+VB;3A<-'JI.&<G+#$X[Z+W&[7V&)7FR]HORC^%'"IZ[AF
M]2.#!)4ZY&5]M1EI:<VWX5FYN1?RLQ)XXK+V1DI1XK(2+QXM&H'<.'CY<ZBS
MMPHH8QE7"RBBJIA$ZAS&$3#YR_V<-E?;U9P)0V<%O'#!"ITAAB:2]\VW)8.;
MF>7TC!#9WZ\V<"U8(+6*&&%-N4*=%-MM[YMN9<0GW$_UA^;7R'Q'+H!H!H!H
M!H"VK>7^Y*W+_P 1&6/ZBSNLKH+XYT7\_NOUT!;MOS5K\G']%F$)M"_:8W!_
M[28F_P#&V_6\_2O^B='?D[?ZNP-Y^J!^O4/"]?76)>E8P V \- (<@,[D8!#
MX@,E$ZY]C^&OXGXH]/ZT43A])5M)XW>PG1/#VCS3S*U5XI1WSX!6Z0!4EFVS
MD(H  4Y"GKN/BG A@X$@& P@/2(<]N?(.-@V*7]U[V\_8V^;R]IE@\%D:]AL
MX%T<;2K'9IQ5=7AMI3)4,LY(A2_-  Y(01X[<B//)C?](P\!R8>3?3W'6N#5
M9S: : : : : : XS>2OX/_E'5N'X<77XH&)-8/W<F>_(?_=W<QV$ $/]#\C^
M8#V$/H'MK,VJ3L8$\'=TGP;/T7Z4I/U=- )U3Z-:#3X-W5,MX9,FDEB/+S"1
M;(/V+EQ26SEH\3*Y;N$!=6 !2716 Z:Q>D>GA0IO9]GR$0UE^B*5I?HK&-3L
MU9MZN%:_O*466$Y'"W0Z)Q7^*PBD[+V5J]22QG$\9:W5.6TGU\'J.81NV)ZR
MCV;9BT:WB81;MFB)&Z"*1"M0(FFFD!"%(4.P% .GC@O'  &OGZ4P0P7^&&!)
M+V<+EE-Q*>,RGI8E#>[.&%24HG+>I)=Q+?KS9Y,: : : : : : : : : : :
M : : : : : : M+WO7F_XTVI9]OF*%F;;(=7Q_*25:<OH0;.W:R!5&Z*RY:Z
M1F_--ODX]=PHQB%F:[9^[29-W(%:K*J%C!=;V+/GSJ.61G>&1))3]]F ?[MW
M6>UW]60L<IC>1VNPV&6%?L*BY5'$V6794"M"\D6"ZRS1- TBZ-W,J4.#<C//
M//F"\#Q-LJWK$>W)K/4*[1&.965RAC>K/;@[I3'),U!Q,]:XR/?OJK17[*0:
MV.QI-EE%&3 6:RX' JK8Q%BD$H%-?"U0]!"YL<?;D?9?5D[)5IV1=2.VR&VZ
M+1<U))V4\K(.&D15ZT-M=S@%05=R#OUY>/\ DU-$BJ?KQP/$N9SV\X^ YYW=
MG EM((B0@B' B4HB''' B <AQR;C@?=R/'Q'SU(-V@.HHJH43  E* #V$0ZA
M'X 8I0$Q2B/'M=_,?F\<Z T%8XB/*@$#I]W28 +[/*H\ASQR/ =Q)W]_8= 1
MV5HPG\5S-9A#@1V$[8@X^K/&[P._EW[=P]P\A[M2\(>'FRAX_P!</@B18_D'
MX!OSZMP8/CY(K,'FZ_??\H?QPVC_ ),;73EE^S"V_ER\&5=#?U[T%\^NOUT)
M5'$_[36XC_L?'']HU=USA;_"C^3@^NC.]_6I_4[HU\YN_P!4CY]H[[=,6A[O
MMO9E^L.:C@PH\#[NPC^, 'S !#V'0I_E+S\A9][M^? Y(Z&MJSC:V6WTXC*R
MV=@ ;6<#\   7%]6   .  /DY$.P!VUY/2?QA?/G%K])GC=*_&-\^6B\BYD@
M  FX]X%'\?&OA,>;] - - - - 6T[S!XVE;EOIP3E</_ -BSNLKH+XYT7\_N
MOUT!;MOS5IO@B74TT_$PA-H7[36X8/<%EQ-Q_P#;+?K>7I6_1.CW\%X[H+ W
MKZH22Z=0RV7KZ^R7D7J6']H/#7_;N1?^91.N?K3X:_B?BCT?K1_M*M?F]A_W
M"M5>[;XL"?[3[9OZNX\UL*Q_5:]_(WC_ +IX%4Z-I[+$RS$3"83<^XI #ZO;
MUK952X(U4Z-\6<^I(&@&@&@&@&@.$!$Q5!'SX-^3J#^[5"I'%P\9,&)//]]\
M>>O^W-S']3\CZS-K2RLOF\/D?HSTI_PZ]'_]-:![_<A;_""(XPRP'N]>I(__
M )VPA^8-9;H?\9OY-^$7V'"?0Y2TI%\C;?2B7D3_ 'A$ 'ZFJ5'W_9]-A^(/
M5P_N#5OI8E_:*6RS7=%0GI>I7RRWPQ/M:)8->7/(C0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0$9._K)4%7+=A/&9\Z9<Q%:,MLLHP\4SQ1"QLL!8B%C:U+6
M;*%N6DF3MO$1&,8Y-(Z,B[]&R,:RN4U!.H1(I0Y^[GOJBQ?PI\WRF0<Z6B,F
M,V;O<@UZ=H\C8\2.L^URGQ-'R=3HFQ.(1Y?J0XKT4Q>]!'C84RD?*#Z1!4ID
MR"4Q3Z O4\5J:J]?V]5:5N%]L>)X)KF_$+E?*]3;Q#B9QLJA=(L[:YII2Z+A
M!1&%7]&[=E21.N"29@*4PCP('W?#ZM5-M,-DUQ3][]@WJ)(.ZB+Q_8&<,T''
MXND9X[1D@6&:-#*#9P2<+JD<@<P?(*1$Q(!E ,!)63GH+R' ])>0Y W \!VZ
M@[#Q\0[#YAH#=H"+CQ7LHW_&^WRK1&.['+TB2RQFW$^*)J[P2Y&LQ6ZQ=[C%
M0L^\BWRA%$H]\M'.EVS=ZH0?5U5"G*'6 !H"@>S3=7+8;I>ZVF95?Y@S35\!
M;N;#A/'4_#5>8R;D![5WU-B[8SBK%\@LQ=.F]><KOX_Y<62( >GCT'0%.4G6
M(SP>_O[]O%'P(7>;4F.^_)6?U\-;H"XYM.U7!^)X>3/M^OQ7RUQH^4MP]OLK
M5Q%C'^M-6J$3D6JJ(/5"@V<+.UFJ!C+-EBEA1**)PMRU9=2:FN-6^&>4TD^V
M>>*P+OONF6'>D!-B;=</3V-T[:LD")2GY#J$OR;U& #!\XG("'?RU$*]]$L$
MFI;*I3J3L[\,>9=<S%]LR64I3Q%+SN!9[==QHXRF\BSEA92QL-VWUHT=(1PM
MFIS1@-/7$A.?VC J0!+Y"'8=;O\ [UW"RZ%+0SM(7;QW9V,>#R4E-2D\5/;*
MC4B]T:@]P=+=&:3MXE#<["WLK1N=879QJ)MN>[!K=O/LU;(\O0ZM>\8VG"^?
MHR]9E9UYAC2O+8@MP/K0ZIEAC[;:$V"7JG)QB:_%O9)<INY4D#"8 +K3$5K#
M;6MJX5$H)N"&:QAABUE)O&;B;?5)R.J/3QZ3="]-.B^B;GHMSM[D[*TB3G2.
M"!)S3RPHOO?U9^4R(]P_1:<TV[;DC3D%D7(]@D4#X7N!4TXVR0&,(^(.586?
MHS'<NZO*H'3 1.EZL0X@ +%YS_1_25GHV&\1QM**-000+'WL*C;FI[8U)]1H
M/06DKMHRZ*TC:<<<,3U9N:UFVW+9-TX/&:)[]N>_['6/,$XIH]HP[NH:6&L4
M: A9EJWVZ9%=(MG[-BDDY12=)QPIKE35 Q?2$$2CQV'6"O5JK>\V]LJJTM(X
MYRE\*)OPW=IYF_VL%O>;2W@PM8G'CMPIE-9%;"^)GAP.?_5)NM$>W_R;<D=N
M [?^S=?.?&;ONFF'/X(]UO\ 1NR1_AF@'W33#G\$>ZW^C=DC_#- /NFF'/X(
M]UO]&[)'^&: ?=-,.?P1[K?Z-V2/\,T ^Z:8<_@CW6_T;LD?X9H"BNY#Q ,<
M9'V_YKH-8PYNJ=6.YXJR!5X%LKMTR&U0<3,[5)6+C$%G:\<5%N15ZZ13%100
M* &$PB %'G[M&6\-VTC<K>)I*QO-C:MO!*SM(8GQHI2WE%I"XH(DG1PQ+*<V
MG+'>C&'VZTS-% QQE^M6;;?N*9S%QFL?/(-%/$%L<I+IP#JQ*274J@U,"1BI
M/FRI 6XY](8@<B36TNGG26Z::L-'0W>-10W.RM)*&3B4=I!9RG+%>]D\%OV[
M7]7;I!<>@_2R'2>F8W!=$K51*%/6;M;114:G2<*<Y2RK.E<'F1Y>=I]5Q%$8
M8SZ_R%CAS/S-OJ[?$-L4D(.,N;ILYK;U\F#3J32DD8]VHW$0]L$3 /?6I'$G
M#9Q1)ZSM'.=*8JF_:O$RGIRZ7:-Z9=-;72^C;11W=P0P)2::5G%%*<U.;AB<
M^Z<BN$/>[4VW0XER<OM_W+)5&K3V%'<P]#"5R6712HT136<_Z-L1GZ53H<Q3
MQ!'H*(J%*"A>=>NL=*6/]D6UQUH5[2RMH5/;&HI5FL'%+.;1Y&RTS91Z,BN;
M:4/L]6'JVO'&:=.PG\2\3##J8!SB7=<8PE+UB.VO)).X%*/8@QO5QR8W</9$
M./Q^,P>KFII=5*,\/'+6BEAK.7"=.XYONFF'/X(]UO\ 1NR1_AFA2/NFF'/X
M(]UO]&[)'^&: ?=-,.?P1[K?Z-V2/\,T ^Z:8<_@CW6_T;LD?X9H!]TTPY_!
M'NM_HW9(_P ,T 'Q-,.<#_ZH]UH?3^IMR1V__3="4G$Y+%X9\S.,?$SPV!1*
M&)-UO)O/C;;D@1'GGR#Y-[CWY  \_+4)5GF^S+GJR&J]:&&B;CAA>.#=<J2S
MF8_<Q=;:XW0Y5R>G@'<B:HVN4S@[AW?VD[H5TLVN5?ND97%E&1V0+)"^>S+%
MNHF< %N!A5-[(#K[([PXK.4JP66HG)ZOO85GFIIUJ=BZ:]*>@[[Z&=&=%K.W
MA>DKGH6Y72*&32]I<XX-1-*<VX;*%3G)OB6_4J_S%EH^6X.N85W SDFWM4?6
MI%&+Q#:WB<38*?)S;6Q0TFLDU,FTD(MVN"#INH(*%7*=(/FCQE- 7^QN5M[?
M"TDU-N:D]VV3>RDLSEW0-]N]PO,5LYJ-P10U?^9MNC26>XF.\//=U!;?,*O:
M7D[">Z&*GG%KE9<C-EM]O\BF#)UZ$$5!7;1YB=0B4>2=7/NX#5O3U[@OMZ5M
M#$G[R3E)8.<\6I.M2WIZ^PWVVAM-9-PII)2JGME1;L]KP+^_NFF'/X(]UO\
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M!P/D &'ZNP?#O\- J)3=7MVO+\#J]  *AA,!@,<"AR;];(;H H@GU\]9#"4
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M 8. -V'J^/("/ >XO/2'?MH#C]6((\B)^> #D!*!NW^L4H''GW@)A*(]^GD
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MDZ93^C2ZBD,/2 BF7D \A#@1DID]KW3EXRJ=[CZ1_)^C0D  AYB(_7Q_< :
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MC&,FS?-"G(S>-GS1)VW=-B*&%4C9PDJ15$JIA/Z,Y>HYA 1U!4?>T T T T
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M:!2B98PJ "10$Q^D '0'FJ[F/&=ND5(FK7ZF6&318)2RS"'LL3(/21*A1/\
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I8.1[?'CO\??H#LZ : : : : : : : : : : : : : : : : : : _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g118907g83k16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g83k16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1964&AO=&]S:&]P(#,N,  X0DE-! 0
M    %CJ^5I X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5]XDP         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              WP   EH
M         0                         !              ):    WP
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    WP
M  !29VAT;&]N9P   EH    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    '
M.$))300,      NC     0   *     [   !X   ;J    N' !@  ?_8_^T
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M!C:-E=JM5/+VEQ$0YS8_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 /_A0!EH='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP
M0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O
M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q
M(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R
M+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP.2TR.%0P.#HQ
M-CHP,2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#(Q+3 Y+3(X5# W.C(Q.C$Y*S U.C,P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP.2TR.%0P
M.#HQ-CHP,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$
M:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!486YG;R M
M($%M96YD;65N="!.;RX@,2!T;R!&;W)M(%,M,2YD;V-X/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @
M(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/G)R,CDS-S0Y/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @
M(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX
M;7!-33I);G-T86YC94E$/GAM<"YI:60Z1$4U-$8Y,S0P-C(P14,Q,4(T,S9$
M1D5#.#,Y0SA%0D0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/GAM<"YD:60Z1D(T-C)$,48P-3(P14,Q,4(T,S9$1D5#
M.#,Y0SA%0D0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I&0C0V,D0Q1C U,C!%0S$Q0C0S
M-D1&14,X,SE#.$5"1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1D(T-C)$,48P-3(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#DM,CA4,#@Z,3,Z-#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$1#4T1CDS
M-# V,C!%0S$Q0C0S-D1&14,X,SE#.$5"1#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP.2TR.%0P.#HQ
M-CHP,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1$4U-$8Y,S0P-C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#DM,CA4,#@Z,38Z,#$K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1$0U-$8Y,S0P-C(P
M14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1D(T-C)$,48P-3(P
M14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I&0C0V
M,D0Q1C U,C!%0S$Q0C0S-D1&14,X,SE#.$5"1#PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H
M;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME
M="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P  1" #@ ET# 1$  A$! Q$!_\0 '@ !  $$ P$!
M              @$!@<) @,% 0K_Q !)$   !@(! P(% @,%!00'"0 ! @,$
M!08'$0 ($B$3,0D4%2)!%E$R87$7(T*!D212H;'P&"7!T28S-$-RDO$9-3=6
M8G2#A.'_Q  < 0$!  ,! 0$!             0(#! 4&!PC_Q  ^$0 ! P($
M! 0% P,#! (" P !  (1 R$$$C%!!5%A\ 9Q@9$3(J&QP131X0<R\14C0A92
M8G(S0R22-$2"_]H # ,!  (1 Q$ /P#]_'")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*('7%FC(6 .GRW9-Q:QK<G
M=XM[4XR#8VUC*R,"NZL=KB:\'SK6'EHA\<A"RIC@9LZ(<ARIG4[DP H]F"PP
MQ54TX,D6U_&]N>Y7S_B7B>+X5PPXC!MI/JFLVF&U6@CYXDB[73 M,C7JH ,_
MB19;M5ZZ/:O38#'PMLR5BK+YI<OXJQR"U0NEJ-<6C:#@5&MH8MX\&4I2)\73
M:7"1=J-@32+Z!RE5-ZW^C"G3KU*TQ3G+\Q!,"=MYM!]P"(^:_P"K,:_'\-P5
M$84_J,+3.)<0?DQ+JE1I8!)&7(UK@!?YKSMFZDYAZVI;JAM>"9ZX]-2D-0Z_
M1KI/2D5BK)+64E8*U.Y9-6)A_G,R.6K&40:Q"WK2KM*39)K.4%B,"$[D"\E7
M!4/]/&)83F-4LB;D0-1) U,7&E[V'IT>*<7/%C@:APA;3IMJ5'03%,D3%@9N
M9#OED$ @ 3UX>ZYKOD#J@L..YZ!JS#!UI>7:N8%O;(DHA(72T8T>),+JQ=2*
MLLO'R";PZBCR#!A#L1(U9.A.Y5$2B7HQ'"*5/A]+$,JYZSLIJ4PYN9F:""1-
MA&FYVC588+Q'C:O&<1A:K*#<&,_Z2M!BL^F<N1KC8D$.+I$"!,3>,43\2?.X
MOXN7<6WI8L1GF>%\2KX @HZ[,,Y_ITME=P*5H8+!DBRM%5$FJ*4RK\_463!5
MF"IC.6_>5(EJ<*ITJ-&2X_$H?&+[1G+B,NLR8N(N),R1/#3\2<4K8BH]O^G$
M,QAP]3"%U5N(R !WQ6-;+<AS1-[R!F @;7\P]1V.L'U5E;KH\E7+"0L4#4DX
MNKL%++.A/V,[A*,:J1$>H+XIW*[<S<A$4E3@N)2BD B;M\FCP^K7JPTY UAC
M/(#@";B)TWN9TZ+ZC'<>PG#L.W$56OQ(-6E0%#!M;6K"K5,-8]KBT@@V(-[W
MV6+:YUT8AG6@&5B\C5Z2)EB+PU)5JV4]U!V.$NLVR4D(TDG%KN3F:Q[AB0'0
M.Q<*E(50I54D#@9(G0[AE4#^]CX8:H-,DRUI@DF(-P=+1U7-1\2X.KG<ZCB<
M.X8IF$?1Q--M.K3JO(RC*'.AOS"\DS/58]R?UN"SRQ3,:8S;,GQD\U3>(LGG
ML<;("+)U%U%2QD4J[MA)M$U5SG!$BJ[A)XW*F)T0;%/I0,J. );3<[_[1\N@
MB\;BU[22/):L7Q^G\:K0I#Y\/5?0J@@$9A3-0?VW-HG[Q*RUT\9_L&1NF]/-
M5VB!7EFOZK=R$)08QVNLY90$J_;%)%1$C+/7CQZHS:@=9$KL!76$0:)(@()\
MT8C"NHXGX!+0Z !,@28Y")Y$B"O0P7$&UL!^KJ->?AYG/#.302;.T,7TVY2K
M1KWQ#^G2VUZX6R F++(57'\+$R=EG4*\[,Q:2TRIZ+"D)J"OZSB]&<[0<5M)
M)1TU5*9-<>X!$,W<)K/(9FN[_M) CG;J/7<67%3\5\.J-?5:RNZFQIEP985"
M8;3L?[W&P $:G-"[ ^(!A="JR5IFH3*=??0=QKM$EZ3+T60)>XJ<MR8FK0KU
MMNJJNX931"[:.F2S[LV(+IHG*;1W":[  U[7?(7223 !@BVIUU(O>TRL:7B[
MA]6E5<<-C!4H56T7T&T/][.]I<R0YP!#FZ92?*(GM0Z_,+'J4Y8GD3DZ)L4%
M>FV-5L5/Z6Y)E5_=GI"+QU=BJJDZ7&0?2#54CYL5)X4J;0WJOSL@*< ,X7B'
MFGE+ VI3=5SN<0V&F#L>@M(U$VML/BC!MP]6M4PN.:^E4;2_2C#@8EU1XEC0
MS-<N$$2X'6&S9?%NO?"B59:3@1>4CVIW>4\;DP^2B2098;7=1I\\-?>5([@!
M24&* THF_%R>-<,2G58O79B& L/#:\B2SX;[MJ R(;$FQL)C<#S*K?$N#=2-
M7]/COCM<&'""BWXX<Z\.IYB!(!-W2(\EYY_B(802JL;;$H7,$A]8R9(8BC:S
M%X[?/[<\O<4P(_=0R-;37/)"X#N%L1,$S*KO$A2(D!3 8TJ8"M2@'(6ZAPS2
M1S$[1'E[K.GX@PE1IJ,HXXO+@UU$T:8>PP3&7,"(ON;[<_;F^N6AURU5FJ63
M'.<JX:V2E;K[2P6'&[R)K+2TVM@@]BZHXD%WP/%)DGS"35Z+"-D(UA(E5C7,
MD5V4R26QG"ZU2'@L+0"06ND1:2=M-#,23H N>OXGPE Y*E#&,<7M815HAL.<
M): 6DDD;@!S@= ;%0:K'Q-LLN+:[4E\73DK5YSJ6'!M>A(3'$XW?PD7&J@=Z
M^<V4UMDFUFNCQ(%?5K)(BMLX$%$5WCYR4R;0_75X;3ITVD.#G!A<8,W.X UG
M8SR@;CR6>*ZE3$.:W#U13.(92_W*1:+22UKRYH=4;'S4X-_0+9OFCJ2I.!D*
M*>X15UEY#(TZK6:G"4NLNK),R,^$,_F4HX\>V=E536=-XY9LDJ84FI7"A#K*
MMVYA70\VE@GUC4R/8&TX:2]T3GT]+>DQ:"OI\;QJA@&X<5:&*JOKM<YK,/1%
M1P#,N;-=L?WM&Y)OH%A['?7_ (<R99J=7(B!RU#*7AS:XJ(F;90G<'7D+72&
M[U[9J6]E1<K@WL$,S8.7K@0:N88$4S)C+JN>Y!':[A->F2"YKA3@.+9.7/=I
M(BTQ OSG9<.'\4X'$NHM9A\93_4?$--U>D&#_9@.$M<Z9S-DW L"1!5?3NO7
M"=TMT/7&K#(L%"VN4GX2AY*LU+E(?&60)NM$?'E(VGVY=0S5^X*E#3*[#YM"
M.:2H1#PL:]=FTF=_I59C'%I:2QS00220:DP=#I'L8 %@<Z?B; U*E-CF5J=*
MH*I%6I3R,>*3@'97.@@$NB8@6S98,890^(U7[7E[!L)1X2<B<.9#',,C8<BY
M%ILU 1L]4L9TJ7L:%NQM.#+)L31",M'$2DW$W'*+.(DYEFD20JA)!#H/!Z[*
M=;,YA?0-+,&D&#7S90YUI/R0!  S:W$><SQ=A:^/H4J-&O3PM5E=YKUZ>5E1
MM  N?1.8Y@SYP^+ML,I7LW#XA]4>X@S!;,:P-IBKE2L'6O-N.V>6:;)UVOY"
MJE?C%UV5OA 0ET'<O4_J1XDSY/ZA$S@1\M'*F9I(O$%E\/\ 2JM-QIO(+M\I
M)@GYHTU(W)(!B9E;*_BO#&G5JX:E5!9\,-^.S(VJU[RW-2^89@"#<6,&)B%?
M==ZXZ0]M5>QB>K9*M-\;P>+%<BOZ%1Y"Q56B3V38.&G81O/'8R#J:9L%F$HW
ME%WK.*FXF'CA3";FVC@X@OB[A54,J/D%H)N26GY2=1$:AVCAI)$%=0\3X1U9
MN'RO.(RX=SV4Z8<&C%"6&QS%H/(2/[1>%.]JH50#"4W< =OD1$1'8FV8/QZ8
MCLI=!L#$.4QA$OCRP(D1$&//KWZW7TQ$$3J6AQ'(.F/?R$CI"JN51.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4?>I;"
M;?J!QA(8W<V%2KIO)JH3GUE.,-+F2_2=LB+1\J+$).)(H61&(!B90[H"MRKF
M<@DLHB0@=&&Q#\-4^(R9B+$@Z[$=[6F5Y7&.&4>*X3]-6<]C14;4S-)!&6^Q
M%_,P+6)A0KH_PT:I2;H^N43D5R51QU&L,[,8X:R4R<;#1T+98]ICA@J:Q@!8
MY&0M4Y+-I=-DW*!E#%-#JK&5?+^E6XS5JL+'-F6P223+K:M,[#62=NJ^;PO@
MG X>J<0*M8/&.;BV.+G9FL8QH;3#RXNRAS77,"7..6Y<9'3W3*\6ROF?,%?R
M(O7IW*V*Z[C2.0+7OG I[F!;3R#2U(N@L#,TVZ,I. NE&"A#HH*MR]S]R4VD
M_/IXI[1\-Q_VLV;+8M%@# ,@"P),'I*][$<'PU2O4Q;'/;7KX?\ 3.<T7+-)
MF XFY !) F;0"HXQ?PM\,5*$Q8\QY.S%4R]C&S0MF-E,KNSS:MB>-CJ#;6SR
MFO;J:NQR-S36=IR184B2K0QQ(W55]-4BW8WBM4#)5^>A$-83#6QI$@GI)DS>
MV@\NIX2P 90-%U2EB*%5M0U6EY>ZX<0YN<""1.6(U$&;R6Z:^EBL]/5;D(]1
M>(M]CDKC:[8>W&JC&'EFPVR9<S*T2FX5<RKM1JT%P+8JZCU(ZZ9"G!LB31"Z
M<5Q&OB($N:QK QK&NAI ,S$@;[_Y[^'\ P'#7U:[:3*F(KU<YK&E3-9K2T T
MQ5<#4RD@N(F 3E&JLO*O0GAN^ROZII\+!8WOC_)].R;;;C&P9Y.4MRM1E'$D
MG&215):,  D%W*G=(@9R**FS_+K&\!KHXU]-\/\ G:*98)N #-KSS, 6ULL>
M)>'L)C/AOI@4*]/%TL6'M!SEU$YLHAS8!(OJ9,B\DVA>NA-S97>1I^#RJI7K
M9<,\U7/%?DUZ<C,Q]5F:O#!"I0;V*4L# UDCWB0G5<*E>PSA-0Z1$0.)#=W5
M2XG\,!A:"SX+J,6!()D0>FWIH==%7PW3?4KXCXCC5Q&/H8YY<V2U],"PO/S0
M#.NMKF+<K_P^)-"\-L@6;,[RQ6 N:)/,DLY-0&$(E,R<I53U=U$(H-K*LA'-
M$^\KU%ZFDY  )\L*1S 9<<?]1(;0:UL"D9,6GYLPTY'SGE,%84O#3?U&-KOJ
M%YQ%<UR7,_Y.IBF1_=<1)!MK'424Q=@.>P_T_.L,U*_I(3A$;&2&O;RL N2+
M<SS]V[2?_ILD_P!CT\7\V8Q"&E&22ZB2:RGHD[T3Z,1CAB<8<1EV!M$&+3L3
MZQ;<ZGUJ'#7X? /PE&KE+\S0\-'RYA8@21Y06DP;@@*(L-\,&$A:#DS%B>89
MZ2H>36<1.2\58J\A/BSRQ%O D'.1V#EY*I-@0G'IUCRU,706@%4%111(3M]0
M>K_4\KF/:PYFZ&<I .H@2(]=>:\3#>%C0I5,.<3FIO>VL[,R3\5EP9)BY,D&
M29*NR ^'LE&U="*=7:A1\NCE.C9)4<XTP)1,6P?I4?0MH(D177_U205E#"9=
MW+S=GEO05,(1K%FW#Y0V3^*N<X_*8--S"7.)F=S?3E:1HMC/"[6EU9U5HK.Q
M%/$#X5*FP@TQERY@&EWFYYB3 NO8MO0.,]/9!O,1EI_6L@V'-<3G2CSA:@SE
MV-)L47$-H@T;*1#F;31MD6]0;;<%4<0*I04%,C@% *H&MG$W 46%DLI4GTM3
M$/=FG+-H'O)TLLZOAIM:K7Q0Q#Z>)K8BGB0X $M?29\-K;F'!P-P8@W(LL#9
MAZ/+]CR B\K5^=R3E3/+K-3'*5GOV.J;1"+QKMM J5Q)9GB6S61A'R]?:0YA
M8A"HW9.;*NJ,@9Z[!'Y8^VACVEHHO:"QH<&@F <QD[V(Z"=;F0O/Q?AZK0^)
MCZ52L[&U*M.I5J-IM<1\-A8(IDC,(,!KG@9@--#Z/3+T=Y!FZM2[KE":L=0L
MU9ZH;+GMG"VF*AG%DL$<^8(QS%M96D'-(Q=6=R!Q6=&;MBS'TEN#9H=)0X"Y
MXQ?$&.RM:P%@;E!D"!8AHD2('D=#*V<&X%7:'XBK5JFJ[$&ME>+P&N +AF);
M))-I VD7%_V_X>LA;,R/\K/<KQBQ396J63XPD[C!E/76#+5/E%!I$;D)U<F;
MB-I#X6AURQL7!19DG*QG#I_)%]1HJ;Q0L8UC9#<I! <X"_0 ";F^TVM=6IX6
M^-B:E>I7>XOK-J0]H<6ALPUKW/! (,%H.4PTZ@+W'G0*^0K:#.MY?)$66-ZG
MG_4K7[*[HB4JQCGLBNV4/574&M:VA))LW0163)+*O4N\RR:P11 3(0>9^/<\
M0 1\F76-.<<XYW,&9"]+_0*=*2' .;B/U#3E'RO((.LZ3>1.T*2V9L ER_9<
M&6)Q:1AE\+WTUZ!LC#E?DL;C]/2\ :.$?JS!2),)919\FY2))D1!OZ)FRX*$
M43YZ6)-(/D!V8M=%_P#CFTOMF_S*[<9PYN*J89XJ%IP['ML!\Q>:9$_,($L$
M:V) B+X/J'0ZVJJ>*4%,@JR;?&65LM92] :VBR/-#E-O;&RD"=P,\X-&IPY;
M.N<91)-P9\+(A 9H@J=/G6[BCG"J  SXV0DB0XBEF&D 3#H F!JO.PWAQM X
M1QK.=^G_ %$MD@.^.:5C\YF,D6G4F! FRJE\/1S"KXYJ=NS2_N>",-VFR77%
MN+OT+%U^6B)J;1L36*/:L@M; J_LK2MDM,XI%HMH6N*NEW#<[]=]\DBF!_$B
M[,X,&=SF.<9%\FP]8F2=!/1_TZ'_  J-2N]]!@J_[9B":A!9+FG,8),_\C)@
MB!'AUKX<TRT=8F@KMGB0MV+,,065*?1J@&/XF E4Z9DRGS%-5CIZU-YAPI(2
MT!'2;1".G"Q#1!R@T60<Q@N'*4DUW5.+N<,46 M=B789Q$D7H!X-P-\_06T,
MWX&>$W_%PC,3BOBTL&S&LP_PJ;6%K<86?$#B'.!)R-(,$C8V"HJ1\,QG5\=Y
M*QVO?\?IMK7A29PG6;!6.G?'M/M41&3K91BG:KK:HYZYMM]M2+<K)*11;6&J
MQ,\=%1Z_C%)MPC,IXU>+/J5&O^<P #+G3;E)D1MMN(VVL\*L%&KA:]6F]CGM
M=1>VA2#V!I))+P"YSW#++@X.)F7$&5Z&3OAQADZZU*Q.\H03!E6$L6MV$RVQ
M#7&&8*TAC)K'MY")I.7H&S04E%QMP7BUG$DRN<-D$89=U(M8%^PCQ;MR7_57
M?"<PAP+B28>X@YB3,'J220+ZP)A85_"E)^);6;4 )&& K"BP5O\ \5I#0:K<
MKWGYY87N/PQ8.^8D[36)0 ZXE[1+I$ ,!P4$#=ICG(8X  _Q*"KVF[SAZHF%
M40."2/C&Y)B)T TB_IK(M: %]F"28(NUK6YM28$ %QN<HB =)G4E>APJG")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")R09F3'+9$Y43D@S,F.6R)RHG")PB<(G")PB<(G")PB<(
MG")PB<(G")PBXF3(<0$Q"F$ $ $Q0$0 1 1 -@/@1 !'^@<(;B#<'4'3V7P$
MTP#0$)K8CKM#6Q]Q]OS^>$7STD@#0)DT!C&UVEUW&$1,;6O<PF$1'\B(B/!O
MK?S4@6L+:=/+DOHID'6R$'7MLH>/Z>.0@$0=.6RH)!D&#S%C[ZK[V$]NPN@]
M@[0\:]OQ_,>5%\%),?=,@^->2E]A_'MQ_CTY(;F3<\SK[IZ2>]^F3>P'?87>
MP]AWKW#\?M^.2!:VFG3R06F-]>NR>FF/_NR?_*7]]_M^_$ Z@>RH)&A(\C"
MFF&]$(&S"<=%#^(WN;V]Q_(^X\  : #R 'V47WL)_N%_^4/_ "Y40"$#V*4/
MZ% /?W_'YX1?!33,&A(00']RA_Y<*R9F3//?W3TDO(^F3R %'["^2AY /;V
M?Q[<==^:AO,WG6;SYKB"*(>R28>1'P0H>1WL? ?S'_7D(!U /G=1H#?[1E\K
M+F!" &@(4 #7@"A^!V'X_ CO^OGWY=%22;DR>93L)K7:70;T':&@W[^-?G\_
MOPAOK?SNOGII[WV$WK6^T-ZV Z]OW !_KYX4@#0 )Z:8"(@0FQ'N$>T-B;QY
M'Q[_ &AY]_ ?MR!K1!  (! @: Z@="LI/,]B/M;R7WL)_NE]]_PA[^^_;WWY
MWRJ+X"9    A0 H !0 H:  ]@#QX /Q^W'\_77WW3OVT]E][2ZUVET/N&@U_
MRX2!K%^:%(4N@*4I0   -  :  T >/V 1 /V 1#A.733I.L>:%(4@"!2E* B
M(B!0 -B(B81'7Y$1$1_F(C^>$7+A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%Q,.@ ?YA_G[^.:WDB()&OX1<O?F8,@'FB<J)PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PBZ5!, CH1*  &QT @ [$?/Y !#6Q !$.$4,5>J*72HU2
MMZE>BR'L>?4\-.6QWZQ4&; TA+M#S::_>4#O )&%/\H<Q2%]0PB(D)VCT4Z!
M?4^&)G(7Z7L)T_96/KI8\XZ_2?PL98_ZQ;WD8M[;1\70H!Q5J>[OWU&<2NZ$
M;$PS"Q/(5Y%NDGK"-7NBAFK,7[.WTI=6J*N%RQ"BA9$@IFS?AQ3(SYA)@ 92
M28FU^LP;QL4CN?>)B=_8CDJJL=7N1F5ZPM6<K4FMUR"R;C2QY!G+/$2$P1*J
MD)+$9TEJK&R::RXFL[$0<JI+J'48K*%1-VJE,'#<-\1E1U,DED "QG2=!-I&
MD'6Q%T GUTTUM[#K_*\?&76;D7,)7L'6ZK1Z9/L+-DM24G+K-3#FL0F-J,]C
MFT795&K)6,>RLK8B2K-P=H,K#MH=FK\RJNY*04>6KA#1,.)G*PP+F7Z#\;Z$
MGDD>?G<]?MLID8$R@7+F/&EL&6H,XZ+)2<0^D\9VYG=*<[<QZQ0!>,EVJJJB
M'S#99LX7B7XED(M186C@5P(F[<<KFEA@ZP#[^I4[[["S/S%$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X11=R5D+)+S,$/A;&<I5:F_4H2^1)RVVRMREQ
M(+)2;<P$7"0E?C;/4^YT=ZP=.9-XZDEB),C()H-B*'.X)L:V6EY$@'+<P),7
MGI/H8G4*_P ]_4?RL45_JJO=;M-@K.6*='2;"LN,=Q,[?<7/&3JE0LG<HA)9
M1X\/9+ TGW+ 9)0@>C'1;\\6BX00<+/5$UUB[AAB6AP)!<"6M<TC-$6!,<];
M['R1Y>_[][Z75/+];";Q/&:]9IDY$L,BW: 90SZWHQ*HV.D/'5BCYB2A6</9
MR+Q4LB\A.Z/).J%*#13YAVU*4X)I6GA2\F7#Y;.BT.B6B;Z\X2(UGO\ CH=N
M:Y1_7S1I>72K<#2[59K-)6&O5^%AZQ9<:V)%ZYL*LD@V!U/0UR>5Z'.U6B7*
M4@@]E1<(JB0B:2XB<4Z_!O:TOS M&I@CZ:F!<V$>1O-3W^^PO>%[276_5'M>
M3M$)CG),U%,8B'E[B=NG4V[FD%FYOZ"R9S+=W;"#(.?F2J/%@KB<HD$:D99)
M<ZQ@;\Q_2O !) S3EBX< ))F0+ WB?HK'>W+7S].J\VM=;M9>UY_8WM>N,S
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M:Q-BEGKQZ266G'<VU?Q]FFY,SN9CWQ9!"46[5G::R:9"8OK5W!N=SR&_VS(
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M(;W[AX*'OLV@$ V'<7>^2 =0#Z(L;0>1V,S?;ACQ"'L#>7ID?7Y63DG[1DA
MNF=F^H!%'BW:,BZ<.3N B9(IDU&2/IG:[#^+N,@'4 ^B<^^_HLFH"(@;8:]O
M'W; -B  83&-LV@V.@+[^W$ : !%W\J)PB<(G")PB<(G")PB^" #X$-^0'S^
MX" @/^0@ A_,.$5B3>+\;V.T1=UL%%J<S<(5BZC(>S2<%'/)V-CGA'!';%C)
MKMSO&[5PF[=$6025*F<CA<IBB"IP,16G'=/>"(EK76$=A_&[-C4Y]S9:JW:4
M^ 2;UZQOE4EG4W$)ILBECI5PJ@@JN]; FNJ=%(YCB*28E)^\^O/S5U5O'M#H
MBD\O2:96ZJM:IEQ-VA:O0\9#*SLVY(4J\O,*,D$3/WRB9.PSI<55S&!,!$0V
M8I/)84Z:)<\Y+9[?J0\O!'/F.:2&.G$6R+\@(1\<D"YR-G;U/TG($!=$P.#=
MZ1RF$J9A$@$4J>$3A$X1?! !]P ?ZAO_ )\(NE)LW0 X(H(I HJ9=0$TR$ Z
MQOXE3@4 [E#:^XX[,(^1$1X1=O83>^TNQ_D'\_\ S'A%\])/Q]A?MWKP'C?O
MK^O,<K>0]N_7GNB^]A!T':7[1 0\!X$/ #_4 YDB^@4H>Q0#SOP !Y_?^O\
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M(<RG:)%F*@VRN7BK5VUT^?BK/5YZ$924)/0<DTEXB38+ID%!RQD&*KAHY2,
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M'(5!&&O^37%]BD:U%.H^1:,AJ55K*;:PO7*JQYR3,:O.)AU(% OS,C,R"X%
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MZR-?@$.V-A&IS"(-TSNU"E<O7 <(LO\ ID\?87Q[>-:]_;7M[_C^GMPBY
M&@#0>1_UX1?>$3A$X1.$44.M"ML;'@.X%FK/2J35X9)O8KE<+W54+A$5NIPH
MJNYF7;1+E=LV++,T !5@_77138!\RL*@ (\*';H52='F*:'A?#R%+QOEN1S-
M7R3TW)J6V2N#*XHM9>2.BNZA8E6.=R#:(AV1EP%C!)NU2L4E>X3]JY!X5[@[
M=%CNP_$<Z6J[61MKBSV![7TLBV_&RSJ.J\FNJD\Q^R82]UM"Z*Q6ZR-(K4;*
M14A*V$Y"))LI!HHDDJ58@"4)_G[GZ>_E=4\M\1OIDB'>0(]27M[B0HDR,(#!
MA47KIU=Y!*UVRC2),>)%5*:W)1%HI%PB)-1KZ(M'%=DE"@HDB50Y73\=??71
M7[G.;HF9NETE\@E6MDJDXWQY>J?)]BR::B3NR5YW"RR)"'(H*IFKL?334[BD
M.?M,40]B*7$2.V#4/'ALWWK\B*"8B/\ NZV/CM\:_GPB]'A$X1.$7P1T CX#
M0?GVX1?"&[@WXWO\#O7"+K4$=Z PAH.[P.@\#^1_(?C7YW[^>$70LY(@0RJZ
MZ:2*9!,JJ<P)D(4 WWF.80*1, \B<P@ ?GQPBTO(_$XI6:>NO(G0AA#)S&5N
MD77S,EER5TI8ZKR,.0KN[R\;;2N#I3SR+B5BA'L&Y.TL@;N%0?2$O"=]]_SM
MWQ]28#']6CJK76PI1\<F(G<+&]1[)/G BL_E9%P/]ZYD9!R<[AXX5$5%53CO
M10*4"*]@  ]@U[!_IPB^\(G")PB<(G")PB<(G")PB<(J1V(E*0P!W 43#VZV
M)A[=E(7?V@8Q@ "B;P4?NV E >$6K6F8&QN'6W.Y&GNH"LQ>6:A:)U1C@['J
ML;0!EXZ[5QY*PQ[[%A(!+9.?GKDLE-NG1H[T$)9B[DB.!,W,4I#<S&_3?ET6
MQ"R8VH5X='>VRK1$XZ4K-AIQ73Y %E0J]M/'FL<,10#%.FPG!AHI1XD @90S
M)L<!*9,!X[[]T6,XOI'Z:(9S4G<9ABC-W=#7E7%6<A%E46BG,T[D'\FX(HNH
MJ9VN[>RTH[45>BY4*ZD':Z9B*KJ&,17OCO#.*\/5]_5L:4:N4Z EY)66D8N*
M9ID9O9)5N@S^9=)*"J*YB-FS1LD50PI(-&C=L@5))%(A2+$G2S-0T^]SO(P#
M1=C%FS'.-46SF-4B52JLF$>U<'^3432,4BBZ:ADU.P 4()3EV4P")%+7A$X1
M.$3A$X1.$3A$X1.$5,Z5*BD)U#@FF&Q4.(@4"$ !$QS&'0%(0 $QS;  * B/
MCA%^<CXJN4_B)7_-'2Y&_#R*A*8U@<E-8_(=N*S:C!NL@+2#$D.R"2?K)(RD
M''17U4946)56:+Y1LF=8YP$I"+>9C#"]>IJH6*;.ZN61GR"*L[=K,N$K+"].
MB0KAK$&7 R<-$)+"Y!DP8$3(V1640%51,VN$\UG$4R"  )0$ UK8;]AW^??S
MYT/"+B9!(Y3$,F42F#1@'?D!$PZ'SO6S&_U_;A%:]-HE0Q[%N(6E0#&NQ3J4
MDIMPQCRJ$05E9AP+R4?&*HHH/KOG1C.7)@$ 47.=40[SG$2*[>$3A$X1.$6F
M;XJS=PYN'3>1E*0Q94B61EJ_&+PRLO*Q,^$IC5"/R,^8(URP*66@4PSD[&WT
MDIXM2P2%GJYDWI08G$KOOS0]S=;-LRXLA\RT)Y0IJ17C6+R5J<V1^S106=MG
M%,MT#<4$D2K@)>UTY@FS%V?8'.U<K%#9M<(H)6/X8E$F<@6[)##)EMA+*ZO;
MS)6+O0BHEZSQ9<9_,J&>+C(MT'!O_2IM:\B&.\<,9<4V[",<*Q[(P)AW@2/Q
M]+KW<(?#?QM@C)&/;U4+I:7,'0J_5TF5+?MX]1J^O-8P[4,$(7MY*E-\Z#UW
MCJCP4<YAT2@P.^^9D0-LXEX12"@:'4:9U)E<5R)+'+SF*'3B4,#^3> JL6V+
M>BH8CYVZ33#:JQ400!(FC*@ :#P3OOO[J5J0:( ;WK8;_P Q]_Y_OPB[.$3A
M$X1.$3A$X1.$3A$X1.$6&,_Y2:8:Q+?<AND5'RM;K,M(1L,W5%*0GI=%DN>-
MAHKL*HLK(R+LJ3=J@V16<*K'*5%,YO'"+2A\$_JLS;UY-,NY5ZB\:72GRV'+
M>I6\7GM_U56- EH=V-S85&9YI@P=N+# ,F<?5W"P(F3C&@+I('!>1=%(1?H.
M;&[D]_CN'6_ Z#7D0]O/OXT&A#P [#A%4<(OFP#W$ _SY"X#4_=%]V ^P[X!
M!T1.5$X1.$4=NK(5"]-F=S$FX"M&+B*^@2P6F/+*5V)4-7WIRO9I@=N[*YC6
M_I"=R06CH2D^\$%3 5,Y%&#X83=PVZ>I-,C-Q#Q9\BV)2NUN29*!/UN*&-A"
M)1UEGQ@ZZ2SR2[TC^3"8;QB:24?(,8<#*&BC&X1468/AN8]RXRL#%Q>[-7 M
MF1LI6Z8&)C8I4CJHYJK5:JV0\<$;+=B3:-EHJH1 LIL@%DH9X@0S4HD$"\*>
M6^O?[:JT9;X6E ?S5CL4?E:Y1$R6S.['BITG#PSE/%#F8R)E')4\BQ16/VVE
M"5L&7KNB49GL.QC7,>R3[@CDU#%>4SRW['J/YS)E?IYQIC?I;K=*C8QR_;X;
MJ>.J?3I)V_E"/$8^N6:L-6:BZ#)XW:.'&VY55SN45]&.;0"0H% H?M?]].DP
MIVQ/_P!WM![0 !;-]:UK7H)Z#QX^W^'N#^+7</D1X57I<(G")PBP9U(Y<+@W
M"V1\GIQQIZ1J50G)>"K""XHR%IGFL>Y6BJ]%@0#KN)&3>)I(-VS5)9T<!4.B
MD84_$ EPN8W][?F8Z)Z<N^^2TT_!]Z^>LGK-PYD*4N> GE7DJMD>2B6=WR38
MYE".>,GA!?%CT(QY&,9R0&#$_P!..:/*#5(Q!3$XJ@(<CY:+&X(ZB#_!M*O?
M^5MY-2\]6)T"UER[$55BH )JP6/:JDIWIZ^X4;%85#R[54??U"("4IM&*&P
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MS@#"*8EV/:(F$H:V.M!L/R(@43:*7R81T/C?"+3K=&!:E\4&IV%<Z;QOD5_
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MSYD3-S S:OQ<,6\PHS9I%*5HUCVQT4C*"<XB<P\UO:RG)JVRSF#3,BUQN-=
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M6O-P1[=1U\[S?HOICFU]IS#K>_8! /SL/Y#[>!UY_GRB"==#>.L]#IRU4=F
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M%QL=!H=+=1IY^8FXB^*/"M:S5J[!1=>8U5A'0L<W1KD61JFPA#"B4Z\<V(Q
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MMTC)J]ZCLR+9+O0!L8R91#?P]N!I%IK4HN3)),"8F3!%HOL/(3]C@*OAWB(
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M3E;VJ=8(^ZDLW/SQL>]0L9R2E3:_J-XNFU!H]3*%1.G%@V.FX,*6UP7!70"
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M5> <*K8AF*?A6&LR[3+Y!!F?[P-3R-_-?483^IGC7 \#K>&\)QK$4.#XC/\
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MFN^6Z<[BLA:TXSJ0S?'*R<21K6U/J=372KDF#5^BI(J(A4"_4RK+JLETVO\
M=@B+00,90%A[:3-[3$: :::!8$DS,01$  ?8#6RMS(F \H,Z[DR1HN?LUOK
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M]9V%IBG1><H<UH:&@2P,EL6 (.VAD'ULE_#3QWEO%"-!N>1\D.9QO%M#%LK
M:1%*GL+1F=-*8.TC*4V749'?B=]]*!T"1B@1%4!,0H\SQ_ ^&<1H?I\7AVU:
M8<'_ #.</F < 1\P( S&+S?9>7X:_J#XK\-XHXWAO$:F'Q#J-2@ZH,N84JA;
MG )!:"2UI)BP&H64Z'T71&)\;U_&6+,X9OJ<%69)H>.2/8ZQ(BFP<VY.?LC0
MQG%1 QUYEN[EV)'0G-\HL^263(<&I4E.G!8'#X.@RAAV%M*E#6-)<0T 6 DG
M;F3N-K^!XCX]C?$O$ZO%N+5_U6/K.SU:Y^5[W0UI<\-+,UF-%QL#8DJ]GN-+
MG5+UB>8K66,E6*(CKT]4R9#VFQ5IW$ITA;&F12MG#YHWK<8\)VW<*89-5-X@
M<##ZBA#-@7*'; +LULT&_=I,=RO*=5=4 F#$:"#!'3T)\N@4M$C@HF0X&*<#
M !@,0>X@@/D.TW^(OX WY#S^>58KGPB<(G"+B)"B(F$H;$-"/Y$-:\Z_EXW[
MZ\<(M7EBK^;VWQ(8:R1ALD3^+)*MH0\E#.8:?CL74^!:T;YI2T1UE1D1K<]8
MWUT,6)=UM['%EDTG@R#9;T&.SN^^_P HMGR)"BF01 ##KP81 1'S_$(@ !WB
M&NX0#S[;$.$7/TD]B/;Y$-#Y-K6Q'VWH/(^X!OV#>@#1%%GK*JV0;9T]9$B<
M56&W5R[HQ/U."-102+8I9S&B+DL&T4.FLHBC(G!--R=JF#HR)3HH*I&4]1,B
MAYAQ;*$AUVNS/Z]U(5>G5W$C./L$S=(6QN\39&MSZ#K@&"MR/RQ*S M:>NW=
M(HF.K]:L,N^E5C*+-6Z2AB=[+;,B4IB )B@(B/G8"(; =AKN\^/P80 >$7;V
M%\> \;T/Y\^_GW\_GSYX1:WNK&@YXD\O0\YC6Y9*959[@[,4,\C*RR4=UZ L
MB<-'+UZ0^58I*/Y"RRSHKMK&'$55T ,8D:U.Z(43%(O.O*PMS]U[OPY(K-L7
M@&0;9Q1LS644R5='%+9W0\R>S-<?&<M?TX21&Q-F=C3+VE=*()3C9"42(H)%
MTRD @<*S))F9_'=_); $R$$H> ,'[B&@$-[\!H UOV\?SX1>7*G!!!VJ!7(]
MC1P;M9IG4>&$B"BFFA0(?U'.@TB4"'$5!*71M@7A%^:.U,.LRTL[--XUKW5I
M6*,OG\RLO0+S!WP;DK!P\#;OTY/QTW\JS7<P]XN+B(6E6U=.I7:G%L8H9)$"
M+O$@7W["FL2)\QW?T7Z2Z4,FYI]76L+ \=/*U^%6FXY5T5ZM'S"L8U/),E'R
M92$>*M'AEFZCM,I".#)BH0I2F  *[SS[TT5T]A/ =H  >P!X //=[!XWOSO6
M][\^1X18/ZB6RB^'+^V;LK\\,YKSQ#T,7BJ%[$%2"035L&Z:KDSTN^X4V@ \
M5)W)M1!<Q!X1:I,10W4BUM_1(O+Q/4<$]7I>PL<ANYY&=)093%3V?R>U:K6@
M7:)6\%96$0ZJ<G]-N!W$^]C&D%&Q:B<J#Y9P4M.\VY^?D>PMX;8B9DM"'=HV
MA[]&':?V$$P^>X>P"CW"(B;>_&] 57>*9!'N$H;UV_RU[:$/8?'@-@.@\!PB
MU;=<O_;.<YRZ9"X&IEAD</UZ]P$S?)BJ6.$9K2,M)*3<.LUN\6]>H2@4.IQ)
MT9IV9JW7;RDE)M/652/#)H.R=]]^RJ/A=174!#8KNR&=D,F,WIY''"C=++'S
MWZC5OJ.'**USB]C1D"%5/3WV6D;(ZKZK346L<[U6)*2..@3A3GW_ )6T(OL(
M;$VC&\CK\CW  :_  8  ?V -^?/"JY<(G")PBI' :,!M_:!/N ?Z'T)0V ;\
MB)PWLP 4/QPB@%G+#^=G>>?[4\*6%V26D>GC*%$9&MU@<EQW4KG*6#&RM2E$
MJZR04,1X1@A;YD7RC=ZNN];MV"BZ+11,A"3K?;?3L0KI^'QC7,&)NFN#H><T
MU/UU"V_(QSN7%F?6Q[(0LI>)R4A)!Y-/DTEUU7<<[;K)$,&T&YDDCD05*H@F
M13=["?[H?G>]CO8:$!_<!#QH=AK\<(N((I@("!?("(@.Q$0$WOK8^ '?L'C6
M@UH #A%X<^42QDCZ35P[-].?F^49* @\<"+94 19K]Q?1=N! $4%.],I%C$.
M=0H!OA%I+Q-TV9VGL8W22E:EF+#]J5ZEJ)?(#%ZV2W4C7T*E!24$P=&5FG4U
M,R-@;+0K-Y,6% [N.:/IQXZ.5BND5,.$6\AL4ARCW%WVZ[1V(AVCY 2B(['^
M8B!1'7D/QPBJ03( "':'D1$?<?(^X[$=[_G[A^.$0$R!_A#SK^8^/(>1\^_G
M^OGA%!/XA57OMOP,M7,:8SL>3;5*V"+:LV%<L[NK'KJ*QSI.[:]58S$(XF48
M-NH=TW@@>E2?/"H"N IICPH>^^_711"Z5NGSJ8H/69(7ZW-<@&Q<O1B0A7%J
MMQGS'Y5K4XIC".5FI)Y^E(6%U*-G1)*%-%LT( YCO4Y6246$1(.^O/G9;HT2
MD4((F I@[A#Q_#X\:$-^3!Y[]AX'Q^ X57;Z*?=W]@=P?GS_ .?^?]=#[@ \
M(NA8I4P+VB8@%#?V@ @/;H0 =B'D=>1$=Z$1$=^>$6KWJPQ3F.Y]1&*+3BVF
MWA(D T=$L%TB[JC&5][7GT'9XB4A5HQW9&3-O*Q3A^QDF+=:$51L+P68J2+9
M*-,H#R19&^'/B_*V)<1VJF9-BIR.C65T;'H2MTDE)/($G!DI538S<A<E_P!0
M6-H+U2W,9U".68OD&[J)0:.",4B*$<.ISUUW_'1%L$!),H  %  #V_EX[?&_
M;0> U[;'7N/*B>F3_=#VT/OH0T)?(>P^!$!W[^-[T&B*E==Q #TA("ARJE(5
M01],Z@)@<A!#>@WZ0>P#X P:'N'A%^=C)73SUW((]6)[YCV1S!.9OR/C!S1)
MC'^39YK#XZBEJSE:M3ELA:X,C53BSQ=69:!)!U=9ZW:V2\-(*7DSD*=P[9+W
MOKWZ\T[O^.6L?PM_F-8YQ#T*FQ#HTP9Q%52M1R@6-TD_L0&8PC%H<;!(('40
MD)HZR"JDH^1,*;A\9P9,QTP*<Q%?'")PB<(G"+B8A3:[B@/:(B&_YAH?Z@(>
MX#L/8=; -$7GOR&(W5^6(0SCT5S($4,8J:C@"!Z(*F #G GJ 0#'*4QRAKL
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MJ\DS.WYI%XQ(";)V_,^>&>.&ZK@SE<R@JF*']OM^5)'A$X1.$3A%Q$A1$1$
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M[DQ:0@'U>5?14#89DD&V;,X5Q+-Y:T2J+E4BZ[&LM9 _RQ55>[M3^XBPPO\
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M0ZQ63AE&/D+&5TT7D%3QY%P,U+Z0J"182'XON+Y^*JJF-J?8;S8'F2*)2;)
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MF1AG>)<FPN48@6*3)VA)2T(PE&#>/D4GJ)CE8'+)G64%HL@L)T2 )C .N>Q
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(.$3A$X1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g118907g83l17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g83l17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %)2^4F@X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            L@   ET          0                         !
M          )=    L@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    L@    !29VAT;&]N9P   ET    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   +(
M    4F=H=&QO;F<   )=     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      H<     0   *     O   !X
M6"    H  !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  O * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M9*'?KME_@_\ X3ELE%:55"\L,:2AWU=MK&;@[Y+>J#"KV&JJP"=DK[M8$A=
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M8[0=B4"\N!QE/#LQ#27 N@0T7,BP%] 9N-T&0O=VULC%8_$;/JT_\9QPQ?\
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MYVG>;,"YB2+V%[>UAOA/&X:OAVMJ4WX:B\/DU<1FZ=YS6-JAOS/J,.<R6DN
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M#CGJ454,83#R)Q'J$QA'D2@BQMQF(SS\U=A4DR  $3(0    "D*4  H<%
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M0:+ 0%FKUJ@Z;*@F?U$P407342.":GSDZBCTG^8O!N^B+ZRD(0 *0I2%
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M2R%8LHU#%&-JUDVV-21UKR! TJM1=SL[)(C1((^=M+!@G,RR*7P]@9TW>/!
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MB=1223210KTDDBDF0I$T4BQCTI4TDR@!4TRE3(4I" !0 A    H<$6/]MO\
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M &E^.Q%''C:-*O4#L.:8:/EFG&[+RYY:';KC8AP,2""MA?64$4QZ3"0J0J$
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ME$)B/1.U[T_M/'RTXK9*U73=-$'*1%DTG*!7!".$5F[DA5B+*%*X;N")N$'
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M(C=)$S!][KWT45/=J)HE766 3)I)@J?I344$J:)3J*<)HAZJAA .>D@*"(
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MW##> 6\PEB:DQ].;6-5F><]UD91\+\8])9NS]Z5FY1Z<AD2N5DR%1#]=0Y0
M53ZY,'LG9^!O@\)0PY-R64FLJ.))=];PW>)DF^8%@8LO:^(?C/XA^*_D?[]M
MO%[3&%!;A3BZKZWRFN#0YM%K@[Y;7%@+V@M:Z 721(SJ(<% B90'K* $. G
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MF'/;1+6U"-T 5#8,L"2#]4K9QC/;[C+%\;"H0M>*_>P;06L5+V)V>?DV)%
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M(2!=-<7Q]VW"V-HG%,46;1-P:G1,E',)%NDDF5R[E'-H(\>^L^*AT+ 4F=3
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M+',7"/K#Y5<3&>LZE(EB".@6"-]-H"*1.;&8SY^)JUJ#&8:FYY+*.' ITJ<
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MY$?T9.XCP B/;OR   _?@.? :%K7  @$#($ @7FP.5[]5@ !D .@ 7H  '@
M#]P<:JJ 4H>"@'T[  =OMI SB_%-(TX:>2Y  #P''[M$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1:H/:X1SMQA3#LTW9F.VJ.Y2EV&6?L8_!$U-1
M406AY,BW4A 0>YBS53#,U*BXDV31S&6=U(KGA74F\@HIY.M&#N*"_?#-0Y=W
MY>/? RMV-R#67VKXFDFAY)9NZ9V@Z2LS X3K4F8I;S94_P#:87;K*3>&60E,
MD!4OP3*.T'*)$7<R9.QK2Z*14?G+KW/-2O!,@!P!" '(&X H '44  !XXXY
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M'RR#['J&1ZE*L)%O&8^?3U@QOM70;R"72Q"^7!6&;9:W)21BLU.M&#HL1A=
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MF>*^\"$#D>D.1 0$1#D1 1Y$!$>1$!'Z"/&HHN>DO'' << '' <<!X#C[!]
M^FBD#@/)<=!.1'H+R/D>D.1_?V[Z) &0 7(  !P   ?8 X#[_P".BJYT1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%;HU:M%LJMQ^!1(VQ
MQ#)5A6R_#F0SQJ^D\7DD8(TOZ'Q 8=&0=.7Z489P+)-XX6=$;@NJ=0Q%<(
M  !W .W]W8>?V\^?VZ(NHID$1,)""8>>1$H<CR!0'D>.1Y A '[@0H#^4."+
MYU1*4PC\A>.D!$Q1X$B8 H<3"*A$^A,IN2F/^4PF H / B14&SF ]9GS 8#%
M&!E!(8H"!1(,=(= E 3&$0$G'S<_,'S   ( !% /*NZ(-E_LS([<T-*D,B%Q
M#MMQ/8$Z3&RB$,O.J.:Y2H1NU&4592B<6T2<2Z3IZ],P=+H,VS@[:.=#R)LJ
M;"]\ YZ3D ),#+0F?OG1H(\A.7#IPUOPMC7;EN/WJ[^=NN+\ZXQKF+MGU!RG
M6EYAO)6]Y*YORZD@26D(D7D% NX"CT.OM>N-7<0TO:"W/XTQ59/GE?BCNCLV
MN56F:=1S#F-W/.[0[@.*A&>7+VX^@.5\EE^M>S_KJUA9WC)^:,PY/OR;<[56
MW/+"G"32C5QR=ZWA;"S1=VVBQ;XYC*N:[C:VU.N$545*UC4V_0F%;6<P -BV
MISN9XVX=."L_K6WCQS.F=E?%@]GYL\M$%)UZR8(JU@:RQVHRLO-'G).XR@,7
M1GS5L\O+R15O#AD+HX+F;_&C-SK(E45]0Z8&'=2VAC:3C\NL6MB&C>M>Y,$$
M3.1.4F,R$+M-ZH+S#7U T:V#7 7U (!)ODI.T.@UC&5.KM"IK \55JK')Q,'
M'+2,G*FCX]N<QF[0KZ8>2$DJ@W#A)H1=TK[LW(@U1!)!%%(G/6K/Q%1[ZSMZ
MH^ XP!, -$#+^(''G>ZQETRW*X&\7$P<P=XDZG/V5U@0H!V H=7/4 %#D0_;
MP'S=@#L/^&M+6-9):T FY.I/,QX=$)D?5'/09]^*^@"@*9P OZP=N.X\=(^.
M X^P=NP?LU0"0=Z\Z&X$6YJ&  6B=!KQ7@0O2(B8.D2]DP   W'?L/'< Y,<
M>_'8PAP//S0L&326C@TP+W-A N<_'62C2XS(@:9_?NRZF#U%"@).$P_6(;@W
M(%[]1@Z>P?4!$2\!QV#OJV_CG:][Z<Y]O)6&D!P)!)N,@0# OZ<?8>R1/F\%
MZ  ?E$0,/V[\B(\\\#SP'/[N $UH:-T  "8 OF9UYI86!DQEJ3&5S/B?9=!(
M43"(@GQR/ &(4Q@^@@/4'(^ #Z#QVY'0DB0 9T,65#GZF!P!/A-XMW"X'DHB
M  F !] 3+HV8$YZSGF4Z9=RO7\R9>2"8W< ,4   [C]"\_W" <]Q ?KK)%V!
M/E,."@!QYYY#@?(_?QVX[\#_ /$,=QI=O;HWN.O#-27"P!CD1[+SZ!)P)BAY
MX\<FX'CD 'QWXYXY\AWT+>;AXG[RA<1:'$9V%IXKJ8"EX*4#!]0 ?E$H!VZ1
M /V<< /;I$. X$!UCN 1))DP(\3K-OMR5:=Z2#E<R8.?W]5V,F)@#DH>GP'(
M]0$^8 #G]P]?(=^W(CX#OK,"/'F3[K$@.%CGKS!GQB)&7Y]"%3Z )QT=_P"D
M43#W$0'GGDW/D.0[\@(<]AU5=T< <\P-22?4KMZ!.>1$X^/)N?'T\<_L[#HJ
MO)4"AR0R('3$0,'(<AR7@0$>>0^4W(AR';L/T#4L)O!-L_"WGZJ9R" 0"(GC
MJ?V@@4HA\O64.1Y$/KQ]![](AR("''8.W;D=!8 $SPDW-YU).J DN)!,6%C$
MP!G&>D=.07NET] =( 4O<   X .!$/H >.. [!V .P: 0(DG.YSS0'>O>_'-
M>FJJFB)HB:(FB)HB:(FB)HB:(FB*C6/^3T]_4TI_D5]1V1Z'V14#&7\V] _L
M75_]$9:JC<AT'LO+(]&KV3J->L;VUFI(5;(=/L5%L[-!RLQ7=5JU0SR!G&:3
MYLLFY9+O(N4D$D'J D5:CUJ$.!REY*]SHODI^(\7T4C!2HX]I5>=1\>$8VD(
M:LP["0*Q!)- R'Q!NT(\436212*L*BYO> (4RH&X  )W?L?99'$I3>2E'MQW
M !["/(AW^G( /'CD-$7E[NWX3#T$>$@$$@](G"8&#@P)AT\$ P=AZ>.0[#VT
M3[9>WM9"I)<J_HT_G$ /\A?F#TP+P;M\P<&,' \AP80\".B*,&,)1C#7[=]+
MR+I"/CHW,M<D)-^Y#TVS=BRVRX&=/G3I<0-_L[)N4BSPP@BD@@8JBKHP"*)*
M 7$ 9G+(2>%X\!Y)W_0U/>BU-;//:/[D?:=73/F*<:5Z$VB5G$-@"'=93L<+
M.VW*]TJ3Z4F8YA,XMI5DCH^H0,N)8IJ:4GK,XM[6$6G(]-A6IMZ+1VTV5*19
M:_ @CB)DY6OK&LPKI/GKT\YCKE)L-K&)=GV%L1BL[91,I>K:ZD?C<O?,GRCF
M\6^<L9D4VZD])RTL4"JSID$TVB4JD@BNFP;M6A3E103 -+2&F&F(FTWO>_&Q
M]9S60>]H DWOZGC,7\>=U*=)%$Q *8"G[&*8@])@ .KCI$ $P&Z> *(B(@(@
M!O/' B5B229[Y^YMD)A?0!  >1 !'MP(@'(<<\=_V=0\>..1^XZC6D9F> T_
MM1=@  [   '(CV#CN(B(C^\1$1$?J(B(]]9(N=$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$00 ?( / \AS]!^_[]$3@ \!QY
M'_J(\B/_ %'N/[=$31%'G<PULCS%[Y"MHV9T4+CBQU:V5+^,#:GN.&63J<ZR
M@T@T*VNC8Y!ZOC]"P$5CJZ8EAD&1EXZ'(]DWD>S5)^>_"_HL%X_7W*1.$3M8
M6EU>9CCR&;G$.;,61,@5.\1F/WV5<B.,3L'D8?&-]D3'8XE7HITFUMDX^Q-3
M&7A9EDQ6;K*Z'(_;/P2.>>1(CT$>6>B^##$GN65VVXA2'$& [/&-L*8X.R8O
M<RW=5S)I-*1$*MD5XP^W]]&(R+P4FQT"$<.T$WQC-0<*(ID,:ASFF6DM(O+2
M0?"+I>/+LQ:<^RKX@;UNL2QI$62.V^X/A1<4YO9T:&GF:\,IR/7=124X:KG8
M(;?4F;>P$7=J-7;=,H-DWI5B%,( )]'.<XESG%SCF7$DF! DF28%NB?K6]^7
M+R])JBN0]W9:0K;2X-PDL^&KA8"U-'.%^-/'??"#R?X:*@I@$$OC9% (S.F;
M]"*Y3%[AWU%+Z0?']+JKD+=RG1CW(N"\,'D!JP61.HCFZ^!/*NRQ)90M9!(,
M >B$L0R2S$Q1,*?O)Q*0>3#R5TO'.Y@<=.%\EY2N0]W$70Y&X(X/PP_>L*@Y
ML;>HMLW7T]@=N&T4:1&N)IGP$")Y<Y2HLDA$W!GIBD*/2JIJ;HF8$\>^$6X)
MX]]^Z]9;(6[>,HKZWIX.PJ^D(^JN[&%399POZTZ[<-(<DD6MMDCX!]-2;46!
M9DF10WHJ.0:I\@!E "H1Q'@1JJ9><N;IZ#BVYY0EL.8-%K2J!8KU*0A,ZWY.
M0%&MP#NPO(TB9=O0A[\+=JNU "&X,Y @E[=/!0 #( =/ZS].:^BT9+W<0./[
M'?(_!F&+.]A*9+VR/I]?S;D1U9+&\CH9W,-JU")'P"1NXEYH$0BXLBA"IED3
MIE6$  !*5D@<O3^\O!?5:+[NXKE*G[:TP?A>RO82KRM@:U2"S9?QL4X[CV"\
M@G78MHYP!Z"T[,JI(1L81<?2"16!,X@@H/+[_92-($<-/++O->=QR+NZJE"M
M=UC\%86M4C7JE/V5C3Z_G#("U@L;V(B'$NUK<0DM@#TU)R;,T")BD51!$TFX
M134X25,(D@9P!$&<CZ@$=//)?5;K_NWK=-L-K981PO974+7I"9:56!S??U;#
M/N6+-9XE PS=? (-U9J27(2/8%7X15?*)IK&! QC:(1(,QTS/6XCO7)?-=\A
M;NJ?2;/:F.#,*6R1K];E)QK4J[G#("]AGI%FT67:UZ%1<;?!17E)5T@9BQ*J
M<40<F_2""?2($RT Y9=.%S;SS.OU7*^;N:O4;#8V&%L+V9U!0TA)HUR!S=?U
M)Z:49("JDRB6ZVWL$%99R9)5)JT6Z4'#DWIJ"*?!M%;Q,=\."HN4LP[G\58X
MNV1Y7$."9)A1ZO,6A[',L\7\\D^;0[%9=1NT(IMYZ3+?H1*H!C<"L B4>DP#
MJ$#@#X*P3?J3PZ9#PZA5BWW_ ';5FL3=E984PG8W,-'*/DH"(SC?%I:0])5,
MH(M$_P"+XFF=<Q".!3)Q\YRJ%$!*F016&0\@IY6ZW[\#E )7:W7K=O6:_(3S
M7".$;$Y8$;=,'%YRR&>2=@X7;-C&0(? ( <&X',HH8P\F*DH8!$.!"J92;"<
MSETT'ZR$KRN-]W<5>N/IUCA'"ME=-UXU(E>@,VW]Q)KFDI1@Q%0H+[??1*5B
M#E5T^*!NA)HW65)P//+I?NZ<+ ?:<]/[-N:]K?=]W%;@',RQPGA&P.4',.U2
MAXG.>0UY);XA+Q\299(JVWP4U$V";P[Q^)^2E:M55PZC<\E1/*_I?F!Y]9Y^
M5SR#NZJD M,L,'X8L[E"2KT>6$@,X9"7D5"S<['0KARFFKMW](Z,020^)R8F
M,/I0[-Z]3$RQ  7KGW;@G6WWO&9$77I;+YNXKD6$DUPEA:RJ_'ZK$GBX'.F0
ME9-)G/V6,@'TSPOMY(F=C7&,HO/S B ')"PTD\0ZG)$>I [&21.D]\(R\=<E
M\ETR]N)QK&P=AN.+,+&K[[(F)Z/+J5S,UV?RS%GE#*-.QH69CHZ2PC#,9%2.
M7M RAFKR6A4/09&Y?@*I@-(!T$\XX]^Z9<(SMGD>7M,^TOD!$R11$.D1$_(<
M"'ZYN_' !P;\P=(G3X']&HJGTJ'J#E^%[:(FB)HB:(FB)HB:(FB)HB:(FB*C
M6/\ D]/?U-*?Y%?4=D>A]D5 QE_-O0/[%U?_ $1EJJ-R'0>RO<0 1Y$ $>!#
MD0#G@>.0_</ <AX'@.? :*KG_P"O[_.B)HB^-4RG6?H$XB0 'HX'YN2\E!,"
M@7JY.!0$5#='YQ!0")+I&)WWW]EKXV[V;.!C7!R#"W6^QIT#&KRZ0V6[->:A
M4V>=5K/D3^%EC2;%-TRR-XVK,X(:HI!Q],@E:&[B4ZVYBFT-\7<2CTID-3%K
MZY:^-_9>N([/N-')6Z(J&&,6J*JYCJ(R+9[GF?02;*_Q>L&("DS6;X'?NGS5
M5H#585G35HLB\.[2 .$Q5.'ES_KS_:M[F 8TF8,6!, 7STY@BYRO7<C;F9QU
M8$!VY8]@E("?=5Y-66SM/,DIDC5A%R(3E?60P O[_ F6D3L&JKA-H0\E'2:*
MR9@;)*&LGB;W-]3F?%)/OKK^]2O:N9*W-V&.>NS;=<?0 ,IZPU])A-9\G&+Y
MTG79N5A"3+,A,$N$"P<ZE'IS5=75$57L&^8O1*B<4T4Y%YM/'5+\+6\K<ND1
MGQ7A3\H;G;5$*R"^W*C5H[2R6^NFCK1G.R1TJX2J5PEZHE-MFH8'%52#LQ84
MEEJ+]4_,Q3Y>'E%@*=\=,"7[X>6E_+-?74\G[G;+!-)D^WC']?6>@^ L/8<]
MSK.3:':R"K(HNVB6 Q])-V":;M@('$5F#ANX,)3KF "7[/Z2JY+W066L0,\;
M;UC^#7FX:-D_@]CSY/,IV*4?M/>SL)]@WP&!&<LT QD'S5%0R*+HG2D($ O0
M37E'KY=^JH,9FO<FZQBPR9([=J5"-7=%0O;FLS.>9YE;XINM H3KF"E(O^ '
MW9O.,"+"SD6X/3D;OT'"2 ID*5,CON5+V]9_6OHN4\V[D'F,R9+BMO%'EV+J
MB%O,978;/$Z^M<D@M!ISK.&CHP,%'!]..TQ*R9MR.2H*O3F17)R'3HJ>[^UC
MY>JJ5GRKN=KE)L%O+MSI,VX@ZW(V-*JP&=K,[M,N:,CEI,L+$1RN!N7LV_%
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M(5B#]S=OF</&"[N-FAJA'J3<V_3<-(:O-W]A;O+#+KQTF6,A49)ZFV<K-P;
M3QCNV?&8M?DOAP!D>KY7QA$V.HQ<9#0\3-W;'*D+#O(Z4@(M]BF[63%L['UV
M2BTD(^1K"$W3I$E<=-VD>1S"^XK*Q,6H<T>V)WWQTR6:R%()>P<@/(")@#DW
M!C#W[=PZA,(<_<1\B.B+N( /D 'GSR'//'C^[1$Z2]_E+W$!'L'<0'D!'[B
M@ @/D!#D-$3I* \@4 '@ YX#G@O5TASYX#J-P'@.HW'D=$0"E 1$  !'R(
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MFB)HB:(FB)HB:(FB)HB:(FB+J)2CSR4H\\"/( /(E[E$>W?@0 0Y\?31%R
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MDWK1KC^?CMM#.5QU;%K3*XL@[)-$?LY12]GL*UH@1[CIKWFFA%_/*]XUD];
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M!W\]@[\@ #S]^0  _< ?;1$Z2\\\!R'/ \!R'///?]O(\_O'[Z(N0
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M ]5G\B:?03Y"?*F!2_*7L40+R4.W8H]!>0#M\I?Z(<1%W A"AP4A2@''  4
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MHB(E#]41$0X$1T1 (0.."%#C@ X* < '(@ =NW B(AQ]Q^^B(!" /4!2@;I
MG4!0 >@HB)2\@'/241$0+X 1'@.XZ(G27O\ *7N %'L'<I>> 'MX#D> \!R/
M'G1%SP'V#Z!X#P'@/^GT^WTT1<=!.0'I+R < /2'( /3R #QV#Y2]@_HE^P<
M$7(E*(@(E*(EYX$0 1#J#@>!'N'(=AX\AV'1%U%-,0Z1(02](EZ1*40Z1  $
MO'''2(%* AX$"AV[!HBY$A!\E*/80[E >P\<AW#P/27D/ ](?8-$7( !0X*
M%#OV   .X\CV#MW$1$?N(\Z(N=$31$T1-$31$T1-$31$T1-$31$T1-$31%__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g118907g84x18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g84x18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %ZR^8& X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !$0   <(          0                         !
M          '"   !$0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !$0    !29VAT;&]N9P   <(    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   1$
M    4F=H=&QO;F<   '"     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      TT     0   *    !A   !X
MM>    T8 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MKUL<YNT 0SW>Y_\ PG_HS^;0_M$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!%P', P$1  (1 0,1 ?_$ !X
M 0 !! ,! 0             ' 00&" (#!0D*_\0 6!   00! P$$ P</"P(%
M @4% 0(#! 4&  <1$@@3(3$4%4$B46%QD[+1%A<C,C,U-D)25'-TD9*T-%6!
ME*&QL\'2T_ D4PD8)7+AU/$F1$5B@F2#HJ3"_\0 ' $!  ,! 0$! 0
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M_P EB-)N-1'U*NK#M ;+U63HPVPW'Q:'DSEU%QX53DYM,UJZF-M.QZZ1PWS
M?E-R&G8JI;[:G75(0P>]4CG$\'XM,_AC%[Z\XWMH;7W$*U#MAP&ECSA_Y@P%
MI=8G<MB]HDR1SUUNKP[Y;0ISM.V:]P,=3G+LKU=]3YEJ3(3;&(B8*U#P8<A^
MFKB+<EFK3*D6,D(+J&5#A&JOX;Q*FTNJT',IB,SXB).4>Y('GZ@[#M7P/%<1
M'#VX]CZHSD,!!.9M,U#H!L# $Z&=+^+%[2FQ4ZS]4PMS\3D6SD2WEHK&;+O)
M*FL?;E*N@AUM(:D38*(3C[T0\2D1PJ;Z)TN<GJH\#K5F=Y%@+& 3MK8Q(T]I
MNN.CV]X!4ITJ3\4Q[J@Q0#9DG\,'S%KD%OE: "++NV9WUP;?#;AK<_%I:VL>
M29QEB>2F37,URW_23-X\4N,LLJ>D =70E25)#RB4#DK<.Q%*H*3!+B2T6B#Y
M?7E:YO(W[+]I.%\;P.-QM*L&-PSGC-) :&N(OH>FD=;JZQ??_9G-KE['L4W)
MQ>[N&(,BT7"AVB"OU;%Y,F2@K1'CRV8G0HRW&G7%Q0D^D!D ZLWA/$2"XL=,
M6B_,B3&G^]PHPW:W@F/Q->CA^(,+\-F[R'_\2<QO>.=XZSI6FW_V8OH&36-/
MN3BMA!PV+(G9/*CV#19J*^.I0D63I<3P]7)4A4=VP9#]>E04$A2@1H.$<1):
MU[2 X@'R(O87/+:8Z%;X;M;V;KMQG=\18X8.F]^,$@'NF E^O_4'G%]-\39[
M2^V=A?Q8M1D6.V>$IQG-K^ZSAG(2F+4C!GJ1%FANM]#0]9,-(NFG)EM'GN08
M[+:2TR\]+;>1J> UH,3)D:G6YL)!(Z0#T,E>2.W'##6O5:<")<,1/AIL;<O(
M@#P@38P3TDFPS+M6[34^W&Z6>X;D='N++VLQ65EUKC=)=H8F/16X[JF0S)=C
MNI5"F)9+7K.#&G06W%E(?:>0KB:79_%/K4V$'Q5&-'7,YHD&8B^\1;DMN)]M
M^!8+AV(XAP>NW%5</AZM>L0[\O=TW.)C6;; P(/(C+,)[0NT6=T=G>T^>8Z&
M\;IHMOE;:[%MM6/QID=#S4BQ>=$<B.IMEP)L(Y]%>4RM#3ZG>6QGC> <2H5@
M&!Q),"]Y! O>P@28GI:$X9VVX!Q+!X?&TZK0U]-K\9XI##8O-Y)@3ZC:0KJ-
MV@]E9F+RLSC;E8L<6K;%JHFVSEF(D:'9R$J=CU\OOFDR8C\AA*G66GT,]^CA
MUE;O4D%6X+Q-CZ <#!R@ZP18&9VU&L'70+N_\U[,5J+ZGXQGX"E4#'O!L'EP
M#;B2+C7021,V5@OM+["HDT<5S=#%TO9(U&D4W_5N)]*:EO*C0W [T);AM2WT
M]VUZ>Y!$IP#H=62D&/Y+6S53%@X6C2"#8S$#>V_6_/5[;=F<.YM'#XMI-=P+
M 8).=U@.DW.EMKRKW;3=^+N1E^[N)QZ1VL7M-EM9B[\QR<B4BZ7/I(]X)B&Q
M';,8(1(]'*5O2QRGQ5U<:TXKPY^'I8>H"8<-" )YR#L/I/+2_ ^U%/BO$.,T
MJ&#[\<(KT*#B)(FL)!)Z3,=)%@IBUY*^H6W=?_(X_P"@C?PS)_O)/].I=J?,
M_=0W0>0^RB[<_>7;+9RKA7>YV94V%UME,56P95Q(?8,V4TV9+Z(C$9N1)>##
M ,AYQM*F8\<=4EQH>.K4Z3ZA+:;"Z-0(WG63T49V\_<:]?+S7AS.T/LG"R?%
M<)D[H8DC*<YB0['$ZI-LPZ]=P)[?>P),=V.%1DJL4)*X:'Y#3LP!1BH="5#4
MG#5GM<\4W96S+HT@P0?KM^Q9V#5PWU,?.<V!N%[VYN].UFS-777.Z6956%5=
MO/555DRX<?2Q.L$LKEJBL(88>6M88:<=^UZNA*CY>&HI4*E0Y:;"XQ>($QO<
M_JA>T7) 'F/T6.S.T7L=!R3$<0L-S\6AY'G\"#;8=52IP9EWL&X6TS5OM-J:
M2B(+-Y:6*U,IV(].?2XU%;==0XD7.%K0[^B[PR# $@@7L+SY>B@U&6EPY#7R
MWZ_57./]H39W)18.4.?4MBFKS"IP*:&$SN];RO(+LT5-4L1G(<=^:FSN&I4:
M+.@-/5[GH%E(]*7%K[!^)#J%2F!F86R";QH!>?(#[#4@*^H!%P1,^>GOUA3B
MT?L39)Y^QH/)Z?'W(_( 3^Z />''&L28U^=$79YZ R)&Z)J431$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4<
M[G?@^U^O-?X;NB* #SSX>?7SR3QPD*25\* )"E("D-@<=;BD-J(2M6H$A](C
M:H"?*'?K"9L0WQ8:,X+<TB0&%P:3[N GJOD'DO8)W1O]V7,Y9M<>KJ?(NT%G
MV9YHRW/=])NMKKJYPG,,8K'&"R6US6LFQ)*I48$-QV9BU(40I0/Z30[24L/@
M&T(&<-; B[2 X$B=(D ;@@\BOYLQ?\)N*8SBG%<:X9SC>-U<15 )#:F'!8X4
MX&P+#)(,EP_XW]FQ[)O:$C[2[7;7U*L7?K:3#\_H,IA0;[U(MJVR66_)I)[=
MVF [)E4;,5P,SZ9D,.272$..E)!UP4.-T\SJKG, =4'B=UN)MKJ- (GJO:QW
M8OC#\!2X<*)#:>'J4BV[0'D$-,B;@&Q!!D08$ST4O8IWDC8)F5#*DXUZPO\
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M8)U@=28]'_\ DC"4*=!^/PE;#5ZC:AHA[B'U@6.G(2<Q):+"3H-1KC-_V_\
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M=\/V9IU7=\YT&B8@2#-X) ) ^:R NSC?\1N%8?"81YPSPY^'[]Q,97!HD@W
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M0Q*LV'DBPD5",5C1O5YZTR.>5:EO9[A@#P&WHT^]<X-V)&T7F8@VWT*Z*?\
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MB55Q55[E==5L>2Q.RS'<6LG8%Q,K&X$Y^KF9+6HFQ8<MV7&?[F.\S'2M:=1
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MT<Q-B><76+Z=1CA2+I?4CNR;"TN)GD6B-#>;!5YX(^T\./MN$I/M\21X$CP
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M?77TM_'LFN<P>L[C)+Z^N;Z]OZ]RMM)^2V]A/DV-LN5'=6V&W)3I2>CT=M'
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MZ7 NS.![*U<3BZ=*KB*^->"ZH][ZQ+C #H>][0T0-M!R4[ IZ@I1 'B"%*2
M!SX*7RI!4W[>ML<_T^.O-RNSX>ID+0/_ '"9(/,Q< &T '6?3ZJC5&(<:=-M
M,NI YJF5OM !%XF(TN#HJ:LBVGQ/\&Z7]08_N.B+V@IQ9)22$#R\!X\?'R>?
M^<:JXG++?/T\O]>:G34?/150I2N 3XI)ZO >(]G]O].DW'(BWGK]O10N[5E
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M))B "!!=ETF1,[DJIQM&1+0YP,/<=R(YWT@#RUTBYA=@O:2T8W#L-RH4?/\
M--Q+W)+RQRBP@]S+KD7/>M5\:M;;>*6!2]37HZ'5+!4R'4H05=(.[0=VYC*1
M[MM,#(UK 0XN)+I)!-S(M,3I%CL./T\.#292_*/Z1: 0<P)(\0OXIL=]" %X
MZ^QIG-6YLS98SO=)JLJV:QRZQ2GNY6+5]OZ=3VLSOV8\N'.[QE;L6.E+)D%!
M6KI"DJ2?./YI3K&I4+0.]/B;, N N<L")Y<N:HSB%*NSO',RO<XR"=#T$B+7
M$"->JR6[[)5WNE<X%-W_ -QV-U:7!9M]9-XTO%H>/UEG.LHJ(U:_-9KG&4*-
M2$O]VOCEX2%(<Z@D:H>*G#2^C#"8D  S].MSI>UUF_'MID]U8D R(/WL)U/3
M3593MYV4,3VEW+S+,-M9OU*X;G6'-X]<8!%CH]6N7,24\]&RAI\O*6S.:AN.
MPTMN=0<;44\#J/-JG%VXBC3J5V@N;5@/(N0 /#:+22(T ,F\**?$2?ZE9TU!
M.7H!OZ<KZ^^+,=CN$QV-_P#RDG,7UQ#"?B+R]RO;$A0D9ZK-07JU"N[227$Q
M.2HI +3X 6 =<S^--;CV5A2D0TQEM(L! %O"-HU\, PL#C'NJ&J]QRET1$$Y
M0(,Z>GO=7V2=EG+:O<7*MR=D-X+#:NYSV#71<]KG*&OR&DO)]/7HKHUY$C32
M$5EPAL+ EH4HK>"G5M*<4I2MV\<H5J+J-6@'_A:A<'.%W4P 13)@RV !E!B)
M7H_SS#%@%2BUY9(#BV2!K$QH#)B3?W5G7=B['ZK!L+Q2'F%K)M:#=>'O!E.5
M6;3<BRS')FW''YQFE'2AD2%NI:92V$AEEI*$ )\]:':*F]];$MI!H-"IAV4V
M@ 4@0026CG.]AYA4''J;JY#*881AZS;"VDZ "8WW$>AR7"^R7BF =H[*-_\
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M ?9QQXC@GP\./(DC]H/!\1J6@-$"?4RJ!H;I/*Z<>))\2>>2?$GD $GV$\
M'S   XU9Y[S*':-,@"U^O-7<<P@P/( ;SKJN943SX  E1X \ %$DI]_I'(X!
M)X"4CR&KBH008;+=#E&G+R4;1MR5.2!P/ > ( \% $JX4#SR"I2E'VE2B2?'
M3O""XAK!F=F=#=3$?Y\R2C(8'- $.,F1,FWTL@/ ('AR>?;S[/A]G'A[WLUF
MV&]\&@ 5ISB! D >'_CH--$@9LP !R.98 >%TAWO*IX>\//GV^_SQY^ \/(:
MJQ@8QC!):P$-DR;\SOT\U  : T:-$#R3X>/^>/TZ.:'1,V,V*E5Y)!3X<<*^
M:?V_\^+5IM'*?KSYHMA<'LF6,:@-NI>)"I7!;:4L<>EO#CE/O<>WQ\=3'E[C
M]U!,;$^066^N(GY$G^KKT@]/<?NHS?\ 5WLGKB)^1)_JZ](/3W'[IF_ZN]D]
M<1/R)/\ 5UZ0>GN/W3-_U=[)ZXB?D2?ZNO2#T]Q^Z9O^KO9/7$3\B3_5UZ0>
MGN/W3-_U=[+@[;Q2TZ B2?L:^?L"_ =)_P ](\O<?NI#KBQ'*1NK6MMXPKX?
M+<D 1F0/L"SS[@?Y#^G2/+U(_P *,PTU(U !^?57OKB)^1)_JZ](/3W'[IF_
MZN]D]<1/R)/]77I!Z>X_=,W_ %=[*-=RI[$NLA(:2\%)FA1[QI2!QZ.^/ GS
M/*O+Z#H1&OW!^RD&>?J%"WD0?:""#[Q!!_M'(/P$_&*.:'  S8S8Q>"/U]U9
MI+2'")!F^B\:UQW'KUZ$_=4-/;O5SPD0';.MB3G(;P" '(RY+3JFC[CJ]P1R
MM2EGW1!'33Q-:D(8\@1%Y/(\^FNNO-<-3AV!K536JX6C4JDR7/8UQF^D@V,Z
M=!NNYRDI71,2Y3U3@L.X$_KKHB_3A&[LL"7U,D20TII"FP\%]VI([OI 2 .)
MK$SWC@9FQ(1_#L$]X?\ AJ32"#X&!H)!D%PB#>]_M9>!D<#%("HV166.U%A9
MPGHT:K?=K(+M@E^0ZAEB/$E.L*?9'CR$LK1TMH(1T@<:N,;B6SEJNN(N3 !U
MUF)TW_55?PS 52YU7"T:CBX/#GL:2QPB"PQX8BT+S+&?M991+9RW1B4^,U,9
M3=.2Z^$^E4X+#3"Y!=CJ]*DM. LQ72'E)*%MA8*2G56XO$-R@570QI: 3L3)
M\[QY3Y*#PKA[FEKL)0<'%I>33:2\M_+G)$NC2^U@O0K7MO\ B+.JVL::2T^V
M[%DPH%<P8\B\?76-.,*;8067;14=V)WK?0Y-5'+#O*$*&JOQ-:IWN:HZ:Q8:
MD%US3'ACVUW*N.'8%E1M5F$H-<UI8P-IM#6M<]KG90!X2<H!,_EMHH*W>P;:
MO<N/C<R/N+(P.1A=I8/PY.,&N;BNR[R%WDII^IDPG8DQQ0B2I4:R0UWC;K$I
MV.ZK[,M/=1XMC*=4U#5+@X@N! ,Y&%K1Y#T$W-Q*^?XWV1X7Q-V"Q#J ;4P
M>,.QARTFBNXMJ!U."'9LYVL;@R%E&TN-[*;-;=X]BN*VE8[0XNB?11[6<\W8
M6DB59RUY!8)DS>Y](6)SLMRPE,@",M,AM9]SW*]1B^*8G%.+WU'9G #PF &F
MUQ-COYK7@_9CAG#,%A\%0PE-E'#&J:3()=_5=GJ$D_F!)Y1!A2;!1M[0HL)-
M8QC-,W/6^JS>@0(483W([0=EF7W#20\E+2@%*7UDI)!'B0>,8K$!@;WC@)FQ
M,R=;V(U/D+V.GK,X3PZD:AI8/#TN^!;5#*3&AX(.L"]_J;JSAUVU[N.V$V#4
MXE]3<IQ<FW4S3UR*J2ZTL$KELJC!+S[3I2I??M%:201[HIX.Q6(<6DU:DL(+
M2'$1?S]3NH_DW"LKF_@,, \ .BDT%P:9$V_PK6/>;2PVJUV.YB,-M^3Z56%N
MMA1R)L9;<-4U'$5"XDF,7FHR7UAM;*'D?9$(*=6?C<4\N<ZO4)<PTR 8\)$&
M +@QRV6E/A?#:1HEF!PP-![JE$]RS^F]W][;0'#4&)!7;'L, N\Y0W!KZ&UR
M2MJ[.8J^3 A.SJSU;8PJXQ3-=CF6VM;UD0AQITM ,O(<'65!.3,158Q[&U79
M7L<QWB)LX&8@ZQ^_-2>&X$XAN)=AJ3J[:AJ->6-S!\ 2+>@&T+O;R/;0)E3(
M\G&R:&4N:](3&AMOP;"Z>DQWI<;IC]XU+M7U2D/OQ^MZ0\W)[Y:PE2=2RO5:
M9#WS&67.)D:$$3!!@3J#;=:?@L(*O>C#T0^<UJ;(+M<Q$:]>G16LJ9M1:>KZ
M.0C#9[-R\FPK(#U=!<9FOR>\?,IJ*Y&4RAY]UN0>^4E#SKX<1UJ(5SI3Q>(I
M5.];5=G(B\D"2)ANVG6+^:YW<(X:\N+L)1(<9<W(,KC-R1&LB_E"S?U+3!;"
MS3UA5%A.5L=9@QN6*YY(2Y":6EKJ3#=X <C(*65GP4@@D:S[^J'NJ=X[,XR9
M)@&9L-!'T6]/ 8*E4959A:&>G2=19-)A#:;M6B1,'37ZW76J@HE);2JDJ%(9
MBK@LH-;"Z&83@X<ALI[CI:BKY)7';"6EDDK0KPX=]5[WO>\>7@S<F+:64'A^
M")DX6@3#FMFDR&-=^9K!E\+3-P%QJL>H*'[QT=/3_8@SS65D*$KN@YWP;*H[
M+:E(#OV0(6I2 OE02"3S?$XJOBVAE=Y<&Z1;[)0P&#PS7-P^'IT0\RXTVM:X
MG34"5[&N==BVGQ/\&Z7]08_N.B+5_MJ[+-[W=G[/<6KL9@Y/F9IGG,(C3@%K
MA7K\F&A<J*5\M-251FUM)<Z2IM!]R4GDGJX=BOPV)HUB8 <2X$#Q- -B#.A(
MG?S659N9IM-CYB8N/D<[2M+]Z^SINU8;TX!E>VFWV256<B%LW#5N] SI",6J
M<?Q)$!K,<>R/$7HZR4F&S+BPT-+*I[SS<D*;4DZ]&AQ(TZ.)H$L[JH'DM+!F
M<7$D97"#$ZC[V)Q&':YX<6F;7D@ -$:'?IZ[J3NTYMUVD+; <VQ&TJ6=^:7<
M"1<5E*K#F:O \MVWKIL&2FLCN2W6I2;RHD3#&C9"L*9?>K52&^#UGC/"XK#4
MJ]*H&Y,A;FS&0X:.UB^X.QCK)U.I+MP= !<:1%X]=[^2U5RSLA=I*PR;',:F
MX926K6?578Y5D^?TD^/$H]NG^SUD<JTR^M3 <;5)6B?72FD4:(#C;4A]E:%A
M(&O3=Q7!-:XT YKF/K$->0X/+[YB.F8EH]M85#0K&0<I#H(,1 !B+WF!MJ==
M"IPW+[,^;;<9?D>:=G/$KBH9Q&SQ*TIBVRUDEE;Y'F63V<?-KS%:FS6(@8V[
MP"ZR^OQF&^LM-66Y>4/,D.Q8Y1Q#B%/$4^[Q>5WAAI: VS0T .BY+C<Z3EN%
M9E%S2<LP+7Y^+2;6F!$@7\E]/MK7\UE;:X(_N0Q%BY^]A^-N9JQ! 3"8RERG
MAKR!F($@)$=NT,M+/2  T$\  <:\6J6=X_)^0O=D'_621[#T76 0 #J  8W(
M%R.GH%GP   'EQX>//\ ;JBE5T1-$31$T10YNU]SI?CG_-BZ*=CYC[.4-:*$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$5>/<J/O _P!J%:(ME<!2!B]?Q[52
MB?Z93QX^(<GC1%F6B)HB:(FB)HBZWON3GZ-?S#HI%R/,*TK!_P"GPB223%9)
MY/AXMI.BA7^B)HBBW=/[U0/UX?PTG1%!.B)HB:(L/S6%*EUU>_$:[]RKOJFU
M7'XY4^U%?*7&T)/@I7#O7TGP4$D>W3YR117$VMRR%)?G1G:) K[./;UE.X_.
M=KY+R+%<]YY32X2GJ@+:6I*F67)[0F*])0T@^Y,?6Q,6GYM]Y3]594.W^9J9
MKE\4<"-*N:6PLFG1.1(C/8GGN073*JN.(/0_$LXD_P#Z9QY3"D(;1WC*@^D-
MM=")B1^_4?12+&X\P5UT&S65)LV;&\FT4L>IJZL<#;TF4X_+@8UF] J>RE=?
M%8@M/G+^J+7QT(]#@Q9 3R\6PY/MT^>D_P"E UO)&XYWD>T?"%[(VQR*LF)M
MJ=W&I,MNG%$B'/5)CUJHTW'J2HE3"N/#=4B7'=H&C&:#'V:NDR"MUH-(:U61
MM)F]IY:GT&GTE7&43$APTF(Y$'K?>UKJR1M/E;"6ZI,K'Y%##3-DLNS%V"K"
M5)LJYEI^'*C(C(;8BJ?:?<3)CREN)94R\ALN#IUKX,IF<VUB1Z]/MS*I (O[
M+)Z_"<JAX#=8VFR@L7=A+>D5Z@\Y.8AL+=:<1"1+D5R9CW#+909C]>MUL*3R
M7E("]9R>4#YL)]U,=0??]0%B<;9N]>K\P8L)=0B5DM#DU9%/I,V:N$]>FE#;
MK\V7&9=46_5JNMQ*$AU3B4=*$I.D#I<W^<Y^6"C;7U_59EAF*7-%DD1=F_1*
MA5]%>4]2J X^NWLV[*[K[0SK%MZ,T@.PTLF.6FWI7>.25/J*%/K5I'H=?7YJ
M;$A%CXVLNH:\4LJZ10KFXO35;;<.4J2Q M9]?97"I3\I],0JCQR;F6N.^IEV
M0)90OH2EI)*1YCG:-M]M?.Q]8@[ZR//4VZB+"W74A=M9M+:QHEBN1+KD3K21
M0S5NQ@\V(IKKN9;SH<5:FDJ89:-DXU!Z4(0>[X6D@^$I'SZ_7?FIDIZQ%- :
MKVI<Z8TTMU8>L9'I4E1>67"E;W0V5)03PV.!TI ')XT4KT]$31$T1;3XG^#=
M+^H,?W'1% N^_:!@;'WFTM5;4%A:0=R\Q^I>3:PW(H9Q=M?HK#-I8,O.I?D1
MW+2QKJXB,A9;7,2\H]*.D[T<,ZNVHYO_ ,0#K Z7GT$;7Z0J.>&VL2;7/Z;R
MHQRGM:3HF9[U8=AFVLW+GME,6;RNUMW;^IIZN[@PVIGU11ZM^5(2XJ=C\R _
M D,.A <E)*.I/B=;?@G-91J/):*Y ; .LQ'VD^HE9BH9RP(&\W]-?V'+9<+3
MM=S,5VNP7<;-=K[.O=W#DU<JBQVINJ>ZL$XO(JDWMQDDIR/)##+=%2AV?+C(
M<+RTM*;9[QPA)?@7/JU:+7@Y-S8DV@=9-A%SK 4FL!$M,'YT/SVR[.^TC946
M>S<-Q+!&<PC4^ T^XD^V=S#&\=9=JKB7*8C)K4W<R&B8\IB \\A:7.Z*76NH
M]+G(I3PP+9>]S"'%L9"ZXYD;F\_6Y3OAL#I-[6_6U_>)4CPM]MN4[.X=OA?7
M+.'8+G&/81?ULS)BF [#3G[%:[CL&P;45*18395K$KD1AUE<M:&V_<K USLH
MU757L;+LH.T3EL3T'2VVLK4.:6AT@6G?<V %R?\ '0D]M3VB-G;RKEW=7GN/
MS*RMQS(LJL7FYB%IKZ'$9TNKR>PG$'F.FDL($VOL4.(!CRXSK3G!3QJ3AWY@
M8,D@-'.0#81,0;^JJ:C 8S"VL7^WU\_.,5Q+M)TV6[E0MNH-/*;,ZQW-@QKA
M3T=41UK;9_%69,IM*%J66[(Y3'5&2H!21'=ZO,:WK81]&FQ[O[FM=!!MFF-N
MAY[=55M3.XAL$ D6O8;ZV]?:;+9I!*DI)XY(\>/$?T'7*M5RT1-$31%#F[7W
M.E^.?\V+HIV/F/LY0UHH3_@T) N3 YE0)WTG;6/W74_(CQ(TB9)=0Q&BM.O/
MOO$MLLM,MJ<6XM7"E=VWP.\7T=" 02HCGC2DSO3#3:)MOY?/=6<6C<@#4G](
M]2>6ZB;:+?# ]Z<;N<HQ1^?$KJ#);+&K)%[&%=*;?@M-/M6#3'>.J?J+*))B
M6518M]4>PKWTNMJ2X0UKJJX)[:<L#N\-P#H1[#W'/0K,5&'^X#SM&U^2DR%<
MT]D@.0+6MG)4^N"@P)K$T.3HY?3+C(<8<5'+T=<=U+S!?#K00I7"PA93S.PU
M<9\HG\N0$?\ 49Y/1V8:"!&X*G.R+'H?/I[[ZE7Z7XRS(4A]IQJ*XMJ4XVXE
M;<=2 HK47.H((;*5)47C&!*F^2GKY$&DZ2T Y@!FF(#B)@&P,=8V];$B)&EY
M/^O\KS(^08_+A/V4:[JWJZ*MQ$JP8L:]^%%4UU!]#TA,P(;4PH#J[TMI(Z_$
M*04FWX;$  EGIH8TMK-].?14%1AT</4\ODK"\FW7Q;&K'#JM?I5M)SQG)'<;
M72!BPCRSBU:W:6*!(](996IV.XE$4LK>;6\H)6XV.5#2A@ZU5[P6D!H!%H(Y
MR;_94?6:TQ(]YDP?\<N1-Q-GFV\F';?X8QF>2KE0FGH-=8>H'%0?JB2U9J80
MTA=>W-<',9<EI,QQIQUIE86CK5[A2[4L'5<][7-<,O(0>FH,VZ"38&-*]]<3
M'.W^YZZ3I;99)DFX&)8G>85C=[:HAW&X-Y(QW%XI;4MR?:PZ.VR.2WTH4KT5
ME%526"T/SS$:>DIC0V%NR)D5M['\/4<*Q:/R3EM>T6(YZ\KD;!7;5:1)(%R-
M#M\_359,;*L1'1+78PA$6P])$D/I#3D5ALOR)+#A(9<3$9:=[YH.EU2N\4VD
MB,Z-9]QB,M+PB7N ,B!!^T<M?4B;YVQ,]9VZ[3ZF/VL!DV-J6E*;^D)<L%5*
M$BV@K"K4+ 16H<:?<2N4M7+?=GI<!\4(<6%-)V.%KRX!A@'4V@1(D?Y"9V_\
MA]?+[V^FRO';BH9L6ZIRSKF[-YOOH]8]-89FO-@\D^CK4'TH2"E)<[I2NM01
MW84>-0<-6&K;7OM\Y<]DSMY_=5BVE9-=D,1+"%*?B)0J6U'EQ7G(O><E*7F6
MWC*3X)/"EQT%?!/0.-9O8ZG&<1(D>4Q]-U((=H9V5]X>P\^)X/!Z2G\4I)X*
MN?'\4<?#K,&Y_8CZ[J57\57Q'YB]2BV6P+\%J[XY/\2[HBS'1$T1-$31$T1=
M;WW)W]&OYIT4MU'F/NK6L^]T']58_P -.BA7VB)HBBW=/[U0/UX?PTG1%!.B
M)HB:(J@\<^ ((X((!!'M!!\"#HB<^YZ1R!R2.DJ3TE1!Y2$%*4J' X4!R.!P
M>?'42!&VP1<B02LE ]WXKZ$MA2N HE2E+^QIX*U+4ZX%)025*2I#80G1PIAH
M,G,1>[3!VF0--?I!V?(^?5:JW.597%S')*XW=FJB]8M"SL*WN@<2QUC(\;A6
M:YL&52MFCEHK7EKJK<3[J%:UB[6]5,B" EIJK<L$V) $:09,.)_V+\]D]#%_
MG/Z7]E;T^X61IA26$Y!96+\^XI8V,R7:_O9-E!9W;OJ>\<[F-7@K5$Q]FL8M
M28P;B>D1UJ7'4XE2IS M,@ R(MM8]8(TZZA28_<1\\]ARY+SZ3)\UO[U%?'O
M+Z+66SM X_)"V9-G6^F2,@1:0)#JJ)$.KF)1#@MR*U$BY5 Z0%NL*<Z=9.#L
MS3)@;#?:_,21T'U0:;3R^"/+0_1>HU;YG6BL8N,JR-JDLHD29D%W(CPVWJCN
M[AZ!PR15H8A-.1FVE/O2X\M2E$.!:4+"=7 %I!B((&L<INHG3?RY>?S[KG$S
MO,FV*Z#,L+1BWM+W#Q6A=.6YDW'7,BM8UM/7'1%;*8[]8S7N2WDA(4IUEQA+
M)>92N#&T[#E,: 1UY&VA,!/UYS;JKO"L@N[5[$DVMA*N+&)F34-NQ2Z9$">Q
M+Q>\=O(C#HJ*.=%=AQXZ)UY3RX0<JIJHC#\AP+0XG1HIEADN#@) D:[;7DZW
MFVO-\^? MGPI7CXDE2NM2B 2M9(*U*!''4YP XH *4/ GQ\* "\S.T<^O[ZH
MN/M!/"B/$E7NE*/2$]2EGE9)(ZN.KI"B2$@>&HCYSVOS1-2B:(FB)HBVGQ/\
M&Z7]08_N.B*#M]MC1O.O'P_;-5;5#49I$2E<?TQU-EDD*I;J[6,KQ0T]0V=6
MU/;)23WC2%)X4GG75A<54PA>6 '/ .8$V!F-1SWG]5F^DVI&:;<B!^A478=V
M4YV,5&619N9,VMUFFR=AMO?77J]YEVSRBYD6\NUS.8RIY149\NT4XY#)4MQ:
M5K*R2.-:N/J5646%K8HO+F6/2 3/( :>J@46#=VD:_X^_)4D]CRFRF3A<7<+
M(;FSI<$V<@[8T%7CM[D>)=4QR+&AWF027:.T@O.N3&&%PV(TAUQGT60XTZRZ
M#RG-N+>RHZHT#,]Q<[, 1J-!SMJ3(V4]TS0R1$;3'3D2/FB\[;WL4XG7W-=9
M[NQL0W?3C^WE9MSCHR7&H]D] I:#([N=2K4;!,E#CL:@F55-+=4CO)+]6I_W
M"''$+L[&U<I;3)IYGYW90!)(@C32P^O-.[9RFP G8"8^^\J7,Y[.V-9'*ASZ
M:;:5$U.X&SV63(<Z^R&QQAF'M;G.+Y1'JJ#$I5D[C5 _(BT#4%EZKJH?*G X
M_P!XD$"K,6Y@>"UA+F.8791F.87ET@W,F1N9N0%4TS,B=9_-:!H(ZZ']-]>,
MX['&=3W]QY.$[A8U5/[I5F_6+9*JZQRPLFH&/[SWL^_BS*@1K")_ZO0/3K&(
M^TXB1'FKF"Q4MLQE,R=VXVE%-KZ3HIAD9' %Q;;Q#>1K<2)%I6?X<RYV8C-,
MCE)FQY_2TJ6-N.S+.P3<BASAW*(TYFG?W2>,%$1UI<@;A*PUQ 0M;B@D5BL7
M=#O//>*F(4GP' KB\>,4P,#<N4-:--&SK!-R"9  '3GK3I-IBQ))%YC4QTF+
M6$P%N*W]HGS\AY^)_;X:\]:KGHB:(FB*'-VON=+\<_YL713L?,?9RAK10FJ5
M&ES2&Z^<3T10=VBZS<7(MJ+[$=KV7$Y?F:H6)M7/5'0UBU;<24,6.3/HG2(;
M4IBH@&1*,%M__K>.Z2 3SKT.%O93>TO&@(,Q%IUY2>5^<+FJM>9(-O?J+=.4
MQ.TZZ+9]V9-\,3AYG@U&ZSN[@6Z6UV/8=9-5>/XO@OU,WFVTVL1B[DJ%-RI2
MIL.[Q=5U32K:&^F4W81J5*U I#S'T+L;AS4:\!H: X&X<#,"Q! WM,CT7)W5
M0S>UYU Z:@0/:($<CFV[^TL/:UG?[<_&\8H<(Q[;@;(;X;6(BOU%!1VF:;3P
M\W.<U=?#8>;[FWS# U-;>6$V1&A>FM7=>M%C-DPBY!RI5Z$T0X@AO>BH;$CO
M*CW"=CX2TS&E@"#"=W4!%HO, &?"#ZS,V,B+F(O.6-;6WZ>RKE&,9)33[;<#
M<O%<ZRW.Z2FOX&+VLS-MS#9Y!D&-U62SH\V-3KJYEX_C&/6=C6+A1(E77PI=
M2Q7,H8;\MSFC'5AK3S,+08< TM!%I((,WM?J0"NQC7"@ 3#H<77FY<3KM'1:
MDXYLENJS6K:G;1JO-O*'/\!R>WQFQQ;;7!<_W"IJ&GLJJTK+S&\)RX[;98,=
MEN4TJ+/G5.(R\F7 4M=:XN/7N2?:.)PK:08 T&#H+ FYV%SN >8OOR=U4+S$
MD$@D$&X T(F =S;7V65HV0W'FW+M_C^UTO!\/M[S>BRQ_;UVPQ>ME8S'R7;Z
M+25KT^LI[1ZGJ9&47C3C[5/4RI46K_\ U!R&%J<U3!XG#M=4:2 0T>+6;S82
M-K3>;*[J3B9(/43$>L&.>A4;7/9WW":P'),2OMA9VX&>Y+%VIF8;GB)FW\AC
M!ZK&*JJCS\>DW-ODS.15KV,V,6=(:BU%=,K[A4]0AS)*6G"F&XS#]]4@@6),
M""028Z"+G0B>4JHH$\P;1!$"-(L>FVM[%;T]H;!)V39SV;LMAX&,WC8%NU86
M%XMEFBD6F/TU_MCN!B;5Q$;NI,,^KX&4W=!86GJJ1(M(_H[=A$K+!^ T6>+#
MXFA&(-KEP$BVPV-OKKLKBG$ 38\Q,&=21?;D;:6!&D>5;1;[9+M!5;1P]GLE
MCV. ;9]K;$I5[.N\%8I<AR'.L7RJGP%O#PQE4B181+QJ6W)EV&05E B@>7 9
MF<.O3Y=;T=]0BD[P_F!$$F -2X$&/<QR $H&., 2($"VNT7V-Y'UG62MQNR3
M +N\$[!MG\;8EV6SFSD'!UUT+&XY3G..9);R+RRJ')4V,FLO8-<Q0/SKQN1#
MF3&V(,55@_-K%1V-68JCF?(!'>.,Q%H%K23!T-Q  M8H6.,Q.@L9%[3I O%]
MQI.RI>;,9N[89?2S-G)E]N/D^YV)Y;A^^0EX<Y!QC&:N;1R'(ZK^5>IR^HD8
MQ3PI^.&DK:V0+-,H+B=['DRGDR<10D7;$$0!<D^HMY#J8U0L?$7YS:WL(/E:
M1Y+8WLD;1#:;:B!"ML/J\6SJTL<@G99)CQJERXLWIE[8OQ7[6S@>E(E+7"=9
M4RGTZ2J,RL,]32@IL>-Q.I3JU*;J>@818V!F8&@L($QZKHH-+6F=20=(,;66
MT?D /'@>7)4H\?&HDG^D^TZ\Q;JOXJOB/S%Z(MEL"_!:N^.3_$NZ(LQT1-$3
M1$T1-$76]]R=_1K^:=%+=1YC[JUK/O=!_56/\-.BA7VB)HBBW=/[U0/UX?PT
MG1%!.B)HB:(FB)P>"?8!U*/!(2D?;*5TA2@D#Q4H)44CQZ5>1SJ EH US ^W
MV3S6#7&Z>V>.9)7X?>;A8939?:/0X]9C%EDM%$OYTBP=6U!;A5<F6;!Q<Y:.
MYKG40VWI$GE,9'>M\#K_  [C3+C();(C37R.MH(F_.$T_7UMTTW\MUG;GB 5
MI!2%!* GOW% A'*&D\M]:E)2IU<1R0'$NQTK2T_);1(&N>G2< 0 ;'[P+$@3
M)TUMNG+RY??WWB#;98'E5Q$VVQB=9UN*W^3/R+@AG',7C"7:V=[D5N^)+S*K
M63!KZN*[,EN3K>=8RZ6LAPVI#Q<>2UZ.[NR@7$9K ?\ &)&@$2.MQ ]0H<Z
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M3ZY.Z%8)ZI3;,=2ZJ>^T7%% URU,:UQ<&@7PX%M+.>")B)L>H-IM?5M-TC8
M1)\Y)@SKI_C3; GGW7A[HDDA04@D'@])!(()!*E D+45+' 5P/)+LT'6T?4K
M9K<N\Z>D?/HJ:A631$T15_%5\1^8O1%LM@7X+5WQR?XEW1%F.B)HB:(FB)HB
MZWON3OZ-?S3HI;J/,?=6M9][H/ZJQ_AIT4*^T1-$7A7N00\?8:D34NJ;>=#*
M.Z2%*ZRAQ?B"1PGI;4>??\/;HBQ(;H47/NF9GE[&@3_:H>&B+E]<^@_[,[Y)
M/^O1$^N?0?\ 9G?))_UZ(GUSZ#_LSODD_P"O1$^N?0?]F=\DG_7HB?7/H/\
MLSODD_Z]$3ZY]!_V9WR2?]>B)]<^@_[,[Y)/^O1$^N?0?]F=\DG_ %Z(GUSZ
M#_LSODD_Z]$3ZY]!_P!F=\DG_7HB?7/H/^S.^23_ *]$3ZY]!_V9WR2?]>B)
M]<^@_P"S.^23_KT1/KGT'_9G?))_UZ(GUSZ#_LSODD_Z]$3ZY]!_V9WR2?\
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M,Q< <ID99YF\\M A)]A/'L\3Y:ECP_2QF(*J 8F#&YV!Y3HJ J/M)\_;\&M
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MV^"_3M5WHZ;95FRGA;L$03,9;!=D1V6_='4<'Q$R!< ?VQ?I?>==[+S'=N.
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M0H>/61[?+PUY3FEIR\NFW3I"^U&+[VM3> .Z(,.S2X],@B+'GU5-54+;V/\
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M&,Y.F1X]6N?/3)BN2FJU;SCXK 7DE2-<G$\11P^"J,%)CW@E])PJM!<'.%@
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M@)X X3RD'CP'$7&G2)_?64#7$^" [6>GL=X3GQ')*@#RGGS1R>3TJ!!)ZB5
MJY//AY#C4RZU]^O+:YO^BL65?_[!KR/+]]M(TA.KWB>2."OI2%JX)Z2HCQ*A
MSP5<\\:JX%T!SO"7"=>=M_ES(0TW/M4?#(U;8@S;69BW4QZB.-V9^?P,(L9.
MV5<BURXS:1J+ 4N(WU0'[>$S<R(JYK;T5N:Q4.37H_?M.LJ?0V7&E^(/H<-I
MX4XBHVHXD%KAK&K3&\V^PVV\7CV(XIA\#W?"ZN9Q=3#P1FEIJ-!!:-2&DD:
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M>UAE;B-73XDC*),/%K*OPF:B=B;-OCCLCT:T%--"G8;G0V7G5$RU2 A(&O\
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MHEJRLHVX4%R=Z3:POJ8%50+&/08:8?1DCBC 3.7';+SCZE39"XCB5I:1XI"
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M;#^<X?[C_P#MZ(GUJ;#^<X?[C_\ MZ(GUJ;#^<X?[C_^WHB?6IL/YSA_N/\
M^WHB?6IL/YSA_N/_ .WHB?6IL/YSA_N/_P"WHB?6IL/YSA_N/_[>B)]:FP_G
M.'^X_P#[>B)]:FP_G.'^X_\ [>B)]:FP_G.'^X__ +>B)]:FP_G.'^X__MZ(
MN7UJ[+^=(?[CW^UHBF=ALM-LM](]R@I4>?M?(\#W^3X'S\>#SX>)%WZ(FB)H
1B:(FB)HB:(FB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g118907g84z19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g84z19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &(2^8G8X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            ZP   A(          0                         !
M          (2    ZP                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    ZP    !29VAT;&]N9P   A(    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .L
M    4F=H=&QO;F<   (2     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    '.$))300,      X+     0   *    !'   !X
MA2    WO !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MCT67V EE32]P:),-&X[6JDWKN"[(&/[P\OV-,#:2'&ISF/#MKVL?]/9_I/\
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M"(=6W>RKU6N;^_6Q)2SNK=.;A-ZA]H8[#=M+;VG<R'QZ9W,W?2T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  #_X4 6:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q
M,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,#DM,CA4,#@Z,3@Z
M,38K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R,2TP.2TR.%0P-SHR,3HQ.2LP-3HS,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#DM,CA4,#@Z
M,3@Z,38K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES
M=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z=&ET;&4^"B @
M(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!
M;65N9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:3YR<C(Y,S<T.3PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT
M(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.D4R-31&.3,T,#8R,$5#,3%"-#,V1$9%
M0S@S.4,X14)$/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ
M1&]C=6UE;G1)1#YX;7 N9&ED.D4P-31&.3,T,#8R,$5#,3%"-#,V1$9%0S@S
M.4,X14)$/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z13 U-$8Y,S0P-C(P14,Q,4(T,S9$
M1D5#.#,Y0SA%0D0\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D4P-31&.3,T,#8R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(Q+3 Y+3(X5# X.C$X.C$Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z13$U-$8Y,S0P
M-C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#DM,CA4,#@Z,3@Z
M,38K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D4R-31&.3,T,#8R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(Q+3 Y+3(X5# X.C$X.C$V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D4Q-31&.3,T,#8R,$5#
M,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D4P-31&.3,T,#8R,$5#
M,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z13 U-$8Y
M,S0P-C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T
M;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@ \ (= P$1  (1 0,1 ?_$ !X  0  !@,!
M           " P8'" D!! 4*_\0 4A    8" 0,"! ,$!0@'! D% 0(#! 4&
M!Q$ "!(A$S$)%")!,E%A%19Q@1<C0I&Q&#@Y<G9WH;8D,U)BM<'P)='A\0HF
M)R@T0T9'@ADW59*B_\0 ' $!  (# 0$!              $" P0%!@<(_\0
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M^/V]N  3(&M% -;UK[;$!'^_0?R\>W .>PFM=H>1 1_B :#^X/ < =A '8%
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M?YY?1K_LQU*?^%XHX!F\7V#^ ?X< YX X X X X X X X X X X X X X X
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MLH#L=^X[WL!]][ !$ $2A])ON ['@ $DP#0% -^!]]C]/;Y'>_PB(>_W'[\
MC[0WO7D//Y?X>_\ /@$()D#>B@&S=PZWY'V 1_/0>  ?   :#P&@(?12WL2
M/O[B(AY\#X$=>W@/'@-@&@$0X!SZ*?\ V0^_W'7GP(:WKM_[OX?TX !),/8@
M?\?T\!^0> T > ^P< X,BF8  Q=@'MY-_(? _B#P(&_$ @ @(" " $7I)^0[
M":'6P[0T/;L V'L.MCK8?E^0: C]N . . . . . 0C^,O^J;_$G -)WP_?\
M2,_%D_WKXX_Y53X!NQ)^$/Y_XCP"+@#@#@'2.L8AE1.H4I2!W#L2@)2^H8 $
M0$! B94R^HH<R@B) $^DB^P=]^!2%>R11;:]?1E7O%2LLE%"*<HP@;!#RCR.
M4*)RF"0;,GKEPQ$ITSE.5RDF)1#P!_Q"!7*8F$A1,&C" "(>/?\ _B8X?W&$
M/UX!'P!P!P!P#"#-W^>7T:_[,=2G_A>*. 9O%]@_@'^' .> . . . . . .
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M%]6<S-,ZC&#LMOR7?+TV(W:L<6KH_)-+=/S#=@H"BRG<JS3144)VD4,8I"@
M&U@H  !K[AL?U$?<1_,1X!SP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P"4J82E 2B ")@*'MYWOP&QUO[^PCH!\#P#RY"5;Q31U(2CUG&Q[-
M)1PZ?2#ANR9-FR8=QUW+EPJFD@B0FS*+*J)D* ;'TP]P/CC^.7\=#J5Z:,[T
M7%G19=:C'4).M(6">R8UJD)>&%OEQ=*I.X2#F[!%RE><,(<$P1?K5\'*PNCE
M3.]+HZ7 -_?PDY=[DOHHQ)U!7.M.HG+?4-%O<CY9EYH%%)RSV16:E(ME)JJK
ME(=O!*PL='+U6%;)I1\- K-&K!,J&Q.!LV!(A3=P (" [#R/CQVZ]_80\B'M
MOS[^> 3. . . . <&'0"/Y (^PC_ , \C_+@'5%<1.5,P=O=L $H@81$"G$0
M[! ?HT!/JV  8P%$?/ (16,(#HQ"B([$3=I@*8!()2FT " B&^X1*&R]@D.4
M1*/ .2K'.("4P"0="'< $..S!^+N#Z=!LH%[-CO?<(^P'<$-@(#[#X'@$'87
MVUX_01#?C7G^7 'I$_[(;WO>QWO6M[WOV\>_C[< CX!T#*&*3P($#>RZ$I1/
MLV@ 3 42]QRB!B)E+W=NMCK@$L?H$FB@4%/I 1#1! !,81/L2J=PZ,*:8 )@
M,(B<!'SP#D>PODOD#ZUXV71A W<H(B!@ 1 0*8 V8X_7L?/ .]Z1#!Y+^(//
MD?(#]A\^0#\O;8>W  I$,&A+XUK0"(!^8?W?;\N =,VRFT  8#&$H!O>@,/;
MVCX,41$1-KN J>Q#_P#,$QA [)4$Q* F*4PF( '$H"!5-]QAV B(B G.8X 8
M3#L=B(CYX"_NW/B3^ . . . . . 0C^,O^J;_$G -)WP_?\ 2,_%D_WKXX_Y
M53X!NQ)^$/Y_XCP"+@#@#@&.O53)5N(Z:^H:8N$#8K34XS">5'EGK%164:VB
MQ5YK2Y]6:@ZZ[0 7#:9EH\KIC'N4"F61>*(G2*<Q1 P&@;X:73BUJ6>L39$K
M_3!=\:5$T1(O(*P3?6U,Y5;1$9)1)P8D>8U<E,T>+*MU$F@(BH?]GJD.H&O2
M > ?3Z"9#% ?J#?G\0_GY#\M#]^ <@@F B/;LQM[,(B(Z']> < @D D$"AL@
M_0/_ &0$  0#]- '@> <B@F(^0'7CQL=; 0$HZ_,N@[?R -< C(0J90(0H%*
M7V*'L&Q$?'\QX!A%F[_/+Z-?]F.I3_PO%' ,WB^P?P#_  X!SP!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P#@=Z\:WX]_\ CP"4<YBZV(?480+H-CH WLOG
M0_F.Q]O'OP F<3&UW=P=N]Z#R.P\CKP AO6@X!$H8Q2@)="/<4-#X 0W]0;^
MP]N^T?\ M:WL-@(%O+WE.C8PB3SF0K?7JC&?UHH.)B01;*/03*0P)Q[(PB^?
MNC;,7Y5DU=.!$IC%3T&@ Q:)U(Y>S.K\CTXX>>%KYG'HGRWF=)_4*>!0,<"O
MJU6FX?O%;6Q0#U"G.O"E X$ R9R"/#OPUZCOOOP.\UZ/T\@.D93J<R-8\[.B
M."/T*DY[*OBZ*<)F Z16=+@S-VL@**@;2?S"KIXJ4I07,<PB(@7=R%TI]-V6
M(VMP^2,*8YN,73W:#ZKL9NL1KEO!NFVO05CR B3T!3[2_2&R&$ $Y3#YX!?"
M+B8V$8,8J(9-HV-C&B+&/8,D4VS1FS;)E2;M6S=(I4D4$$BE323(4I2$*!0#
M0< ]'@#@#@#@' CH!'@%!9+R+7,2T"X9*N:SMM5:- 2UFL#A@Q<23M*(AF:K
M]^JW8-"'=.EB-D5!3;MTSK+' ")D$P@' /F?^+A\5^@Y#Z8['AOIARZGCNSY
M!P7E?+%@NMI;OZ;8V5(H+*1:Q%!J,=((HOS7?+%VCDJG&D*4A6L(RL3])87*
M;73OZ_@=^!8OXAGQ/(R4^'GAWIVP'U 5F"OL]T3T3+N5,FC.F3FWD978MG1B
M8UIKT!,L]OMSR96Y]I9%$SE5B86NRP>L99X< #OOP_H^H#I3R#6,F]/.'KE4
MK,PN$-+T:NBG/QKL'[5\Y;,DFDDJ#LNP453D6RR"^S&,"Q#[+W"(\ R.5.)"
M"8-^/(Z#8Z\[T'W'\@^X\=\@8H3?6-BBOKR*,DE>$"Q*CHL@Z_<:<,Q0!@90
M'9Q=@AZ?HIE2.<RX")/3#O W;OF]1V?7KU*=*$Z+G5<5%>\6LK))\FVUKHGX
MVAM)-O1)OY(QDZ>_BS=.G4*MD1M626H'-$N4C7OEXZ!>3BS^$;@1..LHE8)F
M^5:2KHKI%NDH41+Z) .?:GT][:GL;M;9=.E4Q$L/3C4BF]ZM&^]JTKK1?EMV
M-.CCZ-6;BD\K^?RXW[>KS^QME6O92B7<U7$IINS9OC1RA9V&>0KE1<C=NX]5
M-L](FJ+<2N ("@"(=Q3>=^ \M4I3I2M*<9?_ (::RZJ]UW?*[W>^^^>I#E.*
ML4]C7($-4[DGCRRRE2L<9!WU5L@Z)3I=Q%+MFEI,U=B#98((Z?SZ8/!!!0&X
M@N/HB/*#Q/E?G^H/J/Q?0.J6>Z?.I+,65.G3]I=/V H'/V2I$\P\D,W6[(2<
M'EN\X:E5D")%J["!7(P171$T>E-.#GC2ID:E 7/K_1'R;7?6V3-L/PRK]DI#
M*W6ETX7;(MLRY6,#9.K36@7"\2AIRRMH6TU=E-NH"4F3D*N_7CWZRA@]8?41
M35(40 H ''W),?S?%QZGI.4KSNJ]->-9*FW#JJMW275G3Z_RD?./KM#/7+2+
MFW;<6J[5E# +?_VF0XJ.##W"V,F @  5$T^+5G65K>+8*'P)0GF;+SUB7SH]
MEH!6XR3.D1]FJ<,:39V=A-J)*/S1CLQD?F6JZ*BX) J1#^M.D)0]/'OP[TQK
MZDOBQ7R%K6#;WD"!L>,K9T^_$7-@SJ,H&(WK^UQV0HF)Q%:;@RC*RF0@2,Y'
M60K^'^7C7&U$I-L=-43?U8@!O9Z-<YV[J.Z;<4YVM\'5:VZRQ6H^\PL'39E:
MPQD;5K"FB_KC-[+K@4%IU"+<(DL*:2:23&3(X:%22,@<@ 94E'90'\P ?[PX
M!SP!P!P!P!P"$?QE_P!4W^). :3OA^_Z1GXLG^]?''_*J? -UO<( &M!K[[#
M?O\ EK?\]_RX  XCX 0'8#H=#X$ ]A#Q_+\_[@X!R!QT78^_G>OMY\:^WMP"
M84=AO>]CX\:U^G_SX!B_U>-7-BZ>,XXZ@IQ&(OV2<-98JV/4$9N,@9N4M4A2
M9:.B6D$]E'#9LG(#(/H\2KF4*FT[P74.F4QS%#OY&D/X?O39,8 RSBZR9 ^'
MZXZ?TZK6WC:9S=,]1S&SP<>^+"?*KOAKJLJ5)8DPL58#=K8/EBKE5(0 $V@/
MI39.6[QHV=M%4UVSA%-9!9$X'252.4#$43.41 Y# .RF 1 Q1 0'0\ [7 '
M' ' ,(,W?YY?1K_LQU*?^%XHX!F\7V#^ ?X< YX X X X X X X X X X X
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M?EY8THRJZEYGG=EE:[5R"@A^RJDTEG[Q>&A"^J2-(X.BFN=+M*4"_8> _/\
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MBE9,B0EH5FQD%H]H@Q1KRZ\BZDF#6,2>+NTB !X^?/BM,NGI.&G+ATD=3JE
M@\8XERCU 9""JUZ*K'3Y&Y><MF$3!6%Y.V6-"_6JN2#M!G=(+$W[\N:VL84G
M1CN2F0!^OW\@NM^/Z\C:O'RS:48,I%FJ55I(-4';18"G*95!RFFJ@H"1^U0H
M*)J%$0,!12-])_(:X!WR>IVFWW"(>Q1U]7Z;, [_ +^- =-1T5(IA5*DD %,
M;N,4W:  'GO4 OII>1\"H<H"(:V ;$*N48QWFTDKW_O3G\A"G6G)1C%S<OXI
M-7?@K7>7*^3YG10EFCHWIM'"*R@@']4D?U#F\!O0E'TQ AC%]02'.4H>!$-[
M#'3Q%&J]V%2+;Y--KG:UT[=&S/6PF)P\5.I0J0O;*=.W.RDW-:I-YI9:7U/5
M!;9-?082^-=IC  D#1N[0>#?]D  1\_KS+*Z_CGGR>GV\^MC KOA9]6OO;OU
MMEFBX7NDXDR=<,94=;)F0JQ1K9-47'S-PDS6N=MBX5X]KM:(\<*)$;&FI1)O
M&>H;M #',('((@)9'?>GCX=3XV<+HY"8Y7^)95>ING]2>#;IG3HWQ7-=36=;
M70H+(SNAS\Q9+I^\5L4QQC6_6N52H<K%2[FO4B#K17 URHUY^[EV<:SC7#E4
M._Z[17$KDPD)@GJ4P7A+(V(\^=-L1D#HVKKOJ1P[BK&N+$9./NEHBPN^-;#+
M8O9LX"TNJ^FWC1=N7KAQ.MD9%1K+D,Z4/L#)3(F4.@+$G77\0^K=7DI@YLRE
M\&8E@<9US)\)7K)*RQ$J!\FVBZ1%N8Z9EW$H"A&Q&Z40S!4BPIF.X3.4!*!@
ME$LX3$N.,"+];$:-?I%A^'GU05[IY0RRW[73&;L=LD7U.JU9+.-':T;=YFCN
MHQ. C ;I2SMBLS;,BJG*5%-WW]<^/D#<@[O'6O4OAW8^Q//=,$;9L5*?#Q:#
MD[J ELU04#9J),?T33H+UAUAEY .K1-/8>(95E!XZ++,5G#R4<MS$3<1CCO"
M_P!_EIW]C7EA>_\ 2#ER@_ JH'2 OC&T=:>,;GTPS>:W6&X&/2OE!Q?6L&.V
MO4BIEZT5V-:%2BW:ZB<786=GES*S$P(M-*2"JI%0+B52T4/$?Q!:Z\P;F_&_
M4_ES/G7QFJ.SGT]6[I?K]4S?A*O33*8<SEHB[1;HMMEZM05"(QCX%.>?NF%'
MMT4^4)7V)S++JJ/IG^O35>O,;9?@Y2\^\Z:LA0#Q0YZO1.I;/5)QP=0R@IIT
M6!R!+M(*/CNX0*:.C6I :1X)$*F1!(I2@8  > ;<R^"@ >VOX?\  /O^?Z\
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MO Q;N6(LMVI.P1PYK.WKDVB]:J08X]J+M%M&O2*(F9B]6;@Y6,5)0Q?4.85
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M%W2"J:9Q*0#G KTAA/VF$ #Z3AX$1 =&*&P$0#8#[@(;#0^!$// -*/P_?\
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M  DF1%JBF0I4P "E#7@  /;@'O&;E$! #J%$WN8#B!O??N&A_3]"[*&BB(<
MM!BC",!B)]?I&&LEYGG&1K,A;I[][[7*V(B<VA$M((7,:1^NH5@5:'C8E@ND
M@!4U$(E@ EVB B!>,B8$'8&$=AH0\ &@]M  !K0>/'O[CL> 3. . . . . .
M . . . . . . . . <&*!BB4=@ AH=#H?Y"'MP"1\LGH 'V#\BD*&][WHI0#
M?MH=>-;]][ ?+$$#!W&'O#R(]NM_1LP%UV /T!KZ=%$3=NNX=@!;E$-"8P@(
M"40$?Q%'8:-_VC=FB>H/U]H#]6S&$0(RI !1*(B;>MB8 WL-^=@ :T&@  T
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MX=LN*V.H<B8J]GJ%#2GI[*0QA+H3 4P ;L$X' @CY$H .O(\ [0AL!#\P_\
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MHW>  7ZNX0UO8CP#-Y,O:0 $1,/N(C[B(^?S'7\ \!]@ . 1\ < < E'4[#
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M.F;N JUCM+1)O.HTYN_=J5*MR2B3QX$E^Z<*LT@&THHHDYD&L<V7<ID4[B<
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M,X1L.UM;BSQ4K6W#QY6;33+;8Z99JX_=H)-W+]A)5J5CSN554T$2^E)$D6(
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M$$HF[C%,4 ,4>WWWOQH1!V^ . . . . . . . . . . . . . . . . . .
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MK8@.P\Z'91]];$HB'VUL>//RY_T+NUK)WU?%6Y/7/IZ'7.B01$@B(]P"4PG
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MW%.34<[17'O[.WO,9&/DD$7D>\:O6BY"JH.6BQ'""R8CH#(K)**)*[_L]AS
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M"(%[1$0#R Z V];WX'QKR $P3"!>[MV'CV$!WO\ +\]#_?[\ A,H!?'CN$=
M'< !^FQUX$?L'OO@$P! 0 0]AX!SP"693MWXWH1#\0![:]]^WY_D !O?OH"
M5R[  #P.PWOSO8   &A$0,&Q 0\?3K]0 @^:*)A*!3; 0#0Z'8&$2IB E[BZ
M.8-:,8H@'U"&N 3?5 =Z !T(AKNT.@,!0'R'L.Q$!]AUH!\[X!P*X!KP([WH
M"^1T'ML-  "/W[A* ?F/  +;(!NW7<.@ 1 ?OH/)0,'\?L _<0\\ F%-W /C
M0@(@(?J'Z_</UX!%P!P#'7J/LU*A<5WROVUU,N%[S1<DP4%4*G)A'9"O"K6D
MV*;F:]COM61<J6]>&8R3B)%H<%D%6I7G<5-OX#OOY'S]]%^-WX];.#[+ASIX
MZ\\=TJ!9Y #+DKU-WV;?T8C%U"M$*XXC&+V4>_-S@2)G+=)@8@-%&K@7)Q!5
MNEH.V?483787M'8:#7M[?R\>/;7V]N 8V=3W3+6NJ:AM,>V^TW&KPK6R1%F.
MK2YA6'>/74(L#EDT?J$ Q7<>+@"JKM%0,DH8A!,4=:X!;MST6,'M=K,>\SCG
M%S;:587,]4,CJW5Q^]T F]A'E?>P39<B9&B\ ZC'SE$\:Y;*)$.9-=/M512,
M4"4MT)8T8URCQE)MV1L>6JCK9"60R55;,X;WN>/ER;)9\H&LLPN54TP>YV=)
MK8) [D@BC+1\:\;>FHQ0  X6MIIWQZ&3V-<:U?$M!I>,Z0R&+J% K4-4JW'F
M54<*-H:#:),6H.'*HF6=/%T$2&>NUC&5=+]ZRAA454$0,7LUE G63T;AL=_N
MSU*&*/GZ3?L[$IC" ;^Y2=@!Y*4#&T "/ +[9KP33,]U=M4[O^T/V6VDDI9,
M(UV=FM\TBD=,@BH3SV:4-LO\/X<C/@[/@UZY:/\ ?S9<5?O7R*5P=TMXXZ?E
M9Y6AEE0/8DVR<@,E(*N_#4XG3]'O\IB)O)A+[\NY2>K=^=W?OKJ3*TDDTF\_
MBXM<KZY<,\L^9D2FU[2]HF-H!$==PB(C]NXWN(;WRI5*RMJO_LVY<<KOR)OH
MC]S?W?8/R#\P\![_ 'WP$K:#T0#V'?\ $/'_ ,^1NJ^];.UOE=_<EMVLG;.]
M^.EOH0^B?N[@. >=ZU]_X^_)^VG>C[XYD**7#YDP2&[A, @&_<!#8;'W_P#=
M_#@**7??CXYY#T@'\1C&$??SH/[N"2(A.P!#QY_+?_GP1;-OG^_R1\$D!B]Q
MB#OP4=B'Y^0'_@(;X&?:_9"*8B?NV ?4 _?\_P#W>/\ W\CXN:LKVRYWZ_V1
M99Y:ZG"J9CB&A+H/<#!O\_;\A#[?;R/WT/#OPMUNOVANK2WV.L9D51/TC]@D
MWOM /'W_ )CO8[WO\O;W-7US?G9OKGFO&Y,6X_Q;BK6LLN^EK%A+CT_5Y[)J
MVNDRDAC:[N%""K8*R<J"$D)-F*A.1!P&.EFRAO\ K$W"/D0*<3]Q0'FE5P4:
MDM^,Y4ZB6L&U'S2M>_'[7N>BPOM'B*5#_2QL(8W!/^-.M9UH/A[JL_CBDKV2
M=KYVNKE S>:,@X5B)9_END2-OK\(U.X3N^,XQ>14>(-DS#J7JHJ ZC%]$%,#
MLUEVB[A5,$6R*9Q.3#6Q57!TVZZ=515XNG%YNU[-9VRO?6_F=/"[!P&VZE"E
MLW'T<%7Q%:-&.#VA44=UU+)25:*46KM7<HW6>>6=)=,7Q L+=6%OGJAC6.NK
M=]6H0DS*N;+!IP\<@FO((L&C7UC2"YC/7ACN%&[?TBF.DP?G$Q1;]I]'9FW:
M6T\35PRHSCN4Y5+RCE93IPMXOWBYM\.)Z/V[_P .>UO^/-GX':.WH87W&T)P
MCAGA:KK.I&I1JUH5%:*M3<*,OB;M>RXHSD%9+0%$Q"^^@ P!Y#[!OW 0T(Z$
M?;[\[N[&+RE*/')\+JZMUZ)>C/E*A-YJ+:XY?KMV2S8%4#@&S@4 '7T"4WG]
M???OH0'Q^G+-Y)JSMHWG]%=/C]^4--:IKQ5C@2@("(CK8> $@" B'CSOW$=Z
M#>@#[:$/%FKYW:\'VB.#[?EW?EQ-5O77\,#&'7-;J7:<@Y*M]&_<ALHC$P]/
M;P#5JJ\7<E<'DW:[IJ9XL[$2%3*8RH@F03=@AOSZK8'MCB?9F.)AA72D\71]
MS4E7G)ITW)2BE%R:5FOY);SXNQKU\!+%0C+W$I*$MZ\(N32TNK*U]';PS,AZ
M-T1XCI50@8"JREVJ\I$P[".?V^F6R5JTU87;!J@U&9E08+F:K/G9D"NG I)%
M35<'44 H <0#C8C:V(KUIUG&C45:<JDHN"DEON]E)9I7;5[Z+)V1DAAZ=#^"
ME&5DFFG'+P>CR7*V=N)5"&&\Z5LY34_J-FI=DD<OI0N1JO!V4JQ2ZU\U8446
MUB.8A2B)%$W13&. "<1#?="Q.#DK5<*HM:.E+=X\;WRSY7NS'*-=6W:BLN#5
M\V]<K<$EQ\"4M8NK*MN13E,98IR8PT4%7%3MTK2G94P]05"@PLS6P%=*%V3T
MTB*)@<PB &*4I>4C#!S:M6J4KZ.4-^*SYQ:>G'IS,L)U4K-9VU3W;OB[:J]K
M</D6\R-EK&=VB0K'4-TXY.:0::P+N%;!1@L=/;O (*1ET)B'>JN50!+O %DH
MY(W8F<0*4= .7_7E1GOX7%PG=.*E!N#=[.SB[M9I:].+,M+$XBA+>I7C)_"[
M-2NFTWZKEFUIH557;?TXN\5KXTQ)EF&Q?&.61XZ"=1\J-7FJ^JLH145(AO:B
MLERN$^PR8:35*!#&*&QURM3"XY;N(J8:I.#:^-1WH2S7&-UQ_1=UU*JI5VGQ
M:R66?-:=,D[=&:M.LC'G7I4K!B)#'&;9S*./U;C!#6+,0\<REX^U+K^E&)VE
M]&)IM9:,^HHH+KF,D81[%2G.(#SU&Q:GL_*C7CC\)5ABXTY.4(QE)2@E>32>
M:W5>3XZ:9'M]AU]@5\/6_P!BFJ56E%M;TH/?ROEDLV^;:T3-L.$H?JP82$2&
M9[5BV7@4XD$WZ=8A)=C.*RWR0%(<R[EXHP,0'8BHN=)NF"@$.")"%4 !\QM"
M6RI2D\'"M!N7P*L[JRDV\^'PK)?7,\OCZV"J5JGN*4XQ4FXO>B[_ !9Z<UUR
MLKW>2J2X174NI?V;BE67&#7&8+Q7ST7/P4PZLZK<CD#3)4'K5ZFT*HY;"8&1
MSI"1)4"F.!@\<Q4Y8#W#C*%3_8X2C+X-;_QXY9<=;\&:ZJX90:=&;E9*^_9=
M59+3@N*O>^I@Q\4V)ZM9BET1#I^%Z>KI6:*4M+:K@X+<%I\TNV/5W0BGONKK
M1^5HNZ,GV"D]$IGP+()I]G8]FWLM5ZCVA-4VH5-S?BG!I1:LG?*;>?2*Z,[.
MQ9X&GORQ%/>D[R2WDKIK.S>2W5JN*S5KV-@W3O%90BL24>/S1+1TSDMM$-OW
ME?1B9B(*NQ P !S&T*ZY$@(DZ7*4A%ETQ5*F0IP*'&QKP\\54EAHN-%2?NTW
MPXVMP;NTGP=CD[2G0J8J4L/'<ARO=<5E;)?WX%^N:IH$)M]HZWO7C7OO@%O<
MBRUD@Z;-2]4B0FYYDU]5A$=HF4>J]_8HDW 1 @K*[T3U-D 1#NV'L!8QQ?,O
M2CK#5<(,13+%>8NY.K(F^C/VG\@XK#-@Y311;'.!2 H<ZY#& =!](@ @<  /
MWZ?WGRY'MQ65)^HVBYTO*IV+\U;J$?D&*L5>8N"EF:Z]D7\,K'.HG^L43EXZ
M5CQ21! 3)O4W""A 2#N+P.^^\\SS;?U)QD57;0[C:K<FUFKC:!D?W<L$"$>\
M=1=@E@8-YANB1\L"[))1)9 5!4**3LI43I^3"4"MIK.M=KB*)Y& NK@[>%86
M":"+KAW*5>8/$ 6]294,Z23;B4@BLH1$S@R*9>XX!K@7+@S.0:Y!4I?(#UPH
M:LMXA&<.[;IBLJ:/73353530*(&.(IK)F$H#L 'P \ M^/4'4#,8IRW@[J\?
M39GQXR :UXRD\XCH\B*B\W^SSNDQ2AC)KI*(/%5""L4X 1+U/HX!->]0-(;E
MJA&#6Q6!]=8^5D8"*@(D7TBLG!N&;280=(F70*R=QSAV)72*YR@0K5T)3F,1
M,BHB^5\_EG\CK&ZC* =>I-&*%DE7US;/W47'QD,=T^;)P\N6#FR2[<%R&C5H
M:4.#*126$10=%.B(B8NQ$_<[[3/5)>32$2DC.E9NII:N-+2I&E+4G4Z@JHW/
M&-ID7&E7)W"#A!#3?TEU6ZQ"*"8I0,!'$9XI<W-?LEDVL/RAG<JR0LJL2):P
MZ<0O=^T4T94BYP*+<"'$WS"* "!#=HCK@$J%S[29R1;L46MC8MY$K\\',R<0
M+.%L1(U-55P:$>BN?YO::*AT@.DB*I2]Q ,'G@'D1/471[ ]BV<<RLX%G2RR
M=>DWD(=O#33R(0=.';*/>"X-ZSLA6:Q$TA3)ZJB>BGUY //OD>#2>H:-FJ#!
MVJ?K]C9S%BL$Y"P]6CH@KF9EU(B3?IG<1C+YHOK)-6#8!DEU%D4T'#=R30E(
MF=4.=_+T[\"L%L^THL3"OF#.RR\K.24Y",ZE$Q'S5J1DZVF@K/-'D2=RB#56
M)2<-%'/JN 3['C(2*&!V@)P)N$LB.LG568LKM,$D4KO>82, S<[5<8FN6N3B
MXX7;<XF.F[!FT3,OL0V<^@ !WL%\O/GJB$<]TY*<9PB\=:V[9].JUEE9W4$=
MO5W<XAZY3,$9,ZX'%511LJ1$PM2HJB79%1#@=]_3Q.W!YQJ-AL"<#&L;(HFX
MD7\0SGS0YAK;Z3C3&([9MI-)94?4(8AR%%PW0*<Y#%*;V$0.<I7N4JB$+^P8
MQ.4DI"0!99HJ)@$L#%)&?SZP 4!,FJ,6BX29F.42J/3HHB("8. 4IFZR7FM8
M]L&2J#8X=M&5ZF25E(R>1*<@66,W8G?,E".S'+Z":B)4@*  (:$>X!$1V'?S
M)\C/W^I4 )*6FHR<M%CE*G"58&<.FP29R=KDF,2F15N0Q@=(,OGEWRR@^4VS
M!8X^^RQG=YY96Z<QP/<R)D1]49FJ,(Z/+)MW#@)*X+"'F'JB2S:)3>B! TDJ
MK,2C1P3NT4S&+EC /_1C<D=]]_(D9$O%A:V&E4&E?L\EANC>6DQEY))1TSA(
M*%3:_,2!6I#$!XZ67>HH-4SZ2V)CG 0+VB!ZM-#)T9-2$3<GD+88/Y%)S$6=
MBU"+D#NQ. +Q\A&) +?M(4!.B[1,0#@()F3 X=W'B"[21A,0!$-#L?'OK^8>
M_P"?Z#X^W )G ' -1GQ,NF_/?45DCH70P-=++BB3H&<LDV2SYHJT6QF'V+(=
M[@R^0C61/'2*R+5T6QO7Z=4-ZJ@"@2=.LD'>F&P*PZ=NB_K"Q3E.OWG*7Q%L
MF9WI,8F^"2QG8<>UR!BIPSMH9!N=U(Q\BX=HBS5,5T0I$S 90@$$0((CQWWE
MS[X V@D*!"%( [ H:V/_ ,/' (N . . . 809N_SR^C7_9CJ4_\ "\4< S>+
M[!_ /\. <\ < < < < < < < < < < < < Z[DO<0 [NT=[ VMZT'Y:$! ?8
M?8=".N"'?@E?@WHO'-/Y'FK,P7;'24 @E5 R:I1 !(9,Q1+V]G;[!O0 /L/G
M9O8:U(1FG%O)],[<GGEUUOEIPF-2LI1G&3C4C+*4).+66J>NK37%//H\2*-T
M+]/M*D+_ "$?3VZKO(-QDKG(JD7=QRK)>229@K&,UHQPS4",1=IO'K9L8P$;
MKR+H42% XASFQV3A(S=1;T7+-[KW+WLW=JSL[7MSSU1]*V__ )6]L/:&ALG"
MX['RE0V/LS#;*H4Y?\L)4L+&4(5)JJI+WLHMQE)7NERO>X?^3+0&: H5YY<:
MJ !H#U^V2B2Q=@(")#R*DEV#L2B Z-H2[]M@.1[.H.5U4KIK_P UGT\<N?VL
MC@4O;#:=.DZ3P^S*MW=SJX&E*;\7'=?*W=O)_P GJPQIO5@,[Y<;J .TR6*7
M86)L0WD0#TS,8\QR (!] F_#L-AO8)X%V7NL37A)<9S]XK:/X6EGUN5C[249
MIQQ>Q-EUDW=NE2E0DWXJ4\M<O#0[2-#ZA61R@CFBO3"1#:*C*8[;H*'( : %
M'36;5,(_<5 2V(B(]O'^OBE%QCC'*36:G32CJ\[QSOR7[;F.-]EZSW\7L?%T
MKYVP>+C&S7!*<5QXV_)KHZY>CWJGS=(T2RUFRPS21AYEG#S+>EVNV5Y64KS]
MT4'3QZV6%I')'8A_7',FHJIZ8&(0#>3<\QMS8FTL?+#NEB;.G5C*?NI3BY1W
M6OB;26[FLL\^&5S[M_B3_*/L/['QVUA=I;#IXK"8S"5(82IM7#87&3PU645&
M\7&$VI7M)/DFM69VT*\77&U.@:O/X2OZ;"KP\;"-7T1*1=X>OT8UH1I\XN2.
M=K2*JZI&Z9UA7 #F7.81V)Q'GHL-5G@Z%&A6I5'N14'45IZ)9O.]LF[Y:\K'
MQW:^R]F[;VEC]IX;VAV926)Q-6M2PU>-3"M1J3<X4X1<%!))I)9:<$52WZI,
M3).4F=J?S-"?KZ*@QN<!*P+A4YA#28)JMU V.A'\0?A,(#HH\V'BZ32<HSC!
MO*<HVBW9NUWGFE)K+-19QY^RFU'\>$A3QL=%_KUJ=5M:W44[M/+.W&*U+N1>
M0:1-BB>*MD"^]<@&1*C)-?5,0=:$$3*@KY[@#R0!WKQL>9(8FA*RC4OHTM&\
MUEGS>?ZR.5B-D[2PLI0Q&"Q%*25W&=-Z>MU:^A5A3)F+L@%.4WU!V& 2F\#K
MM'R4=[\CL?\ CS,I2>=DXV=FGFVG9+3BN/H<^47%YQDFKIIJUKYO6SX:<.O"
M@[5C;'=R*;]YZ35)XV@ '$M!1;UP7>P$$G;ALHND;ZAT=)0AB['M'8@',M#'
MXNG4W8SKQ2O9;\G&]\GN9Q;36NN3RXF.K155*[3>3ZVU\<EI;CP-+OQ)NA'J
M!R)$42N]"]=BZ,HUL:5KM]B')3^L@5W#J^I#1+*)DI-=N4A7A4I 7"*":!3H
M%()-CV\]S[*[?V7@JU>>WX/$T*E*=-;M-2JIRA9--)/XI6CEE;5I+/2Q]+%2
MCAX8*$H9IU).3C%I9VUL[KQO;K<SFPIAWJ[A,94-6X=0+YKD4*_'HW2 N%?A
M<C1X6!FE\H_.QL;"0B3 RD?3_:"0$:JJM_7*F8#"B8.>=VA7V35Q^(EAL)-8
M&55NCNMPJQ@W=?#).*=OA=]5GD[FTG.,::;M-)*2D[MRT>:LM;M:<N9=9S+]
M6U=,45*=B/(S(HF35& LDS6IQP3M$H@HWL#%&%;G.&S@ /S)E]N_\/-"JL!*
M5Z$:]/*R]YN2L[9N\<VGDK6ZY%ZCJ[T-V%XM.[;LTE=WZYK@TNEC%'K#^)&K
MT=XG2O\ E[!=NJ\[(V.!@(")5E(.PPLLZ=NVRT\"<]7W+ALB,=7B23]KZG:"
MSI!NV4[/7*<.[L'V5J^T-6<<-B**="G.K.$I2C)0C%M.UK.\ENY7=]4C!6Q,
MZ+RC*.:6]=-7?#)_;.W%&QC%N0:OEBB4[)=*DTI>K76#C9^"D$/J(XC9-H1T
MB<VAVF<2F(50IP*)#%[! ! =^?Q6'J83$5<+6BXU*,Y0EQ5XR<79\=+I\5GD
M;$)[\5*][\^_/S+E\P%AP"09,WD=AH ,( 'OH0$1\:UON\AKV']0#@&/^4:O
M?5;QCB\T"'AYEQ4&MO;/8R9E1B$E"69C&LB'26!)03"@5D=42F .Y02:'R;@
M=]]HH.:Q3E:T#?[R]DX: R!.U:NU&K0D*^<*,(.O1$X,[,MU)AP@"@R5C.X>
MH@[(@=&-/\HJF"A4U!",\_3I_=O7@T"B!Z?[T\<W64:PT7!*3]"AJ['1SFR.
MIE\K+P%H)/D6E9-7U440?E4503.T+Z2)2D54**@J[9]^?TROIX\!W^3V[UB3
M*5T<V,LA'QLDSL-1CXN';N[.Z9Q-1E0B!:29EF3'TEY05W8"LBX*=0@;(51(
MI-AR2'TZ7\.^GRU5Y)/'TV_P>ACE,[;]LDJL1!G,=3;47# K,BZ@+ZV)3_+G
M'0%\@(!]N"2B<C8@F)*Y5R\Q,)'VT8^H*5"0@'TN\@#)"=RR>-)%@^;*I)'%
M!5IZ+E%P8I3('$4P[R@' +?MZU=:!D+$$?6*M7'<NC0LONY>'8.W+")35F;%
M3WYT&4H_%8WSK=PHD8RSLY?G"HOU4RE,<A!>6KTS_.2\_5CN^1<3&>';)5+U
M$W2;<QJRKNN9-5L:3,QS)L;+D/(,5>!CXP3@4ZD;'$(Y8&=&*11TJB*YBAZ@
MB :N_C\[K]EOZST\3%=5@JPK5:I(P<%;RSB5WD9B3<.7,>UDG,C&E)70=%12
ML*1CH$.Z%(K4IRJN4Q.;1#.^^V/EZ]]_/NC@V[N;4*S5E#T]F[D)T)^P5R:<
M)QUHAI9F_; DO4U?5(E+'5<(.7#H 03(=N()F4 X\ BIN"++%*5F,D*A4V[>
MI-9),MK&:DY!U*N3M7#2.6C(A1R*,2MI0AW1ER=A-*%2[BG\!WEX_?B5DAB"
MR-Z]@Z($[$5\>V:2EYPY51*D=!TWFRHF:B4/ZQ4ZL@AWD$>T=F*(^V@+>DP1
M=TX:C*OH6%FWN,+%D$K&(&:=,T[37;H\D7H/$WS8Z!XV89F>,R^BY,+8R"3E
M$Q]J%$@/Y]]_HJ&"Q'=J=*5V^U^NU="QMWM]&9I[.3<_+N8RX)T]N@Z)/OE%
M@=6.,+1XD'CLP$1>HK+() )6C8ZP6Z]O\=W+O86I]DJ%8G6-M_9R4W-WJ\6M
MP6(6,9@DG9K1(3B"3<QBE.4J*3PJ7:8A1$Q1$P ' ,<G&"\G23Z#/.(1LA*0
M606UF<VYY8G:_P"TXALZ=^FTB8)(2-H\Y4G!14([2'TNS22AA,/'EWWXD9\?
MEW^BL(G$%X99&C9]A'1-2;-;6XF;#-U^<<EC;A"JG4$6+NK'[R(2#DAT_5<%
M*B1)1,5"'.)_(GC^WIW_ &75?IVA.^3LNI27$]&%A6<%!+H2\4@F+-XJ9S+B
M9%XJ55-1=5%JF!M 9--)0//?Q]QWWQ*4E*3<K9@?(N.'422&DI>)M=8J23Q^
MV<$&+E6RBL4+Q5H=1))-@9VI'I% >X&S(F@^H-PLO7]=_(=_(N/+U:3EIK%1
M%4TC0M1/)S\LH94.]2;;5S]W8%HFD ;6:G"<F9$RI?*+J+9G#1A 0D%++-+6
M:Q9#=2]$=S4?9O1@(X[>8AVY0JC2.^72:"1PL"J9UY![-2"@B &(,@! \D'0
MA/H]>/3PX/O@4LM1<D.F&.+HT;L4,C8_;S<(YAIE^4&MIK\C\LB8KJ19 LDT
M>F%@TD&_;W(D64624$"B @)[[[^69<.EL,I25G>V6\*L*Y#EC21L73(IY^TD
MOF17]9:6DW_85,SL=F121;]R14@ 3F[Q$ $9].A><@:#6P'M'7C7Y!X\??SY
M^XCYX)(^ . =<41[@.7M[@,<VQ\C]0@(%WH1[>[1QUH0,4H!L-\ GE#M  _(
M-< YX X X!*,LF4PE$P;*'<;R'@/N(AO?C8".MCH?;@$9#=Y0-H0WOP.M^!$
M/M_#@&$6;O\ /+Z-?]F.I3_PO%' ,WB^P?P#_#@'/ ' ' ' ' ' ' ' ' '
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M99>)2A^FRKQC=5*I7')M*,J;_KX2\2LDH01 1VF2W_O.DF&P#1"%*F !H"@
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M1;!]I]M>RF/H[4V96GAL51A."E).4;5X.C44X/W<9QE&=K2;LUHVKNXD)F'
MD#'L(N-RSB=JPCVJ31L@VOU0(W;M6R::*:21"RX%*FF4A2@4 +V#])0U[Y*%
M&%""A3BHKHK>#:RMX*^?B<;%XFOCL57Q6(FZU:M.56I4G?><YO>FWG-W<G>\
MGFW=LN?6[K4+D@NZJ%HKMJ:MEBMW+JMSD7.MFZYB H"+A>*=NTT%>P0,":QB
M'$H@8I1+YYF-<J?@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@&(F;\+Y6E\NT+/.#YS'\??*GC_(.*)6&R3%SK^N3
M=.R!)TZPJ.TW5<D(^6CIJO62B0,@R%N<4I"/4F(E99H>10D8]WVM ^_[UT[1
MZ6+ND[&]1Z>L78 R+6:/F6(Q[$L%7KF]TB!FXF<O)@=/+)>$:Y.MIIE$R<].
MS%CE2^@LLO'IS*[%!V9$I3<=\OR.7=O L9=NB[IL2ZA,'/(OI6P8%<3J&:@M
M;ACA''XPPOW(XT" -/&"LBR<2+A1*7_92KTBKGP_!(I_4.8 =OG\O#ZZF0P=
M''22H0PEZ7NG8HF 0W_0CC<A@$-@'_Z;   HCX$A2E'0=H 'C@%'XVZ"ND['
M])@:>XZ>L$6=:%1=I'G)?"^.%)!^+J0=O^]P8U=4$11!T#=/9S:213#QK0 2
M;+T#=*%@N&/K2ET^8(C$:-)3K]>&:88QP$?9"356F:V5K+IA72E60CU)8LJU
M*8I]/&2 AVB'>4.^^16X]&_28/=_]U[IS 3 8!$N$\; )=B4>U/=9-V$$2B(
M@'MWF\&WP.-_V49C7H)Z4,?TZ.JKGI[P39UF#R==&FI?#&.%7[DLU/RDX1!4
MYJX8?2CB218UH'<.FC- -%_ 4"&Q=!'2C.W*C6Q'I]P1&I4TMB*M!ML,8X+'
M3_[>;QR*9I,@5T .,:9@*C3N34 IG*WMOR'???[K7_(WZ3/?_)<Z<>X!\&'"
M6-CCH/80[ZR($.'GZBAXW]]!P"B\:] _2?CZH1U6<=/F"K0JP4>G&:F<,XW6
MD7(.WB[LI%U1KAC'! %_02V8=))E#Q[ !S9N@GI/L-KQW94^GK \8E0Y>=E5
MX=IA?&X,;(6:JDS6 92I?W<#O08FEPE6^P/IXS0$"@(=X 5@KT>])1 ,)NES
MIQ #; "_T(XV$H 80W_^FR!W[UV&]R=QS  !L. 62Z=.DCI=7Q@5:=Z8,$*O
MC9!S.'?*X3H)GH,2YGOY(LNG=8(["/1BP9(QACHD3&/(V52_J5"&$._7OZ%>
M73H.Z3;F>HBAT\X)@OW5N,=:UPC\+XW($PFQC99@,&_U7 !2.<C*E=K  G**
M[)OX-H>T.7W*U-T;])8_AZ6^G //@381QL8! /  8O[M% PZ !V(_2;R'WV!
M1%&Z!^E"FK7%5?I]P7/A:[E-6U(DIAO'*Q81.7.D8(.- U<-Z48R]+39,.T"
M]YOI#@$Z^=!G2?=&,"S0Z><#U\T+<ZE;#N(S#&.$U7Z57FFLNI".1+72=T?,
M$;"P?D$3 9LLH D/^'@%9FZ..DH1.8O2YTY 8VQ*)\)8W. &, %/W%&M@!BZ
M#8%'0;T/C0< HVG]!O2?5I"]OENGC!$P6YW$UL1;/\-XY50KZ8UFLUL(.)(:
MN&!",#]VPE02(!0!]*OC=HB/><.^271+@3KQT)=*%OBF$:VZ=L"P*C.QUN>,
M\CL,8W3772K\RTEU8M4?W;#;.6(T&.>E\]S5PJ':;\(AS[XHJP.CGI*V?_[K
M?3EL_L;^A/&HG+OP.C?NOL-!Y ???O\ GP"B*ET%])]5E+G)K]/6")DMNL S
M:+-]A?&RB4&0R((A&QNZY]#0!#U *!2;,(_2' SSS\.A;++/2-TP$RYTSHQW
M3'@A*.<W:^$G$6>&,>E8N&Z6+K0LS3E@2K!T%$"/R-U6Z;C1/FRH]IBJ=H\#
MSMR_!?Y/HZZ2Q*8"]+?3@8_84!$^$<:"43 713G3+6_<VQ[B#["4!V @ < H
M:C] /2A3IO)\NMT_8)G$\C7].\-V,CAC'!V]513H%!HX5R$*-<,",2*M)6L(
MI$!,O[4L$D?T]F%10#M9&Z">D^^UI.OM^GO!%:53M-#L@2<5A?&Y'9B4J\UR
MYJQ1A"N$_P"ASR4">"DB[T:/D711*<!$A@*R-T;])8@.NESIRW[!W83QL.P#
M0!WB%8+W;\F,4?[7]H??@%#U7H%Z4:W:+[8E.G[!,LG=9&)?HQ3_  QCE5E7
M@C(PL<+:)3&NB""#L2@Y<$(!0,MY\^_ )F1.@CI1OE<_8*'3[@FLJ!*Q$F$G
M#88QPB]U%OT7IFG>%>#_ *.]!(6[DN_J1.8OD!UP0U=6NUFGET=RM Z-^DP
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M!;VU4M1<V G8F%E &:3-1N /# 9TMQ$R1=B ZV ?GH!T&_ >?S^DO\ X!/X
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M[6;$^AY<5ZG>E9HE>DDI&%,*+=\=>"D6\M#NTR+,'*1"MUWR F7*'?3MF4_
M' ' ' ' ' ' (%!$I#& 0 0#>Q]@_C[Z_N'^ ^W +$9HRS,8N85Y*KXUM>3[
M-:9A6)AJ]6S(L&S5-LU.[?2EAL#XIHV!C40(5,CIV1<[IRJB@V:K%^84;@8Q
MH]>%<GJW2Y?&6)+M?+I<J]8;E8*/'JPL1,5*OTQT>,L3V=EEE5&+E=M(-W$7
M#-V:ZX32[90J#ALD'>8/KV^OKKD9G8LR-7,N4.I9*J2ZJ]>N$2A+1WS20MW:
M**G>DJS>H"8P$>L7:3AFY IA(5=!0"F,7M,8"Y' ' ' ' ' ' ' ' ' ' '
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M!P"$X")1 -;\>!]A#8"8O_\ (-A_/@$@J1@#R&PT/TF'9PV.]=P>! /8/(:
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ML3$*J*Q;><CGKB,D3QHK:7"-<.6BBK/U@%7L,('UH!$1=/3@9O\ !(X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MSBVX[JV5,@57$E^<50$2UYQ>,:PU@0J\XK%$013; =@5,Z21$G8."   '?\
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MQ=^YV_D%W#M0JCIRJ<I#F*1,-%(0"Z#@%[> . . . . . . . . . . . .
D. . . . . . . . . . . . . . . . . . . . . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g118907g85c20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g85c20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CR^9Q8X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !!    1L          0                         !
M          $;   !!                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !!     !29VAT;&]N9P   1L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   00
M    4F=H=&QO;F<   $;     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      _#     0   *    "3   !X  !
M$Z    ^G !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M>P/ (W"8<(/S:DI__]#U5,2.)U\$Z!=AXUUK+K:P^RL$,<>0"YEL?]N4U/\
M^MI*6MR:,:JMUSMC70T&"=8W?F_R6JG=U3I[[*B;@:V?I'0UY,D?H>&_F^][
ME?\ 2KL8S> Z!I/:1L,?V7*(PL0/#VTL#@[<"&@>Z-NY+13*FVNYI=6[<T.<
MV=1JT['C7^4$2$S&-8"&@ $EQCQ)W.*DDI: E"=))31ZGTK&SZ7->T"Z/9:-
M' ]I</=L5?HF9DN]7 S!MR<70$\O9V?Q_P"=K56'U<C#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M410)%3)A<8$6(Z&Q)%*1P? 70E-78M$E)C=SX?_$ !H! 0$  P$!
M       ! @,$!0;_Q  U$0 " 0($ P<"!@(# 0$      1$"(0,Q0? 246$$
M<8&1H<'1L>$%$R(R4O%"D@8S8A2B_]H # ,!  (1 Q$ /P#[^. . . . 0>
MHDJ(^VBH=OG7P-^#_P#GQR2ICW7S/H#'+K+UBM>F?4;TY8E%BU3E1UDZJ7F
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M ',55Q2^K14DK+W]R?RE' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' )9(_*AM1&OYC[[^R?_ #SXX!2DN[9=G,1:ZQC2'&+1
M,&P9CRV7EQG/;+JHDI+:UF,^I(VA#R4+[?.OOP"IPM7:#X^3W$JT=IWL'Q\=
MH!/V_GP#JQ9T.<EQV*^W(2T^67%-K"PE]&PXR3\)"!HD'1\D^. 34+9='N)4
MAQ "@E2=+! 60KM4/I5]20% Z[5 I'D<>X+ Y"AWI/EAR>E09&*9?:L)RO'
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M-J[:^OMUS-U&#C5TNI4-PIA)S"2T\3T6[&*XXAE,UHO*;6X&PZ@N%I*B"Z$
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M):\_+*(R/  =.AK:"3_,E>R?^O\ ^!XY3G2BR)O ' ' ' ' ' ' ' ' ' '
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M1W+E=37$"RL,9O6H%Y#CNK#]=,>BJ>;9DLK;0M(<9)=8>;4XP^@+6VXX&U)
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M-("5N'9) 2@[_(*G#_,I3[H"?^4>!XX.8G\ < < < < < < < < < < < <
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M.SE641'FS?"VH@.'SW#1T4D $ ((V"4$E25$A*R?.SK8WUGS,W:Y$;FBE!)
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M<^H(2D^%*.T@"]#9*D))&OGQ_0D?W^/GQOYT/C@$? ' ' ' ' ' ' ' ' '
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M9.W1?18SON.] J"E ;V0.[X!^- _.OO]AK@XCL\ < < < < < < < < < <
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MGJ''7$179J6Y,:%^GG.1.YU+UE.0\E# ;UW[&33._:;W\]H)\:T3YT!H: ^
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MUM2?9*2E2A$Y\#)UM7<A*M$>-:/\B1X_(.M@_<:/WX*1\ < < < < < < <
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M3#:FK/I/+Z;Y,E=7$Y?KGN]HT-@"%$N*!'V/VU\$ ?Z<VF)/X X X X X X
MX X X X X X X X X X!9'KQTAG]:,)1B5?G%Q@$IG)*'(&[RE1(=D.)I)?Z
ME57*9C650\] G@^W(:1.:V$H*O<0%-J Z.'=+$]/K&PGO7\R^M\PS.3?6\QY
M,QB*HNUS<2)"CUTFSLV(;$-#*UA,%41I]UY3CS"E)!X!?I TA(_ 'WWK^6]#
M8'P/' (N . . . . . . . . . . . . =&P3WLEK83[J'D!1 5HJ:4#])T"
M.PN*/D !/\]%O>_M;0^=H]^_3:-"W37 ;['_ %5LTLUH4R://I<N192R[$$R
M(]()B)8;44K6U.WIA02I"@M.RD@Z;VMSX&WLV+2E50Z*W*<.T6YWZ+3)<Y,C
M/VG#=E)J.G3*$*5!9?M'Y2@^E"4.Z:0WV,!7OK]Q" 4K+?8-GZM[',:DVK./
M<QPZ>)U.%$.)SL]5#E1$7,P?1A2"D]/N"M?N]%>J;!78K2E3:UR%2E E]PMD
MZ6KM [5'NT!X')32Z6YASEGZK<&NI7_3:'>?5=?0RJT/G7G\\S X X X X X
M X X X X X X X X X X X!*4\A'=W;'9K?=I((/W"EE*2/L='Y\:X!3]PX%
M2Z0I2M6[$*[4I*E !A>R0D*/P=[&QK[C@%2)^!X(\?!^?_/]?SH\ YX X X
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MU7_O-CO 4']+4E(&6+8TA(WOY^P3KR?ITD #M_A\ ;UL^> 1\ < < < < <
M< < < < < < < DNI4K7;O0"NY(T.\?3]'<2.SN.B5#9T" #ODO*]=Q[KQ&G
M7?7?-&BSUTR;")ZEX(3)<F>RQB<YB"VB+ *TDL!#*9?NAQ?<L):2X=*4HGN
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M:UUA(JKL0K1B%.BRGJV9^F6O]+/:8=<7#DEM0<#$A+;I1]79K@%:)(*4D?!
MX!%P!P!P!P!P!P!P!P!P!P!P!P!P#KO_  GR0=* /V'P23KSOM"NW7W.N-[W
M[DFZ7.9W[Y>+1I\_:4*]K*NF[JT1WFS D.-H=$@+0(\QQUU:WM^R.Y';VH20
MO:?CR!S577#X7J_;ER\_CKP>R8>)2\1MJI9QD\YNN40Y>:Y-F$G2B6]E/7S
M[27%9M9+M_!:+7N%"2TT\A* AU0*B&4@*3]BI.O@<RHIX5T:4>IAB8^(FJ5E
M3W)/+.;I^O6Q]+4-/8A"=%/:VA)23O6AI(*ON0 ?^O,S1+;EZW?.=>AW. .
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MUIE=7\\Y-\K0'<3H!1!)&]D$D; T  GP"!K?GQXYM.$G\ < < < < < < <
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MM)U1993(>Z_U;3"PXI+[F$8BAE0:[?=*7%+""&RM(<(4>PJ2%:V.)POXU?[
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M-]_A96#IG6%M+SK#8]E)E-Y7CF3NH-=@7^+I4%-<ZVP;01'I*Y9:363FK?\
M7<EO/6%"\)?WI>8[_'E)B_28_P"O._Q'I!0]0(F15F2XG=X3?=3\BQC)NEL6
M%G*QG?2>TM*F"&+20\JKH<9:ZC0,CBR*O'!=K9+=$_;L3(3[[YZ6]]^2\KE#
MGK[+PSY&T*,DI:'<' H@$AW1<\I!TLI4ILJ'PKVB&P00D:UP4[' ' ' ' '
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27Y/D[/ (N . . . . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g118907g85v21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g85v21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %[*^8&8X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            Y@   CX          0                         !
M          (^    Y@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    Y@    !29VAT;&]N9P   CX    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .8
M    4F=H=&QO;F<   (^     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      TZ     0   *    !    !X
M>     T> !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MWVEWML/INV;T0+4ZB2RW=6S=EKF].N<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X4 6
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z
M,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,C$M,#DM,CA4,#@Z,C8Z-#0K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP.2TR.%0P-SHR,3HQ.2LP-3HS
M,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,#DM,CA4,#@Z,C8Z-#0K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7
M;W)D("T@5&%N9V\@+2!!;65N9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C
M>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y,S<T.3PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.CE%.41$,3@V
M,#<R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.CE#.41$,3@V,#<R
M,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.4,Y1$0Q
M.#8P-S(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CE#.41$,3@V,#<R,$5#,3%"-#,V1$9%
M0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# X.C(V.C,Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z.40Y1$0Q.#8P-S(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C$M,#DM,CA4,#@Z,C8Z-#0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CE%.41$,3@V,#<R,$5#,3%"-#,V1$9%
M0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# X.C(V.C0T*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED
M.CE$.41$,3@V,#<R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CII;G-T
M86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED
M.CE#.41$,3@V,#<R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z.4,Y1$0Q.#8P-S(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^
M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#
M;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ZP)* P$1  (1 0,1
M ?_$ !X  0  !@,!               ! P0'" D"!08*_\0 4Q    8! P,!
M!0,&"0D%!@<  0(#! 4&!P ($1(A,1,)%")!415A<187,H&1\!@C5UB8H;'2
MUB1"4G>2E\'1V#,XMN'Q&24G-V)R)C9'4V>RM__$ !T! 0 !!0$! 0
M       ! @,$!08'" G_Q  \$0 " 0($! ,&!@$$ @$%     0(#$00%(3$2
M05'P!F%Q!Q,B@9&A%#*QP='A\14C0E((%C,7)&)CLO_:  P# 0 "$0,1 #\
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M[B,?UZ*R9!A:*(Y;OW]J&P5D?@+:&R%493;MG63.!]U3L,A[I$'?"XCP?^\
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MJ@9FG+MW\OZ<NG[_ +CGV^NN[6ORZ/HO 479=FJ*QILQ>U7$V<F33_VD<_N
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M - - - - - - - - - - - - - - - - - - - - . ^@>./U?3\- 0X /
M'Z@T X#Z!^P- . ^@?+Y?3Q^SY?30#@._8._GMY_']HZ <!] _9^'_(/V!]-
M 1X#Z!H"' ?0/V: < '@ #]6@**38LY..?1S]NFZ8OVCAH\;+  I.&SE,R2Z
M*@=N2*IF,4W?P/UT!9+!>W#!FV>OR%2P)BVIXMK<[.'GI>,J4:6.0DI<R*;8
MTH_,9155TY%LBFV%514X])@%,"B)Q,!?O@/I^_[@'[- 0X#Z!V[AV^?CG]G;
M0#@/H'[/IX_9H".@(<!] ^O@/////[>_XZ CP'T#0$. ^@?3P'@.P!^H.V@(
MZ : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
MAP CR(!SV[\!SV[A^P>X?3Y: C^_[?.@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(<!V#@. \!P';OSV^G?O
M^.@(Z : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M^D)A/F(_/CYB/@//?QS_ %_LU7!MK7Z]>^^8.>J@- - - - - - - - - -
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M(MP+ZBROI)MQ,=4 ,&]]5IOJ7XT T T T T T T T T T T T T T T T T
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M&<H1BHR=[I-=>A4I*6RDK6W5M?+5\K&1>M62- - - - - - - - - - - -
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MZ0Y$3"8"@/S'IX/U 4O@PF$H=A$.0T"6ME%MM_\ %:MW^KTOZ_9\D5.1*(J
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M%*FXP@[<<5>75-M6O8SJ4PGNE6,"RVZE-(P]NEMBZ,31X'Z":QF,'S ![=^
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M:;3NFWYJ_-=_K<J\[>1,$I1\E ?Q -39+9) <!] _9J01$ 'R #SYYT!
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M.<\$36+Z\^364*@FSA)N1<*I2CLIP.H9N@1/E 2KE*4@B0 OI;OO[F?@^!_
M?W\#_8/X#H08M9SV?;9]R,U6['G#$59R#-U1NJUA)*7"0;.$XM9RD[<0;]>-
M>QX2\&X>((.EX*=*]B%'"*:PLS*D*.@.$;LRVO0V;FVXV-PO3([,S5HFV:71
MHU707;>A##74)%I#D<?824XUKIC0+>?0B4YM.'$8TKPK,11T!WNZ, #&]7$
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MP1  #P !SYX#CG4@"4H^2@/X@ ZBR6R2^0 %* " %  'R  ' _B&I   #L
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MGWV'Q^(6"AK4HQQ%54H1<7&RII\*=^'1:_0^Y\%XC]E>"_\ '_+HYWX8P_\
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M4XB7[-E&,<!"F J:(I@4VG;':-GH@' @ =N!#@. _9SV_;VT!UYC&$Q>Y>D
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M8GMQI=@8GFK3!V^8DXV5+8XF_)3:GO3*,,V.F=JC2*G#O8<5!$R,+;(BV1Y
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MP8B9BE$?D!N.>?D/;P/'(> $.=2-;635[?+Z?4E@'' &(!A$O FZA >/F/D
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MBYTU*,)5\35J.*DTVHWD[7:3TYK0[Q&OP@=0C&1X@8P !19MQ H@'( '*0B
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M<)EXY[=/Y\L=\DX_T3 '!@\B CW[Z RDT T T T T T T T T T T T T T
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M!L=,HU[&=)$)^GD:(K+J.=6MK#C$$/!M7$D@U9'?2/K(NP<@"8%T\0;><'8
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MT5Y622222L=X4@%$3!SR;CGG[N ^GW:K,5))M]3GH2- - - - - - - - -
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M^K@/ Z#OO^SHV.]+&\C)S40SHNX!>1KZC-*79I[>\L"X8GD$CKL@5)^37/\
ME*29S)A\(\%$>^@OW9G=?PM*9_)GN-'OY#;QE< _5U5KD>/ CXY = /X6E,_
MDRW'?T><K?X:T _A:4S^3+<=_1YRM_AK0#^%I3/Y,MQW]'G*W^&M 3&&[/'K
MVPU>MNZIF>MN[A/-JU"O;;A7)-<AE)EVV>/&S9S,2E>:QC0%D&#LQ3.'B7)D
MA#@0[Z R=25!4!$/'80[ 4>DW/')>LQ@$.!Y$P%Y_P T.- 3= - - - - -
M- - - 2'"OH)BH(D*4O<QE.H"$* ")C&, <% I0$1,<2)AQP8Y 'D +"8?W0
MX"W!OK9%X7RO3\C2%&=-VMH;5B1([4C#.E%D6KHP&,3WN*>*MG:;*9CQ>P[Q
M5LNBV?JK-UDR!==-]%Z[_/3Y$EN8#;DY9,P*A_\ !F.X #IE. #<G ]70"HF
MZ!_TE$BE'P(".K;<U)[</*^G/3ITU5]>EBF,7";G>4KI*S:LK:OFM'?E_B^I
M$P)V( ]@X 3B4! !$?'!P^H]@[ '8  -7$T]7=WU2TTZZZO]?7K5)SE=\*C>
MUY:ZK?ENUOS=^;W)I2$'CK #<> #T@+Y >>#& O/R$>.H0$?BX$P:B]]U]?+
MT;7>G,?$O^?*VEUIYWO>W(FDZ"G$X"?N @!143Z"@(E$0*0IP /T?(@(^>!#
MD>9(MK?3:W._ZVZ\B;ZA?W,G_?T)(@?J[%\_B0?Z@/SH"'J!S\N/IR3G]OJ?
M\- /4+^YD_[^@'J%_<R?]_0#U"_N9/\ OZ B"@"/  (C] ,01_\ [Z AU]@$
M?F/GD@ /UX^/C^L?PT ]0O[F3_OZ >H7]S)_W] /4+^YD_[^@'J%_<R?]_0#
MU Y'QQ\OB)S]_(^IW_8''WZ >H7]S)_W] /4+^YD_P"_H!ZA?W,G_?T ]0O[
MF3_OZ >H'/RXX\=1.>?Q]3Q]W'Z] /4+^YD_[^@'J%_<R?\ ?T ]0O[F3_OZ
M >H7]S)_W] 2C+FY$ * <<!\7//<>!$>>A,2D >LPD5./2''2 CR %0'(@ B
M' B <ASSP/'<.?GP/;GYZ CH!H!H!H" ^!_ ?W^?]@Z QW3VS;>4,SCN%3PU
MCA/.!VAF0Y1"JQ(7(R!FBC#K++^ZF=F>?9RZS$'A#@Y%@NNR%=-LLJB<#VN4
M:&ADFD2E-=2:D6A)NH-R5^B4%E4C0\[%SA0(B(E!0'2T>5 R91$@I&'T/35$
M.0[[[TWUV=QO6$3B0..L"]8D,<X"0@=0@8?XP3F!4 Z4Q!,.#%4$X<EZ! B5
M<!Y W81$H%^,P\")>KH$/4ZS&X P )2<#TB/'80T!5](?_5_MG_YZ IO4'JZ
M0X'N(#\:A1*!>0,8>3" @(\  =AY_$- <#+@!^@O(CP(CP8P]/''PJ""@ F8
MW(B7J$.0*;@!'@! MGC"B#CBO2,">4+*'?7G(MP*X31%F5 U[NU@MY&0I$55
M%4S!*<!@=Z;_ +4S47)D2$,<B8?W_77O:Q<OUQ "]@X-_F@H/47^,!($Q*"@
M@!C'Y*)N0*F8HD$#&#0?QU]>_/D590 Q2FY-W !_2.']0CR'Z^^@.72'U-_M
MG_O: IE%!3,(=)A#_-X.<1-]0XZP !#Y )@ZOEP/;0%"=,YG8N" )B>[K(#T
M'Y$HJ*)' PF$PF(;E/C@O)2CU#Y$P !5 X 0$2B \<]@44'J'@.E,AQ,!5#F
MYY,8G44G E'DP<B"L_3K^_G\BL "B " FX$ $/B.'8>X=A$!#\![Z CTA]3?
M[9_[V@'2'U-_MG_O: MGE>E!D:A6FCED0BCS[)%HG(&0,[]U%)XU=G.9L+AK
MZ@&]VZ0$5R!\7)3<EZ1#<N,W3Z$$2"<QQ*DF43]1@ZQ*4 Z^ .( !N.H  1#
MOV[<: G=(?4W^V?^]H!TA]3?[9_[V@'2'U-_MG_O: IEA$AA$!X#@/(]Q$1X
M$"F,8 $1    [=Q'D0Y - 6RJE'/6[KDBV_:17@7]W7G1&1&J:1XL8&.7CQ(
M+D7"_O/K&6!03"FAZ(@*8)*";K "Z*)0$@CR;@3#P'6;MXY .!#_ #N?D'?0
M$WI#ZF_VS_WM .D/J;_;/_>T!)4-T&*  8>0$> ,<1[" >>L"E .>H1$1$Q0
M-TE$2]P+6Y+H[J^#0/1D$8XM.R)!W=T"J+AR+YM%1LXQ-'M^E1$R*ZAY1)4'
M(\])43E% 2J%-H/Z[Y<K_P %S4UNW!1*8YNXE'@! 1\<B4..D?\ 2 3\^  1
M[: GHJ&4 1,!>W ?"/(=7?J !Y$1X'Z@4?KW[ !.T T T T T T T T!XO(U
M?<6RA7.K-'0L7=EJMAK[1\ <BR=34,]C&[OL8AN&JKHJYA(HF?I3'I. B "!
MI(]FWM+W)8XLSUQDRE2&WH*'M0Q5MEC;/#2%%M#Z[6VAV>WRTED.M,50M48$
M*#2:8H1AKC$!).%3.RNXDB**"B@??UY;=ZF9[3".9UMQ$LS)O+S0"R>)&"RD
MFECW;$=<Q#6UP1-B<@X(&/*F3@5@$C0KL3C\:YD_@ M//U_IKOZD<]^6W[][
M?-%[OS!YO#QO;SF'(" \8XVK=P'Y=]O^IT_ZK[_7<E73U;DK62>R\U:S^MU]
MK/S!YO\ Y[><^_S'&^U7G]O\'_G4$-:W6C_;FNGF1+@3.!1Y+O;SF \<?_+?
M:H/;]>W[0DY?F'SE_/<SG_NWVI_]/V@+79-Q[N$I:^-TH_>GF=PG<<E1%-DS
MO,;[60]SC9""LLHH[;&2P.V CHKF&:HD,L#A'TUE0%N<XD.F!<M/!V<%> #>
MUG(.0[B&-MJP"!@\A\>W\!, AW Q2B _4- 3OS#YR_GN9S_W;[4_^G[0#\P^
M<OY[F<_]V^U/_I^T _,/G+^>YG/_ ';[4_\ I^T!YZW8=SS 56R3C7>SFY5U
M#P4K)MDE\;[5015<,6*[E!-7HP FH9-15,I#E34(H<HB4ARG$# !Y3#V.]P>
M0<8T*ZR^]/,S21M56AYM\V88SVN)M6[R29IN%D&Z3O SARBDD<Q@(1RLLJ!!
M*!E#" B(%S/S#YR_GN9S_P!V^U/_ *?M /S#YR_GN9S_ -V^U/\ Z?M /S#Y
MR_GN9S_W;[4_^G[0$#8(SD4IC?PW,Y?"41[XWVJ<=@$>_&W[GC0%KJ)C_<'9
M[7F""?[TLS((8_R'%5*'.WQKM<35>1K_ !5C*\N'#TR^!UDW+M&9NDLP(LS1
M:-@9,6R!T/>T73A8"Z7YA\Y?SW,Y_P"[?:G_ -/V@'YA\Y?SW,Y_[M]J?_3]
MH!^8?.7\]S.?^[?:G_T_: ?F'SD'?^&YG/M__&^U/_I^#0%KYK'^X*.RC1:4
MAO2S.I&6FLWF:?.E,;;6S.&SFKN*DBR(@LG@<K1)!4D^\,Z3<(*K+&;)"V41
M]-4%0+H?F'SE_/<SG_NWVI_]/V@'YA\Y?SW,Y_[M]J?_ $_: ?F'SE_/<SG_
M +M]J?\ T_: ?F'SE_/<SG_NWVI_]/V@+29=JV=\0U5O?&V[;*UL-%6VELW-
M=L&/-N2$/+L9:VQ$;)LWRU8PO!3:1%V#I8IEHR38N$PX-ZP#R.@-@I1 0 0[
M@( (#YY 0Y#O\^V@(Z : : : @/8!'[A^O\ P[_L[Z ^;'-4_;6/M*WSQW+W
MIIE.-W/[5(W$\8V/8R1*VV.1C9PV:%DFC0AX1S6?2"54M+AT/J(KHQX*E*<S
M?J=]_8'C?:)92=WO<,K=*):[Q(*%P)M]G-CKFJA;&45.9T<[O&4!E0T.T:-D
M47D\>J,()C8V\JW21;4L9!PIU,#G4$/WT\[Z?VOF5NS!;)5AWN2,6UM^3(7-
M%ND?:/QNZ5^\+(O&M.9Q>=:]#[4IQO%3[9U6$ B*,LW=8X2(W=-Y.O)O"K(N
MV/JF&-?XM^_SZ;_JWY-:=^:[U-F/LNX2RUS$F<ZS;++<[H^JN\C=/7&EIOCU
MU(66:C(3,%FCXMZ\=.B)@L5RT01.D#=,C0X<'0 B8E )&[WUWW^1M"#P'R[!
MV\<?V\: \]857J<+,GBTS&DDXR148%*!3&,_(U5%H0O(?I"X],2_(?GSVT!\
MUWLY\EK4K<6YLMGM5V;).<%9?>[L7%N/:WT3%YX/N68PV.6KML\;K(L9DU47
M.SAVT8@=)2O*)K%Z4?XT (;5C9-M6^"9@X>[9,J^6;9,^T>A=T4T0LB];T6L
MQ]]@(W:E.,XVQM'=404B85: DL>@1HZ2D(X9?UFSID5X.G2_-_W^@-GOLG6-
MBB-GK*'M,S:[%-0.X'># *3UX>O9"SRS"#W=9FBHF0G)&0 '+]VO$-(XXKF#
MTU4A34;""1RCI^X-FI!Y*4>.GX0[?3MX\C_:.@.6@-:7M89"[1NS#(2M)6L;
M/U;#16]T>U7WLTVVQXXL[%*XJ-S,2G?)(EB3*"Y5:D.JBV%42%'N( 8];+8^
M;O>SG<=1*=DG(5+IBV4\W-L W%DJ[<VMIAV/;0QF*M1D;.S>.$8I25<S#&&>
MB4'39)83QQR*I)*IAS^CVO\ URV^NYDE[)PTZY]GEM>6L[N9>V!2D2OVL]L"
MSQ:<=N$[G9B M(.7QA=K.UVY6IO4<&4,9+I$#" @(@;'B?H$[@/PE[AX'L'<
M/N'R&@.6@&@->OM/*E:K1LSS:>HWR\4-_ U9W/*'H;DC&5L2;,Z(C N7J39>
M1;,'9A_RG[,.W>*E+T L4@FY"UOU,J-NZCI7 &#E'HKF>'Q!C4SLSKU!<F=&
MIL,+@S@5?XT5C*]8J"I_&"<1$_Q".@+Q: : : Q=WE5"PW7;7F:'K%\MV.9,
M,=W"1"PTD[-&QK(Q=8F'QHE@\=-':L>62411;N'D>5*0(D)TVRZ1E3"8#YL,
M\S=Y2Q+MA/:9S)S&;CMD-3E=OQHEU;O>I;<2?)D$U?G<#' (R=F)5C.A]*8Y
M$8TSE4Y>@.K3OO[CO^>_T/K/J)Y)2KUY2:)T3*D+%J2X#QR,F=BW,^$>   $
M7(J"(!SP/(<B(".@^YZ+0#0&*.]NIV*Y[6\ZQ%7O-MQY*IXNNLH6?HYVZ%D<
M(P]8FI$81D]5:NG# DPJW29.GD<",FFW6439.$#K&,('SF;CYF[)8/V:DMLO
MD9DT:;!E9K$"K!>S>\/=TR=RJR$,+I>.(+AU;RPA6(L$)00ZVB\D;N KB+<%
MS=M]@RP[WXT)6S2F1E\_R&X7(,/E.$DUK",.AMI:XPBG%;<.V+H @$JZ:?%R
MI%ND3"X&7]4$0,8#!H#ZBVO=/GD! P\AP/(!S_F@' <<?,>W4/(\ /.@*G0#
M0#0#0#0#0#0#0%,[5310.HL?TTB 8RA^>D"$*4QCF,/(   4!'D1  '@>>0#
M0&NC:G[0ZF[J+^\H\1CNU4IO+4=;)N*['8'D>NSRECII:92HN+&R8LTR.8%5
MO+Q)^J,?*.%3M7#5R5<07X*!8MO[7G&K&)MECL.$;W7I ]>AI[$+1T^BG3_,
MU>G[PO1(E2)71; >OG7LB"G6QD_>/=VH"[,8_'3IS_?D"XMC]JACVH8#89BL
M6*<B-;(IEAWA:>QFQ03EG=3NT5,,XF9&=MC5N$"V@F!7S=VG*J@B+XJA&S9J
M9R8": VC-UQ7*!N."B7J#L(";OQVY^11Y*(]P,("8H]/ B!..82@ @'/?OR/
M  ' B(B(^ [>?EH#"3>-O5B-I3>AL28ZL.5;ID%KD><AJA6Y%E$K$J6(*A^6
MV1; XD9!!PV3^R8<S9"/8&(525DG[)JFLB4YE2@=3F3?#0*5@;">:Z[2YO)Y
M\_V"EP>&*;'':1LQ8+%<862G8P%'CY-TUAB-H5@_5<OCE5!$1!$! 5>0 M4Y
M]J5B)K2-M5Q:T2_/W6Y"\1E"8Q2<<<C6A2[E\]BGZ%MLBC;[)27CY1@X9(M$
M#G=21BBLBFFC\8@;0R*&,8"B  (@(_/P''@>1Y[CY[<AWXT!.T!Q.;I*)NW;
MOWY^OW<CW_ >- :Y*][0ZFV[<T[VYDQO9D*XYRKD/ <-EAQ(1YX"?S)BREPE
MYO5+2@2I_:+9I&Q,F]9MYQ=P=M(R4-(M0:H$(FJJ']]]]5L7%N>\*AXYW3X9
MVC)TNV.[1E*+L;QO8VL2I&4:O(UF,B9,C%.3<( WEY!9I+H'48Q(@6.341%X
MMZJH(D S8T T T! W@?P'SQQX^?/;]O;0&$>VS>+0]QV7]QV,J12[;7C8$L5
M)B9:Q6B)6@1NSBTUSWU*8BX=XV;RI(U!M&$9LI"4 BTDR*@[122;^B30&;N@
M&@ ^!X\_+0%*[=I,6:[UP!P2;(*+J@F0RI^A(AE#]!" 8YS=)1Z2E 3&'@H
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M 2_2 1$1$>1^G =Q\C^(Z Z-.K5U([Y0D'#E/)N"NI$X1;$#2#@G2*:[\P(
M+Q5,2@9-1QZAR& #%$! !T!.0KT,TD'DLSC&#23D2E3D9!LR;(OGQ$R"FD5T
M[32*X<>B7@$17.IZ1>2DX*/  &C%E')"U8MT&:)7"RIDFK=)NCZ[UPLNY7!)
M,I2"JL[46>.A !,NJN==0QE%!,(%:#GI*)2D$1('''X 7M^/<!,;L4 'J\:
MK"CU% WU !T!1NV#5^BJW=HIN&RY#)KMUTR+(+IG#@4U4E2F3.00[&(<IBF
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MS<Y)M9!:%8ND?33:$;-''2*@'#0?+Z?W8M(;V0=IF8&;8V[/#25FZC6Z]5<
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M&X<</>C @U,FO7?S7T5&F*E5==70Z+*F1"02,0@&(F(I#R0H&$#++0#0#0'
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M#0#0#0#0#0#0#0#0#0#0'$Y>H #L @(" B'/ AY[?> B'/RYT!)%N @ =9@
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MU0UEAX*:B7B2["S1,?-0YA.""[N*EF:;YD\3;K="Q2*M%2*\&(!R"!B'*50
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M"'ST!/T T!Q$O;@!$._/UX\^/G\_K^&@)1T . _%QSSV$H&+W^1@'@1 ![@
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M4I0,;@@\DY,8>GD1'0%00A4R@0@<%+V*'(B !SR !R(\%#P4H=BE "E "@
M!3^F1118QPZA3,0" (B)0 I"*%'HYZ1,4YC& P@)@YXYXX#0'-N(BD7D1$>1
M[B/(CW\B(]Q'ZB(B(_,= 3] - - - - - - - - - - - - - - - - - -
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MQT@(B!2]@^ O!//P]QY %X,8 $ $"F2X'@.>5 (0XB;CJ$3%.8.1$1 !["'
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<*SZ0=.'CHZKA=50PD]7H!H!H!H!H!H!H!H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g118907g86m23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g86m23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %1B^5  X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            S0   E\          0                         !
M          )?    S0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    S0    !29VAT;&]N9P   E\    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ,T
M    4F=H=&QO;F<   )?     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      J@     0   *     V   !X
M94    J$ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M<S3Q)08
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$1  (1 0,1 ?_$ !X  0 !! ,! 0             ' 08("0($!0,*_\0
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M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$'V'_?\
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MO<S<IW;\RA4%:75Y)."=UN$"H,2QA4E9-G).G+D[@3&:\_\ ($=_-2L4:_\
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MZ[L69ETR.K?>X-)@W>L !JT:E,8Y1(I(Z#/@_P"G-0I6'8_4OIB@W+?BF_\
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M6OPG]G*348#\!9.HZ#_!*W#17X-'O5?7>L(GY%DA^',G:_\ 3.FK/T4'"O\
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MB,*PF4S"DFX.6/<BV.N!4W(\ DH)O&1<:#<T \_F+9QIT:%9[ X\365R TY
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MIN8A/[^/59S?#RH+;6O1SIBM-+93KJD[9V^ZFG->+@ZH8*;+OURV&[@*4JH
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MHF(BZ6>M%;N':UHKJ9TFJYWH*-2@\]]^0SC,?'Y';=;=?AQ5F$JG1MJ%A 6
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M,@<SA;ZMG5M!-:E59Q#W2_BC:=I@P9Y$CU64@&,8@\B!1_\ ^N>?X!_#Z@/
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MH\=H!F-*SHT;5MNUH+))RV<R229'ES.^QC"KWVIW6HWCKZZJN?=G@#W@N'^
M 9#IGB: ,SRD$%>NVJD"RKH51G#LV]>^2/&A%-T$TV18]1,R*C0$"@5,J!R&
M, I@3MX$0[1 1YWT*%"A3-*BUK&09 :&C,SL .?.?NJXO+D7=.\]JYURQX>V
MLXESFO;EI).21M)SYYS"-0Z6M7T0C\E9:SC SY_".U719^2^;2;5YR9S%0S=
MP)_43@V:AE1"* X-CE5.F8G8<P#5M]+MK:LZO2!:]^7& "[)P2(,9/J8(CGZ
M;5_'.N:W3M;>]=;&A9TJC*=*G0939QUX]K6+6@--:IP@OJ07._V<2KEN&CZ+
M=7EODYEK(D>WFI,J185X^0<M55Z\P=O7J*!#)@445!4D')%3D-R9)3M$1+R&
M9/TNT?4N*A:X5+AOLZK@X@@#DTC+<0!!W.>95/3O%6I:8S3S0-%]/3:[[FWI
M5:37M%6I(<7-<"'B<P0?3903)]$]*1AJ#5ZK.6V'K]0O4=;UD'5BDWSDK:,K
M4]!(1\&Z4,)H@I1F$W"A6X B<R)D1*)%#@/(?X9MA2I4Z3ZK0QP?[U1_NF-V
M@$!I\]^1)Y^JMOQ-U1MS=W]W9:;<7=S:/M@66ENU@+WL=QW%,B*IBG&03DG,
MJ[0Z-=%C%(1"U7=N6;-*!:MTG4@NX,5*LV.4M$085E>\RBJ<O.2*JYQ-_=+=
MVJBJ)BE$HVJ?AVR%N;8MD'!<8R!)@R-C)QSDCHJC_P 4O%PNWZ@V[ILKU!#C
M3IAI'_52MMFN$>Y;T\\N%AV.998:7H4=KJ6U86&]>F31YX92)<J*J$<C97[J
M3D^50[%2"HZ>N%4!3$!3,*8E$#% 0NV^FVUO9?D6L;[(@M((&>(\1Y"<YF-Q
M/5><N/$NJW.M?\]4K@ZAQ-=[4- !X6!D.;S!:.$CFW @%1W'=)>IV4-9(A9C
M/RJMI&%&2FY>Q2;^QH$K2JRU:)&3!E2+L$X99PNHR] "&*998RXK"JH)JO\
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MAW%S6JEO$_\ ,3@'EQ$N =,8," >:]7JVO'7+:E3U"WL='JT,4G4K$A]1D&
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M'2%DYW%^X?S#-*TR#L0?BJ"8O'@P<B \>0PI764\@4..X0]S '@1_ESS^O\
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M/;[^?;P/@3" _J)A_M$?N.-X\L\^_EN-U !$DF<0<"8&V=\#;IR7(J9/R#V
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M:!#R]G0V!2I6[2P15:;Z_MEP3? N@8BDA(&;J3+ALB@Q9@J<?Z,"J")2D)R
M<=O2O#]WXB#Z%NRGP6C2X\;@  T8$F"9C G&^%<T_P 5WUA6X*E.A7?<F![:
MV95<7.D#:8))&8Z;+)+6&M+G/:[JU[Z;NJNWR])G(9E*U./V9$LKM%JL5T_5
M2;.Y0?DII(R)Q%)R(^NX35(9(PG[0'.9<47TJQH.8VC4MW\+@W8P8.Q,8F!M
MMTA9U]2HTZSJ>I:/2=5JS[1]'_JJ &?>#8#08VC[A8K_ !!)OJ$-TM;+U_U
M4J*+49Q@T9$VII^RF3^7D$G)'#$DS6)LJ+Y*/?.DDVSM--4Y124$H /:'.K3
M/$-7PMJC=8N;9MS:T7M#&D2!Q'AR -Q,C,^DKT_A'P7I7CW6+?1]$U2O9:M5
MIU*U*WN:0]DYM*FY[VMJB3) @$P),DA>M\&N]:O@>F]CJ"(N$@YL\),/)1Y'
MVI\P;O7*TT)7:A(!@FMWFB6Q@!-("@*@&[A5*3G,+WQO:^+]4O;MM 6WLG\+
M01P@@2,2!)Z?&!TQ\=_A1X@_#ZM9,U$?F:=[0J5Q4H?]C6PXSQ%D@$1Y=/(;
MGW"Q46BSH"BKZ"*JO"0"=102$$_80@?UCFX "E >1$0#],L/ (//!GIZ'X;X
M7S-H:'C_ %!< 3&P)@[]!ORE8_:@W(_VC9+M%I5EY"-Z9,*0S]Y().$/6DD^
MP56:::W(%60(8H. #P7N*)0]\BJRN"R" R 0<>]UCJ.1()&V3NNUJ.G:=9VM
M"M;7KKFXK@.J4BV/9C<YVZ[8Y<L9+YFN&F$3")A$PB81,(F$3")A$PB81,(F
M$3")A%JV^+-IS3&P>E.Z['VS0)*[O]*,RSM+-%627J;R+>S]CJS%^Y?3D,87
M+:GI.&T-+793T5S-8&O.7S8A7L>@J4GP[[_E1+\)PU=AI'J9UY'MZ?.S-+D-
M5/Y;8^J]DW?9FL;@VM$)<)"+@(9[='[]U%VJF?+R/[3,&*_HN&E@K3Q<P+.?
M11=_)%NA('!"ASSP4H<_?P'GSQ_HPBY810%U)#SK(WO_ ,_-3!Y_[SZM_FR
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M2:(("[_KHHZ_JMA?PZ;#%6GHYT[*P5>-68L"7N(2C"V2:MS%RY@]E72$D;!
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MK@''W0=YY3[V?0]F%'FL6-AAZZ:*LD26-=I2\X\0^7>)/TUFTO.24J B= H
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M10PJ*B!0_K*G-Y$P\!R(C[^^2QO"T#[[]^7)5ZE057N<-IV$Q\/A'\;+P[=
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M9W&<R9 ^"^I6GXF7-30Z7A?5K&G?:.2WC%2M5?4I./#QUZ)>XAE5O^IB /=
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MUSE6L#"J3<?*MG+=+E15=%XH5Z(-C/5%#@GGE;V^J7=U?U=,I4Z5N*Q]E3,
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M9OZB8RYTN1+%)C*83I_ Z_QTW\E]!O$R!#C^[.[]Z0*"5,JE3$RP)Q+213,
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M26=O4!Z<]R#.K0CZQE;%>:K]((MF_8,%G(K_ +S>T5/GY%!--'N PIG,)0$
M$0=]_)/ACKR]%<?[Y;\'OTV[?]^W_P"K:H_K<<]O_2=[\>>/?C"+Z_OCOO\
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M<%7IH2)%FE\M%,3R<M*R4B^1BXF%AHM P+OY69DG3>/CVI!]1T[<)()_F.4
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MP*)WPN)AD]<1R)692B9T)W1 ;E 15[>!$"*P2]3'3J,)#6D-Z:D_9ZQS*T!
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M1USZ=]C=)R1'Q^7[]!F<F%*+*C]1]QMD/ 5^0ZLZ[H=1#83]JO;;U?:WL@;
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D1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g118907g86n22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g86n22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &VJ^<!@X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            \@   7           0                         !
M          %P    \@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    \@    !29VAT;&]N9P   7     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /(
M    4F=H=&QO;F<   %P     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    &.$))300,     !#Q     0   *    !I   !X
MQ.   !#5 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M'3>FWP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW*E10@U%=Y*TLE?-W;U.I:?N("81,(B.A'_*)AT/W\![>_CSS3'<WO\ 8F\
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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M*8IBB [\B._QS'!5< < < < < < < < < < < < < < < < < < < < < <
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M!$0$!WY\"&A#0^-" Z$/OQUU[ \]),1$>T-C[^_XUH/P&OL&N1999:-M>;U
M]%/_ )0]M>!$!U^-@(?T_'V]^2!Z*6]]A=_Q#?\ U_\ -^?<. /22\?04-;U
MH-:V(B(AK7D1$=C[CLVQ\CN+):)( 4DQ$H]@?1^[KP ?28OL'@0T<V@'8!W"
M(>?/)MKXZ@\!!(   (&@]@V(AY  WH1T(^-]P^=[-O8B(M >BDF.MD#QK0^=
M^/R.]C_7>_OP!Z2?CZ \;_(CY\CL1'8_UWK[<AI/)@>DGX^@/'M_3V_T_C]_
M/OPTGJ "28#L"^=:WL1'0  :V([^P?U\^XCQNJ][9Y9^6@//12[N[L !T(>!
M$H>1 PCH! -B(>3:[A\AO0B R **0^Y _'@1 ?80]P$!]A$ 'W / >P< ]%%
M,0[>T  0T.A$HZ]M;*(#_OP#TJ9"?NAKP >XCX#V]Q'@$? ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' ' +0MMRKM&K4];KA/QM:K-;CG4K-SDNY;
ML(^+8M$Q57=.G+E0B"*21"B<P*J$.;8% O<8NP,177JFP;CMI5'UMR-$1S6Y
MP"=I@52).W8+U8Q&RAK2[*S;N#1-<(#YF5:>EODXEH=R@DNZ*JLD4X$Y#J>P
MH]OK;&;'(L&\N3TX(LX]L955FY?_ *"I:2PJ,R1(T*K8#UI!>P)P/SZ<JI#$
M&1,V2:$%?@==?CF?2QSU$8AR_.S];QQ>8VQRE<;?/OV[4KA,SR)+*R$%^NP+
MARW09SM>-,Q4G%#88A=_$A)Q[EB#CUB'*4#,Y5S 40$W<=,P>J8H")0'91,'
M;H#$\*" %'9B@0 $1$!-P"L+Y /?V^^M_P!=>-\ ]X X X X X X X X X X
M X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
M X!@+J2QM"Y7PEDRHRM,@[ZNYI5M5KL%.1+":04M)*W,-X!=BUDD56R$LB_=
M$!B[],1;J*BHD8AO/ .=N75\M0U Z>\&-< 93- 3.":K6LZ9>Q;2*?9[Y!Q,
M7#P3=UB*O*35@C$X]S/2#=163GGJTDT@F[,[AE!NY,[8Z(:ZKPSY=7_0MUEA
M#)0QK3I_J>);Y58T>I2K9RKN1'Z,2VJM7Q3!5>H.V$4]E2V):7+=$R5Q3&"]
M;%)=X0'+=ZZ6/" ^DT8>?AKIG;WZ^XMXWR\.5_?FO#(R=TKXKR<M9, Q5GH%
M[Q4UZ<NAZS]+MUGW0P$62RY*G97 J;68QF]CI611FHJ%9X9G;&QL+B'9HH*V
MF$2'_P"Y$LL,SGZ>/7!9\+C\>7B_"_GFN&7&^+_C^VX*RKTCO:]U Y^MC#(7
M44MCFVU_(EWB[37)6JN<!YXNQD3-BUJ,=$61L5*KKTCQN\15_P"%5;E.#%19
MLH'#^+_K^#I0G_Z9/ A](>! H#[?@@B0/Y%$0#[#P"/@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'AAT C^ $?.M?UV(!K\^0X
M!3IJ'-V"([[O("4H=NOXF 3@(_D $O@0'@$\XB!#"'N >-B!?]S (!_4!#@&
M&W&?\,,JW<+B\RWCE"I8^L;FHWBS*W"OIP=0M#0&)G%<L\D9^#2#G&X23#YF
M-?KH.DOG&AS)$(X(( 7?<+]4\>0+NWWVU5ZF5"/5CT9"Q6J6804,R6EWK.*B
MTW4H]528MC/Y9^RCFA%G!#.7CU%-$3#Z:3ASZ]^ON/;\^GMUQCG[W5JJ[K3*
MT66O5QU=)LE9I[2:EF,<[LMD6CI*71@8-)PN 2DP>*A9:21CV(N7:["/?O 0
M*DQ6#@'MEO57I4<E,7&RP=8B5Y&,AD9.PR#.%CU9B:>MXV'C$WCYR5NJ[EI)
MTA'L&R1Q<+/5D6J::SA4B1@+G(JH)@+W (&T("82"&M (B4H%2.8H@/@_:!=
M^?W="(%9P!P!P"T[';Z_3HUS.6RPP=9@68%^;F+#*QT)%M#B!2D(XD)-=FV2
M]4X*B05%"D.F0R@*)D3_ ,0.75_+IEL4?,^*LG@L;&F4,<Y$*W PN#4>[UBV
M"@!3B43K#7Y.1!( '1?\4$R"(@4QTSB( !DX4B& !, B.@\B([_.A\CXV/ML
M?Y\ ]]%,0\E 1T(=W^;0_DWN/X\C[>. /2)YT AL0,.C&#8@  &]#Y#P'C[:
M\< \%!(0$!( ]W@1'>Q#>Q*(^_:( !3%_=,0.P0$OC@&FG5<D0N0^A$ WK^^
M03W,8=ZZ5.J?P.Q'>Q#9M[V(F$?)AV!N> :  #?@->1V/^H^> >\ < < < <
M < < < < < < < < < < < < < < < < < < < < < < @4-V$,81UK7GQH-
MB ;'8" %#>S"/L78^-;X!S<ZO8_XD$CA_.C?IMMN FMF?5FSI8I9#1[HRR&0
M5BG3C&J5K>9-6J+>W_*>HBUEU:TVAD)-1!<R+-,2N&[KA^<@_P!-.G[>AS(^
M#K6OC;Q&+\C_ -["WUU!=:Y+*4U+JB3LN5\@ D""*4B:*D:EDZ(6CJR+PBQ&
M+>1?/#>H4_R31-D9(P!UK^.O(_0OC[^TU*N(IY5D*5)VL5U_F'= AYF!@!;;
M+\N1&.GI^SR17! [_F#GDSICLO8F'D. <+.HCHVZ@)[KDF<=T:L'==(O4I;\
M;]3.8["NZ9_H\%DG +>57+4W$29TV,LWR?+M\;(N%$T#@*<$[6=D431T(&EY
M.GOXC&4.E3J8H&5#9WL]NM53PHVN5)LBC]S$2&;HKJOQQ9YBY8NLEFSA>D8V
M/C,?0=A?$C:15:%41@S5TZC)"9C!CDPY^"OX^/TY7?@;US>(>MBBVNQT;%,S
MF>9J58^(",UBR>R%D>=OJB>&;)T/OW[A6>L5HGY6QS% 8=1LLN@E&RCEX9%X
M H%CD6:*1BL^N&?YOY?EUZ]9?H89K.(>HNZX);5V5QWUBR.4&5\Z19W-#G/.
M5F=UJ,OD^FYDAY;*<[BJ'?W2R#'QL:R:J2+V3@U*]7'T.5LC$P)%$#F!UUU^
MPS9T 4SKKC^JVURO4-/9B_10-DPM^C+'^L2V*IM=:QK'QRYI[R6S?9(:%^2B
M?EOEF5'Q77&;AF )32Q%BCW!;K]>9WXX X X!QT^()A2YY,OJ]\<X,Q/ERA8
MGQ"UEHMAFF6L+VH2EM4F+J]D(R(J8VJ%I+6?5(RK4/(6&>CU7K2-LC%XC*&2
M@S1YPTZOIPY._JO$S7C;HZZ!9JPUB[8EQ[ANJ9)J)X2P'E<$SL3!SL2Z0%(X
ML'[FE29'"\0NHW.P=LG_ *C-^S3.T4(JD8Y1"V7+-\>/'[_I9K+H8L],BFHL
MH<B22?<)U%!("::90$3JJ&$2E*0A0,8#F,0G: B80UY ^<]LD3'E:*.YN':)
MR*J2,:H\?-&R4@LL3O119G663^:55+LQ2MQ4$Y0 4PUL> 3_ -?BSR?Z*26C
MPF!; ^_2?F6XR@,^X2&<!'^I\T*!1*8 <"F*(*%$HF,(=H 1-9V-DEW[:,E(
MY\O&+BTDT&#QJ]7C7':8X)O4T%5#MUO3(H/H+$(KZA2E$G:)A$#4WJM-W9!Z
M#S#K9NL9,P]H]Q?/2GU3C])@\&#\"'N'G@&YW ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' (%#"4@B Z'8!O6];, >W]>-2&TLV2%
M3B8O8!@WH!$W: E]P'V_'C7]1_'&C2?7Z#-Q;B_5^?(E ':77@QNT"[#N$3
M'C6O.]_<!'ZO CO@GUZZ_F^9" :'N$=!L-E$O:(  ^/J]P_'O[?;SREW;34E
MN\5:]_)D7LLWZV_!$H!!$QB@4.X V(&$!#SO8:$-;^X!KN]A]@Y40I+2]WUX
M6(0T)P[B>2J_D!.41 "CX#P43!LQP#P!!$1#SY%1$)@ -@4!'L'M, B(@(J
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MW*1" H==1%1,?234X!U:*;N*4P>P@ _S_P!. 1< < < < < < < < < < <
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MM$2ZT(@(&Z(    ![ &@_P# T' /> . . . . . . . . . . . . . . .
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M]U/JGV(?P_' -S> . . . . . . . . . . . . . . . . . . . 2EE!3
M! !'8CO0;\:$=B.PT'\=" >YA NQX!C[)&3Z3B6ESU_R59HBG4^M,A?3$]+N
MDD6C,ACD2;)F$3[5>.'*B#=BS; X7?.UF[1N0[APDF8%^.?O]#\G'QI^@3J&
M^)]9.G[/]=6C,#8UBK14L"T*IYC<ST?<[.SRG:C";+4E38F$D!HB3MXY9-V%
M6LCAO:Y.&9-W<[#5I^F2.$/'G^B\U[>?$_4WTX8J<X,P=B###RS2-V=8JQG3
M<?KW*5*=.0LZ]3@F,(M,O4CJ.#)KOE&1EQ [E5<?4$%3J@!%3!UUU^#.7 '
M' ' ):INT@CL \E#9AT'DP!K?Y'>@#[B(!]^4RN\LE%ZOD^'%:NR!\X\DV3(
M85G")  #[[U$DQ 2CH2']10.PZ?LH!O/=L->!U7&,G914I/)?*F_#EE?A?-\
M,P\DWP72ZYEBX]RU0\JU]6TT"SQ5FK[>6F()638+D,W)*P3]6-E&?>?TP]1F
M\1414T':8Q![#"&C#<Q.#Q.%J=S6I2I5'&,VG!YQFKQSN\VG?C]R$T]'?.R\
M>>5N&76F0@<E, @D<#B! $! HF PB.]@)3"&B[ #@8Q0+W (F .6(QW59\R3
M1-WUDV=MUJ!TNO,-V& IY,+Y!R>SRM87\<U87&3HDA2V[^*IL0S6?/W<2S1M
MS=-_.2A8M)1\ MHI"2^6?':U T Q;\9"Z9%PW:,@EQEAY&]S=]P3CS#6)&V4
MK\A:EY+J&RN7%]&L&5PL6%:\6M5-,[A*:=35#2R6V6*RE8QJ920;$25<WPY<
M>/OP_ Y+SS\<K9>^=\C-]&^,7@AA5IMAU"L9[&^8\<R&7XS,-(H51R'EVN4Y
MMA',,WAFYW,MPK-)31-10G(QM*IS,I&Q:S6+DV)7C)-RN5(72\<OY]@9J2^*
M/TD%B7\FK-9'2D&>38#$A:FMAC**%U=WFW5 M[IL<RJ*M43G7B%NIXI3T%*H
ML/TMTV<)(_-@Z.5(P=+QT,,27QB\ MLYXHH;958,;9/QW/33>S/8>Y-,BM,G
M0^0'E!#%:>(U*G^U3BQ!(LU/FVO8F_:'(OZD?\NB9R(&S/55U49"Q38\'8BP
MCCF$R!FWJ%F)9C3HR^61_1*=6(6O1!IJPV>Y2S.O6>;0:Q;, [XV-KKZ15<_
M\("1%?8#3:1^)?U!LA=8<_L+Q<EU4U[JCQETTV.!D,JV!'#JQ<JU^0GJKD.)
MNL?C:4M@PSI.+>H.HEY0$)-BNV6(8JI">KP/OY75N/+/2WJ;N](/5%=,[2.=
M<:Y:Q]!8WS=TW9'C\?9*K]1MCF\4R00LU0@KY2[94;*_K]4DWT//UN>24,VD
MZY%2#)XS>MEFXF2X!E/J4N> \?X;N-QZED*@YPU#-F9[*UO%;)=(>0.\?,XV
M)BTZ@O$S+BP2LG+NV<7%PD=#2LE(R;U%NU:+.S"D(&N71=E[H&R(M)QO2%3L
M;X^GC5J)N<_4ZQA1+"UI3K5B=O&T1,RL$>H5=VNV=.X]\V[@!8[!TV70< @H
M0>T#HD'L'\@_C_W'_J/\^ <G.NW+.=ZWD9I5\+R>1G):WA:U9'F87&#S'$4O
M7Y=I9(B,AK??7&1XE^%BI#9DN_;.*U5DW]A6>*).R0,@BB)TG77\CKKK[Y8S
M@^H_+\K6HOJ48Y8F;$R?=2-3Q&WQFQBX%KCVP8[M%2IK9*5C(AU7D[FC/%?V
MM3(S5XZLK1TU:M&D:]12B0?(O@\LS*G3#EO,3NR8#=6*[VS+Q^HWH;L_5'.U
M"44HS)O7,EUV<P2O'U3'@QT;7VD17+ RS--U=NTLTM*-D!IL)(C*IO LDU(N
M?7M]^D@WX>UNK:*WM;55>8,O9/N^9.AB(N733D[$$.EU9K/T;7=+5A>9B73Q
M'I<ZG4$8A-IC_*5SG4W[HCD[E)5Q%)1A4&3LKF30=G8M7D)OBFO;]=.K<CRY
M>_CGI?TY_4ZH .P =:V'MX_["(?Z"/\ /D@]X X X X X X X X X X X X
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M0$0$ $ \!K\@(@&MB ['8^=#KVX!,(GV#ONWL!WL V)A$/(C[^P: /8. 3.
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M^-K^ />2#P=Z'6M_;?MP#PHF$-F "_@/O_7@'OG?VU]OS_[< ]X X X X X
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M[Q[BE O;K8&[A#1AV @ Z$ \F[0\\HA*4FVXN*MDGTGSX<AY%2FIZF_I$ T
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M"G*M3G.;C*<LXO=M9M[NE\_5V);35EK_ .VZ7CE>_BWGK;,WE1 "#Z@%]RB
MZ2!+6Q 3'$O:0PF4, "H/:("8 $H$ ! =7OWTC+UC+\)OZ6\;D6ME^GX)BIN
M\GE,PAW!H [1[]@)0T(CKMV8!-W"4.T![ME$0%O7OPY-[RS_ /=%!>WF:E]7
M"3<<<TI44P,<<^].I/4!/US D7-%/ Q2* 4_:0YE7*1]"98Y3B4H&+I/FSV:
MJDGB5&HDU@Z\LE=2MN)I*Z\V_P#%+3B4SGN-9-NZ2X<4KO737QYMFUC-/M,
M@  !4^P?3*)4P,0>SM #&,!>WMT!4AT0  ACJ=I1#7.\I;UWQNGGGXO*[\;6
M>O&Y5J?1Y(' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .=GQ0,A-,8]&>2+(ZHV+
MKN@]LN+J6L3-%097?$M/)>\I5"EFR5D"M.6ZB4M7\;(S/[8N$%"E;E<PB0.5
MP;IG,(-]9LT@^%]-PE*ZC<VX$A)#HTS0$+B['V05NH3I'P50L,ID-:9.::!B
M^])8Y6D:Y*/HLL=^LQ1F\L"X-94@R3)HJ)BB!WQ#V#P(> \#K8?P'7C?\O'
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MEHDO0-O2S>5_V--^JB!SI=656K6*<?5*S1,7=,;7V0F;)?U:HL1U2+W&VEQ
MMXTM;F#J@^:1"*17YG!$D5'I!,U.5 W=LMGU\/A^_G4G-2JX>MAUN14DN\4?
MFO=/@LN-FN5[=2%2HH**CE-2=Y/1>BRN_5VY,VLJ;F<>PD4\LL8UA)]RP05F
M(=E)#,-8V143*=VR;RGRK('Z+983)).@:-BK%)ZA44P/VAK7&$:DU"\E)N2E
MNVRLD]6\[^]]"ZKJ*333265\EER_/$NCD@< < < < < < < < < < < < <
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MC;>RM9Y(_0JRZLG&4'+R'Z:J*OD]=DY!G)VR;>EJE*AUP .XYU'Y22LN* B
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M<D<6-8A&E+H;&=GY:(3-%UD3(KF>RDK*G([D#J*ID_P4#B4P<#KKK\G:X T
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ME#V$  =!X'8B8>TNP$1#8;67)+RR^PM)/-W2>C6G[Y<L\QZ@^="80#P(CVF
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M]>/<(LP^DY#@/K&*8@E5  -HWTB4 X!R,Z+XQX>V8 2QK 'JUIQKT V;&W4
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MCR.KIVJIIEJF+^NNA41:NU%1"7GEZ:<>%[\>#.N[?_TB>=^//\_XB   C^1
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ME*<@CO7U>0$ X!3%.GVB)3E,B! ,0Y/K)VD,0P"4?\_88IS]A3& H[$1^H
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MA#D'8"4H]H^ 'Z0*'D-C] "?N-VAW#Y^WV J^ . . . . . . . . . . .
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M7.=+:W['4V_A9*2K;R2FHE!P^KTDTFH=Y\_792%F$%V$LR:.T#-9%+M.@ B
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M*6(V-BMKB-8PTR\0LURKS&UPT4[%]%1-W@ZO8H.#O<:P=B+ALPMC"2;)J"8
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M]/V-2-9KNUWIFX2MFDI>773!PY6,BBL^4;LD139LDTFR*9"@95X X X X X
3X X X X X X X X X X X!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g118907g87b23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g118907g87b23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &6Z^91 X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            W    8P          0                         !
M          &,    W                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    W     !29VAT;&]N9P   8P    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -P
M    4F=H=&QO;F<   &,     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      [U     0   *    !9   !X
MIN    [9 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M= Z:!Q]DH_\ /;% ?6# ]5U;A8T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ X0&4 P$1  (1 0,1 ?_$ !X
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M!G;D19BV]P\-PO'\/-)B")._> 7_ %0]0>S=QNPP]%JH]JM5=M;MOBNZ"96
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M66@T\A*75H6H$ C1%H=^]5\7_P#^]?TC_P#D&RO_ /WM$0[5?%^'E75;TC*
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MHKP;*MN.FK;?"LUJ9=%D=(C*$6-3+(]>-]IYCD5E&,CL4IMSF'-CKY2?/?\
MEX(-+Z_3H>ZVTT1-$31$T1-$31$T1-$31$T1-$31$T11=_$Y_9Z'/\^[9O\
MV#G.B*431$T1-$31$T1-$31$T1-$31$T1-$31$(!]P#^NB*+/X20'[P6[IX\
MCJTZBN#^'_=HK1%*6 ![ #]!QHB^Z(FB)HB:(FB)HB:(FB)HB:(A /@CD?@=
M$7SM2""$@$>QX'(\<>/Z/'Z>-$7W1$]_?1%\X'X#^H?E_P"H?U#\-$7W@#V
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MCT5+ >,^4S[:^"==:KQD"%N#88',;DSUAU['\@AV%;=TTR1D$V>]&FHCI@6
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M[PGD$CZ@^"1R/'(UB4+LM$31$T1-$31$T1-$31$T1-$31$T11=_$Y_9Z'/\
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M\_?4!SB=+=1X^7-%21QSRLG@$D'_ $>WY\:F03PZSZ(O.Y-]W%\B) )526O
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M\EB,TD*_BPX7'>UM)6-[+,%4S#&4*-%OSOJ-OJ )$D^_B;:E4J'A:3UZ7/\
M/=KHI\$'JNV_ZC>CZBQ7%F;6LRC9NRNJ#,Z:T8"4LKR?)<BRNGGUTMON8F09
MD6Q=C]P6F2W(KGP\PVV6G'>WVNRZKEV=XJF]H =\)P(_W4F6\R)Y7-]A6B[B
M8.O/O\=.2F9UYA94T1-$5*ARDC\1J'& 2BXZ6 #X"AR>2??Z\^>??@^P/M[#
M\-8PXDZ"Y -OY17?3_\ &)_(@<'\CQ]#K) Y#T1/3'U2CCZ\=P/'Y?GJ8C_)
M/U15>DWR#V#D>W^GZ>W\H\_CSYT1"A'DD#SR2?//GWX^HY_+C4$$Z&+HK/\
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M" 8N0+DZ\K#[A4J<</*0KC@#DA/((/\ XWC_ ./X^VIL!$QL.C_*-<2XCAD
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M*<K=Y\7VW&VF*Y:[8+D!<FDK*Z+3VCN-+;2S)LZQH.R/2D+ ==Z*B#T++C9
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M#S^.D#D$5>I1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$5HM
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M< _$K4JU.J X.+',!$?.UP(<V/E<"'?-\IH*H?2+Z5.JP@#A%:F6%PO< V,
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M/MKKR)4I6(["(2I)6COR+*_N+XX0ESFI':$J"1W'@$$GD'P??SFY;+:5 /N
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M6H.*H2UYUWG>\@&>_F- OC+@&GY2*@<[B+[R),3>3, 2#',WA>@CI"4*2!P
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M_&Z 1WV$Q[JW:R)Y,6<\IT1IK,!I+#@E.!47&D:[C2VW/<W[ME'"QWZN*?\
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MB)HBH7[C]%?ZM$7$9_D_T_\ \K6B+CJ_Q?\ SF?_ #MC1%>8_P"^GO\ \O\
M^;Z(OJOV!^J?^DK1%]'^-1_R8_WZ(JC_ (I7_&;_ -VB*XW_ "/^4=_]+1%]
M>_::_P"./^FC1%:3_P!\?\Y7^IS1%4GW<_Y%'_0.B(OV_P#Q&O\ HC1$'^.<
M_P"=_P!$:(J(_NC]'/\ 6C1%RU>P_P",C_IIT16%>[/ZL_ZG-$0?MC_E7/\
FT=$7)T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
